
<html lang="en"     class="pb-page"  data-request-id="86dd8171-8bce-42dc-bb7a-64ed661fcace"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01192;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases" /></meta><meta name="dc.Creator" content="Na  Ye" /></meta><meta name="dc.Creator" content="Wangzhi  Qin" /></meta><meta name="dc.Creator" content="Sheng  Tian" /></meta><meta name="dc.Creator" content="Qingfeng  Xu" /></meta><meta name="dc.Creator" content="Eric A.  Wold" /></meta><meta name="dc.Creator" content="Jia  Zhou" /></meta><meta name="dc.Creator" content="Xue-Chu  Zhen" /></meta><meta name="dc.Description" content="The sigma-1 (σ1) receptor, an enigmatic protein originally classified as an opioid receptor subtype, is now understood to possess unique structural and functional features of its own and play criti..." /></meta><meta name="Description" content="The sigma-1 (σ1) receptor, an enigmatic protein originally classified as an opioid receptor subtype, is now understood to possess unique structural and functional features of its own and play criti..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 28, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01192" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01192" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01192" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01192" /></link>
        
    
    

<title>Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01192" /></meta><meta property="og:title" content="Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0022.jpeg" /></meta><meta property="og:description" content="The sigma-1 (σ1) receptor, an enigmatic protein originally classified as an opioid receptor subtype, is now understood to possess unique structural and functional features of its own and play critical roles to widely impact signaling transduction by interacting with receptors, ion channels, lipids, and kinases. The σ1 receptor is implicated in modulating learning, memory, emotion, sensory systems, neuronal development, and cognition and accordingly is now an actively pursued drug target for various neurological and neuropsychiatric disorders. Evaluation of the five selective σ1 receptor drug candidates (pridopidine, ANAVEX2-73, SA4503, S1RA, and T-817MA) that have entered clinical trials has shown that reaching clinical approval remains an evasive and important goal. This review provides up-to-date information on the selective targeting of σ1 receptors, including their history, function, reported crystal structures, and roles in neurological diseases, as well as a useful collation of new chemical entities as σ1 selective orthosteric ligands or allosteric modulators." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01192"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01192">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01192&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01192&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01192&amp;href=/doi/10.1021/acs.jmedchem.0c01192" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15187-15217</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01093" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01195" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Na Ye</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Na Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +86 (512) 65881161; fax, +86 (512) 65880369; email, <a href="/cdn-cgi/l/email-protection#225b474c4362515746430c4746570c414c"><span class="__cf_email__" data-cfemail="473e222926073432232669222332692429">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Na++Ye">Na Ye</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3612-1771" title="Orcid link">http://orcid.org/0000-0003-3612-1771</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wangzhi Qin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wangzhi Qin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wangzhi++Qin">Wangzhi Qin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sheng Tian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sheng Tian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sheng++Tian">Sheng Tian</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingfeng Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingfeng Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingfeng++Xu">Qingfeng Xu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric A. Wold</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric A. Wold</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Program, Department of Pharmacology and Toxicology, and Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric+A.++Wold">Eric A. Wold</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6434-7562" title="Orcid link">http://orcid.org/0000-0001-6434-7562</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jia Zhou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jia Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Program, Department of Pharmacology and Toxicology, and Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone:+1 (409) 772-9748; fax, +1 (409) 772-9648; email, <a href="/cdn-cgi/l/email-protection#c3a9aab9abacb683b6b7aea1eda6a7b6"><span class="__cf_email__" data-cfemail="6c0605160403192c1918010e42090819">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Zhou">Jia Zhou</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2811-1090" title="Orcid link">http://orcid.org/0000-0002-2811-1090</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Xue-Chu Zhen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xue-Chu Zhen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: + 86 (512) 65880369; fax, +86 (512) 65880369; email, <a href="/cdn-cgi/l/email-protection#443e2c212a3c3121272c3104373120256a2120316a272a"><span class="__cf_email__" data-cfemail="ed978588839598888e8598ad9e98898cc3888998c38e83">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xue-Chu++Zhen">Xue-Chu Zhen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01192&amp;href=/doi/10.1021%2Facs.jmedchem.0c01192" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15187–15217</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 28, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 July 2020</li><li><span class="item_label"><b>Published</b> online</span>28 October 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01192" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01192</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15187%26pageCount%3D31%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DNa%2BYe%252C%2BWangzhi%2BQin%252C%2BSheng%2BTian%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01192%26title%3DSmall%2BMolecules%2BSelectively%2BTargeting%2BSigma-1%2BReceptor%2Bfor%2Bthe%2BTreatment%2Bof%2BNeurological%2BDiseases%26numPages%3D31%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15217%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01192"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2173</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01192" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Na&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Wangzhi&quot;,&quot;last_name&quot;:&quot;Qin&quot;},{&quot;first_name&quot;:&quot;Sheng&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Qingfeng&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;A. Wold&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Xue-Chu&quot;,&quot;last_name&quot;:&quot;Zhen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15187-15217&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01192&quot;},&quot;abstract&quot;:&quot;The sigma-1 (σ1) receptor, an enigmatic protein originally classified as an opioid receptor subtype, is now understood to possess unique structural and functional features of its own and play critical roles to widely impact signaling transduction by interacting with receptors, ion channels, lipids, and kinases. The σ1 receptor is implicated in modulating learning, memory, emotion, sensory systems, neuronal development, and cognition and accordingly is now an actively pursued drug target for various neurological and neuropsychiatric disorders. Evaluation of the five selective σ1 receptor drug candidates (pridopidine, ANAVEX2-73, SA4503, S1RA, and T-817MA) that have entered clinical trials has shown that reaching clinical approval remains an evasive and important goal. This review provides up-to-date information on the selective targeting of σ1 receptors, including their history, function, reported crystal structures, and roles in neurological diseases, as well as a useful collation of new chemical entities as &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01192&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01192" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01192&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01192" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01192&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01192" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01192&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01192&amp;href=/doi/10.1021/acs.jmedchem.0c01192" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01192" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01192" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01192%26sid%3Dliteratum%253Aachs%26pmid%3D33111525%26genre%3Darticle%26aulast%3DYe%26date%3D2020%26atitle%3DSmall%2BMolecules%2BSelectively%2BTargeting%2BSigma-1%2BReceptor%2Bfor%2Bthe%2BTreatment%2Bof%2BNeurological%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15187%26epage%3D15217%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=290729" title="Nervous system diseases">Nervous system diseases</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The sigma-1 (σ<sub>1</sub>) receptor, an enigmatic protein originally classified as an opioid receptor subtype, is now understood to possess unique structural and functional features of its own and play critical roles to widely impact signaling transduction by interacting with receptors, ion channels, lipids, and kinases. The σ<sub>1</sub> receptor is implicated in modulating learning, memory, emotion, sensory systems, neuronal development, and cognition and accordingly is now an actively pursued drug target for various neurological and neuropsychiatric disorders. Evaluation of the five selective σ<sub>1</sub> receptor drug candidates (pridopidine, ANAVEX2-73, SA4503, S1RA, and T-817MA) that have entered clinical trials has shown that reaching clinical approval remains an evasive and important goal. This review provides up-to-date information on the selective targeting of σ<sub>1</sub> receptors, including their history, function, reported crystal structures, and roles in neurological diseases, as well as a useful collation of new chemical entities as σ<sub>1</sub> selective orthosteric ligands or allosteric modulators.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span></span> Note</h4><p class="last">Due to production error, this paper was published on October 28, 2020, with part of Table 1 missing. The corrected version was reposted on October 29, 2020.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The sigma-1 (σ<sub>1</sub>) receptor is encoded by the <i>sigma-1</i> gene and was originally classified as an opioid receptor subtype, but subsequent research has illuminated a vast and unique array of structural and functional features distinct among other mammalian transmembrane proteins. It is predominately localized to the endoplasmic reticulum (ER) membrane, specifically the ER–mitochondria interface known as the mitochondria-associated membrane (MAM); however, upon ligand-directed activation, the σ<sub>1</sub> receptor can translocate to multiple cellular destinations including the plasma membrane (PM) and nuclear envelope.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The σ<sub>1</sub> receptor is expressed in both the central nervous system (CNS) and peripheral tissues and exhibits complex functions such as regulating mitochondrial functions and autophagy.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5">(2−5)</a> Interest in the σ<sub>1</sub> receptor and its functions has increased in recent years, coinciding with numerous new discoveries about this previously understudied protein (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In the CNS, the σ<sub>1</sub> receptor is involved in neuroprotection, neuroinflammation, neurotransmission, and neuroplasticity and thus is functionally associated with advanced brain functions such as memory, cognition, mood, pain, and neurodegeneration. Unsurprisingly, the σ<sub>1</sub> receptor has become an actively pursued drug target for several CNS disorders, including, but not limited to, neurodegenerative diseases, pain, stroke, retinal degenerations, and depression. So far, five selective σ<sub>1</sub> receptor ligands have been advanced into human phase 2/3 clinical trials. ANAVEX2-73, a σ<sub>1</sub> agonist, is currently under phase 2/3 investigation for Rett syndrome and early stage Alzheimer’s disease (AD). Pridopidine is being investigated in a phase 2 study for Levodopa-induced dyskinesia, and a phase 3 study for early stage Huntington’s disease (HD). The current clinical study of selective σ<sub>1</sub> receptor ligands is a promising trend, and the resultant data should deliver additional guidance for new σ<sub>1</sub> receptor drug candidates reaching clinical phase programs. Herein, this review will introduce the history, functions, and roles of σ<sub>1</sub> receptors in various human CNS diseases and highlight the ongoing clinical efforts and recent advances in developing selective σ<sub>1</sub> receptor orthosteric ligands and allosteric modulators from a medicinal chemistry perspective.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Number of papers published between 1994 and 2019 according to the recent PubMed search using “<i>Sigma-1</i>” as the keyword.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  The History of Sigma-1 Receptor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00573" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00573" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The sigma (σ) receptor was classified as the σ subtype of opioid receptors by Martin<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> in 1976 and was initially thought to mediate psychotomimetic effects of morphine and its analogues (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). However, Su and colleagues<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> in 1982 demonstrated that this “σ opioid receptor” differed from other known opioid receptors due to its low affinity for naltrexone, a nonselective high-affinity opioid receptor antagonist, and subsequent studies with enantiomers of [<sup>3</sup>H]-<i>N</i>-allylnormetazocine showed that the “σ opioid receptor” exhibited a preference for the (+)-enantiomer, while true opioid receptors bind with high affinity only to the (−)-enantiomer.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The σ<sub>1</sub> receptor was also suggested to be a subunit containing the phencyclidine (PCP) binding site of <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptors (PCP/NMDA) for a short time period owing to the polypharmacology of certain ligands (e.g., SKF-10047), whose pharmacological effects are mediated not only via σ receptors but also NMDA receptors or kappa opioid receptors.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The σ receptors were subsequently recognized to form an independent receptor family based on their unique structures and functions. In 1992, two distinct subtypes of σ receptors were classified by their pharmacological profiles: sigma-1 (σ<sub>1</sub>) and sigma-2 (σ<sub>2</sub>) receptors,<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> which are not genetically related to each other and differentiated by their molecular weight, anatomical, and cellular distribution and ligand binding profiles.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Major milestones in the history of sigma-1 receptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It was not until 1996 that structural information about the σ<sub>1</sub> receptor was available when the receptor was first cloned from guinea pig liver<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and subsequently in human cell lines;<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> whereas the σ<sub>2</sub> receptor was not structurally identified until 2017, previously being proposed as the progesterone receptor membrane component 1 (PGRMC1) protein and more recently termed transmembrane protein-97 (TMEM97) using a chemical biology approach.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The σ<sub>1</sub> receptor is a 24 kD molecular mass protein of 223 amino acids, and the σ<sub>2</sub> receptor is known as a transmembrane protein with a molecular weight ranging from 18 to 21.5 kDa.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The amino acid sequence indicates that the σ<sub>1</sub> receptor shares no significant homology with any other known mammalian transmembrane receptors (e.g., G protein-coupled receptors or ligand-gated ion channels). It was initially recognized as containing a sole transmembrane helix, but later, a two-pass transmembrane model was widely adopted as the basis for molecular modeling studies.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In 2003, the first <i>sigma-1</i> knockout (KO) mouse model was generated with the aid of homologous recombination techniques by Langa and colleagues,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> which rendered a powerful tool to investigate the roles of σ<sub>1</sub> receptor in normal and pathological physiology.</div><div class="NLM_p">Functionally, the σ<sub>1</sub> receptor is understood as a Ca<sup>2+</sup>-sensitive and ligand-operated receptor chaperone primarily localized at mitochondrion-associated ER membranes. In addition to the regulation of Ca<sup>2+</sup> flux from the ER, either directly or via chaperone interactions with the inositol triphosphate receptor (InsP<sub>3</sub>-R), σ<sub>1</sub> receptors are known to at least partly modulate neurotransmitter release, inflammation, cell survival including autophagy, and synaptogenesis.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Nevertheless, the σ<sub>2</sub> receptor is distributed and able to translocate among the endoplasmic reticulum, lysosomes, and mitochondria, resulting in a wide range of cellular actions including the release of intracellular Ca<sup>2+</sup>, dopaminergic transmission, and neuroregeneration as well as cholesterol homeostasis, thereby involving in the pathogenesis of cancer and neurological disorders.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Regardless of these unique features of the σ<sub>1</sub> receptor compared to traditional receptors, the International Union of Basic and Clinical Pharmacology (IUPHAR) included the σ<sub>1</sub> receptor in its list of receptors as sigma nonopioid intracellular receptor 1 in 2013,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> even though it may not fit the classical definition of a receptor due to the lack of evidence for coupling through conventional signaling pathways. However, the ligand-operated nature of the σ<sub>1</sub> receptor and the identification of ligands with varying modes of action (e.g., agonists, antagonists, and allosteric modulators) support the receptor classification.</div><div class="NLM_p">In 2016, the first crystal structures of the full-length human σ<sub>1</sub> receptor were successfully solved in a cocomplex with two different ligands, PD144418 and 4-IBP.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Later in 2018, the cocrystal structures of the σ<sub>1</sub> receptor bound to haloperidol, NE-100, and (+)-pentazocine were also disclosed.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, the σ<sub>1</sub> receptor has been crystallized as a homotrimer comprising three tightly associated protomers (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), each of which contains only a single transmembrane domain, consistent with the earliest structural consensus rather than the two-pass models that followed. The high affinity and selective σ<sub>1</sub> receptor antagonist PD144418 and σ<sub>1</sub> receptor agonist (+)-pentazocine are deeply buried and occluded in the binding pocket from the solvent, and each ligand interacts with the receptor through an electrostatic interaction between GLU172 and the basic nitrogen presented in most σ<sub>1</sub> receptor ligands and van der Waals interactions of the hydrophobic binding pocket including residues VAL84, TRP89, MET93, TYR103, LEU105, PHE107, ILE124, and TRP164 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Homotrimer and protomer structure of the σ<sub>1</sub> receptor (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a>). (B) Overlays of the cocrystal structures of the σ<sub>1</sub> receptor bound to the antagonist PD144418 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a>, brown) and the agonist (+)-pentazocine (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK1">6DK1</a>, green). Residues are colored in gray.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3.  Functional Implications of the Sigma-1 Receptor in Neurological Diseases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23531" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23531" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The σ<sub>1</sub> receptor remains an enigmatic protein because a preferential endogenous ligand has yet to be conclusively identified, even though steroids [<i>e.g.</i>, progesterone, dehydroepiandrosterone (DHEA), 25-hydroxycholesterol],<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> the hallucinogen <i>N</i>,<i>N</i>-dimethyltryptamine (DMT),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and sphingolipids <span class="smallcaps smallerCapital">d</span>-<i>erythro</i>-sphingosine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and ceramides<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> have been postulated to act as endogenous ligands. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, the σ<sub>1</sub> receptor is normally in complex with the chaperone protein BiP (binding immunoglobulin protein), which plays a critical role in protein folding and prevents the inactive state σ<sub>1</sub> receptor from translocation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Specific activation of the σ<sub>1</sub> receptor (<i>e.g.</i>, agonist binding) induces its dissociation from BiP, leading to receptor translocation to different organelle membranes, including endoplasmic reticulum membranes, nuclear membranes, mitochondrial membranes, plasma membranes, cytosolic vesicles, and even the extracellular space.<a onclick="showRef(event, 'ref1 ref17'); return false;" href="javascript:void(0);" class="ref ref1 ref17">(1,17)</a> Current research suggests an absence of an intrinsic system for signal transduction upon σ<sub>1</sub> receptor activation. Alternatively, σ<sub>1</sub> receptor activation is generally believed to modulate an array of targets, including receptors, ion channels, lipids, kinases, and other signaling proteins primarily via translocation and protein–protein interactions. These interactions then modulate or fine-tune the partner protein’s associated cellular second messenger systems commonly involved in intracellular calcium signaling and inositol triphosphate (IP3) turnover. There are at least 49 proteins with high divergence in sequence and structure (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), which have been reported to interact with the σ<sub>1</sub> receptor.<a onclick="showRef(event, 'ref12 ref21'); return false;" href="javascript:void(0);" class="ref ref12 ref21">(12,21)</a> Because of the promiscuous nature of its effects on consensus downstream signaling pathways, the σ<sub>1</sub> receptor has unsurprisingly been shown to play a role in maintaining the balance of glutamatergic, cholinergic, dopaminergic, serotoninergic, norepinephrinergic, and GABAergic systems in the brain.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> However, the exact characteristics and extent of σ<sub>1</sub> receptor interactions and influence in each pathway remain to be elucidated.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic summary of the functions and protein interactions of sigma-1 as a receptor chaperone in physiological and pathophysiological conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The σ<sub>1</sub> receptor is widely distributed throughout the brain with the highest densities found in the dentate gyrus of the hippocampus, facial nucleus, thalamic, and hypothalamic nuclei, and moderate densities in the striatum, cerebellum, dorsal raphe nucleus (DRN), and locus coeruleus.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> Thus, drug discovery campaigns should thoroughly interrogate neural circuit-specific biological effects and work to ensure CNS penetrability and sufficient target exposure. Current studies on the σ<sub>1</sub> receptor provide a rationale that selective modulation may alleviate or improve a variety of neurological and neuropsychiatric diseases including neurodegenerative disorders, stroke, depression, pain, seizure, and schizophrenia.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.1.  Neurodegenerative Disorders</h3><div class="NLM_p">Alterations in the function of σ<sub>1</sub> receptors have been associated with observed neurodegenerative disease pathologies, attracting attention to this target for the treatment of neurodegenerative diseases including AD, Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Broadly, σ<sub>1</sub> receptor dysfunction may worsen the progression of neurodegenerative diseases, while σ<sub>1</sub> receptor activation elicits potent neuroprotective effects, promotes neuronal survival, and restores neuronal plasticity to slow disease progression via mechanisms including the modulation of calcium homeostasis and glutamate activities, attenuation of oxidative and nitrosative stress, maintenance of ER and mitochondrial integrity, and attenuation of inflammation.<a onclick="showRef(event, 'ref21 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref21 ref29 ref30 ref31 ref32">(21,29−32)</a></div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7">3.1.1.  Alzheimer’s Disease</h4><div class="NLM_p">Amyloid beta peptide (Aβ) is generated intracellularly at the MAM domain and may influence the function of the ER, mitochondria, and MAM, where the σ<sub>1</sub> receptor is densely located, suggesting a possible correlation between the σ<sub>1</sub> receptor and the pathogenesis of AD.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Certain genetic interactions between the σ<sub>1</sub> receptor and apolipoprotein E (APOE), a commonly recognized genetic risk factor of late-onset AD, were found to synergistically influence AD severity across multiple populations.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Notably, <i>in vivo</i> brain imaging studies with [<sup>11</sup>C]SA4503 have revealed a reduced density of σ<sub>1</sub> receptor in the frontal, temporal, and occipital lobes, cerebellum, and thalamus of early stage AD patients.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Consistent with this observation, σ<sub>1</sub> receptor knockdown destabilizes neuronal mushroom spines whose loss may underlie memory defects in animal models of AD.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Moreover, both pharmacological inactivation of the σ<sub>1</sub> receptor with the antagonist NE-100 and knockout of the σ<sub>1</sub> receptor facilitate amyloid (Aβ<sub>25–35</sub>) toxicity, thereby inducing learning impairment, oxidative stress, and BDNF alteration in AD animal models.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> These results suggest a role for the σ<sub>1</sub> receptor in AD pathology and as a potential disease-modifying drug target.</div><div class="NLM_p">In preclinical studies, treatment with σ<sub>1</sub> receptor agonists (<i>e.g.</i>, igmesine, pridopidine, AF710B, ANAVEX2-73, PRE-084) and positive allosteric modulators (<i>e.g.</i>, OZP002) has resulted in increased cognition, memory improvement, antiamnesic effects, neuroprotection, and antidepressant-like effects. The underling mechanisms may include the modulation of glutamate release and calcium homeostasis, as well as the functional modulation of potassium channels and NMDA, neuroplasticity, and the reduction of oxidative stress.<a onclick="showRef(event, 'ref1 ref21 ref28 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref1 ref21 ref28 ref38 ref39">(1,21,28,38,39)</a> The potential therapeutic effects of σ<sub>1</sub> receptor agonists or positive modulators in AD are further supported by studies in which direct activation of σ<sub>1</sub> receptors produced alterations in NMDA receptor expression, increased synaptic transmission, and plasticity of NMDA receptor via small-conductance calcium-activated K<sup>+</sup> (SK) channels<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and potentiated NMDA-induced neuronal firing in the CA3 region of the hippocampus.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Additionally, van Waarde <i>et al</i>.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> summarized the effects of several σ<sub>1</sub> receptor agonists on cognitive performance in various animal models, including cholinergic deficits, Aβ<sub>25–35</sub> peptide induced pathology, aging-induced memory loss, drug-induced glutamatergic, serotonergic, or calcium channel deficits and neurodegeneration caused by neurotoxicity, in which applications of σ<sub>1</sub> receptor selective antagonists (<i>e.g.</i>, BD-1047, NE-100) blocked the effect, suggesting σ<sub>1</sub> receptor-dependent activity.<a onclick="showRef(event, 'ref21 ref29'); return false;" href="javascript:void(0);" class="ref ref21 ref29">(21,29)</a></div><div class="NLM_p last">Furthermore, the σ<sub>1</sub> receptor functionally interacts with presenilin 1 (PS1) and presenilin 2 (PS2), which are implicated in the pathological process of AD. Knockout of PS1, PS2, or PS1/2 in hippocampal neurons results in mushroom spine aberrations, which may disrupt tonic Ca<sup>2+</sup> release from the ER and detrimentally increase the concentration of calcium in the ER.<a onclick="showRef(event, 'ref36 ref42'); return false;" href="javascript:void(0);" class="ref ref36 ref42">(36,42)</a> Similarly, inactivation of PS1, PS2, or PS1/2 in the mouse forebrain impacts cognition and synaptic plasticity.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Instead, σ<sub>1</sub> receptor agonists (<i>e.g.</i>, AF710B, pridopidine) decrease ER calcium in hippocampal neurons by enhancing ER calcium leakage in the ER membrane, thereby reducing the potentially pathological accumulation and aggregation of Aβ<sub>42</sub>.<a onclick="showRef(event, 'ref36 ref44'); return false;" href="javascript:void(0);" class="ref ref36 ref44">(36,44)</a></div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">3.1.2.  Parkinson’s Disease</h4><div class="NLM_p">The σ<sub>1</sub> receptor is expressed in both astrocytes and dopaminergic neurons of the substantia nigra and striatum.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Positron emission tomography (PET) studies have demonstrated that expression of the σ<sub>1</sub> receptor was decreased in the brains of early stage PD patients.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><i>Sigma-1</i> KO mice experienced an increase in age-related loss of dopaminergic neurons and deficits in motor coordination while also displaying increased aggregation and phosphorylation of α-synuclein (αSyn).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Moreover, <i>sigma-1</i> knockdown Chinese hamster ovary (CHO) cells were sensitized to apoptosis induced by dopamine at physiological concentrations (lower than 10 μM) that was likely attributed to the activation of NF-κB and subsequent downregulation of Bcl-2.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The σ<sub>1</sub> receptor also has been implicated in the regulation of neuroinflammation. It was shown that activation of σ<sub>1</sub> receptor inhibited microglia-mediated neuroinflammation and protected dopaminergic neurons.<a onclick="showRef(event, 'ref32 ref49'); return false;" href="javascript:void(0);" class="ref ref32 ref49">(32,49)</a> These findings indicate that the σ<sub>1</sub> receptor may play a role in the pathological development of PD.</div><div class="NLM_p last">σ<sub>1</sub> receptor agonists were found to modulate dopaminergic neurotransmission. Activation of the σ<sub>1</sub> receptor by cocaine inhibits D<sub>2</sub> receptor-mediated signaling via σ<sub>1</sub>–D<sub>2</sub> receptor heteromers,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> whereas it disrupts the H<sub>3</sub> receptor-mediated brake on D<sub>1</sub> receptor signaling via σ<sub>1</sub>–D<sub>1</sub>–H<sub>3</sub> receptor complexes.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> A recent study illustrated that σ<sub>1</sub> receptor agonists were characterized as neuroprotective and neurorestorative due to the activation of endogenous defense and plasticity mechanisms in PD models.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Dosing of the σ<sub>1</sub> receptor agonist PRE084 at 0.3 mg/kg/day in a preclinical chronic dosing paradigm was shown to produce both histological and behavioral improvements in the 6-hydroxydopamine (6-OHDA)-lesioned PD model, including a modest recovery of dopamine levels, increased dopaminergic fiber densities, the upregulation of multiple neurotrophic factors [brain derived neurotrophic factor (BDNF) and glial cell derived neurotrophic factor (GDNF)], and improvement in spontaneous forelimb use.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In the same study, it was found that PRE084 also significantly attenuated the number of CD68-positive microglia and macrophages induced by 6-OHDA lesions.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In another preclinical model, chronic application of PRE084 to an inducible dicer conditional KO mouse model of PD attenuated the development of motor impairments and dopaminergic neuron death.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Thus, the targeting of σ<sub>1</sub> receptors with selective chemical probes may further illuminate the complex network of dopaminergic and neuroinflammatory factors underlying PD, potentially leading to therapeutic development.</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">3.1.3.  Amyotrophic Lateral Sclerosis (ALS)</h4><div class="NLM_p">In the CNS, one location where σ<sub>1</sub> receptors are enriched is in the brain and spinal cord motor neurons (MNs). Dysfunctional σ<sub>1</sub> receptors have been shown to exacerbate the pathological development of ALS.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Key mutations in the σ<sub>1</sub> receptor have been found in patients with frontotemporal lobar degeneration (FTLD)-ALS<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and consanguineous family segregating juvenile ALS,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and the overall expression levels of the σ<sub>1</sub> receptor was found to be significantly decreased in the lumbar spinal cord of ALS patients.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> σ<sub>1</sub> receptor KO mice also showed locomotor deficits which may be associated with the reduced contacts between mitochondria and ER, ER stress, and calcium dysregulation, which may result in muscle weakness, axonal degeneration, and motor neuron loss.<a onclick="showRef(event, 'ref4 ref52'); return false;" href="javascript:void(0);" class="ref ref4 ref52">(4,52)</a> Moreover, the MNs of σ<sub>1</sub> receptor KO mice showed an increase in firing frequency and a decrease in neuronal longevity in the SOD1G93A mouse model of ALS.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> shRNA knockdown of σ<sub>1</sub> receptor in a MN-like cell line (NSC34) led to aberrant ER and Golgi structural integrity and abnormal calcium signaling.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Collectively, these findings support a role for the σ<sub>1</sub> receptor in the pathogenesis of ALS or in the severity of ALS symptoms.</div><div class="NLM_p">Activation of σ<sub>1</sub> receptors ameliorates protein aggregation, increases availability of neuronal growth factors, and protects MNs, thereby slowing disease progression in animal models of ALS.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In 2009, it was reported that administration of PRE084 protected spinal cord neurons against glutamate excitotoxicity while it also promoted elongation of neurites in MNs through protein kinase C (PKC) activity in an <i>in vitro</i> organotypic model of excitotoxic lesion.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> It was later found that PRE084 can increase the expression of GDNF and the σ<sub>1</sub> receptor cochaperone BiP and promote MNs survival after spinal root avulsion injury in rats.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Navarro <i>et al</i>.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> additionally confirmed the potential therapeutic effect of PRE084 in an ALS mouse model. They found that daily treatment of PRE084 (0.25 mg/kg, ip) from 8 weeks of age significantly improved spinal MN function (<i>e.g.</i>, improvement of locomotor performance, preservation of muscle strength, and reduction of signs of paralysis) and the maintenance of both neuromuscular connections and MNs in the spinal cord.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Delayed treatment with PRE084 from 12 weeks of age also significantly improved spinal MN function, locomotion capacity, and overall survival.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Importantly, these effects by PRE084 were attributable to σ<sub>1</sub> receptor activation due to the parallel administration of the selective σ<sub>1</sub> receptor antagonist BD1036, which blocked all beneficial effects in the treatment cohort.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Additionally, chronic administration of PRE084 reduced microglial immunoreactivity within the MN environment in the ventral spinal cord. PRE084 may also indirectly modulate NMDA-dependent Ca<sup>2+</sup> influx and microglial activation, whereby it is able to significantly slow down the degenerative process of ALS symptoms in the SOD1<sup>G93A</sup> mouse model of ALS.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The potential therapeutic effect of PRE084 was further confirmed by employing another model of spontaneous MN degeneration, not linked to SOD1 mutation,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> in which chronic administration of PRE084 (0.25 mg/kg, ip) for 8 weeks significantly increased the levels of BDNF in the gray matter and improved MN survival and locomotor performances in wobbler mice.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p last">Collectively, σ<sub>1</sub> receptor ligands may serve as promising disease-modifying agents or part of a multitherapeutic approach in the treatment for neurodegenerative diseases.</div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.2.  Stroke</h3><div class="NLM_p">Increased σ<sub>1</sub> receptor expression was observed in penumbra neurons following acute stroke.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Following an ischemic stroke, excess glutamate is released, resulting in overactivation of NMDARs, and consequently, leads to calcium overload inside affected neurons. Overloading calcium alters multiple downstream pro-cell death signaling pathways such as the production of reactive oxygen species (ROS) and mitochondrial damage, resulting in excitotoxic neural damage.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> It is interesting to note that both selective and nonselective σ<sub>1</sub> receptor agonists have been shown to decrease glutamate release and block intracellular calcium overload following ischemia <i>in vitro</i>.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> Numerous studies have also confirmed the acute benefits of σ<sub>1</sub> receptor agonists in multiple animal models of stroke.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Treatment with σ<sub>1</sub> receptor agonists (<i>e.g.</i>, DTG) at 24 h after onset of ischemia can reduce infarct volume and increase neuronal survival in rat models of stroke.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a></div><div class="NLM_p last">Modulation of neuroinflammation after stroke is another potential therapeutic intervention for cerebral ischemia.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Activation of the σ<sub>1</sub> receptor by selective agonists or positive allosteric modulators was shown to inhibit microglia-mediated neuroinflammation and elicit neuroprotection <i>in vitro</i>.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> σ<sub>1</sub> receptor ligands also exert neuroprotective effects against cerebral ischemia. Administration of σ<sub>1</sub> receptor agonists after embolic stroke in rats enhanced neuronal survival and attenuated radical species production,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> while another study showed increased levels of anti-inflammatory cytokines and decreased pro-inflammatory cytokines.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Moreover, σ<sub>1</sub> receptor activation was shown to modulate brain plasticity and facilitate functional recovery after stroke by enhancing cellular transport of biomolecules required for brain tissue repair.<a onclick="showRef(event, 'ref67 ref69'); return false;" href="javascript:void(0);" class="ref ref67 ref69">(67,69)</a> Interestingly, one study also reported that the σ<sub>1</sub> receptor antagonist S1RA reduced stroke damage, highlighting the nuanced nature of σ<sub>1</sub> receptor functionality.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Hence, modulation of the σ<sub>1</sub> receptor holds promising potential for clinical application as a therapeutic agent for ischemic stroke.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.3.  Depression</h3><div class="NLM_p">Many marketed antidepressants, including fluoxetine, sertraline, fluvoxamine, imipramine, and amitriptyline, exhibit a high-to-moderate σ<sub>1</sub> receptor affinity with <i>K</i><sub>i</sub> values ranging from 20 to 400 nM (more details in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), although their initial mechanism of antidepression was attributed to either serotonin reuptake inhibition or noradrenaline-reuptake inhibition.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> It was found that the acute antidepressant effects of fluvoxamine can be blocked by σ<sub>1</sub> receptor antagonist BD1047,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> whereas chronic treatment with antidepressants, including sertraline, citalopram, or paroxetine, can regulate σ<sub>1</sub> receptor expression and functional sensitization.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Furthermore, σ<sub>1</sub> receptor KO mice exhibit a depressive-like phenotype with increased immobility in the forced swimming test.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> σ<sub>1</sub> receptor ligands have also been shown to modulate glutamatergic and serotonergic neuronal activity, leading to antidepressant-like effects. As mentioned earlier, PRE084 showed antidepressant efficacy in AD-relevant models of amnesia. Consistent with that, PRE084 exhibited an antidepressant-like effect in a forced swim test (FST) paradigm in both Albino Swiss and C57BL/6J mice.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Importantly, the antidepressant effect of PRE084 could be counteracted by a σ<sub>1</sub> receptor antagonist BD1047, but not by a σ<sub>2</sub> receptor antagonist SM-21.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The selective σ<sub>1</sub> receptor agonist SA4503<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> also produces antidepressant-like effects (<i>e.g.</i>, agitation, loss of interest, and impaired cognition) in the olfactory bulbectomized (OB) rat model of depression, which may be associated with σ<sub>1</sub> receptor-dependent changes in the expression and function of NMDA receptors. Additionally, the σ<sub>1</sub> receptor plays an important role in regulating the production and function of BDNF, thereby leading to glutamate release and sustaining antidepressant action.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> In addition to σ<sub>1</sub> receptor agonists, allosteric modulators also exhibit promising, fast-acting antidepressant-like effects, attributed to the stimulation of BDNF production (see more details in <a class="ref internalNav" href="#sec5_2" aria-label="section 5.2">section 5.2</a>).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Collectively, these findings suggest that the σ<sub>1</sub> receptor may serve as a target for the discovery development of novel antidepressant drugs.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Therapeutic Drugs with High Affinity for Sigma-1 Receptor</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0020.gif" alt="" id="GRAPHIC-d7e1159-autogenerated" /></img><div></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.4.  Pain</h3><div class="NLM_p">σ<sub>1</sub> receptors are expressed in pain-modulating tissues and brain regions including the dorsal spinal cord, dorsal root ganglion neurons, the periaqueductal gray matter, rostroventral medulla, and locus coeruleus.<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a> The expression of σ<sub>1</sub> receptors in the spinal cord was found to be upregulated during the induction phase of neuropathic pain in animal models.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> Moreover, knockout of σ<sub>1</sub> receptors in mice resulted in an increased mechanical antinociception response to morphine.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Collectively, these studies indicate that the σ<sub>1</sub> receptor may be involved in the modulation of diverse pain mechanisms.</div><div class="NLM_p">Although the σ<sub>1</sub> receptor lacks a specified signaling cascade, as a molecular chaperone it can influence the functionality of multiple ion channels and receptors involved in the transmission and amplification of nociceptive signals. The ion channel partners of the σ<sub>1</sub> receptor involved in nociception include voltage-gated sodium channels (<i>e.g.</i>, Na<sub>v</sub>1.2, Na<sub>v</sub>1.4, Na<sub>v</sub>1.5, Na<sub>v</sub>1.8), acid-sensing ion channels, voltage-gated potassium channels (<i>e.g.</i>, K<sub>v</sub>1.2), calcium-activated potassium channels (<i>e.g.</i>, SK), voltage-gated calcium channels, and ligand-gated calcium channels (NMDAR).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> For example, direct activation of spinal cord σ<sub>1</sub> receptors potentiates NMDA-evoked spontaneous pain behavior and produces pronociceptive actions under certain altered and pathological conditions.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The GPCR partners of the σ<sub>1</sub> receptor implicated in nociception include cannabinoid CB1 and μ-opioid (MOR) receptors. A physical interaction between MOR and the σ<sub>1</sub> receptor was demonstrated by coimmunoprecipitation experiments in transfected HEK cells. Antagonism of the σ<sub>1</sub> receptor (<i>e.g.</i>, haloperidol, E-52862) increases opioid receptor signaling and decreases the responsiveness of NMDA receptors, leading to enhanced opioid antinociception and decreased sensory hypersensitivity. σ<sub>1</sub> receptor antagonists alone (see more details in S1RA Analogues of <a class="ref internalNav" href="#sec5_1_2" aria-label="section 5.1.2">section 5.1.2</a>) have been shown to exert antinociceptive effects in preclinical models of inflammatory pain, ischemic pain, and neuropathic pain induced by nerve trauma or chemical injury (<i>e.g.</i>, the antineoplastic paclitaxel).<a onclick="showRef(event, 'ref84 ref86'); return false;" href="javascript:void(0);" class="ref ref84 ref86">(84,86)</a></div><div class="NLM_p">Notably, unlike opioids, σ<sub>1</sub> receptor antagonists do not effect normal sensory mechanical and thermal sensitivity thresholds, but they exert antihypersensitive effects in sensitizing conditions and restore nociceptive thresholds back to normal values.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Thus, σ<sub>1</sub> receptor antagonists are not classical analgesics rather acting as antiallodynic and antihyperalgesic drugs when the system is sensitized following prolonged noxious stimulation or persistent abnormal afferent input (<i>e.g.</i>, secondary to nerve injury). Additionally, it has been suggested that σ<sub>1</sub> receptor antagonists can be used as an add-on therapy to an opioid regimen to potentiate opioid analgesia and lower the doses of opioids without enhancing opioid-induced adverse effects including tolerance, dependence, or constipation.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Thus, σ<sub>1</sub> receptor antagonists may increase the therapeutic index of opioids for pain treatment.</div><div class="NLM_p last">Taken together, σ<sub>1</sub> receptor antagonists may represent a promising strategy for the management of various pain conditions including neuropathic, inflammatory, orofacial, visceral, and postoperative pain either as monotherapy or opioid adjuvant therapy.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">4.  Clinical Development on Selective Sigma-1 Receptor Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22358" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22358" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because of its uniquely promiscuous binding to numerous pharmacological agents, many clinically used CNS-targeted drugs have moderate to high affinity toward the σ<sub>1</sub> receptor, including antipsychotics such as haloperidol that act as a σ<sub>1</sub> receptor antagonist, and antidepressants (<i>e.g.</i>, fluvoxamine, sertraline, fluoxetine, imipramine), analgesics (<i>e.g.</i>, pentazocine), antitussive (<i>e.g.</i> carbetapentane), and anti-Alzheimer’s drugs (<i>e.g.</i>, donepezil), which all act as σ<sub>1</sub> receptor agonists. Nevertheless, none of them shows σ<sub>1</sub> receptor selectivity over their primary therapeutic targets (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Although the exact therapeutic contribution or extent of contribution of σ<sub>1</sub> receptor binding for these drugs remains to be unraveled, available data suggests that their clinical efficacy is partly ascribed to σ<sub>1</sub> receptor modulation. Therefore, there are no drugs selectively targeting σ<sub>1</sub> receptors yet on the market. Several σ<sub>1</sub> receptor ligands, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, have successfully entered into later phase clinical studies for many therapeutic areas, especially for neurodegenerative disorders, stroke, and pain, which may further validate the σ<sub>1</sub> receptor as a molecular target for the treatment of various human conditions.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Selective sigma-1 receptor ligands in human clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Sigma-1 Selective Ligands in Human Clinical Trials</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">highest clinic trial</th><th class="colsep0 rowsep0" align="center">conditions</th><th class="colsep0 rowsep0" align="center">NCT no.</th><th class="colsep0 rowsep0" align="center">study start</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Pridopidine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 3</td><td class="colsep0 rowsep0" align="left">early Huntington disease</td><td class="colsep0 rowsep0" align="left">NCT04556656</td><td class="colsep0 rowsep0" align="center">2020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">        </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2</td><td class="colsep0 rowsep0" align="left">levodopa-induced</td><td class="colsep0 rowsep0" align="left">NCT03922711</td><td class="colsep0 rowsep0" align="center">2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left">dyskinesia</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">        </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2/3</td><td class="colsep0 rowsep0" align="left">Huntington’s disease</td><td class="colsep0 rowsep0" align="left">NCT00724048</td><td class="colsep0 rowsep0" align="center">2008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">        </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 3</td><td class="colsep0 rowsep0" align="left">Huntington’s disease</td><td class="colsep0 rowsep0" align="left">NCT00665223</td><td class="colsep0 rowsep0" align="center">2008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">ANAVEX2-73 (Blarcamesine, AVex-73, AE-37)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2b/3</td><td class="colsep0 rowsep0" align="left">early Alzheimer’s disease</td><td class="colsep0 rowsep0" align="left">NCT04314934</td><td class="colsep0 rowsep0" align="center">2020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT03790709</td><td class="colsep0 rowsep0" align="center">2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">        </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2/3</td><td class="colsep0 rowsep0" align="left">pediatric patients with Rett syndrome</td><td class="colsep0 rowsep0" align="left">NCT04304482</td><td class="colsep0 rowsep0" align="center">2020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">        </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2</td><td class="colsep0 rowsep0" align="left">Rett syndrome</td><td class="colsep0 rowsep0" align="left">NCT03941444</td><td class="colsep0 rowsep0" align="center">2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT03758924</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">        </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2</td><td class="colsep0 rowsep0" align="left">Parkinson’s disease with dementia</td><td class="colsep0 rowsep0" align="left">NCT03774459</td><td class="colsep0 rowsep0" align="center">2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">        </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2</td><td class="colsep0 rowsep0" align="left">mild to moderate Alzheimer’s disease</td><td class="colsep0 rowsep0" align="left">NCT02756858</td><td class="colsep0 rowsep0" align="center">2016</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">active</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">        </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2a</td><td class="colsep0 rowsep0" align="left">Alzheimer’s disease</td><td class="colsep0 rowsep0" align="left">NCT02244541</td><td class="colsep0 rowsep0" align="center">2014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">SA4503 (Cutamesine, AGY94806)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2</td><td class="colsep0 rowsep0" align="left">major depressive disorder</td><td class="colsep0 rowsep0" align="left">NCT00551109</td><td class="colsep0 rowsep0" align="center">2007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">ischemic stroke</td><td class="colsep0 rowsep0" align="left">NCT00639249</td><td class="colsep0 rowsep0" align="center">2008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">S1RA (E-52862, MR309)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2a</td><td class="colsep0 rowsep0" align="left">oxaliplatin-induced neuropathic pain<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">2014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">T-817MA (Edonerpic Maleate)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2</td><td class="colsep0 rowsep0" align="left">mild to moderate Alzheimer’s disease</td><td class="colsep0 rowsep0" align="left">NCT02079909</td><td class="colsep0 rowsep0" align="center">2014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT00663936</td><td class="colsep0 rowsep0" align="center">2008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">        </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 2</td><td class="colsep0 rowsep0" align="left">mild cognitive impairment</td><td class="colsep0 rowsep0" align="left">NCT04191486</td><td class="colsep0 rowsep0" align="center">2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recruiting</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div></div><div class="NLM_p">Pridopidine (ACR16), developed by Neurosearch, is a selective σ<sub>1</sub> receptor ligand (<i>K</i><sub>i</sub> = 81.7 nM) and D<sub>2</sub> stabilizer (<i>K</i><sub>i</sub><sub>(D2 (low))</sub> = 17.5 μM; <i>K</i><sub>i</sub><sub>(D2 (high))</sub> = 7.5 μM) aimed at alleviating motor impairments and increasing neuron survival through the alteration dopaminergic transmission and modulation of the σ<sub>1</sub> receptor. In 2008, pridopidine advanced into a phase 3 clinical trial (NCT00724048 and NCT00665223) for the symptomatic treatment of Huntington’s disease (HD), but no significant effect was observed in the improvement of voluntary motor function in HD patients.<a onclick="showRef(event, 'ref63 ref90'); return false;" href="javascript:void(0);" class="ref ref63 ref90">(63,90)</a> Later, pridopidine was found not to improve motor impairment at 26 weeks compared with placebo in a randomized, multicenter, dose-ranging phase 2 study in adults (aged ≥21 years) with Huntington’s disease (NCT02006472), with indications of a potentially strong placebo effect.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Recently, pridopidine was investigated in a phase 2 clinical trial (NCT03922711) for the treatment of levodopa-induced dyskinesia in PD patients and a phase 3 clinical trial (NCT04556656) for early stage HD. Additionally, pridopidine was shown to improve fundamental ALS-linked pathologies including reducing mutant SOD1 aggregations in the spinal cord and attenuating neuromuscular junction disruption as well as subsequent muscle wasting in a SOD1<sup>G93A</sup> animal model through σ<sub>1</sub> receptor agonism.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><div class="NLM_p">ANAVEX2-73 (aka blarcamesine, AVex-73, AE-37), developed by Anavex Life Sciences, is a σ<sub>1</sub> receptor agonist (IC<sub>50</sub> = 0.86 μM) and muscarinic receptor modulator with moderate affinity (M<sub>1</sub>–M<sub>4</sub>: IC<sub>50</sub> = 3.3–5.2 μM).<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Chronic dosing of the drug showed marked <i>in vivo</i> neuroprotective activity in AD models.<a onclick="showRef(event, 'ref3 ref94'); return false;" href="javascript:void(0);" class="ref ref3 ref94">(3,94)</a> The drug also reversed learning deficits in Aβ<sub>25–35</sub> injected mice by blockade of Tau hyperphosphorylation and Aβ<sub>1–42</sub> generation.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> In 2014, a phase 1/2 clinical study demonstrated good safety, bioavailability, and tolerability in patients with Alzheimer’s disease (NCT02244541). Phase 2/3 clinical studies in patients with mild to moderate or early Alzheimer’s disease are ongoing (NCT02756858, NCT03790709, and NCT04314934). Additionally, a phase 2 study is ongoing to evaluate its efficacy for cognitive impairment in patients with PD with dementia (PDD) (NCT03774459). Currently, an endeavor is underway to increase clinical indications for ANAVEX2-73 use in Rett syndrome (RTT) and phase 2 studies in patients of 18 years and older with RTT patients for safety, tolerability, and efficacy evaluation (NCT03941444 and NCT03758924) are recruiting patients. In addition, a phase 2/3 study in patients of 5–18 years of age with RTT is also in recruiting (NCT04304482). Preclinically, ANAVEX2-73 was found to positively regulate autophagy, increase proteostasis capacity, and improve protein aggregation-mediated paralysis in <i>Caenorhabditis elegans</i>, indicating the σ<sub>1</sub> receptor is a novel autophagy modulator that may direct drug development in conditions ranging from neurodegeneration to dysfunctional autophagy associated disorders.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">SA4503 (aka Cutamesine, AGY94806) is an orally available, potent, and selective σ<sub>1</sub> receptor agonist with an IC<sub>50</sub> value of 17 nM, 105-fold selectivity over the σ<sub>2</sub> receptor (IC<sub>50</sub> = 1800 nM), and very low or no affinity toward 36 other receptors, ion channels, and second messenger systems.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> SA4503 not only decreased the immobility time in the forced swimming test in rats<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> but also ameliorated the depression-like behavioral deficits (<i>e.g.</i>, agitation, loss of interest, and impaired cognition) in the olfactory bulbectomized (OB) rat and calcium/calmodulin-dependent protein kinase IV (CaMKIV) null mice.<a onclick="showRef(event, 'ref76 ref97'); return false;" href="javascript:void(0);" class="ref ref76 ref97">(76,97)</a> In 2008, a phase 2 study of SA4503, given once daily for 8 weeks, was thus initiated to determine safety and efficacy in 150 subjects with major depressive disorder (NCT00551109). However, the trial data and outcome summaries have yet to be disclosed. In preclinical studies, SA4503 can enhance functional recovery after experimental stroke with a dose administration window of up to 48 h post stroke followed by chronic treatment for 28 days. An ascending dose, phase 2a study of SA4503 was thus conducted to evaluate its safety and motor function restoration after acute ischemic stroke and began with 60 patients in 2008 (NCT00639249). Although SA4503 was safe and well tolerated at a high dosage level, no significant improvement was observed in functional end points. Additional studies warrant further investigation on moderate-to-severe stroke patients.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Recently, SA4503 was found efficacious in suppressing motor neuron degeneration and symptom progression in <i>in vitro</i> and <i>in vivo</i> amyotrophic lateral sclerosis models.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Moreover, it was found to reverse axonal development and rescue dendritic spine abnormalities as well as cognitive dysfunction in an <i>in vivo</i> α-thalassemia X-linked intellectual disability (ATR-X) syndrome models.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><div class="NLM_p">S1RA (MR309; E-52862), developed by Esteve Research and Development, is the only highly potent and selective σ<sub>1</sub> receptor antagonist to progress to clinic stages. It has low nanomolar σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 17 nM)<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> and moderate affinity for the human 5-HT<sub>2B</sub> receptor (<i>K</i><sub>i</sub> = 328 nM) but with low antagonistic activity (IC<sub>50</sub> = 4700 nM). Moreover, it shows high σ<sub>1</sub> receptor selectivity over guinea pig and rat σ<sub>2</sub> receptor (<i>K</i><sub>i</sub> > 1000 nM) and a panel of 170 additional targets (<i>K</i><sub>i</sub> > 1 μM or % inhibition <50% at 1 μM) including receptors, transporters, ion channels, and enzymes.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Preclinical studies reported that S1RA inhibited neuropathic pain, inflammatory hyperalgesia, activity-induced spinal sensitization, and paclitaxel-induced sensory-nerve mitochondrial abnormalities.<a onclick="showRef(event, 'ref5 ref87 ref102 ref103 ref104 ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref5 ref87 ref102 ref103 ref104 ref105 ref106">(5,87,102−106)</a> S1RA displayed good safety, tolerability, and pharmacokinetic properties in phase I clinical studies with 175 healthy subjects.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Thus, a phase 2a clinical trial of S1RA in European patients (aged 18–80 years) receiving oxaliplatin (OXA) for colorectal cancer treatment was initiated. This trial was designed to assess neuroprotective efficacy in ameliorating OXA-induced peripheral neuropathy (OXAIPN), which was the most prominent toxicity both during and after the completion of chemotherapy, compromising therapeutic outcomes and patients’ functional capacity and quality of life.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> S1RA showed a potential neuroprotective role in reducing acute OXAIPN (cold pain and motor symptoms) and was well tolerated with high oxaliplatin exposure and chronic cumulative OXAIPN.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Finally, in an animal model of focal cerebral ischemia, it was shown that S1RA reduces stroke damage, ameliorates poststroke neurological deficits, and significantly decreases the overexpression of matrix metalloproteinase-9 (MMP-9) and reactive astrogliosis surrounding the infarcted cortex, suggesting that it may hold promising therapeutic potential for treatment of ischemic stroke.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><div class="NLM_p">T-817MA (Edonerpic maleate) is an orally available neurotropic agent developed by Toyama Chemical Co.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> It attenuates amyloid-β-induced neurotoxicity and memory deficits as well as motor impairment, promotes neurite outgrowth, and preserves hippocampal synapses and spatial memory in tau transgenic mice.<a onclick="showRef(event, 'ref109 ref110 ref111 ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref109 ref110 ref111 ref112 ref113">(109−113)</a> However, the molecular mechanisms underlying these effects are not fully understood. These effects may be mediated via σ<sub>1</sub> receptor activation, interaction with collapsin-response-mediator-protein 2 (CRMP2), delivery of synaptic glutamate AMPA receptors, or modulation of microglial function.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Of note, it shows the highest binding to the σ<sub>1</sub> receptor among other CNS receptors, with a <i>K</i><sub>i</sub> value of 16 nM.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> It has advanced into phase 2 clinic trials in patients with mild to moderate Alzheimer’s disease (NCT02079909 and NCT00663936). However, the clinical outcome of phase 2 trials demonstrated that T-817MA at maximal doses showed no efficacy in patients with mild to moderate Alzheimer disease but exhibited gastrointestinal adverse effects (diarrhea and vomiting).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Currently, a phase 2 study of T-817MA is ongoing to evaluate its neuroprotective effect on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) of patients diagnosed with mild cognitive impairment due to AD or mild AD (NCT04191486).</div><div class="NLM_p last">Overall, the clinical fate of σ<sub>1</sub> selective ligands pridopidine, ANAVEX2-73 and T-817MA, remains uncertain, and the development of SA4503 and S1RA appears to have halted following missed end points. Thus, it is imperative to develop σ<sub>1</sub> receptor selective ligands or modulators as pharmacological probes for unraveling the complex nature of the σ<sub>1</sub> receptor’s functionality, signaling pathways, and ability to function as a disease modifying target. When surveying other treatment modalities and targets, lessons in patient selection and disease stage qualifications taken from recent clinical trials in AD and other neurological diseases should guide future clinical development attempts.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">5.  Small Molecules Selectively Targeting Sigma-1 Receptor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08810" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08810" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As mentioned earlier, because the identification of the native endogenous ligand of the σ<sub>1</sub> receptor is inconclusive so far, the function of small molecules selectively targeting σ<sub>1</sub> receptor (agonist vs antagonist, positive vs negative allosteric modulator) is defined based on the <i>in vitro</i> or <i>in vivo</i> pharmacological effects compared to the phenotype of σ<sub>1</sub> receptor KO animals or that of the consensus tool compounds. Generally, activation of the σ<sub>1</sub> receptor engenders beneficial effects in stroke,<a onclick="showRef(event, 'ref69 ref70 ref80 ref98'); return false;" href="javascript:void(0);" class="ref ref69 ref70 ref80 ref98">(69,70,80,98)</a> depression and anxiety disorders,<a onclick="showRef(event, 'ref39 ref71 ref78'); return false;" href="javascript:void(0);" class="ref ref39 ref71 ref78">(39,71,78)</a> and neurodegenerative disorders including AD, ALS, and PD,<a onclick="showRef(event, 'ref30 ref31 ref59'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref59">(30,31,59)</a> while blocking the σ<sub>1</sub> receptor may be useful to treat pain and substance abuse.<a onclick="showRef(event, 'ref81 ref89'); return false;" href="javascript:void(0);" class="ref ref81 ref89">(81,89)</a> Given the fundamental role of the receptor in neurological diseases, many intensive efforts have been made to develop σ<sub>1</sub> receptor selective ligands or modulators. Herein, this review seeks to provide an update on research advances in the development of chemical entities as σ<sub>1</sub> receptor selective ligands since 2014 and σ<sub>1</sub> receptor allosteric modulators reported to date.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">5.1.  Small Molecules as Selective Sigma-1 Orthosteric Ligands</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">5.1.1.  Pharmacophore Models for Sigma-1 Receptor</h4><div class="NLM_p">Before the disclosure of the cocrystal structure, pharmacophore models based on the highly conserved orthosteric binding site represent valuable tools for describing certain structural features necessary for receptor binding. Several σ<sub>1</sub> receptor pharmacophore models have been developed for the identification of novel potent orthosteric ligands,<a onclick="showRef(event, 'ref117 ref118 ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref117 ref118 ref119 ref120">(117−120)</a> which also show a degree of commonality with σ<sub>2</sub> receptor pharmacophores.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> The first and most basic σ<sub>1</sub> receptor pharmacophore model was developed by Glennon and co-workers<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> in 1994 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) via investigation of the structure–affinity relationships (SARs) of <i>N</i>-substituted phenyl-2-aminopropanes binding at the proposed σ<sub>1</sub> receptor orthosteric site.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic presentation of the sigma-1 receptor pharmacophores (Glennon’s model).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In Glennon’s model, two hydrophobic binding pockets flank a basic amine moiety that acts as a proton donor site and represents the pharmacophoric elements presumed to be important for σ<sub>1</sub> receptor binding (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> An optimal distance for high σ<sub>1</sub> receptor binding affinity was defined in the range of 6–10 Å between the amine moiety and the primary hydrophobic pocket and 2.5–3.9 Å between the amine and the secondary hydrophobic pocket.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> The primary hydrophobic pocket of the σ<sub>1</sub> receptor accommodates diverse structural moieties, especially bulky aromatic groups, while the secondary hydrophobic pocket is slightly smaller than the primary hydrophobic pocket and tolerates less lipophilic substituents such as 1,3-dioxane<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> and tetrahydrofuran.<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a> Additionally, the amine could be of primary, secondary, or tertiary and cyclic or acyclic nature. Since then, many potent and selective σ<sub>1</sub> receptor ligands have been identified with similar structural features characterized by Glennon’s model.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">5.1.2.  Recent Selective Sigma-1 Receptor Orthosteric Ligands</h4><div class="NLM_p">Several diversified core scaffolds have been identified in σ<sub>1</sub> receptor ligands so far and there appears to be no generally accepted system for classification of such molecules. In 2015, Kassiou and co-workers<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> produced a valuable summary on the development of σ<sub>1</sub> receptor ligands up to the year 2014. Thus, this review relies on broad structural similarity and provides a summation of recent advances in σ<sub>1</sub> receptor orthosteric ligand discovery and development since 2014.</div><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20">5.1.2.1.  SA4503 Analogues</h5><div class="NLM_p">SA4503, a <i>N</i>,<i>N</i>′-disubstituted piperazine with two phenyl moieties separately occupying the two hydrophobic binding pockets in Glennon’s model, is one of the best known σ<sub>1</sub> receptor agonists and has advanced into phase 2 clinical trials for the treatment of major depressive disorder and ischemic stroke. SA4503 displays a 4.6 nM and a 63.09 nM binding affinity (<i>K</i><sub>i</sub>) for σ<sub>1</sub> and σ<sub>2</sub> receptor in guinea pig (gp) brain tissue, respectively.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> At least four groups have reinvestigated the σ receptor binding activity of SA4503 reporting slight differences in affinity and selectivity (<i>K</i><sub>i</sub>: σ1 = 3.3–4.6 nM; σ<sub>1/</sub> σ<sub>2</sub> = 13.7–55).<a onclick="showRef(event, 'ref95 ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref95 ref127 ref128 ref129">(95,127−129)</a> In 2015, Lever <i>et al</i>.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> prepared two series of SA4503 ether analogues (<b>1</b>–<b>5</b>) with different patterns and types of substituents on the phenethyl fragment (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). These compounds typically display a broad spectrum of pharmacological action with relatively high σ<sub>1</sub> receptor binding affinity and low selectivity over the σ<sub>2</sub> receptor, as well as moderate to low DAT and SERT affinity (<i>e.g.</i>, <b>1</b>–<b>5</b>), suggesting that these polyfunctional ligands may be developed as potential medications for treatment of psychostimulant abuse, depression, and anxiety.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Ether modifications of SA4503.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Owing to the flexible spacer between the nitrogen and two hydrophobic binding pockets of the σ<sub>1</sub> receptor, the ethyl and propyl linker of SA4503 can be shortened or lengthened. Recently, 2-(hydroxyalkyl) substituted piperazine derivatives (<i>e.g.</i>, <b>6</b>) represent well established σ<sub>1</sub> receptor ligands with high affinity but compromised σ<sub>1</sub> receptor selectivity (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a> Considering the hydrophobic binding pocket also tolerates the cyclic or linear alkyl groups (<i>e.g.</i>, <b>PB28</b> and <b>7</b>), Wünsch group<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> identified hydroxyethyl derivative <b>8</b> as the most potent and selective σ<sub>1</sub> receptor ligand by replacement of two phenyl rings of <b>6</b> with a cyclohexyl and 2-naphthyl group. <b>8</b> binds to σ<sub>1</sub> and σ<sub>2</sub> receptor from guinea pig brain and rat liver with <i>K</i><sub>i</sub> values of 4.7 and 69 nM, respectively, while it has affinity of 6.8 and 31 nM for σ<sub>1</sub> and σ<sub>2</sub> receptors from human tumor cell lines RPMI 8226 and RT-4, respectively.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Further replacing the phenyl ring of <b>6</b> with conformationally restricted spiro-dioxolane provides a nonhydroxyethyl-substituted piperazine <b>9</b> with a significantly improved σ<sub>1</sub> receptor binding affinity (<i>K</i><sub>i</sub> = 0.74 nM) and selectivity ratio (47-fold).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a><b>9</b> exhibits antiopioid effects in reducing both the KOR agonist (−)-U-50,488H and MOR agonist morphine mediated analgesia in radiant heat tail-flick test, suggesting a σ<sub>1</sub> receptor agonistic behavior.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. SA4503 derivatives with monocyclic piperazine or homopiperazine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ring expansion of the hydroxymethyl-substituted piperazine <b>6</b> led to 2-substituted homopiperazines (or 1,4-diazepanes) <b>10</b>–<b>13</b> with increased σ<sub>1</sub> receptor affinity and selectivity.<a onclick="showRef(event, 'ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref134 ref135">(134,135,)</a><a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10−13)</a> were prepared in a chiral-pool synthesis or solid-phase organic synthesis starting from enantiomerically pure (<i>S</i>)- or (<i>R</i>)-configured α-amino acids. SAR studies indicate the configuration at the 2-position of the homopiperazine seems to have no effects on σ<sub>1</sub> receptor affinity but a slight effect on σ<sub>2</sub> receptor affinity, leading to the <i>R</i> isomers ((<i>R</i>)-<b>10</b> and (<i>R</i>)-<b>11</b>) with higher selectivity.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> The 2-substituent can also tolerate a bulky group including benzyl ((<i>S</i>)-<b>12</b>) and isobutyl ((<i>S</i>)-<b>13</b>) groups but with a slight decrease in σ<sub>1</sub> receptor affinity.<a onclick="showRef(event, 'ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref134 ref135">(134,135)</a> Additionally, homopiperazines <b>10</b>–<b>12</b> at a concentration of 1 μM show no affinity with PCP/NMDA receptor, indicating their high σ<sub>1</sub> receptor/PCP binding site selectivity. Most recently, Zampieri  <i>et al</i>.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> obtained new derivatives with mono- and biheteroaryls linked to homopiperazines through an amide bond. The best results are reached by benzofurane derivative <b>14</b> with <i>K</i><sub>i</sub> values of 8.0, 47, and 1600 nM for σ<sub>1</sub>, σ<sub>2</sub>, and GluN2b subunits containing NMDA receptors (GluN2b/NMDA), respectively, and <b>14</b> is less toxic at 100 μM concentration (viability >100%) against the human pancreatic carcinoma (PANC1) and human neuroblastoma (SH-SY5Y) cell lines and possesses an excellent antioxidant profile with significant radical scavenging capacity for both ABTS and H<sub>2</sub>O<sub>2</sub> with values of 12.71 and 15.89 μg/mL, indicating its potential neuroprotective activity.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><div class="NLM_p">On the basis of the principle that the piperidine basic nitrogen is considered as the positive ionizable site in their own σ<sub>1</sub> receptor 3D pharmacophore model,<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Zampieri and colleagues<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> designed a series of new arylcarboxamide derivatives with the carbonyl oxygen of the acetamide group as the hydrogen bond acceptor. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, <b>15</b> with nonsubstituted phenyl group and <b>16</b> with 4-chloro substituent show the low nanomolar σ<sub>1</sub> receptor affinity (21.2 and 13.6 nM, respectively) and good selectivity (<i>K</i><sub>i</sub>(σ<sub>2</sub>)/<i>K</i><sub>i</sub>(σ<sub>1</sub>) >140 and >40, respectively). Reversal of the amide group by Zampieri <i>et al</i>.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> resulted in the discovery of piperidine-4-carboxamide derivatives. Tetrahydroquinoline <b>17</b> and its 4-chloro derivative <b>18</b> show the most improved σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 4.6 and 3.7 nM, respectively) and σ<sub>1</sub>/σ<sub>2</sub> selectivity ratio (>435- and 351-fold, respectively) in the series and exhibit very low NMDA inhibition at 1 μM (19% and 34%).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Subsequently, they synthesized a second generation of acetamide derivatives with different aliphatic fragments which replaced the aryl group for occupying the primary hydrophobic pocket.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Compound <b>19</b> displays good σ<sub>1</sub> receptor affinity and selectivity with <i>K</i><sub>i</sub> values of 17 and 1117 nM for σ<sub>1</sub> and σ<sub>2</sub> receptor, respectively. <b>19</b> shows low cytotoxic effect in the MTT assay with IC<sub>50</sub> values of 33 μM in Panc-1 cells and 88 μM in SH-SY5Y cells. Additionally, Collina and colleagues<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> employed alkylalkenyl groups as the long linker between the primary hydrophobic pocket and piperidine for development of novel σ receptor modulators, thereby providing compound <b>20</b> with subnanomolar σ<sub>1</sub> affinity (<i>K</i><sub>i</sub> = 0.7 nM) and a good selectivity over σ<sub>2</sub> receptor (67 ratio).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. SA4503 derivatives with monocyclic piperidine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Conformational restriction of flexible ligands is a widely used strategy in drug design for the improvement of bioactivity and selectivity. Wünsch and colleagues<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> designed 2,5-diazabicyclo[2.2.2]octanes <b>21</b>–<b>23</b> by connecting conformationally flexible 2-hydroxyalkyl side chains to the piperazine ring of previously identified monocyclic piperazines <b>6</b> and <b>8</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Bridged piperazines <b>21</b>–<b>23</b>, synthesized by an improved Dieckmann-type cyclization protocol, show similar σ<sub>1</sub> receptor affinity as the corresponding 2-(hydroxyethyl)piperazine <b>8</b>. This configuration has a negligible effect on σ<sub>1</sub> receptor affinity (<i>e.g.</i>, stereoisomer <b>21</b> and <b>22</b> = 4.8 nM vs 6.9 nM). Expansion of the ethano bridge (<b>22</b>) to propano bridged homologue <b>23</b> with the same stereochemistry and substitution pattern results in comparative σ<sub>1</sub> receptor affinity but significantly improves the σ<sub>1</sub>/σ<sub>2</sub> selectivity (8- vs 177-fold).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Later, Martin  <i>et al</i>.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> reported a series of regioisomeric norbenzomorphans with varied σ receptor subtype selectivity, which depends upon the position of substituents (C7 vs C8) on its framework. Generally, C7-substituted norbenzomorphans (<i>e.g.</i>, <b>24</b>–<b>25</b>) preferentially bind at the σ<sub>1</sub> receptor, whereas the corresponding C8-substituted analogues favor the σ<sub>2</sub> receptor over the σ<sub>1</sub> receptor. SARs indicate that the nitrogen atom of the norbenzomorphan scaffold may be decorated with benzyl (<b>24</b>), aryl sulfonamides (<b>25</b>), or carbamates groups (<b>26</b>), whereas the aryl ring may be adorned with morpholine (<b>24</b>), piperazine (<b>25</b>–<b>26</b>), or aryl groups. For example, the <i>N</i>-benzyl and <i>N</i>-sulfonamide regioisomers <b>24</b> and <b>25</b> substituted with morpholine and piperazine at the C7-position, respectively, follow the observed tendency toward σ<sub>1</sub> receptor subtype selectivity (<i>K</i><sub>i</sub>(σ<sub>1</sub>) = 16.5 and 3.4 nM vs <i>K</i><sub>i</sub>(σ<sub>2</sub>) 562.3 and 48.0 nM, respectively).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. SA4503 derivatives with fused and bridged ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To investigate the effects of reducing structural complexity of norbenzomorphans, Martin and colleagues<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> later generated a new collection of analogues substituted with tetrahydro-2-benzazepine, tetrahydroisoquinoline, or isoindoline by using a scaffold hopping strategy. Removal of the bridging methylene group in the norbenzomorphan <b>24</b> afforded a slightly more flexible tetrahydro-2-benzazepine <b>27</b> with better receptor affinity for both σ<sub>1</sub> (<i>K</i><sub>i</sub> = 16.5 nM vs 6.1 nM, respectively) and σ<sub>2</sub> (<i>K</i><sub>i</sub> = 562.3 nM vs 81 nM, respectively) receptors. Likewise, removing a methylene and ethylene group from <b>27</b> provides isoindoline <b>28</b> and tetrahydroisoquinoline <b>29</b>, respectively, with better σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub>: 1.7–5.9 nM) and better selectivity (>19-fold). Wünsch’s group<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a> discovered another series of tetrahydro-2-benzazepines by introduction of diverse linear or branched alk(en)yl substituents at the 2-position and benzyl groups at the 5-position. <i>N</i>-Cyclohexylmethyl (<b>30</b>: <i>K</i><sub>i</sub> = 2.4 nM), <i>N</i>-4-fluorobenzyl (<b>31</b>: <i>K</i><sub>i</sub> = 7.1 nM), and 5-(α-benzyloxy)benzyl (<b>32</b>: <i>K</i><sub>i</sub> = 9 nM) derivatives represent the most potent σ<sub>1</sub> receptor ligands from this series with high selectivity over the σ<sub>2</sub> receptor (<i>K</i><sub>i</sub>(σ<sub>2</sub>)/<i>K</i><sub>i</sub>(σ<sub>1</sub>) > 52). <b>30</b>–<b>32</b> all show poor affinity at the different binding sites of the NMDA receptor at 10 μM, but <b>31</b> has some degree of affinity to the dopamine D<sub>4</sub> (91% inhibition), histamine H<sub>2</sub> (59%), noradrenaline transporter (71%), and dopamine transporter (85%) at 1 μM concentration. <b>31</b> was well tolerated without inducing considerable side effects in the Irwin screen; nevertheless, <b>31</b> barely exhibited weak analgesic and cognition-enhancing activity, and no antidepressant-like effects in the forced swim test, the open field test, and the home cage activity test.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21">5.1.2.2.  S1RA Analogues</h5><div class="NLM_p">S1RA with a biaryl moiety and morpholine separately occupying the two hydrophobic binding pockets in Glennon’s model, is a highly selective σ<sub>1</sub> receptor antagonist (<i>K</i><sub>i</sub> = 17 nM), which is currently undergoing phase 2 clinical trials for the treatment of oxaliplatin-induced neuropathic pain (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). As a back-up program, Esteve R&D<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> identified a new series of aryltriazoles and arylmethyltriazoles by employing a scaffold hopping approach around the arylpyrazole fragment of S1RA. The 3,4-dichorophenyltriazole <b>33</b> exhibits the most potent σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 5 nM) with 67-fold selectivity over the σ<sub>2</sub> receptor. Changing the piperidine of <b>33</b> for a morpholine group provides compound <b>34</b> with 9-fold less potency (<i>K</i><sub>i</sub> = 46 nM) but significantly improved selectivity (>218 ratio). A convergence was observed in the superposition of aryltriazole and arylmethyltriazole derivatives, and likewise the benzylic derivative <b>35</b> displayed comparable activities to its phenyl analogue <b>34</b>. Morpholines <b>34</b> and <b>35</b> show lower hERG inhibition (IC<sub>50</sub> > 10 μM) than piperidine <b>33</b> (1.7 μM) due to the reduction of either cLogP or p<i>K</i><sub>a</sub>, two factors known to affect hERG activity (cLogP = 3.4 vs 4.6; p<i>K</i><sub>a</sub> = 7.0 vs 9.1), suggesting a low incidence of cardiac toxicity.<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147,148)</a> Moreover, compounds <b>34</b> and <b>35</b> were found highly stable in human liver microsomes and highly permeable in Caco-2 cells.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Later, new S1RA derivatives based on the pyrazolo[3,4-<i>d</i>]pyrimidine scaffold in the primary hydrophobic pocket were designed on the basis of Glennon’s σ<sub>1</sub> receptor pharmacophore model and their previous SAR studies.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> 4-Acylaminopyrazolo[3,4-<i>d</i>]pyrimidine <b>36</b> exhibits nanomolar affinity (<i>K</i><sub>i</sub> = 51 nM) for the σ<sub>1</sub> receptor and good selectivity over a panel of 66 receptors including the σ<sub>2</sub> receptor (inhibition at 10 μM < 50%). It is noteworthy is that <b>36</b> has the potential drawback of instability at acidic pH values due to the instable amido linkage. The replacement of the 4-acylamino group in <b>36</b> with aromatic heterocycles was thus utilized for searching more stable alternatives.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> The 4-(1-methylpyrazol-5-yl) derivative <b>37</b> showed no sign of degradation in solution at pH 2 or 7.4 and was later identified as the most selective σ<sub>1</sub> receptor derivative over the σ<sub>2</sub> receptor (<i>K</i><sub>i</sub> = 41 nM vs >1000 nM) and a wider panel of receptors. Moreover, <b>37</b> exhibits no significant inhibition for recombinant human cytochrome P450 (rhCYP) isoforms (1A2, 2C9, 2C19, 2D6, and 3A4; below 50% at 1 μM) and human hERG potassium channel (IC<sub>50</sub> > 10 μM), suggesting low potential for drug–drug interactions and cardiac toxicity.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Biaryl modifications of S1RA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additionally, compounds <b>34</b>–<b>37</b> by either intraperitoneal (ip 40 mg/kg) or oral (po 80 mg/kg) routes showed good activity in the formalin-induced pain model in mice, a classic model of acute and chronic pain, indicating their antagonistic nature.<a onclick="showRef(event, 'ref146 ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref146 ref149 ref150">(146,149,150)</a> Moreover, oral administration of <b>34</b>–<b>37</b> (80 mg/kg) was efficacious in reduction of mechanical hypersensitivity induced by capsaicin in mice (percentage reduction: 68%, 94%, 49%, and 43%, respectively) and dose-dependently inhibited both mechanical and thermal hyperalgesia in the partial sciatic nerve ligation (PSNL) mouse model, one of the most widely accepted neuropathic pain models (percentage reduction: 56%, 140%, 102%, and 46%, respectively). <b>35</b> was more efficacious than its homologue <b>34</b> in these two <i>in vivo</i> pain models, which may be ascribed to better solubility (>4 vs 0.17 mg/mL) and less lipophilicity (log <i>P</i>: 2.4 vs 2.9).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><div class="NLM_p">Zhang and colleagues<a onclick="showRef(event, 'ref151 ref152 ref153 ref154 ref155'); return false;" href="javascript:void(0);" class="ref ref151 ref152 ref153 ref154 ref155">(151−155)</a> also developed several series of structurally diverse σ<sub>1</sub> receptor antagonists based on modifications to the arylpyrazole moiety of S1RA (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). In 2014, they reported a series of 1-benzyl-3,4-dihydro-2(1<i>H</i>)-quinolinone derivatives derived from the 5-HT<sub>1A</sub> receptor agonist OPC-14523, which bound to the σ<sub>1</sub> receptor at nanomolar concentrations (IC<sub>50</sub> = 47 nM). Piperidine derivative <b>38</b> (<i>K</i><sub>i</sub> = 1.22 nM) and 4-methylpiperidine <b>39</b> (<i>K</i><sub>i</sub> = 0.77 nM) containing the same 4-fluorphenyl moiety exhibit the greatest potency and selectivity for σ<sub>1</sub> receptor in the series (1066- and 1246-fold over σ<sub>2</sub> receptor, respectively).<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> In the same year, a new series of 2-phenylpyrimidines as potent σ<sub>1</sub> receptor antagonists was reported by using a three-dimensional (3D) pharmacophore model and virtual screening program.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Analogues <b>40</b> and <b>41</b> substituted separately, with a chlorine and fluorine group at the 4-position of the phenyl groups in 2-phenylpyrimidines, exhibit high affinity for the σ<sub>1</sub> receptor (1.14 and 1.06 nM, respectively), and good σ<sub>1</sub>/σ<sub>2</sub> selectivity (1165- and 1344-fold). Subsequently, cyclization of the 4- and 5-position of the pyrimidine scaffold of <b>40</b> provided two series of cycloalkane compounds based on 6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine and 5,6,7,8-tetrahydroquinazoline skeletons.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Cyclopenta[<i>d</i>]pyrimidine <b>42</b> and tetrahydroquinazoline <b>43</b> with 1-methylpiperidine and 4-chlorophenyl groups on both sides exert low nanomolar affinity for the σ<sub>1</sub> receptor (<i>K</i><sub>i</sub> = 21.1 and 15.6 nM, respectively) and the high selectivity over the σ<sub>2</sub> receptor (<i>K</i><sub>i</sub> > 2000 nM). Later, 2-phenyl-6-hydroxypyridazinones were designed by substituting ring bioisosteres of the pyrimidine moiety of <b>40.</b><a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> 3,4-Dichloro substituted derivative <b>44</b> exhibits the lowest σ<sub>1</sub> receptor affinity binding values (<i>K</i><sub>i</sub> = 1.4 nM) of the series and excellent selectivity over the σ<sub>2</sub> receptor (1366-fold). Recently, Zhang group<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> also designed a series of phenyl-1,2-4-oxadiazole derivatives based on a hybridization approach of privileged fragments. The piperidinyl derivative <b>45</b>, with 2,4-dichlorophenyl-1,2,4-oxadiazole, displays low nanomolar affinity (<i>K</i><sub>i</sub> = 0.28 nM) and high selectivity (587.1-fold) for the σ<sub>1</sub> receptor.</div><div class="NLM_p">Because phenytoin can alter the binding of these compounds, <b>38</b>–<b>45</b> were identified as σ<sub>1</sub> receptor antagonists. <b>40</b> and <b>44</b> also have good σ<sub>1</sub> receptor selectivity profiles with no significant affinity (inhibition <50% at 1 μM) for other relevant pain receptors (<i>e.g.</i>, μ-opioid, serotoninergic, H<sub>3</sub>, cannabinoid, NMDA receptors) and ion channels (voltage-gated sodium channel Nav 1.7 and TRPV-1 protein),<a onclick="showRef(event, 'ref152 ref154'); return false;" href="javascript:void(0);" class="ref ref152 ref154">(152,154)</a> but compound <b>45</b> has moderate affinity for the H<sub>3</sub> receptor (<i>K</i><sub>i</sub> = 23.2 nM). Moreover, <b>40</b> and <b>44</b> show excellent bioavailability (<i>F</i> = 75.1% and 87.5%, respectively) and a better safety profile compared to <b>41</b> in hERG channel assays (6.98 μM and 6.34 μM vs 1.54 μM) and acute toxicity assays ((LD<sub>50</sub> > 2000 vs 884.5 mg/kg). On the basis of their good safety profiles, these compounds were thus further tested in various <i>in vivo</i> pain models. Compounds <b>38</b>–<b>40</b> and <b>43</b>–<b>45</b> are efficacious in attenuation of dose-dependent antinociceptive effects in the mouse formalin-induced pain model.<a onclick="showRef(event, 'ref151 ref152 ref153 ref154 ref155'); return false;" href="javascript:void(0);" class="ref ref151 ref152 ref153 ref154 ref155">(151−155)</a> And <b>40</b> and <b>44</b>–<b>45</b> also dose-dependently inhibited mechanical allodynia and thermal hypersensitivity in the rat chronic constriction injury (CCI) model, a frequently used model of neuropathic pain. In addition, no motor impairments were observed in rotarod tests of <b>40</b> and <b>44</b> at antiallodynic doses.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><div class="NLM_p">Replacement the arylpyrazole moiety of S1RA with a biphenyl ring resulted in the identification of RC-33 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) as a potent and promising σ<sub>1</sub> receptor agonist (<i>K</i><sub>i</sub> = 0.9 nM) with potential in promoting NGF-induced neurite outgrowth in the PC12 cell line at low concentrations.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> To enhance the σ<sub>1</sub>/σ<sub>2</sub> selectivity of RC-33, a hydroxyl group was introduced at the α-position of the phenyl ring, leading to a slight decrease in σ<sub>1</sub> receptor potency and selectivity (<i>e.g.</i>, <b>46</b>).<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Later, a series of RC-33 monoaryl analogues was designed by replacing the biphenyl moiety with a naphthyl or phenyl ring for exploring the necessity of the biaryl group in S1RA analogues.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> The 2-naphthalene derivative <b>47</b> exhibits comparable σ<sub>1</sub> receptor affinity to RC-33 (<i>K</i><sub>i</sub> = 0.9 nM vs 1.5 nM), but lower selectivity (<i>K</i><sub>i</sub>(σ<sub>2</sub>)/<i>K</i><sub>i</sub>(σ<sub>1</sub>) = 33 vs 114), suggesting that the bulky naphthalene portion of <b>47</b> also fits well in the primary hydrophobic binding pocket of the σ<sub>1</sub> receptor.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Further replacement of the monocyclic piperidine of <b>47</b> with the bicyclic granatane moiety and switching the linker from the 2-position of naphthalene to the 1-position provided <b>48</b> with similar σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 1.5 nM vs 1.03 nM) and 10-fold improved selectivity over the σ<sub>2</sub> receptor (ratio: 317 vs 33).<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Monoaryl S1RA derivatives</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The Dukat group<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> found that a bulky 4-<i>tert</i>-butyl phenyl was similar to the naphthalene ring in <b>48</b> and considered as a key contributor to σ<sub>1</sub> receptor binding (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). <b>48</b> was discovered by reevaluation of fenpropimorph, a so-called ‘‘super high-affinity” σ<sub>1</sub> receptor ligand (<i>K</i><sub>i</sub> (pg) = 0.005 nM),<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> by using the ‘‘deconstruction–elaboration” approach. Removal of the entire branched methyl group on the linker and the morpholine ring of fenpropimorph (<i>K</i><sub>i</sub> = 17.3 nM) yielded compound <b>49</b> and <b>50</b> with similarly high σ<sub>1</sub> receptor affinity binding values (<i>K</i><sub>i</sub> = 2.6 nM and 1.5 nM, respectively), suggesting that they were relatively less important. Although the morpholine <i>O</i> atom of fenpropimorph analogues (<i>e.g.</i>, <b>49</b>) is not important for σ<sub>1</sub> receptor affinity, replacement with methylene leads to piperidine <b>50</b> with a dramatic decrease in σ receptor subtype selectivity as mentioned earlier in compounds <b>33</b> and <b>34</b>.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a><i>N</i>-(2-Morpholinoethyl)acetamide <b>51</b> with a 3,4-dichlorophenoxy group occupying in the primary binding pocket of σ<sub>1</sub> receptor was identified by “<i>in combo</i>” screening combined with <i>in silico</i> and <i>in vivo</i> assessments.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a><b>51</b> shows high σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 42 nM) and has 36-fold selectivity over the σ<sub>2</sub> receptor. Ipsilateral local peripheral (10–300 mg/paw) and intrathecal (100 mg/rat) pretreatment with <b>51</b> led to a reduction on the flinching behavior in the formalin-induced nociception test, indicating <b>51</b> may be effective in treating inflammatory pain. <b>51</b> can block the intrathecal pronociceptive effect induced by PRE084 in the formalin test, suggesting the antinociceptive effect of <b>51</b> is mediated via σ<sub>1</sub> receptor functionality.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Using the bioisostere replacement strategy, Romeo  <i>et al</i>.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> designed a set of 5-chlorobenzoxazole- and 5-chlorobenzothiazole-based derivatives containing an azepane ring. SAR studies indicate 5-chlorobenzoxazoles are more selective for σ<sub>1</sub> receptor than 5-chlorobenzothiazoles (<i>e.g.</i>, <b>52</b> vs <b>53</b>). 5-Chlorobenzoxazole <b>52</b> and 5-chlorobenzothiazole <b>54</b> display the most potent σ<sub>1</sub> receptor binding affinities of these derivatives with <i>K</i><sub>i</sub> values of 1.93 nM and 0.78 nM, respectively, but a dramatic decline in σ receptor subtype selectivity was observed in compound <b>54</b>.</div></div><div id="sec5_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22">5.1.2.3.  Spirocyclic Sigma-1 Ligands</h5><div class="NLM_p">In 2002, a conformationally restricted spirocyclic benzofuran <b>55</b> with an endocyclic amino moiety was reported by the Wünsch group<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) as a highly potent σ<sub>1</sub> receptor antagonist (<i>K</i><sub>i</sub> = 1.14 nM) with high σ<sub>1</sub>/σ<sub>2</sub> selectivity (ratio: 1130), in which the benzofuran and benzyl moiety extended to the primary and secondary hydrophobic pocket of σ<sub>1</sub> receptor, respectively. SAR studies indicate that substituents at the 4-position on the aromatic ring of the benzyl group tolerated small groups including fluoro, iodo, methoxy, and fluoroethyl.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> In 2014, the Wünsch group designed pyridine analogues of <b>55</b> by bioisosteric replacement of CH-moieties in the benzene ring with an <i>N</i>-atom.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> However, the four regioisomeric furopyridines (<i>e.g.</i>, <b>56</b>–<b>57</b>) show 7- to 12-fold poorer σ<sub>1</sub> receptor affinity than the benzofuran analogue <b>55</b> (<i>K</i><sub>i</sub> = 4.9–10 nM), indicating that the reduced σ<sub>1</sub> receptor affinity may be attributable to the reduced electron density of the pyridine ring rather than the direct interaction of the pyridine <i>N</i>-atom. Further expansion of the five-member furan ring in furopyridines (<i>e.g.</i>, <b>57</b>) to a six-membered ring provided spirocyclic pyranopyridines.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a><b>58</b> with a double bond in the pyran ring was identified as the most promising σ<sub>1</sub> receptor ligand in the pyranopyridine class with a <i>K</i><sub>i</sub> value of 4.6 nM and a high selectivity over the σ<sub>2</sub> receptor (>217-fold). The above results conclude that an electron deficient pyridine ring is less well tolerated by the σ<sub>1</sub> receptor than the neutral benzene ring.<a onclick="showRef(event, 'ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref166 ref167">(166,167)</a> Hence, a series of 2-benzopyran σ<sub>1</sub> receptor ligands were synthesized via an oxa-Pictet–Spengler reaction.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> The benzyl substituted spirocyclic alcohol <b>59</b> achieved a low nanomolar σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 20 nM) and good σ<sub>1</sub>/σ<sub>2</sub> selectivity (<i>K</i><sub>i</sub>(σ<sub>2</sub>) > 1 μM). Further, a lipase-catalyzed kinetic resolution afforded enantiomerically pure 2-benzopyran derivatives, (<i>R</i>)-<b>59</b> and (<i>S</i>)-<b>59</b>.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> (<i>R</i>)-<b>59</b> is 4.8-fold more potent than its enantiomer (<i>S</i>)-<b>59</b> (<i>K</i><sub>i</sub> = 10 nM vs 48 nM) in σ<sub>1</sub> receptor binding, and both show high selectivity over the σ<sub>2</sub> receptor (<i>K</i><sub>i</sub> > 1000 nM), PCP/NMDA receptor (IC<sub>50</sub> > 10000 nM), and the most structurally similar sterol-D<sub>8</sub>/D<sub>7</sub>-isomerases (IC<sub>50</sub> > 1000 nM) in both yeast <i>Yarrowia lipolytica</i> and human HL-60 cells.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Spirocyclic benzofuran and benzopyran derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, another series of rigid spirocyclic σ<sub>1</sub> receptor ligands based on the 2-benzopyran scaffold (<i>e.g.</i>, <b>59</b>) were synthesized by Wünsch and colleagues<a onclick="showRef(event, 'ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref170 ref171">(170,171)</a> via replacement of the spiro-piperidine with an exocyclic amino moiety (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). The benzyl group and spiro[benzopyran-1,1′-cyclohexane] scaffold separately occupy the two hydrophobic pockets of σ<sub>1</sub> receptor. However, benzopyran <i>trans</i>-<b>60</b> with the benzylamino moiety displays remarkable MOR affinity (<i>K</i><sub>i</sub> = 38 nM) and high MOR: σ<sub>1</sub> receptor selectivity (14-fold). Excitingly, replacement of the benzyl moiety with a cyclohexylmethyl group shifts the receptor profile from MOR receptor selective ligands toward σ<sub>1</sub> receptor selective ligands.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Transformation of the secondary cyclohexylmethylamines <b>61a</b> and <b>61b</b> (<b>61a</b>, <i>K</i><sub>i</sub>(σ<sub>1</sub>) = 19 nM, <i>K</i><sub>i</sub>(σ<sub>2</sub>) = 128 nM; <b>61b</b>, <i>K</i><sub>i</sub>(σ<sub>1</sub>) = 5.8 nM, <i>K</i><sub>i</sub>(σ<sub>2</sub>) = 101 nM) into methylated tertiary amines <b>62a</b> and <b>62b</b> (<b>62a</b>, <i>K</i><sub>i</sub>(σ<sub>1</sub>) = 3.1 nM, <i>K</i><sub>i</sub>(σ<sub>2</sub>) = 154 nM; <b>62b</b>, <i>K</i><sub>i</sub>(σ<sub>1</sub>) = 1.9 nM, <i>K</i><sub>i</sub>(σ<sub>2</sub>) = 12 nM) leads to improved σ<sub>1</sub> receptor affinity. Although the <i>cis</i>-configured 3-methoxy-2-benzopyran <i>cis</i>-<b>62b</b> bearing a tertiary cyclohexylmethylamino group shows the best σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 1.9 nM) in these series, the corresponding <i>trans</i>-configured isomer <i>trans</i>-<b>62a</b> shows higher σ<sub>1</sub>/σ<sub>2</sub> selectivity (ratio: 49.7 vs 6.3). The secondary and tertiary cyclohexylmethylamines <b>61a</b>, <b>61b</b>, <b>62a</b>, and <b>62b</b> show no significant interaction with PCP/NMDA receptor up to a concentration of 1 μM. <i>trans</i>-<b>61a</b> and <i>cis</i>-<b>61b</b> also display no cytotoxicity and improved metabolic stability. Moreover, they show no inhibition against CYP enzymes CYP1A2, CYP2C9, CYP2C19, and CYP3A4 except modest CYP2D6 inhibition. Additionally, <i>trans</i>-<b>62a</b> and <i>cis</i>-<b>62b</b> do not interact with noradrenalin (NET), dopamine (DAT), and serotonin transporters (SET). However, <i>cis</i>-<b>62b</b> displays moderate displacement at a concentration of 1 μM toward α<sub>1A</sub> (68%), α<sub>2A</sub> (93%), 5-HT<sub>1A</sub> (60%), and 5-HT<sub>2B</sub> (62%) receptors. <i>cis</i>-<b>62b</b> was later confirmed as a σ<sub>1</sub> receptor antagonist in a KCl-induced Ca<sup>2+</sup> influx assay.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></div><div class="NLM_p">Amines <i>trans</i>-<b>63a</b> and <i>cis</i>-<b>63b</b> bearing a cyclohexylpiperazinyl moiety also show high σ<sub>1</sub> affinity (<i>K</i><sub>i</sub> = 6.3 nM and 4.4 nM, respectively) with 10- to 50-fold selectivity over the σ<sub>2</sub> receptor.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> To increase metabolic stability, exchanging the 3-methoxy group in the 2-benzopyrans of <i>trans</i>-<b>63a</b> and <i>cis</i>-<b>63b</b> with a fluoroethyl side chain provided fluorinated compounds <i>trans</i>-<b>64a</b> and <i>cis</i>-<b>64b</b>. Although <i>trans</i>-<b>64a</b> and <i>cis</i>-<b>64b</b> decrease σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 12 nM and 19 nM, respectively) and selectivity over the σ<sub>2</sub> receptor (<i>K</i><sub>i</sub> = 45 nM and 432 nM, respectively),<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> they show good selectivity over a panel of other receptors, channels, and transporters, including opioid receptors, PCP/NMDA receptor, 5-HT<sub>2B</sub> receptor, hERG channel, NET, DAT, and SERT. However, they display high affinity to the ifenprodil binding site of GluN2B subunit containing NMDA receptors. In mice, <i>trans</i>-<b>64a</b> and <i>cis</i>-<b>64b</b> were confirmed to have stronger effects on capsaicin induced mechanical allodynia than that of the reference σ<sub>1</sub> receptor antagonist BD-1063, suggestive of an antagonist profiles. The antiallodynic activity of <i>trans</i>-<b>64a</b> could only be partially reversed by the σ<sub>1</sub> receptor agonist PRE084. However, the antiallodynic effect of its diastereomer <i>cis</i>-<b>64b</b> was observed probably due only to its interaction with the σ<sub>1</sub> receptor.</div><div class="NLM_p">Multicomponent reactions (MCRs) are powerful synthetic strategies extensively employed to construct biologically interesting spiro compounds. In 2016, Ghandi  <i>et al</i>.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> described a one-pot synthesis of spirocyclic-2,6-diketopiperazines (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) as σ<sub>1</sub> receptor selective ligands via two-step sequential, four-component Ugi multicomponent reaction/intramolecular <i>N</i>-amidation reactions by utilizing various acids, cyclic ketones, ethylglycinate hydrochloride, and cyclohexyl isocyanide. Compound <b>65</b> was identified with the best σ<sub>1</sub> binding affinity and subtype selectivity of the series (<i>K</i><sub>i</sub> σ<sub>1</sub> = 5.9 nM; σ<sub>2</sub> = 563 nM). Later, a three component reaction of various amino acids, ketones, and isocyanides was reported by Majumdar and colleagues<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> to generate a library of various spiro-2,6-dioxopiperazines and spiro-2,6-pyrazine scaffolds with a piperidinyl group. The unsaturated spiro-2,6-dioxopyrazine <b>66</b> (UVM147) was identified as the most potent σ<sub>1</sub> selective ligand (<i>K</i><sub>i</sub> = 8 nM) from this approach, screening over 50 different CNS receptors including GPCRs, ion channels, transporters, and enzymes through the psychoactive drug screening program (PDSP) funded by the National Institute of Mental Health (NIMH). Importantly, <b>66</b> shows highly selective binding to σ<sub>1</sub> over σ<sub>2</sub> receptors (<i>K</i><sub>i</sub> σ<sub>2</sub> = 696 nM) and several crucial CNS targets including 5-HT<sub>2B</sub> (<i>K</i><sub>i</sub> = 231 nM), 5-HT<sub>7</sub> (<i>K</i><sub>i</sub> = 2765 nM), α<sub>2A</sub> (<i>K</i><sub>i</sub> = 3364 nM), D<sub>4</sub> (<i>K</i><sub>i</sub> = 1283 nM), DAT (<i>K</i><sub>i</sub> = 2562 nM), H<sub>2</sub> (<i>K</i><sub>i</sub> = 823 nM), and KOR (<i>K</i><sub>i</sub> = 1707 nM).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> In addition, Lepovitz and Martin<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> synthesized bioactive azaspirocycles via a novel, efficient diversity-oriented synthesis (DOS) strategy that featured a tandem sequence involving imine formation and an aza-Sakurai reaction to form the spirocyclic system, and subsequently intramolecular Pictet–Spengler cyclization with formaldehyde to build tetrahydroisoquinoline rings. Azaspirocycle <b>67</b> shows a preference for the σ<sub>1</sub> receptor (<i>K</i><sub>i</sub> = 8 nM) with moderate binding at σ<sub>2</sub> (<i>K</i><sub>i</sub> = 152 nM) and α<sub>2A</sub> (<i>K</i><sub>i</sub> = 531 nM) receptor and weak affinity against a panel of approximately 44 other CNS proteins tested by the PDSP.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Spirocyclic sigma-1 ligands synthesized by multicomponent reactions or diversity-oriented synthesis strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Beyond that, opening the spiro scaffold of potent spirocyclic σ<sub>1</sub> receptor ligands represents an efficient structural modification strategy for development of novel σ<sub>1</sub> receptor ligands with promising biopharmaceutical properties. For example, as shown in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, (±)-haloperidol (HP) and its derivatives <b>69</b>–<b>70</b> may be treated as the ring-opened arylpiperidine analogues of <b>59</b>. HP is conventionally viewed as a dopamine D<sub>2</sub> (<i>K</i><sub>i</sub> = 2.5 nM) and D<sub>3</sub> (<i>K</i><sub>i</sub> = 6.1 nM) antagonist with antipsychotic effects but also is a σ<sub>1</sub> receptor (<i>K</i><sub>i</sub> = 2.7 nM) antagonist and σ<sub>2</sub> receptor (<i>K</i><sub>i</sub> = 17 nM) agonist with blockade of formalin-induced pain.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Further valproate esterification of HP metabolite II <b>68</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) provided compound <b>69</b> [(±)-MRJF22] with preferential activity at the σ<sub>1</sub> receptor over the σ<sub>2</sub> receptor (<i>K</i><sub>i</sub> σ<sub>1</sub> = 1.3 nM; <i>K</i><sub>i</sub> σ<sub>2</sub> = 124 nM) and dopamine D<sub>2</sub> and D<sub>3</sub> receptors (<i>K</i><sub>i</sub> > 5000 nM).<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> On the other hand, methoxycarbonyl-1-phenyl-2-cyclopropylmethyl derivatives of HP (<i>e.g.</i>, <i>trans</i>-(±)-<b>70</b>) display a double-digit nanomolar affinity for σ<sub>1</sub> and σ<sub>2</sub> receptors and low affinity toward D<sub>1</sub> and D<sub>2</sub> receptors.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> The most promising compound, <i>trans</i>-(+)-<b>70</b>, has a low nanomolar affinity for σ<sub>1</sub> receptors (<i>K</i><sub>i</sub> = 7 nM) and possesses the best selectivity ratio over σ<sub>2</sub> receptors (<i>K</i><sub>i</sub> = 1837 nM) and more than 15 other receptors (<i>K</i><sub>i</sub> > 2500 nM), including opioid, dopaminergic, serotoninergic, and adrenergic receptors. <i>trans</i>-(+)-<b>70</b> also has good chemical stability at both pH 1.3 and 7.4 (<i>t</i><sub>1/2</sub>, 84 and 91 h, respectively), as well as enzymatic stability in human plasma (<i>t</i><sub>1/2</sub> = 65.2 h). An <i>in vivo</i> pharmacological evaluation evidenced that <i>trans</i>-(+)-<b>70</b> (16–32 mg/kg, sc) did not enhance the antinociceptive effect of morphine. In contrast to the other three isomers which behaved as σ<sub>1</sub> receptor antagonists, <i>trans</i>-(+)-<b>70</b> exhibited a σ<sub>1</sub> receptor agonist profile.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Spiro ring opened arylpiperidine derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To reduce lipophilicity and enhance polarity, the Wünsch group<a onclick="showRef(event, 'ref178 ref179'); return false;" href="javascript:void(0);" class="ref ref178 ref179">(178,179)</a> designed thiazole-based σ<sub>1</sub> receptor ligands by bioisosterically replacing the thiophene ring and opening the pyran ring of spirocyclic thiophene derivatives <b>71</b>–<b>72</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Although spirocyclic thiophene <b>71</b> with an aryl substituent at the β-position shows considerably higher σ<sub>1</sub> affinity than its regioisomer <b>72</b> with the aryl moiety at the α-position, their corresponding ring-opened thiazole derivatives <b>73</b> and <b>74</b>, separately arylated at the C5- and C4-position, display conserved σ<sub>1</sub> receptor affinity due to free rotation around the piperidine–thiazole bond.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> However, the C5-arylated thiazole <b>73</b> shows higher σ<sub>1</sub> receptor selectivity over σ<sub>2</sub> receptors. The 5-pyridyl substituted thiazole derivatives <b>75</b> and <b>76</b> were the most promising candidates and exhibit low nanomolar affinity at the σ<sub>1</sub> receptor (<i>K</i><sub>i</sub> = 1.3–1.9 nM), high σ<sub>1</sub>/σ<sub>2</sub> selectivity (>1500-fold), and good ligand efficiency.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Additionally, Efange and colleagues<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> described a series of ring-opening spipethiane analogues by replacing the sulfur atom with a carbonyl (<b>77</b>), hydroxylmethenyl (<b>78</b>–<b>79</b>), or 3-bromobenzylamine (<b>80</b>) bridge (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). Although the σ<sub>1</sub> receptor affinities of <b>77</b>–<b>80</b> were slightly lower than that of spipethiane, their good σ<sub>1</sub> receptor selectivity over σ<sub>2</sub> receptors was achieved.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Spiro ring opened monocyclic piperidine derivatives</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23">5.1.2.4.  Polycyclic Sigma-1 Ligands</h5><div class="NLM_p">Because the primary hydrophobic region of the σ<sub>1</sub> receptor sterically tolerated a bulky group, including spirocyclic and polycyclic fragments, analogues with a substituted 1,4-dioxane ring were rationally designed and prepared by the Quaglia group.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, 2,2-diphenyl-1,4-dioxane derivatives (<i>e.g.</i>, <b>81</b>) can be viewed as ANAVEX2-73 analogues which have a <i>gem</i>-diphenyl group on the 2-position of its tetrahydrofuran. Compound <b>81</b> was identified as the most promising compound in the series with the highest affinity (<i>K</i><sub>i</sub> = 7.37 nM) and good selectivity for σ<sub>1</sub> over σ<sub>2</sub> receptors and the NMDA receptor (<i>K</i><sub>i</sub> σ<sub>2</sub> = 1000 nM, NMDA > 10 μM), and converged with the superimposed structure of haloperidol. <i>In vivo</i>, <b>81</b> had no antinociceptive effects at the highest tested dose (50 mg/kg) in the rodent hot plate assay when administrated alone, but it significantly increased morphine-induced (4 mg/kg) antinociceptive response until 60 min after its injection, suggesting a σ<sub>1</sub> receptor antagonist profile of compound <b>81</b>.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Later, a series of conformationally restricted 1,3-dioxanes bearing an axially oriented phenyl moiety in the 2-position was designed by mimicking the steric conformation of the benzomorphan scaffold of pentazocine and synthesized by two successive intramolecular transacetalization reactions.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> The benzylamine <b>82b</b> with equatorially oriented aminoethyl side chain shows 5-fold higher σ<sub>1</sub> receptor affinity than its diastereomer <b>82a</b> with axially oriented aminoethyl moiety (<i>K</i><sub>i</sub> = 5.9 nM vs 30 nM), representing the most potent σ<sub>1</sub> receptor ligand of this series. However, benzylamine <b>82a</b> displays slightly higher selectivity over the σ<sub>2</sub> receptor than its diastereomer <b>82b</b> (>33- vs 26-fold), and both benzylamines <b>82a</b> and <b>82b</b> display poor affinity for PCP/NMDA receptors.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Polycyclic sigma-1 ligands</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, Joubert  <i>et al</i>.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> designed a series of oxa- and aza- hexaxcyclododecylamines as σ<sub>1</sub> receptor ligands based on their therapeutic potential for the development of CNS drugs. Although both the oxa- and aza-hexaxcyclododecylamine moieties are able to occupy the hydrophobic region of the σ<sub>1</sub> receptor, the aza compounds are generally more favorable for σ<sub>1</sub> receptor binding compared to their oxa counterparts (compound <b>83</b> vs <b>84</b>). The aza-hexaxcyclododecylamine compound <b>83</b> shows moderate calcium flux inhibition (51% @ 100 μM), whereas the oxa-derivative <b>84</b> exhibits weak calcium flux inhibition (26% @ 100 μM), indicating a link between σ<sub>1</sub> receptor activity and intracellular calcium levels.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></div><div class="NLM_p last">Compounds <b>85</b>–<b>87</b> represent structurally unique polycyclic σ<sub>1</sub> receptor ligands and lack many characterizations described by Glennon’s model. Decahydrobenzoquinolin-5-one <b>85</b> synthesized by successive Diels–Alder and aza-Wittig reactions possesses high σ<sub>1</sub> receptor affinity with a <i>K</i><sub>i</sub> value of 1.5 nM and 98.7-fold selectivity over σ<sub>2</sub> receptors.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> However, <b>85</b> shows moderate affinity for H<sub>3</sub> (<i>K</i><sub>i</sub> = 814 nM) and M<sub>3</sub> (<i>K</i><sub>i</sub> = 661 nM) receptors, and weak affinity (<i>K</i><sub>i</sub> > 1000 nM) for the dopamine transporter as well as the 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> serotonin receptors. Further decorating this scaffold produced the indolenine <b>86</b> via interrupted Fischer indole synthesis.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a><b>86</b> retains σ<sub>1</sub> receptor affinity, but its selectivity decreases over σ<sub>2</sub> receptors, with <i>K</i><sub>i</sub> values of 7 nM and 76 nM, respectively. 3-Amino-chromane <b>87</b> was synthesized by a newly developed tandem Winstein rearrangement Friedel–Crafts alkylation reaction.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Compound <b>87</b> was identified as a new lead targeting σ<sub>1</sub> receptor due to its respectable affinity (<i>K</i><sub>i</sub> = 44 nM) and good selectivity versus σ<sub>2</sub> receptors (>200-fold),and other GPCRs (>5-fold versus 5-HT<sub>2B</sub> receptor, and >20-fold versus 38 other GPCRs). <b>87</b> displays comparable protective effects to (+)-pentazocine against oxidative stress in the well-characterized cone photoreceptor cell line 661W and no cytotoxicity at tested concentrations using the MTT assay.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a></div></div><div id="sec5_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24">5.1.2.5.  Acyclic Amines</h5><div class="NLM_p">In Glennon’s model, the basic amine of σ<sub>1</sub> receptor ligands not only could be embedded into various rings including monocycles (<i>e.g.</i>, piperidine, piperazine, and morpholine), spirocycles, and polycycles but also could be acyclic in nature as a linear secondary or tertiary amine. The basic amine is believed to form a salt bridge with the carboxylate group of the GLU172 residue displayed in the crystal structures of the σ<sub>1</sub> receptor (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).</div><div class="NLM_p">Yu and colleagues<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> identified novel alkoxyisoxazoles as selective σ<sub>1</sub> receptor ligands by scaffold repurposing α<sub>4</sub>β<sub>2</sub>-nicotinic acetylcholine receptor (nAChR) ligands based on an isoxazole ether framework. As shown in <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>88</b> displays high σ<sub>1</sub> receptor affinity and good selectivity over σ<sub>2</sub> receptors (<i>K</i><sub>i</sub> (σ<sub>1</sub>) = 4.1 nM, (σ<sub>2</sub>) = 1312 nM) but possesses good to moderate affinity for DAT (<i>K</i><sub>i</sub> = 373 nM) and NET (<i>K</i><sub>i</sub> = 203 nM). Further rational design and SAR studies provide <i>N</i>-cyclopropylmethyl analogue <b>89</b> as the most potent and selective σ<sub>1</sub> receptor antagonist (<i>K</i><sub>i</sub> (σ<sub>1</sub>) = 0.8 nM, (σ<sub>2</sub>) = 225 nM) devoid of binding interactions with the monoamine transporters DAT, NET, or SERT at a 10 μM concentration.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Possessing good brain exposure (B/P ratio: 3.6), <b>89</b> was found to demonstrate significant <i>in vivo</i> analgesic effects in a mouse formalin test at 80 mg/kg (ip) and produced no interference with motor coordination in the rotarod test. In addition, <i>N</i>-cyclobutylamine <b>90</b> exhibited synergistic neurite outgrowth effects at a level similar to that of positive control RC-33.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Further <i>N</i>-demethylation of <b>90</b> afforded compound <b>91</b> with an improved binding affinity for σ<sub>1</sub> receptors (<i>K</i><sub>i</sub> = 0.2 nM vs 1.8 nM) and excellent selectivity over σ<sub>2</sub> receptors (ratio: 990 vs 171) and neurotransmitter transporters including DAT, NET, and SERT (<i>K</i><sub>i</sub> > 7 μM), indicating that the hydrogen bond donor on basic nitrogen atom of the secondary amines (<i>e.g.</i>, <b>91</b>) was beneficial for increased binding affinity to the σ<sub>1</sub> receptor. <b>91</b> produced significant neuritogenesis effects at 10 μM concentrations and superior efficacy to increase average neurite length compared to that of the parent compound <b>90</b> and positive control RC-33 in N1E-115 neuronal cells.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Acyclic amines as sigma-1 ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Melnyk and colleagues describe several series of heterocycles interacting with the hydrophobic region of the σ<sub>1</sub> receptor based on their previously identified Tic-hydantoin derivative <b>92</b> (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). <b>92</b> shows nanomolar σ<sub>1</sub> receptor binding affinity, high selectivity over σ<sub>2</sub> receptors, and low cytotoxicity, but its development is limited by metabolic instability.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> A series of tricyclic derivatives including carbolines and phenothiazines was thus synthesized to replace the tic-hydantoin core of <b>92</b>.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Tetrahydrobenzofuropyridine <b>93</b> and phenothiazine <b>95</b> bearing an <i>N</i>-methyl-<i>N</i>-phenylethylamine moiety show the best σ<sub>1</sub>/σ<sub>2</sub> selectivity (ratio: 31 for <b>93</b>, 28 for <b>95</b>), whereas their corresponding γ-carboline <b>94</b> and phenoxazine analogue <b>96</b> show lower σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub>: 11 nM for <b>94</b> vs 2.5 nM for <b>93</b>; 18 nM for <b>96</b> vs 11 nM for <b>95</b>) and lower σ<sub>1</sub>/σ<sub>2</sub> selectivity (4–18-fold). Except <b>95</b> (8.6 μM), these tricyclic derivatives all exhibited low cytotoxicity (25.4–46.9 μM) in the human neuroblastoma cell line SY5Y employed in a colorimetric MTT assay. Because the most promising compound <b>93</b> has moderate selectivity over σ<sub>2</sub> receptors (31-fold), a new series of benzannulated heterocycles were designed and synthesized as alternatives to the tic-hydantoin <b>92</b>.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Benzothiazolinonic compound <b>97</b> possesses high σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 0.6 nM), good σ<sub>1</sub>/σ<sub>2</sub> subtype selectivity (48-fold), and no cytotoxic effects in SY5Y cells. Replacement of the sulfur atom of <b>97</b> by an oxygen atom resulted in benzoxazolinone <b>98</b> with decreased binding affinity and selectivity for σ<sub>1</sub> receptors, similarly seen in <b>95</b> and <b>96</b>. To improve the σ<sub>1</sub> receptor selectivity and simplify the structure, benzamide-derived compounds with no heterocycles were recently designed.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> Compounds <b>99</b> and <b>100</b> with cyano or nitro group at the 4-position of the benzamide scaffold exhibit excellent σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 1.2–3.6 nM) and very low cytotoxicity. <b>99</b> and <b>100</b> hold excellent σ<sub>1</sub> receptor selectivity profiles over σ<sub>2</sub> receptors (ratio: up to 389) and 40 other receptors including H<sub>1</sub>, 5-HT<sub>3</sub>, and μ opioid receptors.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a></div><div class="NLM_p">In 2016, Zampieri  <i>et al</i>.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> designed 1-(4-(aryl(methyl)amino)butyl)-heterocyclic derivatives as substitutes for benzoxazolones (<i>e.g.</i>, <b>98</b>) based upon modeling. As shown in <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, the 4-phenyloxazolidin-2-one derivatives (<i>R</i>)-<b>101</b> and (<i>R</i>)-<b>102</b> achieved low nanomolar σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 2.9 nM and 7.7 nM, respectively) and selectivity over σ<sub>2</sub> receptors (<i>K</i><sub>i</sub> > 3000 nM and 603 nM, respectively), and minimal cytotoxicity in the MTT viability assay employing human SH-SY5Y neuroblastoma cells (<15% inhibition @ 50 μM).<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Chromene <b>103</b>, with a tertiary amine, shows high σ<sub>1</sub> receptor affinity (<i>K</i><sub>i</sub> = 0.95 nM) and good selectivity over the σ<sub>2</sub> receptor (568-fold), whereas the <i>N</i>-demethyl analogue <b>104</b> with a secondary amine results in decreased binding affinity (<i>K</i><sub>i</sub> = 11 nM) and selectivity for the σ<sub>1</sub> receptor (77-fold).<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Tetrahydroindazole <b>105</b> also potently binds to the σ<sub>1</sub> receptor (<i>K</i><sub>i</sub> = 17 nM) and shows high selectivity over σ<sub>2</sub> receptors (<i>K</i><sub>i</sub> > 10 μM).<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> From molecular docking results, a potential hydrogen bond was described between the C-5 amine and residues Tyr120 and Glu172 of the σ<sub>1</sub> receptor. However, <b>105</b> was found to have poor solubility and only moderate stability in mouse liver microsomes, likely due to the 2-p-F-Ph-tetrahydroindazole fragment.</div><div class="NLM_p last">Collectively, because σ<sub>1</sub> receptor pharmacophores highly converge and tolerate diverse side groups, a variety σ<sub>1</sub> receptor ligands have been identified. AVA-2-73, RC-33, pridopidine, pentazocine, SA4503, and its analogue <b>9</b> and spiro ring-opened derivative <i>trans</i>-(+)-<b>70</b> are identified as σ<sub>1</sub> receptor agonists, while S1RA and its analogues <b>34</b>–<b>45</b>, spirocyclic ligands <b>55</b>, <b>62b</b>, and <b>64a-b</b>, the other three isomers of <i>trans</i>-(+)-<b>70</b>, polycyclic ligand <b>81</b>, and acyclic amine <b>89</b> are σ<sub>1</sub> receptor antagonists. The overlay of σ<sub>1</sub> receptor cocrystal structures (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) indicates that the antagonist PD144418 and the agonist (+)-pentazocine extend into different regions of the hydrophobic pocket, which is consistent with the opposite spatial configurations of <i>trans</i>-(+)-<b>70</b> and its <i>cis</i> isomers. However, there is no direct structural information to differentiate between σ<sub>1</sub> receptor agonists and antagonists. Hence, it is important to address the question as to how two diastereomers (epimers) of <b>70</b> bind to the σ<sub>1</sub> receptor and exert opposite effects to identify the structural determinants of σ<sub>1</sub> receptor function to guide the rational drug design.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">5.2.  Small Molecules as Selective Sigma-1 Allosteric Modulators</h3><div class="NLM_p">Allosterically modulating receptors represents an alternative and promising strategy for CNS drug discovery to achieve subtype selectivity.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> Compared to the well characterized, selective σ<sub>1</sub> receptor agonists and antagonists, allosteric modulators are less studied due to both the unknown endogenous ligand and the elusive understanding of σ<sub>1</sub> receptor mechanics that may facilitate allosteric modulation. Generally, σ<sub>1</sub> receptor allosteric modulators are artificially defined based on their ability to regulate the binding activity of defined σ<sub>1</sub> radioligands including [<sup>3</sup>H](+)-pentazocine, [<sup>3</sup>H]dextromethorphan ([<sup>3</sup>H]DM), [<sup>3</sup>H]1,3-di(2-tolyl)guanidine ([<sup>3</sup>H]DTG), and [<sup>3</sup>H](+)-3-(3-hydroxyphenyl)-<i>N</i>-propylpiperidine ([<sup>3</sup>H](+)-3-PPP), which are thought to bind to the σ<sub>1</sub> receptor orthosteric binding site with high affinity and selectivity. To date, there are no reported negative allosteric modulators (NAMs), but several described σ<sub>1</sub> receptor positive allosteric modulators (PAMs) including phenytoin, piracetam derivatives, and benzazepines (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Sigma-1 receptor allosteric modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Phenytoin, used clinically since 1930 as an anticonvulsant drug, was identified as the first σ<sub>1</sub> receptor allosteric modulator in virtue of the capability to increase the binding of [<sup>3</sup>H]DM<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> and [<sup>3</sup>H](+)-3-PPP in guinea pig brain preparations.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Curiously, its modulator effects were only found in rat brain tissue but not in rat liver tissue.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Another anticonvulsant compound, Ropizine (SC-13504), with a benzhydryl piperazine structure, was also shown to increase the binding of [<sup>3</sup>H]DM<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> and [<sup>3</sup>H](+)-3-PPP<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> in a concentration-dependent manner in guinea pig brain preparations. Notably, its allosteric effects are 10-fold greater than that of phenytoin on [<sup>3</sup>H]DM binding. Phenytoin and Ropizine are typically considered nonselective σ<sub>1</sub> receptor allosteric modulators due to their unclear pharmacological effects.</div><div class="NLM_p">Piracetam, a cyclic derivative of γ-aminobutyric acid (GABA), is one of the most common nootropic drugs for the treatment of cognitive and memory disorders (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> In 2013, Veinberg and co-workers<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> synthesized 4,5-disubstituted piracetam derivatives as σ<sub>1</sub> receptors modulators via an asymmetric Michael addition reaction using 2,2′-cyclopropylidene-bis-oxazoline as the chiral catalyst. The 4<i>R</i> stereoisomers, E1R and T1R, were identified as the most effective σ<sub>1</sub> receptor PAMs with weak σ<sub>1</sub> receptor binding affinity. At 10 μM concentration, E1R and T1R enhanced the effects of the selective σ<sub>1</sub> receptor agonist PRE084 to 222% and 191%, respectively, in the electrically stimulated rat vas deferens model.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> E1R enhances the binding of the nonselective σ<sub>1</sub> receptor radioligand [<sup>3</sup>H]DTG by 38% at 10 μM in Jurkat cells, but it did not displace [<sup>3</sup>H](+)-pentazocine from the σ<sub>1</sub> receptor. E1R shows little or no activity at 10 μM concentration in a radioligand displacement assay covering 77 different targets including numerous ion channels, GPCR and CNS transporter targets, suggesting its overall good selectivity.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Further <i>in vivo</i> studies in rodents found E1R improved cognitive functions and alleviated scopolamine-induced cholinergic dysfunction without influencing locomotor activity.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Recently, E1R was also reported to show anticonvulsive effects at a dose of 50 mg/kg in pentylenetetrazol (PTZ)- and (+)-bicuculline (BIC)-induced clonic and tonic seizure models in mice.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> Notably, the antiseizure activity of E1R can be blocked by a selective σ<sub>1</sub> receptor antagonist (<i>e.g.</i>, NE-100); conversely, E1R also can significantly alleviate the convulsive behavior induced by the administration of NE-100. These findings support a σ<sub>1</sub> receptor-mediated activity profile <i>in vitro</i> and <i>in vivo</i>.</div><div class="NLM_p">In 2013, our team has identified several benzazepine derivatives as novel σ<sub>1</sub> receptor allosteric modulators by screening our own chemical library of dopamine receptor ligands (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> SKF83959, originally a potent dopamine D<sub>1</sub>-like receptor partial agonist, was found to increase the binding of [<sup>3</sup>H](+)-pentazocine to the σ<sub>1</sub> receptor in both rat brain and liver tissues. Its cooperativity factor (α) was 2.277 in the brain and 2.604 in the liver, greater than that of phenytoin (α = 1.562). Intriguingly, no PAM effects of the D<sub>1</sub> receptor selective agonist SCH22390 or D<sub>1</sub> receptor antagonist SKF38393 were detectable in brain tissues,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> but PAM effects were observed in liver tissues with α values of 2.507 and 1.882 for SCH23390 and SKF38393, respectively. Additionally, all of the above three compounds elicited no significant effect on [<sup>3</sup>H]-DTG binding to the σ<sub>2</sub> receptor, indicating that they are selective σ<sub>1</sub> receptor PAMs. Further <i>in vivo</i> studies found that the anticonvulsant activity of SKF83959 was attributed to σ<sub>1</sub> receptor modulation and its anti-Parkinson’s, antidepressant, and memory improvement activities were mainly mediated by interactions with dopamine receptors.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> SKF83959 at doses of 20 and 40 mg/kg demonstrated anticonvulsant effects in PTZ- and kainic acid (KA)-induced seizures models. SKF83959 reduced cortical epileptiform activity and did not alter spontaneous motor activity or motor coordination, which are common side effects of current antiepileptic drugs and σ<sub>1</sub> receptor agonists. The antiseizure effects can be blocked by the selective σ<sub>1</sub> receptor antagonist BD-1047 and not the dopamine D<sub>1</sub> receptor antagonist SCH23390, indicating the antiseizure effects of SKF83959 are D<sub>1</sub> receptor independent and attributable to its σ<sub>1</sub> receptor positive allosteric modulation activity.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a></div><div class="NLM_p">Further medicinal chemistry efforts led to the discovery of SOMCL-668, which displays potent σ<sub>1</sub> receptor positive allosteric modulation with no significant affinity for the D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, α<sub>1</sub>, and α<sub>2</sub> receptors.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> At a dose of 40 mg/kg, SOMCL-668 exerted similar antiseizure activities as SKF83959 in the PTZ-induced seizure model. Moreover, SOMCL-668 also produced potent and rapid antidepressant activity.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> SOMCL-668 at doses of 10 and 20 mg/kg significantly decreased the immobility time of mice in the forced-swimming and tail suspension tests. Daily administration of SOMCL-668 at a dose of 10 mg/kg for 1 week significantly reversed the decrease in the sucrose preference in the chronic mild stress model in mice.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Importantly, the antiseizure and antidepressant effects of SOMCL-668 were found to be σ<sub>1</sub> receptor dependent and could be abolished by BD-1047.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p last">Taken together, there are limited well-characterized σ<sub>1</sub> receptor PAMs that have been identified, and it remains unclear whether these structurally different PAMs bind to the same pocket or exert similar allosteric influence on the σ<sub>1</sub> receptor. Therefore, the development of new biochemical assays to identify PAMs binding to conserved sites, the establishment of σ<sub>1</sub> receptor PAM SAR and pharmacophore models to find novel modulators, and the solution of cocrystal structures of the σ<sub>1</sub> receptor and allosteric modulators will each be important contributions made in their respective fields of study to spur innovations in σ<sub>1</sub> receptor PAM drug discovery.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">6.  Conclusions and Future Directions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88135" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88135" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the discovery of the σ<sub>1</sub> receptor and the early misclassification as an opioid receptor subtype in 1976, the scientific community has witnessed significant progress in understanding the σ<sub>1</sub> receptor’s functions and roles in physiological and pathophysiological conditions. Both of the σ<sub>1</sub> receptor pharmacophore model first established by Glennon and the first crystal structure revealed by Schmidt provided pivotal insights into the essential structural features that guide ligand binding at the orthosteric site of the σ<sub>1</sub> receptor. Extensive drug discovery campaigns have provided several drug candidates, including pridopidine, S1RA, SA4503, ANAVEX2-73, and T-817MA, which have progressed into phase 2/3 human clinical trials. Thus, confirming the idea that by developing selective σ<sub>1</sub> receptor orthosteric ligands a valid therapeutic may be achieved for pain, neurodegenerative diseases (<i>e.g.</i>, AD, PD, HD, Rett syndrome), depression, and ischemic stroke. In addition, the identification of several σ<sub>1</sub> receptor PAMs (<i>e.g.</i>, E1R and SOMCL-668) further offers new avenues for the treatment of neurological diseases, including cognition dysfunction, seizure, and depression. Hence, selectively targeting the σ<sub>1</sub> receptor with associated small molecule ligands may represent a unique approach and viable therapeutic strategy for various CNS diseases.</div><div class="NLM_p">However, progress in the efforts to clearly define the molecular mechanisms of the σ<sub>1</sub> receptor has been hampered by the inability to clearly identify a σ<sub>1</sub> receptor-preferring or selective endogenous ligand. It may be the case that the σ<sub>1</sub> receptor’s functionality has evolved to be activated or modulated by a number of endogenous agents, which may be uncovered to act in tissue-specific manners. A full understanding of σ<sub>1</sub> receptor activity would also require revealing the structural basis of σ<sub>1</sub> receptor interactions with various effector proteins, the mechanisms of σ<sub>1</sub> receptor activation and the likely important role of σ<sub>1</sub> receptor oligomerization. Newly developed gene editing technologies such as clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR/Cas9), transcription activator-like effector nucleases (TALENs), and zinc-finger nucleases (ZFNs) may facilitate the screening σ<sub>1</sub> receptor functions and the elucidation of relevant molecular mechanisms. Additionally, it is worth noting that the fate of the currently active drug candidates is dependent on the outcomes of ongoing phase 2/3 human clinical trials. Although there have been no disclosures on the potential side effects or the adverse effect profile of σ<sub>1</sub> receptor drug candidates, their safety concerns should be considered in the drug development process due to the wide distribution and multiple signaling pathways associated with the σ<sub>1</sub> receptor. Disease indications such as AD and other neurological conditions have historically posed great difficulties to the design and execution of clinical trials. With the recent wealth of clinical trial data, especially in AD, describing patient selection and identifying outcomes, the future progression of new σ<sub>1</sub> receptor ligands through clinical studies stands to benefit from these prior efforts.</div><div class="NLM_p last">On the basis of the diverse pathogenesis of neurological diseases, polypharmacological agents that additionally exhibit σ<sub>1</sub> receptor activity may be attractive therapeutic development targets, as exemplified by clinically used CNS drugs as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Currently, dual opioid receptor agonists and σ<sub>1</sub> receptor antagonists are being developed for pain treatment<a onclick="showRef(event, 'ref208 ref209'); return false;" href="javascript:void(0);" class="ref ref208 ref209">(208,209)</a> and dual β-secretase inhibitors and σ<sub>1</sub> receptor agonists for AD.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> It is the opinion of these authors that further development of new high-throughput screening assay methods, new organic methodology, or computer-aided drug design (<i>e.g.</i>, virtual screening, structure- or fragment-based drug design) to discover novel σ<sub>1</sub> receptor orthosteric/allosteric chemotypes, and further medicinal chemistry efforts to optimize the currently available σ<sub>1</sub> receptor agonists, antagonists, and modulators with enhanced potency and subtype selectivity as well as improved druglike properties, are highly anticipated to pave the way for the development of new medications by selectively targeting this receptor.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01192" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Na Ye</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3612-1771" title="Orcid link">http://orcid.org/0000-0003-3612-1771</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9de4f8f3fcddeee8f9fcb3f8f9e8b3fef3"><span class="__cf_email__" data-cfemail="abd2cec5caebd8decfca85cecfde85c8c5">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Zhou</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Program, Department of Pharmacology and Toxicology, and Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2811-1090" title="Orcid link">http://orcid.org/0000-0002-2811-1090</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#03696a796b6c764376776e612d666776"><span class="__cf_email__" data-cfemail="2f45465547405a6f5a5b424d014a4b5a">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xue-Chu Zhen</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b6ccded3d8cec3d3d5dec3f6c5c3d2d798d3d2c398d5d8"><span class="__cf_email__" data-cfemail="067c6e63687e7363656e73467573626728636273286568">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wangzhi Qin</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng Tian</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingfeng Xu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric A. Wold</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Program, Department of Pharmacology and Toxicology, and Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6434-7562" title="Orcid link">http://orcid.org/0000-0001-6434-7562</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45217" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45217" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Na Ye</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Na Ye</b> is currently an Associate Professor in the Department of Medicinal Chemistry, College of Pharmaceutical Sciences, at Soochow University, leading a drug discovery research group. She earned her Ph.D. in Medicinal Chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, under the supervision of Dr. Ao Zhang in 2013, and then started her postdoctoral training under the direction of Dr. Jia Zhou at the University of Texas Medical Branch (UTMB) for three years. Dr. Ye is an author of more than 40 papers and an inventor of 15 patents. Her research topics focus on target-based drug design and the chemical synthesis of bioactive small molecules for the treatment of CNS disorders and cancer.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Wangzhi Qin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wangzhi Qin</b> is currently pursuing his M.S. degree in Medicinal Chemistry under the supervision of Dr. Na Ye at the College of Pharmaceutical Science, Soochow University. In 2018, he completed his graduation project at the Institute of Materia Medica, Chinese Academy of Medical Sciences, and received his bachelor’s degree from Changzhi Medical College. His main interest focuses on the design and synthesis of sigma-1 receptor selective agonists and positive allosteric modulators as potential medications.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Sheng Tian</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=bio3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sheng Tian</b> received his Ph.D. in Chemical Biology from the Institute of Functional Nano and Soft Materials (FUNSOM) at Soochow University under the tutelage of Dr. Tingjun Hou in 2014 and then studied as a postdoctoral associate with Dr. Xue-Chu Zhen in the College of Pharmaceutical Sciences at Soochow University. Currently he is an Associate Professor in the College of Pharmaceutical Sciences at Soochow University. His research focuses on computer-aided drug design and theoretical predictions of important ADME/T properties. To date, he has coauthored more than 40 publications in peer-reviewed journals.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Qingfeng Xu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=bio4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Qingfeng Xu</b> studied Pharmaceutical Engineering at Qiqihaer University, China, where he received his bachelor’s degree. Currently, Qingfeng Xu is pursuing his master’s degree in the Department of Medicinal Chemistry at the College of Pharmaceutical Sciences, Soochow University, under the supervision of Dr. Na Ye. His research focus is on the development of organic methodologies for the synthesis of bioactive small molecules targeting CNS disorders and cancer.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Eric A. Wold</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=bio5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Eric A. Wold</b> received his B.S. degree in Biotechnology from the University of Houston, completing undergraduate capstone research on microbial expression systems and enzymatic organophosphate hydrolysis under the guidance of Dr. Rupa Iyer. He is pursuing a Ph.D. with a focus in neuropharmacology and medicinal chemistry at the University of Texas Medical Branch under the training of Professor Jia Zhou. Currently, Eric is using computational methods to identify prospective GPCR binding sites for small molecule allosteric modulators, enabling the rational design of new CNS-targeted ligands. Additionally, his work on targeting membrane proteins has contributed to the discovery of pharmacological probes for CNS disorders, human cancers, and infectious diseases.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Jia Zhou</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=bio6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jia Zhou</b> received his Ph.D. in Organic Chemistry from Nankai University, China in 1997. Then he joined the chemistry faculty in the same university and was promoted to Associate Professor there. He started his postdoctoral research in organic chemistry with Dr. Sidney M. Hecht at University of Virginia in 1999. After further postdoctoral training in Medicinal Chemistry with Dr. Alan P. Kozikowski at Georgetown University Medical Center, he worked in the US pharmaceutical industry as a Senior Principal Scientist for seven years. Dr. Zhou is currently a tenured Professor at UTMB, leading a drug discovery team with research programs for human cancers, CNS disorders and infectious diseases. He is an author of more than 180 peer-reviewed papers, seven book chapters, and an inventor of 26 patents.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Xue-Chu Zhen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=bio7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xue-Chu Zhen</b> is a Professor in the Department of Pharmacology and the Dean of Pharmaceutical Sciences at Soochow University since 2010 and was formerly Principal Investigator and Professor of Neuropharmacology at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, since 2006. He received his doctoral degree in 1996 at University of Geneva and then moved to Medical College of Pennsylvania and Pennsylvania State University Medical School for postdoctoral training. He was appointed as a faculty member in 1999 at Drexel University Medical School prior to moving to the City University of New York as an Associate Professor in the Department of Physiology and Pharmacology. Dr. Zhen’s research interests include the functional regulation and signaling transduction of neurotransmitter receptors and σ<sub>1</sub> receptor related disorders.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84548" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84548" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Bang Li for his assistance during the preparation in the manuscript. This work was supported by the National Natural Science Foundation of China (81703330, 81773702, 81973334), the Natural Science Foundation of Jiangsu Province (BK20170347), the Priority Academic Program Development of the Jiangsu Higher Education Institutes (PAPD), and the Jiangsu Key Laboratory of Neuropsychiatric Diseases (BM2013003). J.Z. is partially supported by the John D. Stobo, MD, Distinguished Chair Endowment Fund at UTMB. E.A.W. is supported by the National Institutes of Health (NIH) National Research Service Award (NRSA) F31 DA04551. E.A.W. and J.Z. have no financial connections with the above Chinese funding sources, and thus there is no conflict of interest to disclose.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">σ<sub>1</sub></td><td class="NLM_def"><p class="first last">sigma-1</p></td></tr><tr><td class="NLM_term">σ<sub>2</sub></td><td class="NLM_def"><p class="first last">sigma-2</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">endoplasmic reticulum</p></td></tr><tr><td class="NLM_term">MAM</td><td class="NLM_def"><p class="first last">mitochondria-associated membrane</p></td></tr><tr><td class="NLM_term">PM</td><td class="NLM_def"><p class="first last">plasma membrane</p></td></tr><tr><td class="NLM_term">PGRMC1</td><td class="NLM_def"><p class="first last">progesterone receptor membrane component 1</p></td></tr><tr><td class="NLM_term">TMEM97</td><td class="NLM_def"><p class="first last">transmembrane protein-97</p></td></tr><tr><td class="NLM_term">IUPHAR</td><td class="NLM_def"><p class="first last">International Union of Basic and Clinical Pharmacology</p></td></tr><tr><td class="NLM_term">PCP</td><td class="NLM_def"><p class="first last">phencyclidine</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">DMT</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethyltryptamine</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor kappa-light-chain-enhancer of activated B cells</p></td></tr><tr><td class="NLM_term">IP3</td><td class="NLM_def"><p class="first last">inositol triphosphate</p></td></tr><tr><td class="NLM_term">InsP<sub>3</sub>R</td><td class="NLM_def"><p class="first last">inositol triphosphate receptor</p></td></tr><tr><td class="NLM_term">DHEA</td><td class="NLM_def"><p class="first last">dehydroepiandrosterone</p></td></tr><tr><td class="NLM_term">GABA</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid</p></td></tr><tr><td class="NLM_term">DRN</td><td class="NLM_def"><p class="first last">dorsal raphe nucleus</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">ALS</td><td class="NLM_def"><p class="first last">amyotrophic lateral sclerosis</p></td></tr><tr><td class="NLM_term">APOE</td><td class="NLM_def"><p class="first last">apolipoprotein E</p></td></tr><tr><td class="NLM_term">SK</td><td class="NLM_def"><p class="first last">small-conductance calcium-activated K<sup>+</sup></p></td></tr><tr><td class="NLM_term">PS1/2</td><td class="NLM_def"><p class="first last">presenilin 1/2</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">KO</td><td class="NLM_def"><p class="first last">knockout</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">6-OHDA</td><td class="NLM_def"><p class="first last">6-hydroxydopamine</p></td></tr><tr><td class="NLM_term">BDNF</td><td class="NLM_def"><p class="first last">brain derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">GDNF</td><td class="NLM_def"><p class="first last">glial cell derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">MNs</td><td class="NLM_def"><p class="first last">motor neurons</p></td></tr><tr><td class="NLM_term">FTLD</td><td class="NLM_def"><p class="first last">frontotemporal lobar degeneration</p></td></tr><tr><td class="NLM_term">MMPs</td><td class="NLM_def"><p class="first last">matrix metallopeptidases</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">serotonin selective reuptake inhibitors</p></td></tr><tr><td class="NLM_term">FST</td><td class="NLM_def"><p class="first last">forced swim test</p></td></tr><tr><td class="NLM_term">MAO-A</td><td class="NLM_def"><p class="first last">Monoamine oxidase A</p></td></tr><tr><td class="NLM_term">PDD</td><td class="NLM_def"><p class="first last">Parkinson’s disease with dementia</p></td></tr><tr><td class="NLM_term">RTT</td><td class="NLM_def"><p class="first last">Rett syndrome</p></td></tr><tr><td class="NLM_term">OXA</td><td class="NLM_def"><p class="first last">oxaliplatin</p></td></tr><tr><td class="NLM_term">OXAIPN</td><td class="NLM_def"><p class="first last">oxaliplatin-induced peripheral neuropathy</p></td></tr><tr><td class="NLM_term">CRMP2</td><td class="NLM_def"><p class="first last">collapsin-response-mediator-protein 2</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebrospinal fluid</p></td></tr><tr><td class="NLM_term">gp</td><td class="NLM_def"><p class="first last">guinea pig</p></td></tr><tr><td class="NLM_term">DAT</td><td class="NLM_def"><p class="first last">dopaminergic transporter</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">NET</td><td class="NLM_def"><p class="first last">norepinephrine transporter</p></td></tr><tr><td class="NLM_term">CCI</td><td class="NLM_def"><p class="first last">chronic constriction injury</p></td></tr><tr><td class="NLM_term">MOR</td><td class="NLM_def"><p class="first last">mu-opioid receptor</p></td></tr><tr><td class="NLM_term">DOR</td><td class="NLM_def"><p class="first last">deta-opioid receptor</p></td></tr><tr><td class="NLM_term">KOR</td><td class="NLM_def"><p class="first last">kappa-opioid receptor</p></td></tr><tr><td class="NLM_term">MCRs</td><td class="NLM_def"><p class="first last">multicomponent reactions</p></td></tr><tr><td class="NLM_term">PDSP</td><td class="NLM_def"><p class="first last">psychoactive drug screening program</p></td></tr><tr><td class="NLM_term">NIMH</td><td class="NLM_def"><p class="first last">National Institute of Mental Health</p></td></tr><tr><td class="NLM_term">DOS</td><td class="NLM_def"><p class="first last">diversity-oriented synthesis</p></td></tr><tr><td class="NLM_term">HP</td><td class="NLM_def"><p class="first last">haloperidol</p></td></tr><tr><td class="NLM_term">nAChR</td><td class="NLM_def"><p class="first last">nicotinic acetylcholine receptor</p></td></tr><tr><td class="NLM_term">[<sup>3</sup>H]DM[<sup>3</sup>H]</td><td class="NLM_def"><p class="first last">dextromethorphan</p></td></tr><tr><td class="NLM_term">[<sup>3</sup>H](+)-3-PPP</td><td class="NLM_def"><p class="first last">[<sup>3</sup><i>H</i>](+)-3-(3-hydroxyphenyl)-<i>N</i>-propylpiperidine</p></td></tr><tr><td class="NLM_term">[<sup>3</sup>H]DTG</td><td class="NLM_def"><p class="first last">[<sup>3</sup><i>H</i>]1,3-di(2-tolyl)guanidine</p></td></tr><tr><td class="NLM_term">NAMs</td><td class="NLM_def"><p class="first last">negative allosteric modulators</p></td></tr><tr><td class="NLM_term">PAMs</td><td class="NLM_def"><p class="first last">positive allosteric modulators</p></td></tr><tr><td class="NLM_term">PTZ</td><td class="NLM_def"><p class="first last">pentylenetetrazol</p></td></tr><tr><td class="NLM_term">BIC</td><td class="NLM_def"><p class="first last">(+)-bicuculline</p></td></tr><tr><td class="NLM_term">KA</td><td class="NLM_def"><p class="first last">kainic acid</p></td></tr><tr><td class="NLM_term">CRISPR/Cas9</td><td class="NLM_def"><p class="first last">clustered regularly interspaced short palindromic repeats-associated protein 9</p></td></tr><tr><td class="NLM_term">TALENs</td><td class="NLM_def"><p class="first last">transcription activator-like effector nucleases</p></td></tr><tr><td class="NLM_term">ZFNs</td><td class="NLM_def"><p class="first last">zinc-finger nucleases</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03361" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03361" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 210 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor chaperone as an inter-organelle signaling modulator</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2010.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.tips.2010.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20869780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGisbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=557-566&author=T.+P.+Suauthor=T.+Hayashiauthor=T.+Mauriceauthor=S.+Buchauthor=A.+E.+Ruoho&title=The+sigma-1+receptor+chaperone+as+an+inter-organelle+signaling+modulator&doi=10.1016%2Fj.tips.2010.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor chaperone as an inter-organelle signaling modulator</span></div><div class="casAuthors">Su, Tsung-Ping; Hayashi, Teruo; Maurice, Tangui; Buch, Shilpa; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">557-566</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inter-organelle signaling plays important roles in many physiol. functions.  Endoplasmic reticulum (ER)-mitochondrion signaling affects intramitochondrial calcium (Ca2+) homeostasis and cellular bioenergetics.  ER-nucleus signaling attenuates ER stress.  ER-plasma membrane signaling regulates cytosolic Ca2+ homeostasis and ER-mitochondrion-plasma membrane signaling regulates hippocampal dendritic spine formation.  Here, we propose that the sigma-1 receptor (Sig-1R), an ER chaperone protein, acts as an inter-organelle signaling modulator.  Sig-1Rs normally reside at the ER-mitochondrion contact called the MAM (mitochondrion-assocd. ER membrane), where Sig-1Rs regulate ER-mitochondrion signaling and ER-nucleus crosstalk.  When cells are stimulated by ligands or undergo prolonged stress, Sig-1Rs translocate from the MAM to the ER reticular network and plasmalemma/plasma membrane to regulate a variety of functional proteins, including ion channels, receptors and kinases.  Thus, the Sig-1R serves as an inter-organelle signaling modulator locally at the MAM and remotely at the plasmalemma/plasma membrane.  Many pharmacol./physiol. effects of Sig-1Rs might relate to this unique action of Sig-1Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqgD87pznGvLVg90H21EOLACvtfcHk0ljc7W4nitkzQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGisbbE&md5=a768850c77087ebf6732c0d57577f111</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2010.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2010.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DBuch%26aufirst%3DS.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DThe%2520sigma-1%2520receptor%2520chaperone%2520as%2520an%2520inter-organelle%2520signaling%2520modulator%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2010%26volume%3D31%26spage%3D557%26epage%3D566%26doi%3D10.1016%2Fj.tips.2010.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christ, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huesmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behl, C.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">211</span>, <span class="refDoi"> DOI: 10.3390/cells8030211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3390%2Fcells8030211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKnsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=211&author=M.+G.+Christauthor=H.+Huesmannauthor=H.+Nagelauthor=A.+Kernauthor=C.+Behl&title=Sigma-1+receptor+activation+induces+autophagy+and+increases+proteostasis+capacity+in+vitro+and+in+vivo&doi=10.3390%2Fcells8030211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo</span></div><div class="casAuthors">Christ, Maximilian G.; Huesmann, Heike; Nagel, Heike; Kern, Andreas; Behl, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Dysfunction of autophagy and disturbed protein homeostasis are linked to the pathogenesis of human neurodegenerative diseases and the modulation of autophagy as the protein clearance process has become one key pharmacol. target.  Due to the role of sigma-1 receptors (Sig-1R) in learning and memory, and the described pleiotropic neuroprotective effects in various exptl. paradigms, Sig-1R activation is recognized as one potential approach for prevention and therapy of neurodegeneration and, interestingly, in amyotrophic lateral sclerosis assocd. with mutated Sig-1R, autophagy is disturbed.  Here we analyzed the effects of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73), a muscarinic receptor ligand and Sig-1R agonist, on autophagy and proteostasis.  We describe, at the mol. level, for the first time, that pharmacol. Sig-1R activation a) enhances the autophagic flux in human cells and in Caenorhabditis elegans and b) increases proteostasis capacity, ultimately ameliorating paralysis caused by protein aggregation in C. elegans.  ANAVEX2-73 is already in clin. investigation for the treatment of Alzheimer's disease, and the novel activities of this compd. on autophagy and proteostasis described here may have consequences for the use and further development of the Sig-1R as a drug target in the future.  Moreover, our study defines the Sig-1R as an upstream modulator of canonical autophagy, which may have further implications for various conditions with dysfunctional autophagy, besides neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmdn1zzN_AnLVg90H21EOLACvtfcHk0ljc7W4nitkzQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKnsr%252FP&md5=d2aa7fdfe7eb6b828859dd20d1cf613f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3390%2Fcells8030211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8030211%26sid%3Dliteratum%253Aachs%26aulast%3DChrist%26aufirst%3DM.%2BG.%26aulast%3DHuesmann%26aufirst%3DH.%26aulast%3DNagel%26aufirst%3DH.%26aulast%3DKern%26aufirst%3DA.%26aulast%3DBehl%26aufirst%3DC.%26atitle%3DSigma-1%2520receptor%2520activation%2520induces%2520autophagy%2520and%2520increases%2520proteostasis%2520capacity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D211%26doi%3D10.3390%2Fcells8030211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goguadze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuravliova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikeladze, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor agonists induce oxidative stress in mitochondria and enhance complex I activity in physiological condition but protect against pathological oxidative stress</span>. <i>Neurotoxic. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1007/s12640-017-9838-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs12640-017-9838-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29127580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSrsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=1-18&author=N.+Goguadzeauthor=E.+Zhuravliovaauthor=D.+Morinauthor=D.+Mikeladzeauthor=T.+Maurice&title=Sigma-1+receptor+agonists+induce+oxidative+stress+in+mitochondria+and+enhance+complex+I+activity+in+physiological+condition+but+protect+against+pathological+oxidative+stress&doi=10.1007%2Fs12640-017-9838-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress</span></div><div class="casAuthors">Goguadze, Nino; Zhuravliova, Elene; Morin, Didier; Mikeladze, Davit; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-18</span>CODEN:
                <span class="NLM_cas:coden">NURRFI</span>;
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The sigma1 receptor (σ1R) is a chaperone protein residing at mitochondria-assocd. endoplasmic reticulum (ER) membranes (MAMs), where it modulates Ca2+ exchange between the ER and mitochondria by interacting with inositol-1,4,5 trisphosphate receptors (IP3Rs).  The σ1R is highly expressed in the central nervous system and its activation stimulates neuromodulation and neuroprotection, for instance in Alzheimer's disease (AD) models in vitro and in vivo. σ1R effects on mitochondria pathophysiol. and the downstream signaling are still not fully understood.  We here evaluated the impacts of σ1R ligands in mouse mitochondria prepns. on reactive oxygen species (ROS) prodn., mitochondrial respiration, and complex activities, in physiol. condition and after direct application of amyloid Aβ1-42 peptide. σ1R agonists (2-(4-morpholinethyl)-1-phenylcyclohexanecarboxylate hydrochloride (PRE-084), tetrahydro-N,N-dimethyl-5,5-diphenyl-3-furanmethanamine (ANAVEX1-41, AN1-41), (S)-1-(2,8-dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one (ANAVEX3-71, AN3-71), dehydroepiandrosterone-3 sulfate (DHEA), donepezil) increased mitochondrial ROS in a σ1R antagonist-sensitive manner but decreased Aβ1-42-induced increase in ROS. σ1R ligands (agonists or antagonists) did not impact respiration but attenuated Aβ1-42-induced alteration. σ1R agonists (PRE-084, AN1-41, tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AN2-73), AN3-71) increased complex I activity, in a Ca2+-dependent and σ1R antagonist-sensitive manner. σ1R ligands failed to affect complex II, III, and IV activities.  The increase in complex I activity explain the σ1R-induced increase in ROS since ligands failed to affect other sources of ROS accumulation in mitochondria and homogenates, namely NADPH oxidase (NOX) and superoxide dismutase (SOD) activities.  Furthermore, Aβ1-42 significantly decreased the activity of complexes I and IV and σ1R agonists attenuated the Aβ1-42-induced complex I and IV dysfunctions. σ1R activity in mitochondria therefore results in a Ying-Yang effect, by triggering moderate ROS increase acting as a physiol. signal and promoting a marked anti-oxidant effect in pathol. (Aβ) conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnPQT4YFFSzbVg90H21EOLACvtfcHk0ljc7W4nitkzQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSrsLnI&md5=765cb6c0c43cf8bea84bb3087a1e5ad6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs12640-017-9838-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12640-017-9838-2%26sid%3Dliteratum%253Aachs%26aulast%3DGoguadze%26aufirst%3DN.%26aulast%3DZhuravliova%26aufirst%3DE.%26aulast%3DMorin%26aufirst%3DD.%26aulast%3DMikeladze%26aufirst%3DD.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DSigma-1%2520receptor%2520agonists%2520induce%2520oxidative%2520stress%2520in%2520mitochondria%2520and%2520enhance%2520complex%2520I%2520activity%2520in%2520physiological%2520condition%2520but%2520protect%2520against%2520pathological%2520oxidative%2520stress%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2019%26volume%3D35%26spage%3D1%26epage%3D18%26doi%3D10.1007%2Fs12640-017-9838-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Marissal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medard, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzedine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrast, R.</span></span> <span> </span><span class="NLM_article-title">Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1093/brain/awv008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1093%2Fbrain%2Fawv008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25678561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC2MrltFyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2015&pages=875-890&author=N.+Bernard-Marissalauthor=J.+J.+Medardauthor=H.+Azzedineauthor=R.+Chrast&title=Dysfunction+in+endoplasmic+reticulum-mitochondria+crosstalk+underlies+SIGMAR1+loss+of+function+mediated+motor+neuron+degeneration&doi=10.1093%2Fbrain%2Fawv008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration</span></div><div class="casAuthors">Bernard-Marissal Nathalie; Medard Jean-Jacques; Azzedine Hamid; Chrast Roman</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">Pt 4</span>),
    <span class="NLM_cas:pages">875-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutations in Sigma 1 receptor (SIGMAR1) have been previously identified in patients with amyotrophic lateral sclerosis and disruption of Sigmar1 in mouse leads to locomotor deficits.  However, cellular mechanisms underlying motor phenotypes in human and mouse with disturbed SIGMAR1 function have not been described so far.  Here we used a combination of in vivo and in vitro approaches to investigate the role of SIGMAR1 in motor neuron biology.  Characterization of Sigmar1(-/-) mice revealed that affected animals display locomotor deficits associated with muscle weakness, axonal degeneration and motor neuron loss.  Using primary motor neuron cultures, we observed that pharmacological or genetic inactivation of SIGMAR1 led to motor neuron axonal degeneration followed by cell death.  Disruption of SIGMAR1 function in motor neurons disturbed endoplasmic reticulum-mitochondria contacts, affected intracellular calcium signalling and was accompanied by activation of endoplasmic reticulum stress and defects in mitochondrial dynamics and transport.  These defects were not observed in cultured sensory neurons, highlighting the exacerbated sensitivity of motor neurons to SIGMAR1 function.  Interestingly, the inhibition of mitochondrial fission was sufficient to induce mitochondria axonal transport defects as well as axonal degeneration similar to the changes observed after SIGMAR1 inactivation or loss.  Intracellular calcium scavenging and endoplasmic reticulum stress inhibition were able to restore mitochondrial function and consequently prevent motor neuron degeneration.  These results uncover the cellular mechanisms underlying motor neuron degeneration mediated by loss of SIGMAR1 function and provide therapeutically relevant insight into motor neuronal diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhjJvMF5NoGgpJitSxOdIlfW6udTcc2eZ9plj7tCzRkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrltFyjsw%253D%253D&md5=a9d9cbc7790f896feeb4c5fad68606e8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawv008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawv008%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Marissal%26aufirst%3DN.%26aulast%3DMedard%26aufirst%3DJ.%2BJ.%26aulast%3DAzzedine%26aufirst%3DH.%26aulast%3DChrast%26aufirst%3DR.%26atitle%3DDysfunction%2520in%2520endoplasmic%2520reticulum-mitochondria%2520crosstalk%2520underlies%2520SIGMAR1%2520loss%2520of%2520function%2520mediated%2520motor%2520neuron%2520degeneration%26jtitle%3DBrain%26date%3D2015%26volume%3D138%26spage%3D875%26epage%3D890%26doi%3D10.1093%2Fbrain%2Fawv008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canizares, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubero, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Segura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span> <span> </span><span class="NLM_article-title">Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice</span>. <i>Mol. Pain</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi"> DOI: 10.1186/1744-8069-10-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1186%2F1744-8069-10-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24517272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12ms7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=11&author=F.+R.+Nietoauthor=C.+M.+Cendanauthor=F.+J.+Canizaresauthor=M.+A.+Cuberoauthor=J.+M.+Velaauthor=E.+Fernandez-Seguraauthor=J.+M.+Baeyens&title=Genetic+inactivation+and+pharmacological+blockade+of+sigma-1+receptors+prevent+paclitaxel-induced+sensory-nerve+mitochondrial+abnormalities+and+neuropathic+pain+in+mice&doi=10.1186%2F1744-8069-10-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice</span></div><div class="casAuthors">Nieto, Francisco R.; Cendan, Cruz M.; Canizares, Francisco J.; Cubero, Maria A.; Vela, Jose M.; Fernandez-Segura, Eduardo; Baeyens, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pain</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11/1-11/12, 12</span>CODEN:
                <span class="NLM_cas:coden">MPOAC5</span>;
        ISSN:<span class="NLM_cas:issn">1744-8069</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Paclitaxel, a widely-used antineoplastic drug, produces a painful peripheral neuropathy that in rodents is assocd. with peripheral-nerve mitochondrial alterations.  The sigma-1 receptor (σ1R) is a ligand-regulated mol. chaperone involved in mitochondrial calcium homeostasis and pain hypersensitivity.  This receptor plays a key role in paclitaxel-induced neuropathic pain, but it is not known whether it also modulates mitochondrial abnormalities.  In this study, we used a mouse model of paclitaxel-induced neuropathic pain to test the involvement of the σ1R in the mitochondrial abnormalities assocd. with paclitaxel, by using genetic (σ1R knockout mice) and pharmacol. (σ1R antagonist) approaches.  Results: Paclitaxel administration to wild-type (WT) mice produced cold- and mech.-allodynia, and an increase in the frequency of swollen and vacuolated mitochondria in myelinated A-fibers, but not in C-fibers, of the saphenous nerve.  Behavioral and mitochondrial alterations were marked at 10 days after paclitaxel-administration and had resolved at day 28.  In contrast, paclitaxel treatment did not induce allodynia or mitochondrial abnormalities in σ1R knockout mice.  Moreover, the prophylactic treatment of WT mice with BD-1063 also prevented the neuropathic pain and mitochondrial abnormalities induced by paclitaxel.  Conclusions: These results suggest that activation of the σ1R is necessary for development of the sensory nerve mitochondrial damage and neuropathic pain produced by paclitaxel.  Therefore, σ1R antagonists might have therapeutic value for the prevention of paclitaxel-induced neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7RZewhZNEx7Vg90H21EOLACvtfcHk0limL_6gCJ6JAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12ms7rP&md5=2e3d7a755bd25fc4bc80d172e71dee57</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2F1744-8069-10-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1744-8069-10-11%26sid%3Dliteratum%253Aachs%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DCendan%26aufirst%3DC.%2BM.%26aulast%3DCanizares%26aufirst%3DF.%2BJ.%26aulast%3DCubero%26aufirst%3DM.%2BA.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DFernandez-Segura%26aufirst%3DE.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26atitle%3DGenetic%2520inactivation%2520and%2520pharmacological%2520blockade%2520of%2520sigma-1%2520receptors%2520prevent%2520paclitaxel-induced%2520sensory-nerve%2520mitochondrial%2520abnormalities%2520and%2520neuropathic%2520pain%2520in%2520mice%26jtitle%3DMol.%2520Pain%26date%3D2014%26volume%3D10%26spage%3D11%26doi%3D10.1186%2F1744-8069-10-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eades, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppler, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, P. E.</span></span> <span> </span><span class="NLM_article-title">The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=945347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaE28XltlOhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=1976&pages=517-532&author=W.+R.+Martinauthor=C.+G.+Eadesauthor=J.+A.+Thompsonauthor=R.+E.+Hupplerauthor=P.+E.+Gilbert&title=The+effects+of+morphine-+and+nalorphine-+like+drugs+in+the+nondependent+and+morphine-dependent+chronic+spinal+dog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog</span></div><div class="casAuthors">Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">517-32</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Three different syndromes produced by congeners of morphine sulfate (I sulfate) [64-31-3] were identified in the nondependent chronic spinal dog.  These syndromes were attributed to interaction of agonists with three distinguishable receptors (μ, κ and σ).  I was the prototype agonist for the μ receptor, ketocyclazocine lactate [59985-33-0] for the κ receptor and SKF-10,047 lactate [59985-34-1] for the σ receptor.  The I syndrome (μ) in the dog was characterized by miosis, bradycardia, hypothermia, a general depression of the nociceptive responses and indifferences to environmental stimuli.  Ketocyclazocine (κ) constricted pupils, depressed the flexor reflex and produced sedation but did not markedly alter pulse rate or the skin twitch reflex.  SKF-10,047 (σ) caused mydriasis, tachypnea, tachycardia and mania.  The effects of these three drugs was antagonized by the pure antagonist naltrexone-HCl, indicating that they are agonists.  Further, chronic administration of I, ketocyclazocine and SKF-10,047 induced tolerance to their agonistic effects.  I suppressed abstinence in I-dependent dogs while ketocyclazocine did not.  Ketocyclazocine at best pptd. only a liminal abstinence syndrome in the I-dependent dog, indicating that it had little affinity for the I receptor.  Ketocyclazocine thus appears to be a selective agonist at the κ receptor.  Buprenorphine-HCl [53152-21-9] was a partial agonist of the μ type which both suppressed and pptd. abstinence in the I-dependent dog while I and d-propoxyphene-HCl [1639-60-7] were stronger agonists.  Apomorphine-HCl [314-19-2] and SKF-10,047 produced similar pharmacol. effects suggesting that σ activity may involve a dopaminergic mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6rgyf41iRTbVg90H21EOLACvtfcHk0limL_6gCJ6JAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XltlOhurw%253D&md5=ca7c637f336ac9ecc2c3bb040dbcdbee</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DW.%2BR.%26aulast%3DEades%26aufirst%3DC.%2BG.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DHuppler%26aufirst%3DR.%2BE.%26aulast%3DGilbert%26aufirst%3DP.%2BE.%26atitle%3DThe%2520effects%2520of%2520morphine-%2520and%2520nalorphine-%2520like%2520drugs%2520in%2520the%2520nondependent%2520and%2520morphine-dependent%2520chronic%2520spinal%2520dog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1976%26volume%3D197%26spage%3D517%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Evidence for sigma opioid receptor: binding of [<sup>3</sup>H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>223</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=6290634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL3sXksV0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=1982&pages=284-290&author=T.+P.+Su&title=Evidence+for+sigma+opioid+receptor%3A+binding+of+%5B3H%5DSKF-10047+to+etorphine-inaccessible+sites+in+guinea-pig+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for sigma opioid receptor:  binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea pig brain</span></div><div class="casAuthors">Su, Tsung Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-90</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">A portion of the specific binding of tritiated dl-SKF-10047  [7313-95-3] to the guinea-pig brain suspension of the particulate fraction was not inhibited by the strong narcotic analgesic l-etorphine.  The binding properties of these etorphine-inaccessible (EI) sites were examd.  The specific binding of [3H]SKF-10047 to the EI sites was saturable.  Scatchard anal. of the satn. curve revealed a single class of binding sites with apparent Kd of 252 nM and an estd. Bmax of 663 fmol/mg of protein.  The EI binding was reduced by heat treatment, trypsin digestion and phospholipase C digestion.  The presence of Na+ slightly increased specific EI binding.  Li increased the EI binding by about 38% at the optimal concn. of 1 mM.  Divalent cations such as Mg2+, Ca2+ and Mn2+ reduced EI binding.  Morphine-like drugs such as l-morphine  [57-27-2], levorphanol  [77-07-6] and naltrexone  [16590-41-3] were poor inhibitors for the EI binding, whereas opioid derivs. such as dl-pentazocine  [359-83-1], dextrallorphan  [5822-43-5], dl-cyclazocine  [63903-61-7], SKF-10047 and dextrorphan  [125-73-5] were potent inhibitors.  Nonopioid drugs such as haloperidol  [52-86-8], imipramine  [50-49-7], pimozide  [2062-78-4] and dl-propranolol  [525-66-6] were also potent inhibitors of the EI binding.  Distribution of the EI sites in brain was different from that of the μ receptor: highest concn. of EI sites was found in brainstem, midbrain and cerebellum, whereas lower concns. were found in striatum and cortex.  Apparently, EI sites are not μ receptors but may represent σ receptors in the central nervous system, mediating psychotomimetic effects of several opioids and other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ7zMdhq6AbVg90H21EOLACvtfcHk0liTPlsPivnwbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXksV0%253D&md5=d5710578a9c7cdaaba979289cb753e01</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DEvidence%2520for%2520sigma%2520opioid%2520receptor%253A%2520binding%2520of%2520%255B3H%255DSKF-10047%2520to%2520etorphine-inaccessible%2520sites%2520in%2520guinea-pig%2520brain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1982%26volume%3D223%26spage%3D284%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. L.</span></span> <span> </span><span class="NLM_article-title">Stereoisomers of [<sup>3</sup>H]-<i>N</i>-allylnormetazocine bind to different sites in mouse brain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">544</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=6094791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL2MXhtVKjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1984&pages=539-544&author=B.+R.+Martinauthor=J.+S.+Katzenauthor=J.+A.+Woodsauthor=H.+L.+Tripathiauthor=L.+S.+Harrisauthor=E.+L.+May&title=Stereoisomers+of+%5B3H%5D-N-allylnormetazocine+bind+to+different+sites+in+mouse+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain</span></div><div class="casAuthors">Martin, Billy R.; Katzen, Judith S.; Woods, Judith A.; Tripathi, Hem L.; Harris, Louis S.; May, Everette L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">539-44</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The 3H-labeled (+)-  [58640-82-7] and (-)-  [14198-28-8] isomers of N-allylnormetazocine (NANM) were synthesized and evaluated for binding to mouse brain membranes.  Scatchard anal. of the saturable binding of (-)-[3H]NANM suggested a single class of binding sites with an apparent dissocn. const. KD of 2.1 nM and an estd. max. binding of 197 fmol/mg protein.  Increasing the concn. of Na+, K+, Mn2+, or Ca2+ decreased (-)-[3H]NANM specific binding.  (-)-[3H]NANM apparently binds to the μ opiate receptor in that (-)-isomers, but not the (+)-isomers, of N-cis-3-chloroallylnormetazocine, N-propynylnormetazocine, pentazocine, cyclazocine, naloxone, phenazocine, and morphine competed for binding.  The (-)-isomers of ethyloxocyclazocine and oxocyclazocine and NIH 9101  [57287-02-2] also displaced (-)-[3H]NANM binding which suggested κ activity in addn. to μ activity.  Phencyclidine  [77-10-1] and its analogs did not bind to the (-)-[3H]NANM site.  Scatchard anal. of saturable binding of (+)-[3H]NANM also revealed a homogeneous population of binding sites with apparent KD of 12 nM and an estd. max. binding of 360 fmol/mg protein.  This binding site was unaffected by increasing concns. of Na+ and K+, but binding was decreased by high concns. of Mn2+ and Ca2+.  The (+)-isomers of the benzomorphans N-cis-3-chloroallylnormetazocine, phenazocine, pentazocine, and cyclazocine effectively displaced (+)-[3H]NANM binding.  In addn., the (+)-isomers of osocyclazocine and ethyloxocyclazocine, as well as dextrorphan  [125-73-5], a (+)-morphinan, bound to the (+)-[3H]NANM site.  The (-)-isomers of μ agonist/antagonists and κ agonists competed poorly, or not at all, for the (+)-[3H]NANM site, whereas phencyclidine and related compds. exhibited a low affinity for this site.  Thus, the isomers of NANM bind to 2 distinct sites in mouse brain membranes, suggesting a heterogeneity of actions of the putative σ agonist (±)-NANM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAQjOmoHWNRbVg90H21EOLACvtfcHk0liTPlsPivnwbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXhtVKjtLc%253D&md5=37f85af241ade71eefc44545d8b0f3a9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DKatzen%26aufirst%3DJ.%2BS.%26aulast%3DWoods%26aufirst%3DJ.%2BA.%26aulast%3DTripathi%26aufirst%3DH.%2BL.%26aulast%3DHarris%26aufirst%3DL.%2BS.%26aulast%3DMay%26aufirst%3DE.%2BL.%26atitle%3DStereoisomers%2520of%2520%255B3H%255D-N-allylnormetazocine%2520bind%2520to%2520different%2520sites%2520in%2520mouse%2520brain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1984%26volume%3D231%26spage%3D539%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaupel, D. B.</span></span> <span> </span><span class="NLM_article-title">Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(83)90297-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2F0014-2999%2883%2990297-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=6313397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL3sXlvVOmurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1983&pages=269-274&author=D.+B.+Vaupel&title=Naltrexone+fails+to+antagonize+the+sigma+effects+of+PCP+and+SKF+10%2C047+in+the+dog&doi=10.1016%2F0014-2999%2883%2990297-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Naltrexone fails to antagonize the σ effects of PCP and SKF 10,047 in the dog</span></div><div class="casAuthors">Vaupel, D. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">269-74</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">SKF 10047 (N-allylnormetazocine)(I)  [14198-28-8] a benzomorphan narcotic antagonist, and the arylcyclohexylamine anesthetic phencyclidine (PCP)(II)  [77-10-1] produced similar reflex, autonomic and behavioral effects in the chronic spinal dog which were not antagonized by naltrexone pretreatment.  Naltrexone prevented the effects of morphine.  Apparently, the acute effects of phencyclidine and SKF 10,047 are alike and that their principal mechanism of action does not involve opiate activity of the morphine type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorcABIoaRnvLVg90H21EOLACvtfcHk0liTPlsPivnwbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlvVOmurs%253D&md5=b14cdb8ad58619f5170d009b005c6a34</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2883%2990297-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252883%252990297-2%26sid%3Dliteratum%253Aachs%26aulast%3DVaupel%26aufirst%3DD.%2BB.%26atitle%3DNaltrexone%2520fails%2520to%2520antagonize%2520the%2520sigma%2520effects%2520of%2520PCP%2520and%2520SKF%252010%252C047%2520in%2520the%2520dog%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1983%26volume%3D92%26spage%3D269%26epage%3D274%26doi%3D10.1016%2F0014-2999%2883%2990297-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor ligands: neurobiological effects</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.2174/0929867322666150114163607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F0929867322666150114163607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25620095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=989-1003&author=L.+Guoauthor=X.+Zhen&title=Sigma-2+receptor+ligands%3A+neurobiological+effects&doi=10.2174%2F0929867322666150114163607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 Receptor Ligands: Neurobiological Effects</span></div><div class="casAuthors">Guo, Lin; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">989-1003</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Sigma-2 receptor is a widely distributed protein, which can modulate cell proliferation and involved in the pathogenesis of tumor.  Photoaffinity labeling techniques testified that its mol. size is about 18 kDa.  Recent studies indicated that sigma-2 receptor modulates the cytosolic Ca2+ concn., dopaminergic transmission, and cocaine-induced addiction behavior.  Some sigma-2 receptor ligands (ditolylguanidine, afobazole, etc) display the neuroprotective effect.  Although sigma-2 receptor hasn't been cloned, tens of sigma-2 receptor ligands, which demonstrate high affinity and selectivity, have been identified in the past decade.  In this review, we mainly focus on these series of selective sigma-2 receptor ligands, their neuropsychol. effects, and mol. probes for tracing sigma-2 receptors in central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrATDnlV7WgQbVg90H21EOLACvtfcHk0lgYIgGB8QxL6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslCnsLs%253D&md5=bf46a950d9559199eb858f5381271167</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150114163607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150114163607%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DSigma-2%2520receptor%2520ligands%253A%2520neurobiological%2520effects%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D989%26epage%3D1003%26doi%3D10.2174%2F0929867322666150114163607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quirion, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itzhak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junien, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. P.</span></span> <span> </span><span class="NLM_article-title">A proposal for the classification of sigma binding sites</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/0165-6147(92)90030-A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2F0165-6147%2892%2990030-A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1315463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADyaK383ksFGrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1992&pages=85-86&author=R.+Quirionauthor=W.+D.+Bowenauthor=Y.+Itzhakauthor=J.+L.+Junienauthor=J.+M.+Musacchioauthor=R.+B.+Rothmanauthor=T.-P.+Suauthor=S.+W.+Tamauthor=D.+P.+Taylor&title=A+proposal+for+the+classification+of+sigma+binding+sites&doi=10.1016%2F0165-6147%2892%2990030-A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A proposal for the classification of sigma binding sites</span></div><div class="casAuthors">Quirion R; Bowen W D; Itzhak Y; Junien J L; Musacchio J M; Rothman R B; Su T P; Tam S W; Taylor D P</div><div class="citationInfo"><span class="NLM_cas:title">Trends in pharmacological sciences</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">85-6</span>
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9QiJWG_oOy3p3bfzSLaX5fW6udTcc2eZFYjvYIzN3SLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK383ksFGrsQ%253D%253D&md5=bdbde1d04c3c3e627e4ff512102ddf5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0165-6147%2892%2990030-A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-6147%252892%252990030-A%26sid%3Dliteratum%253Aachs%26aulast%3DQuirion%26aufirst%3DR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DItzhak%26aufirst%3DY.%26aulast%3DJunien%26aufirst%3DJ.%2BL.%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DSu%26aufirst%3DT.-P.%26aulast%3DTam%26aufirst%3DS.%2BW.%26aulast%3DTaylor%26aufirst%3DD.%2BP.%26atitle%3DA%2520proposal%2520for%2520the%2520classification%2520of%2520sigma%2520binding%2520sites%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1992%26volume%3D13%26spage%3D85%26epage%3D86%26doi%3D10.1016%2F0165-6147%2892%2990030-A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">The molecular function of sigma receptors: past, present, and future</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2019.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.tips.2019.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31387763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeqs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=636-654&author=H.+R.+Schmidtauthor=A.+C.+Kruse&title=The+molecular+function+of+sigma+receptors%3A+past%2C+present%2C+and+future&doi=10.1016%2Fj.tips.2019.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Function of σ Receptors: Past, Present, and Future</span></div><div class="casAuthors">Schmidt, Hayden R.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">636-654</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The σ1 and σ2 receptors are enigmatic proteins that have attracted attention for decades due to the chem. diversity and therapeutic potential of their ligands.  However, despite ongoing clin. trials with σ receptor ligands for multiple conditions, relatively little is known regarding the mol. function of these receptors.  In this review, we revisit past research on σ receptors and discuss the interpretation of these data in light of recent developments.  We provide a synthesis of emerging structural and genetic data on the σ1 receptor and discuss the recent cloning of the σ2 receptor.  Finally, we discuss the major questions that remain in the study of σ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonQzGSQdFecbVg90H21EOLACvtfcHk0lgHTi1B_OlJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeqs7bJ&md5=03896ad7b332beb873ad3fbc32c96423</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DThe%2520molecular%2520function%2520of%2520sigma%2520receptors%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26spage%3D636%26epage%3D654%26doi%3D10.1016%2Fj.tips.2019.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flandorfer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossmann, H.</span></span> <span> </span><span class="NLM_article-title">Purification, molecular cloning, and expression of the mammalian sigma1-binding site</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">8072</span>– <span class="NLM_lpage">8077</span>, <span class="refDoi"> DOI: 10.1073/pnas.93.15.8072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1073%2Fpnas.93.15.8072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=8755605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK28XksFSqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=8072-8077&author=M.+Hannerauthor=F.+F.+Moebiusauthor=A.+Flandorferauthor=H.+G.+Knausauthor=J.+Striessnigauthor=E.+Kempnerauthor=H.+Glossmann&title=Purification%2C+molecular+cloning%2C+and+expression+of+the+mammalian+sigma1-binding+site&doi=10.1073%2Fpnas.93.15.8072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Purification, molecular cloning, and expression of the mammalian sigma1-binding site</span></div><div class="casAuthors">Hanner, Markus; Moebius, Fabian F.; Flandorfer, Astrid; Knaus, Hans-Guenther; Striessnig, Joerg; Kempner, Ellis; Glossman, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8072-8077</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sigma-ligands comprise several chem. unrelated drugs such as haloperidol, pentazocine, and ditolylguanidine, which bind to a family of low mol. mass proteins in the endoplasmic reticulum.  These so-called sigma-receptors are believed to mediate various pharmacol. effects of sigma-ligands by as yet unknown mechanisms.  Based on their opposite enantioselectivity for benzomorphans and different mol. masses, two subtypes are differentiated.  We purified the sigma1-binding site as a single 30-kDa protein from guinea pig liver employing the benzomorphan (+)[3H]pentazocine and the aryladize (-)[3H]azidopamil as specific probes.  The purified (+)[3H]pentazocine-binding protein retained its high affinity for haloperidol, pentazocine, and ditolylguanidine.  Partial amino acid sequence obtained after trypsinolysis revealed no homol. to known proteins.  Radiation inactivation of the pentazocine-labeled sigma1-binding site yielded a mol. mass of 24 kDa.  The corresponding cDNA was cloned using degenerate oligonucleotides and cDNA library screening.  Its open reading frame encoded a 25.3-kDa protein with at least one putative transmembrane segment.  The protein expressed in yeast cells transformed with the cDNA showed the pharmacol. characteristics of the brain and liver sigma1-binding site.  The deduced amino acid sequence was structurally unrelated to known mammalian proteins but it shared homol. with fungal proteins involved in sterol synthesis.  Northern blots showed high densities of the sigma1-binding site mRNA in sterol-producing tissues.  This is also in agreement with the known ability of sigma1-binding sites to interact with steroids, such as progesterone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3kp2l6ZPKdrVg90H21EOLACvtfcHk0lgHTi1B_OlJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFSqsr8%253D&md5=01c7d3bbab83dd5d18531845213bf267</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.15.8072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.15.8072%26sid%3Dliteratum%253Aachs%26aulast%3DHanner%26aufirst%3DM.%26aulast%3DMoebius%26aufirst%3DF.%2BF.%26aulast%3DFlandorfer%26aufirst%3DA.%26aulast%3DKnaus%26aufirst%3DH.%2BG.%26aulast%3DStriessnig%26aufirst%3DJ.%26aulast%3DKempner%26aufirst%3DE.%26aulast%3DGlossmann%26aufirst%3DH.%26atitle%3DPurification%252C%2520molecular%2520cloning%252C%2520and%2520expression%2520of%2520the%2520mammalian%2520sigma1-binding%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D8072%26epage%3D8077%26doi%3D10.1073%2Fpnas.93.15.8072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kekuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibach, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1996.1842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1006%2Fbbrc.1996.1842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=8954936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK28Xns1ehtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=1996&pages=553-558&author=R.+Kekudaauthor=P.+D.+Prasadauthor=Y.+J.+Feiauthor=F.+H.+Leibachauthor=V.+Ganapathy&title=Cloning+and+functional+expression+of+the+human+type+1+sigma+receptor+%28hSigmaR1%29&doi=10.1006%2Fbbrc.1996.1842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1)</span></div><div class="casAuthors">Kekuda, Ramesh; Prasad, Puttur D.; Fei, You-Jun; Leibach, Frederich H.; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">553-558</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">We have isolated a cDNA clone from a human placental choriocarcinoma cell (JAR) cDNA library which codes for a functional type 1 sigma receptor.  An RT-PCR product obtained from guinea pig kidney mRNA using primers specific for the guineas pig sigma receptor cDNA was used to screen the cDNA library.  The hSigmaR1 cDNA predicts a protein of 223 amino acids with a single putative transmembrane domain.  The amino acid sequence exhibits 93% identity with the guinea pig sigma receptor.  When functionally expressed in HeLa cells, the hSigmaR1 cDNA enhances the binding of [3H]-haloperidol, a sigma receptor ligand, to the HeLa cell membranes.  The inhibitor specificity of the cloned hSigmaR1 indicates that it is the type 1 sigma receptor.  Several human tissues, including placenta, liver, and brain, and several human cell lines express the SigmaR1 mRNA (1.7 kb) to a variable extent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSSxDn_6je4bVg90H21EOLACvtfcHk0lgHTi1B_OlJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xns1ehtrw%253D&md5=8a128351bb8a55e5b3fc3dd31d879b90</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1996.1842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1996.1842%26sid%3Dliteratum%253Aachs%26aulast%3DKekuda%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DFei%26aufirst%3DY.%2BJ.%26aulast%3DLeibach%26aufirst%3DF.%2BH.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DCloning%2520and%2520functional%2520expression%2520of%2520the%2520human%2520type%25201%2520sigma%2520receptor%2520%2528hSigmaR1%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1996%26volume%3D229%26spage%3D553%26epage%3D558%26doi%3D10.1006%2Fbbrc.1996.1842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Identification of the gene that codes for the sigma2 receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7165</span>, <span class="refDoi"> DOI: 10.1073/pnas.1705154114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1073%2Fpnas.1705154114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28559337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=7160-7165&author=A.+Alonauthor=H.+R.+Schmidtauthor=M.+D.+Woodauthor=J.+J.+Sahnauthor=S.+F.+Martinauthor=A.+C.+Kruse&title=Identification+of+the+gene+that+codes+for+the+sigma2+receptor&doi=10.1073%2Fpnas.1705154114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the gene that codes for the σ2 receptor</span></div><div class="casAuthors">Alon, Assaf; Schmidt, Hayden R.; Wood, Michael D.; Sahn, James J.; Martin, Stephen F.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7160-7165</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The σ2 receptor is an enigmatic protein that has attracted significant attention because of its involvement in diseases as diverse as cancer and neurol. disorders.  Unlike virtually all other receptors of medical interest, it has eluded mol. cloning since its discovery, and the gene that codes for the receptor remains unknown, precluding the use of modern biol. methods to study its function.  Using a chem. biol. approach, we purified the σ2 receptor from tissue, revealing its identity as TMEM97, an endoplasmic reticulum-resident transmembrane protein that regulates the sterol transporter NPC1.  We show that TMEM97 possesses the full suite of mol. properties that define the σ2 receptor, and we identify Asp29 and Asp56 as essential for ligand recognition.  Cloning the σ2 receptor resolves a longstanding mystery and will enable therapeutic targeting of this potential drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoAS9Q6KtY7Vg90H21EOLACvtfcHk0lgHTi1B_OlJFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D&md5=71d3c246ebe6ac84c33980b97cb9889c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1705154114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1705154114%26sid%3Dliteratum%253Aachs%26aulast%3DAlon%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DIdentification%2520of%2520the%2520gene%2520that%2520codes%2520for%2520the%2520sigma2%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D7160%26epage%3D7165%26doi%3D10.1073%2Fpnas.1705154114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guitart, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montoliu, L.</span></span> <span> </span><span class="NLM_article-title">Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2188</span>– <span class="NLM_lpage">2196</span>, <span class="refDoi"> DOI: 10.1046/j.1460-9568.2003.02950.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1046%2Fj.1460-9568.2003.02950.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=14622179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BD3srksVWgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=2188-2196&author=F.+Langaauthor=X.+Codonyauthor=V.+Tovarauthor=A.+Lavadoauthor=E.+Gimenezauthor=P.+Cozarauthor=M.+Canteroauthor=A.+Dordalauthor=E.+Hernandezauthor=R.+Perezauthor=X.+Monroyauthor=D.+Zamanilloauthor=X.+Guitartauthor=L.+Montoliu&title=Generation+and+phenotypic+analysis+of+sigma+receptor+type+I+%28sigma+1%29+knockout+mice&doi=10.1046%2Fj.1460-9568.2003.02950.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice</span></div><div class="casAuthors">Langa Francina; Codony Xavier; Tovar Victoria; Lavado Alfonso; Gimenez Estela; Cozar Patricia; Cantero Marta; Dordal Albert; Hernandez Enric; Perez Raquel; Monroy Xavier; Zamanillo Daniel; Guitart Xavier; Montoliu Lluis</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2188-96</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Sigma (sigma) sites are a type of nonopiate receptor whose role has been associated with several behaviours, including anxiety, depression, analgesia, learning processes and psychosis.  Although there are several known sigma receptor types, only the type I receptor (sigma 1) has been cloned.  To uncover the in vivo relevance of sigma-receptors, we have generated knockout mice for sigma 1.  Despite the broad expression pattern found for the sigma 1-gene, homozygous mutant mice are viable, fertile and do not display any overt phenotype, compared with their wild-type litter-mates, in mixed genetic backgrounds.  However, a significant decrease in the hypermotility response has been measured in knockout mice upon challenge with (+)SKF-10 047, in agreement with the involvement of sigma 1-receptors in the induction of psychostimulant actions.  The activity of sigma 2-receptors seems to be unaffected in sigma 1-mutant mice.  These knockout mice could contribute to better understand the in vivo role of sigma-receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8ySfPf0Y6GEEksK8CslK8fW6udTcc2eZfg_7IpNh-l7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srksVWgsg%253D%253D&md5=eb1171c29ecada32dca53fe0effd3f01</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1046%2Fj.1460-9568.2003.02950.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1460-9568.2003.02950.x%26sid%3Dliteratum%253Aachs%26aulast%3DLanga%26aufirst%3DF.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DTovar%26aufirst%3DV.%26aulast%3DLavado%26aufirst%3DA.%26aulast%3DGimenez%26aufirst%3DE.%26aulast%3DCozar%26aufirst%3DP.%26aulast%3DCantero%26aufirst%3DM.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DE.%26aulast%3DPerez%26aufirst%3DR.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DGuitart%26aufirst%3DX.%26aulast%3DMontoliu%26aufirst%3DL.%26atitle%3DGeneration%2520and%2520phenotypic%2520analysis%2520of%2520sigma%2520receptor%2520type%2520I%2520%2528sigma%25201%2529%2520knockout%2520mice%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2003%26volume%3D18%26spage%3D2188%26epage%3D2196%26doi%3D10.1046%2Fj.1460-9568.2003.02950.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">596</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.08.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.cell.2007.08.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=17981125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWitrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=596-610&author=T.+Hayashiauthor=T.+P.+Su&title=Sigma-1+receptor+chaperones+at+the+ER-mitochondrion+interface+regulate+Ca%282%2B%29+signaling+and+cell+survival&doi=10.1016%2Fj.cell.2007.08.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival</span></div><div class="casAuthors">Hayashi, Teruo; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">596-610</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Communication between the endoplasmic reticulum (ER) and mitochondrion is important for bioenergetics and cellular survival.  The ER supplies Ca2+ directly to mitochondria via inositol 1,4,5-trisphosphate receptors (IP3Rs) at close contacts between the two organelles referred to as mitochondrion-assocd. ER membrane (MAM).  We found here that the ER protein sigma-1 receptor (Sig-1R), which is implicated in neuroprotection, carcinogenesis, and neuroplasticity, is a Ca2+-sensitive and ligand-operated receptor chaperone at MAM.  Normally, Sig-1Rs form a complex at MAM with another chaperone, BiP.  Upon ER Ca2+ depletion or via ligand stimulation, Sig-1Rs dissoc. from BiP, leading to a prolonged Ca2+ signaling into mitochondria via IP3Rs.  Sig-1Rs can translocate under chronic ER stress.  Increasing Sig-1Rs in cells counteracts ER stress response, whereas decreasing them enhances apoptosis.  These results reveal that the orchestrated ER chaperone machinery at MAM, by sensing ER Ca2+ concns., regulates ER-mitochondrial interorganellar Ca2+ signaling and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFqHhdVumdO7Vg90H21EOLACvtfcHk0lg_xxh8dQlkFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWitrzK&md5=7bb4e806d7ad895f9ed1a8c4f7eb7f6c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DSigma-1%2520receptor%2520chaperones%2520at%2520the%2520ER-mitochondrion%2520interface%2520regulate%2520Ca%25282%252B%2529%2520signaling%2520and%2520cell%2520survival%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D596%26epage%3D610%26doi%3D10.1016%2Fj.cell.2007.08.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faccenda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catterall, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spedding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmar, A. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The concise guide to pharmacology 2013/14: overview</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1111/bph.12444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fbph.12444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24528237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeqtLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=1449-1458&author=S.+P.+Alexanderauthor=H.+E.+Bensonauthor=E.+Faccendaauthor=A.+J.+Pawsonauthor=J.+L.+Sharmanauthor=J.+C.+McGrathauthor=W.+A.+Catterallauthor=M.+Speddingauthor=J.+A.+Petersauthor=A.+J.+Harmar&title=The+concise+guide+to+pharmacology+2013%2F14%3A+overview&doi=10.1111%2Fbph.12444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Concise Guide to PHARMACOLOGY 2013/14: Overview</span></div><div class="casAuthors">Alexander, Stephen P. H.; Benson, Helen E.; Faccenda, Elena; Pawson, Adam J.; Sharman, Joanna L.; McGrath, John C.; Catterall, William A.; Spedding, Michael; Peters, John A.; Harmar, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1449-1458</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The Concise Guide to PHARMACOl. 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacol., plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacol.org), which provides more detailed views of target and ligand properties from the IUPHAR database.  The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.12444/full.  This compilation of the major pharmacol. targets is divided into seven areas of focus: G protein-coupled receptors, ligand-gated ion channels, ion channels, catalytic receptors, nuclear hormone receptors, transporters and enzymes.  These are presented with nomenclature guidance and summary information on the best available pharmacol. tools, alongside key refs. and suggestions for further reading.  A new landscape format has easy to use tables comparing related targets.  It is a condensed version of material contemporary to late 2013, which is presented in greater detail and constantly updated on the website www.guidetopharmacol.org, superseding data presented in previous Guides to Receptors & Channels.  It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate.  It consolidates information previously curated and displayed sep. in IUPHAR-DB and GRAC and provides a permanent, citable, point-in-time record that will survive database updates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY6GzsPrSnGLVg90H21EOLACvtfcHk0liESnXK9BH_vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeqtLvM&md5=c52bfad1955f4967940f62215bde6c4a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fbph.12444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12444%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DS.%2BP.%26aulast%3DBenson%26aufirst%3DH.%2BE.%26aulast%3DFaccenda%26aufirst%3DE.%26aulast%3DPawson%26aufirst%3DA.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BL.%26aulast%3DMcGrath%26aufirst%3DJ.%2BC.%26aulast%3DCatterall%26aufirst%3DW.%2BA.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DHarmar%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520concise%2520guide%2520to%2520pharmacology%25202013%252F14%253A%2520overview%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D1449%26epage%3D1458%26doi%3D10.1111%2Fbph.12444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurpinar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human sigma1 receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1038/nature17391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fnature17391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27042935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=527-530&author=H.+R.+Schmidtauthor=S.+Zhengauthor=E.+Gurpinarauthor=A.+Koehlauthor=A.+Manglikauthor=A.+C.+Kruse&title=Crystal+structure+of+the+human+sigma1+receptor&doi=10.1038%2Fnature17391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human σ1 receptor</span></div><div class="casAuthors">Schmidt, Hayden R.; Zheng, Sanduo; Gurpinar, Esin; Koehl, Antoine; Manglik, Aashish; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7600</span>),
    <span class="NLM_cas:pages">527-530</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human σ1 receptor is an enigmatic endoplasmic reticulum (ER)-resident transmembrane protein implicated in a variety of disorders including depression, drug addiction, and neuropathic pain.  Recently, an addnl. connection to amyotrophic lateral sclerosis has emerged from studies of human genetics and mouse models.  Unlike many transmembrane receptors that belong to large, extensively studied families such as G-protein-coupled receptors or ligand-gated ion channels, the σ1 receptor is an evolutionary isolate with no discernible similarity to any other human protein.  Despite its increasingly clear importance in human physiol. and disease, the mol. architecture of the σ1 receptor and its regulation by drug-like compds. remain poorly defined.  Here, the authors report crystal structures of the human σ1 receptor in complex with 2 chem. divergent ligands, PD 144418 and 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP).  The structures revealed a trimeric architecture with a single transmembrane domain in each protomer.  The C-terminal domain of the receptor showed an extensive flat, hydrophobic membrane-proximal surface, suggesting an intimate assocn. with the cytosolic surface of the ER membrane in cells.  This domain included a cupin-like β-barrel with the ligand-binding site buried at its center.  This large, hydrophobic ligand-binding cavity showed remarkable plasticity in ligand recognition, binding the 2 ligands in similar positions despite dissimilar chem. structures.  Taken together, these results revealed the overall architecture, oligomerization state, and mol. basis for ligand recognition by this important but poorly understood protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokQBAf03Pml7Vg90H21EOLACvtfcHk0liESnXK9BH_vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D&md5=fb6df7814060fbd05ba41261ad1061f5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature17391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17391%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DGurpinar%26aufirst%3DE.%26aulast%3DKoehl%26aufirst%3DA.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520sigma1%2520receptor%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D527%26epage%3D530%26doi%3D10.1038%2Fnature17391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for sigma1 receptor ligand recognition</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0137-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fs41594-018-0137-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30291362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=981-987&author=H.+R.+Schmidtauthor=R.+M.+Betzauthor=R.+O.+Drorauthor=A.+C.+Kruse&title=Structural+basis+for+sigma1+receptor+ligand+recognition&doi=10.1038%2Fs41594-018-0137-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for σ1 receptor ligand recognition</span></div><div class="casAuthors">Schmidt, Hayden R.; Betz, Robin M.; Dror, Ron O.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-987</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The s1 receptor is a poorly understood membrane protein expressed throughout the human body.  Ligands targeting the s1 receptor are in clin. trials for treatment of Alzheimer's disease, ischemic stroke, and neuropathic pain.  However, relatively little is known regarding the s1 receptor's mol. function.  Here, we present crystal structures of human s1 receptor bound to the antagonists haloperidol and NE-100, and the agonist (+)-pentazocine, at crystallog. resolns. of 3.1 Å, 2.9 Å, and 3.1 Å, resp.  These structures reveal a unique binding pose for the agonist.  The structures and accompanying mol. dynamics (MD) simulations identify agonist-induced structural rearrangements in the receptor.  Addnl., we show that ligand binding to s1 is a multistep process that is rate limited by receptor conformational change.  We used MD simulations to reconstruct a ligand binding pathway involving two major conformational changes.  These data provide a framework for understanding the mol. basis for s1 agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ2dgVTV70vbVg90H21EOLACvtfcHk0liESnXK9BH_vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM&md5=d12d12aecbd89684824975977ec03e4b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0137-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0137-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DStructural%2520basis%2520for%2520sigma1%2520receptor%2520ligand%2520recognition%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D981%26epage%3D987%26doi%3D10.1038%2Fs41594-018-0137-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhemkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraskovskaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">862</span>, <span class="refDoi"> DOI: 10.3389/fnins.2019.00862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffnins.2019.00862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31551669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=862&author=D.+A.+Ryskampauthor=S.+Korbanauthor=V.+Zhemkovauthor=N.+Kraskovskayaauthor=I.+Bezprozvanny&title=Neuronal+sigma-1+receptors%3A+signaling+functions+and+protective+roles+in+neurodegenerative+diseases&doi=10.3389%2Ffnins.2019.00862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span></div><div class="casAuthors">Ryskamp Daniel A; Zhemkov Vladimir; Bezprozvanny Ilya; Korban Svetlana; Kraskovskaya Nina; Bezprozvanny Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">862</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer's (AD) and Huntington's diseases (HD).  S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic; yet, relatively little is known regarding the exact mechanisms of receptor functioning at the molecular level.  This review summarizes therapeutically relevant mechanisms by which S1R modulates neurophysiology and implements neuroprotective functions in neurodegenerative diseases.  These mechanisms are diverse due to the fact that S1R can bind to and modulate a large range of client proteins, including many ion channels in both ER and plasma membranes.  We summarize the effect of S1R on its interaction partners and consider some of the cell type- and disease-specific aspects of these actions.  Besides direct protein interactions in the endoplasmic reticulum, S1R is likely to function at the cellular/interorganellar level by altering the activity of several plasmalemmal ion channels through control of trafficking, which may help to reduce excitotoxicity.  Moreover, S1R is situated in lipid rafts where it binds cholesterol and regulates lipid and protein trafficking and calcium flux at the mitochondrial-associated membrane (MAM) domain.  This may have important implications for MAM stability and function in neurodegenerative diseases as well as cellular bioenergetics.  We also summarize the structural and biochemical features of S1R proposed to underlie its activity.  In conclusion, S1R is incredibly versatile in its ability to foster neuronal homeostasis in the context of several neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnXmondofHvmyYR5VtavbzfW6udTcc2ebMwbHUsQAFw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D&md5=b8a65774a44e82a94e5049247c993883</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2019.00862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2019.00862%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%2BA.%26aulast%3DKorban%26aufirst%3DS.%26aulast%3DZhemkov%26aufirst%3DV.%26aulast%3DKraskovskaya%26aufirst%3DN.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DNeuronal%2520sigma-1%2520receptors%253A%2520signaling%2520functions%2520and%2520protective%2520roles%2520in%2520neurodegenerative%2520diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D862%26doi%3D10.3389%2Ffnins.2019.00862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, J. H.</span></span> <span> </span><span class="NLM_article-title">Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1126/science.2832949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1126%2Fscience.2832949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=2832949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL1cXhvVShsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=1988&pages=219-221&author=T.+P.+Suauthor=E.+D.+Londonauthor=J.+H.+Jaffe&title=Steroid+binding+at+sigma+receptors+suggests+a+link+between+endocrine%2C+nervous%2C+and+immune+systems&doi=10.1126%2Fscience.2832949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Steroid binding at σ receptors suggests a link between endocrine, nervous, and immune systems</span></div><div class="casAuthors">Su, Tsung Ping; London, Edythe D.; Jaffe, Jerome H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">4849</span>),
    <span class="NLM_cas:pages">219-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review, with 27 refs., which shows that steroids are naturally occurring ligands for σ receptors.  These sites may mediate some aspects of steroid-induced mental disturbances and alterations in immune functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ8c6ri5jc4LVg90H21EOLACvtfcHk0lgQ3DVytfAN8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhvVShsrk%253D&md5=7bea36e8c31598c9652d93b991c71ef4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscience.2832949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2832949%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DLondon%26aufirst%3DE.%2BD.%26aulast%3DJaffe%26aufirst%3DJ.%2BH.%26atitle%3DSteroid%2520binding%2520at%2520sigma%2520receptors%2520suggests%2520a%2520link%2520between%2520endocrine%252C%2520nervous%252C%2520and%2520immune%2520systems%26jtitle%3DScience%26date%3D1988%26volume%3D240%26spage%3D219%26epage%3D221%26doi%3D10.1126%2Fscience.2832949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontanilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzi, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">The hallucinogen <i>N</i>,<i>N</i>-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">934</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1126/science.1166127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1126%2Fscience.1166127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19213917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslSgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2009&pages=934-937&author=D.+Fontanillaauthor=M.+Johannessenauthor=A.+R.+Hajipourauthor=N.+V.+Cozziauthor=M.+B.+Jacksonauthor=A.+E.+Ruoho&title=The+hallucinogen+N%2CN-dimethyltryptamine+%28DMT%29+is+an+endogenous+sigma-1+receptor+regulator&doi=10.1126%2Fscience.1166127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator</span></div><div class="casAuthors">Fontanilla, Dominique; Johannessen, Molly; Hajipour, Abdol R.; Cozzi, Nicholas V.; Jackson, Meyer B.; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">5916</span>),
    <span class="NLM_cas:pages">934-937</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The sigma-1 receptor is widely distributed in the central nervous system and periphery.  Originally mischaracterized as an opioid receptor, the sigma-1 receptor binds a vast no. of synthetic compds. but does not bind opioid peptides; it is currently considered an orphan receptor.  The sigma-1 receptor pharmacophore includes an alkylamine core, also found in the endogenous compd. N,N-dimethyltryptamine (DMT).  DMT acts as a hallucinogen, but its receptor target has been unclear.  DMT bound to sigma-1 receptors and inhibited voltage-gated sodium ion (Na+) channels in both native cardiac myocytes and heterologous cells that express sigma-1 receptors.  DMT induced hypermobility in wild-type mice but not in sigma-1 receptor knockout mice.  These biochem., physiol., and behavioral expts. indicate that DMT is an endogenous agonist for the sigma-1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAp8p0wmc1wLVg90H21EOLACvtfcHk0lgQ3DVytfAN8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslSgsbw%253D&md5=480f24607d42dbe5c5fcd9cdc8ee5e5c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscience.1166127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1166127%26sid%3Dliteratum%253Aachs%26aulast%3DFontanilla%26aufirst%3DD.%26aulast%3DJohannessen%26aufirst%3DM.%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DCozzi%26aufirst%3DN.%2BV.%26aulast%3DJackson%26aufirst%3DM.%2BB.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DThe%2520hallucinogen%2520N%252CN-dimethyltryptamine%2520%2528DMT%2529%2520is%2520an%2520endogenous%2520sigma-1%2520receptor%2520regulator%26jtitle%3DScience%26date%3D2009%26volume%3D323%26spage%3D934%26epage%3D937%26doi%3D10.1126%2Fscience.1166127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">The sigma1 receptor interacts with <i>N</i>-alkyl amines and endogenous sphingolipids</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>609</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2009.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejphar.2009.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19285059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslyhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=609&publication_year=2009&pages=19-26&author=S.+Ramachandranauthor=U.+B.+Chuauthor=T.+A.+Mavlyutovauthor=A.+Palauthor=S.+Pyneauthor=A.+E.+Ruoho&title=The+sigma1+receptor+interacts+with+N-alkyl+amines+and+endogenous+sphingolipids&doi=10.1016%2Fj.ejphar.2009.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids</span></div><div class="casAuthors">Ramachandran, Subramaniam; Chu, Uyen B.; Mavlyutov, Timur A.; Pal, Arindam; Pyne, Susan; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">609</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma1 receptor is distinguished for its ability to bind various pharmacol. agents including drugs of abuse such as cocaine and methamphetamine.  Some endogenous ligands have been identified as putative sigma1 receptor regulators.  High affinity ligands for the sigma1 receptor contain a nitrogen atom connected to long alkyl chains.  It was found that long alkyl chain primary amines including endogenous amines belonging to the sphingolipid family such as D-erythro-sphingosine and sphinganine bind with considerable affinity to the sigma1 receptor but not to the sigma2 receptor.  The binding of D-erythro-sphingosine to the sigma1 receptor appears to be competitive in nature as assessed against the radioligand [3H]-(+)-pentazocine.  Interestingly, the well studied sphingolipid mediator sphingosine-1 phosphate did not bind to the sigma1 or the sigma2 receptor.  Sphingosine is converted to sphingosine-1 phosphate by a family of sphingosine kinases that regulate the relative levels of these two bioactive lipids in the cell.  The selective binding of sphingosine but not sphingosine-1 phosphate to the sigma1 receptor suggests a mechanism for regulation of sigma1 receptor activity by the sphingosine kinase.  This hypothetical model was successfully reconstituted in HEK-293 cells over-expressing both the sigma1 receptor and sphingosine kinase-1.  The data presented here strongly supports sphingosine as an endogenous modulator of the sigma1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqlBCB_WLlKrVg90H21EOLACvtfcHk0lgQ3DVytfAN8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslyhtrw%253D&md5=346fe65ca526c85856fd6f836f966b8b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2009.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2009.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DU.%2BB.%26aulast%3DMavlyutov%26aufirst%3DT.%2BA.%26aulast%3DPal%26aufirst%3DA.%26aulast%3DPyne%26aufirst%3DS.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DThe%2520sigma1%2520receptor%2520interacts%2520with%2520N-alkyl%2520amines%2520and%2520endogenous%2520sphingolipids%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D609%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.ejphar.2009.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, M.</span></span> <span> </span><span class="NLM_article-title">Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1124/mol.109.062539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fmol.109.062539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20053954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2010&pages=517-528&author=T.+Hayashiauthor=M.+Fujimoto&title=Detergent-resistant+microdomains+determine+the+localization+of+sigma-1+receptors+to+the+endoplasmic+reticulum-mitochondria+junction&doi=10.1124%2Fmol.109.062539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Detergent-resistant microdomains determine the localization of σ-1 receptors to the endoplasmic reticulum-mitochondria junction</span></div><div class="casAuthors">Hayashi, Teruo; Fujimoto, Michiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">σ-1 Receptors (Sig-1Rs) that bind diverse synthetic and endogenous compds. have been implicated in the pathophysiol. of several human diseases such as drug addiction, depression, neurodegenerative disorders, pain-related disorders, and cancer.  Sig-1Rs were identified recently as novel ligand-operated mol. chaperones.  Although Sig-1Rs are predominantly expressed at endoplasmic reticulum (ER) subdomains apposing mitochondria [i.e., the mitochondria-assocd. ER membrane (MAM)], they dynamically change the cellular distribution, thus regulating both MAM-specific and plasma membrane proteins.  However, what dets. the location of Sig-1R at the MAM and how the receptor translocation is initiated is unknown.  Here we report that the detergent-resistant membranes (DRMs) play an important role in anchoring Sig-1Rs to the MAM.  The MAM, which is highly capable of accumulating ceramides, is enriched with both cholesterol and simple sphingolipids, thus forming Triton X-114-resistant DRMs.  Sig-1Rs assoc. with MAM-derived DRMs but not with those from microsomes.  A lipid overlay assay found that solubilized Sig-1Rs preferentially assoc. with simple sphingolipids such as ceramides.  Disrupting DRMs by lowering cholesterol or inhibiting de novo synthesis of ceramides at the ER largely decreases Sig-1R at DRMs and causes translocation of Sig-1R from the MAM to ER cisternae.  These findings suggest that the MAM, bearing cholesterol and ceramide-enriched microdomains at the ER, may use the microdomains to anchor Sig-1Rs to the location; thus, it serves to stage Sig-1R at ER-mitochondria junctions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZYY_eReHQzbVg90H21EOLACvtfcHk0lh5jJe4dS9BlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyktbY%253D&md5=f36cef4c5a43f799cf7fbdef27bb968f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.062539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.062539%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DM.%26atitle%3DDetergent-resistant%2520microdomains%2520determine%2520the%2520localization%2520of%2520sigma-1%2520receptors%2520to%2520the%2520endoplasmic%2520reticulum-mitochondria%2520junction%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D77%26spage%3D517%26epage%3D528%26doi%3D10.1124%2Fmol.109.062539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. Y.</span></span> <span> </span><span class="NLM_article-title">A role for sigma receptors in stimulant self administration and addiction</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">914</span>, <span class="refDoi"> DOI: 10.3390/ph4060880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3390%2Fph4060880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21904468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVWgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=880-914&author=J.+L.+Katzauthor=T.+P.+Suauthor=T.+Hiranitaauthor=T.+Hayashiauthor=G.+Tandaauthor=T.+Kopajticauthor=S.+Y.+Tsai&title=A+role+for+sigma+receptors+in+stimulant+self+administration+and+addiction&doi=10.3390%2Fph4060880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A role for sigma receptors in stimulant self administration and addiction</span></div><div class="casAuthors">Katz, Jonathan L.; Su, Tsung-Ping; Hiranita, Takato; Hayashi, Teruo; Tanda, Gianluigi; Kopajtic, Theresa; Tsai, Shang-Yi</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">880-914</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Sigma1 receptors (σ1Rs) represent a structurally unique class of intracellular proteins that function as chaperones.  σ1Rs translocate from the mitochondria-assocd. membrane to the cell nucleus or cell membrane, and through protein-protein interactions influence several targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins.  Several studies have demonstrated that σR antagonists block stimulant-induced behavioral effects, including ambulatory activity, sensitization, and acute toxicities.  Curiously, the effects of stimulants have been blocked by σR antagonists tested under place-conditioning but not self-administration procedures, indicating fundamental differences in the mechanisms underlying these two effects.  The self administration of σR agonists has been found in subjects previously trained to self administer cocaine.  The reinforcing effects of the σR agonists were blocked by σR antagonists.  Addnl., σR agonists were found to increase dopamine concns. in the nucleus accumbens shell, a brain region considered important for the reinforcing effects of abused drugs.  Although the effects of the σR agonist, DTG, on dopamine were obtained at doses that approximated those that maintained self administration behavior those of another agonist, PRE-084 required higher doses.  The effects of DTG were antagonized by non-selective or a preferential σ2R antagonist but not by a preferential σ1R antagonist.  The effects of PRE-084 on dopamine were insensitive to σR antagonists.  The data suggest that the self administration of σR agonists is independent of dopamine and the findings are discussed in light of a hypothesis that cocaine has both intracellular actions mediated by σRs, as well as extracellular actions mediated through conventionally studied mechanisms.  The co-activation and potential interactions among these mechanisms, in particular those involving the intracellular chaperone σRs, may lead to the pernicious addictive effects of stimulant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-C58BXc2OEbVg90H21EOLACvtfcHk0lh5jJe4dS9BlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVWgt7o%253D&md5=91e115c03c04656ead69abe04c02eb2e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3390%2Fph4060880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph4060880%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DTsai%26aufirst%3DS.%2BY.%26atitle%3DA%2520role%2520for%2520sigma%2520receptors%2520in%2520stimulant%2520self%2520administration%2520and%2520addiction%26jtitle%3DPharmaceuticals%26date%3D2011%26volume%3D4%26spage%3D880%26epage%3D914%26doi%3D10.3390%2Fph4060880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, S. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitlock, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, P.</span></span> <span> </span><span class="NLM_article-title">Differential localization of three distinct binding sites for sigma receptor ligands in rat spleen</span>. <i>J. Neuroimmunol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/S0165-5728(96)00140-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS0165-5728%2896%2900140-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=9003244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1Ois7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1997&pages=45-58&author=S.+A.+Wolfeauthor=B.+K.+Haauthor=B.+B.+Whitlockauthor=P.+Saini&title=Differential+localization+of+three+distinct+binding+sites+for+sigma+receptor+ligands+in+rat+spleen&doi=10.1016%2FS0165-5728%2896%2900140-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Differential localization of three distinct binding sites for sigma receptor ligands in rat spleen</span></div><div class="casAuthors">Wolfe, Seth A., Jr.; Keun Ha, Byeong; Whitlock, Ben B.; Saini, Priya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-58</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In vitro receptor autoradiog. was used to localize σ1 receptors, σ2 receptors, and novel haloperidol/DTG-inaccessible sites for sigma and opiate ligands in rat spleen.  Sigma-1 receptors were present throughout the spleen, but were most concd. in the T cell zones.  Binding under σ2 receptor-selective' conditions was 70% nonspecific, and σ2 receptors could not be detected.  Haloperidol/DTG-inaccessible sites had a coarse, punctate distribution in the red pulp and marginal zones of the white pulp.  This anatomical localization suggests types of cells and functions that should be examd. for modulation by sigma receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIocw7I4Y6j7Vg90H21EOLACvtfcHk0lh5jJe4dS9BlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1Ois7k%253D&md5=d850f70f54fc4172039bf5a51eb5b808</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0165-5728%2896%2900140-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-5728%252896%252900140-3%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DS.%2BA.%26aulast%3DHa%26aufirst%3DB.%2BK.%26aulast%3DWhitlock%26aufirst%3DB.%2BB.%26aulast%3DSaini%26aufirst%3DP.%26atitle%3DDifferential%2520localization%2520of%2520three%2520distinct%2520binding%2520sites%2520for%2520sigma%2520receptor%2520ligands%2520in%2520rat%2520spleen%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D1997%26volume%3D72%26spage%3D45%26epage%3D58%26doi%3D10.1016%2FS0165-5728%2896%2900140-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermack, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debonnel, G.</span></span> <span> </span><span class="NLM_article-title">The role of sigma receptors in depression</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1254/jphs.CRJ04005X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1254%2Fjphs.CRJ04005X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=15750289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVGjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=317-336&author=J.+E.+Bermackauthor=G.+Debonnel&title=The+role+of+sigma+receptors+in+depression&doi=10.1254%2Fjphs.CRJ04005X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The role of sigma receptors in depression</span></div><div class="casAuthors">Bermack, Jordanna E.; Debonnel, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-336</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">A review.  Behavioral models used to test potential antidepressants have shown that ligands that bind to sigma receptors possess "antidepressant-like" properties.  The focus of this review is to discuss the literature concerning sigma receptors and their ligands, with respect to their antidepressants properties.  In addn. to the behavioral data, we discuss electrophysiol. and biochem. models demonstrating sigma receptors' ability to modulate important factors in the pathophysiol. of depression and/or the mechanisms of action of antidepressants such as the serotonergic neurotransmission in the dorsal raphe nucleus (DRN) and the glutamatergic transmission in the hippocampus.  We also discuss the significance of these two systems in the mechanism of action of antidepressants.  Sigma ligands have potential as antidepressant medications with a fast onset of action as they produce a rapid modulation of the serotonergic system in the DRN and the glutamatergic transmission in the hippocampus.  As these effects of sigma ligands may produce antidepressant properties by completely novel mechanisms of action, they may provide an alternative to the antidepressants currently available and may prove to be beneficial for treatment-resistant depressed patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTc8adYlmpSrVg90H21EOLACvtfcHk0lh5jJe4dS9BlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVGjtL4%253D&md5=1cdda174b9b1e5087118ae49526b3eb0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1254%2Fjphs.CRJ04005X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.CRJ04005X%26sid%3Dliteratum%253Aachs%26aulast%3DBermack%26aufirst%3DJ.%2BE.%26aulast%3DDebonnel%26aufirst%3DG.%26atitle%3DThe%2520role%2520of%2520sigma%2520receptors%2520in%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D97%26spage%3D317%26epage%3D336%26doi%3D10.1254%2Fjphs.CRJ04005X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucke-Wold, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptors and neurodegenerative diseases: towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>964</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-50174-1_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2F978-3-319-50174-1_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28315269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFegsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=964&publication_year=2017&pages=133-152&author=L.+Nguyenauthor=B.+P.+Lucke-Woldauthor=S.+Mookerjeeauthor=N.+Kaushalauthor=R.+R.+Matsumoto&title=Sigma-1+receptors+and+neurodegenerative+diseases%3A+towards+a+hypothesis+of+sigma-1+receptors+as+amplifiers+of+neurodegeneration+and+neuroprotection&doi=10.1007%2F978-3-319-50174-1_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptors and neurodegenerative diseases: towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection</span></div><div class="casAuthors">Nguyen, Linda; Lucke-Wold, Brandon P.; Mookerjee, Shona; Kaushal, Nidhi; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">964</span>
        (<span class="NLM_cas:issue">Sigma Receptors: Their Role in Disease and as Therapeutic Targets</span>),
    <span class="NLM_cas:pages">133-152</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Sigma-1 receptors are mol. chaperones that may act as pathol. mediators and targets for novel therapeutic applications in neurodegenerative diseases.  Accumulating evidence indicates that sigma-1 ligands can either directly or indirectly modulate multiple neurodegenerative processes, including excitotoxicity, calcium dysregulation, mitochondrial and endoplasmic reticulum dysfunction, inflammation, and astrogliosis.  In addn., sigma-1 ligands may act as disease-modifying agents in the treatment for central nervous system (CNS) diseases by promoting the activity of neurotrophic factors and neural plasticity.  Here, we summarize their neuroprotective and neurorestorative effects in different animal models of acute brain injury and chronic neurodegenerative diseases, and highlight their potential role in mitigating disease.  Notably, current data suggest that sigma-1 receptor dysfunction worsens disease progression, whereas enhancement amplifies pre-existing functional mechanisms of neuroprotection and/or restoration to slow disease progression.  Collectively, the data support a model of the sigma-1 receptor as an amplifier of intracellular signaling, and suggest future clin. applications of sigma-1 ligands as part of multi-therapy approaches to treat neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO4KO0RLJ4fLVg90H21EOLACvtfcHk0li9CdG_iAbXjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFegsLfN&md5=72a736369a3912dd64fa1913ec00d3fb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-50174-1_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-50174-1_10%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DLucke-Wold%26aufirst%3DB.%2BP.%26aulast%3DMookerjee%26aufirst%3DS.%26aulast%3DKaushal%26aufirst%3DN.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSigma-1%2520receptors%2520and%2520neurodegenerative%2520diseases%253A%2520towards%2520a%2520hypothesis%2520of%2520sigma-1%2520receptors%2520as%2520amplifiers%2520of%2520neurodegeneration%2520and%2520neuroprotection%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D964%26spage%3D133%26epage%3D152%26doi%3D10.1007%2F978-3-319-50174-1_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucke-Wold, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavendish, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scandinaro, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Role of sigma-1 receptors in neurodegenerative diseases</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.jphs.2014.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jphs.2014.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25704014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XislaksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=17-29&author=L.+Nguyenauthor=B.+P.+Lucke-Woldauthor=S.+A.+Mookerjeeauthor=J.+Z.+Cavendishauthor=M.+J.+Robsonauthor=A.+L.+Scandinaroauthor=R.+R.+Matsumoto&title=Role+of+sigma-1+receptors+in+neurodegenerative+diseases&doi=10.1016%2Fj.jphs.2014.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Role of sigma-1 receptors in neurodegenerative diseases</span></div><div class="casAuthors">Nguyen, Linda; Lucke-Wold, Brandon P.; Mookerjee, Shona A.; Cavendish, John Z.; Robson, Matthew J.; Scandinaro, Anna L.; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-29</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neurodegenerative diseases with distinct genetic etiologies and pathol. phenotypes appear to share common mechanisms of neuronal cellular dysfunction, including excitotoxicity, calcium dysregulation, oxidative damage, ER stress and mitochondrial dysfunction.  Glial cells, including microglia and astrocytes, play an increasingly recognized role in both the promotion and prevention of neurodegeneration.  Sigma receptors, particularly the sigma-1 receptor subtype, which are expressed in both neurons and glia of multiple regions within the central nervous system, are a unique class of intracellular proteins that can modulate many biol. mechanisms assocd. with neurodegeneration.  These receptors therefore represent compelling putative targets for pharmacol. treating neurodegenerative disorders.  In this review, we provide an overview of the biol. mechanisms frequently assocd. with neurodegeneration, and discuss how sigma-1 receptors may alter these mechanisms to preserve or restore neuronal function.  In addn., we speculate on their therapeutic potential in the treatment of various neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdBzbVUAlU9rVg90H21EOLACvtfcHk0li9CdG_iAbXjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XislaksLY%253D&md5=1aa1ab1a9eb49ef2d69eef975a568a2d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jphs.2014.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jphs.2014.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DLucke-Wold%26aufirst%3DB.%2BP.%26aulast%3DMookerjee%26aufirst%3DS.%2BA.%26aulast%3DCavendish%26aufirst%3DJ.%2BZ.%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DScandinaro%26aufirst%3DA.%2BL.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DRole%2520of%2520sigma-1%2520receptors%2520in%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D127%26spage%3D17%26epage%3D29%26doi%3D10.1016%2Fj.jphs.2014.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieloch, T.</span></span> <span> </span><span class="NLM_article-title">The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.jphs.2014.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jphs.2014.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25704015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislalu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=30-35&author=K.+Ruscherauthor=T.+Wieloch&title=The+involvement+of+the+sigma-1+receptor+in+neurodegeneration+and+neurorestoration&doi=10.1016%2Fj.jphs.2014.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration</span></div><div class="casAuthors">Ruscher, Karsten; Wieloch, Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-35</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor (Sig-1R) is a single 25 kD polypeptide and a chaperone protein immersed in lipid rafts of the endoplasmic reticulum (ER) where it interacts with mitochondria at the mitochondria-assocd. ER membrane domain (MAM).  Upon activation, the Sig-1R binds to the inositol trisphosphate receptor (IP3R), and modulates cellular calcium (Ca2+) homeostasis.  Also, the activated Sig-1R modulates plasma membrane receptor and ion channel functions, and may regulate cellular excitability.  Further, the Sig-1R promotes trafficking of lipids and proteins essential for neurotransmission, cell growth and motility.  Activation of the Sig-1R provides neuroprotection and is neurorestorative in cellular and animal models of neurodegenerative diseases and brain ischemia.  Neuroprotection appears to be due to inhibition of cellular Ca2+ toxicity and/or inflammation, and neurorestoration may include balancing abberant neurotransmission or stimulation of synaptogenesis, thus remodelling brain connectivity.  Single nucleotide polymorphisms and mutations of the SIGMAR1 gene worsen outcome in Alzheimer's disease and myotrophic lateral sclerosis supporting a role of Sig-1R in neurodegenerative disease.  The combined neuroprotective and neurorestorative actions of the Sig-1R, provide a broad therapeutic time window of Sig-1R agonists.  The Sig-1R is therefore a strong therapeutic target for the development of new treatments for neurodegenerative diseases and stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8YOx7k1TXx7Vg90H21EOLACvtfcHk0li9CdG_iAbXjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislalu7c%253D&md5=7c18045bd413a002427b9e7f9abbecf1</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jphs.2014.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jphs.2014.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DRuscher%26aufirst%3DK.%26aulast%3DWieloch%26aufirst%3DT.%26atitle%3DThe%2520involvement%2520of%2520the%2520sigma-1%2520receptor%2520in%2520neurodegeneration%2520and%2520neurorestoration%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D127%26spage%3D30%26epage%3D35%26doi%3D10.1016%2Fj.jphs.2014.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor-modulated neuroinflammation in neurological diseases</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">314</span>, <span class="refDoi"> DOI: 10.3389/fncel.2018.00314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffncel.2018.00314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30294261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=314&author=J.+Jiaauthor=J.+Chengauthor=C.+Wangauthor=X.+Zhen&title=Sigma-1+receptor-modulated+neuroinflammation+in+neurological+diseases&doi=10.3389%2Ffncel.2018.00314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor-modulated neuroinflammation in neurological diseases</span></div><div class="casAuthors">Jia, Jia; Cheng, Jian; Wang, Cheng; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">314</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A large body of evidence indicates that sigma-1 receptors (Sig-1R) are important drug targets for a no. of neuropsychiatric disorders.  Sig-1Rs are enriched in central nervous system (CNS).  In addn. to neurons, both cerebral microglia and astrocytes express Sig-1Rs.  Activation of Sig-1Rs is known to elicit potent neuroprotective effects and promote neuronal survival via multiple mechanisms, including promoting mitochondrial functions, decreasing oxidative stress and regulating neuroimmnol. functions.  In this review article, we focus on the emerging role of Sig-1Rs in regulating neuroinflammation and discuss the recent advances on the Sig-1R-modulating neuroinflammation in the pathophysiol. and therapy of neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6jkx0g1TjobVg90H21EOLACvtfcHk0lhsDpfWRCeSwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7nM&md5=265ed5482d3ee53c3e7b6a8541d81221</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2018.00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2018.00314%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DSigma-1%2520receptor-modulated%2520neuroinflammation%2520in%2520neurological%2520diseases%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2018%26volume%3D12%26spage%3D314%26doi%3D10.3389%2Ffncel.2018.00314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhasz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakaski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janka, Z.</span></span> <span> </span><span class="NLM_article-title">Association between a variant of the sigma-1 receptor gene and Alzheimer’s disease</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>517</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2012.04.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neulet.2012.04.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22561649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFKlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=517&publication_year=2012&pages=136-139&author=A.+Feherauthor=A.+Juhaszauthor=A.+Laszloauthor=J.+Kalmanauthor=M.+Pakaskiauthor=J.+Kalmanauthor=Z.+Janka&title=Association+between+a+variant+of+the+sigma-1+receptor+gene+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neulet.2012.04.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Association between a variant of the sigma-1 receptor gene and Alzheimer's disease</span></div><div class="casAuthors">Feher, Agnes; Juhasz, Anna; Laszlo, Anna; Kalman, Janos; Pakaski, Magdolna; Janka, Zoltan</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">517</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-139</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a progressive neurodegenerative disorder with complex etiol. and strong genetic predisposition.  A no. of investigations support the possible involvement of sigma non-opioid intracellular receptor 1 (SIGMAR1) in the pathophysiol. of AD.  We aimed to investigate the assocn. between SIGMAR1 polymorphisms and late-onset AD, therefore we genotyped rs1799729 (GC-241-240TT) and rs1800866 (Q2P) in 322 Hungarian late-onset AD patients and 250 ethnically matched, elderly control individuals.  The investigated polymorphisms were in nearly complete linkage disequil. resulting in the GC-Q and TT-P predominant haplotypes that were subjected to the statistical analyses.  Our data demonstrates an assocn. between the SIGMAR1 TT-P variant and the risk for developing AD (p = 0.019), and a potential modest interaction effect (p = 0.058) of the co-presence of the TT-P haplotype with apolipoprotein E4 allele on the risk for AD.  Based on this mild significance, we could not fully support the hypothesis that TT-P haplotype in interaction with APOE E4 allele confers risk for developing AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwEWSD-BqIcrVg90H21EOLACvtfcHk0lhsDpfWRCeSwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFKlurg%253D&md5=2affc9e415ba1214d3a32d1558a015c4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2012.04.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2012.04.046%26sid%3Dliteratum%253Aachs%26aulast%3DFeher%26aufirst%3DA.%26aulast%3DJuhasz%26aufirst%3DA.%26aulast%3DLaszlo%26aufirst%3DA.%26aulast%3DKalman%26aufirst%3DJ.%26aulast%3DPakaski%26aufirst%3DM.%26aulast%3DKalman%26aufirst%3DJ.%26aulast%3DJanka%26aufirst%3DZ.%26atitle%3DAssociation%2520between%2520a%2520variant%2520of%2520the%2520sigma-1%2520receptor%2520gene%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D2012%26volume%3D517%26spage%3D136%26epage%3D139%26doi%3D10.1016%2Fj.neulet.2012.04.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson-Stone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallupp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. D.</span></span> <span> </span><span class="NLM_article-title">Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer’s disease</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.2174/156720511797633232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F156720511797633232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21605063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWhsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=765-770&author=Y.+Huangauthor=L.+Zhengauthor=G.+Hallidayauthor=C.+Dobson-Stoneauthor=Y.+Wangauthor=H.+D.+Tangauthor=L.+Caoauthor=Y.+L.+Dengauthor=G.+Wangauthor=Y.+M.+Zhangauthor=J.+H.+Wangauthor=M.+Halluppauthor=J.+Kwokauthor=S.+D.+Chen&title=Genetic+polymorphisms+in+sigma-1+receptor+and+apolipoprotein+E+interact+to+influence+the+severity+of+Alzheimer%E2%80%99s+disease&doi=10.2174%2F156720511797633232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease</span></div><div class="casAuthors">Huang, Yue; Zheng, Lan; Halliday, Glenda; Dobson-Stone, Carol; Wang, Ying; Tang, Hui-Dong; Cao, Li; Deng, Yu-Lei; Wang, Gang; Zhang, Yu-Mei; Wang, Jian-Hua; Hallupp, Marianne; Kwok, John; Chen, Sheng-Di</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">765-770</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Apolipoprotein E (APOE) ε4 allele and sigma-1 receptor (SIGMAR1) c.5C (Q2P) polymorphisms were acknowledged as risk factors for developing Alzheimer's disease (AD).  However, whether these polymorphisms influence the disease process is unclear.  Therefore, 2 cohorts with a clin. diagnosis of AD were recruited, a postmortem confirmed Australian cohort (82 cases) from the Australian Brain Bank Network, and a Chinese cohort with detailed clin. assessments recruited through an epidemiol. study in Shanghai and through the neurol. department outpatients clinic of Shanghai Ruijin Hospital (330 cases).  SIGMAR1 Q2P and APOE genotyping was performed on all cases.  Dementia severity in the Chinese cohort was assessed using MMSE scores, and the stages of senile plaques and neurofibrillary tangles (NFT) assessed in the Australian cohort.  Assocns. between SIGMAR1 Q2P and APOE genotypes and disease severity were assessed using SPSS.  Results confirmed that APOE ε4 allele assocd. with increased NFT stages and cognitive decline, with carriers with one APOE ε2 or ε3 allele often having better clin. outcomes compared to carriers with none or 2 ε2 or ε3 alleles resp.  SIGMAR1 c.5C polymorphism alone did not assoc. with MMSE score variability in Chinese or with pathol. stages in Caucasians.  However, the assocn. studies revealed a significant genetic interaction between the APOE ε4 allele and SIGMAR1 2P carriers in both populations, i.e., in APOE non ε4 allele carriers, SIGMAR1 2P variant had increased cognitive dysfunction and more advanced stages of NFT.  The authors' data demonstrate that SIGMAR1 and APOE interact to influence AD severity across ethnic populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Qk9dxRhwMbVg90H21EOLACvtfcHk0lhsDpfWRCeSwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWhsrvO&md5=e5ad2ebca7fd1cea4cda742e1cc65792</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F156720511797633232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720511797633232%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DHalliday%26aufirst%3DG.%26aulast%3DDobson-Stone%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DH.%2BD.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DHallupp%26aufirst%3DM.%26aulast%3DKwok%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%2BD.%26atitle%3DGenetic%2520polymorphisms%2520in%2520sigma-1%2520receptor%2520and%2520apolipoprotein%2520E%2520interact%2520to%2520influence%2520the%2520severity%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2011%26volume%3D8%26spage%3D765%26epage%3D770%26doi%3D10.2174%2F156720511797633232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span> <span> </span><span class="NLM_article-title">Low density of sigma1 receptors in early Alzheimer’s disease</span>. <i>Ann. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1007/s12149-007-0094-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs12149-007-0094-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18498028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1yntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=151-156&author=M.+Mishinaauthor=M.+Ohyamaauthor=K.+Ishiiauthor=S.+Kitamuraauthor=Y.+Kimuraauthor=K.+Odaauthor=K.+Kawamuraauthor=T.+Sasakiauthor=S.+Kobayashiauthor=Y.+Katayamaauthor=K.+Ishiwata&title=Low+density+of+sigma1+receptors+in+early+Alzheimer%E2%80%99s+disease&doi=10.1007%2Fs12149-007-0094-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Low density of sigma1 receptors in early Alzheimer's disease</span></div><div class="casAuthors">Mishina, Masahiro; Ohyama, Masashi; Ishii, Kenji; Kitamura, Shin; Kimura, Yuichi; Oda, Kei-ichi; Kawamura, Kazunori; Sasaki, Toru; Kobayashi, Shiro; Katayama, Yasuo; Ishiwata, Kiichi</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-156</span>CODEN:
                <span class="NLM_cas:coden">ANMEEX</span>;
        ISSN:<span class="NLM_cas:issn">0914-7187</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">Objective: The sigma1 receptor is considered to be involved in cognitive function.  A postmortem study reported that the sigma1 receptors were reduced in the hippocampus in Alzheimer's disease (AD).  However, in vivo imaging of sigma1 receptors in the brain of AD patients has not been reported.  The aim of this study is to investigate the mapping of sigma1 receptors in AD using [11C]SA4503 positron emission tomog. (PET).  Methods: We studied five AD patients and seven elderly volunteers.  A dynamic series of decay-cor. PET data acquisition was performed for 90 min starting at the time of the injection of 500 MBq of [11C]SA4503.  A two-tissue three-compartment model was used to est. K1 k2, k3, k4, and the delay between metabolite-cor. plasma and tissue time activity using a Gauss-Newton algorithm.  The ratio of k3 to k4 was computed as the binding potential (BP), which is linearly related to the d. of sigma1 receptors.  Unpaired t tests were used to compare K1 and BP in patients with AD and normal subjects.  Results: As compared with normals, BP in the AD was significantly lower in the frontal, temporal, and occipital lobe, cerebellum and thalamus, whereas K1 was significantly lower in the parietal lobe.  Conclusions: [11C]SA4503 PET can demonstrate that the d. of cerebral and cerebellar sigma1 receptors is reduced in early AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC4SpMfV0TfrVg90H21EOLACvtfcHk0likcrwV4JC6jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1yntb8%253D&md5=31fd013a70d4b4c4df83ddca47d7e0d7</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs12149-007-0094-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12149-007-0094-z%26sid%3Dliteratum%253Aachs%26aulast%3DMishina%26aufirst%3DM.%26aulast%3DOhyama%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DY.%26aulast%3DIshiwata%26aufirst%3DK.%26atitle%3DLow%2520density%2520of%2520sigma1%2520receptors%2520in%2520early%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAnn.%2520Nucl.%2520Med.%26date%3D2008%26volume%3D22%26spage%3D151%26epage%3D156%26doi%3D10.1007%2Fs12149-007-0094-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rammes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Pridopidine stabilizes mushroom spines in mouse models of Alzheimer’s disease by acting on the sigma-1 receptor</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2018.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.nbd.2018.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30594810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=489-504&author=D.+Ryskampauthor=L.+Wuauthor=J.+Wuauthor=D.+Kimauthor=G.+Rammesauthor=M.+Gevaauthor=M.+Haydenauthor=I.+Bezprozvanny&title=Pridopidine+stabilizes+mushroom+spines+in+mouse+models+of+Alzheimer%E2%80%99s+disease+by+acting+on+the+sigma-1+receptor&doi=10.1016%2Fj.nbd.2018.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor</span></div><div class="casAuthors">Ryskamp, Daniel; Wu, Lili; Wu, Jun; Kim, Dabin; Rammes, Gerhard; Geva, Michal; Hayden, Michael; Bezprozvanny, Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">489-504</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There is evidence that cognitive decline in Alzheimer's disease (AD) results from deficiencies in synaptic communication (e.g., loss of mushroom-shaped 'memory spines') and neurodegenerative processes.  This might be treated with sigma-1 receptor (S1R) agonists, which are broadly neuroprotective and modulate synaptic plasticity.  For example, we previously found that the mixed muscarinic/S1R agonist AF710B prevents mushroom spine loss in hippocampal cultures from APP knock-in (APP-KI) and presenilin-1-M146 V knock-in (PS1-KI) mice.  We also found that the "dopaminergic stabilizer" pridopidine (structurally similar to the S1R agonist R(+)-3-PPP), is a high-affinity S1R agonist and is synaptoprotective in a mouse model of Huntington disease.  Here we tested whether pridopidine and R(+)-3-PPP are synaptoprotective in models of AD and whether this requires S1R.  We also examd. the effects of pridopidine on long-term potentiation (LTP), endoplasmic reticulum calcium and neuronal store-operated calcium entry (nSOC) in spines, all of which are dysregulated in AD, contributing to synaptic pathol.  We report here that pridopidine and 3-PPP protect mushroom spines from Aβ42 oligomer toxicity in primary WT hippocampal cultures from mice.  Pridopidine also reversed LTP defects in hippocampal slices resulting from application of Aβ42 oligomers.  Pridopidine and 3-PPP rescued mushroom spines in hippocampal cultures from APP-KI and PS1-KI mice.  S1R knockdown from lenti-viral shRNA expression destabilized WT mushroom spines and prevented the synaptoprotective effects of pridopidine in PS1-KI cultures.  Knockout of PS1/2 destabilized mushroom spines and pridopidine was unable to prevent this.  Pridopidine lowered endoplasmic reticulum calcium levels in WT, PS1-KO, PS1-KI and PS2 KO neurons, but not in PS1/2 KO neurons.  S1R was required for pridopidine to enhance spine nSOC in PS1-KI neurons.  Pridopidine was unable to rescue PS1-KI mushroom spines during pharmacol. or genetic inhibition of nSOC.  Oral pridopidine treatment rescued mushroom spines in vivo in aged PS1-KI-GFP mice.  Pridopidine stabilizes mushroom spines in mouse models of AD and this requires S1R, endoplasmic reticulum calcium leakage through PS1/2 and nSOC.  Thus, pridopidine may be useful to explore for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZa0vjyeC-9rVg90H21EOLACvtfcHk0likcrwV4JC6jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFCrsg%253D%253D&md5=70e9a25da577b8469533fda8b9316348</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2018.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2018.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DRammes%26aufirst%3DG.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DPridopidine%2520stabilizes%2520mushroom%2520spines%2520in%2520mouse%2520models%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520by%2520acting%2520on%2520the%2520sigma-1%2520receptor%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2019%26volume%3D124%26spage%3D489%26epage%3D504%26doi%3D10.1016%2Fj.nbd.2018.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strehaiano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duhr, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevallier, N.</span></span> <span> </span><span class="NLM_article-title">Amyloid toxicity is enhanced after pharmacological or genetic invalidation of the sigma1 receptor</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2017.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbr.2017.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29129596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSiu7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2018&pages=1-10&author=T.+Mauriceauthor=M.+Strehaianoauthor=F.+Duhrauthor=N.+Chevallier&title=Amyloid+toxicity+is+enhanced+after+pharmacological+or+genetic+invalidation+of+the+sigma1+receptor&doi=10.1016%2Fj.bbr.2017.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid toxicity is enhanced after pharmacological or genetic invalidation of the σ1 receptor</span></div><div class="casAuthors">Maurice, Tangui; Strehaiano, Manon; Duhr, Fanny; Chevallier, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor (S1R) is a mol. chaperone which activity modulates several intracellular signals including calcium mobilization at mitochondria-assocd. endoplasmic reticulum membranes.  S1R agonists are potent neuroprotectants against neurodegenerative insults and particularly in rodent models of Alzheimer's disease (AD).  We here analyzed whether S1R inactivation modifies vulnerability to amyloid toxicity in AD models.  Two strategies were used: (1) amyloid β[25-35] (Aβ25-35) peptide (1, 3, 9 nmol) was injected intracerebroventricularly in mice treated repeatedly with the S1R antagonist NE-100 or in S1RKO mice, and (2) WT, APPSweInd, S1RKO, and APPSweInd/S1RKO mice were created and female littermates analyzed at 8 mo of age.  Learning deficits, oxidative stress, Bax level and BDNF content in the hippocampus were analyzed.  Aβ25-35 induced learning impairment, oxidative stress, Bax induction and BDNF alteration at lower dose in NE-100-treated mice or S1RKO mice as compared to WT animals.  The extent of learning deficits and biochem. alterations were also higher in APPSweInd/S1RKO mice as compared to WT, APPSweInd, and S1RKO animals.  S1R inactivation or altered S1R expression augmented the pathol. status in pharmacol. and genetic AD mouse models.  These observations, in relation with the well-known protective effects of S1R agonists, are coherent with a role of signal amplifier in neurodegeneration and neuroprotection proposed for S1R in AD and related neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcOulohjzwbbVg90H21EOLACvtfcHk0likcrwV4JC6jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSiu7zM&md5=3fb7d4e21f964fa32d9d33733e59a39f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2017.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2017.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DStrehaiano%26aufirst%3DM.%26aulast%3DDuhr%26aufirst%3DF.%26aulast%3DChevallier%26aufirst%3DN.%26atitle%3DAmyloid%2520toxicity%2520is%2520enhanced%2520after%2520pharmacological%2520or%2520genetic%2520invalidation%2520of%2520the%2520sigma1%2520receptor%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2018%26volume%3D339%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.bbr.2017.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Waarde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybczynska, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsinga, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijholt, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luiten, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierckx, R. A.</span></span> <span> </span><span class="NLM_article-title">The cholinergic system, sigma-1 receptors and cognition</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>221</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2009.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbr.2009.12.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20060423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFClu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=221&publication_year=2011&pages=543-554&author=A.+van%0AWaardeauthor=N.+K.+Ramakrishnanauthor=A.+A.+Rybczynskaauthor=P.+H.+Elsingaauthor=K.+Ishiwataauthor=I.+M.+Nijholtauthor=P.+G.+Luitenauthor=R.+A.+Dierckx&title=The+cholinergic+system%2C+sigma-1+receptors+and+cognition&doi=10.1016%2Fj.bbr.2009.12.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The cholinergic system, sigma-1 receptors and cognition</span></div><div class="casAuthors">van Waarde, Aren; Ramakrishnan, Nisha K.; Rybczynska, Anna A.; Elsinga, Philip H.; Ishiwata, Kiichi; Nijholt, Ingrid M.; Luiten, Paul G. M.; Dierckx, Rudi A.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">221</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">543-554</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article provides an overview of present knowledge regarding the relationship between the cholinergic system and sigma-1 receptors, and discusses potential applications of sigma-1 receptor agonists in the treatment of memory deficits and cognitive disorders.  Sigma-1 receptors, initially considered as a subtype of the opioid family, are unique ligand-regulated mol. chaperones in the endoplasmatic reticulum playing a modulatory role in intracellular calcium signaling and in the activity of several neurotransmitter systems, particularly the cholinergic and glutamatergic pathways.  Several central nervous system (CNS) drugs show high to moderate affinities for sigma-1 receptors, including acetylcholinesterase inhibitors (donepezil), antipsychotics (haloperidol, rimcazole), selective serotonin reuptake inhibitors (fluvoxamine, sertraline) and monoamine oxidase inhibitors (clorgyline).  These compds. can influence cognitive functions both via their primary targets and by activating sigma-1 receptors in the CNS.  Sigma-1 agonists show powerful anti-amnesic and neuroprotective effects in a large variety of animal models of cognitive dysfunction involving, among others (i) pharmacol. target blockade (with muscarinic or NMDA receptor antagonists or p-chloroamphetamine); (ii) selective lesioning of cholinergic neurons; (iii) CNS administration of β-amyloid peptides; (iv) aging-induced memory loss, both in normal and senescent-accelerated rodents; (v) neurodegeneration induced by toxic compds. (CO, trimethyltin, cocaine), and (vi) prenatal restraint stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYOwSZZsWJLVg90H21EOLACvtfcHk0li5ilnH_tdp1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFClu7Y%253D&md5=ef059d9c2c5efa713f80c7a280c379ad</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2009.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2009.12.043%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BWaarde%26aufirst%3DA.%26aulast%3DRamakrishnan%26aufirst%3DN.%2BK.%26aulast%3DRybczynska%26aufirst%3DA.%2BA.%26aulast%3DElsinga%26aufirst%3DP.%2BH.%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DNijholt%26aufirst%3DI.%2BM.%26aulast%3DLuiten%26aufirst%3DP.%2BG.%26aulast%3DDierckx%26aufirst%3DR.%2BA.%26atitle%3DThe%2520cholinergic%2520system%252C%2520sigma-1%2520receptors%2520and%2520cognition%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2011%26volume%3D221%26spage%3D543%26epage%3D554%26doi%3D10.1016%2Fj.bbr.2009.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.560837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1517%2F14728222.2011.560837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21375464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksV2mu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=557-577&author=T.+Hayashiauthor=S.+Y.+Tsaiauthor=T.+Moriauthor=M.+Fujimotoauthor=T.+P.+Su&title=Targeting+ligand-operated+chaperone+sigma-1+receptors+in+the+treatment+of+neuropsychiatric+disorders&doi=10.1517%2F14728222.2011.560837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders</span></div><div class="casAuthors">Hayashi, Teruo; Tsai, Shang-Yi; Mori, Tomohisa; Fujimoto, Michiko; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">557-577</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Current drugs for the treatment of psychiatric or neurodegenerative disorders have limitations.  Psychotherapeutic drugs such as typical and atypical antipsychotics, tricyclic antidepressants and selective monoamine reuptake inhibitors, aim to normalize the hyper- or hypo-neurotransmission of monoaminergic systems.  Despite their contribution to the outcomes of psychiatric patients, these agents often exert severe side effects and require chronic treatments to promote amelioration of symptoms.  Drugs available for the treatment of neurodegenerative disorders are severely limited.Areas covered: Recent evidence that has shed light on sigma-1 receptor ligands, which may serve as a new class of antidepressants or neuroprotective agents.  Sigma-1 receptors are novel ligand-operated mol. chaperones regulating signal transduction, ER stress, cellular redox, cellular survival and synaptogenesis.  Selective sigma-1 receptor ligands exert rapid antidepressant-like, anxiolytic, antinociceptive and robust neuroprotective actions in preclin. studies.  Recent studies that suggest that reactive oxygen species might play a role as signal integrators downstream of Sig-1Rs are also covered.Expert opinion: The advances in sigma receptor research in the last decade have begun to elucidate the intracellular signal cascades upstream and downstream of sigma-1 receptors.  The novel ligand-operated properties of the sigma-1 receptor chaperone may enable interventions by which stress-related cellular systems can be pharmacol. controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocF6RNqv-abLVg90H21EOLACvtfcHk0li5ilnH_tdp1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksV2mu7s%253D&md5=ec71b2f1add05e37b3273b3070dfdb84</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.560837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.560837%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DTsai%26aufirst%3DS.%2BY.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DTargeting%2520ligand-operated%2520chaperone%2520sigma-1%2520receptors%2520in%2520the%2520treatment%2520of%2520neuropsychiatric%2520disorders%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D557%26epage%3D577%26doi%3D10.1517%2F14728222.2011.560837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, R.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>578</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.2006.116178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1113%2Fjphysiol.2006.116178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=17068104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1Smsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=578&publication_year=2007&pages=143-157&author=M.+Martinaauthor=M.+E.+Turcotteauthor=S.+Halmanauthor=R.+Bergeron&title=The+sigma-1+receptor+modulates+NMDA+receptor+synaptic+transmission+and+plasticity+via+SK+channels+in+rat+hippocampus&doi=10.1113%2Fjphysiol.2006.116178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus</span></div><div class="casAuthors">Martina Marzia; Turcotte Marie-Eve B; Halman Samantha; Bergeron Richard</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">578</span>
        (<span class="NLM_cas:issue">Pt 1</span>),
    <span class="NLM_cas:pages">143-57</span>
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">The sigma receptor (sigmaR), once considered a subtype of the opioid receptor, is now described as a distinct pharmacological entity.  Modulation of N-methyl-D-aspartate receptor (NMDAR) functions by sigmaR-1 ligands is well documented; however, its mechanism is not fully understood.  Using patch-clamp whole-cell recordings in CA1 pyramidal cells of rat hippocampus and (+)pentazocine, a high-affinity sigmaR-1 agonist, we found that sigmaR-1 activation potentiates NMDAR responses and long-term potentiation (LTP) by preventing a small conductance Ca2+-activated K+ current (SK channels), known to shunt NMDAR responses, to open.  Therefore, the block of SK channels and the resulting increased Ca2+ influx through the NMDAR enhances NMDAR responses and LTP.  These results emphasize the importance of the sigmaR-1 as postsynaptic regulator of synaptic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQu6zsw05NSA7YtC3U5jeOifW6udTcc2ebRXmleYfBxyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1Smsg%253D%253D&md5=a2add2be7909667c437f77bae985ea61</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2006.116178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2006.116178%26sid%3Dliteratum%253Aachs%26aulast%3DMartina%26aufirst%3DM.%26aulast%3DTurcotte%26aufirst%3DM.%2BE.%26aulast%3DHalman%26aufirst%3DS.%26aulast%3DBergeron%26aufirst%3DR.%26atitle%3DThe%2520sigma-1%2520receptor%2520modulates%2520NMDA%2520receptor%2520synaptic%2520transmission%2520and%2520plasticity%2520via%2520SK%2520channels%2520in%2520rat%2520hippocampus%26jtitle%3DJ.%2520Physiol.%26date%3D2007%26volume%3D578%26spage%3D143%26epage%3D157%26doi%3D10.1113%2Fjphysiol.2006.116178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pabba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlskog, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biscaro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassrallah, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngsee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beique, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, R.</span></span> <span> </span><span class="NLM_article-title">NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">11325</span>– <span class="NLM_lpage">11338</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0458-14.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1523%2FJNEUROSCI.0458-14.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25143613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=11325-11338&author=M.+Pabbaauthor=A.+Y.+Wongauthor=N.+Ahlskogauthor=E.+Hristovaauthor=D.+Biscaroauthor=W.+Nassrallahauthor=J.+K.+Ngseeauthor=M.+Snyderauthor=J.+C.+Beiqueauthor=R.+Bergeron&title=NMDA+receptors+are+upregulated+and+trafficked+to+the+plasma+membrane+after+sigma-1+receptor+activation+in+the+rat+hippocampus&doi=10.1523%2FJNEUROSCI.0458-14.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus</span></div><div class="casAuthors">Pabba, Mohan; Wong, Adrian Y. C.; Ahlskog, Nina; Hristova, Elitza; Biscaro, Dante; Nassrallah, Wissam; Ngsee, Johnny K.; Snyder, Melissa; Beique, Jean-Claude; Bergeron, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">11325-11338, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Sigma-1 receptors (σ-1Rs) are endoplasmic reticulum resident chaperone proteins implicated in many physiol. and pathol. processes in the CNS.  A striking feature of σ-1Rs is their ability to interact and modulate a large no. of voltage- and ligand-gated ion channels at the plasma membrane.  We have reported previously that agonists for σ-1Rs potentiate NMDA receptor (NMDAR) currents, although the mechanism by which this occurs is still unclear.  In this study, we show that in vivo administration of the selective σ-1R agonists (+)-SKF 10,047 [2S-(2α,6α,11R*]-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(2-propenyl)-2,6-methano-3-benzazocin-8-ol hydrochloride (N-allylnormetazocine) hydrochloride), PRE-084 (2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate hydrochloride), and (+)-pentazocine increases the expression of GluN2A and GluN2B subunits, as well as postsynaptic d. protein 95 in the rat hippocampus.  We also demonstrate that σ-1R activation leads to an increased interaction between GluN2 subunits and σ-1Rs and mediates trafficking of NMDARs to the cell surface.  These results suggest that σ-1R may play an important role in NMDAR-mediated functions, such as learning and memory.  It also opens new avenues for addnl. studies into a multitude of pathol. conditions in which NMDARs are involved, including schizophrenia, dementia, and stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHT-QqvmMZ-7Vg90H21EOLACvtfcHk0li5ilnH_tdp1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjtb%252FO&md5=c12aab696738fe1960e39b098366cbe6</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0458-14.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0458-14.2014%26sid%3Dliteratum%253Aachs%26aulast%3DPabba%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DA.%2BY.%26aulast%3DAhlskog%26aufirst%3DN.%26aulast%3DHristova%26aufirst%3DE.%26aulast%3DBiscaro%26aufirst%3DD.%26aulast%3DNassrallah%26aufirst%3DW.%26aulast%3DNgsee%26aufirst%3DJ.%2BK.%26aulast%3DSnyder%26aufirst%3DM.%26aulast%3DBeique%26aufirst%3DJ.%2BC.%26aulast%3DBergeron%26aufirst%3DR.%26atitle%3DNMDA%2520receptors%2520are%2520upregulated%2520and%2520trafficked%2520to%2520the%2520plasma%2520membrane%2520after%2520sigma-1%2520receptor%2520activation%2520in%2520the%2520rat%2520hippocampus%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D11325%26epage%3D11338%26doi%3D10.1523%2FJNEUROSCI.0458-14.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herreman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Role of presenilins in neuronal calcium homeostasis</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">8566</span>– <span class="NLM_lpage">8580</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1554-10.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1523%2FJNEUROSCI.1554-10.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20573903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Knur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=8566-8580&author=H.+Zhangauthor=S.+Sunauthor=A.+Herremanauthor=B.+De+Strooperauthor=I.+Bezprozvanny&title=Role+of+presenilins+in+neuronal+calcium+homeostasis&doi=10.1523%2FJNEUROSCI.1554-10.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Role of presenilins in neuronal calcium homeostasis</span></div><div class="casAuthors">Zhang, Hua; Sun, Suya; Herreman, An; De Strooper, Bart; Bezprozvanny, Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">8566-8580</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder.  Familial AD (FAD) mutations in presenilins have been linked to calcium (Ca2+) signaling abnormalities.  To explain these results, we previously proposed that presenilins function as endoplasmic reticulum (ER) passive Ca2+ leak channels.  To directly investigate the role of presenilins in neuronal ER Ca2+ homeostasis, we here performed a series of Ca2+ imaging expts. with primary neuronal cultures from conditional presenilin double-knock-out mice (PS1dTAG/dTAG, PS2-/-) and from triple-transgenic AD mice (KI-PS1M146V, Thy1-APPKM670/671NL, Thy1-tauP301L).  Obtained results provided addnl. support to the hypothesis that presenilins function as ER Ca2+ leak channels in neurons.  Interestingly, we discovered that presenilins play a major role in ER Ca2+ leak function in hippocampal but not in striatal neurons.  We further discovered that, in hippocampal neurons, loss of presenilin-mediated ER Ca2+ leak function was compensated by an increase in expression and function of ryanodine receptors (RyanRs).  Long-term feeding of the RyanR inhibitor dantrolene to amyloid precursor protein-presenilin-1 mice (Thy1-APPKM670/671NL, Thy1-PS1L166P) resulted in an increased amyloid load, loss of synaptic markers, and neuronal atrophy in hippocampal and cortical regions.  These results indicate that disruption of ER Ca2+ leak function of presenilins may play an important role in AD pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcprlFcryprbVg90H21EOLACvtfcHk0lg5bFi-url7Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Knur0%253D&md5=35b43ca2c8664b2faf9beac06ac3991a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1554-10.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1554-10.2010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DHerreman%26aufirst%3DA.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DRole%2520of%2520presenilins%2520in%2520neuronal%2520calcium%2520homeostasis%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D8566%26epage%3D8580%26doi%3D10.1523%2FJNEUROSCI.1554-10.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beglopoulos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Hippocampal spatial memory impairments caused by the familial Alzheimer’s disease-linked presenilin 1 M146V mutation</span>. <i>Neurodegener. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1159/000086426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1159%2F000086426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16908998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFSns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=6-15&author=X.+Sunauthor=V.+Beglopoulosauthor=M.+P.+Mattsonauthor=J.+Shen&title=Hippocampal+spatial+memory+impairments+caused+by+the+familial+Alzheimer%E2%80%99s+disease-linked+presenilin+1+M146V+mutation&doi=10.1159%2F000086426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Hippocampal spatial memory impairments caused by the familial Alzheimer's disease-linked presenilin 1 M146V mutation</span></div><div class="casAuthors">Sun, Xiaoyan; Beglopoulos, Vassilios; Mattson, Mark P.; Shen, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-15</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Mutations in presenilins (PS) 1 and 2 are the major cause of familial Alzheimer's disease.  Conditional inactivation of PS1 in the mouse postnatal forebrain leads to mild deficits in spatial learning and memory, whereas inactivation of both PS1 and PS2 results in severe memory and synaptic plasticity impairments, followed by progressive and substantial neurodegeneration.  Here we investigate the effect of a familial Alzheimer's disease-linked PS1 missense mutation using knock-in (KI) mice, in which the wild-type PS1 allele is replaced with the M146V mutant allele.  In the Morris water maze task,PS1 KI mice at 3 mo of age exhibit reduced quadrant occupancy and platform crossing in the probe trial after 6 days of training, though their performance was normal in the probe trial after 12 days of training.  By the age of 9 mo, even after 12 days of training,PS1 homozygous KI mice still exhibit reduced platform crossing in the post-training probe trial.  ELISA anal. revealed a selective increase in cortical levels of β-amyloid 42 in PS1 KI mice, whereas prodn. of β-amyloid 40 was normal.  Histol. and quant. real-time RT-PCR analyses showed normal gross hippocampal morphol. and unaltered expression of three genes involved in inflammatory responses in PS1 KI mice.  These results show hippocampal spatial memory impairments caused by the PS1 M146V mutation and age-related deterioration of the memory impairment, suggesting that PS1 KI mice are a valuable model system for the study of memory loss in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1rkdLKmgaL7Vg90H21EOLACvtfcHk0lg5bFi-url7Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFSns7w%253D&md5=7980c416e696f59cd38da7184f7b8dbc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1159%2F000086426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000086426%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DBeglopoulos%26aufirst%3DV.%26aulast%3DMattson%26aufirst%3DM.%2BP.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DHippocampal%2520spatial%2520memory%2520impairments%2520caused%2520by%2520the%2520familial%2520Alzheimer%25E2%2580%2599s%2520disease-linked%2520presenilin%25201%2520M146V%2520mutation%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2005%26volume%3D2%26spage%3D6%26epage%3D15%26doi%3D10.1159%2F000086426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Ner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandeis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahum, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershonov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFerla, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, R.</span></span> <span> </span><span class="NLM_article-title">AF710B, a novel M1/sigma1 agonist with therapeutic efficacy in animal models of Alzheimer’s disease</span>. <i>Neurodegener. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1159/000440864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1159%2F000440864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=26606130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFSgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=95-110&author=A.+Fisherauthor=I.+Bezprozvannyauthor=L.+Wuauthor=D.+A.+Ryskampauthor=N.+Bar-Nerauthor=N.+Natanauthor=R.+Brandeisauthor=H.+Elkonauthor=V.+Nahumauthor=E.+Gershonovauthor=F.+M.+LaFerlaauthor=R.+Medeiros&title=AF710B%2C+a+novel+M1%2Fsigma1+agonist+with+therapeutic+efficacy+in+animal+models+of+Alzheimer%E2%80%99s+disease&doi=10.1159%2F000440864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease</span></div><div class="casAuthors">Fisher, Abraham; Bezprozvanny, Ilya; Wu, Lili; Ryskamp, Daniel A.; Bar-Ner, Nira; Natan, Niva; Brandeis, Rachel; Elkon, Hanoch; Nahum, Victoria; Gershonov, Eitan; La Ferla, Frank M.; Medeiros, Rodrigo</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">95-110</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and potential disease modifiers.  We now report on a novel compd., AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist.  AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concns. of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB).  AF710B (1-30 μg/kg, p.o.) was a potent and safe cognitive enhancer in rats treated with the M1 antagonist trihexyphenidyl (passive avoidance impairment).  These effects of AF710B involve σ1 receptor activation.  In agreement with its antiamnesic properties, AF710B (at 30 nM), via activation of M1 and a possible involvement of σ1 receptors, rescued mushroom synapse loss in PS1-KI and APP-KI neuronal cultures, while AF267B (1 μM) was less potent in PS1-KI and ineffective in APP-KI models, resp.  In female 3xTg-AD mice, AF710B (10 μg/kg, i.p./daily/2 mo) (i) mitigated cognitive impairments in the Morris water maze; (ii) decreased BACE1, GSK3β activity, p25/CDK5, neuroinflammation, sol. and insol. Aβ40, Aβ42, plaques and tau pathologies.  AF710B differs from conventional σ1 and M1 muscarinic (orthosteric, allosteric or bitopic) agonists.  These results highlight AF710B as a potential treatment for Alzheimer's disease (e.g. improving cognitive deficits, synaptic loss, amyloid and tau pathologies, and neuroinflammation) with a superior profile over a plethora of other therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTz3y9CSkTfbVg90H21EOLACvtfcHk0liIlXmQ-WUQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFSgur4%253D&md5=f309d08291b52ef002413ad48eba1acc</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1159%2F000440864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000440864%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DA.%26aulast%3DBezprozvanny%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DRyskamp%26aufirst%3DD.%2BA.%26aulast%3DBar-Ner%26aufirst%3DN.%26aulast%3DNatan%26aufirst%3DN.%26aulast%3DBrandeis%26aufirst%3DR.%26aulast%3DElkon%26aufirst%3DH.%26aulast%3DNahum%26aufirst%3DV.%26aulast%3DGershonov%26aufirst%3DE.%26aulast%3DLaFerla%26aufirst%3DF.%2BM.%26aulast%3DMedeiros%26aufirst%3DR.%26atitle%3DAF710B%252C%2520a%2520novel%2520M1%252Fsigma1%2520agonist%2520with%2520therapeutic%2520efficacy%2520in%2520animal%2520models%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2016%26volume%3D16%26spage%3D95%26epage%3D110%26doi%3D10.1159%2F000440864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francardo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieloch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissbrandt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, M. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1998</span>– <span class="NLM_lpage">2014</span>, <span class="refDoi"> DOI: 10.1093/brain/awu107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1093%2Fbrain%2Fawu107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24755275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC2cnlslOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2014&pages=1998-2014&author=V.+Francardoauthor=F.+Bezauthor=T.+Wielochauthor=H.+Nissbrandtauthor=K.+Ruscherauthor=M.+A.+Cenci&title=Pharmacological+stimulation+of+sigma-1+receptors+has+neurorestorative+effects+in+experimental+parkinsonism&doi=10.1093%2Fbrain%2Fawu107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism</span></div><div class="casAuthors">Francardo Veronica; Bez Francesco; Cenci M Angela; Wieloch Tadeusz; Ruscher Karsten; Nissbrandt Hans</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">Pt 7</span>),
    <span class="NLM_cas:pages">1998-2014</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The sigma-1 receptor, an endoplasmic reticulum-associated molecular chaperone, is attracting great interest as a potential target for neuroprotective treatments.  We provide the first evidence that pharmacological modulation of this protein produces functional neurorestoration in experimental parkinsonism.  Mice with intrastriatal 6-hydroxydopamine lesions were treated daily with the selective sigma-1 receptor agonist, PRE-084, for 5 weeks.  At the dose of 0.3 mg/kg/day, PRE-084 produced a gradual and significant improvement of spontaneous forelimb use.  The behavioural recovery was paralleled by an increased density of dopaminergic fibres in the most denervated striatal regions, by a modest recovery of dopamine levels, and by an upregulation of neurotrophic factors (BDNF and GDNF) and their downstream effector pathways (extracellular signal regulated kinases 1/2 and Akt).  No treatment-induced behavioural-histological restoration occurred in sigma-1 receptor knockout mice subjected to 6-hydroxydopamine lesions and treated with PRE-084.  Immunoreactivity for the sigma-1 receptor protein was evident in both astrocytes and neurons in the substantia nigra and the striatum, and its intracellular distribution was modulated by PRE-084 (the treatment resulted in a wider intracellular distribution of the protein).  Our results suggest that sigma-1 receptor regulates endogenous defence and plasticity mechanisms in experimental parkinsonism.  Boosting the activity of this protein may have disease-modifying effects in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnve9PDTl05D0SWnHPWbmmfW6udTcc2eZExGgmdVZMsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnlslOruw%253D%253D&md5=9beba8f569133d7d32a9c7c52f2ff533</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawu107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawu107%26sid%3Dliteratum%253Aachs%26aulast%3DFrancardo%26aufirst%3DV.%26aulast%3DBez%26aufirst%3DF.%26aulast%3DWieloch%26aufirst%3DT.%26aulast%3DNissbrandt%26aufirst%3DH.%26aulast%3DRuscher%26aufirst%3DK.%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DPharmacological%2520stimulation%2520of%2520sigma-1%2520receptors%2520has%2520neurorestorative%2520effects%2520in%2520experimental%2520parkinsonism%26jtitle%3DBrain%26date%3D2014%26volume%3D137%26spage%3D1998%26epage%3D2014%26doi%3D10.1093%2Fbrain%2Fawu107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakayori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, Y.</span></span> <span> </span><span class="NLM_article-title">Function of sigma1 receptors in Parkinson’s disease</span>. <i>Acta Neurol. Scand.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0404.2005.00432.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fj.1600-0404.2005.00432.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16008536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Crtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2005&pages=103-107&author=M.+Mishinaauthor=K.+Ishiwataauthor=K.+Ishiiauthor=S.+Kitamuraauthor=Y.+Kimuraauthor=K.+Kawamuraauthor=K.+Odaauthor=T.+Sasakiauthor=O.+Sakayoriauthor=M.+Hamamotoauthor=S.+Kobayashiauthor=Y.+Katayama&title=Function+of+sigma1+receptors+in+Parkinson%E2%80%99s+disease&doi=10.1111%2Fj.1600-0404.2005.00432.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Function of sigma1 receptors in Parkinson's disease</span></div><div class="casAuthors">Mishina, M.; Ishiwata, K.; Ishii, K.; Kitamura, S.; Kimura, Y.; Kawamura, K.; Oda, K.; Sasaki, T.; Sakayori, O.; Hamamoto, M.; Kobayashi, S.; Katayama, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neurologica Scandinavica</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-107</span>CODEN:
                <span class="NLM_cas:coden">ANRSAS</span>;
        ISSN:<span class="NLM_cas:issn">0001-6314</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Objective: The objective of this study was to investigate the mapping of sigma1 receptors in Parkinson's disease (PD) using [11C]SA4503 and positron emission tomog. (PET), and to assess whether sigma1 receptors are involved in the damaged dopaminergic system in PD patients.  Materials and methods: We studied seven normal volunteers and six PD patients.  The low d. of dopamine transporters and the normal or high d. of dopamine receptors were confirmed in the putamen of all patients using [11C]CFT and [11C]RAC PET.  A dynamic series of PET data acquisition was performed with arterial blood sampling.  We computed the binding potential (BP) of [11C]SA4503.  Results: In PD patients, the BP was significantly lower on the more affected than the less affected side of the anterior putamen, although there was no significant difference with respect to the BP between patients and controls.  Conclusions: Release of dopamine is reduced asym. in the putamen of early PD.  [11C]SA4503 PET is an indicator of presynaptic dopaminergic damage in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHGDd-UqykhrVg90H21EOLACvtfcHk0liIlXmQ-WUQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Crtbc%253D&md5=674dec4286720f7d8dfc54d4d168d5ec</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0404.2005.00432.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0404.2005.00432.x%26sid%3Dliteratum%253Aachs%26aulast%3DMishina%26aufirst%3DM.%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DSakayori%26aufirst%3DO.%26aulast%3DHamamoto%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DY.%26atitle%3DFunction%2520of%2520sigma1%2520receptors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DActa%2520Neurol.%2520Scand.%26date%3D2005%26volume%3D112%26spage%3D103%26epage%3D107%26doi%3D10.1111%2Fj.1600-0404.2005.00432.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor knockout increases alpha-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2017.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neurobiolaging.2017.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28870519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2ltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2017&pages=171-183&author=J.+Hongauthor=L.+Wangauthor=T.+Zhangauthor=B.+Zhangauthor=L.+Chen&title=Sigma-1+receptor+knockout+increases+alpha-synuclein+aggregation+and+phosphorylation+with+loss+of+dopaminergic+neurons+in+substantia+nigra&doi=10.1016%2Fj.neurobiolaging.2017.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor knockout increases α-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra</span></div><div class="casAuthors">Hong, Juan; Wang, Ling; Zhang, Tingting; Zhang, Baofeng; Chen, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171-183</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sigma-1 receptor (σ1R) is expressed in dopaminergic neurons of substantia nigra.  Here, we show that σ1R knockout (σ1R-/-) mice, at age 6-12 mo, appeared with age-related loss of dopaminergic neurons and decline of motor coordination.  Levels of α-synuclein (αSyn) oligomers and fibrillar αSyn in substantia nigra of σ1R-/- mice were age-dependently increased without the changes in αSyn monomers.  The phosphorylation of αSyn monomers or oligomers in dopaminergic neurons was enhanced in σ1R-/- mice.  Levels of phosphorylated eIF2a and C/EBP homologous protein expression were elevated in σ1R-/- mice with decline of proteasome activity.  Inhibition of endoplasmic reticulum stress by salubrinal recovered the αSyn phosphorylation and proteasome activity and prevented early oligomerization of αSyn in σ1R-/- mice.  Rifampicin reduced the late increase of αSyn oligomers in σ1R-/- mice.  Rifampicin or salubrinal could reduce the loss of dopaminergic neurons in σ1R-/- mice and improved their motor coordination.  The results indicate that the σ1R deficiency through enhanced aggregation and phosphorylation of αSyn causes the loss of dopaminergic neurons leading to the decline of motor coordination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowE7N9mIPRP7Vg90H21EOLACvtfcHk0lgnoWtaFXvZaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2ltLnL&md5=77edf6dab969d045ef7118ae85a600a3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2017.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2017.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSigma-1%2520receptor%2520knockout%2520increases%2520alpha-synuclein%2520aggregation%2520and%2520phosphorylation%2520with%2520loss%2520of%2520dopaminergic%2520neurons%2520in%2520substantia%2520nigra%26jtitle%3DNeurobiol.%2520Aging%26date%3D2017%26volume%3D59%26spage%3D171%26epage%3D183%26doi%3D10.1016%2Fj.neurobiolaging.2017.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Compromising sigma-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-kappaB/Bcl-2-dependent mechanism: potential relevance to Parkinson’s disease</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.190868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.111.190868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22399814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=663-671&author=T.+Moriauthor=T.+Hayashiauthor=T.+P.+Su&title=Compromising+sigma-1+receptors+at+the+endoplasmic+reticulum+render+cytotoxicity+to+physiologically+relevant+concentrations+of+dopamine+in+a+nuclear+factor-kappaB%2FBcl-2-dependent+mechanism%3A+potential+relevance+to+Parkinson%E2%80%99s+disease&doi=10.1124%2Fjpet.111.190868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Compromising σ-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-κB/Bcl-2-dependent mechanism: potential relevance to Parkinson's disease</span></div><div class="casAuthors">Mori, Tomohisa; Hayashi, Teruo; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">663-671</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The endoplasmic reticulum (ER) chaperone σ-1 receptor (Sig-1R) is cytoprotective against ER stress-induced apoptosis.  The level of Sig-1Rs in the brain was reported to be lower in early parkinsonian patients.  Because dopamine (DA) toxicity is well known to be involved in the etiol. of Parkinson's disease, we tested in this study whether a relationship might exist between Sig-1Rs and DA-induced cytotoxicity in a cellular model by using Chinese hamster ovary (CHO) cells.  DA in physiol. concns. (e.g., lower than 10 μM) does not cause apoptosis.  However, the same concns. of DA cause apoptosis in Sig-1R knockdown CHO cells.  In search of a mechanistic explanation, we found that unfolded protein response is not involved.  Rather, the level of protective protein Bcl-2 is critically involved in this DA/Sig-1R knockdown-induced apoptosis.  Specifically, the DA/Sig-1R knockdown causes a synergistic proteasomal conversion of nuclear factor κB (NF-κB) p105 to the active form of p50, which is known to down-regulate the transcription of Bcl-2.  It is noteworthy that the DA/Sig-1R knockdown-induced apoptosis is blocked by the overexpression of Bcl-2.  Our results therefore indicate that DA is involved in the activation of NF-κB and suggest that endogenous Sig-1Rs are tonically inhibiting the proteasomal conversion/activation of NF-κB caused by physiol. relevant concns. of DA that would otherwise cause apoptosis.  Thus, Sig-1Rs and assocd. ligands may represent new therapeutic targets for the treatment of parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsgrWkRvcZ7Vg90H21EOLACvtfcHk0lgnoWtaFXvZaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWlt7c%253D&md5=dc5fe9352b05306ab0d736079f375c75</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.190868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.190868%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DCompromising%2520sigma-1%2520receptors%2520at%2520the%2520endoplasmic%2520reticulum%2520render%2520cytotoxicity%2520to%2520physiologically%2520relevant%2520concentrations%2520of%2520dopamine%2520in%2520a%2520nuclear%2520factor-kappaB%252FBcl-2-dependent%2520mechanism%253A%2520potential%2520relevance%2520to%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D663%26epage%3D671%26doi%3D10.1124%2Fjpet.111.190868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span> <span> </span><span class="NLM_article-title">Trends in sigma-1 receptor research: a 25-year bibliometric analysis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">564</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffphar.2019.00564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31178733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BB3M3kslejtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=564&author=L.+Romeroauthor=E.+Portillo-Salido&title=Trends+in+sigma-1+receptor+research%3A+a+25-year+bibliometric+analysis&doi=10.3389%2Ffphar.2019.00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in Sigma-1 Receptor Research: A 25-Year Bibliometric Analysis</span></div><div class="casAuthors">Romero Luz; Portillo-Salido Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">564</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Purpose: There are previous reviews focused on Sigma-1 receptor but no bibliometric studies examining this field as a whole.  This article aims to present a global view of Sigma-1 receptor research and its intellectual structure.  Methods: We used bibliometric indicators of a basic nature as well as techniques for the visualization and analysis of networks of scientific information extracted from Scopus database.  Results: In total, 1,102 articles from 1992 to 2017 were identified.  The growth in the production of articles is not constant over time, with periods of stagnation of approximately 5 years.  Only 247 authors have five or more publications.  The authors appear grouped in relatively independent clusters, thus suggesting a low level of collaborations between those dedicated to the Sigma-1 receptor.  The United States was the country with the highest production followed by Japan and Germany.  Spain, Japan, and Italy showed the highest per million inhabitants ratio.  The highest citation/article ratio was reached in France, United States, and Canada.  The leading institutions were the University of Munster, the National Institutes of Health, ESTEVE, and INSERM.  The top authors in number of publications were Wunsch-B, Schepmann-D, and Maurice-T.  Hayashi-T, Su-TP and Bowen-WD showed the highest citations per article.  The article by Hayashi-T and Su-TP in Cell (2007) describing the Sigma-1 receptor as a chaperone protein is the top cited reference.  Cluster labeling from author co-citation analysis shows that research has been focused on specific diseases such as addiction, neuroprotection and neurodegenerative diseases, psychiatric disorders, and pain.  High-frequency terms in author keywords suggest that the research efforts in some areas such as neuroimaging, cocaine addiction or psychiatric disorders have declined over time, while others such as neurodegenerative diseases or pain are currently most popular.  Perspective: A greater involvement of the scientific community, with an increase in the scientific production related to Sigma-1, is desirable.  Additional boost needed to improve research performance is likely to come from combining data from different laboratories to overcome the limitations of individual approaches.  The resulting maps are a useful and attractive tool for the Sigma-1 receptor research community, as they reveal the main lines of exploration at a glance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX1yhwJRUF1Ptos8R3JUhXfW6udTcc2eY9E7-LWeb6d7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3kslejtw%253D%253D&md5=d8094c2a7c2f0fb53d0ca183e59fc059</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00564%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26atitle%3DTrends%2520in%2520sigma-1%2520receptor%2520research%253A%2520a%252025-year%2520bibliometric%2520analysis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D564%26doi%3D10.3389%2Ffphar.2019.00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugarolas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguinaga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e61245</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0061245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1371%2Fjournal.pone.0061245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23637801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=G.+Navarroauthor=E.+Morenoauthor=J.+Bonaventuraauthor=M.+Brugarolasauthor=D.+Farreauthor=D.+Aguinagaauthor=J.+Mallolauthor=A.+Cortesauthor=V.+Casadoauthor=C.+Lluisauthor=S.+Ferreauthor=R.+Francoauthor=E.+Canelaauthor=P.+J.+McCormick&title=Cocaine+inhibits+dopamine+D2+receptor+signaling+via+sigma-1-D2+receptor+heteromers&doi=10.1371%2Fjournal.pone.0061245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers</span></div><div class="casAuthors">Navarro, Gemma; Moreno, Estefania; Bonaventura, Jordi; Brugarolas, Marc; Farre, Daniel; Aguinaga, David; Mallol, Josefa; Cortes, Antoni; Casado, Vicent; Lluis, Carmen; Ferre, Sergi; Franco, Rafael; Canela, Enric; McCormick, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e61245</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Under normal conditions the brain maintains a delicate balance between inputs of reward seeking controlled by neurons contg. the D1-like family of dopamine receptors and inputs of aversion coming from neurons contg. the D2-like family of dopamine receptors.  Cocaine is able to subvert these balanced inputs by altering the cell signaling of these two pathways such that D1 reward seeking pathway dominates.  Here, we provide an explanation at the cellular and biochem. level how cocaine may achieve this.  Exploring the effect of cocaine on dopamine D2 receptors function, we present evidence of σ1 receptor mol. and functional interaction with dopamine D2 receptors.  Using biophys., biochem. and cell biol. approaches, we discovered that D2 receptors (the long isoform of the D2 receptor) can complex with σ1 receptors, a result that is specific to D2 receptors, as D3 and D4 receptors did not form heteromers.  We demonstrate that the σ1-D2 receptor heteromers consist of higher order oligomers, are found in mouse striatum and that cocaine, by binding to σ1-D2 receptor heteromers, inhibits downstream signaling in both cultured cells and in mouse striatum.  In contrast, in striatum from σ1 knockout animals these complexes are not found and this inhibition is not seen.  Taken together, these data illuminate the mechanism by which the initial exposure to cocaine can inhibit signaling via D2 receptor contg. neurons, destabilizing the delicate signaling balance influencing drug seeking that emanates from the D1 and D2 receptor contg. neurons in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR4PjTJlFvzLVg90H21EOLACvtfcHk0lgxCxdJxCOOzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFaqs7g%253D&md5=61bcdce4f07ad8dc8582c3d1b692359d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0061245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0061245%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DBonaventura%26aufirst%3DJ.%26aulast%3DBrugarolas%26aufirst%3DM.%26aulast%3DFarre%26aufirst%3DD.%26aulast%3DAguinaga%26aufirst%3DD.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DCasado%26aufirst%3DV.%26aulast%3DLluis%26aufirst%3DC.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DCanela%26aufirst%3DE.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DCocaine%2520inhibits%2520dopamine%2520D2%2520receptor%2520signaling%2520via%2520sigma-1-D2%2520receptor%2520heteromers%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0061245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Delgado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell-Vilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medrano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine disrupts histamine H<sub>3</sub> receptor modulation of dopamine D<sub>1</sub> receptor signaling: sigma1-D<sub>1</sub>-H<sub>3</sub> receptor complexes as key targets for reducing cocaine’s effects</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3545</span>– <span class="NLM_lpage">3558</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4147-13.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1523%2FJNEUROSCI.4147-13.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24599455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1ajtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=3545-3558&author=E.+Morenoauthor=D.+Moreno-Delgadoauthor=G.+Navarroauthor=H.+M.+Hoffmannauthor=S.+Fuentesauthor=S.+Rosell-Vilarauthor=P.+Gasperiniauthor=M.+Rodriguez-Ruizauthor=M.+Medranoauthor=J.+Mallolauthor=A.+Cortesauthor=V.+Casadoauthor=C.+Lluisauthor=S.+Ferreauthor=J.+Ortizauthor=E.+Canelaauthor=P.+J.+McCormick&title=Cocaine+disrupts+histamine+H3+receptor+modulation+of+dopamine+D1+receptor+signaling%3A+sigma1-D1-H3+receptor+complexes+as+key+targets+for+reducing+cocaine%E2%80%99s+effects&doi=10.1523%2FJNEUROSCI.4147-13.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine's effects</span></div><div class="casAuthors">Moreno, Estefania; Moreno-Delgado, David; Navarro, Gemma; Hoffmann, Hanne M.; Fuentes, Silvia; Rosell-Vilar, Santi; Gasperini, Paola; Rodriguez-Ruiz, Mar; Medrano, Mireia; Mallol, Josefa; Cortes, Antoni; Casado, Vicent; Lluis, Carme; Ferre, Sergi; Ortiz, Jordi; Canela, Enric; McCormick, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3545-3558</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The general effects of cocaine are not well understood at the mol. level.  What is known is that the dopamine D1 receptor plays an important role.  Here we show that a key mechanism may be cocaine's blockade of the histamine H3 receptor-mediated inhibition of D1 receptor function.  This blockade requires the σ1 receptor and occurs upon cocaine binding to σ1-D1-H3 receptor complexes.  The cocaine-mediated disruption leaves an uninhibited D1 receptor that activates Gs, freely recruits β-arrestin, increases p-ERK 1/2 levels, and induces cell death when over activated.  Using in vitro assays with transfected cells and in ex vivo expts. using both rats acutely treated or self-administered with cocaine along with mice depleted of σ1 receptor, we show that blockade of σ1 receptor by an antagonist restores the protective H3 receptor-mediated brake on D1 receptor signaling and prevents the cell death from elevated D1 receptor signaling.  These findings suggest that a combination therapy of σ1R antagonists with H3 receptor agonists could serve to reduce some effects of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ARavI4E7T7Vg90H21EOLACvtfcHk0lgxCxdJxCOOzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1ajtrc%253D&md5=6aea1fdccecd4373e3a36ecea9e5d9dd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4147-13.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4147-13.2014%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DMoreno-Delgado%26aufirst%3DD.%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DH.%2BM.%26aulast%3DFuentes%26aufirst%3DS.%26aulast%3DRosell-Vilar%26aufirst%3DS.%26aulast%3DGasperini%26aufirst%3DP.%26aulast%3DRodriguez-Ruiz%26aufirst%3DM.%26aulast%3DMedrano%26aufirst%3DM.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DCasado%26aufirst%3DV.%26aulast%3DLluis%26aufirst%3DC.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DOrtiz%26aufirst%3DJ.%26aulast%3DCanela%26aufirst%3DE.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DCocaine%2520disrupts%2520histamine%2520H3%2520receptor%2520modulation%2520of%2520dopamine%2520D1%2520receptor%2520signaling%253A%2520sigma1-D1-H3%2520receptor%2520complexes%2520as%2520key%2520targets%2520for%2520reducing%2520cocaine%25E2%2580%2599s%2520effects%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D3545%26epage%3D3558%26doi%3D10.1523%2FJNEUROSCI.4147-13.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbny, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaitoun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziskind-Conhaim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Lack of sigma-1 receptor exacerbates ALS progression in mice</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2013.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuroscience.2013.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23458708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=2013&pages=129-134&author=T.+A.+Mavlyutovauthor=M.+L.+Epsteinauthor=Y.+I.+Verbnyauthor=M.+S.+Huertaauthor=I.+Zaitounauthor=L.+Ziskind-Conhaimauthor=A.+E.+Ruoho&title=Lack+of+sigma-1+receptor+exacerbates+ALS+progression+in+mice&doi=10.1016%2Fj.neuroscience.2013.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of sigma-1 receptor exacerbates ALS progression in mice</span></div><div class="casAuthors">Mavlyutov, T. A.; Epstein, M. L.; Verbny, Y. I.; Huerta, M. S.; Zaitoun, I.; Ziskind-Conhaim, L.; Ruoho, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-134</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The function of the sigma-1 receptor (S1R) has been implicated in modulating the activity of various ion channels.  In the CNS S1R is enriched in cholinergic postsynaptic densities in spinal cord motoneurons (MNs).  Mutations in S1R have been found in familial cases of amyotrophic lateral sclerosis (ALS).  In this study we show that a knockout of S1R in the SOD1*G93A mouse model of ALS significantly reduces longevity (end stage).  Electrophysiol. expts. demonstrate that MN of mice lacking S1R exhibit increased excitability.  Taken together the data suggest the S1R acts as a brake on excitability, an effect that might enhance longevity in an ALS mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdrWA4qm3FVLVg90H21EOLACvtfcHk0lgxCxdJxCOOzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCrsLs%253D&md5=dfeed9f2618149f5976306e84dd09602</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2013.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2013.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DMavlyutov%26aufirst%3DT.%2BA.%26aulast%3DEpstein%26aufirst%3DM.%2BL.%26aulast%3DVerbny%26aufirst%3DY.%2BI.%26aulast%3DHuerta%26aufirst%3DM.%2BS.%26aulast%3DZaitoun%26aufirst%3DI.%26aulast%3DZiskind-Conhaim%26aufirst%3DL.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DLack%2520of%2520sigma-1%2520receptor%2520exacerbates%2520ALS%2520progression%2520in%2520mice%26jtitle%3DNeuroscience%26date%3D2013%26volume%3D240%26spage%3D129%26epage%3D134%26doi%3D10.1016%2Fj.neuroscience.2013.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luty, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson-Stone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loy, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coupland, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlstrom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchorzewska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruszak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcikowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panegyres, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zekanowski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span> <span> </span><span class="NLM_article-title">Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1002/ana.22274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fana.22274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21031579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOnsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2010&pages=639-649&author=A.+A.+Lutyauthor=J.+B.+Kwokauthor=C.+Dobson-Stoneauthor=C.+T.+Loyauthor=K.+G.+Couplandauthor=H.+Karlstromauthor=T.+Sobowauthor=J.+Tchorzewskaauthor=A.+Maruszakauthor=M.+Barcikowskaauthor=P.+K.+Panegyresauthor=C.+Zekanowskiauthor=W.+S.+Brooksauthor=K.+L.+Williamsauthor=I.+P.+Blairauthor=K.+A.+Matherauthor=P.+S.+Sachdevauthor=G.+M.+Hallidayauthor=P.+R.+Schofield&title=Sigma+nonopioid+intracellular+receptor+1+mutations+cause+frontotemporal+lobar+degeneration-motor+neuron+disease&doi=10.1002%2Fana.22274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease</span></div><div class="casAuthors">Luty, Agnes A.; Kwok, John B. J.; Dobson-Stone, Carol; Loy, Clement T.; Coupland, Kirsten G.; Karlstrom, Helena; Sobow, Tomasz; Tchorzewska, Joanna; Maruszak, Aleksandra; Barcikowska, Maria; Panegyres, Peter K.; Zekanowski, Cezary; Brooks, William S.; Williams, Kelly L.; Blair, Ian P.; Mather, Karen A.; Sachdev, Perminder S.; Halliday, Glenda M.; Schofield, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-649</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Frontotemporal lobar degeneration (FTLD) is the most common cause of early-onset dementia.  Pathol. ubiquitinated inclusion bodies obsd. in FTLD and motor neuron disease (MND) comprise transactivating response element (TAR) DNA binding protein (TDP-43) and/or fused in sarcoma (FUS) protein.  Our objective was to identify the causative gene in an FTLD-MND pedigree with no mutations in known dementia genes.  Methods: A mutation screen of candidate genes, luciferase assays, and quant. polymerase chain reaction (PCR) was performed to identify the biol. role of the putative mutation.  Neuropathol. characterization of affected individuals and western blot studies of cell lines were performed to identify the pathol. mechanism of the mutation.  Results: We identified a nonpolymorphic mutation (c.672*51G>T) in the 3'-untranslated region (UTR) of the Sigma nonopioid intracellular receptor 1 (SIGMAR1) gene in affected individuals from the FTLD-MND pedigree.  The c.672*51G>T mutation increased gene expression by 1.4-fold, corresponding with a significant 1.5-fold to 2-fold change in the SIGMAR1 transcript or Sigma-1 protein in lymphocyte or brain tissue.  Brains of SIGMAR1 mutation carriers displayed a unique pathol. with cytoplasmic inclusions immunopos. for either TDP-43 or FUS but not Sigma-1.  Overexpression of SIGMAR1 shunted TDP-43 and FUS from the nucleus to the cytoplasm by 2.3-fold and 5.2-fold, resp.  Treatment of cells with Sigma-1 ligands significantly altered translocation of TDP-43 by up to 2-fold.  Interpretation: SIGMAR1 is a causative gene for familial FTLD-MND with a unique neuropathol. that differs from other FTLD and MND cases.  Our findings also suggest Sigma-1 drugs as potential treatments for the TDP-43/FUS proteinopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLlsN4nYXas7Vg90H21EOLACvtfcHk0lgtVu2r_7XTzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOnsrbM&md5=910ad11aa17d829a5d241efd932e96a6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fana.22274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22274%26sid%3Dliteratum%253Aachs%26aulast%3DLuty%26aufirst%3DA.%2BA.%26aulast%3DKwok%26aufirst%3DJ.%2BB.%26aulast%3DDobson-Stone%26aufirst%3DC.%26aulast%3DLoy%26aufirst%3DC.%2BT.%26aulast%3DCoupland%26aufirst%3DK.%2BG.%26aulast%3DKarlstrom%26aufirst%3DH.%26aulast%3DSobow%26aufirst%3DT.%26aulast%3DTchorzewska%26aufirst%3DJ.%26aulast%3DMaruszak%26aufirst%3DA.%26aulast%3DBarcikowska%26aufirst%3DM.%26aulast%3DPanegyres%26aufirst%3DP.%2BK.%26aulast%3DZekanowski%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DW.%2BS.%26aulast%3DWilliams%26aufirst%3DK.%2BL.%26aulast%3DBlair%26aufirst%3DI.%2BP.%26aulast%3DMather%26aufirst%3DK.%2BA.%26aulast%3DSachdev%26aufirst%3DP.%2BS.%26aulast%3DHalliday%26aufirst%3DG.%2BM.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26atitle%3DSigma%2520nonopioid%2520intracellular%2520receptor%25201%2520mutations%2520cause%2520frontotemporal%2520lobar%2520degeneration-motor%2520neuron%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2010%26volume%3D68%26spage%3D639%26epage%3D649%26doi%3D10.1002%2Fana.22274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Saif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mohanna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlega, S.</span></span> <span> </span><span class="NLM_article-title">A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1002/ana.22534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fana.22534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21842496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1CqurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=913-919&author=A.+Al-Saifauthor=F.+Al-Mohannaauthor=S.+Bohlega&title=A+mutation+in+sigma-1+receptor+causes+juvenile+amyotrophic+lateral+sclerosis&doi=10.1002%2Fana.22534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis</span></div><div class="casAuthors">Al-Saif, Amr; Al-Mohanna, Futwan; Bohlega, Saeed</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">913-919</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by loss of motor neurons in the brain and spinal cord, leading to muscle weakness and eventually death from respiratory failure.  ALS is familial in about 10% of cases, with SOD1 mutations accounting for 20% of familial cases.  Here we describe a consanguineous family segregating juvenile ALS in an autosomal recessive pattern and describe the genetic variant responsible for the disorder.  Methods: We performed homozygosity mapping and direct sequencing to detect the genetic variant and tested the effect of this variant on a motor neuron-like cell line model (NSC34) expressing the wild-type or mutant gene.  Results: We identified a shared homozygosity region in affected individuals that spans ∼120kbp on chromosome 9p13.3 contg. 9 RefSeq genes.  Sequencing the SIGMAR1 gene revealed a mutation affecting a highly conserved amino acid located in the transmembrane domain of the encoded protein, sigma-1 receptor.  The mutated protein showed an aberrant subcellular distribution in NSC34 cells.  Furthermore, cells expressing the mutant protein were less resistant to apoptosis induced by endoplasmic reticulum stress.  Interpretation: Sigma-1 receptors are known to have neuroprotective properties, and recently Sigmar1 knockout mice have been described to have motor deficiency.  Our findings emphasize the role of sigma-1 receptors in motor neuron function and disease.  ANN NEUROL 2011;.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBYWm6mJA60LVg90H21EOLACvtfcHk0lgtVu2r_7XTzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1CqurfI&md5=ca3b6746092861e44b37088f3c4f86ea</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fana.22534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22534%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Saif%26aufirst%3DA.%26aulast%3DAl-Mohanna%26aufirst%3DF.%26aulast%3DBohlega%26aufirst%3DS.%26atitle%3DA%2520mutation%2520in%2520sigma-1%2520receptor%2520causes%2520juvenile%2520amyotrophic%2520lateral%2520sclerosis%26jtitle%3DAnn.%2520Neurol.%26date%3D2011%26volume%3D70%26spage%3D913%26epage%3D919%26doi%3D10.1002%2Fana.22534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prause, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnizler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushuven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchkremer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troost, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, J.</span></span> <span> </span><span class="NLM_article-title">Altered localization, abnormal modification and loss of function of sigma receptor-1 in amyotrophic lateral sclerosis</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1581</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddt008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1093%2Fhmg%2Fddt008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23314020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFWhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1581-1600&author=J.+Prauseauthor=A.+Goswamiauthor=I.+Katonaauthor=A.+Roosauthor=M.+Schnizlerauthor=E.+Bushuvenauthor=A.+Dreierauthor=S.+Buchkremerauthor=S.+Johannauthor=C.+Beyerauthor=M.+Deschauerauthor=D.+Troostauthor=J.+Weis&title=Altered+localization%2C+abnormal+modification+and+loss+of+function+of+sigma+receptor-1+in+amyotrophic+lateral+sclerosis&doi=10.1093%2Fhmg%2Fddt008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Altered localization, abnormal modification and loss of function of Sigma receptor-1 in amyotrophic lateral sclerosis</span></div><div class="casAuthors">Prause, J.; Goswami, A.; Katona, I.; Roos, A.; Schnizler, M.; Bushuven, E.; Dreier, A.; Buchkremer, S.; Johann, S.; Beyer, C.; Deschauer, M.; Troost, D.; Weis, J.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1581-1600</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Intracellular accumulations of mutant, misfolded proteins are major pathol. hallmarks of amyotrophic lateral sclerosis (ALS) and related disorders.  Recently, mutations in Sigma receptor 1 (SigR1) have been found to cause a form of ALS and frontotemporal lobar degeneration (FTLD).  Our goal was to pinpoint alterations and modifications of SigR1 in ALS and to det. how these changes contribute to the pathogenesis of ALS.  In the present study, we found that levels of the SigR1 protein were reduced in lumbar ALS patient spinal cord.  SigR1 was abnormally accumulated in enlarged C-terminals and endoplasmic reticulum (ER) structures of alpha motor neurons.  These accumulations co-localized with the 20s proteasome subunit.  SigR1 accumulations were also obsd. in SOD1 transgenic mice, cultured ALS-8 patient's fibroblasts with the P56S-VAPB mutation and in neuronal cell culture models.  Along with the accumulation of SigR1 and several other proteins involved in protein quality control, severe disturbances in the unfolded protein response and impairment of protein degrdn. pathways were detected in the above-mentioned cell culture systems.  Furthermore, shRNA knockdown of SigR1 lead to deranged calcium signaling and caused abnormalities in ER and Golgi structures in cultured NSC-34 cells.  Finally, pharmacol. activation of SigR1 induced the clearance of mutant protein aggregates in these cells.  Our results support the notion that SigR1 is abnormally modified and contributes to the pathogenesis of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCFL_fGrhAaLVg90H21EOLACvtfcHk0lgtVu2r_7XTzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFWhs7g%253D&md5=92be0eece152502d0d2e1c708eead883</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddt008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddt008%26sid%3Dliteratum%253Aachs%26aulast%3DPrause%26aufirst%3DJ.%26aulast%3DGoswami%26aufirst%3DA.%26aulast%3DKatona%26aufirst%3DI.%26aulast%3DRoos%26aufirst%3DA.%26aulast%3DSchnizler%26aufirst%3DM.%26aulast%3DBushuven%26aufirst%3DE.%26aulast%3DDreier%26aufirst%3DA.%26aulast%3DBuchkremer%26aufirst%3DS.%26aulast%3DJohann%26aufirst%3DS.%26aulast%3DBeyer%26aufirst%3DC.%26aulast%3DDeschauer%26aufirst%3DM.%26aulast%3DTroost%26aufirst%3DD.%26aulast%3DWeis%26aufirst%3DJ.%26atitle%3DAltered%2520localization%252C%2520abnormal%2520modification%2520and%2520loss%2520of%2520function%2520of%2520sigma%2520receptor-1%2520in%2520amyotrophic%2520lateral%2520sclerosis%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2013%26volume%3D22%26spage%3D1581%26epage%3D1600%26doi%3D10.1093%2Fhmg%2Fddt008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Role of the sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS)</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.jphs.2014.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jphs.2014.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25704013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislaksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=10-16&author=T.+A.+Mavlyutovauthor=L.+W.+Guoauthor=M.+L.+Epsteinauthor=A.+E.+Ruoho&title=Role+of+the+sigma-1+receptor+in+Amyotrophic+Lateral+Sclerosis+%28ALS%29&doi=10.1016%2Fj.jphs.2014.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS)</span></div><div class="casAuthors">Mavlyutov, Timur A.; Guo, Lian-Wang; Epstein, Miles L.; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-16</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease affecting spinal cord motoneurons (MN) with an associative connection to Frontotemporal Lobar Dementia (FTLD).  The endoplasmic reticulum (ER) bound Sigma-1 Receptor (S1R) chaperone protein localizes to specialized ER cisternae within 10 nm of the plasma membrane in spinal cord ventral horn cholinergic post synaptic C-terminals.  Removal of the S1R gene in the Superoxide Dismutase-1 (SOD-1) mouse model of ALS exacerbated the neurodegenerative condition and resulted in a significantly reduced longevity when compared to the SOD-1/S1R wild type (WT) mouse.  The proposed amelioration of the ALS phenotype by the S1R is likely due to a "brake" on excitation of the MN as evidenced by a redn. in action potential generation in the MN of the WT when compared to the S1R KO mouse MN.  Although the precise signal transduction pathway(s) regulated by the S1R in the MN has/have not been elucidated at present, it is likely that direct or indirect functional interactions occur between the S1R in the ER cisternae with voltage gated potassium channels and/or with muscarinic M2 receptor signaling in the post synaptic plasma membrane.  Possible mechanisms for regulation of MN excitability by S1R are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbysHgXVhmt7Vg90H21EOLACvtfcHk0lgBlKQ7QNWM1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislaksbs%253D&md5=cd83eb6b7497ce9049cb1a85e75fe744</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.jphs.2014.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jphs.2014.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DMavlyutov%26aufirst%3DT.%2BA.%26aulast%3DGuo%26aufirst%3DL.%2BW.%26aulast%3DEpstein%26aufirst%3DM.%2BL.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DRole%2520of%2520the%2520sigma-1%2520receptor%2520in%2520Amyotrophic%2520Lateral%2520Sclerosis%2520%2528ALS%2529%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D127%26spage%3D10%26epage%3D16%26doi%3D10.1016%2Fj.jphs.2014.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Lenis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, C.</span></span> <span> </span><span class="NLM_article-title">Selective sigma receptor agonist 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2009.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuroscience.2009.03.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19345724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvFymu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2009&pages=31-38&author=M.+S.+Guzman-Lenisauthor=X.+Navarroauthor=C.+Casas&title=Selective+sigma+receptor+agonist+2-%284-morpholinethyl%291-phenylcyclohexanecarboxylate+%28PRE084%29+promotes+neuroprotection+and+neurite+elongation+through+protein+kinase+C+%28PKC%29+signaling+on+motoneurons&doi=10.1016%2Fj.neuroscience.2009.03.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Selective sigma receptor agonist 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons</span></div><div class="casAuthors">Guzman-Lenis, M.-S.; Navarro, X.; Casas, C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-38</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neuronal loss and interruption of axonal pathways occur after spinal cord injury.  This is initiated by the mech. damage and propagated by secondary events that include the fast rise of glutamate concn. and the subsequent over-activation of glutamate receptors, triggering noxious processes to the cell.  Excitotoxic processes are also obsd. in degenerative diseases that involve motoneuron loss.  Sigma-1 receptors (Sig-1Rs) are expressed in the CNS and their ligands have been shown to prevent neuronal death assocd. to glutamate toxicity.  In the present study, we used organotypic cultures of spinal cord slices and dorsal root ganglia (DRG) explants from 7-8 days old postnatal rats to assess whether the agonist of the Sig-1R, 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084), protects the spinal cord against glutamate excitotoxicity and promotes neurite elongation.  The results showed that PRE084 exerted a bell-shape dose-dependent protective response of the motoneurons, with a significant neuroprotection obtained with 10 μM PRE084.  PRE084 also caused an increase in the length of neurites in both motoneurons and neurons in DRG explants.  Both effects were abrogated with the addn. of BD 1063, an antagonist of Sig-1R, and the use of chelerythrine, a protein kinase C (PKC) pan-inhibitor indicating that PKC is implicated in the obsd. effects.  These results suggest the use of PRE084 as a neuroprotective agent for spinal cord damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps_4sw8EYDA7Vg90H21EOLACvtfcHk0lgEDTP05cne6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvFymu7w%253D&md5=aab657c16e7163f8c5e344765a2c00d8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2009.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2009.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DGuzman-Lenis%26aufirst%3DM.%2BS.%26aulast%3DNavarro%26aufirst%3DX.%26aulast%3DCasas%26aufirst%3DC.%26atitle%3DSelective%2520sigma%2520receptor%2520agonist%25202-%25284-morpholinethyl%25291-phenylcyclohexanecarboxylate%2520%2528PRE084%2529%2520promotes%2520neuroprotection%2520and%2520neurite%2520elongation%2520through%2520protein%2520kinase%2520C%2520%2528PKC%2529%2520signaling%2520on%2520motoneurons%26jtitle%3DNeuroscience%26date%3D2009%26volume%3D162%26spage%3D31%26epage%3D38%26doi%3D10.1016%2Fj.neuroscience.2009.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual-Font, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fores, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor agonist 2-(4-morpholinethyl)1 phenylcyclohexanecarboxylate (PRE084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury</span>. <i>J. Neurotrauma</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1089/neu.2010.1674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1089%2Fneu.2010.1674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21332255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC3MvpvVegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=831-840&author=C.+Penasauthor=A.+Pascual-Fontauthor=R.+Mancusoauthor=J.+Foresauthor=C.+Casasauthor=X.+Navarro&title=Sigma+receptor+agonist+2-%284-morpholinethyl%291+phenylcyclohexanecarboxylate+%28PRE084%29+increases+GDNF+and+BiP+expression+and+promotes+neuroprotection+after+root+avulsion+injury&doi=10.1089%2Fneu.2010.1674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptor agonist 2-(4-morpholinethyl)1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury</span></div><div class="casAuthors">Penas Clara; Pascual-Font Aran; Mancuso Renzo; Fores Joaquim; Casas Caty; Navarro Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurotrauma</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">831-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spinal root avulsion leads to a progressive loss of axotomized motoneurons (MNs).  Nowadays, there is no effective treatment to prolong MN survival that could permit recovery as a result of delayed surgical repair.  Administration of Sigma-1 receptor (Sig-1R) ligands has been reported to promote beneficial effects after several types of neural injury.  In order to shed light of whether Sig-1R ligands could promote MN survival after root avulsion, L4-L5 spinal roots were unilaterally avulsed in adult rats and the Sig-1R agonist Pre084 was administered at different doses.  The ventral spinal cords of the animals were studied from 3 to 21 days post-operation (DPO) by using histological, immunohistochemical, and Western blot techniques.  Daily treatment with 0.25 mg/kg Pre084 significantly promoted MN survival (68% vs 43% in untreated rats) at 21 DPO, an effect that was antagonized by coadministration of BD1063, an antagonist of Sig-1R.  There was a reduction in astroglial- associated immunoreactivity in rats treated with Pre084.  Moreover, Pre084 produced an increase in the Sig-1R co-chaperone BiP within MNs, and an increase of GDNF expression by astrocytes in the ventral horn early after injury.  Although the mechanisms promoting MN survival by Pre084 remain unclear, we hypothesize that it is mediated at least in part through the increase in these cytoprotective factors.  Therefore, early application of Sig-1R agonist appears to be a promising therapy to improve MN survival after root avulsion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZdy7tFHm5d8NIRw0GKUoEfW6udTcc2ea_tTCmPKLALrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvpvVegsQ%253D%253D&md5=b437f44edb0c64ca843031cf3d864ab6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1089%2Fneu.2010.1674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fneu.2010.1674%26sid%3Dliteratum%253Aachs%26aulast%3DPenas%26aufirst%3DC.%26aulast%3DPascual-Font%26aufirst%3DA.%26aulast%3DMancuso%26aufirst%3DR.%26aulast%3DFores%26aufirst%3DJ.%26aulast%3DCasas%26aufirst%3DC.%26aulast%3DNavarro%26aufirst%3DX.%26atitle%3DSigma%2520receptor%2520agonist%25202-%25284-morpholinethyl%25291%2520phenylcyclohexanecarboxylate%2520%2528PRE084%2529%2520increases%2520GDNF%2520and%2520BiP%2520expression%2520and%2520promotes%2520neuroprotection%2520after%2520root%2520avulsion%2520injury%26jtitle%3DJ.%2520Neurotrauma%26date%3D2011%26volume%3D28%26spage%3D831%26epage%3D840%26doi%3D10.1089%2Fneu.2010.1674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span> <span> </span><span class="NLM_article-title">Sigma-1R agonist improves motor function and motoneuron survival in ALS mice</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1007/s13311-012-0140-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs13311-012-0140-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22935988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqtbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=814-826&author=R.+Mancusoauthor=S.+Olivanauthor=A.+Randoauthor=C.+Casasauthor=R.+Ostaauthor=X.+Navarro&title=Sigma-1R+agonist+improves+motor+function+and+motoneuron+survival+in+ALS+mice&doi=10.1007%2Fs13311-012-0140-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice</span></div><div class="casAuthors">Mancuso, Renzo; Olivan, Sara; Rando, Amaya; Casas, Caty; Osta, Rosario; Navarro, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">814-826</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by progressive weakness, muscle atrophy, and paralysis due to the loss of upper and lower motoneurons (MNs).  Sigma-1 receptor (sigma-1R) activation promotes neuroprotection after ischemic and traumatic injuries to the central nervous system.  We recently reported that sigma-1R agonist (PRE-084) improves the survival of MNs after root avulsion injury in rats.  Moreover, a mutation of the sigma-1R leading to frontotemporal lobar degeneration/amyotrophic lateral sclerosis (ALS) was recently described in human patients.  In the present study, we analyzed the potential therapeutic effect of the sigma-1R agonist (PRE-084) in the SOD1G93A mouse model of ALS.  Mice were daily administered with PRE-084 (0.25 mg/kg) from 8 to 16 wk of age.  Functional outcome was assessed by electrophysiol. tests and computerized anal. of locomotion.  Histol., immunohistochem. analyses and Western blot of the spinal cord were performed.  PRE-084 administration from 8 wk of age improved the function of MNs, which was manifested by maintenance of the amplitude of muscle action potentials and locomotor behavior, and preserved neuromuscular connections and MNs in the spinal cord.  Moreover, it extended survival in both female and male mice by more than 15 %.  Delayed administration of PRE-084 from 12 wk of age also significantly improved functional outcome and preservation of the MNs.  There was an induction of protein kinase C-specific phosphorylation of the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor in SOD1G93A animals, and a redn. of the microglial reactivity compared with untreated mice.  PRE-084 exerts a dual therapeutic contribution, modulating NMDA Ca2+ influx to protect MNs, and the microglial reactivity to ameliorate the MN environment.  In conclusion, sigma-1R agonists, such as PRE-084, may be promising candidates for a therapeutical strategy of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo752Zuu4G6tbVg90H21EOLACvtfcHk0lgEDTP05cne6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqtbnO&md5=d058d70a447dbc778d0bec822a01225b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs13311-012-0140-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-012-0140-y%26sid%3Dliteratum%253Aachs%26aulast%3DMancuso%26aufirst%3DR.%26aulast%3DOlivan%26aufirst%3DS.%26aulast%3DRando%26aufirst%3DA.%26aulast%3DCasas%26aufirst%3DC.%26aulast%3DOsta%26aufirst%3DR.%26aulast%3DNavarro%26aufirst%3DX.%26atitle%3DSigma-1R%2520agonist%2520improves%2520motor%2520function%2520and%2520motoneuron%2520survival%2520in%2520ALS%2520mice%26jtitle%3DNeurotherapeutics%26date%3D2012%26volume%3D9%26spage%3D814%26epage%3D826%26doi%3D10.1007%2Fs13311-012-0140-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peviani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvaneschi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bontempi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, D.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of the sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">218</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2013.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.nbd.2013.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24141020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlarsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2014&pages=218-232&author=M.+Pevianiauthor=E.+Salvaneschiauthor=L.+Bontempiauthor=A.+Peteseauthor=A.+Manzoauthor=D.+Rossiauthor=M.+Salmonaauthor=S.+Collinaauthor=P.+Biginiauthor=D.+Curti&title=Neuroprotective+effects+of+the+sigma-1+receptor+%28S1R%29+agonist+PRE-084%2C+in+a+mouse+model+of+motor+neuron+disease+not+linked+to+SOD1+mutation&doi=10.1016%2Fj.nbd.2013.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation</span></div><div class="casAuthors">Peviani, Marco; Salvaneschi, Eleonora; Bontempi, Leonardo; Petese, Alessandro; Manzo, Antonio; Rossi, Daniela; Salmona, Mario; Collina, Simona; Bigini, Paolo; Curti, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">218-232</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The identification of novel mol. targets crucially involved in motor neuron degeneration/survival is a necessary step for the development of hopefully more effective therapeutic strategies for amyotrophic lateral sclerosis (ALS) patients.  In this view, S1R, an endoplasmic reticulum (ER)-resident receptor with chaperone-like activity, has recently attracted great interest.  S1R is involved in several processes leading to acute and chronic neurodegeneration, including ALS pathol.  Treatment with the S1R agonist PRE-084 improves locomotor function and motor neuron survival in presymptomatic and early symptomatic mutant SOD1-G93A ALS mice.  Here, we tested the efficacy of PRE-084 in a model of spontaneous motor neuron degeneration, the wobbler mouse (wr) as a proof of concept that S1R may be regarded as a key therapeutic target also for ALS cases not linked to SOD1 mutation.  Increased staining for S1R was detectable in morphol. spared cervical spinal cord motor neurons of wr mice both at early (6th week) and late (12th week) phases of clin. progression.  S1R signal was also detectable in hypertrophic astrocytes and reactive microglia of wr mice.  Chronic treatment with PRE-084 (three times a week, for 8 wk), starting at symptom onset, significantly increased the levels of BDNF in the gray matter, improved motor neuron survival and ameliorated paw abnormality and grip strength performance.  In addn., the treatment significantly reduced the no. of reactive astrocytes whereas, that of CD11b + microglial cells was increased.  A deeper evaluation of microglial markers revealed significant increased no. of cells pos. for the pan-macrophage marker CD68 and of CD206 + cells, involved in tissue restoration, in the white matter of PRE-084-treated mice.  The mRNA levels of TNF-α and IL-1β were not affected by PRE-084 treatment.  Thus, our results support pharmacol. manipulation of S1R as a promising strategy to cure ALS and point to increased availability of growth factors and modulation of astrocytosis and of macrophage/microglia as part of the mechanisms involved in S1R-mediated neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5m02NQMRO7Vg90H21EOLACvtfcHk0lgVUry-7d_ZDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlarsA%253D%253D&md5=af372183f209c89a30a6c63ab24a0c3a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2013.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2013.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeviani%26aufirst%3DM.%26aulast%3DSalvaneschi%26aufirst%3DE.%26aulast%3DBontempi%26aufirst%3DL.%26aulast%3DPetese%26aufirst%3DA.%26aulast%3DManzo%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DSalmona%26aufirst%3DM.%26aulast%3DCollina%26aufirst%3DS.%26aulast%3DBigini%26aufirst%3DP.%26aulast%3DCurti%26aufirst%3DD.%26atitle%3DNeuroprotective%2520effects%2520of%2520the%2520sigma-1%2520receptor%2520%2528S1R%2529%2520agonist%2520PRE-084%252C%2520in%2520a%2520mouse%2520model%2520of%2520motor%2520neuron%2520disease%2520not%2520linked%2520to%2520SOD1%2520mutation%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2014%26volume%3D62%26spage%3D218%26epage%3D232%26doi%3D10.1016%2Fj.nbd.2013.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span> <span> </span><span class="NLM_article-title">An increase of sigma-1 receptor in the penumbra neuron after acute ischemic stroke</span>. <i>J. Stroke Cerebrovasc. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1981</span>– <span class="NLM_lpage">1987</span>, <span class="refDoi"> DOI: 10.1016/j.jstrokecerebrovasdis.2017.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jstrokecerebrovasdis.2017.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28687423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlsFChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=1981-1987&author=X.+Zhangauthor=F.+Wuauthor=Y.+Jiaoauthor=T.+Tangauthor=L.+Yangauthor=C.+Luauthor=Y.+Zhangauthor=Y.+Zhangauthor=Y.+Baiauthor=J.+Chaoauthor=G.+Tengauthor=H.+Yao&title=An+increase+of+sigma-1+receptor+in+the+penumbra+neuron+after+acute+ischemic+stroke&doi=10.1016%2Fj.jstrokecerebrovasdis.2017.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">An Increase of Sigma-1 Receptor in the Penumbra Neuron after Acute Ischemic Stroke</span></div><div class="casAuthors">Zhang Xiaotian; Yang Li; Zhang Yanhong; Zhang Yuan; Bai Ying; Wu Fangfang; Jiao Yun; Tang Tianyu; Lu Chunqiang; Teng Gaojun; Chao Jie; Yao Honghong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1981-1987</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Penumbra salvage from infarction by early reperfusion within the time window is the target of acute ischemic stroke therapies.  Although the penumbral imaging is potently usable in clinic trial, additional work needs to be performed to advancing the field with better-defined, evaluated, and validated imaging measures.  METHODS:  Mice were subjected to permanent stroke by right middle cerebral artery (MCA) occlusion.  Multimodel magnetic resonance imaging (MRI) method was assessed to define the penumbra as that brain region in which the perfusion and diffusion-weighted MR images are mismatched (perfusion-weighted imaging [PWI]-diffusion-weighted imaging [DWI] mismatch).  MRI measurements were performed at 1 hour after MCA occlusion (MCAO).  Sigma-1 receptor expression was assessed by immunoblotting and immunostaining in PWI-DWI-defined penumbra and core compared with sham or contralateral slice.  Penumbral sigma-1 receptor identified the correlation with the neuron, astrocyte, and microglia by immuno-colocalization.  RESULTS:  Sigma-1 receptor was significantly upregulated in penumbra or peri-infarct compared with sham and core tissue at 1 hour and 24 hours after MCAO.  There was a colocalization of sigma-1 receptor and neuron in penumbra at 1 hour after stroke.  Sigma-1 receptor is specifically increased in ischemic penumbral neuron at 1 hour after MCAO.  CONCLUSIONS:  Sigma-1 receptor may act as an endogenous marker of penumbra after acute ischemic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOuudjsPZ3sTslzEEsg76ufW6udTcc2eb3h6xUJMAgqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlsFChug%253D%253D&md5=338df0841468b4f15eba0a7423eb9315</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.jstrokecerebrovasdis.2017.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jstrokecerebrovasdis.2017.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DTeng%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DH.%26atitle%3DAn%2520increase%2520of%2520sigma-1%2520receptor%2520in%2520the%2520penumbra%2520neuron%2520after%2520acute%2520ischemic%2520stroke%26jtitle%3DJ.%2520Stroke%2520Cerebrovasc.%2520Dis.%26date%3D2017%26volume%3D26%26spage%3D1981%26epage%3D1987%26doi%3D10.1016%2Fj.jstrokecerebrovasdis.2017.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hazell, A. S.</span></span> <span> </span><span class="NLM_article-title">Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/j.neuint.2007.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuint.2007.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=17576023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVKmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=941-953&author=A.+S.+Hazell&title=Excitotoxic+mechanisms+in+stroke%3A+an+update+of+concepts+and+treatment+strategies&doi=10.1016%2Fj.neuint.2007.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Excitotoxic mechanisms in stroke: An update of concepts and treatment strategies</span></div><div class="casAuthors">Hazell, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">941-953</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cerebral damage as a consequence of glutamate-mediated excitotoxicity represents a major consequence of stroke.  However, the development of effective clin. treatments for this potentially devastating condition was largely unsuccessful to date, despite promising basic research.  This review will focus on the latest advances in the understanding of the excitotoxic process including the release of glutamate as a neurotransmitter and the potential contribution of complexins, the important role of astrocytes, including its involvement in glutamate uptake, alterations in glutamate transporter levels, reversed glutamate uptake, and the vesicular release of glutamate.  Recent progress in the understanding of the involvement of excitotoxicity in white matter injury following ischemic insults is also discussed, as is oxidative stress and ischemic tolerance, along with an update on the use of treatment strategies with potential therapeutic benefit including stimulation of neurogenesis.  Such key issues are at the heart of future interventions directed at limiting the extent of the excitotoxic process, and remain a viable consideration for effective stroke management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAOOx_KUQIVLVg90H21EOLACvtfcHk0lgVUry-7d_ZDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVKmsLo%253D&md5=3cce1e63a63a64fa0ae8bcd5e3c6c658</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2007.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2007.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DHazell%26aufirst%3DA.%2BS.%26atitle%3DExcitotoxic%2520mechanisms%2520in%2520stroke%253A%2520an%2520update%2520of%2520concepts%2520and%2520treatment%2520strategies%26jtitle%3DNeurochem.%2520Int.%26date%3D2007%26volume%3D50%26spage%3D941%26epage%3D953%26doi%3D10.1016%2Fj.neuint.2007.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Yebenes, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landwehrmeyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squitieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saft, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnet, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sword, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rembratt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedroff, J.</span></span> <span> </span><span class="NLM_article-title">Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(11)70233-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS1474-4422%2811%2970233-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22071279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2gsbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1049-1057&author=J.+G.+de%0AYebenesauthor=B.+Landwehrmeyerauthor=F.+Squitieriauthor=R.+Reilmannauthor=A.+Rosserauthor=R.+A.+Barkerauthor=C.+Saftauthor=M.+K.+Magnetauthor=A.+Swordauthor=A.+Rembrattauthor=J.+Tedroff&title=Pridopidine+for+the+treatment+of+motor+function+in+patients+with+Huntington%E2%80%99s+disease+%28MermaiHD%29%3A+a+phase+3%2C+randomised%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS1474-4422%2811%2970233-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial</span></div><div class="casAuthors">de Yebenes, Justo Garcia; Landwehrmeyer, Bernhard; Squitieri, Ferdinando; Reilmann, Ralf; Rosser, Anne; Barker, Roger A.; Saft, Carsten; Magnet, Markus K.; Sword, Alastair; Rembratt, Asa; Tedroff, Joakim</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1049-1057</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Huntington's disease is a progressive neurodegenerative disorder, characterised by motor, cognitive, and behavioral deficits.  Pridopidine belongs to a new class of compds. known as dopaminergic stabilizers, and results from a small phase 2 study in patients with Huntington's disease suggested that this drug might improve voluntary motor function.  We aimed to assess further the effects of pridopidine in patients with Huntington's disease.  We undertook a 6 mo, randomised, double-blind, placebo-controlled trial to assess the efficacy of pridopidine in the treatment of motor deficits in patients with Huntington's disease.  Our primary endpoint was change in the modified motor score (mMS; derived from the unified Huntington's disease rating scale) at 26 wk.  We recruited patients with Huntington's disease from 32 European centers; patients were aged 30 years or older and had an mMS of 10 points or greater at baseline.  Patients were randomly assigned (1:1:1) to receive placebo, 45 mg per day pridopidine, or 90 mg per day pridopidine by use of centralised computer-generated codes.  Patients and investigators were masked to treatment assignment.  We also assessed the safety and tolerability profile of pridopidine.  For our primary anal., all patients were eligible for inclusion in our full anal. set, in which we used the last observation carried forward method for missing values.  We used an anal. of covariance model and the Bonferroni method to adjust for multiple comparisons.  We used a prespecified per-protocol population as our sensitivity anal.  The α level was 0.025 for our primary anal. and 0.05 overall.  This trial is registered with ClinicalTrials.gov, no. NCT00665223.  At 26 wk, in our full anal. set the difference in mean mMS was -0.99 points (97.5% CI -2.08 to 0.10, p = 0.042) in patients who received 90 mg per day pridopidine (n = 145) vs. those who received placebo (n = 144), and -0.36 points (-1.44 to 0.72, p = 0.456) in those who received 45 mg per day pridopidine (n = 148) vs. those who received placebo.  At the 90 mg per day dose, in our per-protocol population (n = 114), the redn. in the mMS was of -1.29 points (-2.47 to -0.12; p = 0.014) compared with placebo (n = 120).  We did not identify any changes in non-motor endpoints at either dose.  Pridopidine was well tolerated and had an adverse event profile similar to that of placebo.  This study did not provide evidence of efficacy as measured by the mMS, but a potential effect of pridopidine on the motor phenotype of Huntington's disease merits further investigation.  Pridopidine up to 90 mg per day was well tolerated in patients with Huntington's disease.  Funding: NeuroSearch A/S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVDXQbNRAMqLVg90H21EOLACvtfcHk0ljHpWMYmEAffA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2gsbrO&md5=ed31da6ccaad5c90745d35aacbbb6f4a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2811%2970233-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252811%252970233-2%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BYebenes%26aufirst%3DJ.%2BG.%26aulast%3DLandwehrmeyer%26aufirst%3DB.%26aulast%3DSquitieri%26aufirst%3DF.%26aulast%3DReilmann%26aufirst%3DR.%26aulast%3DRosser%26aufirst%3DA.%26aulast%3DBarker%26aufirst%3DR.%2BA.%26aulast%3DSaft%26aufirst%3DC.%26aulast%3DMagnet%26aufirst%3DM.%2BK.%26aulast%3DSword%26aufirst%3DA.%26aulast%3DRembratt%26aufirst%3DA.%26aulast%3DTedroff%26aufirst%3DJ.%26atitle%3DPridopidine%2520for%2520the%2520treatment%2520of%2520motor%2520function%2520in%2520patients%2520with%2520Huntington%25E2%2580%2599s%2520disease%2520%2528MermaiHD%2529%253A%2520a%2520phase%25203%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%2520Neurol.%26date%3D2011%26volume%3D10%26spage%3D1049%26epage%3D1057%26doi%3D10.1016%2FS1474-4422%2811%2970233-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katnik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennypacker, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1365</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.107557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.106.107557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16988055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2006&pages=1355-1365&author=C.+Katnikauthor=W.+R.+Guerreroauthor=K.+R.+Pennypackerauthor=Y.+Herreraauthor=J.+Cuevas&title=Sigma-1+receptor+activation+prevents+intracellular+calcium+dysregulation+in+cortical+neurons+during+in+vitro+ischemia&doi=10.1124%2Fjpet.106.107557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia</span></div><div class="casAuthors">Katnik, Christopher; Guerrero, Waldo R.; Pennypacker, Keith R.; Herrera, Yelenis; Cuevas, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1355-1365</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sigma receptors are putative targets for neuroprotection following ischemia; however, little is known on their mechanism of action.  One of the key components in the demise of neurons following ischemic injury is the disruption of intracellular calcium homeostasis.  Fluorometric calcium imaging was used to examine the effects of sigma receptor activation on changes in intracellular calcium concns. ([Ca2+]i) evoked by in vitro ischemia in cultured cortical neurons from embryonic rats.  The sigma receptor agonist, 1,3-di-o-tolyl-guanidine (DTG), was shown to depress [Ca2+]i elevations obsd. in response to ischemia induced by sodium azide and glucose deprivation.  Two sigma receptor antagonists, metaphit and BD-1047, were shown to blunt the ability of DTG to inhibit ischemia-evoked increases in [Ca2+]i, revealing that the effects are mediated by activation of sigma receptors and not via the actions of DTG on nonspecific targets such as N-methyl-D-aspartate receptors.  DTG inhibition of ischemia-induced increases in [Ca2+]i was mimicked by the σ-1 receptor-selective agonists, carbetapentane, (+)-pentazocine and PRE-084 [2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate hydrochloride], but not by the sigma-2-selective agonist, ibogaine, showing that activation of sigma-1 receptors is responsible for the effects.  In contrast, DTG, carbetapentane, and ibogaine blocked spontaneous, synchronous calcium transients obsd. in our prepn. at concns. consistent with sigma receptor-mediated effects, indicating that both sigma-1 and sigma-2 receptors regulate events that affect [Ca2+]i in cortical neurons.  Our studies show that activation of sigma receptors can ameliorate [Ca2+]i dysregulation assocd. with ischemia in cortical neurons and, thus, identify one of the mechanisms by which these receptors may exert their neuroprotective properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUF4Cm8IUXC7Vg90H21EOLACvtfcHk0ljHpWMYmEAffA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltLrN&md5=56403735f0ab724612afb2746fd8d07f</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.107557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.107557%26sid%3Dliteratum%253Aachs%26aulast%3DKatnik%26aufirst%3DC.%26aulast%3DGuerrero%26aufirst%3DW.%2BR.%26aulast%3DPennypacker%26aufirst%3DK.%2BR.%26aulast%3DHerrera%26aufirst%3DY.%26aulast%3DCuevas%26aufirst%3DJ.%26atitle%3DSigma-1%2520receptor%2520activation%2520prevents%2520intracellular%2520calcium%2520dysregulation%2520in%2520cortical%2520neurons%2520during%2520in%2520vitro%2520ischemia%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D319%26spage%3D1355%26epage%3D1365%26doi%3D10.1124%2Fjpet.106.107557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, P.</span></span> <span> </span><span class="NLM_article-title">Sigma-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1016/0304-3940(90)90139-Z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2F0304-3940%2890%2990139-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1963213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK3MXjslE%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1990&pages=169-174&author=D.+Lobnerauthor=P.+Lipton&title=Sigma-ligands+and+non-competitive+NMDA+antagonists+inhibit+glutamate+release+during+cerebral+ischemia&doi=10.1016%2F0304-3940%2890%2990139-Z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">σ-Ligands and noncompetitive NMDA antagonists inhibit glutamate release during cerebral ischemia</span></div><div class="casAuthors">Lobner, Doug; Lipton, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">169-74</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    </div><div class="casAbstract">Release of glutamate from brain cells is increased during ischemia and is thought to be involved in ischemic damage.  In rat hippocampal slices the release of glutamate during in vitro ischemia (anoxia without glucose) is shown to be blocked by two groups of compds.: non-competitive N-methyl-D-aspartate (NMDA) antagonists and sigma ligands.  The effects are selective for the ischemic glutamate release, which is independent of extracellular Ca2+.  High K+, Ca2+ dependent, induced release of glutamate is not inhibited.  NMDA receptor blockade normally does not prevent ischemic transmission damage in the rat hippocampal slice.  However, when ischemic glutamate release is attenuated, NMDA receptor antagonists do prevent the damage.  This indicates that high levels of glutamate may cause damage via non-NMDA as well as NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWQFtVXDOwZ7Vg90H21EOLACvtfcHk0ljHpWMYmEAffA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXjslE%253D&md5=d763713e9146fd59bf60c15d63db8850</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0304-3940%2890%2990139-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3940%252890%252990139-Z%26sid%3Dliteratum%253Aachs%26aulast%3DLobner%26aufirst%3DD.%26aulast%3DLipton%26aufirst%3DP.%26atitle%3DSigma-ligands%2520and%2520non-competitive%2520NMDA%2520antagonists%2520inhibit%2520glutamate%2520release%2520during%2520cerebral%2520ischemia%26jtitle%3DNeurosci.%2520Lett.%26date%3D1990%26volume%3D117%26spage%3D169%26epage%3D174%26doi%3D10.1016%2F0304-3940%2890%2990139-Z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ajmo, C. T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernon, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennypacker, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, J.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor activation reduces infarct size at 24 h after permanent middle cerebral artery occlusion in rats</span>. <i>Curr. Neurovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.2174/156720206776875849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F156720206776875849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16719792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Ors74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=89-98&author=C.+T.+Ajmoauthor=D.+O.+Vernonauthor=L.+Collierauthor=K.+R.+Pennypackerauthor=J.+Cuevas&title=Sigma+receptor+activation+reduces+infarct+size+at+24+h+after+permanent+middle+cerebral+artery+occlusion+in+rats&doi=10.2174%2F156720206776875849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptor activation reduces infract size at 24 hours after permanent middle cerebral artery occlusion in rats</span></div><div class="casAuthors">Ajmo, Craig T., Jr.; Vernon, Dionne O. L.; Collier, Lisa; Pennypacker, Keith R.; Cuevas, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Current Neurovascular Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">CNRUAM</span>;
        ISSN:<span class="NLM_cas:issn">1567-2026</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The only available treatment for embolic stroke is recombinant tissue plasminogen activator, which must be administered within three hours of stroke onset.  We examd. the effects of 1,3-di-o-tolyguanidine (DTG), a high affinity sigma receptor agonist, as a potential treatment for decreasing infarct area at delayed time points.  Rats were subjected to permanent embolic middle cerebral artery occlusion (MCAO) and allowed to recover before receiving s.c. injections of 15 mg/kg of DTG at 24, 48, and 72 h.  At 96 h the rats were euthanized, and brains harvested and sectioned.  Infarct areas were quantified at the level of the cortical/striatal and cortical/hippocampal regions in control (MCAO-only) and DTG treated animals using a marker for neurodegeneration, Fluoro-Jade.  DTG treatment significantly reduced infarct area in both cortical/striatal and cortical/hippocampal regions by >80%, relative to control rats.  These findings were confirmed by immunohistochem. expts. using the neuronal marker, mouse anti-neuronal nuclei monoclonal antibody (NeuN), which showed that application of DTG significantly increased the no. of viable neurons in these regions.  Furthermore, DTG blocked the inflammatory response evoked by MCAO, as indicated by decreases in the no. of reactive astrocytes and activated microglia/macrophages detected by immunostaining for glial fibrillary acidic protein (GFAP) and binding of isolectin IB4, resp.  Thus, our results demonstrate that the sigma receptor-selective agonist, DTG, can enhance neuronal survival when administered 24 h after an ischemic stroke.  In addn., the efficacy of sigma receptors for stroke treatment at delayed time points is likely the result of combined neuroprotective and anti-inflammatory properties of these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8VrhYX_Dt5LVg90H21EOLACvtfcHk0lhXH0gHeuAyGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Ors74%253D&md5=2e9a6d25b30ba69fed8d9626f48aa5ea</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.2174%2F156720206776875849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720206776875849%26sid%3Dliteratum%253Aachs%26aulast%3DAjmo%26aufirst%3DC.%2BT.%26aulast%3DVernon%26aufirst%3DD.%2BO.%26aulast%3DCollier%26aufirst%3DL.%26aulast%3DPennypacker%26aufirst%3DK.%2BR.%26aulast%3DCuevas%26aufirst%3DJ.%26atitle%3DSigma%2520receptor%2520activation%2520reduces%2520infarct%2520size%2520at%252024%2520h%2520after%2520permanent%2520middle%2520cerebral%2520artery%2520occlusion%2520in%2520rats%26jtitle%3DCurr.%2520Neurovasc.%2520Res.%26date%3D2006%26volume%3D3%26spage%3D89%26epage%3D98%26doi%3D10.2174%2F156720206776875849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katnik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behensky, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasny, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seredenin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAleer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, J.</span></span> <span> </span><span class="NLM_article-title">Treatment with afobazole at delayed time points following ischemic stroke improves long-term functional and histological outcomes</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2013.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.nbd.2013.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24141021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2014&pages=354-364&author=C.+Katnikauthor=A.+Garciaauthor=A.+A.+Behenskyauthor=I.+E.+Yasnyauthor=A.+M.+Shusterauthor=S.+B.+Seredeninauthor=A.+V.+Petrovauthor=S.+Seifuauthor=J.+McAleerauthor=A.+Willingauthor=J.+Cuevas&title=Treatment+with+afobazole+at+delayed+time+points+following+ischemic+stroke+improves+long-term+functional+and+histological+outcomes&doi=10.1016%2Fj.nbd.2013.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with afobazole at delayed time points following ischemic stroke improves long-term functional and histological outcomes</span></div><div class="casAuthors">Katnik, C.; Garcia, A.; Behensky, A. A.; Yasny, I. E.; Shuster, A. M.; Seredenin, S. B.; Petrov, A. V.; Seifu, S.; McAleer, J.; Willing, A.; Cuevas, J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">354-364</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There is currently a significant lack of therapeutic options for acute ischemic stroke, and no drug has been approved for treating patients at delayed time points (≥ 6 h post-stroke).  Afobazole, an anxiolytic currently used clin. in Russia, has been shown to reduce neuronal and glial cell injury in vitro following ischemia.  Expts. using the permanent middle cerebral artery occlusion (MCAO) rat model were carried out to det. if afobazole can reduce ischemic stroke damage in vivo and expand the therapeutic window for stroke treatment.  Post-stroke (24 h) application of afobazole (0.3-3 mg/kg) significantly decreased infarct vol. at 96 h post-surgery, as detd. by Fluoro-Jade and NeuN staining of brain sections.  Moreover, afobazole helped preserve both the levels and normal histol. distribution of myelin basic protein, indicating a redn. in white matter injury.  A time-dependence study showed that either pre-treatment or treatment started 6 to 48 h post-stroke with the drug yields improved outcomes at 96 h.  The decrease in infarct vol. produced by afobazole was blocked by the application of either a σ-1 (BD 1063, 30 mg/kg) or a σ-2 (SM-21, 1 mg/kg) antagonist, indicating that both receptor subtypes are involved in the effects of afobazole.  Treatment with afobazole starting at 24 h post-stroke resulted in enhanced survival one month following surgery.  Behavioral testing of animals 28-32 days post-surgery using the elevated body swing and forelimb grip-strength tests revealed that treatment with afobazole starting 24 h post-stroke significantly reduces behavioral deficits caused by ischemic stroke.  The increase in survival and improved functional outcomes are accompanied by a redn. in infarct vol., as detd. by thionin staining of brain sections.  Taken together, our data support the use of afobazole as a post-stroke pharmacol. agent to expand the current therapeutic window.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEZe5ZFCdkQrVg90H21EOLACvtfcHk0lhXH0gHeuAyGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlemsg%253D%253D&md5=39491a39c38c4e39c1a39a1f5c15e4b7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2013.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2013.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DKatnik%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DBehensky%26aufirst%3DA.%2BA.%26aulast%3DYasny%26aufirst%3DI.%2BE.%26aulast%3DShuster%26aufirst%3DA.%2BM.%26aulast%3DSeredenin%26aufirst%3DS.%2BB.%26aulast%3DPetrov%26aufirst%3DA.%2BV.%26aulast%3DSeifu%26aufirst%3DS.%26aulast%3DMcAleer%26aufirst%3DJ.%26aulast%3DWilling%26aufirst%3DA.%26aulast%3DCuevas%26aufirst%3DJ.%26atitle%3DTreatment%2520with%2520afobazole%2520at%2520delayed%2520time%2520points%2520following%2520ischemic%2520stroke%2520improves%2520long-term%2520functional%2520and%2520histological%2520outcomes%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2014%26volume%3D62%26spage%3D354%26epage%3D364%26doi%3D10.1016%2Fj.nbd.2013.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allahtavakoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarrott, B.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2011.03.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.brainresbull.2011.03.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21453760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=219-224&author=M.+Allahtavakoliauthor=B.+Jarrott&title=Sigma-1+receptor+ligand+PRE-084+reduced+infarct+volume%2C+neurological+deficits%2C+pro-inflammatory+cytokines+and+enhanced+anti-inflammatory+cytokines+after+embolic+stroke+in+rats&doi=10.1016%2Fj.brainresbull.2011.03.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats</span></div><div class="casAuthors">Allahtavakoli, Mohammad; Jarrott, Bevyn</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">219-224</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma receptor agonists have been found to provide potent neuroprotection in rats and mice.  This neuroprotection is thought to be mediated through anti-excitotoxic mechanisms.  Neuroprotective and immune modulatory effects of sigma ligands have not been investigated in embolic stroke.  In the present study, rats were subjected to embolic stroke or sham stroke and were treated with the sigma-1 receptor agonist PRE-084 (5 mg/kg i.p.) or saline vehicle 3 and 24 h after stroke.  Infarct vol. and behavioral tests were conducted, and cytokine levels (ILs-1α and β, IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-α) were detd. in ischemic and non-ischemic cortices.  Axonal damage was detd. using the pNF-H ELISA assay.  Treatment with PRE-084 afforded neuroprotection following embolic stroke as evidenced by significantly reduced infarct vol. and improved behavioral outcome.  Remarkably, treatment with PRE-084 reduced levels of pro-inflammatory cytokines and enhanced anti-inflammatory cytokines.  Levels of pNF-H were lower in rats treated with PRE-084 suggesting reduced axonal damage but this finding did not reach statistical significance.  The findings of the present study suggest that part of the neuroprotective effects of sigma-1 receptor agonists may be mediated through a dual effect on cytokine release following stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobFI49nXcFRbVg90H21EOLACvtfcHk0lhXH0gHeuAyGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFCrsbk%253D&md5=9388655859dcffdd21437099d07798d3</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2011.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2011.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DAllahtavakoli%26aufirst%3DM.%26aulast%3DJarrott%26aufirst%3DB.%26atitle%3DSigma-1%2520receptor%2520ligand%2520PRE-084%2520reduced%2520infarct%2520volume%252C%2520neurological%2520deficits%252C%2520pro-inflammatory%2520cytokines%2520and%2520enhanced%2520anti-inflammatory%2520cytokines%2520after%2520embolic%2520stroke%2520in%2520rats%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2011%26volume%3D85%26spage%3D219%26epage%3D224%26doi%3D10.1016%2Fj.brainresbull.2011.03.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamloo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickhag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladunga, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisselsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toresson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruslim-Litrus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urfer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieloch, T.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1093/brain/awq367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1093%2Fbrain%2Fawq367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21278085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC3M3itVGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2011&pages=732-746&author=K.+Ruscherauthor=M.+Shamlooauthor=M.+Rickhagauthor=I.+Ladungaauthor=L.+Sorianoauthor=L.+Gisselssonauthor=H.+Toressonauthor=L.+Ruslim-Litrusauthor=D.+Oksenbergauthor=R.+Urferauthor=B.+B.+Johanssonauthor=K.+Nikolichauthor=T.+Wieloch&title=The+sigma-1+receptor+enhances+brain+plasticity+and+functional+recovery+after+experimental+stroke&doi=10.1093%2Fbrain%2Fawq367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke</span></div><div class="casAuthors">Ruscher Karsten; Shamloo Mehrdad; Rickhag Mattias; Ladunga Istvan; Soriano Liza; Gisselsson Lennart; Toresson Hakan; Ruslim-Litrus Lily; Oksenberg Donna; Urfer Roman; Johansson Barbro B; Nikolich Karoly; Wieloch Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">Pt 3</span>),
    <span class="NLM_cas:pages">732-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Stroke leads to brain damage with subsequent slow and incomplete recovery of lost brain functions.  Enriched housing of stroke-injured rats provides multi-modal sensorimotor stimulation, which improves recovery, although the specific mechanisms involved have not been identified.  In rats housed in an enriched environment for two weeks after permanent middle cerebral artery occlusion, we found increased sigma-1 receptor expression in peri-infarct areas.  Treatment of rats subjected to permanent or transient middle cerebral artery occlusion with 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride, an agonist of the sigma-1 receptor, starting two days after injury, enhanced the recovery of lost sensorimotor function without decreasing infarct size.  The sigma-1 receptor was found in the galactocerebroside enriched membrane microdomains of reactive astrocytes and in neurons.  Sigma-1 receptor activation increased the levels of the synaptic protein neurabin and neurexin in membrane rafts in the peri-infarct area, while sigma-1 receptor silencing prevented sigma-1 receptor-mediated neurite outgrowth in primary cortical neuronal cultures.  In astrocytic cultures, oxygen and glucose deprivation induced sigma-1 receptor expression and actin dependent membrane raft formation, the latter blocked by sigma-1 receptor small interfering RNA silencing and pharmacological inhibition.  We conclude that sigma-1 receptor activation stimulates recovery after stroke by enhancing cellular transport of biomolecules required for brain repair, thereby stimulating brain plasticity.  Pharmacological targeting of the sigma-1 receptor provides new opportunities for stroke treatment beyond the therapeutic window of neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3TsV5rFaPgP69nzq6467DfW6udTcc2ebt-7Cce7TKcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3itVGksg%253D%253D&md5=d336b50f51488568b4fb6d2f72d794ec</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawq367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawq367%26sid%3Dliteratum%253Aachs%26aulast%3DRuscher%26aufirst%3DK.%26aulast%3DShamloo%26aufirst%3DM.%26aulast%3DRickhag%26aufirst%3DM.%26aulast%3DLadunga%26aufirst%3DI.%26aulast%3DSoriano%26aufirst%3DL.%26aulast%3DGisselsson%26aufirst%3DL.%26aulast%3DToresson%26aufirst%3DH.%26aulast%3DRuslim-Litrus%26aufirst%3DL.%26aulast%3DOksenberg%26aufirst%3DD.%26aulast%3DUrfer%26aufirst%3DR.%26aulast%3DJohansson%26aufirst%3DB.%2BB.%26aulast%3DNikolich%26aufirst%3DK.%26aulast%3DWieloch%26aufirst%3DT.%26atitle%3DThe%2520sigma-1%2520receptor%2520enhances%2520brain%2520plasticity%2520and%2520functional%2520recovery%2520after%2520experimental%2520stroke%26jtitle%3DBrain%26date%3D2011%26volume%3D134%26spage%3D732%26epage%3D746%26doi%3D10.1093%2Fbrain%2Fawq367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Blazquez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozo-Rodrigalvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzon, J.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor antagonist, S1RA, reduces stroke damage, ameliorates post-stroke neurological deficits and suppresses the overexpression of MMP-9</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4940</span>– <span class="NLM_lpage">4951</span>, <span class="refDoi"> DOI: 10.1007/s12035-017-0697-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs12035-017-0697-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28779350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yhs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2018&pages=4940-4951&author=P.+Sanchez-Blazquezauthor=A.+Pozo-Rodrigalvarezauthor=M.+Merlosauthor=J.+Garzon&title=The+sigma-1+receptor+antagonist%2C+S1RA%2C+reduces+stroke+damage%2C+ameliorates+post-stroke+neurological+deficits+and+suppresses+the+overexpression+of+MMP-9&doi=10.1007%2Fs12035-017-0697-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor antagonist, s1ra, reduces stroke damage, ameliorates post-stroke neurological deficits and suppresses the overexpression of mmp-9</span></div><div class="casAuthors">Sanchez-Blazquez, Pilar; Pozo-Rodrigalvarez, Andrea; Merlos, Manuel; Garzon, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">4940-4951</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">The glutamate N-methyl-D-aspartate receptor (NMDAR) plays an essential role in the excitotoxic neural damage that follows ischemic stroke.  Because the sigma-1 receptor (σ1R) can regulate NMDAR transmission, exogenous and putative endogenous regulators of σ1R have been investigated using animal models of ischemic stroke.  As both agonists and antagonists provide some neural protection, the selective involvement of σ1Rs in these effects has been questioned.  The availability of S1RA (E-52862/MR309), a highly selective σ1R antagonist, prompted us to explore its therapeutic potential in an animal model of focal cerebral ischemia.  Mice were subjected to right middle cerebral artery occlusion (MCAO), and post-ischemic infarct vol. and neurol. deficits were detd. across a range of intervals after the stroke-inducing surgery.  Intracerebroventricular or i.v. treatment with S1RA significantly reduced the cerebral infarct size and neurol. deficits caused by permanent MCAO (pMCAO).  Compared with the control/sham-operated mice, the neuroprotective effects of S1RA were obsd. when delivered up to 5 h prior to surgery and 3 h after ischemic onset.  Interestingly, neither mice with the genetic deletion of σ1R nor wild-type mice that were pre-treated with the σ1R agonist PRE084 showed beneficial effects after S1RA administration with regard to stroke infarction.  S1RA-treated mice showed faster behavioral recovery from stroke; this finding complements the significant decreases in matrix metalloproteinase-9 (MMP-9) expression and reactive astrogliosis surrounding the infarcted cortex.  Our data indicate that S1RA, via σ1R, holds promising potential for clin. application as a therapeutic agent for ischemic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZUGbqL3A9JrVg90H21EOLACvtfcHk0lgi48yg-xrR9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yhs7jP&md5=44394f0ed6fa849eb5cfe1e46c492535</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs12035-017-0697-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-017-0697-x%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Blazquez%26aufirst%3DP.%26aulast%3DPozo-Rodrigalvarez%26aufirst%3DA.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DGarzon%26aufirst%3DJ.%26atitle%3DThe%2520sigma-1%2520receptor%2520antagonist%252C%2520S1RA%252C%2520reduces%2520stroke%2520damage%252C%2520ameliorates%2520post-stroke%2520neurological%2520deficits%2520and%2520suppresses%2520the%2520overexpression%2520of%2520MMP-9%26jtitle%3DMol.%2520Neurobiol.%26date%3D2018%26volume%3D55%26spage%3D4940%26epage%3D4951%26doi%3D10.1007%2Fs12035-017-0697-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fishback, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Sigma receptors: potential targets for a new class of antidepressant drug</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2010.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.pharmthera.2010.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20438757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosV2htro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=271-282&author=J.+A.+Fishbackauthor=M.+J.+Robsonauthor=Y.+T.+Xuauthor=R.+R.+Matsumoto&title=Sigma+receptors%3A+potential+targets+for+a+new+class+of+antidepressant+drug&doi=10.1016%2Fj.pharmthera.2010.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptors: Potential targets for a new class of antidepressant drug</span></div><div class="casAuthors">Fishback, James A.; Robson, Matthew J.; Xu, Yan-Tong; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-282</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Despite the widespread and devastating impact of depression on society, our current understanding of its pathogenesis is limited.  Likewise, existing treatments are inadequate, providing relief to only a subset of people suffering from depression.  The search for more effective antidepressant drugs includes the investigation of new mol. targets.  Among them, current data suggests that sigma receptors are involved in multiple processes effecting antidepressant-like actions in vivo and in vitro.  This review summarizes accumulated evidence supporting a role for sigma receptors in antidepressant effects and provides a conceptual framework for delineating their potential roles over the course of antidepressant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLgoPQq-jsCbVg90H21EOLACvtfcHk0lgi48yg-xrR9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosV2htro%253D&md5=8bc10680890e356f82ccd21b7885e9db</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DFishback%26aufirst%3DJ.%2BA.%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DXu%26aufirst%3DY.%2BT.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSigma%2520receptors%253A%2520potential%2520targets%2520for%2520a%2520new%2520class%2520of%2520antidepressant%2520drug%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D127%26spage%3D271%26epage%3D282%26doi%3D10.1016%2Fj.pharmthera.2010.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevallier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacological interaction with the sigma1 (sigma1)-receptor in the acute behavioral effects of antidepressants</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1254/jphs.10191FP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1254%2Fjphs.10191FP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21427517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2011&pages=279-292&author=V.+Villardauthor=J.+Meunierauthor=N.+Chevallierauthor=T.+Maurice&title=Pharmacological+interaction+with+the+sigma1+%28sigma1%29-receptor+in+the+acute+behavioral+effects+of+antidepressants&doi=10.1254%2Fjphs.10191FP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological interaction with the σ1-receptor in the acute behavioral effects of antidepressants</span></div><div class="casAuthors">Villard, Vanessa; Meunier, Johann; Chevallier, Nathalie; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-292</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">Selective agonists of the sigma-1 σ1-ligand-operated chaperone protein, like igmesine or PRE-084, are antidepressants in preclin. depression models.  σ1-Protein activation may contribute to the antidepressant efficacy of drugs known to act as selective serotonin-reuptake inhibitors (SSRI) or noradrenaline reuptake inhibitors through direct or indirect involvement of the σ1-receptor in the drug effect.  We here compared antidepressant effects in two behavioral procedures, the forced swimming test (FST) and conditioned fear stress (CFS).  The involvement of the σ1-receptor was examd. using a co-treatment with the σ1-antagonist BD1047 or using σ1-knockout (KO) mice.  Igmesine but not PRE-084 decreased FST immobility.  The SSRI fluoxetine and sertraline, but not fluvoxamine, and the tricyclic antidepressants imipramine, desipramine, and amitriptyline were also effective.  Only the effect of igmesine was blocked by BD1047 or in σ1-KO mice.  Igmesine, PRE-084, fluvoxamine, and sertraline decreased the CFS immobility in a BD1047- and σ1-KO-sensitive manner.  Among tricyclics, only amitriptyline was effective and its effect was unaffected by BD1047 or in σ1-KO mice.  The behavioral effects induced by mixed σ1-receptor/SSRI antidepressants, like fluvoxamine or sertraline, may therefore involve a non-selective action at both targets.  Moreover, the CFS appears to more reliably uncover a σ1 pharmacol. component in antidepressant screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruQxCYdwY51LVg90H21EOLACvtfcHk0liUWwxbV2WeWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOktr4%253D&md5=06dbe2071d402573e5b0ed24ea776f14</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1254%2Fjphs.10191FP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.10191FP%26sid%3Dliteratum%253Aachs%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DChevallier%26aufirst%3DN.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DPharmacological%2520interaction%2520with%2520the%2520sigma1%2520%2528sigma1%2529-receptor%2520in%2520the%2520acute%2520behavioral%2520effects%2520of%2520antidepressants%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D115%26spage%3D279%26epage%3D292%26doi%3D10.1254%2Fjphs.10191FP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faherty, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harkin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, B. E.</span></span> <span> </span><span class="NLM_article-title">The functional sensitisation of sigma receptors following chronic selective serotonin reuptake inhibitor treatment</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(98)00041-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS0014-2999%2898%2900041-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=9617747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK1cXitVKit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=1998&pages=15-21&author=C.+J.+Fahertyauthor=A.+J.+Harkinauthor=B.+E.+Leonard&title=The+functional+sensitisation+of+sigma+receptors+following+chronic+selective+serotonin+reuptake+inhibitor+treatment&doi=10.1016%2FS0014-2999%2898%2900041-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The functional sensitization of sigma receptors following chronic selective serotonin reuptake inhibitor treatment</span></div><div class="casAuthors">Faherty, Ciaran J.; Harkin, Andrew J.; Leonard, Brian E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The purpose of the present study was to investigate the potential impairment of normal motor function following chronic selective serotonin reuptake inhibitor treatment that may result from sensitization of σ receptors.  Rats were chronically treated with either sertraline, citalopram, paroxetine or fluvoxamine and a selective σ receptor ligand, di-o-tolylguanidine (DTG), for 28 days.  All animals then received an acute intra-rubral injection of either DTG or saline.  Following the direct injection of DTG into the red nucleus, rats chronically treated with DTG exhibit a maximal behavioral response characterized as a pronounced dystonia.  Animals chronically treated with sertraline and citalopram elicited a response similar to that of control animals following the acute DTG challenge, whereas chronic treatment with paroxetine and fluvoxamine significantly decreased and increased the dystonic response, resp.  Facial spasticity and vacuous chewing movements were assocd. with, and reflected the extent of, the DTG-induced dystonia.  Changes in regional biogenic amine concns. were also detd.  The concns. of serotonin and noradrenaline were detd. in the brain stem and cerebellum following the intra-rubral injection of either saline or DTG in animals that had been chronically treated with a selective serotonin reuptake inhibitor or DTG.  There was a significant increase in serotonin concn. in the brainstem as a result of chronic DTG and fluvoxamine treatments.  The increase in serotonin correlated with the reported potentiation of dystonia in animals that received 28 days treatment with these drugs.  The potentiation of dystonia following chronic DTG and fluvoxamine treatments suggests that these drugs sensitize the σ2 receptors, an effect that does not appear to be shared by citalopram, sertraline or paroxetine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokq65Pu3jG-7Vg90H21EOLACvtfcHk0liUWwxbV2WeWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVKit70%253D&md5=e1b3f3ddee1db510ee8e6ac414c55a4b</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2898%2900041-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252898%252900041-7%26sid%3Dliteratum%253Aachs%26aulast%3DFaherty%26aufirst%3DC.%2BJ.%26aulast%3DHarkin%26aufirst%3DA.%2BJ.%26aulast%3DLeonard%26aufirst%3DB.%2BE.%26atitle%3DThe%2520functional%2520sensitisation%2520of%2520sigma%2520receptors%2520following%2520chronic%2520selective%2520serotonin%2520reuptake%2520inhibitor%2520treatment%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D346%26spage%3D15%26epage%3D21%26doi%3D10.1016%2FS0014-2999%2898%2900041-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parylak, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorrilla, E. P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor knockout mice display a depressive-like phenotype</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2008.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbr.2008.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19100292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFGqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2009&pages=472-476&author=V.+Sabinoauthor=P.+Cottoneauthor=S.+L.+Parylakauthor=L.+Steardoauthor=E.+P.+Zorrilla&title=Sigma-1+receptor+knockout+mice+display+a+depressive-like+phenotype&doi=10.1016%2Fj.bbr.2008.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor knockout mice display a depressive-like phenotype</span></div><div class="casAuthors">Sabino, Valentina; Cottone, Pietro; Parylak, Sarah L.; Steardo, Luca; Zorrilla, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">472-476</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Activation of sigma-1 receptors (Sig-1R) reportedly has antidepressant-like action.  Limited data suggest that Sig-1Rs also modulate anxiety-related behaviors.  The present expts. measured depressive-like, anxiety-like and motor behavior in Sig-1R knockout mice and their wildtype littermates.  Sig-1R knockout mutants showed increased immobility in the forced swimming test, a depressive-like phenotype, but normal anxiety-like behavior in the elevated plus-maze and light/dark box tests and normal locomotor activity.  The results further suggest that Sig-1Rs inversely modulate depressive-like behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOL-G59QQprVg90H21EOLACvtfcHk0liUWwxbV2WeWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFGqs7c%253D&md5=a0c344f5de45c63439b50ab7b77ea8e5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2008.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2008.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DSabino%26aufirst%3DV.%26aulast%3DCottone%26aufirst%3DP.%26aulast%3DParylak%26aufirst%3DS.%2BL.%26aulast%3DSteardo%26aufirst%3DL.%26aulast%3DZorrilla%26aufirst%3DE.%2BP.%26atitle%3DSigma-1%2520receptor%2520knockout%2520mice%2520display%2520a%2520depressive-like%2520phenotype%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2009%26volume%3D198%26spage%3D472%26epage%3D476%26doi%3D10.1016%2Fj.bbr.2008.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skuza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoz, Z.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like effect of PRE-084, a selective sigma1 receptor agonist, in Albino Swiss and C57BL/6J mice</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1183</span>, <span class="refDoi"> DOI: 10.1016/S1734-1140(09)70181-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS1734-1140%2809%2970181-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20081254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Ggtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1179-1183&author=G.+Skuzaauthor=Z.+Rogoz&title=Antidepressant-like+effect+of+PRE-084%2C+a+selective+sigma1+receptor+agonist%2C+in+Albino+Swiss+and+C57BL%2F6J+mice&doi=10.1016%2FS1734-1140%2809%2970181-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like effect of PRE-084, a selective σ1 receptor agonist, in Albino Swiss and C57BL/6J mice</span></div><div class="casAuthors">Skuza, Grazyna; Rogoz, Zofia</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1179-1183</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">1734-1140</span>.
    
            (<span class="NLM_cas:orgname">Polish Academy of Sciences, Institute of Pharmacology</span>)
        </div><div class="casAbstract">PRE-084, a selective a receptor agonist, exhibited an antidepressant-like effect in the forced swim test (FST) in Albino Swiss and C57BL/6J mice.  This effect was counteracted by BD 1047 (5 and 10 mg/kg) but not by SM-21 (3 and 10 mg/kg), which are σ1- and σ2-receptor antagonists, resp.  The results indicated that PRE-084 has an antidepressant-like effect in C57BL/6J and, to a lesser extent, in Albino Swiss mice.  These results support the idea that σ1-receptors, but not σ2-receptors, contribute to the mechanism of antidepressant activity of σ agonists in FST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHrd8gw1CyRrVg90H21EOLACvtfcHk0litq9Ac_kO7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Ggtbg%253D&md5=84aed69e8c3b1a8433c6a4c95d445ac8</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2FS1734-1140%2809%2970181-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1734-1140%252809%252970181-1%26sid%3Dliteratum%253Aachs%26aulast%3DSkuza%26aufirst%3DG.%26aulast%3DRogoz%26aufirst%3DZ.%26atitle%3DAntidepressant-like%2520effect%2520of%2520PRE-084%252C%2520a%2520selective%2520sigma1%2520receptor%2520agonist%252C%2520in%2520Albino%2520Swiss%2520and%2520C57BL%252F6J%2520mice%26jtitle%3DPharmacol.%2520Rep.%26date%3D2009%26volume%3D61%26spage%3D1179%26epage%3D1183%26doi%3D10.1016%2FS1734-1140%2809%2970181-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsunekawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senzaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabeshima, T.</span></span> <span> </span><span class="NLM_article-title">Role of <i>N</i>-methyl-<i>D</i>-aspartate receptors in antidepressant-like effects of sigma 1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA-4503) in olfactory bulbectomized rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.124685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.107.124685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=17556637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslKrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=1305-1314&author=D.+Wangauthor=Y.+Nodaauthor=H.+Tsunekawaauthor=Y.+Zhouauthor=M.+Miyazakiauthor=K.+Senzakiauthor=A.+Nittaauthor=T.+Nabeshima&title=Role+of+N-methyl-D-aspartate+receptors+in+antidepressant-like+effects+of+sigma+1+receptor+agonist+1-%283%2C4-dimethoxyphenethyl%29-4-%283-phenylpropyl%29piperazine+dihydrochloride+%28SA-4503%29+in+olfactory+bulbectomized+rats&doi=10.1124%2Fjpet.107.124685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Role of N-methyl-D-aspartate receptors in antidepressant-like effects of σ1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA-4503) in olfactory bulbectomized rats</span></div><div class="casAuthors">Wang, Dayong; Noda, Yukihiro; Tsunekawa, Hiroko; Zhou, Yuan; Miyazaki, Masayuki; Senzaki, Koji; Nitta, Atsumi; Nabeshima, Toshitaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1305-1314</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In the present study, we aimed to investigate the role of N-methyl-D-aspartate (NMDA) receptors in the antidepressant-like effects of a σ1 receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA-4503), in the olfactory bulbectomized (OB) rat model of depression.  A symptomatol.-based behavioral investigation was made by reconstructing in OB rats the symptoms of depression, such as psychomotor agitation, loss of interest, and cognitive dysfunction, using a typical antidepressant, desipramine, as a pos. control.  Repeated treatment with SA-4503 ameliorated the behavioral deficits in OB rats resembling depression symptoms in the open-field test, sexual behavior test, and cued and contextual fear-conditioning test.  SA-4503 displayed advantages over desipramine in the sexual behavior test.  SA-4503 also reversed the decrease in the protein expression of NMDA receptor subunit (NR)1, but not NR2A or NR2B, in the prefrontal cortex, hippocampus, and amygdala of OB rats.  The behavioral and neurochem. effects of SA-4503 were blocked by combined treatment with a specific σ1 receptor antagonist, N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride (NE-100).  Furthermore, the effects of SA-4503 on the performance of OB rats in the behavioral tests were abrogated by acute treatment with an NMDA receptor antagonist, (-)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801).  The present study indicated for the first time that the σ1 receptor agonist SA-4503 may have effects on depressive symptoms such as agitation, loss of interest, and impaired cognition, which are mediated by NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq77Az-VXFvtLVg90H21EOLACvtfcHk0litq9Ac_kO7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslKrtLs%253D&md5=4c619f3b2a1b6870aa8f2ef92bfe3aa6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.124685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.124685%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DNoda%26aufirst%3DY.%26aulast%3DTsunekawa%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DSenzaki%26aufirst%3DK.%26aulast%3DNitta%26aufirst%3DA.%26aulast%3DNabeshima%26aufirst%3DT.%26atitle%3DRole%2520of%2520N-methyl-D-aspartate%2520receptors%2520in%2520antidepressant-like%2520effects%2520of%2520sigma%25201%2520receptor%2520agonist%25201-%25283%252C4-dimethoxyphenethyl%2529-4-%25283-phenylpropyl%2529piperazine%2520dihydrochloride%2520%2528SA-4503%2529%2520in%2520olfactory%2520bulbectomized%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D1305%26epage%3D1314%26doi%3D10.1124%2Fjpet.107.124685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi-Utsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakaki, T.</span></span> <span> </span><span class="NLM_article-title">Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>440</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2008.05.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neulet.2008.05.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18547721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Slu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2008&pages=19-22&author=K.+Kikuchi-Utsumiauthor=T.+Nakaki&title=Chronic+treatment+with+a+selective+ligand+for+the+sigma-1+receptor+chaperone%2C+SA4503%2C+up-regulates+BDNF+protein+levels+in+the+rat+hippocampus&doi=10.1016%2Fj.neulet.2008.05.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus</span></div><div class="casAuthors">Kikuchi-Utsumi, Kazue; Nakaki, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-22</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Numerous studies have shown the sigma-1 receptor chaperone (previously designated as the sigma-1 receptor) to play an important role in various neuronal functions, and selective ligands for sigma-1 receptor chaperone have been found to have therapeutic potential in certain psychiatric disorders and some forms of neuronal damage.  Brain-derived neurotrophic factor (BDNF) is postulated to be related to the pharmacol. action of sigma ligands, though the functional interaction between sigma-1 receptor chaperone ligands and BDNF remains to be clarified.  This study was undertaken to investigate whether or not administration of SA4503, a selective ligand for sigma-1 receptor chaperone, affects BDNF levels in several regions of the rat brain.  Rats were injected with SA4503 (0.3, 1 and 3 mg/(kg day), i.p.) once or repeatedly for 2 or 4 wk.  BDNF protein levels were estd. by Western blot anal. in the striatum, midbrain, frontal cortex, hippocampus and thalamus.  A single injection of SA4503 did not change BDNF protein levels, while chronic injection for 2 or 4 wk tended to increase BDNF levels in the hippocampus.  In particular, 1 mg/kg of SA4503 daily for 2 wk led to a statistically significant, i.e. twofold, increase in the BDNF protein level in the hippocampus.  On the other hand, the TrkB receptor, a primary receptor for BDNF, exists in truncated and full-length isoforms, hippocampal levels of which were unaffected by SA4503 treatments.  Our findings indicate that chronic administration of SA4503 may regulate region-specific BDNF functions in the rat brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUJt-rR0sYFrVg90H21EOLACvtfcHk0litq9Ac_kO7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Slu7g%253D&md5=4b246e8f3bf935ba5e4baf277e1f8c39</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2008.05.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2008.05.055%26sid%3Dliteratum%253Aachs%26aulast%3DKikuchi-Utsumi%26aufirst%3DK.%26aulast%3DNakaki%26aufirst%3DT.%26atitle%3DChronic%2520treatment%2520with%2520a%2520selective%2520ligand%2520for%2520the%2520sigma-1%2520receptor%2520chaperone%252C%2520SA4503%252C%2520up-regulates%2520BDNF%2520protein%2520levels%2520in%2520the%2520rat%2520hippocampus%26jtitle%3DNeurosci.%2520Lett.%26date%3D2008%26volume%3D440%26spage%3D19%26epage%3D22%26doi%3D10.1016%2Fj.neulet.2008.05.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X. C.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of sigma-1 receptors elicits rapid antidepressant activity</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1111/cns.12502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fcns.12502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=26854125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVentLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=368-377&author=Y.+Wangauthor=L.+Guoauthor=H.+F.+Jiangauthor=L.+T.+Zhengauthor=A.+Zhangauthor=X.+C.+Zhen&title=Allosteric+modulation+of+sigma-1+receptors+elicits+rapid+antidepressant+activity&doi=10.1111%2Fcns.12502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Sigma-1 Receptors Elicits Rapid Antidepressant Activity</span></div><div class="casAuthors">Wang, Yun; Guo, Lin; Jiang, Hua-Feng; Zheng, Long-Tai; Zhang, Ao; Zhen, Xue-Chu</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">368-377</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Aims : Sigma-1 receptors are involved in the pathophysiol. process of several neuropsychiatric diseases such as epilepsy, depression.  Allosteric modulation represents an important mechanism for receptor functional regulation.  In this study, we examd. antidepressant activity of the latest identified novel and selective allosteric modulator of sigma-1 receptor 3-methyl-phenyl-2, 3, 4, 5-tetrahydro-1H-benzo[d]azepin-7-ol (SOMCL-668).  Methods and Results : A single administration of SOMCL-668 decreased the immobility time in the forced swimming test (FST) and tailing suspended test in mice, which were abolished by pretreatment of sigma-1 receptor antagonist BD1047.  In the chronic unpredicted mild stress (CUMS) model, chronic application of SOMCL-668 rapidly ameliorated anhedonia-like behavior (within a week), accompanying with the enhanced expression of brain-derived neurotrophic factor (BDNF) and phosphorylation of glycogen synthase kinase 3β (GSK3β) (Ser-9) in the hippocampus.  SOMCL-668 also rapidly promoted the phosphorylation of GSK3β (Ser-9) in an allosteric manner in vitro.  In the cultured primary neurons, SOMCL-668 enhanced the sigma-1 receptor agonist-induced neurite outgrowth and the secretion of BDNF.  Conclusion : SOMCL-668, a novel allosteric modulator of sigma-1 receptors, elicits a potent and rapid acting antidepressant effect.  The present data provide the first evidence that allosteric modulation of sigma-1 receptors may represent a new approach for antidepressant drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCiQyRvtg11bVg90H21EOLACvtfcHk0lgxN2nTTUkqyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVentLo%253D&md5=feb669192dd6113e0d9f93fa5c6bc3f4</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fcns.12502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcns.12502%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%2BF.%26aulast%3DZheng%26aufirst%3DL.%2BT.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DX.%2BC.%26atitle%3DAllosteric%2520modulation%2520of%2520sigma-1%2520receptors%2520elicits%2520rapid%2520antidepressant%2520activity%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2016%26volume%3D22%26spage%3D368%26epage%3D377%26doi%3D10.1111%2Fcns.12502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anoal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/S0306-4522(00)00014-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS0306-4522%2800%2900014-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10771347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFGhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=155-170&author=G.+Alonsoauthor=V.+Phanauthor=I.+Guillemainauthor=M.+Saunierauthor=A.+Legrandauthor=M.+Anoalauthor=T.+Maurice&title=Immunocytochemical+localization+of+the+sigma%281%29+receptor+in+the+adult+rat+central+nervous+system&doi=10.1016%2FS0306-4522%2800%2900014-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system</span></div><div class="casAuthors">Alonso, G.; Phan, V.-L.; Guillemain, I.; Saunier, M.; Legrand, A.; Anoal, M.; Maurice, T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-170</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">To characterize the localization of the sigma1 receptor in the adult rat central nervous system, a polyclonal antibody was raised against a 20 amino acid peptide, corresponding to the fragment 143-162 of the cloned sigma1 receptor protein.  Throughout the rostrocaudal regions of the central nervous system extending from the olfactory bulb to the spinal cord, intense to moderate immunostaining was found to be assocd. with: (i) ependymocytes bordering the entire ventricular system, and (ii) neuron-like structures located within the parenchyma.  Double fluorescence studies confirmed that, throughout the parenchyma, sigma1 receptor-immunostaining was essentially assocd. with neuronal structures immunostained for the neuronal marker βIII-tubulin.  In all rats examd., high levels of immunostaining were always assocd. with neurons located within specific regions including the granular layer of the olfactory bulb, various hypothalamic nuclei, the septum, the central gray, motor nuclei of the hindbrain and the dorsal horn of the spinal cord.  In contrast, only faint immunostaining was assocd. with neurons located in the caudate-putamen and the cerebellum.  Electron microscope studies indicated that sigma1 receptor immunostaining was mostly assocd. with neuronal perikarya and dendrites, where it was localized to the limiting plasma membrane, the membrane of mitochondria and of some cisternae of the endoplasmic reticulum.  At the level of synaptic contacts, intense immunostaining was assocd. with postsynaptic structures including the postsynaptic thickening and some polymorphous vesicles, whereas the presynaptic axons were devoid of immunostaining.  These data indicate that the sigma1 receptor antibody prepd. here, represents a promising tool for further investigating the role of σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsAacDelSDfbVg90H21EOLACvtfcHk0lgxN2nTTUkqyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFGhurg%253D&md5=2df1ba6a60488364ad458069e059354d</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2800%2900014-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252800%252900014-2%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DG.%26aulast%3DPhan%26aufirst%3DV.%26aulast%3DGuillemain%26aufirst%3DI.%26aulast%3DSaunier%26aufirst%3DM.%26aulast%3DLegrand%26aufirst%3DA.%26aulast%3DAnoal%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DImmunocytochemical%2520localization%2520of%2520the%2520sigma%25281%2529%2520receptor%2520in%2520the%2520adult%2520rat%2520central%2520nervous%2520system%26jtitle%3DNeuroscience%26date%3D2000%26volume%3D97%26spage%3D155%26epage%3D170%26doi%3D10.1016%2FS0306-4522%2800%2900014-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of sigma-1 receptors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.pharmthera.2009.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19619582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGktLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2009&pages=195-206&author=T.+Mauriceauthor=T.+P.+Su&title=The+pharmacology+of+sigma-1+receptors&doi=10.1016%2Fj.pharmthera.2009.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of sigma-1 receptors</span></div><div class="casAuthors">Maurice, Tangui; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Originally considered an enigmatic protein, the sigma-1 receptor has recently been identified as a unique ligand-regulated mol. chaperone in the endoplasmic reticulum of cells.  This discovery causes us to look back at the many proposed roles of this receptor, even before its mol. function was identified, in many diseases such as methamphetamine or cocaine addiction, amnesia, pain, depression, Alzheimer's disease, stroke, retinal neuroprotection, HIV infection, and cancer.  In this review, we examine the reports that have clearly shown an agonist-antagonist relationship regarding sigma-1 receptors in models of those diseases and also review the relatively known mechanisms of action of sigma-1 receptors in an attempt to spur the speculation of readers on how the sigma-1 receptor at the endoplasmic reticulum might relate to so many diseases.  We found that the most prominent action of sigma-1 receptors in biol. systems including cell lines, primary cultures, and animals is the regulation and modulation of voltage-regulated and ligand-gated ion channels, including Ca2+-, K+-, Na+, Cl-, and SK channels, and NMDA and IP3 receptors.  We found that the final output of the action of sigma-1 receptor agonists is to inhibit all above-mentioned voltage-gated ion channels, while they potentiate ligand-gated channels.  The inhibition or potentiation induced by agonists is blocked by sigma-1 receptor antagonists.  Other mechanisms of action of sigma-1 receptors, and to some extent those of sigma-2 receptors, were also considered.  We conclude that the sigma-1 and sigma-2 receptors represent potential fruitful targets for therapeutic developments in combating many human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4d_UAy6J4KbVg90H21EOLACvtfcHk0lgxN2nTTUkqyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGktLnM&md5=7b5e251decc29edef42ffef1d65dd487</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DThe%2520pharmacology%2520of%2520sigma-1%2520receptors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D124%26spage%3D195%26epage%3D206%26doi%3D10.1016%2Fj.pharmthera.2009.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artacho-Cordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of peripheral mu-opioid analgesia by sigma1 receptors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.208272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.113.208272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24155346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=32-45&author=C.+Sanchez-Fernandezauthor=A.+Montilla-Garciaauthor=R.+Gonzalez-Canoauthor=F.+R.+Nietoauthor=L.+Romeroauthor=A.+Artacho-Cordonauthor=R.+Montesauthor=B.+Fernandez-Pastorauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=J.+M.+Entrenaauthor=E.+J.+Cobos&title=Modulation+of+peripheral+mu-opioid+analgesia+by+sigma1+receptors&doi=10.1124%2Fjpet.113.208272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of peripheral μ-opioid analgesia by σ1 receptors</span></div><div class="casAuthors">Sanchez-Fernandez, Cristina; Montilla-Garcia, Angeles; Gonzalez-Cano, Rafael; Nieto, Francisco Rafael; Romero, Lucia; Artacho-Cordon, Antonia; Montes, Rosa; Fernandez-Pastor, Begona; Merlos, Manuel; Baeyens, Jose Manuel; Entrena, Jose Manuel; Cobos, Enrique Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the effects of σ1-receptor inhibition on μ-opioid-induced mech. antinociception and constipation. σ1-Knockout mice exhibited marked mech. antinociception in response to several μ-opioid analgesics (fentanyl, oxycodone, morphine, buprenorphine, and tramadol) at systemic (s.c.) doses that were inactive in wild-type mice and even unmasked the antinociceptive effects of the peripheral μ-opioid agonist loperamide.  Likewise, systemic (s.c.) or local (intraplantar) treatment of wild-type mice with the selective σ1 antagonists BD-1063 [1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihydrochloride] or S1RA [4-[2-[[5-methyl-1-(2-naphthalenyl)1H-pyrazol-3-yl]oxy]ethyl] morpholine hydrochloride] potentiated μ-opioid antinociception; these effects were fully reversed by the σ1 agonist PRE-084 [2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate) hydrochloride], showing the selectivity of the pharmacol. approach.  The μ-opioid antinociception potentiated by σ1 inhibition (by σ1-receptor knockout or σ1-pharmacol. antagonism) was more sensitive to the peripherally restricted opioid antagonist naloxone methiodide than opioid antinociception under normal conditions, indicating a key role for peripheral opioid receptors in the enhanced antinociception.  Direct interaction between the opioid drugs and σ1 receptor cannot account for our results, since the former lacked affinity for σ1 receptors (labeled with [3H](+)-pentazocine).  A peripheral role for σ1 receptors was also supported by their higher d. (Western blot results) in peripheral nervous tissue (dorsal root ganglia) than in several central areas involved in opioid antinociception (dorsal spinal cord, basolateral amygdala, periaqueductal gray, and rostroventral medulla).  In contrast to its effects on nociception, σ1-receptor inhibition did not alter fentanyl- or loperamide-induced constipation, a peripherally mediated nonanalgesic opioid effect.  Therefore, σ1-receptor inhibition may be used as a systemic or local adjuvant to enhance peripheral μ-opioid analgesia without affecting opioid-induced constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXDUF69QHTL7Vg90H21EOLACvtfcHk0lgxN2nTTUkqyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju74%253D&md5=3448ecaf8c215210a48a8413b89db2a5</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208272%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DGonzalez-Cano%26aufirst%3DR.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DArtacho-Cordon%26aufirst%3DA.%26aulast%3DMontes%26aufirst%3DR.%26aulast%3DFernandez-Pastor%26aufirst%3DB.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DModulation%2520of%2520peripheral%2520mu-opioid%2520analgesia%2520by%2520sigma1%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D32%26epage%3D45%26doi%3D10.1124%2Fjpet.113.208272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roh, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span> <span> </span><span class="NLM_article-title">Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1097/ALN.0b013e3181895a83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1097%2FALN.0b013e3181895a83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18946301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Oks7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2008&pages=879-889&author=D.+H.+Rohauthor=H.+W.+Kimauthor=S.+Y.+Yoonauthor=H.+S.+Seoauthor=Y.+B.+Kwonauthor=K.+W.+Kimauthor=H.+J.+Hanauthor=A.+J.+Beitzauthor=H.+S.+Naauthor=J.+H.+Lee&title=Intrathecal+injection+of+the+sigma%281%29+receptor+antagonist+BD1047+blocks+both+mechanical+allodynia+and+increases+in+spinal+NR1+expression+during+the+induction+phase+of+rodent+neuropathic+pain&doi=10.1097%2FALN.0b013e3181895a83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Intrathecal Injection of the varsigma1 Receptor Antagonist BD1047 Blocks Both Mechanical Allodynia and Increases in Spinal NR1 Expression during the Induction Phase of Rodent Neuropathic Pain</span></div><div class="casAuthors">Roh, Dae-Hyun; Kim, Hyun-Woo; Yoon, Seo-Yeon; Seo, Hyoung-Sig; Kwon, Young-Bae; Kim, Kee-Won; Han, Ho-Jae; Beitz, Alvin J.; Na, Heung-Sik; Lee, Jang-Hern</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">879-889</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Selective blockade of spinal varsigm receptors (Sig-1R) suppresses nociceptive behaviors in the mouse formalin test.  The current study was designed to verify whether intrathecal Sig-1R antagonists can also suppress chronic neuropathic pain.  Neuropathic pain was produced by chronic constriction injury (CCI) of the right sciatic nerve in rats.  The Sig-1R antagonist BD1047 was administered intrathecally twice daily from postoperative days 0 to 5 (induction phase of neuropathic pain) or from days 15 to 20 (maintenance phase).  Western blot and immunohistochem. were performed to det. changes in Sig-1R expression and to examine the effect of BD1047 on N-methyl-d-aspartate receptor subunit 1 expression and phosphorylation in spinal cord dorsal horn from neuropathic rats.  BD1047 administered on postoperative days 0-5 significantly attenuated CCI-induced mech. allodynia, but not thermal hyperalgesia, and this suppression was blocked by intrathecal administration of the Sig-1R agonist PRE084.  In contrast, BD1047 treatment during the maintenance phase of neuropathic pain had no effect on mech. allodynia.  Sig-1R expression significantly increased in the ipsilateral spinal cord dorsal horn from days 1 to 3 after CCI.  Importantly, BD1047 (30 nmol) administered intrathecally during the induction, but not the maintenance phase, blocked the CCI-induced increase in N-methyl-d-aspartate receptor subunit 1 expression and phosphorylation.  These results demonstrate that spinal Sig-1Rs play a crit. role in both the induction of mech. allodynia and the activation of spinal N-methyl-d-aspartate receptors in CCI rats and suggest a potential therapeutic role for the use of Sig-1R antagonists in the clin. management of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxfKToM8cePbVg90H21EOLACvtfcHk0lil3v2scYg4rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Oks7fE&md5=aabc720d7c9d15df821d2442bf7586a9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1097%2FALN.0b013e3181895a83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0b013e3181895a83%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DYoon%26aufirst%3DS.%2BY.%26aulast%3DSeo%26aufirst%3DH.%2BS.%26aulast%3DKwon%26aufirst%3DY.%2BB.%26aulast%3DKim%26aufirst%3DK.%2BW.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26aulast%3DBeitz%26aufirst%3DA.%2BJ.%26aulast%3DNa%26aufirst%3DH.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26atitle%3DIntrathecal%2520injection%2520of%2520the%2520sigma%25281%2529%2520receptor%2520antagonist%2520BD1047%2520blocks%2520both%2520mechanical%2520allodynia%2520and%2520increases%2520in%2520spinal%2520NR1%2520expression%2520during%2520the%2520induction%2520phase%2520of%2520rodent%2520neuropathic%2520pain%26jtitle%3DAnesthesiology%26date%3D2008%26volume%3D109%26spage%3D879%26epage%3D889%26doi%3D10.1097%2FALN.0b013e3181895a83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artacho-Cordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Potentiation of morphine-induced mechanical antinociception by sigma(1) receptor inhibition: role of peripheral sigma(1) receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuropharm.2013.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23524304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVSqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=348-358&author=C.+Sanchez-Fernandezauthor=F.+R.+Nietoauthor=R.+Gonzalez-Canoauthor=A.+Artacho-Cordonauthor=L.+Romeroauthor=A.+Montilla-Garciaauthor=D.+Zamanilloauthor=J.+M.+Baeyensauthor=J.+M.+Entrenaauthor=E.+J.+Cobos&title=Potentiation+of+morphine-induced+mechanical+antinociception+by+sigma%281%29+receptor+inhibition%3A+role+of+peripheral+sigma%281%29+receptors&doi=10.1016%2Fj.neuropharm.2013.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of morphine-induced mechanical antinociception by σ1 receptor inhibition: Role of peripheral σ1 receptors</span></div><div class="casAuthors">Sanchez-Fernandez, Cristina; Nieto, Francisco Rafael; Gonzalez-Cano, Rafael; Artacho-Cordon, Antonia; Romero, Lucia; Montilla-Garcia, Angeles; Zamanillo, Daniel; Baeyens, Jose Manuel; Entrena, Jose Manuel; Cobos, Enrique Jose</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">348-358</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We studied the modulation of morphine-induced mech. antinociception and side effects by σ1 receptor inhibition.  Both wild-type (WT) and σ1 receptor knockout (σ1-KO) mice showed similar responses to paw pressure (100-600 g).  The systemic (s.c.) or local (intraplantar) administration of σ1 antagonists (BD-1063, BD-1047, NE-100 and S1RA) was devoid of antinociceptive effects in WT mice.  However, σ1-KO mice exhibited an enhanced mech. antinociception in response to systemic morphine (1-16 mg/kg).  Similarly, systemic treatment of WT mice with σ1 antagonists markedly potentiated morphine-induced antinociception, and its effects were reversed by the selective σ1 agonist PRE-084.  Although the local administration of morphine (50-200 μg) was devoid of antinociceptive effects in WT mice, it induced dose-dependent antinociception in σ1-KO mice.  This effect was limited to the injected paw.  Enhancement of peripheral morphine antinociception was replicated in WT mice locally co-administered with σ1 antagonists and the opioid.  None of the σ1 antagonists tested enhanced morphine-antinociception in σ1-KO mice, confirming a σ1-mediated action.  Morphine-induced side-effects (hyperlocomotion and inhibition of gastrointestinal transit) were unaltered in σ1-KO mice.  These results cannot be explained by a direct interaction of σ1 ligands with μ-opioid receptors or adaptive changes of μ-receptors in σ1-KO mice, given that [3H]DAMGO binding in forebrain, spinal cord, and hind-paw skin membranes was unaltered in mutant mice, and none of the σ1 drugs tested bound to μ-opioid receptors.  These results show that σ1 receptor inhibition potentiates morphine-induced mech. analgesia but not its acute side effects, and that this enhanced analgesia can be induced at peripheral level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc2KFSqih3HbVg90H21EOLACvtfcHk0lil3v2scYg4rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVSqt7s%253D&md5=d21562671453852a7e07c15232726ade</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DGonzalez-Cano%26aufirst%3DR.%26aulast%3DArtacho-Cordon%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DPotentiation%2520of%2520morphine-induced%2520mechanical%2520antinociception%2520by%2520sigma%25281%2529%2520receptor%2520inhibition%253A%2520role%2520of%2520peripheral%2520sigma%25281%2529%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D70%26spage%3D348%26epage%3D358%26doi%3D10.1016%2Fj.neuropharm.2013.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salaman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological modulation of the sigma 1 receptor and the treatment of pain</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>964</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-50174-1_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2F978-3-319-50174-1_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28315267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=964&publication_year=2017&pages=85-107&author=M.+Merlosauthor=J.+Burguenoauthor=E.+Portillo-Salidoauthor=C.+R.+Plata-Salamanauthor=J.+M.+Vela&title=Pharmacological+modulation+of+the+sigma+1+receptor+and+the+treatment+of+pain&doi=10.1007%2F978-3-319-50174-1_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological modulation of the sigma 1 receptor and the treatment of pain</span></div><div class="casAuthors">Merlos, Manuel; Burgueno, Javier; Portillo-Salido, Enrique; Plata-Salaman, Carlos Ramon; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">964</span>
        (<span class="NLM_cas:issue">Sigma Receptors: Their Role in Disease and as Therapeutic Targets</span>),
    <span class="NLM_cas:pages">85-107</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">There is a crit. need for new analgesics acting through new mechanisms of action, which could increase the efficacy with respect to existing therapies and reduce their unwanted effects.  Current preclin. evidence supports the modulatory role of sigma-1 receptors (σ1R) in nociception, mainly based on the pain-attenuated phenotype of σ1R knockout mice and on the antinociceptive effect exerted by σ1R antagonists on pains of different etiologies. σ1R is highly expressed in different pain areas of the CNS and the periphery (particularly dorsal root ganglia), and interacts and modulates the functionality of different receptors and ion channels.  The antagonism of σ1R leads to decreased amplification of pain signaling within the spinal cord (central sensitization), but recent data also support a role at the periphery. σ1R antagonists have consistently demonstrated efficacy in neuropathic pain, but also in other types of pain including inflammatory, orofacial, visceral, and post-operative pain.  Apart from acting alone, when combined with opioids, σ1R antagonists enhance opioid analgesia but not opioid-induced unwanted effects.  Interestingly, unlike opioids, σ1R antagonists do not modify normal sensory mech. and thermal sensitivity thresholds but they exert antihypersensitive effects in sensitizing conditions, enabling the reversal of nociceptive thresholds back to normal values.  Accordingly, σ1R antagonists are not strictly analgesics; they are antiallodynic and antihyperalgesic drugs acting when the system is sensitized following prolonged noxious stimulation or persistent abnormal afferent input (e.g., secondary to nerve injury).  These are distinctive features allowing σ1R antagonists to exert a modulatory effect specifically in pathophysiol. conditions such as chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwcRJqz4BxF7Vg90H21EOLACvtfcHk0lhgZMBSIl1etA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7O&md5=212a8fac96a772a7888762da8e70fc0d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-50174-1_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-50174-1_8%26sid%3Dliteratum%253Aachs%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBurgueno%26aufirst%3DJ.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DPlata-Salaman%26aufirst%3DC.%2BR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DPharmacological%2520modulation%2520of%2520the%2520sigma%25201%2520receptor%2520and%2520the%2520treatment%2520of%2520pain%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D964%26spage%3D85%26epage%3D107%26doi%3D10.1007%2F978-3-319-50174-1_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span> <span> </span><span class="NLM_article-title">Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fbjp.2008.159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18493253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVGru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1125-1134&author=H.+W.+Kimauthor=D.+H.+Rohauthor=S.+Y.+Yoonauthor=H.+S.+Seoauthor=Y.+B.+Kwonauthor=H.+J.+Hanauthor=K.+W.+Kimauthor=A.+J.+Beitzauthor=J.+H.+Lee&title=Activation+of+the+spinal+sigma-1+receptor+enhances+NMDA-induced+pain+via+PKC-+and+PKA-dependent+phosphorylation+of+the+NR1+subunit+in+mice&doi=10.1038%2Fbjp.2008.159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice</span></div><div class="casAuthors">Kim, H.-W.; Roh, D.-H.; Yoon, S.-Y.; Seo, H.-S.; Kwon, Y.-B.; Han, H.-J.; Kim, K.-W.; Beitz, A. J.; Lee, J.-H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1125-1134</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background and purpose: Previously we demonstrated that the spinal sigma-1 receptor (Sig-1 R) plays an important role in pain transmission, although the exact mechanism is still unclear.  It has been suggested that Sig-1 R agonists increase glutamate-induced calcium influx through N-methyl-D-aspartate (NMDA) receptors.  Despite data suggesting a link between Sig-1 Rs and NMDA receptors, there are no studies addressing whether Sig-1 R activation directly affects NMDA receptor sensitivity.  Exptl. approach: We studied the effect of intrathecal (i.t.) administration of Sig-1 R agonists on protein kinase C (PKC) and protein kinase A (PKA) dependent phosphorylation of the NMDA receptor subunit NR1 (pNR1) as a marker of NMDA receptor sensitization.  In addn., we examd. whether this Sig-1 R mediated phosphorylation of NR1 plays an important role in sensory function using a model of NMDA-induced pain.  Key results: Both Western blot assays and image anal. of pNR1 immunohistochem. staining in the spinal cord indicated that i.t. injection of the Sig-1 R agonists, PRE-084 or carbetapentane dose dependently enhanced pNR1 expression in the murine dorsal horn.  This increased pNR1 expression was significantly reduced by pretreatment with the specific Sig-1 R antagonist, BD-1047.  In another set of expts. Sig-1 R agonists further potentiated NMDA-induced pain behavior and pNR1 immunoreactivity and this was also reversed with BD-1047.  Conclusions and implications: The results of this study suggest that the activation of spinal Sig-1 R enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NMDA receptor NR 1 subunit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt_HsZ1tEMobVg90H21EOLACvtfcHk0lhgZMBSIl1etA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVGru7s%253D&md5=03b6027eeecb8ae4b3dfa8695434132f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.159%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DRoh%26aufirst%3DD.%2BH.%26aulast%3DYoon%26aufirst%3DS.%2BY.%26aulast%3DSeo%26aufirst%3DH.%2BS.%26aulast%3DKwon%26aufirst%3DY.%2BB.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DK.%2BW.%26aulast%3DBeitz%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26atitle%3DActivation%2520of%2520the%2520spinal%2520sigma-1%2520receptor%2520enhances%2520NMDA-induced%2520pain%2520via%2520PKC-%2520and%2520PKA-dependent%2520phosphorylation%2520of%2520the%2520NR1%2520subunit%2520in%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1125%26epage%3D1134%26doi%3D10.1038%2Fbjp.2008.159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>964</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-50174-1_9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2F978-3-319-50174-1_9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28315268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=964&publication_year=2017&pages=109-132&author=C.+Sanchez-Fernandezauthor=J.+M.+Entrenaauthor=J.+M.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+receptor+antagonists%3A+a+new+class+of+neuromodulatory+analgesics&doi=10.1007%2F978-3-319-50174-1_9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics</span></div><div class="casAuthors">Sanchez-Fernandez, Cristina; Entrena, Jose Manuel; Baeyens, Jose Manuel; Cobos, Enrique Jose</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">964</span>
        (<span class="NLM_cas:issue">Sigma Receptors: Their Role in Disease and as Therapeutic Targets</span>),
    <span class="NLM_cas:pages">109-132</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The sigma-1 receptor is a unique ligand-operated chaperone present in key areas for pain control, in both the peripheral and central nervous system.  Sigma-1 receptors interact with a variety of protein targets to modify their function.  These targets include several G-protein-coupled receptors such as the μ-opioid receptor, and ion channels such as the N-methyl-D-aspartate receptor (NMDAR).  Sigma-1 antagonists modify the chaperoning activity of sigma-1 receptor by increasing opioid signaling and decreasing NMDAR responses, consequently enhancing opioid antinociception and decreasing the sensory hypersensitivity that characterizes pathol. pain conditions.  However, the participation in pain relief of other protein partners of sigma-1 receptors in addn. to opioid receptors and NMDARs cannot be ruled out.  The enhanced opioid antinociception by sigma-1 antagonism is not accompanied by an increase in opioid side effects, including tolerance, dependence or constipation, so the use of sigma-1 antagonists may increase the therapeutic index of opioids.  Furthermore, sigma-1 antagonists (in the absence of opioids) have been shown to exert antinociceptive effects in preclin. models of neuropathic pain induced by nerve trauma or chem. injury (the antineoplastic paclitaxel), and more recently in inflammatory and ischemic pain.  Although most studies attributed the analgesic properties of sigma-1 antagonists to their central actions, it is now known that peripheral sigma-1 receptors also participate in their effects.  Overwhelming preclin. evidence of the role of sigma-1 receptors in pain has led to the development of the first selective sigma-1 antagonist with an intended indication for pain treatment, which is currently in Phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqngb6OQfqKNbVg90H21EOLACvtfcHk0lhgZMBSIl1etA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7L&md5=b8bb957dd762dfdce939ef326e865302</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-50174-1_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-50174-1_9%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520receptor%2520antagonists%253A%2520a%2520new%2520class%2520of%2520neuromodulatory%2520analgesics%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D964%26spage%3D109%26epage%3D132%26doi%3D10.1007%2F978-3-319-50174-1_9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arroyos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera-Arconada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laloya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escriche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Garcia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salaman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">2289</span>– <span class="NLM_lpage">2306</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.01942.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fj.1476-5381.2012.01942.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22404321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1artL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=2289-2306&author=L.+Romeroauthor=D.+Zamanilloauthor=X.+Nadalauthor=R.+Sanchez-Arroyosauthor=I.+Rivera-Arconadaauthor=A.+Dordalauthor=A.+Monteroauthor=A.+Muroauthor=A.+Buraauthor=C.+Segalesauthor=M.+Laloyaauthor=E.+Hernandezauthor=E.+Portillo-Salidoauthor=M.+Escricheauthor=X.+Codonyauthor=G.+Encinaauthor=J.+Burguenoauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=J.+Giraldoauthor=J.+A.+Lopez-Garciaauthor=R.+Maldonadoauthor=C.+R.+Plata-Salamanauthor=J.+M.+Vela&title=Pharmacological+properties+of+S1RA%2C+a+new+sigma-1+receptor+antagonist+that+inhibits+neuropathic+pain+and+activity-induced+spinal+sensitization&doi=10.1111%2Fj.1476-5381.2012.01942.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization</span></div><div class="casAuthors">Romero, L.; Zamanillo, D.; Nadal, X.; Sanchez-Arroyos, R.; Rivera-Arconada, I.; Dordal, A.; Montero, A.; Muro, A.; Bura, A.; Segales, C.; Laloya, M.; Hernandez, E.; Portillo-Salido, E.; Escriche, M.; Codony, X.; Encina, G.; Burgueno, J.; Merlos, M.; Baeyens, J. M.; Giraldo, J.; Lopez-Garcia, J. A.; Maldonado, R.; Plata-Salaman, C. R.; Vela, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2289-2306</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose The sigma-1 (σ1) receptor is a ligand-regulated mol. chaperone that has been involved in pain, but there is limited understanding of the actions assocd. with its pharmacol. modulation.  Indeed, the selectivity and pharmacol. properties of σ1 receptor ligands used as pharmacol. tools are unclear and the demonstration that σ1 receptor antagonists have efficacy in reversing central sensitization-related pain sensitivity is still missing.  Exptl. Approach The pharmacol. properties of a novel σ1 receptor antagonist (S1RA) were first characterized.  S1RA was then used to investigate the effect of pharmacol. antagonism of σ1 receptors on in vivo nociception in sensitizing conditions and on in vitro spinal cord sensitization in mice.  Drug levels and autoradiog., ex vivo binding for σ1 receptor occupancy were measured to substantiate behavioral data.  Key Results Formalin-induced nociception (both phases), capsaicin-induced mech. hypersensitivity and sciatic nerve injury-induced mech. and thermal hypersensitivity were dose-dependently inhibited by systemic administration of S1RA.  Occupancy of σ1 receptors in the CNS was significantly correlated with the antinociceptive effects.  No pharmacodynamic tolerance to the antiallodynic and antihyperalgesic effect developed following repeated administration of S1RA to nerve-injured mice.  As a mechanistic correlate, electrophysiol. recordings demonstrated that pharmacol. antagonism of σ1 receptors attenuated the wind-up responses in spinal cords sensitized by repetitive nociceptive stimulation.  Conclusions and Implications These findings contribute to evidence identifying the σ1 receptor as a modulator of activity-induced spinal sensitization and pain hypersensitivity, and suggest σ1 receptor antagonists as potential novel treatments for neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK7puaGCXwhrVg90H21EOLACvtfcHk0lhgZMBSIl1etA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1artL3L&md5=f84eec105e338b08175e476b63f6208f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01942.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01942.x%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DNadal%26aufirst%3DX.%26aulast%3DSanchez-Arroyos%26aufirst%3DR.%26aulast%3DRivera-Arconada%26aufirst%3DI.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DMontero%26aufirst%3DA.%26aulast%3DMuro%26aufirst%3DA.%26aulast%3DBura%26aufirst%3DA.%26aulast%3DSegales%26aufirst%3DC.%26aulast%3DLaloya%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DE.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DEscriche%26aufirst%3DM.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DEncina%26aufirst%3DG.%26aulast%3DBurgueno%26aufirst%3DJ.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DGiraldo%26aufirst%3DJ.%26aulast%3DLopez-Garcia%26aufirst%3DJ.%2BA.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DPlata-Salaman%26aufirst%3DC.%2BR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DPharmacological%2520properties%2520of%2520S1RA%252C%2520a%2520new%2520sigma-1%2520receptor%2520antagonist%2520that%2520inhibits%2520neuropathic%2520pain%2520and%2520activity-induced%2520spinal%2520sensitization%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D2289%26epage%3D2306%26doi%3D10.1111%2Fj.1476-5381.2012.01942.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocasalbas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tourino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bura, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>711</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2013.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejphar.2013.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23632394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVyksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=711&publication_year=2013&pages=63-72&author=A.+Vidal-Torresauthor=B.+de+la+Puenteauthor=M.+Rocasalbasauthor=C.+Tourinoauthor=S.+A.+Buraauthor=B.+Fernandez-Pastorauthor=L.+Romeroauthor=X.+Codonyauthor=D.+Zamanilloauthor=H.+Buschmannauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=R.+Maldonadoauthor=J.+M.+Vela&title=Sigma-1+receptor+antagonism+as+opioid+adjuvant+strategy%3A+enhancement+of+opioid+antinociception+without+increasing+adverse+effects&doi=10.1016%2Fj.ejphar.2013.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects</span></div><div class="casAuthors">Vidal-Torres, Alba; de la Puente, Beatriz; Rocasalbas, Maria; Tourino, Clara; Andreea Bura, Simona; Fernandez-Pastor, Begona; Romero, Luz; Codony, Xavier; Zamanillo, Daniel; Buschmann, Helmut; Merlos, Manuel; Manuel Baeyens, Jose; Maldonado, Rafael; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">711</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">While opioids are potent analgesics widely used in the management of pain, a no. of well-known adverse effects limit their use.  The sigma-1 receptor is a ligand-regulated mol. chaperone involved in pain processing, including modulation of opioid antinociception.  However, data supporting the potential use of sigma-1 receptor ligands as suitable opioid adjuvants are based on studies that use non selective ligands.  Also, safety issues derived from combination therapy are poorly addressed.  In this study we used the new selective sigma-1 receptor antagonist S1RA (E-52862) to characterize the effect of selective sigma-1 receptor blockade on opioid-induced efficacy- and safety-related outcomes in mice.  S1RA (40 mg/kg) had no effect in the tail-flick test but did enhance the antinociceptive potency of several opioids by a factor between 2 and 3.3.  The potentiating effect of S1RA on morphine antinociception did not occur in sigma-1 receptor knockout mice, which supports the selective involvement of the sigma-1 receptor.  Interestingly, S1RA co-administration restored morphine antinociception in tolerant mice and reverted the reward effects of morphine in the conditioned place preference paradigm.  In addn., enhancement of antinociception was not accompanied by potentiation of other opioid-induced effects, such as the development of morphine analgesic tolerance, phys. dependence, inhibition of gastrointestinal transit, or mydriasis.  The use of sigma-1 receptor antagonists as opioid adjuvants could represent a promising pharmacol. strategy to enhance opioid potency and, most importantly, to increase the safety margin of opioids.  S1RA is currently in phase II clin. trials for the treatment of several pain conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVTGE08MufobVg90H21EOLACvtfcHk0lhR4S444qvT0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVyksLc%253D&md5=c2cd0eb6fe5a9232bff11fe1539f74d4</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DB.%26aulast%3DRocasalbas%26aufirst%3DM.%26aulast%3DTourino%26aufirst%3DC.%26aulast%3DBura%26aufirst%3DS.%2BA.%26aulast%3DFernandez-Pastor%26aufirst%3DB.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSigma-1%2520receptor%2520antagonism%2520as%2520opioid%2520adjuvant%2520strategy%253A%2520enhancement%2520of%2520opioid%2520antinociception%2520without%2520increasing%2520adverse%2520effects%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D711%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.ejphar.2013.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Selective sigma-1 receptor antagonists for the treatment of pain</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.4155%2Ffmc.14.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25078137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1179-1199&author=C.+Almansaauthor=J.+M.+Vela&title=Selective+sigma-1+receptor+antagonists+for+the+treatment+of+pain&doi=10.4155%2Ffmc.14.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Selective sigma-1 receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Almansa, Carmen; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1179-1199</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The sigma-1 receptor (σ1R) is located in areas of the CNS key for pain control and belongs to a unique target class with chaperoning functions over different mol. targets involved in transmission and amplification of nociceptive messages.  Preclin. evidence supports a role for σ1R antagonists in the treatment of pain states where hypersensitivity develops as hyperalgesia and allodynia, two common symptoms encountered in neuropathic and other chronic pain conditions.  Addnl., σ1R antagonists increase opioid analgesia without increasing opioid-related unwanted effects, which point to their potential use as opioid adjuvant therapy.  This review summarizes the structure and function of the σ1R as well as the medicinal chem. and pharmacol. studies directed to the identification of σ1R antagonists for the treatment of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ0qGYS21i37Vg90H21EOLACvtfcHk0lhR4S444qvT0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurjK&md5=3ced452012e44f478a377f0fa52995d4</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.54%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSelective%2520sigma-1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1179%26epage%3D1199%26doi%3D10.4155%2Ffmc.14.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huntington
Study Group, H. I.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1407</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1002/mds.25362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fmds.25362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23450660" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=1407-1415&author=H.+I.+Huntington%0AStudy+Group&title=A+randomized%2C+double-blind%2C+placebo-controlled+trial+of+pridopidine+in+Huntington%E2%80%99s+disease&doi=10.1002%2Fmds.25362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1002%2Fmds.25362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25362%26sid%3Dliteratum%253Aachs%26aulast%3DHuntington%2BStudy%2BGroup%26aufirst%3DH.%2BI.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520pridopidine%2520in%2520Huntington%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2013%26volume%3D28%26spage%3D1407%26epage%3D1415%26doi%3D10.1002%2Fmds.25362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grachev, I. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savola, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowsky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbehn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenberg, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapetropoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squitieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieburtz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landwehrmeyer, G B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, N. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azulay, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachoud-Levi, A. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biglan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey-Bloom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craufurd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decorte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Michele, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dornhege, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feigin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallehawk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauteul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjermind, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illarioshkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenckes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampstra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konkel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopishinskaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystkowiak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komati, S. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwako, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakoning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latipova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFarlane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevitt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Neill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panegyres, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarrell, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragosta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rialland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romoli, A. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, C. V</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saft, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seppi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shprecher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skitt, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliveri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squitieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sungmee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temirbaeva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torvin-Moller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangsted-Hansen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalyalova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, D.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(18)30391-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS1474-4422%2818%2930391-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30563778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFekur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=165-176&author=R.+Reilmannauthor=A.+McGarryauthor=I.+D+Grachevauthor=J.-M.+Savolaauthor=B.+Borowskyauthor=E.+Eyalauthor=N.+Grossauthor=D.+Langbehnauthor=R.+Schubertauthor=A.+T.+Wickenbergauthor=S.+Papapetropoulosauthor=M.+Haydenauthor=F.+Squitieriauthor=K.+Kieburtzauthor=G+B.+Landwehrmeyerauthor=P.+Agarwalauthor=K.+E+Andersonauthor=N.+A+Azizauthor=J.-P.+Azulayauthor=A.+C+Bachoud-Leviauthor=R.+Barkerauthor=A.+Bebakauthor=M.+Beuthauthor=K.+Biglanauthor=S.+Blinauthor=S.+Bohlenauthor=R.+Bonelliauthor=S.+Caldwellauthor=F.+Calvasauthor=J.+Carlosauthor=S.+Castagliuoloauthor=T.+Chongauthor=P.+Chuaauthor=A.+Colemanauthor=J.+Corey-Bloomauthor=R.+Cousinsauthor=D.+Craufurdauthor=J.+Davisonauthor=E.+Decorteauthor=G.+De+Micheleauthor=L.+Dornhegeauthor=A.+Feiginauthor=S.+Gallehawkauthor=P.+Gauteulauthor=C.+Gonzalesauthor=J.+Griffithauthor=A.+Gustovauthor=M.+Guttmanauthor=B.+Heimauthor=H.+Hellerauthor=L.+Hjermindauthor=S.+Illarioshkinauthor=L.+Ivankoauthor=J.+Jaynesauthor=M.+Jenckesauthor=B.+Kaminskiauthor=A.+Kampstraauthor=A.+Konkelauthor=S.+Kopishinskayaauthor=P.+Krystkowiakauthor=S.+K+Komatiauthor=A.+Kwakoauthor=S.+Lakoningauthor=G.+Latipovaauthor=B.+Leavittauthor=C.+Loyauthor=C.+MacFarlaneauthor=L.+Madsenauthor=K.+Marderauthor=S.+Masonauthor=N.+Mendisauthor=T.+Mendisauthor=A.+Nemethauthor=L.+Nevittauthor=V.+Norrisauthor=C.+O%27Neillauthor=A.+Olivierauthor=M.+Orthauthor=A.+Owensauthor=P.+Panegyresauthor=S.+Perlmanauthor=J.+Prestonauthor=J.+Prillerauthor=A.+Puchauthor=O.+Quarrellauthor=D.+Ragostaauthor=A.+Riallandauthor=H.+Rickardsauthor=A.+M+Romoliauthor=C.+Rossauthor=A.+Rosserauthor=M.+Rudzinskaauthor=C.+V+Russoauthor=C.+Saftauthor=V.+Segroauthor=K.+Seppiauthor=B.+Shannonauthor=D.+Shprecherauthor=C.+Simoninauthor=Z.+Skittauthor=J.+Slawekauthor=P.+Soliveriauthor=S.+Sorbiauthor=F.+Squitieriauthor=V.+Suskiauthor=I.+Stepniakauthor=P.+Sungmeeauthor=S.+Temirbaevaauthor=C.+Testaauthor=A.+Torvin-Mollerauthor=S.+Uhlauthor=C.+Vangsted-Hansenauthor=C.+Vernyauthor=P.+Wallauthor=F.+Walkerauthor=P.+Wassermanauthor=G.+Witkowskiauthor=J.+Wrightauthor=Z.+Zalyalovaauthor=D.+Zielonka&title=Safety+and+efficacy+of+pridopidine+in+patients+with+Huntington%E2%80%99s+disease+%28PRIDE-HD%29%3A+a+phase+2%2C+randomised%2C+placebo-controlled%2C+multicentre%2C+dose-ranging+study&doi=10.1016%2FS1474-4422%2818%2930391-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study</span></div><div class="casAuthors">Reilmann, Ralf; McGarry, Andrew; Grachev, Igor D.; Savola, Juha-Matti; Borowsky, Beth; Eyal, Eli; Gross, Nicholas; Langbehn, Douglas; Schubert, Robin; Wickenberg, Anna Teige; Papapetropoulos, Spyros; Hayden, Michael; Squitieri, Ferdinando; Kieburtz, Karl; Landwehrmeyer, G. Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-176</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Previous trials have shown that pridopidine might reduce motor impairment in patients with Huntington's disease.  The aim of this study was to ascertain whether higher doses of pridopidine than previously tested reduce motor symptoms in a dose-dependent manner while maintaining acceptable safety and tolerability.  PRIDE-HD was a randomised, placebo-controlled, phase 2, dose-ranging study in adults (aged ≥21 years) with Huntington's disease at outpatient clinics in 53 sites across 12 countries (Australia, Austria, Canada, Denmark, France, Germany, Italy, Poland, Russia, the Netherlands, the UK, and the USA).  Eligible patients had clin. onset after age 18 years, 36 or more cytosine-adenine-guanine repeats in the huntingtin gene, motor symptoms (Unified Huntington's Disease Rating Scale total motor score [UHDRS-TMS] ≥25 points), and reduced independence (UHDRS independence score ≤90%).  Patients were randomly assigned (1:1:1:1:1) with centralised interactive-response technol. to receive one of four doses of pridopidine (45, 67.5, 90, or 112.5 mg) or placebo orally twice a day for 52 wk.  Randomisation was stratified within centers by neuroleptic drug use.  The primary efficacy endpoint was change in the UHDRS-TMS from baseline to 26 wk, which was assessed in all randomised patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment (full anal. set).  Participants and investigators were masked to treatment assignment.  This trial is registered with EudraCT (2013-001888-23) and ClinicalTrials.gov (NCT02006472).  Between Feb 13, 2014, and July 5, 2016, 408 patients were enrolled and randomly assigned to receive placebo (n = 82) or pridopidine 45 mg (n = 81), 67.5 mg (n = 82), 90 mg (n = 81), or 112.5 mg (n = 82) twice daily for 26 wk.  The full anal. set included 397 patients (81 in the placebo group, 75 in the 45 mg group, 79 in the 67.5 mg group, 81 in the 90 mg group, and 81 in the 112.5 mg group).  Pridopidine did not significantly change the UHDRS-TMS at 26 wk compared with placebo at any dose.  The most frequent adverse events across all groups were diarrhoea, vomiting, nasopharyngitis, falls, headache, insomnia, and anxiety.  The most common treatment-related adverse events were insomnia, diarrhoea, nausea, and dizziness.  Serious adverse events occurred in the pridopidine groups only and were most frequently falls (n = 5), suicide attempt (n = 4), suicidal ideation (n = 3), head injury (n = 3), and aspiration pneumonia (n = 3).  No new safety or tolerability concerns emerged in this study.  One death in the pridopidine 112.5 mg group due to aspiration pneumonia was considered to be possibly related to the study drug.  Pridopidine did not improve the UHDRS-TMS at week 26 compared with placebo and, thus, the results of secondary or tertiary anal. in previous trials were not replicated.  A potentially strong placebo effect needs to be ruled out in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1SGKkDZwj77Vg90H21EOLACvtfcHk0ligf2OByXNueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFekur%252FJ&md5=11fdc45c6b554f7069650126629714f3</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2818%2930391-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252818%252930391-0%26sid%3Dliteratum%253Aachs%26aulast%3DReilmann%26aufirst%3DR.%26aulast%3DMcGarry%26aufirst%3DA.%26aulast%3DGrachev%26aufirst%3DI.%2BD%26aulast%3DSavola%26aufirst%3DJ.-M.%26aulast%3DBorowsky%26aufirst%3DB.%26aulast%3DEyal%26aufirst%3DE.%26aulast%3DGross%26aufirst%3DN.%26aulast%3DLangbehn%26aufirst%3DD.%26aulast%3DSchubert%26aufirst%3DR.%26aulast%3DWickenberg%26aufirst%3DA.%2BT.%26aulast%3DPapapetropoulos%26aufirst%3DS.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DSquitieri%26aufirst%3DF.%26aulast%3DKieburtz%26aufirst%3DK.%26aulast%3DLandwehrmeyer%26aufirst%3DG%2BB.%26aulast%3DAgarwal%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DK.%2BE%26aulast%3DAziz%26aufirst%3DN.%2BA%26aulast%3DAzulay%26aufirst%3DJ.-P.%26aulast%3DBachoud-Levi%26aufirst%3DA.%2BC%26aulast%3DBarker%26aufirst%3DR.%26aulast%3DBebak%26aufirst%3DA.%26aulast%3DBeuth%26aufirst%3DM.%26aulast%3DBiglan%26aufirst%3DK.%26aulast%3DBlin%26aufirst%3DS.%26aulast%3DBohlen%26aufirst%3DS.%26aulast%3DBonelli%26aufirst%3DR.%26aulast%3DCaldwell%26aufirst%3DS.%26aulast%3DCalvas%26aufirst%3DF.%26aulast%3DCarlos%26aufirst%3DJ.%26aulast%3DCastagliuolo%26aufirst%3DS.%26aulast%3DChong%26aufirst%3DT.%26aulast%3DChua%26aufirst%3DP.%26aulast%3DColeman%26aufirst%3DA.%26aulast%3DCorey-Bloom%26aufirst%3DJ.%26aulast%3DCousins%26aufirst%3DR.%26aulast%3DCraufurd%26aufirst%3DD.%26aulast%3DDavison%26aufirst%3DJ.%26aulast%3DDecorte%26aufirst%3DE.%26aulast%3DDe%2BMichele%26aufirst%3DG.%26aulast%3DDornhege%26aufirst%3DL.%26aulast%3DFeigin%26aufirst%3DA.%26aulast%3DGallehawk%26aufirst%3DS.%26aulast%3DGauteul%26aufirst%3DP.%26aulast%3DGonzales%26aufirst%3DC.%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DGustov%26aufirst%3DA.%26aulast%3DGuttman%26aufirst%3DM.%26aulast%3DHeim%26aufirst%3DB.%26aulast%3DHeller%26aufirst%3DH.%26aulast%3DHjermind%26aufirst%3DL.%26aulast%3DIllarioshkin%26aufirst%3DS.%26aulast%3DIvanko%26aufirst%3DL.%26aulast%3DJaynes%26aufirst%3DJ.%26aulast%3DJenckes%26aufirst%3DM.%26aulast%3DKaminski%26aufirst%3DB.%26aulast%3DKampstra%26aufirst%3DA.%26aulast%3DKonkel%26aufirst%3DA.%26aulast%3DKopishinskaya%26aufirst%3DS.%26aulast%3DKrystkowiak%26aufirst%3DP.%26aulast%3DKomati%26aufirst%3DS.%2BK%26aulast%3DKwako%26aufirst%3DA.%26aulast%3DLakoning%26aufirst%3DS.%26aulast%3DLatipova%26aufirst%3DG.%26aulast%3DLeavitt%26aufirst%3DB.%26aulast%3DLoy%26aufirst%3DC.%26aulast%3DMacFarlane%26aufirst%3DC.%26aulast%3DMadsen%26aufirst%3DL.%26aulast%3DMarder%26aufirst%3DK.%26aulast%3DMason%26aufirst%3DS.%26aulast%3DMendis%26aufirst%3DN.%26aulast%3DMendis%26aufirst%3DT.%26aulast%3DNemeth%26aufirst%3DA.%26aulast%3DNevitt%26aufirst%3DL.%26aulast%3DNorris%26aufirst%3DV.%26aulast%3DO%2527Neill%26aufirst%3DC.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DOrth%26aufirst%3DM.%26aulast%3DOwens%26aufirst%3DA.%26aulast%3DPanegyres%26aufirst%3DP.%26aulast%3DPerlman%26aufirst%3DS.%26aulast%3DPreston%26aufirst%3DJ.%26aulast%3DPriller%26aufirst%3DJ.%26aulast%3DPuch%26aufirst%3DA.%26aulast%3DQuarrell%26aufirst%3DO.%26aulast%3DRagosta%26aufirst%3DD.%26aulast%3DRialland%26aufirst%3DA.%26aulast%3DRickards%26aufirst%3DH.%26aulast%3DRomoli%26aufirst%3DA.%2BM%26aulast%3DRoss%26aufirst%3DC.%26aulast%3DRosser%26aufirst%3DA.%26aulast%3DRudzinska%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DC.%2BV%26aulast%3DSaft%26aufirst%3DC.%26aulast%3DSegro%26aufirst%3DV.%26aulast%3DSeppi%26aufirst%3DK.%26aulast%3DShannon%26aufirst%3DB.%26aulast%3DShprecher%26aufirst%3DD.%26aulast%3DSimonin%26aufirst%3DC.%26aulast%3DSkitt%26aufirst%3DZ.%26aulast%3DSlawek%26aufirst%3DJ.%26aulast%3DSoliveri%26aufirst%3DP.%26aulast%3DSorbi%26aufirst%3DS.%26aulast%3DSquitieri%26aufirst%3DF.%26aulast%3DSuski%26aufirst%3DV.%26aulast%3DStepniak%26aufirst%3DI.%26aulast%3DSungmee%26aufirst%3DP.%26aulast%3DTemirbaeva%26aufirst%3DS.%26aulast%3DTesta%26aufirst%3DC.%26aulast%3DTorvin-Moller%26aufirst%3DA.%26aulast%3DUhl%26aufirst%3DS.%26aulast%3DVangsted-Hansen%26aufirst%3DC.%26aulast%3DVerny%26aufirst%3DC.%26aulast%3DWall%26aufirst%3DP.%26aulast%3DWalker%26aufirst%3DF.%26aulast%3DWasserman%26aufirst%3DP.%26aulast%3DWitkowski%26aufirst%3DG.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DZalyalova%26aufirst%3DZ.%26aulast%3DZielonka%26aufirst%3DD.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520pridopidine%2520in%2520patients%2520with%2520Huntington%25E2%2580%2599s%2520disease%2520%2528PRIDE-HD%2529%253A%2520a%2520phase%25202%252C%2520randomised%252C%2520placebo-controlled%252C%2520multicentre%252C%2520dose-ranging%2520study%26jtitle%3DLancet%2520Neurol.%26date%3D2019%26volume%3D18%26spage%3D165%26epage%3D176%26doi%3D10.1016%2FS1474-4422%2818%2930391-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ionescu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maimon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf Avraham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlson, E.</span></span> <span> </span><span class="NLM_article-title">Targeting the sigma-1 receptor via Pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">210</span>, <span class="refDoi"> DOI: 10.1038/s41419-019-1451-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fs41419-019-1451-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30824685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BB3cfpsFSlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=210&author=A.+Ionescuauthor=T.+Gradusauthor=T.+Altmanauthor=R.+Maimonauthor=N.+Saraf+Avrahamauthor=M.+Gevaauthor=M.+Haydenauthor=E.+Perlson&title=Targeting+the+sigma-1+receptor+via+Pridopidine+ameliorates+central+features+of+ALS+pathology+in+a+SOD1%28G93A%29+model&doi=10.1038%2Fs41419-019-1451-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1(G93A) Model</span></div><div class="casAuthors">Ionescu Ariel; Gradus Tal; Altman Topaz; Maimon Roy; Saraf Avraham Noi; Perlson Eran; Ionescu Ariel; Perlson Eran; Geva Michal; Hayden Michael; Geva Michal; Hayden Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease affecting both the upper and lower motor neurons (MNs), with no effective treatment currently available.  Early pathological events in ALS include perturbations in axonal transport (AT), formation of toxic protein aggregates and Neuromuscular Junction (NMJ) disruption, which all lead to axonal degeneration and motor neuron death.  Pridopidine is a small molecule that has been clinically developed for Huntington disease.  Here we tested the efficacy of pridopidine for ALS using in vitro and in vivo models.  Pridopidine beneficially modulates AT deficits and diminishes NMJ disruption, as well as motor neuron death in SOD1(G93A) MNs and in neuromuscular co-cultures.  Furthermore, we demonstrate that pridopidine activates the ERK pathway and mediates its beneficial effects through the sigma-1 receptor (S1R).  Strikingly, in vivo evaluation of pridopidine in SOD1(G93A) mice reveals a profound reduction in mutant SOD1 aggregation in the spinal cord, and attenuation of NMJ disruption, as well as subsequent muscle wasting.  Taken together, we demonstrate for the first time that pridopidine improves several cellular and histological hallmark pathologies of ALS through the S1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtbLKZwETEnn6HPRus0rAafW6udTcc2eZJ02xdaRIAbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfpsFSlsQ%253D%253D&md5=78d838109b873db3b0912223768d9d47</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fs41419-019-1451-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-019-1451-2%26sid%3Dliteratum%253Aachs%26aulast%3DIonescu%26aufirst%3DA.%26aulast%3DGradus%26aufirst%3DT.%26aulast%3DAltman%26aufirst%3DT.%26aulast%3DMaimon%26aufirst%3DR.%26aulast%3DSaraf%2BAvraham%26aufirst%3DN.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DPerlson%26aufirst%3DE.%26atitle%3DTargeting%2520the%2520sigma-1%2520receptor%2520via%2520Pridopidine%2520ameliorates%2520central%2520features%2520of%2520ALS%2520pathology%2520in%2520a%2520SOD1%2528G93A%2529%2520model%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2019%26volume%3D10%26spage%3D210%26doi%3D10.1038%2Fs41419-019-1451-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahmy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmstrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Blockade of Tau hyperphosphorylation and Abeta(1)(−)(4)(2) generation by the aminotetrahydrofuran derivative ANAVEX2–73, a mixed muscarinic and sigma(1) receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1723</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.70</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fnpp.2013.70" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23493042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCjs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=1706-1723&author=V.+Lahmyauthor=J.+Meunierauthor=S.+Malmstromauthor=G.+Naertauthor=L.+Givaloisauthor=S.+H.+Kimauthor=V.+Villardauthor=A.+Vamvakidesauthor=T.+Maurice&title=Blockade+of+Tau+hyperphosphorylation+and+Abeta%281%29%28%E2%88%92%29%284%29%282%29+generation+by+the+aminotetrahydrofuran+derivative+ANAVEX2%E2%80%9373%2C+a+mixed+muscarinic+and+sigma%281%29+receptor+agonist%2C+in+a+nontransgenic+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnpp.2013.70"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease</span></div><div class="casAuthors">Lahmy, Valentine; Meunier, Johann; Malmstroem, Susanna; Naert, Gaelle; Givalois, Laurent; Kim, Seung Hyun; Villard, Vanessa; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1706-1723</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The main objective of the present study was to establish whether the mixed σ1/muscarinic ligand ANAVEX2-73, shown to be neuroprotective in Alzheimer's disease (AD) models in vivo and currently in clin. phase I/IIa, could have the ability to reduce the appearance of hyperphosphorylated Tau and amyloid-β1-42 (Aβ1-42) in the Aβ25-35 mouse model of AD.  We therefore first confirmed that Aβ25-35 injection induced hyperphosphorylation of Tau protein, by showing that it rapidly decreased Akt activity and activated glycogen synthase kinase-3β (GSK-3β) in the mouse hippocampus.  Second, we showed that the kinase activation, and resulting Tau alteration, directly contributed to the amyloid toxicity, as co-administration of the selective GSK-3β inhibitor 2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxidiazole blocked both Tau phosphorylation and Aβ25-35-induced memory impairments.  Third, we analyzed the ANAVEX2-73 effect on Tau phosphorylation and activation of the related kinase pathways (Akt and GSK-3β).  And fourth, we also addressed the impact of the drug on Aβ25-35-induced Aβ1-42 seeding and obsd. that the compd. significantly blocked the increase in Aβ1-42 and C99 levels in the hippocampus, suggesting that it may alleviate amyloid load in AD models.  The comparison with PRE-084, a selective and ref. σ1 receptor agonist, and xanomeline, a muscarinic ligand presenting similar profile as ANAVEX2-73 on M1 and M2 subtypes, confirmed that both muscarinic and σ1 targets are involved in the ANAVEX2-73 effects.  The drug, acting synergistically on both targets, but with moderate affinity, presents a promising pharmacol. profile.  Neuropsychopharmacol. (2013) 38, 1706-1723; doi:10.1038/npp.2013.70; published online 3 Apr. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8Ullin5U0GbVg90H21EOLACvtfcHk0lgteW8m-lv5hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCjs7nP&md5=84921702de85f5bc6152b178915adb44</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.70&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.70%26sid%3Dliteratum%253Aachs%26aulast%3DLahmy%26aufirst%3DV.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DMalmstrom%26aufirst%3DS.%26aulast%3DNaert%26aufirst%3DG.%26aulast%3DGivalois%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DBlockade%2520of%2520Tau%2520hyperphosphorylation%2520and%2520Abeta%25281%2529%2528%25E2%2588%2592%2529%25284%2529%25282%2529%2520generation%2520by%2520the%2520aminotetrahydrofuran%2520derivative%2520ANAVEX2%25E2%2580%259373%252C%2520a%2520mixed%2520muscarinic%2520and%2520sigma%25281%2529%2520receptor%2520agonist%252C%2520in%2520a%2520nontransgenic%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuropsychopharmacology%26date%3D2013%26volume%3D38%26spage%3D1706%26epage%3D1723%26doi%3D10.1038%2Fnpp.2013.70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahmy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial protection by the mixed muscarinic/sigma1 ligand ANAVEX2–73, a tetrahydrofuran derivative, in Abeta25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">463</span>, <span class="refDoi"> DOI: 10.3389/fncel.2014.00463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffncel.2014.00463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25653589" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=463&author=V.+Lahmyauthor=R.+Longauthor=D.+Morinauthor=V.+Villardauthor=T.+Maurice&title=Mitochondrial+protection+by+the+mixed+muscarinic%2Fsigma1+ligand+ANAVEX2%E2%80%9373%2C+a+tetrahydrofuran+derivative%2C+in+Abeta25%E2%80%9335+peptide-injected+mice%2C+a+nontransgenic+Alzheimer%E2%80%99s+disease+model&doi=10.3389%2Ffncel.2014.00463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2014.00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2014.00463%26sid%3Dliteratum%253Aachs%26aulast%3DLahmy%26aufirst%3DV.%26aulast%3DLong%26aufirst%3DR.%26aulast%3DMorin%26aufirst%3DD.%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DMitochondrial%2520protection%2520by%2520the%2520mixed%2520muscarinic%252Fsigma1%2520ligand%2520ANAVEX2%25E2%2580%259373%252C%2520a%2520tetrahydrofuran%2520derivative%252C%2520in%2520Abeta25%25E2%2580%259335%2520peptide-injected%2520mice%252C%2520a%2520nontransgenic%2520Alzheimer%25E2%2580%2599s%2520disease%2520model%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2015%26volume%3D8%26spage%3D463%26doi%3D10.3389%2Ffncel.2014.00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, S.</span></span> <span> </span><span class="NLM_article-title">Binding properties of SA4503, a novel and selective sigma 1 receptor agonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00201-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2F0014-2999%2896%2900201-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=8813641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK28Xktl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=1996&pages=271-279&author=K.+Matsunoauthor=M.+Nakazawaauthor=K.+Okamotoauthor=Y.+Kawashimaauthor=S.+Mita&title=Binding+properties+of+SA4503%2C+a+novel+and+selective+sigma+1+receptor+agonist&doi=10.1016%2F0014-2999%2896%2900201-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Binding properties of SA4503, a novel and selective σ1 receptor agonist</span></div><div class="casAuthors">Matsuno, Kiyoshi; Nakazawa, Minako; Okamoto, Kazuyoshi; Kawashima, Yoichi; Mita, Shiro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">271-279</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The binding profiles of SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride), a novel σ receptor ligand, to σ1 and σ2 receptor subtypes in guinea pig and rat brain membranes were evaluated.  SA4503 showed a high affinity for the σ1 receptor subtype labeled by (+)-[3H]pentazocine (IC50 = 17.4±1.9 nM), while it had about 100-fold less affinity for the σ2 receptor subtype labeled by [3H]1,3-di(2-tolyl)guanidine ([3H]DTG) in the presence of 200 nM (+)-pentazocine.  SA4503 showed little affinity for 36 other receptors, ion channels and second messenger systems.  The inhibition curves of SA4503 for (+)-[3H]pentazocine binding were shifted to the right in the presence of guanosine 5'-o-(3-thiotriphosphate)(GTPγS), as similar to those of (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3-PPP) and (+)-pentazocine, σ1 receptor agonists.  SA4503 significantly increased the KD value, but did not affect the Bmax value for specific (+)-[3H]pentazocine binding.  These results indicated that SA4503 is a potent and selective agonist for the σ1 receptor subtype in the brain.  In addn., SA4503 inhibited specific (+)-[3H]pentazocine binding in a competitive manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Wso8XHzUE7Vg90H21EOLACvtfcHk0lhUnGf2Fu5pAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xktl2ntbs%253D&md5=587287bfffd018c8b316255cbf14a026</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900201-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900201-4%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DNakazawa%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKawashima%26aufirst%3DY.%26aulast%3DMita%26aufirst%3DS.%26atitle%3DBinding%2520properties%2520of%2520SA4503%252C%2520a%2520novel%2520and%2520selective%2520sigma%25201%2520receptor%2520agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D306%26spage%3D271%26epage%3D279%26doi%3D10.1016%2F0014-2999%2896%2900201-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skuza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoz, Z.</span></span> <span> </span><span class="NLM_article-title">A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1097/00008877-200211000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1097%2F00008877-200211000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=12409992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot12murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=537-543&author=G.+Skuzaauthor=Z.+Rogoz&title=A+potential+antidepressant+activity+of+SA4503%2C+a+selective+sigma+1+receptor+agonist&doi=10.1097%2F00008877-200211000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">A potential antidepressant activity of SA4503, a selective σ1 receptor agonist</span></div><div class="casAuthors">Skuza, G.; Rogoz, Z.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">537-543</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The aim of the present study was to examine SA4503 [1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride], a novel selective σ1 receptor agonist, in respect of its potential antidepressant action.  To this end we used a forced swimming test in rats to study SA4503 alone, as well as its interaction with imipramine, a classic tricyclic antidepressant.  SA4503 decreased the immobility time in the forced swimming test in rats (although only at one of the three doses used); at the same time it did not change the locomotor activity recorded under the same exptl. conditions.  Moreover, SA4503 showed a synergistic effect with imipramine in the forced swimming test (both those compds. given jointly decreased the immobility time, but were ineffective when administered sep.).  It had previously been shown that repeated administration of antidepressants with different pharmacol. profiles enhanced the action of D-amphetamine, quinpirole and other dopamine stimulants.  SA4503 administered repeatedly increased the locomotor hyperactivity induced by D-amphetamine and quinpirole (a dopamine D2/D3 receptor agonist), but not by (±)-7-hydroxy-dipropyloamino-tetralin hydrobromide [(±)-7-OH-DPAT; a dopamine D3 receptor agonist].  The results presented in this paper support the suggestion that SA4503 may have potential antidepressive properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0R2FaXEnYP7Vg90H21EOLACvtfcHk0lhUnGf2Fu5pAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot12murs%253D&md5=52790865e6d818b37edaffaf558827d4</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1097%2F00008877-200211000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008877-200211000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DSkuza%26aufirst%3DG.%26aulast%3DRogoz%26aufirst%3DZ.%26atitle%3DA%2520potential%2520antidepressant%2520activity%2520of%2520SA4503%252C%2520a%2520selective%2520sigma%25201%2520receptor%2520agonist%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2002%26volume%3D13%26spage%3D537%26epage%3D543%26doi%3D10.1097%2F00008877-200211000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga, K.</span></span> <span> </span><span class="NLM_article-title">Stimulation of sigma-1 receptor ameliorates depressive-like behaviors in CaMKIV null mice</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1210</span>– <span class="NLM_lpage">1222</span>, <span class="refDoi"> DOI: 10.1007/s12035-014-8923-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs12035-014-8923-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25316382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2015&pages=1210-1222&author=S.+Moriguchiauthor=H.+Sakagamiauthor=Y.+Yabukiauthor=Y.+Sasakiauthor=H.+Izumiauthor=C.+Zhangauthor=F.+Hanauthor=K.+Fukunaga&title=Stimulation+of+sigma-1+receptor+ameliorates+depressive-like+behaviors+in+CaMKIV+null+mice&doi=10.1007%2Fs12035-014-8923-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of Sigma-1 Receptor Ameliorates Depressive-like Behaviors in CaMKIV Null Mice</span></div><div class="casAuthors">Moriguchi, Shigeki; Sakagami, Hiroyuki; Yabuki, Yasushi; Sasaki, Yuzuru; Izumi, Hisanao; Zhang, Chen; Han, Feng; Fukunaga, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1210-1222</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Sigma-1 receptor (Sig-1R) is a mol. chaperone regulating calcium efflux from the neuronal endoplasmic reticulum to the mitochondria.  Calcium/calmodulin-dependent protein kinase IV (CaMKIV) null mice exhibit depressive-like behaviors and impaired neurogenesis as assessed by bromodeoxyuridine (BrdU) incorporation into newborn cells of the hippocampal dentate gyrus (DG).  Here, we demonstrate that chronic stimulation of Sig-1R by treatment with the agonist SA4503 or the SSRI fluvoxamine for 14 days improves depressive-like behaviors in CaMKIV null mice.  By contrast, treatment with paroxetine, which lacks affinity for Sig-1R, did not alter these behaviors.  Reduced nos. of BrdU-pos. cells and decreased brain-derived neurotrophic factor (BDNF) mRNA expression and protein kinase B (Akt; Ser-473) phosphorylation seen in the DG of CaMKIV null mice were significantly rescued by chronic Sig-1R stimulation.  Interestingly, reduced ATP prodn. obsd. in the DG of CaMKIV null mice was improved by chronic Sig-1R stimulation.  Such stimulation also improved hippocampal long-term potentiation (LTP) induction and maintenance, which are impaired in the DG of CaMKIV null mice.  LTP rescue was closely assocd. with both increases in calcium/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation and GluA1 (Ser-831) phosphorylation.  Taken together, Sig-1R stimulation by SA4503 or fluvoxamine treatment increased hippocampal neurogenesis, which is closely assocd. with amelioration of depressive-like behaviors in CaMKIV null mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMv5yHpsoYQLVg90H21EOLACvtfcHk0lhUnGf2Fu5pAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjurvM&md5=7b86fcdb769ab1427ae6cbf02b253374</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1007%2Fs12035-014-8923-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-014-8923-2%26sid%3Dliteratum%253Aachs%26aulast%3DMoriguchi%26aufirst%3DS.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DYabuki%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DIzumi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DFukunaga%26aufirst%3DK.%26atitle%3DStimulation%2520of%2520sigma-1%2520receptor%2520ameliorates%2520depressive-like%2520behaviors%2520in%2520CaMKIV%2520null%2520mice%26jtitle%3DMol.%2520Neurobiol.%26date%3D2015%26volume%3D52%26spage%3D1210%26epage%3D1222%26doi%3D10.1007%2Fs12035-014-8923-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urfer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoloudik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamarina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, K. W.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of the sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3304</span>– <span class="NLM_lpage">3310</span>, <span class="refDoi"> DOI: 10.1161/STROKEAHA.114.005835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1161%2FSTROKEAHA.114.005835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25270629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVKrtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=3304-3310&author=R.+Urferauthor=H.+J.+Moebiusauthor=D.+Skoloudikauthor=E.+Santamarinaauthor=W.+Satoauthor=S.+Mitaauthor=K.+W.+Muir&title=Phase+II+trial+of+the+sigma-1+receptor+agonist+cutamesine+%28SA4503%29+for+recovery+enhancement+after+acute+ischemic+stroke&doi=10.1161%2FSTROKEAHA.114.005835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke</span></div><div class="casAuthors">Urfer, Roman; Moebius, Hans J.; Skoloudik, David; Santamarina, Estevo; Sato, Wakao; Mita, Shiro; Muir, Keith W.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3304-3310</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND AND PURPOSE-: The σ-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after exptl. stroke with a treatment initiation window of 48 h and chronic treatment for 28 days.  We conducted a phase 2 clin. trial exploring the safety, tolerability, dose range, and functional effects of cutamesine in patients with ischemic stroke.  METHODS-: Subjects were randomized between 48 and 72 h after stroke to receive cutamesine 1 mg/d, 3 mg/d, or placebo for 28 days.  Effects on safety and function were assessed at baseline, at end of treatment (day 28), and at end of follow-up (day 56).  RESULTS-: In 60 patients, treatment with both cutamesine dosages was safe and well tolerated without significant differences in nos. of treatment emergent or serious adverse events.  No significant effect was obsd. on the primary efficacy measure (change in National Institutes of Health Stroke Scale from baseline to day 56) or modified Rankin Scale and Barthel Index scores.  Post hoc anal. of moderately and severely affected patients (baseline National Institutes of Health Stroke Scale, ≥7 and ≥10) showed greater National Institutes of Health Stroke Scale improvements in the 3 mg/d cutamesine group when compared with placebo (P=0.034 and P=0.038, resp.).  A trend toward a higher proportion being able to complete a 10m timed walk was obsd. for cutamesine-treated subjects.  CONCLUSIONS-: Cutamesine was safe and well tolerated at both dosage levels.  Although no significant effects on functional end points were seen in the population as a whole, greater improvement in National Institutes of Health Stroke Scale scores among patients with greater pretreatment deficits seen in post hoc anal. warrants further investigation.  Addnl. studies should focus on the patient population with moderate-to-severe stroke.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov/show/NCT00639249.  Unique identifier: NCT00639249.  The EudraCT no. is 2007-004840-60 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004840-60/GB).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDEGW1pd0NnLVg90H21EOLACvtfcHk0ljgtNKU39L1jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVKrtrbP&md5=cdf635de1aff93573aab643921d25acf</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.114.005835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.114.005835%26sid%3Dliteratum%253Aachs%26aulast%3DUrfer%26aufirst%3DR.%26aulast%3DMoebius%26aufirst%3DH.%2BJ.%26aulast%3DSkoloudik%26aufirst%3DD.%26aulast%3DSantamarina%26aufirst%3DE.%26aulast%3DSato%26aufirst%3DW.%26aulast%3DMita%26aufirst%3DS.%26aulast%3DMuir%26aufirst%3DK.%2BW.%26atitle%3DPhase%2520II%2520trial%2520of%2520the%2520sigma-1%2520receptor%2520agonist%2520cutamesine%2520%2528SA4503%2529%2520for%2520recovery%2520enhancement%2520after%2520acute%2520ischemic%2520stroke%26jtitle%3DStroke%26date%3D2014%26volume%3D45%26spage%3D3304%26epage%3D3310%26doi%3D10.1161%2FSTROKEAHA.114.005835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimazawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hozumi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, H.</span></span> <span> </span><span class="NLM_article-title">SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2013.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neulet.2013.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24334165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1Clsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2014&pages=174-178&author=Y.+Onoauthor=H.+Tanakaauthor=M.+Takataauthor=Y.+Nagaharaauthor=Y.+Nodaauthor=K.+Tsurumaauthor=M.+Shimazawaauthor=I.+Hozumiauthor=H.+Hara&title=SA4503%2C+a+sigma-1+receptor+agonist%2C+suppresses+motor+neuron+damage+in+in+vitro+and+in+vivo+amyotrophic+lateral+sclerosis+models&doi=10.1016%2Fj.neulet.2013.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models</span></div><div class="casAuthors">Ono, Yoko; Tanaka, Hirotaka; Takata, Masafumi; Nagahara, Yuki; Noda, Yasuhiro; Tsuruma, Kazuhiro; Shimazawa, Masamitsu; Hozumi, Isao; Hara, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">174-178</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.  Recently, it has been reported that a mutation in the sigma-1 receptor causes juvenile ALS.  Therefore, the function of the sigma-1 receptor may be important in the pathol. of ALS.  In the present study, we investigated the effect of SA4503, a sigma-1 receptor agonist, against in in vitro and in vivo ALS models.  We first investigated whether SA4503, a sigma-1 receptor agonist, prevented superoxide dismutase 1 (SOD1G93A)- and serum free-induced cell death of mice motor neuron cells (NSC34) in in vitro model of an ALS.  At concns. of 1-10 μM, SA4503 reduced SOD1G93A-induced cell death in a concn.-dependent manner, and BD1047, a sigma-1 receptor antagonist, inhibited the protective effect of SA4503.  Next, we investigated whether SA4503 affected the phosphorylation levels of Akt (Ser 473) and extracellular signal-regulated kinase (ERK) 1/2 and the expression of the sigma-1 receptor.  SA4503 promoted the phosphorylation of Akt (Ser 473) and ERK1/2 in a time-dependent manner, but SA4503 did not affect the expression of the sigma-1 receptor.  These results suggest that the protective effect of SA4503 might be involved in promoting the phosphorylation of Akt and ERK1/2.  We then investigated whether SA4503 suppressed the progression of ALS in an SOD1G93A ALS mouse model.  SA4503 did not affect the onset time of ALS.  However, it significantly extended the survival time in the SOD1G93A mice compared with a vehicle-treated group.  These findings indicate that SA4503 is effective in suppressing motor neuron degeneration and symptom progression in ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhpwPNu8EqVbVg90H21EOLACvtfcHk0ljgtNKU39L1jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1Clsw%253D%253D&md5=88135ada3683080b388904b6c63db74b</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2013.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2013.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DTakata%26aufirst%3DM.%26aulast%3DNagahara%26aufirst%3DY.%26aulast%3DNoda%26aufirst%3DY.%26aulast%3DTsuruma%26aufirst%3DK.%26aulast%3DShimazawa%26aufirst%3DM.%26aulast%3DHozumi%26aufirst%3DI.%26aulast%3DHara%26aufirst%3DH.%26atitle%3DSA4503%252C%2520a%2520sigma-1%2520receptor%2520agonist%252C%2520suppresses%2520motor%2520neuron%2520damage%2520in%2520in%2520vitro%2520and%2520in%2520vivo%2520amyotrophic%2520lateral%2520sclerosis%2520models%26jtitle%3DNeurosci.%2520Lett.%26date%3D2014%26volume%3D559%26spage%3D174%26epage%3D178%26doi%3D10.1016%2Fj.neulet.2013.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga, K.</span></span> <span> </span><span class="NLM_article-title">SA4503, a potent sigma-1 receptor ligand, ameliorates synaptic abnormalities and cognitive dysfunction in a mouse model of ATR-X syndrome</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2811</span>, <span class="refDoi"> DOI: 10.3390/ijms19092811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3390%2Fijms19092811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFSgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2811&author=K.+Yamaguchiauthor=N.+Shiodaauthor=Y.+Yabukiauthor=C.+Zhangauthor=F.+Hanauthor=K.+Fukunaga&title=SA4503%2C+a+potent+sigma-1+receptor+ligand%2C+ameliorates+synaptic+abnormalities+and+cognitive+dysfunction+in+a+mouse+model+of+ATR-X+syndrome&doi=10.3390%2Fijms19092811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">SA4503, a potent sigma-1 receptor ligand, ameliorates synaptic abnormalities and cognitive dysfunction in a mouse model of ATR-X syndrome</span></div><div class="casAuthors">Yamaguchi, Kouya; Shioda, Norifumi; Yabuki, Yasushi; Zhang, Chen; Han, Feng; Fukunaga, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2811/1-2811/15</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">α-thalassemia X-linked intellectual disability (ATR-X) syndrome is caused by mutations in ATRX.  An ATR-X model mouse lacking Atrx exon 2 displays phenotypes that resemble symptoms in the human intellectual disability: cognitive defects and abnormal dendritic spine formation.  We herein target activation of sigma-1 receptor (Sig-1R) that can induce potent neuroprotective and neuroregenerative effects by promoting the activity of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF).  We demonstrated that treatment with SA4503, a potent activator of Sig-1R, reverses axonal development and dendritic spine abnormalities in cultured cortical neurons from ATR-X model mice.  Moreover, the SA4503 treatment rescued cognitive deficits exhibited by the ATR-X model mice.  We further found that significant decreases in the BDNF-protein level in the medial prefrontal cortex of ATR-X model mice were recovered with treatment of SA4503.  These results indicate that the rescue of dendritic spine abnormalities through the activation of Sig-1R has a potential for post-diagnostic therapy in ATR-X syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFO975AtzgWbVg90H21EOLACvtfcHk0ljgtNKU39L1jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFSgsrY%253D&md5=4dea390b9f1d534b8b857a46dddf94fd</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.3390%2Fijms19092811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19092811%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShioda%26aufirst%3DN.%26aulast%3DYabuki%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DFukunaga%26aufirst%3DK.%26atitle%3DSA4503%252C%2520a%2520potent%2520sigma-1%2520receptor%2520ligand%252C%2520ameliorates%2520synaptic%2520abnormalities%2520and%2520cognitive%2520dysfunction%2520in%2520a%2520mouse%2520model%2520of%2520ATR-X%2520syndrome%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D2811%26doi%3D10.3390%2Fijms19092811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuberes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrocal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contijoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laggner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of the 1-arylpyrazole class of sigma(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1<i>H</i>-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8211</span>– <span class="NLM_lpage">8224</span>, <span class="refDoi"> DOI: 10.1021/jm3007323</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3007323" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWht7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8211-8224&author=J.+L.+Diazauthor=R.+Cuberesauthor=J.+Berrocalauthor=M.+Contijochauthor=U.+Christmannauthor=A.+Fernandezauthor=A.+Portauthor=J.+Holenzauthor=H.+Buschmannauthor=C.+Laggnerauthor=M.+T.+Serafiniauthor=J.+Burguenoauthor=D.+Zamanilloauthor=M.+Merlosauthor=J.+M.+Velaauthor=C.+Almansa&title=Synthesis+and+biological+evaluation+of+the+1-arylpyrazole+class+of+sigma%281%29+receptor+antagonists%3A+identification+of+4-%7B2-%5B5-methyl-1-%28naphthalen-2-yl%29-1H-pyrazol-3-yloxy%5Dethyl%7Dmorpholine+%28S1RA%2C+E-52862%29&doi=10.1021%2Fjm3007323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of the 1-Arylpyrazole Class of σ1 Receptor Antagonists: Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)</span></div><div class="casAuthors">Diaz, Jose Luis; Cuberes, Rosa; Berrocal, Joana; Contijoch, Montserrat; Christmann, Ute; Fernandez, Ariadna; Port, Adriana; Holenz, Jorg; Buschmann, Helmut; Laggner, Christian; Serafini, Maria Teresa; Burgueno, Javier; Zamanillo, Daniel; Merlos, Manuel; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8211-8224</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 1-arylpyrazoles as potent σ1 receptor (σ1R) antagonists are reported.  The new compds. were evaluated in vitro in human σ1R and guinea pig σ2 receptor (σ2R) binding assays.  The nature of the pyrazole substituents was crucial for activity, and a basic amine was shown to be necessary, in accordance with known receptor pharmacophores.  A wide variety of amines and spacer lengths between the amino and pyrazole groups was tolerated, but only the ethylenoxy spacer and small cyclic amines provided compds. with sufficient selectivity for σ1R vs σ2R.  The most selective compds. were further profiled, and 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862, I), which showed high activity in the mouse capsaicin model of neurogenic pain, emerged as the most interesting candidate.  In addn., compd. I exerted dose-dependent antinociceptive effects in several neuropathic pain models.  This, together with its good physicochem., safety, and ADME properties, led compd. I to be selected as clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQxd7-vnvc7Vg90H21EOLACvtfcHk0lgyg6BDHB3Ttw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWht7bI&md5=0d6a5c8008d27635117c3901ec1db3c4</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm3007323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3007323%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DCuberes%26aufirst%3DR.%26aulast%3DBerrocal%26aufirst%3DJ.%26aulast%3DContijoch%26aufirst%3DM.%26aulast%3DChristmann%26aufirst%3DU.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DSerafini%26aufirst%3DM.%2BT.%26aulast%3DBurgueno%26aufirst%3DJ.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520the%25201-arylpyrazole%2520class%2520of%2520sigma%25281%2529%2520receptor%2520antagonists%253A%2520identification%2520of%25204-%257B2-%255B5-methyl-1-%2528naphthalen-2-yl%2529-1H-pyrazol-3-yloxy%255Dethyl%257Dmorpholine%2520%2528S1RA%252C%2520E-52862%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8211%26epage%3D8224%26doi%3D10.1021%2Fjm3007323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carceller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span> <span> </span><span class="NLM_article-title">Effects of the selective sigma-1 receptor antagonist S1RA on formalin-induced pain behavior and neurotransmitter release in the spinal cord in rats</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1111/jnc.12648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fjnc.12648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24384038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2hsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2014&pages=484-494&author=A.+Vidal-Torresauthor=B.+Fernandez-Pastorauthor=A.+Carcellerauthor=J.+M.+Velaauthor=M.+Merlosauthor=D.+Zamanillo&title=Effects+of+the+selective+sigma-1+receptor+antagonist+S1RA+on+formalin-induced+pain+behavior+and+neurotransmitter+release+in+the+spinal+cord+in+rats&doi=10.1111%2Fjnc.12648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the selective sigma-1 receptor antagonist S1RA on formalin-induced pain behavior and neurotransmitter release in the spinal cord in rats</span></div><div class="casAuthors">Vidal-Torres, Alba; Fernandez-Pastor, Begona; Carceller, Alicia; Vela, Jose Miguel; Merlos, Manuel; Zamanillo, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-494</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We have previously shown that the selective sigma-1 receptor (σ1R) antagonist S1RA (E-52862) inhibits neuropathic pain and activity-induced spinal sensitization in various pre-clin. pain models.  In this study we characterized both the behavioral and the spinal neurochem. effects of S1RA in the rat formalin test.  Systemic administration of S1RA produced a dose-related attenuation of flinching and lifting/licking behaviors in the formalin test.  Neurochem. studies using concentric microdialysis in the ipsilateral dorsal horn of awake, freely moving rats revealed that the systemic S1RA-induced antinociceptive effect occurs concomitantly with an enhancement of noradrenaline levels and an attenuation of formalin-evoked glutamate release in the spinal dorsal horn.  Intrathecal pre-treatment with idazoxan prevented the systemic S1RA antinociceptive effect, suggesting that the S1RA antinociception depends on the activation of spinal α2-adrenoceptors which, in turn, could induce an inhibition of formalin-evoked glutamate release.  When administered locally, intrathecal S1RA inhibited only the flinching behavior, whereas intracerebroventricularly or intraplantarly injected also attenuated the lifting/licking behavior.  These results suggest that S1RA supraspinally activates the descending noradrenergic pain inhibitory system, which may explain part of its antinociceptive properties in the formalin test; however, effects at other central and peripheral sites also account for the overall effect.  Formalin-induced nociceptive effect occurs concomitantly with an enhancement of glutamate (Glu) level in the dorsal horn spinal cord.  The selective σ1 receptor antagonist S1RA results in inhibition of formalin-evoked Glu release, no modification of GABA levels, and enhancement of noradrenaline (NA) levels.  This increased spinal NA activates spinal α2-adrenoceptors producing the attenuation of the formalin-induced pain behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpidtqKXnW5wrVg90H21EOLACvtfcHk0lj4EA9OtoXdrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2hsLw%253D&md5=23e47349eed9a544bbdf70dc9f40626b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12648%26sid%3Dliteratum%253Aachs%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3DFernandez-Pastor%26aufirst%3DB.%26aulast%3DCarceller%26aufirst%3DA.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DZamanillo%26aufirst%3DD.%26atitle%3DEffects%2520of%2520the%2520selective%2520sigma-1%2520receptor%2520antagonist%2520S1RA%2520on%2520formalin-induced%2520pain%2520behavior%2520and%2520neurotransmitter%2520release%2520in%2520the%2520spinal%2520cord%2520in%2520rats%26jtitle%3DJ.%2520Neurochem.%26date%3D2014%26volume%3D129%26spage%3D484%26epage%3D494%26doi%3D10.1111%2Fjnc.12648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bravo-Caparros, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perazzoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeste, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor inhibition reduces neuropathic pain induced by partial sciatic nerve transection in mice by opioid-dependent and -independent mechanisms</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">613</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffphar.2019.00613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31263413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVaqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=613&author=I.+Bravo-Caparrosauthor=G.+Perazzoliauthor=S.+Yesteauthor=D.+Cikesauthor=J.+M.+Baeyensauthor=E.+J.+Cobosauthor=F.+R.+Nieto&title=Sigma-1+receptor+inhibition+reduces+neuropathic+pain+induced+by+partial+sciatic+nerve+transection+in+mice+by+opioid-dependent+and+-independent+mechanisms&doi=10.3389%2Ffphar.2019.00613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor inhibition reduces neuropathic pain induced by partial sciatic nerve transection in mice by opioid-dependent and -independent mechanisms</span></div><div class="casAuthors">Bravo-Caparros, Inmaculada; Perazzoli, Gloria; Yeste, Sandra; Cikes, Domagoj; Baeyens, Jose Manuel; Cobos, Enrique Jose; Nieto, Francisco Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">613</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Sigma-1 (σ1) receptor antagonists are promising tools for neuropathic pain treatment, but it is unknown whether σ1 receptor inhibition ameliorates the neuropathic signs induced by nerve transection, in which the pathophysiol. mechanisms and response to drug treatment differ from other neuropathic pain models.  In addn., σ1 antagonism ameliorates inflammatory pain through modulation of the endogenous opioid system, but it is unknown whether this occurs during neuropathic pain.  We investigated the effect of σ1 inhibition on the painful hypersensitivity assocd. with the spared nerve injury (SNI) model in mice.  Wild-type (WT) mice developed prominent cold (acetone test), mech. (von Frey test), and heat hypersensitivity (Hargreaves test) after SNI. σ1 receptor knockout (σ1-KO) mice did not develop cold allodynia and showed significantly less mech. allodynia, although they developed heat hyperalgesia after SNI.  The systemic acute administration of the selective σ1 receptor antagonist S1RA attenuated all three types of SNI-induced hypersensitivity in WT mice.  These ameliorative effects of S1RA were reversed by the administration of the σ1 agonist PRE-084, and were absent in σ1-KO mice, indicating the selectivity of S1RA-induced effects.  The opioid antagonist naloxone and its peripherally restricted analog naloxone methiodide prevented S1RA-induced effects in mech. and heat hypersensitivity, but not in cold allodynia, indicating that opioid-dependent and -independent mechanisms are involved in the effects of this σ1 antagonist.  The repeated administration of S1RA twice a day during 10 days reduced SNI-induced cold, mech., and heat hypersensitivity without inducing analgesic tolerance during treatment.  These effects were obsd. up to 12 h after the last administration, when S1RA was undetectable in plasma or brain, indicating long-lasting pharmacodynamic effects.  These data suggest that σ1 antagonism may have therapeutic value for the treatment of neuropathic pain induced by the transection of peripheral nerves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEctnyokyyKbVg90H21EOLACvtfcHk0lj4EA9OtoXdrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVaqtLs%253D&md5=2de9eb133abf509e1006d13ebb9d0376</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00613%26sid%3Dliteratum%253Aachs%26aulast%3DBravo-Caparros%26aufirst%3DI.%26aulast%3DPerazzoli%26aufirst%3DG.%26aulast%3DYeste%26aufirst%3DS.%26aulast%3DCikes%26aufirst%3DD.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26atitle%3DSigma-1%2520receptor%2520inhibition%2520reduces%2520neuropathic%2520pain%2520induced%2520by%2520partial%2520sciatic%2520nerve%2520transection%2520in%2520mice%2520by%2520opioid-dependent%2520and%2520-independent%2520mechanisms%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D613%26doi%3D10.3389%2Ffphar.2019.00613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perazzoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1007/s00213-014-3524-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs00213-014-3524-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24639046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=3855-3869&author=M.+A.+Tejadaauthor=A.+Montilla-Garciaauthor=C.+Sanchez-Fernandezauthor=J.+M.+Entrenaauthor=G.+Perazzoliauthor=J.+M.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+receptor+inhibition+reverses+acute+inflammatory+hyperalgesia+in+mice%3A+role+of+peripheral+sigma-1+receptors&doi=10.1007%2Fs00213-014-3524-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors</span></div><div class="casAuthors">Tejada, M. A.; Montilla-Garcia, A.; Sanchez-Fernandez, C.; Entrena, J. M.; Perazzoli, G.; Baeyens, J. M.; Cobos, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Sigma-1 (σ1) receptor inhibition ameliorates neuropathic pain by inhibiting central sensitization.  However, it is unknown whether σ1 receptor inhibition also decreases inflammatory hyperalgesia, or whether peripheral σ1 receptors are involved in this process.  Objective: The purpose of this study was to det. the role of σ1 receptors in carrageenan-induced inflammatory hyperalgesia, particularly at the inflammation site.  Results: The s.c. (s.c.) administration of the selective σ1 antagonists BD-1063 and S1RA to wild-type mice dose-dependently and fully reversed inflammatory mech. (paw pressure) and thermal (radiant heat) hyperalgesia.  These antihyperalgesic effects were abolished by the s.c. administration of the σ1 agonist PRE-084 and also by the intraplantar (i.pl.) administration of this compd. in the inflamed paw, suggesting that blockade of peripheral σ1 receptors in the inflamed site is involved in the antihyperalgesic effects induced by σ1 antagonists.  In fact, the i.pl. administration of σ1 antagonists in the inflamed paw (but not in the contralateral paw) was sufficient to completely reverse inflammatory hyperalgesia. σ1 knockout (σ1-KO) mice did not develop mech. hyperalgesia but developed thermal hypersensitivity; however, the s.c. administration of BD-1063 or S1RA had no effect on thermal hyperalgesia in σ1-KO mice, supporting on-target mechanisms for the effects of both drugs.  The antiedematous effects of σ1 inhibition do not account for the decreased hyperalgesia, since carrageenan-induced edema was unaffected by σ1 knockout or systemic σ1 pharmacol. antagonism.  Conclusions: σ1 receptors play a major role in inflammatory hyperalgesia.  Targeting σ1 receptors in the inflamed tissue may be useful for the treatment of inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTvS0b6PcEhLVg90H21EOLACvtfcHk0lj4EA9OtoXdrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlGlsb4%253D&md5=b62ff92aeee8ae0fbc9a4c1c4d272c82</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3524-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3524-3%26sid%3Dliteratum%253Aachs%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DPerazzoli%26aufirst%3DG.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520receptor%2520inhibition%2520reverses%2520acute%2520inflammatory%2520hyperalgesia%2520in%2520mice%253A%2520role%2520of%2520peripheral%2520sigma-1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D3855%26epage%3D3869%26doi%3D10.1007%2Fs00213-014-3524-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Cantero, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">8396</span>– <span class="NLM_lpage">8401</span>, <span class="refDoi"> DOI: 10.1073/pnas.1620068114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1073%2Fpnas.1620068114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28716934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=8396-8401&author=M.+A.+Tejadaauthor=A.+Montilla-Garciaauthor=S.+J.+Croninauthor=D.+Cikesauthor=C.+Sanchez-Fernandezauthor=R.+Gonzalez-Canoauthor=M.+C.+Ruiz-Canteroauthor=J.+M.+Penningerauthor=J.+M.+Velaauthor=J.+M.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+receptors+control+immune-driven+peripheral+opioid+analgesia+during+inflammation+in+mice&doi=10.1073%2Fpnas.1620068114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice</span></div><div class="casAuthors">Tejada, Miguel A.; Montilla-Garcia, Angeles; Cronin, Shane J.; Cikes, Domagoj; Sanchez-Fernandez, Cristina; Gonzalez-Cano, Rafael; Ruiz-Cantero, M. Carmen; Penninger, Josef M.; Vela, Jose M.; Baeyens, Jose M.; Cobos, Enrique J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">8396-8401</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sigma-1 antagonism potentiates the antinociceptive effects of opioid drugs, so sigma-1 receptors constitute a biol. brake to opioid drug-induced analgesia.  The pathophysiol. role of this process is unknown.  We aimed to investigate whether sigma-1 antagonism reduces inflammatory pain through the disinhibition of the endogenous opioidergic system in mice.  The selective sigma-1 antagonists BD-1063 and S1RA abolished mech. and thermal hyperalgesia in mice with carrageenan-induced acute (3 h) inflammation.  Sigma-1-mediated antihyperalgesia was reversed by the opioid antagonists naloxone and naloxone methiodide (a peripherally restricted naloxone analog) and by local administration at the inflamed site of monoclonal antibody 3-E7, which recognizes the pan-opioid sequence Tyr-Gly-Gly-Phe at the N terminus of most endogenous opioid peptides (EOPs).  Neutrophils expressed pro-opiomelanocortin, the precursor of β-endorphin (a known EOP), and constituted the majority of the acute immune infiltrate. β-endorphin levels increased in the inflamed paw, and this increase and the antihyperalgesic effects of sigma-1 antagonism were abolished by reducing the neutrophil load with in vivo administration of an anti-Ly6G antibody.  The opioid-dependent sigma-1 antihyperalgesic effects were preserved 5 d after carrageenan administration, where macrophages/monocytes were found to express pro-opiomelanocortin and to now constitute the majority of the immune infiltrate.  These results suggest that immune cells harboring EOPs are needed for the antihyperalgesic effects of sigma-1 antagonism during inflammation.  In conclusion, sigma-1 receptors curtail immune-driven peripheral opioid analgesia, and sigma-1 antagonism produces local opioid analgesia by enhancing the action of EOPs of immune origin, maximizing the analgesic potential of immune cells that naturally accumulate in painful inflamed areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktSX7oMTPDrVg90H21EOLACvtfcHk0lhfLPGduBMyaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOru73P&md5=ede5abe4e1e51845e9bd46960a39d54a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1620068114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1620068114%26sid%3Dliteratum%253Aachs%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DCronin%26aufirst%3DS.%2BJ.%26aulast%3DCikes%26aufirst%3DD.%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DGonzalez-Cano%26aufirst%3DR.%26aulast%3DRuiz-Cantero%26aufirst%3DM.%2BC.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520receptors%2520control%2520immune-driven%2520peripheral%2520opioid%2520analgesia%2520during%2520inflammation%2520in%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D8396%26epage%3D8401%26doi%3D10.1073%2Fpnas.1620068114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span> <span> </span><span class="NLM_article-title">Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1121</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2012.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jpain.2012.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23063344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gltr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1107-1121&author=F.+R.+Nietoauthor=C.+M.+Cendanauthor=C.+Sanchez-Fernandezauthor=E.+J.+Cobosauthor=J.+M.+Entrenaauthor=M.+A.+Tejadaauthor=D.+Zamanilloauthor=J.+M.+Velaauthor=J.+M.+Baeyens&title=Role+of+sigma-1+receptors+in+paclitaxel-induced+neuropathic+pain+in+mice&doi=10.1016%2Fj.jpain.2012.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Sigma-1 Receptors in Paclitaxel-Induced Neuropathic Pain in Mice</span></div><div class="casAuthors">Nieto, Francisco Rafael; Cendan, Cruz Miguel; Sanchez-Fernandez, Cristina; Cobos, Enrique Jose; Entrena, Jose Manuel; Tejada, Miguel Angel; Zamanillo, Daniel; Vela, Jose Miguel; Baeyens, Jose Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1107-1121</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sigma-1 (σ1) receptors play a role in different types of pain and in central sensitization mechanisms; however, it is unknown whether they are involved in chemotherapy-induced neuropathic pain.  We compared the ability of paclitaxel to induce cold (acetone test) and mech. (electronic Von Frey test) allodynia in wild-type (WT) and σ1 receptor knockout (σ1-KO) mice.  We also tested the effect on paclitaxel-induced painful neuropathy of BD-1063 (16-64 mg/kg, s.c.) and S1RA (32-128 mg/kg, s.c.), 2 selective σ1 receptor antagonists that bind to the σ1 receptor with high affinity and competitively.  The responses to cold and mech. stimuli were similar in WT and σ1-KO mice not treated with paclitaxel; however, treatment with paclitaxel (2 mg/kg, i.p., once per day during 5 consecutive days) produced cold and mech. allodynia and an increase in spinal cord diphosphorylated extracellular signal-regulated kinase (pERK) in WT but not in σ1-KO mice.  The administration of BD-1063 or S1RA 30 min before each paclitaxel dose prevented the development of cold and mech. allodynia in WT mice.  Moreover, the acute administration of both σ1 receptor antagonists dose dependently reversed both types of paclitaxel-induced allodynia after they had fully developed.  These results suggest that σ1 receptors play a key role in paclitaxel-induced painful neuropathy.  Perspective: Antagonists of the σ1 receptor may have therapeutic value for the treatment and/or prevention of paclitaxel-induced neuropathic pain.  This possibility is esp. interesting in the context of chemotherapy-induced neuropathy, where the onset of nerve damage is predictable and preventive treatment could be administered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHYCYBeIn__bVg90H21EOLACvtfcHk0lhfLPGduBMyaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gltr7I&md5=798467267c69e426eae9df6cde797d6d</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2012.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2012.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DCendan%26aufirst%3DC.%2BM.%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26atitle%3DRole%2520of%2520sigma-1%2520receptors%2520in%2520paclitaxel-induced%2520neuropathic%2520pain%2520in%2520mice%26jtitle%3DJ.%2520Pain%26date%3D2012%26volume%3D13%26spage%3D1107%26epage%3D1121%26doi%3D10.1016%2Fj.jpain.2012.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abadias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escriche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sust, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encina, G.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04333.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fj.1365-2125.2012.04333.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22607269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGmtr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=103-117&author=M.+Abadiasauthor=M.+Escricheauthor=A.+Vaqueauthor=M.+Sustauthor=G.+Encina&title=Safety%2C+tolerability+and+pharmacokinetics+of+single+and+multiple+doses+of+a+novel+sigma-1+receptor+antagonist+in+three+randomized+phase+I+studies&doi=10.1111%2Fj.1365-2125.2012.04333.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies</span></div><div class="casAuthors">Abadias, Montserrat; Escriche, Marisol; Vaque, Anna; Sust, Mariano; Encina, Gregorio</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-117</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • A novel and highly selective sigma-1 receptor antagonist (S1RA) provides a new approach for pain management.  S1RA has shown activity in animal models of neuropathic pain and potentiation of opioid analgesia.  WHAT THIS STUDY ADDS • Phase I studies of single and multiple oral dose administration show that S1RA is safe and well tolerated by healthy subjects.  S1RA is rapidly absorbed and its rate and extent of exposure increases with dose. • The safety, tolerability, pharmacokinetic and pharmacodynamic profiles of S1RA support its further phase II development in different pain indications.  AIM To assess the safety, tolerability, pharmacodynamics and pharmacokinetics in healthy subjects of a novel, highly selective, sigma-1 receptor antagonist (S1RA).  METHODS Three randomized, double-blind, placebo-controlled trials evaluated single oral doses (5-500 mg, study 101; 500-800 mg, study 106) and multiple doses (50-400 mg once daily for 8 days, study 102) of S1RA.  Safety and tolerability were assessed by adverse event reporting, clin. lab., phys. examns., vital signs and electrocardiog., including Holter monitoring.  Pharmacodynamic assessments included computerized cognitive testing.  Plasma samples were analyzed using validated HPLC-MS/MS methods.  RESULTS One hundred and seventy-five subjects were enrolled.  Single and multiple doses were safe and well tolerated, with no serious adverse events.  The most common side effects were headache and dizziness.  The highest single doses were assocd. with some mild to moderate transient CNS effects.  The max. tolerated dose was not reached.  There were no clin. significant changes in the ECG (ECG), 24 h Holter monitoring, or in vital signs and lab. assessments.  Subjective CNS pharmacodynamics evaluations showed no relevant differences vs. placebo.  Cognitive testing showed no effects on visual memory, executive function, attention or somnolence, while revealing some transient slowing of response for simple reaction time and choice reaction time at 2 h following the administration of higher doses.  A fast absorption, rapid distribution and slow elimination were obsd. (tmax 0.75-2.0 h, t1/2 compatible with once a day administration) and steady-state was reached.  No gender differences were obsd.  CONCLUSIONS S1RA exhibited an acceptable safety, tolerability, pharmacodynamic and pharmacokinetic profile in healthy subjects over the dose range studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqhIOMVL8V7Vg90H21EOLACvtfcHk0lhfLPGduBMyaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGmtr%252FI&md5=8d45c779e14abd98d209ecf90fe73caa</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04333.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04333.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbadias%26aufirst%3DM.%26aulast%3DEscriche%26aufirst%3DM.%26aulast%3DVaque%26aufirst%3DA.%26aulast%3DSust%26aufirst%3DM.%26aulast%3DEncina%26aufirst%3DG.%26atitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520single%2520and%2520multiple%2520doses%2520of%2520a%2520novel%2520sigma-1%2520receptor%2520antagonist%2520in%2520three%2520randomized%2520phase%2520I%2520studies%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D103%26epage%3D117%26doi%3D10.1111%2Fj.1365-2125.2012.04333.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyriou, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villoria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalofonos, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sust, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salaman, C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: a randomized, double-blind, placebo-controlled phase IIa clinical trial</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1007/s13311-017-0572-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs13311-017-0572-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28924870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=178-189&author=J.+Brunaauthor=S.+Videlaauthor=A.+A.+Argyriouauthor=R.+Velascoauthor=J.+Villoriaauthor=C.+Santosauthor=C.+Nadalauthor=G.+Cavalettiauthor=P.+Albertiauthor=C.+Brianiauthor=H.+P.+Kalofonosauthor=D.+Cortinovisauthor=M.+Sustauthor=A.+Vaqueauthor=T.+Kleinauthor=C.+Plata-Salaman&title=Efficacy+of+a+novel+sigma-1+receptor+antagonist+for+oxaliplatin-induced+neuropathy%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+IIa+clinical+trial&doi=10.1007%2Fs13311-017-0572-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial</span></div><div class="casAuthors">Bruna, Jordi; Videla, Sebastian; Argyriou, Andreas A.; Velasco, Roser; Villoria, Jesus; Santos, Cristina; Nadal, Cristina; Cavaletti, Guido; Alberti, Paola; Briani, Chiara; Kalofonos, Haralabos P.; Cortinovis, Diego; Sust, Mariano; Vaque, Anna; Klein, Thomas; Plata-Salaman, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This trial assessed the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in ameliorating oxaliplatin-induced peripheral neuropathy (oxaipn).  A discontinuous regimen of MR309 (400 mg/day, 5 days per cycle) was tested in patients with colorectal cancer receiving FOLFOX in a phase II, randomized, double-blind, placebo-controlled, multicenter clin. trial.  Outcome measures included changes in 24-wk quant. measures of thermal sensitivity and total neuropathy score.  In total, 124 patients were randomized (1:1) to MR309 or placebo.  Sixty-three (50.8%) patients withdrew prematurely before completing 12 planned oxaliplatin cycles.  Premature withdrawal because of cancer progression was less frequent in the MR309 group (7.4% vs 25.0% with placebo; p = 0.054).  MR309 significantly reduced cold pain threshold temp. [mean treatment effect difference (SE) vs placebo: 5.29 (1.60)°C; p = 0.001] and suprathreshold cold stimulus-evoked pain intensity [mean treatment effect difference: 1.24 (0.57) points; p = 0.032].  Total neuropathy score, health-related quality-of-life measures, and nerve-conduction parameters changed similarly in both arms, whereas the proportion of patients with severe chronic neuropathy (National Cancer Institute Common Terminol. Criteria for Adverse Events ≥ 3) was significantly lower in the MR309 group (3.0% vs 18.2% with placebo; p = 0.046).  The total amt. of oxaliplatin delivered was greater in the active arm (1618.9 mg vs 1453.8 mg with placebo; p = 0.049).  Overall, 19.0% of patients experienced at least 1 treatment-related adverse event (25.8% and 11.9% with MR309 and placebo, resp.).  Intermittent treatment with MR309 was assocd. with reduced acute oxaipn and higher oxaliplatin exposure, and showed a potential neuroprotective role for chronic cumulative oxaipn.  Furthermore, MR309 showed an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkVyo1fPRe7Vg90H21EOLACvtfcHk0lhNeoEjOUuIDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E&md5=78eac14b1175a004af19c4c9a53af1be</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1007%2Fs13311-017-0572-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-017-0572-5%26sid%3Dliteratum%253Aachs%26aulast%3DBruna%26aufirst%3DJ.%26aulast%3DVidela%26aufirst%3DS.%26aulast%3DArgyriou%26aufirst%3DA.%2BA.%26aulast%3DVelasco%26aufirst%3DR.%26aulast%3DVilloria%26aufirst%3DJ.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DNadal%26aufirst%3DC.%26aulast%3DCavaletti%26aufirst%3DG.%26aulast%3DAlberti%26aufirst%3DP.%26aulast%3DBriani%26aufirst%3DC.%26aulast%3DKalofonos%26aufirst%3DH.%2BP.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DSust%26aufirst%3DM.%26aulast%3DVaque%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DPlata-Salaman%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520a%2520novel%2520sigma-1%2520receptor%2520antagonist%2520for%2520oxaliplatin-induced%2520neuropathy%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520clinical%2520trial%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D178%26epage%3D189%26doi%3D10.1007%2Fs13311-017-0572-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span> <span> </span><span class="NLM_article-title">A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.083543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.105.083543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=15798005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVeju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2005&pages=252-259&author=K.+Hirataauthor=H.+Yamaguchiauthor=Y.+Takamuraauthor=A.+Takagiauthor=T.+Fukushimaauthor=N.+Iwakamiauthor=A.+Saitohauthor=M.+Nakagawaauthor=T.+Yamada&title=A+novel+neurotrophic+agent%2C+T-817MA+%5B1-%7B3-%5B2-%281-benzothiophen-5-yl%29+ethoxy%5D+propyl%7D-3-azetidinol+maleate%5D%2C+attenuates+amyloid-beta-induced+neurotoxicity+and+promotes+neurite+outgrowth+in+rat+cultured+central+nervous+system+neurons&doi=10.1124%2Fjpet.105.083543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons</span></div><div class="casAuthors">Hirata, Kazunari; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">252-259</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Progressive neuronal loss in Alzheimer's disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-β peptides (Aβ).  T-817MA was screened as a candidate therapeutic agent for the treatment of AD based on its neuroprotective potency against Aβ-induced neurotoxicity and its effect of enhancing axonal regeneration in the sciatic nerve axotomy model.  The neuroprotective effect of T-817MA against Aβ(1-42) or oxidative stress-induced neurotoxicity was assessed using a coculture of rat cortical neurons with glia.  T-817MA (0.1 and 1 μM) was strongly protective against Aβ(1-42)-induced (10 μM for 48 h) or H2O2-induced (100 μM for 24 h) neuronal death.  T-817MA suppressed the decrease of GSH levels induced by H2O2 exposure (30 μM for 4 h) in cortical neuron culture; therefore, T-817MA was likely to alleviate oxidative stress.  Besides the neuroprotective effect, T-817MA (0.1 and 1 μM) promoted neurite outgrowth in hippocampal slice cultures and reaggregation culture of rat cortical neurons.  T-817MA also increased the growth-assocd. protein 43 content in the reaggregation culture of cortical neurons.  These findings suggest that T-817MA exerts neuroprotective effect and promotes neurite outgrowth in rat primary cultured neurons.  Based on these neurotrophic features, T-817MA may have a potential for disease modification and be useful for patients with neurodegenerative diseases, such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYEzJ50bSUcbVg90H21EOLACvtfcHk0lhNeoEjOUuIDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVeju7w%253D&md5=bab946365eb087fe5302b3aa91e376d3</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.083543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.083543%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DTakamura%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DIwakami%26aufirst%3DN.%26aulast%3DSaitoh%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DT.%26atitle%3DA%2520novel%2520neurotrophic%2520agent%252C%2520T-817MA%2520%255B1-%257B3-%255B2-%25281-benzothiophen-5-yl%2529%2520ethoxy%255D%2520propyl%257D-3-azetidinol%2520maleate%255D%252C%2520attenuates%2520amyloid-beta-induced%2520neurotoxicity%2520and%2520promotes%2520neurite%2520outgrowth%2520in%2520rat%2520cultured%2520central%2520nervous%2520system%2520neurons%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D314%26spage%3D252%26epage%3D259%26doi%3D10.1124%2Fjpet.105.083543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ago, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nashida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, T.</span></span> <span> </span><span class="NLM_article-title">A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.05.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuropharm.2008.05.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18573265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFajtbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=654-660&author=T.+Kawasakiauthor=Y.+Agoauthor=T.+Kitaoauthor=T.+Nashidaauthor=A.+Takagiauthor=K.+Takumaauthor=T.+Matsuda&title=A+neuroprotective+agent%2C+T-817MA+%281-%7B3-%5B2-%281-benzothiophen-5-yl%29ethoxy%5Dpropyl%7D+azetidin-3-ol+maleate%29%2C+prevents+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine-induced+neurotoxicity+in+mice&doi=10.1016%2Fj.neuropharm.2008.05.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice</span></div><div class="casAuthors">Kawasaki, Toshiyuki; Ago, Yukio; Kitao, Tatsuya; Nashida, Tetsuaki; Takagi, Akiko; Takuma, Kazuhiro; Matsuda, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">654-660</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate) is a candidate therapeutic agent for Alzheimer's disease that inhibits oxidative stress and nitric oxide-induced neurotoxicity and acts as a neurotrophic factor.  The present study examines the effect of T-817MA on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in C57BL/6J mice.  MPTP treatment (10 mg/kg, s.c. × 4 at 2-h intervals) impaired rotarod performance, and T-817MA improved this deficit.  MPTP treatment also decreased dopamine levels and tyrosine hydroxylase immunostaining in the substantia nigra (SNc) and striatum.  Pretreatment with T-817MA (10 and 30 mg/kg as T-817, p.o.) attenuated these decreases in dopamine levels and tyrosine hydroxylase immunoreactivity, but did not affect brain levels of 1-methyl-4-phenylpyridinium ion, an active metabolite of MPTP.  The protective effect was almost complete in the SNc, but only partial in the striatum.  MPTP increased levels of the lipid peroxidn. product, thiobarbituric acid reactive substance, only in the midbrain, which could be blocked by T-817MA.  MPTP caused microglial activation both in the SNc and striatum, but T-817MA did not affect the activation of microglia.  These results suggest that T-817MA protects against MPTP-induced neurotoxicity by blocking lipid peroxidn. in the SNc, and imply that this compd. may be useful for treating neurodegenerative disorders related to oxidative stress, such as Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4gZyqmnlb97Vg90H21EOLACvtfcHk0lhNeoEjOUuIDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFajtbfN&md5=4d2d266525503b585977551e517019b7</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.05.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.05.032%26sid%3Dliteratum%253Aachs%26aulast%3DKawasaki%26aufirst%3DT.%26aulast%3DAgo%26aufirst%3DY.%26aulast%3DKitao%26aufirst%3DT.%26aulast%3DNashida%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DTakuma%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DT.%26atitle%3DA%2520neuroprotective%2520agent%252C%2520T-817MA%2520%25281-%257B3-%255B2-%25281-benzothiophen-5-yl%2529ethoxy%255Dpropyl%257D%2520azetidin-3-ol%2520maleate%2529%252C%2520prevents%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine-induced%2520neurotoxicity%2520in%2520mice%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D55%26spage%3D654%26epage%3D660%26doi%3D10.1016%2Fj.neuropharm.2008.05.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong Nguyen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishijo, H.</span></span> <span> </span><span class="NLM_article-title">T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-beta peptide</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00141.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fj.1476-5381.2009.00141.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19371351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Ggtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2009&pages=451-463&author=T.+Kimuraauthor=P.+T.+Hong+Nguyenauthor=S.+A.+Hoauthor=A.+H.+Tranauthor=T.+Onoauthor=H.+Nishijo&title=T-817MA%2C+a+neurotrophic+agent%2C+ameliorates+the+deficits+in+adult+neurogenesis+and+spatial+memory+in+rats+infused+i.c.v.+with+amyloid-beta+peptide&doi=10.1111%2Fj.1476-5381.2009.00141.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-β peptide</span></div><div class="casAuthors">Kimura, Tatsuo; Nguyen, Phuong Thi Hong; Ho, Son Anh; Tran, Anh Hai; Ono, Taketoshi; Nishijo, Hisao</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-463</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: Adult neurogenesis occurs throughout life in the subgranular zone and the dentate gyrus of the hippocampus.  Deficient neurogenesis may be responsible for deficient hippocampal functions in neurodegenerative disorders such as Alzheimer's disease (AD).  T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate] is a newly synthesized agent for AD treatment with neuroprotective effects against toxicity from amyloid-β peptide (Aβ) and actions promoting neurite outgrowth in vitro.  Furthermore, systemic administration of T-817MA ameliorated cognitive dysfunctions caused by neurodegeneration in a rat model of AD, induced by intracerebroventricular (i.c.v.) infusion of Aβ.  The present study investigated quant. relationships between spatial memory performance in Aβ-infused rats and hippocampal neurogenesis, and the effects of T-817MA on neuronal proliferation in vivo.  Exptl. approach: Seven weeks after infusion of Aβ (peptide 1-40; 300 pmol/day-1; i.c.v.), rats were tested in a place learning task in which they were required to alternately visit two reward places in an open field to obtain intracranial self-stimulation as rewards.  Key results: Rats given Aβ infusions for 10 wk displayed spatial memory impairments and a decrease in neurogenesis compared with those infused with vehicle.  Treatment of the Aβ-infused rats with T-817MA (8.4 mg/kg-1/day-1, p.o.) significantly increased hippocampal neurogenesis and ameliorated spatial learning impairments.  Furthermore, spatial learning in the task was significantly correlated with neurogenesis.  Conclusions and implications: These results suggest that defective hippocampal neurogenesis is a new target for AD treatment.  The neurotrophic compd. T-817MA increased hippocampal neurogenesis in an AD model and might be useful for treatment of AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotNB9EkGRF4rVg90H21EOLACvtfcHk0lg-7zE51EOlTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Ggtr8%253D&md5=0a1d5f87d9212061cc7238fd82ef3213</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00141.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00141.x%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DHong%2BNguyen%26aufirst%3DP.%2BT.%26aulast%3DHo%26aufirst%3DS.%2BA.%26aulast%3DTran%26aufirst%3DA.%2BH.%26aulast%3DOno%26aufirst%3DT.%26aulast%3DNishijo%26aufirst%3DH.%26atitle%3DT-817MA%252C%2520a%2520neurotrophic%2520agent%252C%2520ameliorates%2520the%2520deficits%2520in%2520adult%2520neurogenesis%2520and%2520spatial%2520memory%2520in%2520rats%2520infused%2520i.c.v.%2520with%2520amyloid-beta%2520peptide%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D157%26spage%3D451%26epage%3D463%26doi%3D10.1111%2Fj.1476-5381.2009.00141.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishijo, H.</span></span> <span> </span><span class="NLM_article-title">Effects of the neurotrophic agent T-817MA on oligomeric amyloid-beta-induced deficits in long-term potentiation in the hippocampal CA1 subfield</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2013.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neurobiolaging.2013.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24112791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyrsbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=532-536&author=Y.+Takamuraauthor=K.+Onoauthor=J.+Matsumotoauthor=M.+Yamadaauthor=H.+Nishijo&title=Effects+of+the+neurotrophic+agent+T-817MA+on+oligomeric+amyloid-beta-induced+deficits+in+long-term+potentiation+in+the+hippocampal+CA1+subfield&doi=10.1016%2Fj.neurobiolaging.2013.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the neurotrophic agent T-817MA on oligomeric amyloid-β-induced deficits in long-term potentiation in the hippocampal CA1 subfield</span></div><div class="casAuthors">Takamura, Yusaku; Ono, Kenjiro; Matsumoto, Jumpei; Yamada, Masahito; Nishijo, Hisao</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">532-536</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Formation of oligomeric amyloid-β (oAβ) is 1 of the most likely causes of Alzheimer's disease (AD).  We hypothesized that in the early phase of AD, cognitive impairments obsd. before marked neuronal loss and brain atrophy might be assocd. with oAβ-induced synaptic dysfunction.  T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol maleate] has both neuroprotective and neurotrophic effects and is used to treat AD.  Although T-817MA has been shown to ameliorate amyloid-induced learning deficits in exptl. AD models, it remains unclear whether this drug would be able to prevent oAβ-induced synaptotoxicity.  In the present study, we investigated the effects of T-817MA on the disturbances in synaptic plasticity induced by oAβ42 and oligomeric photo-cross-linked Aβ42 (oXLAβ42) in a slice prepn. of the CA1 subfield of mouse hippocampus.  Both oAβ42 and oXLAβ42 treatments significantly reduced the induction of long-term potentiation (LTP).  In addn., oAβ42 treatment significantly facilitated long-term depression (LTD).  Treatment with T-817MA ameliorated the LTP redn.; however, T-817MA treatment did not inhibit the facilitation of LTD induction by oAβ42.  These results suggest that T-817MA reverses oAβ-induced LTP redn. as it may occur in the early phase of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDKgeJSLqR17Vg90H21EOLACvtfcHk0lg-7zE51EOlTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyrsbjM&md5=6ba73c8065dd3d048a9e5166102d1fcf</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2013.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2013.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DTakamura%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DJ.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DNishijo%26aufirst%3DH.%26atitle%3DEffects%2520of%2520the%2520neurotrophic%2520agent%2520T-817MA%2520on%2520oligomeric%2520amyloid-beta-induced%2520deficits%2520in%2520long-term%2520potentiation%2520in%2520the%2520hippocampal%2520CA1%2520subfield%26jtitle%3DNeurobiol.%2520Aging%26date%3D2014%26volume%3D35%26spage%3D532%26epage%3D536%26doi%3D10.1016%2Fj.neurobiolaging.2013.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terashima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, H.</span></span> <span> </span><span class="NLM_article-title">T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2011.03.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbrc.2011.03.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21439944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFCjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2011&pages=730-734&author=T.+Fukushimaauthor=A.+Nakamuraauthor=N.+Iwakamiauthor=Y.+Nakadaauthor=H.+Hattoriauthor=S.+Hokiauthor=H.+Yamaguchiauthor=M.+Nakagawaauthor=N.+Terashimaauthor=H.+Narita&title=T-817MA%2C+a+neuroprotective+agent%2C+attenuates+the+motor+and+cognitive+impairments+associated+with+neuronal+degeneration+in+P301L+tau+transgenic+mice&doi=10.1016%2Fj.bbrc.2011.03.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice</span></div><div class="casAuthors">Fukushima, Tetsuo; Nakamura, Asako; Iwakami, Noboru; Nakada, Yasushi; Hattori, Hiroshi; Hoki, Satoru; Yamaguchi, Hidetoshi; Nakagawa, Masaya; Terashima, Nobuo; Narita, Hirokazu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">730-734</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tau pathol. is implicated in mechanisms of neurodegenerative tauopathies, including Alzheimer's disease (AD) and hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).  It was reported that transgenic mice expressing FTDP-17 mutation P301L of human tau (P301L mice) display extensive tau pathol. and exhibit behavioral deficits with aging.  In this study, we investigated the effects of T-817MA, a neuroprotective agent, on the motor and cognitive impairments assocd. with neuronal degeneration in P301L mice.  T-817MA prevented the progression of motor deficit and the loss of spinal cord motor neurons in P301L mice.  Furthermore, T-817MA significantly attenuated the spatial memory impairment and the redn. in synaptic terminal d. in the hippocampal dentate gyrus of P301L mice.  These results indicate that T-817MA improved the motor and cognitive impairments as a result of inhibiting neuronal degeneration derived from tau pathol. in the P301L mice.  Therefore, it is expected that T-817MA has a therapeutic potential for tau-related neurodegenerative diseases such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNXAV7gTEydbVg90H21EOLACvtfcHk0lg-7zE51EOlTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFCjsrk%253D&md5=ae64959ce423238551cb56c0d77be371</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2011.03.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2011.03.091%26sid%3Dliteratum%253Aachs%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DIwakami%26aufirst%3DN.%26aulast%3DNakada%26aufirst%3DY.%26aulast%3DHattori%26aufirst%3DH.%26aulast%3DHoki%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DTerashima%26aufirst%3DN.%26aulast%3DNarita%26aufirst%3DH.%26atitle%3DT-817MA%252C%2520a%2520neuroprotective%2520agent%252C%2520attenuates%2520the%2520motor%2520and%2520cognitive%2520impairments%2520associated%2520with%2520neuronal%2520degeneration%2520in%2520P301L%2520tau%2520transgenic%2520mice%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2011%26volume%3D407%26spage%3D730%26epage%3D734%26doi%3D10.1016%2Fj.bbrc.2011.03.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitsuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitsuki-Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochizuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span> <span> </span><span class="NLM_article-title">CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1126/science.aao2300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1126%2Fscience.aao2300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29622647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmvFamsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2018&pages=50-57&author=H.+Abeauthor=S.+Jitsukiauthor=W.+Nakajimaauthor=Y.+Murataauthor=A.+Jitsuki-Takahashiauthor=Y.+Katsunoauthor=H.+Tadaauthor=A.+Sanoauthor=K.+Suyamaauthor=N.+Mochizukiauthor=T.+Komoriauthor=H.+Masuyamaauthor=T.+Okudaauthor=Y.+Goshimaauthor=N.+Higoauthor=T.+Takahashi&title=CRMP2-binding+compound%2C+edonerpic+maleate%2C+accelerates+motor+function+recovery+from+brain+damage&doi=10.1126%2Fscience.aao2300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage</span></div><div class="casAuthors">Abe, Hiroki; Jitsuki, Susumu; Nakajima, Waki; Murata, Yumi; Jitsuki-Takahashi, Aoi; Katsuno, Yuki; Tada, Hirobumi; Sano, Akane; Suyama, Kumiko; Mochizuki, Nobuyuki; Komori, Takashi; Masuyama, Hitoshi; Okuda, Tomohiro; Goshima, Yoshio; Higo, Noriyuki; Takahashi, Takuya</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">6384</span>),
    <span class="NLM_cas:pages">50-57</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Brain damage such as stroke is a devastating neurol. condition that may severely compromise patient quality of life.  No effective medication-mediated intervention to accelerate rehabilitation has been established.  The authors found that a small compd., edonerpic maleate, facilitated experience-driven synaptic glutamate AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic-acid) receptor delivery and resulted in the acceleration of motor function recovery after motor cortex cryoinjury in mice in a training-dependent manner through cortical reorganization.  Edonerpic bound to collapsin-response-mediator-protein 2 (CRMP2) and failed to augment recovery in CRMP2-deficient mice.  Edonerpic maleate enhanced motor function recovery from internal capsule hemorrhage in nonhuman primates.  Thus, edonerpic maleate, a neural plasticity enhancer, could be a clin. potent small compd. with which to accelerate rehabilitation after brain damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBtDXtc6Rd1LVg90H21EOLACvtfcHk0ljVdtxtGAf7Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmvFamsLk%253D&md5=f3a598e5c07cc2c1617c9a0a32f94fa9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.aao2300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aao2300%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DJitsuki%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DW.%26aulast%3DMurata%26aufirst%3DY.%26aulast%3DJitsuki-Takahashi%26aufirst%3DA.%26aulast%3DKatsuno%26aufirst%3DY.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DSano%26aufirst%3DA.%26aulast%3DSuyama%26aufirst%3DK.%26aulast%3DMochizuki%26aufirst%3DN.%26aulast%3DKomori%26aufirst%3DT.%26aulast%3DMasuyama%26aufirst%3DH.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DGoshima%26aufirst%3DY.%26aulast%3DHigo%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DT.%26atitle%3DCRMP2-binding%2520compound%252C%2520edonerpic%2520maleate%252C%2520accelerates%2520motor%2520function%2520recovery%2520from%2520brain%2520damage%26jtitle%3DScience%26date%3D2018%26volume%3D360%26spage%3D50%26epage%3D57%26doi%3D10.1126%2Fscience.aao2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabetani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor is a molecular target for novel neuroprotectant T-817MA</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">P861</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2015.08.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jalz.2015.08.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=P861&author=T.+Yanoauthor=H.+Tanabeauthor=K.+Kobayashiauthor=H.+Kobayashiauthor=A.+Nabetaniauthor=Y.+Sakaiauthor=T.+Okudaauthor=M.+Nakagawaauthor=T.+Nakamura&title=Sigma-1+receptor+is+a+molecular+target+for+novel+neuroprotectant+T-817MA&doi=10.1016%2Fj.jalz.2015.08.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2015.08.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2015.08.038%26sid%3Dliteratum%253Aachs%26aulast%3DYano%26aufirst%3DT.%26aulast%3DTanabe%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DNabetani%26aufirst%3DA.%26aulast%3DSakai%26aufirst%3DY.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DSigma-1%2520receptor%2520is%2520a%2520molecular%2520target%2520for%2520novel%2520neuroprotectant%2520T-817MA%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2015%26volume%3D11%26spage%3DP861%26doi%3D10.1016%2Fj.jalz.2015.08.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rissman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oltersdorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, H. H.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of Edonerpic maleate for patients with mild to moderate Alzheimer disease: a phase 2 randomized clinical trial</span>. <i>JAMA Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1330</span>– <span class="NLM_lpage">1339</span>, <span class="refDoi"> DOI: 10.1001/jamaneurol.2019.1868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1001%2Fjamaneurol.2019.1868" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2019&pages=1330-1339&author=L.+S.+Schneiderauthor=R.+G.+Thomasauthor=S.+Hendrixauthor=R.+A.+Rissmanauthor=J.+B.+Brewerauthor=D.+P.+Salmonauthor=T.+Oltersdorfauthor=T.+Okudaauthor=H.+H.+Feldman&title=Safety+and+efficacy+of+Edonerpic+maleate+for+patients+with+mild+to+moderate+Alzheimer+disease%3A+a+phase+2+randomized+clinical+trial&doi=10.1001%2Fjamaneurol.2019.1868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1001%2Fjamaneurol.2019.1868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaneurol.2019.1868%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DL.%2BS.%26aulast%3DThomas%26aufirst%3DR.%2BG.%26aulast%3DHendrix%26aufirst%3DS.%26aulast%3DRissman%26aufirst%3DR.%2BA.%26aulast%3DBrewer%26aufirst%3DJ.%2BB.%26aulast%3DSalmon%26aufirst%3DD.%2BP.%26aulast%3DOltersdorf%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DFeldman%26aufirst%3DH.%2BH.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520Edonerpic%2520maleate%2520for%2520patients%2520with%2520mild%2520to%2520moderate%2520Alzheimer%2520disease%253A%2520a%2520phase%25202%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA%2520Neurol.%26date%3D2019%26volume%3D76%26spage%3D1330%26epage%3D1339%26doi%3D10.1001%2Fjamaneurol.2019.1868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaiel, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">el-Ashmawy, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, K. B.</span></span> <span> </span><span class="NLM_article-title">Structural features important for sigma 1 receptor binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1214</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1021/jm00034a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00034a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK2cXksV2lsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1214-1219&author=R.+A.+Glennonauthor=S.+Y.+Ablordeppeyauthor=A.+M.+Ismaielauthor=M.+B.+el-Ashmawyauthor=J.+B.+Fischerauthor=K.+B.+Howie&title=Structural+features+important+for+sigma+1+receptor+binding&doi=10.1021%2Fjm00034a020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Features Important for σ1 Receptor Binding</span></div><div class="casAuthors">Glennon, Richard A.; Ablordeppey, Seth Y.; Ismaiel, Abd M.; El-Ashmawy, Mahmoud B.; Fischer, James B.; Howie, Kathleen Burke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1214-19</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Two problems that have hampered σ receptor research are a lack of high-affinity agents and the recent identification of multiple populations of σ receptors (i.e., σ1 and σ2 sites).  Recently, several high-affinity σ ligands have been identified, and the term superpotent σ ligands has been coined to describe agents with Ki values of <1 nM.  It was previously shown that appropriately N-substituted phenylalkylamines bind at σ receptors with high affinity.  The structure-affinity relationships of these phenylalkylamine derivs. for σ1 binding are examd. and some of the first superpotent σ1 ligands described.  A binding model was developed to account for the structural features of the phenylalkylamines that appear to be important for the interaction of these agents with σ1 sites.  Some of the amines were prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6nnZHspQ0MLVg90H21EOLACvtfcHk0lju8AO100mIPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksV2lsrY%253D&md5=3c9b4ff203d7c304da3779a874837bf5</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm00034a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00034a020%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DIsmaiel%26aufirst%3DA.%2BM.%26aulast%3Del-Ashmawy%26aufirst%3DM.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BB.%26aulast%3DHowie%26aufirst%3DK.%2BB.%26atitle%3DStructural%2520features%2520important%2520for%2520sigma%25201%2520receptor%2520binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1214%26epage%3D1219%26doi%3D10.1021%2Fjm00034a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the “deconstruction-reconstruction-elaboration” approach</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.2174/138955705774329519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F138955705774329519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16250835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWku7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=927-940&author=R.+A.+Glennon&title=Pharmacophore+identification+for+sigma-1+%28sigma1%29+receptor+binding%3A+application+of+the+%E2%80%9Cdeconstruction-reconstruction-elaboration%E2%80%9D+approach&doi=10.2174%2F138955705774329519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore identification for sigma-1 (σ1) receptor binding: Application of the deconstruction - reconstruction - elaboration approach</span></div><div class="casAuthors">Glennon, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">927-940</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  At least two different types of sigma σ (σ1 and σ2) receptors have been identified.  A structural feature common to high-affinity (Ki <10 nM) σ1 ligands is: C-N(R)-X-Ph; both C and Ph are assocd. with regions of bulk tolerance.  Numerous other ligands bind, but typically do so with lower affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot_9JlDBLhrbVg90H21EOLACvtfcHk0lju8AO100mIPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWku7rM&md5=66ae2e51d57fa97cd3954ae90e7e3167</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.2174%2F138955705774329519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774329519%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DPharmacophore%2520identification%2520for%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520binding%253A%2520application%2520of%2520the%2520%25E2%2580%259Cdeconstruction-reconstruction-elaboration%25E2%2580%259D%2520approach%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D927%26epage%3D940%26doi%3D10.2174%2F138955705774329519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posocco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paneni, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3<i>H</i>)-one derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5380</span>– <span class="NLM_lpage">5393</span>, <span class="refDoi"> DOI: 10.1021/jm900366z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900366z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpslaht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5380-5393&author=D.+Zampieriauthor=M.+G.+Mamoloauthor=E.+Lauriniauthor=C.+Florioauthor=C.+Zanetteauthor=M.+Fermegliaauthor=P.+Posoccoauthor=M.+S.+Paneniauthor=S.+Priclauthor=L.+Vio&title=Synthesis%2C+biological+evaluation%2C+and+three-dimensional+in+silico+pharmacophore+model+for+sigma%281%29+receptor+ligands+based+on+a+series+of+substituted+benzo%5Bd%5Doxazol-2%283H%29-one+derivatives&doi=10.1021%2Fjm900366z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Three-Dimensional in Silico Pharmacophore Model for σ1 Receptor Ligands Based on a Series of Substituted Benzo[d]oxazol-2(3H)-one Derivatives</span></div><div class="casAuthors">Zampieri, Daniele; Mamolo, Maria Grazia; Laurini, Erik; Florio, Chiara; Zanette, Caterina; Fermeglia, Maurizio; Posocco, Paola; Paneni, Maria Silvia; Pricl, Sabrina; Vio, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5380-5393</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel benzo[d]oxazol-2(3H)-one derivs. were designed and synthesized, and their affinities against σ receptors were evaluated.  On the basis of 31 compds., a three-dimensional pharmacophore model for the σ1 receptor binding site was developed using the Catalyst 4.9 software package.  The best 3D pharmacophore hypothesis, consisting of one pos. ionizable, one hydrogen bond acceptor, two hydrophobic arom., and one hydrophobic features provided a 3D-QSAR model with a correlation coeff. of 0.89.  The best hypothesis was also validated by three independent methods, i.e., the Fisher randomization test included in the CatScramble functionality of Catalyst, the leave-one-out test, and activity prediction of an addnl. test set.  The achieved results will allow researchers to use this 3D pharmacophore model for the design and synthesis of a second generation of high affinity σ1 ligands, as well as to discover other lead compds. for this class of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ7dYDBRve47Vg90H21EOLACvtfcHk0lju8AO100mIPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpslaht78%253D&md5=678e879dd9b79c55fc61bfec02d3b927</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm900366z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900366z%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFlorio%26aufirst%3DC.%26aulast%3DZanette%26aufirst%3DC.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPosocco%26aufirst%3DP.%26aulast%3DPaneni%26aufirst%3DM.%2BS.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DVio%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520three-dimensional%2520in%2520silico%2520pharmacophore%2520model%2520for%2520sigma%25281%2529%2520receptor%2520ligands%2520based%2520on%2520a%2520series%2520of%2520substituted%2520benzo%255Bd%255Doxazol-2%25283H%2529-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5380%26epage%3D5393%26doi%3D10.1021%2Fjm900366z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Col, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span> <span> </span><span class="NLM_article-title">Another brick in the wall. Validation of the sigma1 receptor 3D model by computer-assisted design, synthesis, and activity of new sigma1 ligands</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3107</span>– <span class="NLM_lpage">3126</span>, <span class="refDoi"> DOI: 10.1021/mp300233y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300233y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVamt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=3107-3126&author=E.+Lauriniauthor=D.+Marsonauthor=V.+Dal+Colauthor=M.+Fermegliaauthor=M.+G.+Mamoloauthor=D.+Zampieriauthor=L.+Vioauthor=S.+Pricl&title=Another+brick+in+the+wall.+Validation+of+the+sigma1+receptor+3D+model+by+computer-assisted+design%2C+synthesis%2C+and+activity+of+new+sigma1+ligands&doi=10.1021%2Fmp300233y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Another Brick in the Wall. Validation of the σ1 Receptor 3D Model by Computer-Assisted Design, Synthesis, and Activity of New σ1 Ligands</span></div><div class="casAuthors">Laurini, Erik; Marson, Domenico; Dal Col, Valentina; Fermeglia, Maurizio; Mamolo, Maria Grazia; Zampieri, Daniele; Vio, Luciano; Pricl, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3107-3126</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Originally considered an enigmatic polypeptide, the σ1 receptor has recently been identified as a unique ligand-regulated protein.  Many studies have shown the potential of σ1 receptor ligands for the treatment of various diseases of the central nervous system (CNS); nevertheless, almost no information about the 3D structure of the receptor and/or the possible modes of interaction of the σ1 protein with its ligands have been unveiled so far.  With the present work we validated our σ1 3D homol. model and assessed its reliability as a platform for σ1 ligand structure-based drug design.  To this purpose, the 3D σ1 model was exploited in the design of 33 new σ1 ligands and in their ranking for receptor affinity by extensive mol. dynamics simulation-based free energy calcns.  Also, the main interactions involved in receptor/ligand binding were analyzed by applying a per residue free energy deconvolution and in silico alanine scanning mutagenesis calcns.  Subsequently, all compds. were synthesized in our lab. and tested for σ1 binding activity in vitro.  The agreement between in silico and in vitro results confirms the reliability of the proposed σ1 3D model in the a priori prediction of the affinity of new σ1 ligands.  Moreover, it also supports and corroborates the currently available biochem. data concerning the σ1 protein residues considered essential for σ1 ligand binding and activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7eSBYAAydoLVg90H21EOLACvtfcHk0liv2xspwC9Cbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVamt7fL&md5=9f3867b8cbfc2d063a07d1b55fb8354d</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fmp300233y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300233y%26sid%3Dliteratum%253Aachs%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DMarson%26aufirst%3DD.%26aulast%3DDal%2BCol%26aufirst%3DV.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DPricl%26aufirst%3DS.%26atitle%3DAnother%2520brick%2520in%2520the%2520wall.%2520Validation%2520of%2520the%2520sigma1%2520receptor%25203D%2520model%2520by%2520computer-assisted%2520design%252C%2520synthesis%252C%2520and%2520activity%2520of%2520new%2520sigma1%2520ligands%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D3107%26epage%3D3126%26doi%3D10.1021%2Fmp300233y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichiara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittala, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span> <span> </span><span class="NLM_article-title">Hyphenated 3D-QSAR statistical model-scaffold hopping analysis for the identification of potentially potent and selective sigma-2 receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2017.08.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28866257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyrurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=884-891&author=G.+Florestaauthor=A.+Rescifinaauthor=A.+Marrazzoauthor=M.+Dichiaraauthor=V.+Pistaraauthor=V.+Pittalaauthor=O.+Prezzaventoauthor=E.+Amata&title=Hyphenated+3D-QSAR+statistical+model-scaffold+hopping+analysis+for+the+identification+of+potentially+potent+and+selective+sigma-2+receptor+ligands&doi=10.1016%2Fj.ejmech.2017.08.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Hyphenated 3D-QSAR statistical model-scaffold hopping analysis for the identification of potentially potent and selective sigma-2 receptor ligands</span></div><div class="casAuthors">Floresta, Giuseppe; Rescifina, Antonio; Marrazzo, Agostino; Dichiara, Maria; Pistara, Venerando; Pittala, Valeria; Prezzavento, Orazio; Amata, Emanuele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">884-891</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A 3D quant. structure-activity relationship (3D-QSAR) model for predicting the σ2 receptor affinity has been constructed with the aim of providing a useful tool for the identification, design, and optimization of novel σ2 receptor ligands.  The model has been built using a set of 500 selective σ2 receptor ligands recovered from the sigma-2 receptor selective ligand database (S2RSLDB) and developed with the software Forge.  The present model showed high statistical quality as confirmed by its robust predictive potential and satisfactory descriptive capability.  The drawn up 3D map allows for a prompt visual comprehension of the electrostatic, hydrophobic, and shaping features underlying σ2 receptor ligands interaction.  A theoretic approach for the generation of new lead compds. with optimized σ2 receptor affinity has been performed by means of scaffold hopping anal.  Obtained results further confirmed the validity of our model being some of the identified moieties have already been successfully employed in the development of potent σ2 receptor ligands.  For the first time is herein reported a 3D-QSAR model which includes a no. of chem. diverse σ2 receptor ligands and well accounts for the individual ligands affinities.  These features will ensure prospectively advantageous applications to speed up the identification of new potent and selective σ2 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS4b9EH7P7C7Vg90H21EOLACvtfcHk0liv2xspwC9Cbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyrurzO&md5=dcad5568aa0ec2111284f295c216e4e9</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.053%26sid%3Dliteratum%253Aachs%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26aulast%3DMarrazzo%26aufirst%3DA.%26aulast%3DDichiara%26aufirst%3DM.%26aulast%3DPistara%26aufirst%3DV.%26aulast%3DPittala%26aufirst%3DV.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DAmata%26aufirst%3DE.%26atitle%3DHyphenated%25203D-QSAR%2520statistical%2520model-scaffold%2520hopping%2520analysis%2520for%2520the%2520identification%2520of%2520potentially%2520potent%2520and%2520selective%2520sigma-2%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D884%26epage%3D891%26doi%3D10.1016%2Fj.ejmech.2017.08.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kniess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietzsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">(18)F-Labeled 1,4-dioxa-8-azaspiro[4.5]decane derivative: synthesis and biological evaluation of a sigma1 receptor radioligand with low lipophilicity as potent tumor imaging agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5395</span>– <span class="NLM_lpage">5407</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00593</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00593" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKisbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5395-5407&author=F.+Xieauthor=R.+Bergmannauthor=T.+Kniessauthor=W.+Deuther-Conradauthor=C.+Mamatauthor=C.+Neuberauthor=B.+Liuauthor=J.+Steinbachauthor=P.+Brustauthor=J.+Pietzschauthor=H.+Jia&title=%2818%29F-Labeled+1%2C4-dioxa-8-azaspiro%5B4.5%5Ddecane+derivative%3A+synthesis+and+biological+evaluation+of+a+sigma1+receptor+radioligand+with+low+lipophilicity+as+potent+tumor+imaging+agent&doi=10.1021%2Facs.jmedchem.5b00593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">18F-Labeled 1,4-Dioxa-8-azaspiro[4.5]decane Derivative: Synthesis and Biological Evaluation of a σ1 Receptor Radioligand with Low Lipophilicity as Potent Tumor Imaging Agent</span></div><div class="casAuthors">Xie, Fang; Bergmann, Ralf; Kniess, Torsten; Deuther-Conrad, Winnie; Mamat, Constantin; Neuber, Christin; Liu, Boli; Steinbach, Joerg; Brust, Peter; Pietzsch, Jens; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5395-5407</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the syntheses and evaluation of series of novel piperidine compds., e.g., I (R = Me, H, OH, CH2OH, n = 3, 4), with low lipophilicity as σ1 receptor ligands.  8-[4-(2-Fluoroethoxy)benzyl]-1,4-dioxa-8-azaspiro[4.5]decane (II) possessed high affinity (Ki = 5.4 ± 0.4 nM) for σ1 receptors and selectivity for σ2 receptors (30-fold) and the vesicular acetylcholine transporter (1404-fold).  [18F]II was prepd. using a one-pot, two-step labeling procedure in an automated synthesis module, with a radiochem. purity of >95%, and a specific activity of 25-45 GBq/μmol.  Cellular assocn., biodistribution, and autoradiog. with blocking expts. indicated specific binding of [18F]II to σ1 receptors in vitro and in vivo.  Small animal positron emission tomog. (PET) imaging using mouse tumor xenograft models demonstrated a high accumulation in human carcinoma and melanoma.  Treatment with haloperidol significantly reduced the accumulation of the radiotracer in tumors.  These findings suggest that radiotracer with suitable lipophilicity and appropriate affinity for σ1 receptors could be used for tumor imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTTJrIl8aEvLVg90H21EOLACvtfcHk0liv2xspwC9Cbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKisbvE&md5=78e4f3a3b01064869e696fe4615998b3</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00593%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DF.%26aulast%3DBergmann%26aufirst%3DR.%26aulast%3DKniess%26aufirst%3DT.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DMamat%26aufirst%3DC.%26aulast%3DNeuber%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DPietzsch%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DH.%26atitle%3D%252818%2529F-Labeled%25201%252C4-dioxa-8-azaspiro%255B4.5%255Ddecane%2520derivative%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520sigma1%2520receptor%2520radioligand%2520with%2520low%2520lipophilicity%2520as%2520potent%2520tumor%2520imaging%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5395%26epage%3D5407%26doi%3D10.1021%2Facs.jmedchem.5b00593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">1-(4-[(18)F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: a novel suitable radioligand with low lipophilicity for imaging sigma1 receptors in the brain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4161</span>– <span class="NLM_lpage">4172</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4161-4172&author=Y.+Heauthor=F.+Xieauthor=J.+Yeauthor=W.+Deuther-Conradauthor=B.+Cuiauthor=L.+Wangauthor=J.+Luauthor=J.+Steinbachauthor=P.+Brustauthor=Y.+Huangauthor=J.+Luauthor=H.+Jia&title=1-%284-%5B%2818%29F%5DFluorobenzyl%29-4-%5B%28tetrahydrofuran-2-yl%29methyl%5Dpiperazine%3A+a+novel+suitable+radioligand+with+low+lipophilicity+for+imaging+sigma1+receptors+in+the+brain&doi=10.1021%2Facs.jmedchem.6b01723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">1-(4-[18F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: A Novel Suitable Radioligand with Low Lipophilicity for Imaging σ1 Receptors in the Brain</span></div><div class="casAuthors">He, Yingfang; Xie, Fang; Ye, Jiajun; Deuther-Conrad, Winnie; Cui, Bixiao; Wang, Liang; Lu, Jie; Steinbach, Jorg; Brust, Peter; Huang, Yiyun; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4161-4172</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have designed and synthesized novel piperazine compds. with low lipophilicity as σ1 receptor ligands. 1-(4-Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine (10) possessed a low nanomolar σ1 receptor affinity and a high selectivity toward the vesicular acetylcholine transporter (>2000-fold), σ2 receptors (52-fold), and adenosine A2A, adrenergic α2, cannabinoid CB1, dopamine D1, D2L, γ-aminobutyric acid A (GABAA), NMDA, melatonin MT1, MT2, and serotonin 5-HT1 receptors.  The corresponding radiotracer [18F]10 demonstrated high brain uptake and extremely high brain-to-blood ratios in biodistribution studies in mice.  Pretreatment with the selective σ1 receptor agonist SA4503 significantly reduced the level of accumulation of the radiotracer in the brain.  No radiometabolite of [18F]10 was obsd. to enter the brain.  Positron emission tomog. and magnetic resonance imaging confirmed suitable kinetics and a high specific binding of [18F]10 to σ1 receptors in rat brain.  Ex vivo autoradiog. showed a reduced level of binding of [18F]10 in the cortex and hippocampus of the senescence-accelerated prone (SAMP8) compared to that of the senescence-accelerated resistant (SAMR1) mice, indicating the potential dysfunction of σ1 receptors in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNq2WOuF4xHLVg90H21EOLACvtfcHk0livjWTS3YtoOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCntrs%253D&md5=86a5d03c3129895d3eb6bc61d4730b94</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01723%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DCui%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DH.%26atitle%3D1-%25284-%255B%252818%2529F%255DFluorobenzyl%2529-4-%255B%2528tetrahydrofuran-2-yl%2529methyl%255Dpiperazine%253A%2520a%2520novel%2520suitable%2520radioligand%2520with%2520low%2520lipophilicity%2520for%2520imaging%2520sigma1%2520receptors%2520in%2520the%2520brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4161%26epage%3D4172%26doi%3D10.1021%2Facs.jmedchem.6b01723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115560</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2020.115560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=32616183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFSks77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115560&author=J.+Tianauthor=Y.+Heauthor=W.+Deuther-Conradauthor=H.+Fuauthor=F.+Xieauthor=Y.+Zhangauthor=T.+Wangauthor=X.+Zhangauthor=J.+Zhangauthor=P.+Brustauthor=Y.+Huangauthor=H.+Jia&title=Synthesis+and+evaluation+of+new+1-oxa-8-azaspiro%5B4.5%5Ddecane+derivatives+as+candidate+radioligands+for+sigma-1+receptors&doi=10.1016%2Fj.bmc.2020.115560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors</span></div><div class="casAuthors">Tian, Jiale; He, Yingfang; Deuther-Conrad, Winnie; Fu, Hualong; Xie, Fang; Zhang, Ying; Wang, Tao; Zhang, Xiaojun; Zhang, Jinming; Brust, Peter; Huang, Yiyun; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">115560</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design, synthesis, and evaluation of a series of 1-oxa-8-azaspiro[4.5]decane I (R = F, I, OCH2CH2F) and 1,5-dioxa-9-azaspiro[5.5]undecane derivs. II (R = F, I, OCH2CH2F, OMe) as selective σ1 receptor ligands has been reported.  All seven ligands exhibited nanomolar affinity for σ1 receptors (Ki(σ1) = 0.47 - 12.1 nM) and moderate selectivity over σ2 receptors (Ki(σ2)/ Ki(σ1) = 2 - 44).  Compd. I (R = OCH2CH2F), with the best selectivity among these ligands, was selected for radiolabeling and further evaluation.  Radioligand II (R = OCH2CH2F18) was prepd. via nucleophilic 18F-substitution of the corresponding tosylate precursor, with an overall isolated radiochem. yield of 12-35%, a radiochem. purity of greater than 99%, and molar activity of 94 - 121 GBq/μmol.  Biodistribution studies of II (R = OCH2CH2F18) in mice demonstrated high initial brain uptake at 2 min.  Pretreatment with SA4503 resulted in significantly reduced brain-to-blood ratio (70% - 75% at 30 min).  Ex vivo autoradiog. in ICR mice demonstrated high accumulation of the radiotracer in σ1 receptor-rich brain areas.  These findings suggest that II (R = OCH2CH2F18) could be a lead compd. for further structural modifications to develop potential brain imaging agents for σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowOn8LA7sx17Vg90H21EOLACvtfcHk0livjWTS3YtoOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFSks77K&md5=eb642b42faeef2f1b5d6814b2698ba9a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115560%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520new%25201-oxa-8-azaspiro%255B4.5%255Ddecane%2520derivatives%2520as%2520candidate%2520radioligands%2520for%2520sigma-1%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115560%26doi%3D10.1016%2Fj.bmc.2020.115560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of sigma-1 receptor ligands</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">600</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1071/CH14590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1071%2FCH14590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlCgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2015&pages=600-609&author=M.+Manoharauthor=S.+D.+Banisterauthor=C.+Beinatauthor=J.+O%E2%80%99Brien-Brownauthor=M.+Kassiou&title=Recent+advances+in+the+development+of+sigma-1+receptor+ligands&doi=10.1071%2FCH14590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Development of Sigma-1 Receptor Ligands</span></div><div class="casAuthors">Manohar, Madhura; Banister, Samuel D.; Beinat, Corinne; O'Brien-Brown, James; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Australian Journal of Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">600-609</span>CODEN:
                <span class="NLM_cas:coden">AJCHAS</span>;
        ISSN:<span class="NLM_cas:issn">0004-9425</span>.
    
            (<span class="NLM_cas:orgname">CSIRO Publishing</span>)
        </div><div class="casAbstract">A review.  The existence of two distinct sigma (σ) receptor subtypes was established in the early 1990s.  Sigma-1 and sigma-2 receptors (S1Rs and S2Rs, resp.) were shown to possess distinct mol. size, anatomical distribution, and ligand discrimination.  S2R is overexpressed in numerous human cancers, and has therapeutic potential for the imaging and treatment of certain tumors.  In contrast, S1R is more broadly involved in a wide variety of central nervous system (CNS) diseases including motor disorders, memory deficits, depression, schizophrenia, anxiety, pain, drug addiction, and many more.  Since the human S1R was cloned in 1996, numerous high affinity ligands with excellent selectivity for S1R have been developed.  This review focuses on recent developments in the generation of structurally diverse S1R-selective ligands and novel therapeutic candidates targeting S1Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFO8GN480HerVg90H21EOLACvtfcHk0lhh-ke3Gz2ung"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlCgtrY%253D&md5=101367291b60831da45faa372bf02f7e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1071%2FCH14590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1071%252FCH14590%26sid%3Dliteratum%253Aachs%26aulast%3DManohar%26aufirst%3DM.%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DBeinat%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien-Brown%26aufirst%3DJ.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520sigma-1%2520receptor%2520ligands%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2015%26volume%3D68%26spage%3D600%26epage%3D609%26doi%3D10.1071%2FCH14590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lever, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allmon, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S. Z.</span></span> <span> </span><span class="NLM_article-title">Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1002/syn.20253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fsyn.20253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16463398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtF2qtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=350-358&author=J.+R.+Leverauthor=J.+L.+Gustafsonauthor=R.+Xuauthor=R.+L.+Allmonauthor=S.+Z.+Lever&title=Sigma1+and+sigma2+receptor+binding+affinity+and+selectivity+of+SA4503+and+fluoroethyl+SA4503&doi=10.1002%2Fsyn.20253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">σ1 and σ2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503</span></div><div class="casAuthors">Lever, John R.; Gustafson, Jennifer L.; Xu, Rong; Allmon, Rachel L.; Lever, Susan Z.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">350-358</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">SA4503, a potent σ1 receptor agonist, is reported as having 103-fold higher affinity for σ1 (IC50 = 17.4 nM) than σ2 (IC50 = 1784 nM) sites in guinea pig brain membranes.  Modest structural changes appear to have major effects on σ1/σ2 selectivity.  The fluoroethyl analog, FE-SA4503, is described as having high primary affinity for σ2 sites (IC50 = 2.11 nM) and a weaker interaction with σ1 sites (IC50 = 6.48 nM).  SA4503 and FE-SA4503 have been radiolabeled for PET studies, and both bind selectively to σ1 receptors in animal and human brain in vivo.  We prepd. SA4503 and FE-SA4503 as ref. compds. for radioligand development efforts.  In our hands, SA4503 is 14-fold selective for σ1 (Ki = 4.6 nM) over σ2 (Ki = 63.1 nM) sites in guinea pig brain homogenates.  Further, FE-SA4503 exhibits the same 14-fold selectivity for σ1 (Ki = 8.0 nM) over σ2 (Ki = 113.2 nM) receptors.  The main differences from previously reported values stem from σ2 affinity detns.  This protocol, displacement of [3H]DTG binding to σ2 sites using (+)-pentazocine (200 nM) to mask σ1 sites, was validated by the proper rank order of σ2 inhibitory potencies shown by a panel of addnl. ligands: ifenprodil > haloperidol > DTG >> (+)-pentazocine.  Robust Pearson correlation (r = 1.0, P = 0.002; slope = 0.97) was obsd. for our pKi values against those from a prior study by others.  The findings have bearing on structure-activity relationships for this active series, and on conclusions that might be drawn from expts. relying upon defined σ1/σ2 binding selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroCWxEMb91BLVg90H21EOLACvtfcHk0lhh-ke3Gz2ung"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtF2qtrw%253D&md5=cdde02213b531f7d212f9e00d0e3af74</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20253%26sid%3Dliteratum%253Aachs%26aulast%3DLever%26aufirst%3DJ.%2BR.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DAllmon%26aufirst%3DR.%2BL.%26aulast%3DLever%26aufirst%3DS.%2BZ.%26atitle%3DSigma1%2520and%2520sigma2%2520receptor%2520binding%2520affinity%2520and%2520selectivity%2520of%2520SA4503%2520and%2520fluoroethyl%2520SA4503%26jtitle%3DSynapse%26date%3D2006%26volume%3D59%26spage%3D350%26epage%3D358%26doi%3D10.1002%2Fsyn.20253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yajima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2620</span>– <span class="NLM_lpage">2626</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.11.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2005.11.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16434200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ymtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=2620-2626&author=K.+Shibaauthor=K.+Ogawaauthor=K.+Ishiwataauthor=K.+Yajimaauthor=H.+Mori&title=Synthesis+and+binding+affinities+of+methylvesamicol+analogs+for+the+acetylcholine+transporter+and+sigma+receptor&doi=10.1016%2Fj.bmc.2005.11.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor</span></div><div class="casAuthors">Shiba, Kazuhiro; Ogawa, Kazuma; Ishiwata, Kiichi; Yajima, Kazuyoshi; Mori, Hirofumi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2620-2626</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We synthesized methylvesamicol analogs 13-16 and investigated the binding characteristics of 2-[4-phenylpiperidino]cyclohexanol (vesamicol) and methylvesamicol analogs 13-16, with a Me group introduced into the 4-phenylpiperidine moiety, to sigma receptors (σ-1, σ-2) and to vesicular acetylcholine transporters (VAChT) in membranes of the rat brain and liver.  In competitive inhibition studies, (-)-o-methylvesamicol [(-)-OMV] (13) (Ki = 6.7 nM), as well as (-)-vesamicol (Ki = 4.4 nM), had a high affinity for VAChT. (+)-p-Methylvesamicol [(+)-PMV] (16) (Ki = 3.0 nM), as well as SA4503 (K i = 4.4 nM), reported as a σ-1 mapping agent for positron emission tomog. (PET), had a high affinity for the σ-1 receptor.  The binding affinity of (+)-PMV (16) for the σ-1 receptor (Ki = 3.0 nM) was about 13 times higher than that for the sigma-2 (σ-2) receptor (Ki = 40.7 nM). (+)-PMV (16) (Ki = 199 nM) had a much lower affinity for VAChT than SA4503 (K i = 50.2 nM) and haloperidol (Ki = 41.4 nM).  These results showed that the binding characteristics of (-)-OMV (13) to VAChT were similar to those of (-)-vesamicol and that (+)-PMV (16) bound to the σ-1 receptor with high affinity.  In conclusion, (-)-OMV (13) and (+)-PMV (16), which had a suitable structure, with a Me group for labeling with 11C, may become not only a new VAChT ligand and a new type of σ receptor ligand, resp., but may also become a new target compd. of VAChT and the σ-1 receptor radioligand for PET, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp22XLhJlJErVg90H21EOLACvtfcHk0lhh-ke3Gz2ung"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ymtro%253D&md5=13faa91541d6280e4864ba71c130be56</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.11.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.11.044%26sid%3Dliteratum%253Aachs%26aulast%3DShiba%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DYajima%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520binding%2520affinities%2520of%2520methylvesamicol%2520analogs%2520for%2520the%2520acetylcholine%2520transporter%2520and%2520sigma%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D2620%26epage%3D2626%26doi%3D10.1016%2Fj.bmc.2005.11.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">In, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure and quantitative structure-activity relationships of sigma receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl) piperazines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1675</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(97)00093-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS0968-0896%2897%2900093-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=9313869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVGrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1997&pages=1675-1683&author=K.+Fujimuraauthor=J.+Matsumotoauthor=M.+Niwaauthor=T.+Kobayashiauthor=Y.+Kawashimaauthor=Y.+Inauthor=T.+Ishida&title=Synthesis%2C+structure+and+quantitative+structure-activity+relationships+of+sigma+receptor+ligands%2C+1-%5B2-%283%2C4-dimethoxyphenyl%29ethyl%5D-4-%283-phenylpropyl%29+piperazines&doi=10.1016%2FS0968-0896%2897%2900093-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure and quantitative structure-activity relationships of σ receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines</span></div><div class="casAuthors">Fujimura, Ken-Ichi; Matsumoto, Junzo; Niwa, Masashi; Kobayashi, Tadayuki; Kawashima, Yoichi; In, Yasuko; Ishida, Toshimasa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1675-1683</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A set of the title compds. (I) (R1 = Cl, H, CF3; R2 = Cl, CF3, H, OH, Br, F, OCH2Ph) was synthesized to find σ receptor binding affinity.  Among the compds., I (R1=R2=Cl) (II) has the most potent σ1-binding activity, while I (R1=R2=H, SA4503) (III) was most selective to σ1 over σ2 receptor.  The crystal structures of III and II were shown, by X-ray crystallog., to be similar except for the one torsional angle of their propylene parts.  Quant. structure-activity relationship study suggested the affinity of the compds. to the σ1 receptor was dependent on the electronic feature, Swain-Lupton's R or Sπ that was derived by MO method, of R1 and R2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJUWcpOIiaGrVg90H21EOLACvtfcHk0lhh-ke3Gz2ung"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVGrs74%253D&md5=ca4636f167b7252638e16ec6d4fd3551</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2897%2900093-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252897%252900093-X%26sid%3Dliteratum%253Aachs%26aulast%3DFujimura%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DJ.%26aulast%3DNiwa%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DKawashima%26aufirst%3DY.%26aulast%3DIn%26aufirst%3DY.%26aulast%3DIshida%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520structure%2520and%2520quantitative%2520structure-activity%2520relationships%2520of%2520sigma%2520receptor%2520ligands%252C%25201-%255B2-%25283%252C4-dimethoxyphenyl%2529ethyl%255D-4-%25283-phenylpropyl%2529%2520piperazines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1997%26volume%3D5%26spage%3D1675%26epage%3D1683%26doi%3D10.1016%2FS0968-0896%2897%2900093-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">Novel cyclopentadienyl tricarbonyl (99m)tc complexes containing 1-piperonylpiperazine moiety: potential imaging probes for sigma-1 receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7113</span>– <span class="NLM_lpage">7125</span>, <span class="refDoi"> DOI: 10.1021/jm5009488</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5009488" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egs7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7113-7125&author=X.+Wangauthor=D.+Liauthor=W.+Deuther-Conradauthor=J.+Luauthor=Y.+Xieauthor=B.+Jiaauthor=M.+Cuiauthor=J.+Steinbachauthor=P.+Brustauthor=B.+Liuauthor=H.+Jia&title=Novel+cyclopentadienyl+tricarbonyl+%2899m%29tc+complexes+containing+1-piperonylpiperazine+moiety%3A+potential+imaging+probes+for+sigma-1+receptors&doi=10.1021%2Fjm5009488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Cyclopentadienyl Tricarbonyl 99mTc Complexes Containing 1-Piperonylpiperazine Moiety: Potential Imaging Probes for Sigma-1 Receptors</span></div><div class="casAuthors">Wang, Xia; Li, Dan; Deuther-Conrad, Winnie; Lu, Jie; Xie, Ying; Jia, Bing; Cui, Mengchao; Steinbach, Jorg; Brust, Peter; Liu, Boli; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7113-7125</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the design, synthesis, and evaluation of a series of novel cyclopentadienyl tricarbonyl 99mTc complexes as potent σ1 receptor radioligands.  Rhenium compds. 3-(4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl)propylcarbonylcyclopentadienyl tricarbonyl rhenium (10a) and 4-(4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl)butylcarbonylcyclopentadienyl tricarbonyl rhenium (10b) possessed high in vitro affinity for σ1 receptors and moderate to high selectivity for σ2 receptors and the vesicular acetylcholine transporter.  Biodistribution studies in mice demonstrated high initial brain uptake for corresponding 99mTc derivs. [99mTc]23 and [99mTc]24 of 2.94 and 2.13% injected dose (ID)/g, resp., at 2 min postinjection.  Pretreatment of haloperidol significantly reduced the radiotracer accumulation of [99mTc]23 or [99mTc]24 in the brain.  Studies of the cellular uptake of [99mTc]23 in C6 and DU145 tumor cells demonstrated a redn. of accumulation by incubation with haloperidol, 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine (SA4503), or 1,3-di-o-tolyl-guanidine (DTG).  Furthermore, blocking studies in C6 glioma-bearing mice confirmed the specific binding of [99mTc]23 to σ1 receptors in the tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmqY0f1Jf77Vg90H21EOLACvtfcHk0liqBEktiJNOmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egs7jJ&md5=47ad2ee73f8711b9f26e27119d1d0a93</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm5009488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5009488%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DB.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DJia%26aufirst%3DH.%26atitle%3DNovel%2520cyclopentadienyl%2520tricarbonyl%2520%252899m%2529tc%2520complexes%2520containing%25201-piperonylpiperazine%2520moiety%253A%2520potential%2520imaging%2520probes%2520for%2520sigma-1%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7113%26epage%3D7125%26doi%3D10.1021%2Fjm5009488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fergason-Cantrell, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S. Z.</span></span> <span> </span><span class="NLM_article-title">Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2014.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25468036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFegsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=222-230&author=R.+Xuauthor=S.+A.+Lordauthor=R.+M.+Petersonauthor=E.+A.+Fergason-Cantrellauthor=J.+R.+Leverauthor=S.+Z.+Lever&title=Ether+modifications+to+1-%5B2-%283%2C4-dimethoxyphenyl%29ethyl%5D-4-%283-phenylpropyl%29piperazine+%28SA4503%29%3A+effects+on+binding+affinity+and+selectivity+for+sigma+receptors+and+monoamine+transporters&doi=10.1016%2Fj.bmc.2014.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): Effects on binding affinity and selectivity for sigma receptors and monoamine transporters</span></div><div class="casAuthors">Xu, Rong; Lord, Sarah A.; Peterson, Ryan M.; Fergason-Cantrell, Emily A.; Lever, John R.; Lever, Susan Z.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">222-230</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two series of novel ether analogs of the sigma (σ) receptor ligand 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503) have been prepd.  In one series, the alkyl portion of the 4-methoxy group was replaced with allyl, Pr, bromoethyl, benzyl, phenethyl, and phenylpropyl moieties.  In the second series, the 3,4-dimethoxy was replaced with cyclic methylenedioxy, ethylenedioxy and propylenedioxy groups.  These ligands, along with 4-O-des-Me SA4503, were evaluated for σ1 and σ2 receptor affinity, and compared to SA4503 and several known ether analogs.  SA4503 and a subset of ether analogs were also evaluated for dopamine transporter (DAT) and serotonin transporter (SERT) affinity.  The highest σ1 receptor affinities, Ki values of 1.75-4.63 nM, were obsd. for 4-O-des-Me SA4503, SA4503 and the methylenedioxy analog.  As steric bulk increased, σ1 receptor affinity decreased, but only to a point.  Allyl, Pr and bromoethyl substitutions gave σ1 receptor Ki values in the 20-30 nM range, while bulkier analogs having phenylalkyl, and Z- and E-iodoallyl, ether substitutions showed higher σ1 affinities, with Ki values in the 13-21 nM range.  Most ligands studied exhibited comparable σ1 and σ2 affinities, resulting in little to no subtype selectivity.  SA4503, the fluoroethyl analog and the methylenedioxy congener showed modest six- to fourteen-fold selectivity for σ1 sites.  DAT and SERT interactions proved much more sensitive than σ receptor interactions to these structural modifications.  For example, the benzyl congener (σ1Ki = 20.8 nM; σ2Ki = 16.4 nM) showed over 100-fold higher DAT affinity (Ki = 121 nM) and 6-fold higher SERT affinity (Ki = 128 nM) than the parent SA4503 (DAT Ki = 12650 nM; SERT Ki = 760 nM).  Thus, ether modifications to the SA4503 scaffold can provide polyfunctional ligands having a broader spectrum of possible pharmacol. actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe5N5hhz8TlLVg90H21EOLACvtfcHk0liqBEktiJNOmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFegsLrJ&md5=f0ff94c1cb25a64fa002aaa236bcc751</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%26aulast%3DLord%26aufirst%3DS.%2BA.%26aulast%3DPeterson%26aufirst%3DR.%2BM.%26aulast%3DFergason-Cantrell%26aufirst%3DE.%2BA.%26aulast%3DLever%26aufirst%3DJ.%2BR.%26aulast%3DLever%26aufirst%3DS.%2BZ.%26atitle%3DEther%2520modifications%2520to%25201-%255B2-%25283%252C4-dimethoxyphenyl%2529ethyl%255D-4-%25283-phenylpropyl%2529piperazine%2520%2528SA4503%2529%253A%2520effects%2520on%2520binding%2520affinity%2520and%2520selectivity%2520for%2520sigma%2520receptors%2520and%2520monoamine%2520transporters%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D222%26epage%3D230%26doi%3D10.1016%2Fj.bmc.2014.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Col, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis, pharmacological evaluation, and sigma1 receptor interaction analysis of hydroxyethyl substituted piperazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2884</span>– <span class="NLM_lpage">2894</span>, <span class="refDoi"> DOI: 10.1021/jm401707t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401707t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvF2qurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2884-2894&author=F.+Weberauthor=S.+Bruneauthor=K.+Korpisauthor=P.+J.+Bednarskiauthor=E.+Lauriniauthor=V.+Dal+Colauthor=S.+Priclauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis%2C+pharmacological+evaluation%2C+and+sigma1+receptor+interaction+analysis+of+hydroxyethyl+substituted+piperazines&doi=10.1021%2Fjm401707t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Pharmacological Evaluation, and σ1 Receptor Interaction Analysis of Hydroxyethyl Substituted Piperazines</span></div><div class="casAuthors">Weber, Frauke; Brune, Stefanie; Korpis, Katharina; Bednarski, Patrick J.; Laurini, Erik; Dal Col, Valentina; Pricl, Sabrina; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2884-2894</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic arylmethyl piperazineethanols I (R = Ph, 4-PhC6H4, 1-naphthyl, 2-naphthyl, 6-MeO-2-naphthyl, 4-MeOC6H4; R1 = Me, Bu, i-BuCH2, PhCH2CH2, cyclohexylmethyl) or their enantiomers were prepd. from L- or D-aspartic acid as potential selective σ1 receptor ligands; their binding to σ1 and σ2 receptors and the inhibition of human cancer cell lines by selected piperazineethanols was detd.  σ1 Affinities detd. with guinea pig brain and human RPMI 8226 tumor cell lines differed slightly but showed the same binding tendencies.  Of the compds. tested, I (R = 2-naphthyl; R1 = cyclohexylmethyl) bound human σ1 receptors with the highest affinity (Ki = 6.8 nM); it inhibited the growth of three human cancer cell lines at micromolar concns., and the reduced growth in one of the cancer cell lines was caused by apoptosis.  The interaction of I (R = 2-naphthyl; R1 = cyclohexylmethyl) with the σ1 receptor was analyzed in detail using the 3D homol. model of the σ1 receptor; the binding energies and entropies and enthalpies of binding of I to the human σ1 receptor were calcd., and correlated to the exptl. binding affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTSY6dIeenlrVg90H21EOLACvtfcHk0ljrbanzHEDzZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvF2qurw%253D&md5=b2780618ed60d3b36051faf8261fbfb8</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm401707t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401707t%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DDal%2BCol%26aufirst%3DV.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%252C%2520pharmacological%2520evaluation%252C%2520and%2520sigma1%2520receptor%2520interaction%2520analysis%2520of%2520hydroxyethyl%2520substituted%2520piperazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2884%26epage%3D2894%26doi%3D10.1021%2Fjm401707t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span> <span> </span><span class="NLM_article-title">Involvement of apoptosis and autophagy in the death of RPMI 8226 multiple myeloma cells by two enantiomeric sigma receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.11.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2013.11.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24331758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOgsbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=221-233&author=K.+Korpisauthor=F.+Weberauthor=S.+Bruneauthor=B.+Wunschauthor=P.+J.+Bednarski&title=Involvement+of+apoptosis+and+autophagy+in+the+death+of+RPMI+8226+multiple+myeloma+cells+by+two+enantiomeric+sigma+receptor+ligands&doi=10.1016%2Fj.bmc.2013.11.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of apoptosis and autophagy in the death of RPMI 8226 multiple myeloma cells by two enantiomeric sigma receptor ligands</span></div><div class="casAuthors">Korpis, Katharina; Weber, Frauke; Brune, Stefanie; Wuensch, Bernhard; Bednarski, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over-expression of σ receptors by many tumor cell lines makes ligands for these receptors attractive as potential chemotherapeutic drugs.  Enantiomeric piperazines (S)-4 and (R)-4 were prepd. as potential σ-receptor ligands in a chiral pool synthesis starting from (S)- and (R)-aspartate.  Both compds. showed high affinities for the σ1 and σ2 receptors.  In the human multiple myeloma cell line RPMI 8226, a line expressing high levels of σ receptors, both compds. inhibited cell proliferation with IC50 values in the low μM range.  No chiral differentiation between either the σ receptor binding affinity or the cytotoxicity of the two enantiomers was obsd.  Both compds. induced apoptosis, which was evidenced by nuclear condensation, binding of annexin-V to phosphatidylserine in the outer leaf of the cell membrane, cleavage products of poly(ADP-ribose) polymerase-1 (PARP-1) and caspase-8 as well as the expression of bcl2 family members bax, bad and bid.  However, apoptosis appeared to be caspase independent.  Increased levels of the phosphorylated form of the microtubule assocd. protein light chain 3-II (LC3-II), an autophagosome marker, gave evidence that both compds. induced autophagy.  However, further data (e.g., treatment with wortmannin) indicate that autophagy is incomplete and not cytoprotective.  Lipid peroxidn. (LPO) was obsd. in RPMI 8226 cells treated with the two compds., and the lipid antioxidant α-tocopherol attenuated LPO.  Interestingly, α-tocopherol reduced significantly both apoptosis and autophagy induced by the compds.  These results provide evidence that, by initiating LPO and changes in mitochondrial membrane potential, both compds. induce apoptosis and autophagy in RPMI 8226 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcLGqAcjD1xbVg90H21EOLACvtfcHk0ljrbanzHEDzZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOgsbvN&md5=b292b81c7183d928fc153a43ab0829af</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.11.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.11.033%26sid%3Dliteratum%253Aachs%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26atitle%3DInvolvement%2520of%2520apoptosis%2520and%2520autophagy%2520in%2520the%2520death%2520of%2520RPMI%25208226%2520multiple%2520myeloma%2520cells%2520by%2520two%2520enantiomeric%2520sigma%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D221%26epage%3D233%26doi%3D10.1016%2Fj.bmc.2013.11.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battisti, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tait, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cichero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronsisvalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arico, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasili, L.</span></span> <span> </span><span class="NLM_article-title">Scouting new sigma receptor ligands: synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.01.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2016.01.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=26874044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVejtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2016&pages=1-19&author=S.+Franchiniauthor=U.+M.+Battistiauthor=A.+Prandiauthor=A.+Taitauthor=C.+Borsariauthor=E.+Cicheroauthor=P.+Fossaauthor=A.+Ciliaauthor=O.+Prezzaventoauthor=S.+Ronsisvalleauthor=G.+Aricoauthor=C.+Parentiauthor=L.+Brasili&title=Scouting+new+sigma+receptor+ligands%3A+synthesis%2C+pharmacological+evaluation+and+molecular+modeling+of+1%2C3-dioxolane-based+structures+and+derivatives&doi=10.1016%2Fj.ejmech.2016.01.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives</span></div><div class="casAuthors">Franchini, Silvia; Battisti, Umberto Maria; Prandi, Adolfo; Tait, Annalisa; Borsari, Chiara; Cichero, Elena; Fossa, Paola; Cilia, Antonio; Prezzavento, Orazio; Ronsisvalle, Simone; Arico, Giuseppina; Parenti, Carmela; Brasili, Livio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-19</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Herein the authors report the synthesis and biol. activity of new sigma receptor (σR) ligands [i.e., sigma-1 receptors, σ-receptor 1 σ-non-opioid intracellular receptors, sigma-2 receptors, σ-receptor 2 σ-non-opioid intracellular receptors] obtained by combining different substituted five-membered heterocyclic rings with appropriate σR pharmacophoric amines.  Radioligand binding assay, performed on guinea pig brain membranes, identified one 1-(1,4-dioxaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperazine as the most interesting compd. of the series, displaying high affinity and selectivity for σ1R (pKiσ1 = 9.13; σ1/σ2 = 47).  The ability of this compd. to modulate the analgesic effect of the κ agonist (-)-U-50,488H and μ agonist morphine was evaluated in vivo by radiant heat tail-flick test (nociceptive model).  It exhibited anti-opioid effects on both κ and μ receptor-mediated analgesia, suggesting an agonistic behavior at σ1R.  Docking studies were performed on the theor. σ1R homol. model.  The present work represents a new starting point for the design of more potent and selective σ1R ligands.  Suitable starting materials included 4-(chloromethyl)-2,2-diphenyl-1,3-dioxolane, 5-(chloromethyl)-2,2-diphenyl-1,3-oxathiolane, 5-(chloromethyl)-2,2-diphenyl-1,3-dithiolan e derivs. and 4-(benzyl)piperidine and 1-(benzyl)piperazine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzeNBNZCdlLVg90H21EOLACvtfcHk0ljrbanzHEDzZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVejtrg%253D&md5=a0887c8dcdd728e645d1c58e93ea9dfe</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.01.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.01.059%26sid%3Dliteratum%253Aachs%26aulast%3DFranchini%26aufirst%3DS.%26aulast%3DBattisti%26aufirst%3DU.%2BM.%26aulast%3DPrandi%26aufirst%3DA.%26aulast%3DTait%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DCichero%26aufirst%3DE.%26aulast%3DFossa%26aufirst%3DP.%26aulast%3DCilia%26aufirst%3DA.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DRonsisvalle%26aufirst%3DS.%26aulast%3DArico%26aufirst%3DG.%26aulast%3DParenti%26aufirst%3DC.%26aulast%3DBrasili%26aufirst%3DL.%26atitle%3DScouting%2520new%2520sigma%2520receptor%2520ligands%253A%2520synthesis%252C%2520pharmacological%2520evaluation%2520and%2520molecular%2520modeling%2520of%25201%252C3-dioxolane-based%2520structures%2520and%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D112%26spage%3D1%26epage%3D19%26doi%3D10.1016%2Fj.ejmech.2016.01.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel sigma1 receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4778</span>– <span class="NLM_lpage">4799</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.07.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2017.07.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28764962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Gisb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=4778-4799&author=L.+Fanterauthor=C.+Mullerauthor=D.+Schepmannauthor=F.+Bracherauthor=B.+Wunsch&title=Chiral-pool+synthesis+of+1%2C2%2C4-trisubstituted+1%2C4-diazepanes+as+novel+sigma1+receptor+ligands&doi=10.1016%2Fj.bmc.2017.07.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ1 receptor ligands</span></div><div class="casAuthors">Fanter, Lena; Mueller, Christoph; Schepmann, Dirk; Bracher, Franz; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4778-4799</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from enantiomerically pure amino acids, 1,4-diazepanes with various substituents in 1, 2, and 4-position were synthesized following the late stage diversification strategy.  The key step in the formation of the seven-membered ring was the intramol. EDC coupling of amino acids.  The configuration in 2-position does not influence the σ1 affinity and selectivity over related receptors.  A cyclohexylmethyl or a Bu group are the preferred substituents in 4-position, whereas a Me moiety in 2-position and a (substituted) benzyl moiety in 1-position result in the highest σ1 affinity.  These results fit nicely to the reported σ1 pharmacophore models.  The compds. did not inhibit the structurally related fungal enzyme sterol Δ8,7-isomerase, but showed inhibition of diverse enzymes in late cholesterol biosynthesis at high concns.  In a screening against more than 50 target proteins, (2S)-1-benzyl-4-(4-methoxybenzyl)-2-methyl-1,4-diazepane ((S)-I, Ki(σ1) = 0.86 nM) showed a clean receptor profile.  The dose dependent potentiation of elec. stimulated contractions of guinea pig vas deferens indicates σ1 agonistic activity of (S)-I.  Even at a dose of 100 mg/kg (S)-I did not induce severe toxic or behavioral effects in the Irwin screen.  Clear cognition enhancing effects were obsd. for (S)-I after inducing amnesia by scopolamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooVrEXowkjrbVg90H21EOLACvtfcHk0liv9FkKNIDcPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Gisb3E&md5=8d998375ecd36b7f93148112912bce74</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.07.027%26sid%3Dliteratum%253Aachs%26aulast%3DFanter%26aufirst%3DL.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DBracher%26aufirst%3DF.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DChiral-pool%2520synthesis%2520of%25201%252C2%252C4-trisubstituted%25201%252C4-diazepanes%2520as%2520novel%2520sigma1%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D4778%26epage%3D4799%26doi%3D10.1016%2Fj.bmc.2017.07.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Solid-phase organic synthesis of chiral, non-racemic 1,2,4-trisubstituted 1,4-diazepanes with high sigma1 receptor affinity</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1700334</span>, <span class="refDoi"> DOI: 10.1002/ardp.201700334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fardp.201700334" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2018&pages=1700334&author=L.+Fanterauthor=D.+Schepmannauthor=B.+Wunsch&title=Solid-phase+organic+synthesis+of+chiral%2C+non-racemic+1%2C2%2C4-trisubstituted+1%2C4-diazepanes+with+high+sigma1+receptor+affinity&doi=10.1002%2Fardp.201700334"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1002%2Fardp.201700334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201700334%26sid%3Dliteratum%253Aachs%26aulast%3DFanter%26aufirst%3DL.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSolid-phase%2520organic%2520synthesis%2520of%2520chiral%252C%2520non-racemic%25201%252C2%252C4-trisubstituted%25201%252C4-diazepanes%2520with%2520high%2520sigma1%2520receptor%2520affinity%26jtitle%3DArch.%2520Pharm.%26date%3D2018%26volume%3D351%26spage%3D1700334%26doi%3D10.1002%2Fardp.201700334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortuna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabretti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menegazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, cytotoxicity evaluation, and computational insights of novel 1,4-diazepane-based sigma ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSnsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=651-656&author=D.+Zampieriauthor=S.+Fortunaauthor=A.+Calabrettiauthor=M.+Romanoauthor=R.+Menegazziauthor=D.+Schepmannauthor=B.+Wunschauthor=M.+G.+Mamolo&title=Synthesis%2C+cytotoxicity+evaluation%2C+and+computational+insights+of+novel+1%2C4-diazepane-based+sigma+ligands&doi=10.1021%2Facsmedchemlett.9b00524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands</span></div><div class="casAuthors">Zampieri, Daniele; Fortuna, Sara; Calabretti, Antonella; Romano, Maurizio; Menegazzi, Renzo; Schepmann, Dirk; Wunsch, Bernhard; Mamolo, Maria Grazia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">651-656</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among several potential applications, sigma receptor ligands can be used as antipsychotics, antiamnesics, and against other neurodegenerative disorders as well as neuroprotective agents.  We present herein a new series of diazepane-contg. derivs. as σR ligands obtained by a conformational expansion approach of our previously synthesized piperidine-based compds.  The best results were reached by benzofuran (e.g., 2c) and quinoline-substituted diazepane derivs., which showed the highest σR affinity.  The cytotoxic activities of synthesized compds. were evaluated against two cancer cell lines, and the results indicated that none of the compds. induced significant toxicity in these cells.  We also evaluated the antioxidant activity by radical scavenging capacity of our best compds. on ABTS and H2O2.  The results obtained reveal that our new derivs. possess an excellent antioxidant profile and could be protective for the cells.  Overall, the benzofurane deriv. 2c due to its strong interaction with the active site of the receptor, as confirmed by mol. dynamic simulations, emerged as the optimum compd. with high σ1R affinity, low cytotoxicity, and a potent antioxidant activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqKPjw5RD9AbVg90H21EOLACvtfcHk0liv9FkKNIDcPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSnsLvK&md5=0c06c9690ccf4d98b0db506b49182e3e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00524%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DFortuna%26aufirst%3DS.%26aulast%3DCalabretti%26aufirst%3DA.%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DMenegazzi%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26atitle%3DSynthesis%252C%2520cytotoxicity%2520evaluation%252C%2520and%2520computational%2520insights%2520of%2520novel%25201%252C4-diazepane-based%2520sigma%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D651%26epage%3D656%26doi%3D10.1021%2Facsmedchemlett.9b00524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golob, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and receptor binding studies of some new arylcarboxamide derivatives as sigma-1 ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1025</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2014.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24486131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1021-1025&author=D.+Zampieriauthor=E.+Lauriniauthor=L.+Vioauthor=S.+Golobauthor=M.+Fermegliaauthor=S.+Priclauthor=M.+G.+Mamolo&title=Synthesis+and+receptor+binding+studies+of+some+new+arylcarboxamide+derivatives+as+sigma-1+ligands&doi=10.1016%2Fj.bmcl.2014.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and receptor binding studies of some new arylcarboxamide derivatives as sigma-1 ligands</span></div><div class="casAuthors">Zampieri, Daniele; Laurini, Erik; Vio, Luciano; Golob, Samuel; Fermeglia, Maurizio; Pricl, Sabrina; Mamolo, Maria Grazia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1021-1025</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors describe here the synthesis and the binding interaction with σ1 and σ2 receptors of a series of new arylcarboxamide derivs. variously substituted on the arom. portions.  Maintaining a partial scaffold of a series of compds. previously synthesized by the authors, the authors evaluate the effect of the substitution on σ binding.  The synthesized compds. were tested to est. their affinity and selectivity toward σ1 and σ2 receptors.  Two out of 16 derivs. showed an interesting σ1 affinity (21.2 and 13.6 nM-compds.) N-((1-benzylpiperidin-4-yl)methyl)-N-ethylfuran-2-carboxamide hydrochloride and N-((1-(4-chlorobenzyl)piperidin-4-yl)methyl)-N-ethylfuran-2-carboxamide hydrochloride and a good selectivity (Ki(σ2)/Ki(σ1) >140 and >40, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrId_zR_Dnz07Vg90H21EOLACvtfcHk0liv9FkKNIDcPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cru7o%253D&md5=710aa2dd4c9e1f27c051c6c1e3f605bd</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DGolob%26aufirst%3DS.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26atitle%3DSynthesis%2520and%2520receptor%2520binding%2520studies%2520of%2520some%2520new%2520arylcarboxamide%2520derivatives%2520as%2520sigma-1%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D1021%26epage%3D1025%26doi%3D10.1016%2Fj.bmcl.2014.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span> <span> </span><span class="NLM_article-title">Improving selectivity preserving affinity: new piperidine-4-carboxamide derivatives as effective sigma-1-ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25528334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=797-808&author=D.+Zampieriauthor=E.+Lauriniauthor=L.+Vioauthor=M.+Fermegliaauthor=S.+Priclauthor=B.+Wunschauthor=D.+Schepmannauthor=M.+G.+Mamolo&title=Improving+selectivity+preserving+affinity%3A+new+piperidine-4-carboxamide+derivatives+as+effective+sigma-1-ligands&doi=10.1016%2Fj.ejmech.2014.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Improving selectivity preserving affinity: New piperidine-4-carboxamide derivatives as effective sigma-1-ligands</span></div><div class="casAuthors">Zampieri, Daniele; Laurini, Erik; Vio, Luciano; Fermeglia, Maurizio; Pricl, Sabrina; Wunsch, Bernhard; Schepmann, Dirk; Mamolo, Maria Grazia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">797-808</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We report the design, synthesis and binding evaluation against σ1 and σ2 receptors of a series of new piperidine-4-carboxamide derivs. variously substituted on the amide nitrogen atom.  Specifically, we assessed the effects exerted on σ receptor affinity by substituting the N-benzylcarboxamide group present on a series of compds. previously synthesized in our lab. with different cyclic or linear moieties.  The synthesized compds. were tested to est. their affinity and selectivity toward σ1 and σ2 receptors.  Very high σ1 affinity (Ki = 3.7 nM) and Kiσ2/Kiσ1 selectivity ratio (351) were found for the tetrahydroquinoline deriv. (I), featuring a 4-chlorobenzyl moiety linked to the piperidine nitrogen atom.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNp9cq6AJhLVg90H21EOLACvtfcHk0ljdBljKDQAEwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFOhtQ%253D%253D&md5=64e12545c5515b59656f239e429b2dad</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26atitle%3DImproving%2520selectivity%2520preserving%2520affinity%253A%2520new%2520piperidine-4-carboxamide%2520derivatives%2520as%2520effective%2520sigma-1-ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D90%26spage%3D797%26epage%3D808%26doi%3D10.1016%2Fj.ejmech.2014.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menegazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span> <span> </span><span class="NLM_article-title">New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3206</span>– <span class="NLM_lpage">3209</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2018.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30143421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGltrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3206-3209&author=D.+Zampieriauthor=M.+Romanoauthor=R.+Menegazziauthor=M.+G.+Mamolo&title=New+piperidine-based+derivatives+as+sigma+receptor+ligands.+Synthesis+and+pharmacological+evaluation&doi=10.1016%2Fj.bmcl.2018.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation</span></div><div class="casAuthors">Zampieri, Daniele; Romano, Maurizio; Menegazzi, Renzo; Mamolo, Maria Grazia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3206-3209</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma receptor (σR) family has been considered mysterious for a long time.  In fact, the σ2R subtype has been cloned only recently, revealing its identity as TMEM97, a NPC1-binding protein involved in cholesterol biosynthesis and implicated in the pathogenesis of cancer and neurol. disorders.  With the aim of developing new chem. entities gifted with σR affinity, herein we report the design and synthesis of new piperidine-based alkylacetamide derivs. with mixed affinity towards both σ1 and σ2R subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxNLFUGT_J7LVg90H21EOLACvtfcHk0ljdBljKDQAEwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGltrnJ&md5=09f6823bcda9917a642140a0727a492f</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DMenegazzi%26aufirst%3DR.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26atitle%3DNew%2520piperidine-based%2520derivatives%2520as%2520sigma%2520receptor%2520ligands.%2520Synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3206%26epage%3D3209%26doi%3D10.1016%2Fj.bmcl.2018.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamagni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.08.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2016.08.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27614411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWisL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=649-665&author=M.+Ruiauthor=D.+Rossiauthor=A.+Marraauthor=M.+Paolilloauthor=S.+Schinelliauthor=D.+Curtiauthor=A.+Teseiauthor=M.+Cortesiauthor=A.+Zamagniauthor=E.+Lauriniauthor=S.+Priclauthor=D.+Schepmannauthor=B.+Wunschauthor=E.+Urbanauthor=V.+Paceauthor=S.+Collina&title=Synthesis+and+biological+evaluation+of+new+aryl-alkyl%28alkenyl%29-4-benzylpiperidines%2C+novel+Sigma+Receptor+%28SR%29+modulators%2C+as+potential+anticancer-agents&doi=10.1016%2Fj.ejmech.2016.08.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents</span></div><div class="casAuthors">Rui, Marta; Rossi, Daniela; Marra, Annamaria; Paolillo, Mayra; Schinelli, Sergio; Curti, Daniela; Tesei, Anna; Cortesi, Michela; Zamagni, Alice; Laurini, Erik; Pricl, Sabrina; Schepmann, Dirk; Wunsch, Bernhard; Urban, Ernst; Pace, Vittorio; Collina, Simona</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">649-665</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis and biol. profile of aryl-alkyl(alkenyl)-4-benzylpiperidine derivs., e.g., I (Ar = 2-naphthyl, phenyl), as novel potential anticancer drugs targeting SR is reported.  Among them, I (Ar = 2-naphthyl) (RC-106) exhibited a preclin. profile of antitumor efficacy on a panel of cell lines representative of different cancer types (i.e. Paca3, MDA-MB 231) expressing both SRs, and emerged as a hit compd. of a new class of SR modulators potentially useful for the treatment of cancer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVGoFaQvZxE7Vg90H21EOLACvtfcHk0ljdBljKDQAEwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWisL3J&md5=4131677175477bfe65931c00e61babf5</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.08.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.08.067%26sid%3Dliteratum%253Aachs%26aulast%3DRui%26aufirst%3DM.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DMarra%26aufirst%3DA.%26aulast%3DPaolillo%26aufirst%3DM.%26aulast%3DSchinelli%26aufirst%3DS.%26aulast%3DCurti%26aufirst%3DD.%26aulast%3DTesei%26aufirst%3DA.%26aulast%3DCortesi%26aufirst%3DM.%26aulast%3DZamagni%26aufirst%3DA.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DUrban%26aufirst%3DE.%26aulast%3DPace%26aufirst%3DV.%26aulast%3DCollina%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520new%2520aryl-alkyl%2528alkenyl%2529-4-benzylpiperidines%252C%2520novel%2520Sigma%2520Receptor%2520%2528SR%2529%2520modulators%252C%2520as%2520potential%2520anticancer-agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D649%26epage%3D665%26doi%3D10.1016%2Fj.ejmech.2016.08.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Rigidity versus flexibility: Is this an issue in sigma1 receptor ligand affinity and activity?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5505</span>– <span class="NLM_lpage">5519</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00585</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00585" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVyitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5505-5519&author=F.+Weberauthor=S.+Bruneauthor=F.+Borgelauthor=C.+Langeauthor=K.+Korpisauthor=P.+J.+Bednarskiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=D.+Schepmannauthor=B.+Wunsch&title=Rigidity+versus+flexibility%3A+Is+this+an+issue+in+sigma1+receptor+ligand+affinity+and+activity%3F&doi=10.1021%2Facs.jmedchem.6b00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?</span></div><div class="casAuthors">Weber, Frauke; Brune, Stefanie; Boergel, Frederik; Lange, Carsten; Korpis, Katharina; Bednarski, Patrick J.; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5505-5519</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stereoisomeric 2,5-diazabicyclo[2.2.2]octanes 14 and 15 were prepd. in a chiral-pool synthesis starting from (S)- or (R)-aspartate.  The key step in the synthesis was a Dieckmann-analogous cyclization of (dioxopiperazinyl)acetates 8, which involved trapping of the intermediate hemiketal anion with Me3SiCl.  The σ1 affinity was tested using membrane prepns. from animal (guinea pig) and human origin.  The binding of bicyclic compds. was analyzed by mol. dynamics simulations based on a 3D homol. model of the σ1 receptor.  The good correlation between Ki values obsd. in the σ1 assays and calcd. free binding energy, coupled with the identification of four crucial ligand/receptor interactions, allowed the formulation of structure-affinity relationships.  In an in vitro antitumor assay with seven human tumor cell lines, the bicyclic compds. inhibited selectively the growth of the cell line A427, which is due to induction of apoptosis.  In this assay, the compds. behave like the known σ1 receptor antagonist haloperidol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMpZXtybW1V7Vg90H21EOLACvtfcHk0lhLuROXeP7Eng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVyitr0%253D&md5=d5fc4600fcd605c8b191a921bddf5e56</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00585%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DBorgel%26aufirst%3DF.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DRigidity%2520versus%2520flexibility%253A%2520Is%2520this%2520an%2520issue%2520in%2520sigma1%2520receptor%2520ligand%2520affinity%2520and%2520activity%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5505%26epage%3D5519%26doi%3D10.1021%2Facs.jmedchem.6b00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span> <span> </span><span class="NLM_article-title">Norbenzomorphan scaffold: chemical tool for modulating sigma receptor-subtype selectivity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=455-460&author=J.+J.+Sahnauthor=T.+R.+Hodgesauthor=J.+Z.+Chanauthor=S.+F.+Martin&title=Norbenzomorphan+scaffold%3A+chemical+tool+for+modulating+sigma+receptor-subtype+selectivity&doi=10.1021%2Facsmedchemlett.7b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Norbenzomorphan Scaffold: Chemical Tool for Modulating Sigma Receptor-Subtype Selectivity</span></div><div class="casAuthors">Sahn, James J.; Hodges, Timothy R.; Chan, Jessica Z.; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">455-460</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Some norbenzomorphans exhibit high affinity for sigma 1 and sigma 2 receptors, and varying the position of substituents on the arom. ring of this scaffold has a significant effect on subtype selectivity.  In particular, compds. bearing several different substituents at C7 of the norbenzomorphan ring system exhibit a general preference for the sigma 1 receptor, whereas the corresponding C8-substituted analogs preferentially bind at the sigma 2 receptor.  These findings suggest that the norbenzomorphan scaffold may be a unique chem. template that can be easily tuned to prep. small mols. for use as tool compds. to study the specific biol. effects arising from preferential binding at either sigma receptor subtype.  In the absence of structural characterization data for the sigma 2 receptor, such compds. will be useful toward refining the pharmacophore model of its binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwvE0Es1OLS7Vg90H21EOLACvtfcHk0lhLuROXeP7Eng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKlsLs%253D&md5=2ccfff058d5a97c7f09d42bcf0428ef6</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00066%26sid%3Dliteratum%253Aachs%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DHodges%26aufirst%3DT.%2BR.%26aulast%3DChan%26aufirst%3DJ.%2BZ.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DNorbenzomorphan%2520scaffold%253A%2520chemical%2520tool%2520for%2520modulating%2520sigma%2520receptor-subtype%2520selectivity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D455%26epage%3D460%26doi%3D10.1021%2Facsmedchemlett.7b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linkens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span> <span> </span><span class="NLM_article-title">Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2018.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29656199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslShu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=557-567&author=K.+Linkensauthor=H.+R.+Schmidtauthor=J.+J.+Sahnauthor=A.+C.+Kruseauthor=S.+F.+Martin&title=Investigating+isoindoline%2C+tetrahydroisoquinoline%2C+and+tetrahydrobenzazepine+scaffolds+for+their+sigma+receptor+binding+properties&doi=10.1016%2Fj.ejmech.2018.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties</span></div><div class="casAuthors">Linkens, Kathryn; Schmidt, Hayden R.; Sahn, James J.; Kruse, Andrew C.; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">557-567</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Substituted norbenzomorphans are known to display high affinity and selectivity for the two sigma receptor (σR) subtypes.  In order to study the effects of simplifying the structures of these compds., a scaffold hopping strategy was used to design several novel sets of substituted isoindolines, tetrahydroisoquinolines and tetrahydro-2-benzazepines.  The binding affinities of these new compds. for the sigma 1 (σ1R) and sigma 2 (σ2R) receptors were detd., and some analogs were identified that exhibit high affinity (Ki ≤ 25 nM) and significant selectivity (>10-fold) for σ1R or σ2R.  The preferred binding modes of selected compds. for the σ1R are predicted by modeling studies, and the nature of substituents on the arom. ring and the nitrogen atom of the bicyclic skeleton appears to affect the preferred binding orientation of σ1R-preferring ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmY1yq5EydQLVg90H21EOLACvtfcHk0lj89zHsU2R6lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslShu7w%253D&md5=f4781ad271db779747c333f55e1c1ada</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DLinkens%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DInvestigating%2520isoindoline%252C%2520tetrahydroisoquinoline%252C%2520and%2520tetrahydrobenzazepine%2520scaffolds%2520for%2520their%2520sigma%2520receptor%2520binding%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D557%26epage%3D567%26doi%3D10.1016%2Fj.ejmech.2018.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasebein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frehland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis, sigma receptor affinity, and pharmacological evaluation of 5-phenylsulfanyl- and 5-benzyl-substituted tetrahydro-2-benzazepines</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fcmdc.201402110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24895069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVegt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1697-1703&author=P.+Hasebeinauthor=B.+Frehlandauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis%2C+sigma+receptor+affinity%2C+and+pharmacological+evaluation+of+5-phenylsulfanyl-+and+5-benzyl-substituted+tetrahydro-2-benzazepines&doi=10.1002%2Fcmdc.201402110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, σ Receptor Affinity, and Pharmacological Evaluation of 5-Phenylsulfanyl- and 5-Benzyl-Substituted Tetrahydro-2-benzazepines</span></div><div class="casAuthors">Hasebein, Peer; Frehland, Bastian; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1697-1703</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">N-Alkyl and N-benzyl benzyl- and phenylthio-substituted benzazepines I [R = H, Me, Bu, BuCH2, i-Bu, Me2C:CHCH2, cyclopropylmethyl, cyclohexylmethyl, Ph(CH2)n, 2-furanylmethyl, 2-thienylmethyl, 4-FC6H4CH2, 4-MeOC6H4CH2; X = S, CH2; n = 1, 2, 4] were prepd. as selective σ-receptor inhibitors; benzazepines with linear or branched alkyl or alkenyl substituents contg. at least an Bu substructure had high affinities for σ1 receptors.  I (X = CH2) were prepd. using a Heck reaction with acrylonitrile, a Stetter reaction with benzaldehyde, reductive cyclization, and reductive amination or alkylation reactions to introduce the azepine substituents as the key steps.  I (R = Bu, 4-FC6H4CH2; X = CH2) showed high selectivity for σ1 receptors over more than 50 other relevant targets, including the σ2 receptor subtype and various binding sites of the N-methyl-D-aspartate receptor; side effects upon i.p. injection of I (R = Bu, 4-FC6H4CH2; X = CH2) were not obsd. in mice at doses < 100 mg/kg.  I (R = Bu, 4-FC6H4CH2; X = CH2) did not show significant analgesic and cognition-enhancing activities, and I (R = 4-FC6H4CH2; X = CH2) did not have any antidepressant-like effects in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzbox_QwlbIbVg90H21EOLACvtfcHk0li6dpRLkLlIpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVegt7k%253D&md5=83bb1519eca885023b34d39e6ccb25df</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402110%26sid%3Dliteratum%253Aachs%26aulast%3DHasebein%26aufirst%3DP.%26aulast%3DFrehland%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%252C%2520sigma%2520receptor%2520affinity%252C%2520and%2520pharmacological%2520evaluation%2520of%25205-phenylsulfanyl-%2520and%25205-benzyl-substituted%2520tetrahydro-2-benzazepines%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1697%26epage%3D1703%26doi%3D10.1002%2Fcmdc.201402110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasebein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frehland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmkuhl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohlich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of like- and unlike-configured tetrahydro-2-benzazepines with the alpha-substituted benzyl moiety in the 5-position</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5407</span>– <span class="NLM_lpage">5426</span>, <span class="refDoi"> DOI: 10.1039/C4OB00510D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC4OB00510D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24934693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSru7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=5407-5426&author=P.+Hasebeinauthor=B.+Frehlandauthor=K.+Lehmkuhlauthor=R.+Frohlichauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis+and+pharmacological+evaluation+of+like-+and+unlike-configured+tetrahydro-2-benzazepines+with+the+alpha-substituted+benzyl+moiety+in+the+5-position&doi=10.1039%2FC4OB00510D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of like- and unlike-configured tetrahydro-2-benzazepines with the α-substituted benzyl moiety in the 5-position</span></div><div class="casAuthors">Hasebein, Peer; Frehland, Bastian; Lehmkuhl, Kirstin; Froehlich, Roland; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">5407-5426</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A large set of tetrahydro-2-benzazepine derivs. with an α-hydroxy or α-(aryl)alkoxy substituted benzyl moiety in the 5-position was prepd. according to a recently reported [C6C1 + C3N] synthetic strategy.  A Heck reaction of 2-iodobenzaldehyde acetal and a subsequent Stetter reaction led to a ketone intermediate which was reduced diastereoselectively to form a like-configured alc.  A diastereomeric unlike-configured alc. was obtained by a Mitsunobu inversion (Mitsunobu epimerization).  Alkylation and reductive cyclization of the diastereomeric alcs. provided like-configured and unlike-configured 2-benzazepine derivs., which allowed the introduction of various substituents at the N-atom.  Anal. of a relationship between the structure and the σ1-affinity revealed that large substituents such as the Bu, benzyl or 4-phenylbutyl moiety at the benzazepine N-atom resulted in high affinity ligands.  A methoxybenzyl ether is less tolerated by a σ1-receptor [i.e., σ-non-opioid intracellular receptors, σ-receptor 1] than a Me ether or an alc.  Unlike-configured alcs. show slightly higher σ1-affinity than their like-configured diastereomers.  With respect to the σ1-affinity, σ1/σ2 selectivity and lipophilic ligand efficiency, like-configured and unlike-configured alcs. represent the most promising σ1-ligands of this series.  Interactions of the novel 2-benzazepines with various binding sites of the NMDA receptor were not obsd.  The synthesis of the target compds. was achieved using (βR,γR)-rel-γ-hydroxy-β-[2-(dimethoxymethyl)phenyl]benzenebutanenitrile and (βR,γS)-rel-γ-hydroxy-β-[2-(dimethoxymethyl)phenyl]benzenebutanenitrile as key intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDj7RiKA5nS7Vg90H21EOLACvtfcHk0liK8pFeM6KRSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSru7fL&md5=58bec6e51e01aaf652ca38398aa9537e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1039%2FC4OB00510D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB00510D%26sid%3Dliteratum%253Aachs%26aulast%3DHasebein%26aufirst%3DP.%26aulast%3DFrehland%26aufirst%3DB.%26aulast%3DLehmkuhl%26aufirst%3DK.%26aulast%3DFrohlich%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520like-%2520and%2520unlike-configured%2520tetrahydro-2-benzazepines%2520with%2520the%2520alpha-substituted%2520benzyl%2520moiety%2520in%2520the%25205-position%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26spage%3D5407%26epage%3D5426%26doi%3D10.1039%2FC4OB00510D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship study of a new series of selective sigma(1) receptor ligands for the treatment of pain: 4-aminotriazoles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2441</span>– <span class="NLM_lpage">2451</span>, <span class="refDoi"> DOI: 10.1021/jm501920g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501920g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlWms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2441-2451&author=J.+L.+Diazauthor=U.+Christmannauthor=A.+Fernandezauthor=A.+Torrensauthor=A.+Portauthor=R.+Pascualauthor=I.+Alvarezauthor=J.+Burguenoauthor=X.+Monroyauthor=A.+Monteroauthor=A.+Baladaauthor=J.+M.+Velaauthor=C.+Almansa&title=Synthesis+and+structure-activity+relationship+study+of+a+new+series+of+selective+sigma%281%29+receptor+ligands+for+the+treatment+of+pain%3A+4-aminotriazoles&doi=10.1021%2Fjm501920g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationship Study of a New Series of Selective σ1 Receptor Ligands for the Treatment of Pain: 4-Aminotriazoles</span></div><div class="casAuthors">Diaz, Jose Luis; Christmann, Ute; Fernandez, Ariadna; Torrens, Antoni; Port, Adriana; Pascual, Rosalia; Alvarez, Ines; Burgueno, Javier; Monroy, Xavier; Montero, Ana; Balada, Ariadna; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2441-2451</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 4-aminotriazoles I [R1 = 4-Cl-C6H4, 3,4-Cl2-C6H3, benzyl, cyclohexyl, etc; R2 = H, COMe, SO2Me, etc; R3 = piperidin-1-yl, morpholin-1-yl, 4-cyclohexylpiperizin-1-yl, etc; n = 1, 2] as potent σ1 receptor (σ1R) ligands are reported.  The compds. were prepd. using a 4-5-step process, involving as a key step a click chem. reaction between ynamides and azides.  The most active compds. exhibited nanomolar potency for the σ1R, and the selectivity over the σ2R was improved on decreasing the central amine basicity.  It was concluded that in order to achieve good σ1R potency a min. lipophilicity was required, while limiting to a defined range of cLogP avoided human ether-a-go-go-related gene channel inhibition.  This made the most interesting derivs. to be concd. in a narrow margin of lipophilicity.  Among them, compd. I [R1 = 2,3-Cl2-benzyl, R2 = H, R3 = morpholin-1-yl, n = 1] exhibited the most potent in vivo antinociceptive properties, which are indicative of its antagonist character.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxmyKI9YzVhbVg90H21EOLACvtfcHk0liK8pFeM6KRSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlWms78%253D&md5=7dc178db143bbce4f8c7f33e62a062b6</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm501920g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501920g%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DChristmann%26aufirst%3DU.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DTorrens%26aufirst%3DA.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DAlvarez%26aufirst%3DI.%26aulast%3DBurgueno%26aufirst%3DJ.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DMontero%26aufirst%3DA.%26aulast%3DBalada%26aufirst%3DA.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520study%2520of%2520a%2520new%2520series%2520of%2520selective%2520sigma%25281%2529%2520receptor%2520ligands%2520for%2520the%2520treatment%2520of%2520pain%253A%25204-aminotriazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2441%26epage%3D2451%26doi%3D10.1021%2Fjm501920g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1010</span>, <span class="refDoi"> DOI: 10.1021/mp300023x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300023x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFWhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=996-1010&author=S.+Wangauthor=Y.+Liauthor=J.+Wangauthor=L.+Chenauthor=L.+Zhangauthor=H.+Yuauthor=T.+Hou&title=ADMET+evaluation+in+drug+discovery.+12.+Development+of+binary+classification+models+for+prediction+of+hERG+potassium+channel+blockage&doi=10.1021%2Fmp300023x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">ADMET Evaluation in Drug Discovery. 12. Development of Binary Classification Models for Prediction of hERG Potassium Channel Blockage</span></div><div class="casAuthors">Wang, Sichao; Li, Youyong; Wang, Junmei; Chen, Lei; Zhang, Liling; Yu, Huidong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">996-1010</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the human ether-a-go-go related gene (hERG) potassium channel may result in QT interval prolongation, which causes severe cardiac side effects and is a major problem in clin. studies of drug candidates.  The development of in silico tools to filter out potential hERG potassium channel blockers in early stages of the drug discovery process is of considerable interest.  Here, a diverse set of 806 compds. with hERG inhibition data was assembled, and the binary hERG classification models using naive Bayesian classification and recursive partitioning (RP) techniques were established and evaluated.  The naive Bayesian classifier based on mol. properties and the ECFP_8 fingerprints yielded 84.8% accuracy for the training set using the leave-one-out (LOO) cross-validation procedure and 85% accuracy for the test set of 120 mols.  For the two addnl. test sets, the model achieved 89.4% accuracy for the WOMBAT-PK test set, and 86.1% accuracy for the PubChem test set.  The naive Bayesian classifiers gave better predictions than the RP classifiers.  Moreover, the Bayesian classifier, employing mol. fingerprints, highlights the important structural fragments favorable or unfavorable for hERG potassium channel blockage, which offers extra valuable information for the design of compds. avoiding undesirable hERG activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJvb2LvQcBbVg90H21EOLACvtfcHk0liK8pFeM6KRSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFWhsLs%253D&md5=4949da9ed18a0769f471bc200cf475cf</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fmp300023x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300023x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DADMET%2520evaluation%2520in%2520drug%2520discovery.%252012.%2520Development%2520of%2520binary%2520classification%2520models%2520for%2520prediction%2520of%2520hERG%2520potassium%2520channel%2520blockage%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D996%26epage%3D1010%26doi%3D10.1021%2Fmp300023x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">ADMET evaluation in drug discovery. 16. Predicting hERG blockers by combining multiple pharmacophores and machine learning approaches</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2855</span>– <span class="NLM_lpage">2866</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.6b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2gsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=2855-2866&author=S.+Wangauthor=H.+Sunauthor=H.+Liuauthor=D.+Liauthor=Y.+Liauthor=T.+Hou&title=ADMET+evaluation+in+drug+discovery.+16.+Predicting+hERG+blockers+by+combining+multiple+pharmacophores+and+machine+learning+approaches&doi=10.1021%2Facs.molpharmaceut.6b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches</span></div><div class="casAuthors">Wang, Shuangquan; Sun, Huiyong; Liu, Hui; Li, Dan; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2855-2866</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockade of human ether-´a-go-go related gene (hERG) channel by compds. may lead to drug-induced QT prolongation, arrhythmia, and Torsades de Pointes (TdP), and therefore reliable prediction of hERG liability in the early stages of drug design is quite important to reduce the risk of cardiotoxicity-related attritions in the later development stages.  In this study, pharmacophore modeling and machine learning approaches were combined to construct classification models to distinguish hERG active from inactive compds. based on a diverse data set.  First, an optimal ensemble of pharmacophore hypotheses that had good capability to differentiate hERG active from inactive compds. was identified by the recursive partitioning (RP) approach.  Then, the naive Bayesian classification (NBC) and support vector machine (SVM) approaches were employed to construct classification models by integrating multiple important pharmacophore hypotheses.  The integrated classification models showed improved predictive capability over any single pharmacophore hypothesis, suggesting that the broad binding polyspecificity of hERG can only be well characterized by multiple pharmacophores.  The best SVM model achieved the prediction accuracies of 84.7% for the training set and 82.1% for the external test set.  Notably, the accuracies for the hERG blockers and nonblockers in the test set reached 83.6% and 78.2%, resp.  Anal. of significant pharmacophores helps to understand the multimechanisms of action of hERG blockers.  We believe that the combination of pharmacophore modeling and SVM is a powerful strategy to develop reliable theor. models for the prediction of potential hERG liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpus3X-YCxqnbVg90H21EOLACvtfcHk0lgHjExx4q9F8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2gsbbE&md5=4e7e3187e7ce589a48ed78e9d212fdf4</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00471%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DADMET%2520evaluation%2520in%2520drug%2520discovery.%252016.%2520Predicting%2520hERG%2520blockers%2520by%2520combining%2520multiple%2520pharmacophores%2520and%2520machine%2520learning%2520approaches%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D2855%26epage%3D2866%26doi%3D10.1021%2Facs.molpharmaceut.6b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuberes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contijoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enrech, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeste, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 1:4-acylamino derivatives</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1039/C7MD00077D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC7MD00077D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30108834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsVWju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1235-1245&author=J.+L.+Diazauthor=J.+Corberaauthor=R.+Cuberesauthor=M.+Contijochauthor=R.+Enrechauthor=S.+Yesteauthor=A.+Monteroauthor=A.+Dordalauthor=X.+Monroyauthor=C.+Almansa&title=Pyrazolo%5B3%2C4-d%5Dpyrimidines+as+sigma-1+receptor+ligands+for+the+treatment+of+pain.+Part+1%3A4-acylamino+derivatives&doi=10.1039%2FC7MD00077D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 1: 4-acylamino derivatives</span></div><div class="casAuthors">Diaz, Jose Luis; Corbera, Jordi; Cuberes, Rosa; Contijoch, Montserrat; Enrech, Raquel; Yeste, Sandra; Montero, Ana; Dordal, Albert; Monroy, Xavier; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-1245</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis of a new series of 4-acylaminopyrazolo[3,4-d]pyrimidines active on the sigma-1 receptor (σ1R) is reported.  Compds. were efficiently prepd. using a two to three step process starting from com. available 1H-pyrazolo[3,4-d]pyrimidin-4-amine.  A SAR study shows that the σ1R requires the presence of relatively highly lipophilic substituents at opposite sides of the central scaffold, while selectivity vs. the σ2R can be improved by shortening the distance of the basic nitrogen to it.  Compd. I was among the most active and selective in vitro derivs. and exhibited potent antinociceptive properties in several pain models in mice, indicating its antagonistic behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzRN1Voysu0rVg90H21EOLACvtfcHk0lgHjExx4q9F8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsVWju7g%253D&md5=32326626a8e324cd3093d2bc9f814919</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1039%2FC7MD00077D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00077D%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DCorbera%26aufirst%3DJ.%26aulast%3DCuberes%26aufirst%3DR.%26aulast%3DContijoch%26aufirst%3DM.%26aulast%3DEnrech%26aufirst%3DR.%26aulast%3DYeste%26aufirst%3DS.%26aulast%3DMontero%26aufirst%3DA.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DPyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520sigma-1%2520receptor%2520ligands%2520for%2520the%2520treatment%2520of%2520pain.%2520Part%25201%253A4-acylamino%2520derivatives%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1235%26epage%3D1245%26doi%3D10.1039%2FC7MD00077D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 2: introduction of cyclic substituents in position 4</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1246</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1039/C7MD00078B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC7MD00078B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30108835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsVWju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1246-1254&author=J.+L.+Diazauthor=J.+Corberaauthor=D.+Martinezauthor=M.+Bordasauthor=C.+Sicreauthor=R.+Pascualauthor=M.+J.+Pretelauthor=A.+P.+Marinauthor=A.+Monteroauthor=A.+Dordalauthor=I.+Alvarezauthor=C.+Almansa&title=Pyrazolo%5B3%2C4-d%5Dpyrimidines+as+sigma-1+receptor+ligands+for+the+treatment+of+pain.+Part+2%3A+introduction+of+cyclic+substituents+in+position+4&doi=10.1039%2FC7MD00078B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 2: Introduction of cyclic substituents in position 4</span></div><div class="casAuthors">Diaz, Jose Luis; Corbera, Jordi; Martinez, Daniel; Bordas, Magda; Sicre, Cristina; Pascual, Rosalia; Pretel, Ma Jose; Marin, Ana Paz; Montero, Ana; Dordal, Albert; Alvarez, Ines; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1246-1254</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The replacement of acylamino group by cyclic substituents in the position 4 of the pyrazolo[3,4-d]pyrimidine scaffold I [R = Ph, pyridin-3-yl, 1-methyl-1H-pyrazol-5-yl, etc.], led to highly active sigma-1 receptor (σ1R) ligands.  Ph or pyrazolyl groups were the best in terms of affinity for the σ1R and the compd. I [R = 1-methyl-1H-pyrazol-5-yl], was the most selective.  Compd. I [R = 1-methyl-1H-pyrazol-5-yl] was also one of the best σ1R ligands ever described in terms of lipophilic ligand efficiency, which translated into a good physicochem. and ADMET profile.  In addn., compd. I [R = 1-methyl-1H-pyrazol-5-yl] was identified as an antagonist of the σ1R in view of its potent antinociceptive profile in several pain models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWZ6GM1HCoxbVg90H21EOLACvtfcHk0lgHjExx4q9F8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsVWju7k%253D&md5=a09c39a7a40cb87acd7ad477fe4a67a9</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1039%2FC7MD00078B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00078B%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DCorbera%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DD.%26aulast%3DBordas%26aufirst%3DM.%26aulast%3DSicre%26aufirst%3DC.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DPretel%26aufirst%3DM.%2BJ.%26aulast%3DMarin%26aufirst%3DA.%2BP.%26aulast%3DMontero%26aufirst%3DA.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DAlvarez%26aufirst%3DI.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DPyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520sigma-1%2520receptor%2520ligands%2520for%2520the%2520treatment%2520of%2520pain.%2520Part%25202%253A%2520introduction%2520of%2520cyclic%2520substituents%2520in%2520position%25204%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1246%26epage%3D1254%26doi%3D10.1039%2FC7MD00078B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1<i>H</i>)-quinolinone scaffold as a potential analgesic</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24735647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=216-230&author=Y.+Lanauthor=Y.+Chenauthor=X.+Xuauthor=Y.+Qiuauthor=S.+Liuauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+a+novel+sigma-1+receptor+antagonist+based+on+3%2C4-dihydro-2%281H%29-quinolinone+scaffold+as+a+potential+analgesic&doi=10.1016%2Fj.ejmech.2014.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic</span></div><div class="casAuthors">Lan, Yu; Chen, Yin; Xu, Xiangqing; Qiu, Yinli; Liu, Shicheng; Liu, Xin; Liu, Bi-Feng; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">216-230</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis and sigma-1 receptor (σ1R) antagonist activity of a new series of 3,4-dihydro-2(1H)-quinolinones, e.g. I [R = PhCH2, 4-MeC6H4CH2, 4-FC6H4CH2, etc.] are reported.  The new compds. were evaluated in vitro in sigma-1 and sigma-2 receptor-binding assays in guinea pig brain membranes.  The structure-activity relationship led us to the promising deriv. I [R = 4-FC6H4CH2].  The compds. with highest affinity and greatest selectivity were further profiled, and compd. I [R = 4-FC6H4CH2] had a high binding const. for sigma-1 receptor (Kiσ1 = 1.22 nM) and high sigma-1/2 selectivity (1066-fold).  Thus, this compd., which proved to be an antagonist of sigma-1 receptor, emerged as the most interesting candidate.  In addn., this compd. exerted dose-dependent antinociceptive effects in the formalin test.  These characteristics suggested that the potent and selective compd. I [R = 4-FC6H4CH2] could be a potent candidate for pain treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo56iTGYzwCw7Vg90H21EOLACvtfcHk0lgQ5EzJVCa8Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWns7o%253D&md5=04009cdd675bf12a18a5869979c2cf10</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520sigma-1%2520receptor%2520antagonist%2520based%2520on%25203%252C4-dihydro-2%25281H%2529-quinolinone%2520scaffold%2520as%2520a%2520potential%2520analgesic%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D216%26epage%3D230%26doi%3D10.1016%2Fj.ejmech.2014.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10404</span>– <span class="NLM_lpage">10423</span>, <span class="refDoi"> DOI: 10.1021/jm501207r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501207r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10404-10423&author=Y.+Lanauthor=Y.+Chenauthor=X.+Caoauthor=J.+Zhangauthor=J.+Wangauthor=X.+Xuauthor=Y.+Qiuauthor=T.+Zhangauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+sigma-1+receptor+antagonists+based+on+pyrimidine+scaffold+as+agents+for+treating+neuropathic+pain&doi=10.1021%2Fjm501207r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Novel Sigma-1 Receptor Antagonists Based on Pyrimidine Scaffold As Agents for Treating Neuropathic Pain</span></div><div class="casAuthors">Lan, Yu; Chen, Yin; Cao, Xudong; Zhang, Juecheng; Wang, Jie; Xu, Xiangqing; Qiu, Yinli; Zhang, Tan; Liu, Xin; Liu, Bi-Feng; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10404-10423</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and synthesis of a new series of pyrimidines as potent sigma-1 receptor (σ1R) antagonists, assocd. with pharmacol. antineuropathic pain activity, are the focus of this article.  The new compds. were evaluated in vitro in σ-1 and σ-2 receptor binding assays.  The nature of the pyrimidine scaffold was crucial for activity, and a basic amine was shown to be necessary according to the known pharmacophoric model.  The most promising deriv. was 5-chloro-2-(4-chlorophenyl)-4-methyl-6-(3-(piperidin-1-yl)propoxy)pyrimidine (I), which exhibited a high binding affinity to σ1R receptor (Ki σ1 = 1.06 nM) and good σ-1/2 selectivity (1344-fold).  In in vivo tests, I exerted dose-dependent antinociceptive effects in mice formalin model and rats CCI models of neuropathic pain.  In addn., no motor impairments were found in rotarod tests; acceptable pharmacokinetic properties were also noted.  These data suggest I may constitute a novel class of drugs for the treatment of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-dkiomNDrPLVg90H21EOLACvtfcHk0lgQ5EzJVCa8Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsbbE&md5=bd003488b014b40e739cc42c825424ce</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm501207r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501207r%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520sigma-1%2520receptor%2520antagonists%2520based%2520on%2520pyrimidine%2520scaffold%2520as%2520agents%2520for%2520treating%2520neuropathic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10404%26epage%3D10423%26doi%3D10.1021%2Fjm501207r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of sigma-1 (sigma1) receptor ligands based on phenyl-1,2,4-oxadiazole derivatives</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">e1800599</span> <span class="refDoi"> DOI: 10.1002/cbdv.201800599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fcbdv.201800599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30549193" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&author=X.+Caoauthor=Z.+Yaoauthor=F.+Douauthor=Y.+Zhangauthor=Y.+Qiuauthor=S.+Zhaoauthor=X.+Xuauthor=X.+Liuauthor=B.+F.+Liuauthor=Y.+Chenauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+sigma-1+%28sigma1%29+receptor+ligands+based+on+phenyl-1%2C2%2C4-oxadiazole+derivatives&doi=10.1002%2Fcbdv.201800599"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201800599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201800599%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DDou%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520ligands%2520based%2520on%2520phenyl-1%252C2%252C4-oxadiazole%2520derivatives%26jtitle%3DChem.%2520Biodiversity%26date%3D2019%26volume%3D16%26doi%3D10.1002%2Fcbdv.201800599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel sigma1 receptor ligands for treating neuropathic pain: 6-hydroxypyridazinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2942</span>– <span class="NLM_lpage">2961</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2942-2961&author=X.+Caoauthor=Y.+Chenauthor=Y.+Zhangauthor=Y.+Lanauthor=J.+Zhangauthor=X.+Xuauthor=Y.+Qiuauthor=S.+Zhaoauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+sigma1+receptor+ligands+for+treating+neuropathic+pain%3A+6-hydroxypyridazinones&doi=10.1021%2Facs.jmedchem.5b01416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones</span></div><div class="casAuthors">Cao, Xudong; Chen, Yin; Zhang, Yifang; Lan, Yu; Zhang, Juecheng; Xu, Xiangqing; Qiu, Yinli; Zhao, Song; Liu, Xin; Liu, Bi-Feng; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2942-2961</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By use of the 6-hydroxypyridazinone framework, a new series of potent σ1 receptor ligands assocd. with pharmacol. antineuropathic pain activity was synthesized and is described in this article.  In vitro receptor binding studies revealed high σ1 receptor affinity (Ki σ1 = 1.4 nM) and excellent selectivity over not only σ2 receptor (1366-fold) but also other CNS targets (adrenergic, μ-opioid, sertonerigic receptors, etc.) for 2-(3,4-dichlorophenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (compd. 54).  Compd. 54 exhibited dose-dependent antiallodynic properties in mouse formalin model and rats chronic constriction injury (CCI) model of neuropathic pain.  In addn., functional activity of compd. 54 was evaluated using phenytoin and indicated that the compd. was a σ1 receptor antagonist.  Moreover, no motor impairments were found in rotarod tests at antiallodynic doses and no sedative side effect was evident in locomotor activity tests.  Last but not least, good safety and favorable pharmacokinetic properties were also noted.  These profiles suggest that compd. 54 may be a member of a novel class of candidate drugs for treatment of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouqLloqg6937Vg90H21EOLACvtfcHk0lgQ5EzJVCa8Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFGrsL8%253D&md5=fd377bf365861bc550f6d4dd5db20af4</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01416%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520sigma1%2520receptor%2520ligands%2520for%2520treating%2520neuropathic%2520pain%253A%25206-hydroxypyridazinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2942%26epage%3D2961%26doi%3D10.1021%2Facs.jmedchem.5b01416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Songyang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel 6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine and 5,6,7,8-tetrahydroquinazoline derivatives as sigma-1 (sigma1) receptor antagonists for the treatment of pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.02.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2016.02.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=26947609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslGisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2051-2056&author=Y.+Lanauthor=Y.+Songyangauthor=L.+Zhangauthor=Y.+Pengauthor=J.+Song&title=Synthesis+and+biological+evaluation+of+novel+6%2C7-dihydro-5H-cyclopenta%5Bd%5Dpyrimidine+and+5%2C6%2C7%2C8-tetrahydroquinazoline+derivatives+as+sigma-1+%28sigma1%29+receptor+antagonists+for+the+treatment+of+pain&doi=10.1016%2Fj.bmcl.2016.02.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel 6,7-dihydro-5H-cyclopenta[d]pyrimidine and 5,6,7,8-tetrahydroquinazoline derivatives as sigma-1 (σ1) receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Lan, Yu; Songyang, Yiyan; Zhang, Lingli; Peng, Yan; Song, Jinchun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2056</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of new series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine and 5,6,7,8-tetrahydroquinazoline derivs. as selective sigma-1 receptor (σ1R) antagonists are reported.  The receptor affinities of new compds. were evaluated in vitro in σ1 and σ2 receptor binding assays.  The structure-active relationship study leads the authors to the most promising compd., 2-(4-chlorophenyl)-4-(3-(4-methyl-1-piperidinyl)propoxy)-5,6,7,8-tetra-hydroquinazoline.  This compd. has exerted nanomolar affinity for σ1R (Kiσ1 = 15.6 nM) and high σ1/σ2 selectivity (Kiσ2 >2000 nM), and identified to be a σ1R antagonist.  In an animal model, that compd. exhibited dose dependent anti-nociceptive effects in the formalin test.  These results suggest that this compd. could be a potent analgesic for pain treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqStWdqtAESdbVg90H21EOLACvtfcHk0lghxodZ1EY33A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslGisrw%253D&md5=38ada314d89307fc732c1b21a1223920</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.077%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DY.%26aulast%3DSongyang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%25206%252C7-dihydro-5H-cyclopenta%255Bd%255Dpyrimidine%2520and%25205%252C6%252C7%252C8-tetrahydroquinazoline%2520derivatives%2520as%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2051%26epage%3D2056%26doi%3D10.1016%2Fj.bmcl.2016.02.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picconi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catenacci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirante, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peviani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span> <span> </span><span class="NLM_article-title">Identification of RC-33 as a potent and selective sigma1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-scale synthesis, physicochemical characterization and in vitro metabolic stability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2577</span>– <span class="NLM_lpage">2586</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2013.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23498917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlSisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2577-2586&author=D.+Rossiauthor=A.+Marraauthor=P.+Picconiauthor=M.+Serraauthor=L.+Catenacciauthor=M.+Sorrentiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=S.+Brambillaauthor=N.+Almiranteauthor=M.+Pevianiauthor=D.+Curtiauthor=S.+Collina&title=Identification+of+RC-33+as+a+potent+and+selective+sigma1+receptor+agonist+potentiating+NGF-induced+neurite+outgrowth+in+PC12+cells.+Part+2%3A+g-scale+synthesis%2C+physicochemical+characterization+and+in+vitro+metabolic+stability&doi=10.1016%2Fj.bmc.2013.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of RC-33 as a potent and selective σ1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-Scale synthesis, physicochemical characterization and in vitro metabolic stability</span></div><div class="casAuthors">Rossi, Daniela; Marra, Annamaria; Picconi, Pietro; Serra, Massimo; Catenacci, Laura; Sorrenti, Milena; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Brambilla, Stefania; Almirante, Nicoletta; Peviani, Marco; Curti, Daniela; Collina, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2577-2586</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Strong pharmacol. evidences indicate that σ1 receptors are implicated in the pathophysiol. of all major CNS disorders.  In the last years our research group has conducted extensive studies aimed at discovering novel σ1 ligands and we recently selected (R/S)-RC-33 as a novel potent and selective σ1 receptor agonist.  As continuation of our work in this field, here we report our efforts in the development of this new σ1 receptor agonist.  Initially, we investigated the binding of (R) and (S) enantiomers of RC-33 to the σ1 receptor by in silico expts.  The close values of the predicted affinity of (R)-RC-33 and (S)-RC-33 for the protein evidenced the non-stereoselective binding of RC-33 to the σ1 receptor; this, in turn, supported further development and characterization of RC-33 in its racemic form.  Subsequently, we set-up a scaled-up, optimized synthesis of (R/S)-RC-33 along with some compd. characterization data (e.g., soly. in different media and solid state characterization by thermal anal. techniques).  In such conditions, the compd. is subjected to a relevant oxidative metab., with a degrdn. of approx. 65% in rat and 69% in human.  Taken together, our results demonstrated that (R/S)-RC-33 is a highly potent, selective, metabolically stable σ1 agonist, a promising novel neuroprotective drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVi4udNFzvCbVg90H21EOLACvtfcHk0lghxodZ1EY33A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlSisrg%253D&md5=1005960a530e0904e4cde4caa4f016bd</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DMarra%26aufirst%3DA.%26aulast%3DPicconi%26aufirst%3DP.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DCatenacci%26aufirst%3DL.%26aulast%3DSorrenti%26aufirst%3DM.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DBrambilla%26aufirst%3DS.%26aulast%3DAlmirante%26aufirst%3DN.%26aulast%3DPeviani%26aufirst%3DM.%26aulast%3DCurti%26aufirst%3DD.%26aulast%3DCollina%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520RC-33%2520as%2520a%2520potent%2520and%2520selective%2520sigma1%2520receptor%2520agonist%2520potentiating%2520NGF-induced%2520neurite%2520outgrowth%2520in%2520PC12%2520cells.%2520Part%25202%253A%2520g-scale%2520synthesis%252C%2520physicochemical%2520characterization%2520and%2520in%2520vitro%2520metabolic%2520stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2577%26epage%3D2586%26doi%3D10.1016%2Fj.bmc.2013.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuensch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peviani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span> <span> </span><span class="NLM_article-title">A step forward in the sigma enigma: a role for chirality in the sigma1 receptor-ligand interaction?</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1039/C4MD00349G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC4MD00349G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKqsrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=138-146&author=D.+Rossiauthor=A.+Marraauthor=M.+Ruiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=D.+Schepmannauthor=B.+Wuenschauthor=M.+Pevianiauthor=D.+Curtiauthor=S.+Collina&title=A+step+forward+in+the+sigma+enigma%3A+a+role+for+chirality+in+the+sigma1+receptor-ligand+interaction%3F&doi=10.1039%2FC4MD00349G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A step forward in the sigma enigma: a role for chirality in the sigma1 receptor-ligand interaction?</span></div><div class="casAuthors">Rossi, Daniela; Marra, Annamaria; Rui, Marta; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Schepmann, Dirk; Wuensch, Bernhard; Peviani, Marco; Curti, Daniela; Collina, Simona</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">138-146</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In our recent research racemic RC-33 was identified as a potent and highly promising σ1 receptor agonist, showing excellent σ1 receptor affinity and promoting NGF-induced neurite outgrowth in PC12 cells at very low concns.  Surprisingly, both its interaction with the biol. target and its effect on neurite sprouting proved to be non-stereoselective.  Starting from the observation that a hydrogen bond center in the scaffold of a σ1 ligand is an important pharmacophoric element for receptor/ligand interaction, we hypothesized that the absence of such pharmacophoric feature in the structure of RC-33 could be also responsible for the lack of enantioselectivity in its interaction with the target receptor.  To verify our hypothesis, in this paper we evaluated - both in silico and in vitro - the ability of a series of enantiomeric arylalkylaminoalcs. and arylpyrrolidinols 1-5 to interact with the receptor.  All these compds. are structurally related to RC-33 and are characterized by the presence of an -OH group as the addnl. pharmacophore feature.  Interestingly, the results of our study show that the σ1 receptor exhibits enantiopreference toward compds. characterized by (S)-configuration at the stereogenic center bearing the arom. moiety only when the alc. group is also present at that chiral center, thus supporting our original hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOkoAJRbPJnrVg90H21EOLACvtfcHk0lhBf3mN-Vxb_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKqsrnM&md5=602f5db02f4a3e06feb4a139f2205fe0</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1039%2FC4MD00349G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00349G%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DMarra%26aufirst%3DA.%26aulast%3DRui%26aufirst%3DM.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWuensch%26aufirst%3DB.%26aulast%3DPeviani%26aufirst%3DM.%26aulast%3DCurti%26aufirst%3DD.%26aulast%3DCollina%26aufirst%3DS.%26atitle%3DA%2520step%2520forward%2520in%2520the%2520sigma%2520enigma%253A%2520a%2520role%2520for%2520chirality%2520in%2520the%2520sigma1%2520receptor-ligand%2520interaction%253F%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D138%26epage%3D146%26doi%3D10.1039%2FC4MD00349G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giacomo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteleone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liedl, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span> <span> </span><span class="NLM_article-title">Gaining in pan-affinity towards sigma 1 and sigma 2 receptors. SAR studies on arylalkylamines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2016.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27838169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVarsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=11-19&author=D.+Rossiauthor=M.+Ruiauthor=M.+Di+Giacomoauthor=D.+Schepmannauthor=B.+Wunschauthor=S.+Monteleoneauthor=K.+R.+Liedlauthor=S.+Collina&title=Gaining+in+pan-affinity+towards+sigma+1+and+sigma+2+receptors.+SAR+studies+on+arylalkylamines&doi=10.1016%2Fj.bmc.2016.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Gaining in pan-affinity towards sigma 1 and sigma 2 receptors. SAR studies on arylalkylamines</span></div><div class="casAuthors">Rossi, Daniela; Rui, Marta; Di Giacomo, Marcello; Schepmann, Dirk; Wunsch, Bernhard; Monteleone, Stefania; Liedl, Klaus R.; Collina, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma Receptor (SR) modulators are involved in different signal transduction pathways, representing important pharmacol./therapeutic tools in several pathol. conditions, such as neurodegenerative diseases and cancers.  To this purpose, numerous compds. have been developed in order to target selectively one of the two subtypes (S1R and S2R) as chemotherapeutic agent.  However, expts. have also shown that ligands which are able to bind both SR subtypes can be useful for the diagnosis and/or the treatment of cancers.  Therefore, the discovery of compds. with good affinity towards both S1R and S2R ('pan-modulators') is also of great interest and still represents a challenge up to now.  For this reason, the authors synthesized novel arylalkylamines with the aim to obtain compds. with S1R and S2R affinity in the nM range and, by modeling quant. structure-activity relationships (QSARs), the authors identified the essential structural features to obtain promising pan-compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCZxQQJDaiDbVg90H21EOLACvtfcHk0lhBf3mN-Vxb_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVarsL7I&md5=5e272850b6f8d9a770f627ba69b6f3c7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DRui%26aufirst%3DM.%26aulast%3DDi%2BGiacomo%26aufirst%3DM.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DMonteleone%26aufirst%3DS.%26aulast%3DLiedl%26aufirst%3DK.%2BR.%26aulast%3DCollina%26aufirst%3DS.%26atitle%3DGaining%2520in%2520pan-affinity%2520towards%2520sigma%25201%2520and%2520sigma%25202%2520receptors.%2520SAR%2520studies%2520on%2520arylalkylamines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D11%26epage%3D19%26doi%3D10.1016%2Fj.bmc.2016.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marottoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span> <span> </span><span class="NLM_article-title">High-affinity sigma-1 (sigma1) receptor ligands based on the sigma1 antagonist PB212</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2562</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.4155%2Ffmc-2019-0042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31633399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvF2hu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=2547-2562&author=M.+Nisoauthor=P.+D.+Mosierauthor=R.+Marottoliauthor=S.+Ferorelliauthor=G.+Cassanoauthor=G.+Gasparreauthor=M.+Leopoldoauthor=F.+Berardiauthor=C.+Abate&title=High-affinity+sigma-1+%28sigma1%29+receptor+ligands+based+on+the+sigma1+antagonist+PB212&doi=10.4155%2Ffmc-2019-0042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity sigma-1 (σ1) receptor ligands based on the σ1 antagonist PB212</span></div><div class="casAuthors">Niso, Mauro; Mosier, Philip D.; Marottoli, Roberta; Ferorelli, Savina; Cassano, Giuseppe; Gasparre, Giuseppe; Leopoldo, Marcello; Berardi, Francesco; Abate, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2547-2562</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The σ1 receptor is a druggable target involved in many physiol. processes and diseases.  To clarify its physiol. and derive therapeutic benefit, nine analogs based on the σ1 antagonist PB212 were synthesized replacing the 4-methylpiperidine with basic moieties of varying size and degree of conformational freedom.  A 3-Phenylpyrrolidine, 4-phenylpiperidine or granatane derivs. displayed the highest affinity (Ki.#x00A0; = 0.12, 0.31 or 1.03 nM).  Calcium flux assays in MCF7s1 cells indicated that the highest σ1 receptor affinity are σ1 antagonists.  Mol. models provided a structural basis for understanding the σ1 affinity and functional activity of the analogs and incorporated Glennon's σ1 pharmacophore model.  Herein, we identify new compds. exploitable as therapeutic drug leads or as tools to study σ1 receptor physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNdKWlbfMVGbVg90H21EOLACvtfcHk0lhBf3mN-Vxb_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvF2hu77F&md5=7aeacec7b3775acb3dffc268b4cd81be</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0042%26sid%3Dliteratum%253Aachs%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DMosier%26aufirst%3DP.%2BD.%26aulast%3DMarottoli%26aufirst%3DR.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DCassano%26aufirst%3DG.%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26atitle%3DHigh-affinity%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520ligands%2520based%2520on%2520the%2520sigma1%2520antagonist%2520PB212%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D2547%26epage%3D2562%26doi%3D10.4155%2Ffmc-2019-0042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sguazzini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukat, M.</span></span> <span> </span><span class="NLM_article-title">Reevaluation of fenpropimorph as a sigma receptor ligand: structure-affinity relationship studies at human sigma1 receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2912</span>– <span class="NLM_lpage">2919</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2017.04.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28495085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVahu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2912-2919&author=E.+Sguazziniauthor=H.+R.+Schmidtauthor=K.+A.+Iyerauthor=A.+C.+Kruseauthor=M.+Dukat&title=Reevaluation+of+fenpropimorph+as+a+sigma+receptor+ligand%3A+structure-affinity+relationship+studies+at+human+sigma1+receptors&doi=10.1016%2Fj.bmcl.2017.04.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Reevaluation of fenpropimorph as a σ receptor ligand: Structure-affinity relationship studies at human σ1 receptors</span></div><div class="casAuthors">Sguazzini, Elena; Schmidt, Hayden R.; Iyer, Kavita A.; Kruse, Andrew C.; Dukat, Malgorzata</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2912-2919</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fenpropimorph (1) is considered a "super high-affinity" σ1 receptor ligand (Ki = 0.005 nM for guinea pig σ1 receptors).  Here, we examine the binding of 1 and several of its deconstructed analogs at human σ1 (hσ1) receptors.  We monitored their subtype selectivity by detg. the binding affinity at σ2 receptors.  In addn., we validated an existing pharmacophore model at the mol. level by conducting 3D mol. modeling studies, using the crystal structure of hσ1 receptors, and Hydrophatic INTeractions (HINT) anal.  Our structure affinity relationship studies showed that 1 binds with lower affinity at hσ1 receptors (Ki = 17.3 nM) compared to guinea pig; moreover, we found that none of the fenpropimorph Me groups is important for its binding at hσ1 receptors, nor is stereochem.  For example, removal of all Me groups as seen in 4 resulted in an almost 5-fold higher affinity at hσ1 receptors compared to 1 and 350-fold selectivity vs. σ2 receptors.  In addn., although the O atom of the morpholine ring does not contribute to affinity at hσ1 receptors (and might even detract from it), it plays role in subtype (σ1 vs. σ2 receptor) selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMtrUEJ2w9JbVg90H21EOLACvtfcHk0lhGShSjQc_RfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVahu74%253D&md5=0ec7b28d19b5dc29acc1eaefc2dc52f9</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.088%26sid%3Dliteratum%253Aachs%26aulast%3DSguazzini%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DIyer%26aufirst%3DK.%2BA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DDukat%26aufirst%3DM.%26atitle%3DReevaluation%2520of%2520fenpropimorph%2520as%2520a%2520sigma%2520receptor%2520ligand%253A%2520structure-affinity%2520relationship%2520studies%2520at%2520human%2520sigma1%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2912%26epage%3D2919%26doi%3D10.1016%2Fj.bmcl.2017.04.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbabian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of <i>N</i>,<i>N</i>-dialkyl and <i>N</i>-alkyl-<i>N</i>-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4397</span>– <span class="NLM_lpage">4404</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.04.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2010.04.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20493718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2rurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4397-4404&author=A.+R.+Hajipourauthor=D.+Fontanillaauthor=U.+B.+Chuauthor=M.+Arbabianauthor=A.+E.+Ruoho&title=Synthesis+and+characterization+of+N%2CN-dialkyl+and+N-alkyl-N-aralkyl+fenpropimorph-derived+compounds+as+high+affinity+ligands+for+sigma+receptors&doi=10.1016%2Fj.bmc.2010.04.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors</span></div><div class="casAuthors">Hajipour, Abdol R.; Fontanilla, Dominique; Chu, Uyen B.; Arbabian, Marty; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4397-4404</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor is a unique non-opioid, non-PCP binding site that has been implicated in many different pathophysiol. conditions including psychosis, drug addiction, retinal degeneration and cancer.  Based on the structure of fenpropimorph, a high affinity (K i = 0.005 nM) sigma-1 receptor ligand and strong inhibitor of the yeast sterol isomerase (ERG2), we previously deduced a basic sigma-1 receptor pharmacophore or chem. backbone composed of a Ph ring attached to a di-substituted nitrogen atom via an alkyl chain.  Here, we report the design and synthesis of various N,N-dialkyl or N-alkyl-N-aralkyl derivs. based on this pharmacophore as well as their binding affinities to the sigma-1 receptor.  We introduce three high affinity sigma-1 receptor compds., N,N-dibutyl-3-(4-fluorophenyl)propylamine (9)(I), N,N-dibutyl-3-(4-nitrophenyl)propylamine (3)(II), and N-propyl-N'-4-aminophenylethyl-3-(4-nitrophenyl)propylamine (20)(III) with K i values of 17.7 nM, 0.36 nM, and 6 nM, resp.  In addn. to sigma receptor affinity, we show through cytotoxicity assays that growth inhibition of various tumor cell lines occurs with our high affinity N,N-dialkyl or N-alkyl-N-aralkyl derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQLoE6p6LHRrVg90H21EOLACvtfcHk0lhGShSjQc_RfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2rurY%253D&md5=26b58c34a1ba0337bd0f7a4258f7df00</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.04.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.04.078%26sid%3Dliteratum%253Aachs%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DFontanilla%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DU.%2BB.%26aulast%3DArbabian%26aufirst%3DM.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520N%252CN-dialkyl%2520and%2520N-alkyl-N-aralkyl%2520fenpropimorph-derived%2520compounds%2520as%2520high%2520affinity%2520ligands%2520for%2520sigma%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4397%26epage%3D4404%26doi%3D10.1016%2Fj.bmc.2010.04.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarrete-Vazquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austrich-Olivares, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godinez-Chaparro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Soto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Nunez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Gomez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(3,4-dichlorophenoxy)-<i>N</i>-(2-morpholin-4-ylethyl)acetamide: a selective sigma1 receptor ligand with antinociceptive effect</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2016.02.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.biopha.2016.02.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27044839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Wmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=284-293&author=G.+Navarrete-Vazquezauthor=A.+Austrich-Olivaresauthor=B.+Godinez-Chaparroauthor=S.+Hidalgo-Figueroaauthor=S.+Estrada-Sotoauthor=E.+Hernandez-Nunezauthor=H.+Torres-Gomezauthor=D.+Schepmannauthor=B.+Wunsch&title=Discovery+of+2-%283%2C4-dichlorophenoxy%29-N-%282-morpholin-4-ylethyl%29acetamide%3A+a+selective+sigma1+receptor+ligand+with+antinociceptive+effect&doi=10.1016%2Fj.biopha.2016.02.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(3,4-dichlorophenoxy)-N-(2-morpholin-4-ylethyl)acetamide: A selective σ1 receptor ligand with antinociceptive effect</span></div><div class="casAuthors">Navarrete-Vazquez, Gabriel; Austrich-Olivares, Amaya; Godinez-Chaparro, Beatriz; Hidalgo-Figueroa, Sergio; Estrada-Soto, Samuel; Hernandez-Nunez, Emanuel; Torres-Gomez, Hector; Schepmann, Dirk; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">284-293</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Compd. 2-(3,4-dichlorophenoxy)-N-(2-morpholin-4-ylethyl)acetamide (1) was designed, prepd. and the in vitro binding evaluation against σ1 and σ2 receptors was measured.  Compd. 1 showed high σ1 receptor affinity (Ki = 42 nM) and it was 36-times more selective for σ1 than σ2 receptor.  Also, it was performed a mol. docking of compd. 1 into the ligand binding pocket homol. model of σ1 receptor, showing a salt bridge between the ionized morpholine ring and Asp126, as well as important short contacts with residues Tyr120, His154 and Trp164.  Ligand efficiency indexes and predicted toxicity anal. revealed an excellent intrinsic quality of 1.  The antinociceptive effect of compd. 1 was detd. using the formalin test.  The ipsilateral local peripheral (10-300 μg/paw) and intrathecal (100 μg/rat) administration of 1 produced a redn. in formalin-induced nociception.  The in vivo results indicated that 1 may be effective in treating inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6zMh8vU3obVg90H21EOLACvtfcHk0lhGShSjQc_RfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Wmtb8%253D&md5=e3f66f5b70ae674e67db2c368cbaa30f</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2016.02.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2016.02.038%26sid%3Dliteratum%253Aachs%26aulast%3DNavarrete-Vazquez%26aufirst%3DG.%26aulast%3DAustrich-Olivares%26aufirst%3DA.%26aulast%3DGodinez-Chaparro%26aufirst%3DB.%26aulast%3DHidalgo-Figueroa%26aufirst%3DS.%26aulast%3DEstrada-Soto%26aufirst%3DS.%26aulast%3DHernandez-Nunez%26aufirst%3DE.%26aulast%3DTorres-Gomez%26aufirst%3DH.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DDiscovery%2520of%25202-%25283%252C4-dichlorophenoxy%2529-N-%25282-morpholin-4-ylethyl%2529acetamide%253A%2520a%2520selective%2520sigma1%2520receptor%2520ligand%2520with%2520antinociceptive%2520effect%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2016%26volume%3D79%26spage%3D284%26epage%3D293%26doi%3D10.1016%2Fj.biopha.2016.02.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romeo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittala, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modica, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnaturi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiechio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sposito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.04.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2019.04.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31042618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12isLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=226-235&author=G.+Romeoauthor=O.+Prezzaventoauthor=S.+Intagliataauthor=V.+Pittalaauthor=M.+N.+Modicaauthor=A.+Marrazzoauthor=R.+Turnaturiauthor=C.+Parentiauthor=S.+Chiechioauthor=E.+Arenaauthor=A.+Campisiauthor=G.+Spositoauthor=L.+Salerno&title=Synthesis%2C+in+vitro+and+in+vivo+characterization+of+new+benzoxazole+and+benzothiazole-based+sigma+receptor+ligands&doi=10.1016%2Fj.ejmech.2019.04.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands</span></div><div class="casAuthors">Romeo, Giuseppe; Prezzavento, Orazio; Intagliata, Sebastiano; Pittala, Valeria; Modica, Maria N.; Marrazzo, Agostino; Turnaturi, Rita; Parenti, Carmela; Chiechio, Santina; Arena, Emanuela; Campisi, Agata; Sposito, Giovanni; Salerno, Loredana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">226-235</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new set of 5-chlorobenzoxazole- and 5-chlorobenzothiazole-based derivs. I and II [X = O, S; n = 2, 3, 4] contg. the azepane ring as a basic moiety was designed, synthesized and evaluated through binding assays to measure their affinity and selectivity towards σ1 and σ2 receptors.  Compds. I [X = S; n = 3] and II [X = O; n = 4; X = S, n = 4], with a four units spacer between the bicyclic scaffold and the azepane ring, showed nanomolar affinity towards both receptor subtype and the best Ki values (Ki σ1 = 1.27, 2.30 and 0.78 and Ki σ2 = 7.9, 3.8 and 7.61 nM, resp.).  Evaluation of cytotoxic and apoptotic effects in MCF-7 human cancer cells was useful to assess σ2 receptor activity, while an in-vivo mice model of inflammatory pain allowed to analyze σ1 receptor pharmacol. properties.  In-vitro and in-vivo results suggested that compd. I [X = S, n = 3] was a σ1/σ2 agonist, compd. II [X = S, n = 4] a σ1 antagonist/σ2 agonist, whereas compd. II [X = O, n = 4] might act as σ1 antagonist/σ2 partial agonist.  Due to their pharmacol. profile, a potential therapeutic application in cancer of aforesaid novel σ1/σ2 receptor ligands, esp. compds. II [X = O; n = 4; X = S; n = 4], was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2eACohvx7VLVg90H21EOLACvtfcHk0lgocVTppi-5kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12isLY%253D&md5=6a2ff604f935292ea9d5a0218baefa52</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.056%26sid%3Dliteratum%253Aachs%26aulast%3DRomeo%26aufirst%3DG.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DPittala%26aufirst%3DV.%26aulast%3DModica%26aufirst%3DM.%2BN.%26aulast%3DMarrazzo%26aufirst%3DA.%26aulast%3DTurnaturi%26aufirst%3DR.%26aulast%3DParenti%26aufirst%3DC.%26aulast%3DChiechio%26aufirst%3DS.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DCampisi%26aufirst%3DA.%26aulast%3DSposito%26aufirst%3DG.%26aulast%3DSalerno%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520new%2520benzoxazole%2520and%2520benzothiazole-based%2520sigma%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D226%26epage%3D235%26doi%3D10.1016%2Fj.ejmech.2019.04.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maier, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1021/jm010992z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010992z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFyjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=438-448&author=C.+A.+Maierauthor=B.+Wunsch&title=Novel+spiropiperidines+as+highly+potent+and+subtype+selective+sigma-receptor+ligands.+Part+1&doi=10.1021%2Fjm010992z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Spiropiperidines as Highly Potent and Subtype Selective σ-Receptor Ligands. Part 1</span></div><div class="casAuthors">Maier, Christoph A.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">438-448</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of spiro[[2]benzopyran-1,4'-piperidines] and spiro[[2]benzofuran-1,4'-piperidines] of general structure I [X = (CH2)n] is prepd., and the affinity for σ1- and σ2-receptors is investigated by means of radioligand binding assays.  The synthesis of the spiropiperidines, 1'-benzyl-3-methoxy-3,4-dihydrospiro[[2]benzopyran-1,4'-piperidine] (II) and the 1'-benzyl-3-methoxy-3H-spiro[[2]benzofuran-1,4'-piperidine] (III), proceeds via bromine/lithium exchange of the bromoacetals, e.g., 2-(2-bromophenyl)acetaldehyde di-Me acetal in the case of II, addn. to N-benzylpiperidin-4-one, and subsequent cyclization.  Systematic variations of the substituent R at the nitrogen atom, the group Y in position 3, and the ring size of the oxygen heterocycle are performed.  The σ1- and σ2-receptor affinities are detd. with guinea pig brain and rat liver membrane prepns. using [3H]-labeled (+)-pentazocine and ditolylguanidine, resp.  Test results show that a benzyl residue at the piperidine nitrogen atom and a methoxy group in position 3 are advantageous for high σ1-receptor affinity.  In this series II and III are among the most potent σ1-ligands interacting in the low nanomolar range with σ1-receptors (14a, Ki = 1.29 nM; 23, Ki = 1.14 nM).  Variation of the nitrogen substituent R from benzyl to H, alkyl, Ph, or ω-phenylalkyl and the group Y from methoxy to hydroxy, carbonyl, or alkyloxy led to reduced σ1-receptor affinity.  In addn. to their high σ1-receptor affinity, the spiropiperidines II and III display excellent selectivity toward σ2-receptors (σ1/σ2 = 2708 and 1130) and several other receptor and reuptake systems.  Introduction of a polar hydroxy group in position 3 and elongation of the distance between the piperidine nitrogen atom and the Ph moiety result in ligands with considerable σ2-receptor affinity and therefore diminished σ1/σ2-receptor selectivity.  The hemiacetalic 1'-(3-phenylpropyl)-3,4-dihydrospiro[[2]benzopyran-1,4'-piperidin]-3-ol represents the most active σ2-receptor ligand in this series with a Ki value of 83.1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVYGDmsjdLLVg90H21EOLACvtfcHk0lgocVTppi-5kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFyjsLg%253D&md5=13fb1c59fd2f82c128a18d487a6ee8b8</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fjm010992z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010992z%26sid%3Dliteratum%253Aachs%26aulast%3DMaier%26aufirst%3DC.%2BA.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DNovel%2520spiropiperidines%2520as%2520highly%2520potent%2520and%2520subtype%2520selective%2520sigma-receptor%2520ligands.%2520Part%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D438%26epage%3D448%26doi%3D10.1021%2Fjm010992z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel (18)F-labeled spirocyclic piperidine derivatives as sigma1 receptor ligands for positron emission tomography imaging</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3478</span>– <span class="NLM_lpage">3491</span>, <span class="refDoi"> DOI: 10.1021/jm301734g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301734g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3478-3491&author=Y.+Liauthor=X.+Wangauthor=J.+Zhangauthor=W.+Deuther-Conradauthor=F.+Xieauthor=X.+Zhangauthor=J.+Liuauthor=J.+Qiaoauthor=M.+Cuiauthor=J.+Steinbachauthor=P.+Brustauthor=B.+Liuauthor=H.+Jia&title=Synthesis+and+evaluation+of+novel+%2818%29F-labeled+spirocyclic+piperidine+derivatives+as+sigma1+receptor+ligands+for+positron+emission+tomography+imaging&doi=10.1021%2Fjm301734g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Novel 18F-Labeled Spirocyclic Piperidine Derivatives as σ1 Receptor Ligands for Positron Emission Tomography Imaging</span></div><div class="casAuthors">Li, Yan; Wang, Xia; Zhang, Jinming; Deuther-Conrad, Winnie; Xie, Fang; Zhang, Xiaojun; Liu, Jian; Qiao, Jinping; Cui, Mengchao; Steinbach, Jorg; Brust, Peter; Liu, Boli; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3478-3491</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of spirocyclic piperidine derivs. were designed and synthesized as σ1 receptor ligands.  In vitro competition binding assays showed that 1'-[4-(2-fluoroethoxy)benzyl]-3H-spiro[2-benzofuran-1,4'-piperidine] [I (R = F)] possessed high σ1 receptor affinity (Ki = 0.79 nM) and excellent σ1/σ2 subtype selectivity (350-fold) as well as high σ1/VAChT selectivity (799-fold).  The radiolabeled compd. I (R = 18F) was synthesized by substitution of the tosylate precursor I (R = OTs) with [18F]fluoride, with an isolated radiochem. yield of 35-60%, a radiochem. purity of >99%, and a specific activity of 30-55 GBq/μmol.  Biodistribution studies in imprinting control region mice indicated that I (R = 18F) displayed excellent initial brain uptake and slow washout.  Ex vivo autoradiog. in Sprague-Dawley rats demonstrated high accumulation of the radiotracer in brain areas known to express high levels of σ1 receptors.  Micro positron emission tomog. imaging and blocking studies confirmed the specific binding of I (R = 18F) to σ1 receptors in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosXEMXGF6bF7Vg90H21EOLACvtfcHk0lgocVTppi-5kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt74%253D&md5=ca2ccb146e2722e4ae0d98513b7b53c0</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm301734g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301734g%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DJia%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520%252818%2529F-labeled%2520spirocyclic%2520piperidine%2520derivatives%2520as%2520sigma1%2520receptor%2520ligands%2520for%2520positron%2520emission%2520tomography%2520imaging%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3478%26epage%3D3491%26doi%3D10.1021%2Fjm301734g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and sigma receptor affinity of regioisomeric spirocyclic furopyridines</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.06.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.06.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25016157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1aks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=709-716&author=K.+Miyataauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis+and+sigma+receptor+affinity+of+regioisomeric+spirocyclic+furopyridines&doi=10.1016%2Fj.ejmech.2014.06.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and σ receptor affinity of regioisomeric spirocyclic furopyridines</span></div><div class="casAuthors">Miyata, Kengo; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">709-716</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In order to investigate systematically the effect of the position of the pyridine N-atom on the σ1 receptor affinity four regioisomeric furopyridines, e.g., I, were synthesized and pharmacol. evaluated.  The key steps of the synthesis comprise bromine/lithium exchange at regioisomeric bromopyridinecarbaldehyde acetals, e.g., II, subsequent addn. to 1-benzylpiperidin-4-one and cyclization.  The regioisomeric acetals were obtained either by ortho-metalation of bromopyridines or by oxidn. of bromopicolines.  In radioligand binding studies the regioisomeric furopyridines showed 7- to 12-fold lower σ1 affinity than the benzofuran analog.  The reduced σ1 affinity of the furopyridines is explained with the reduced electron d. of the pyridine ring.  Since the four regioisomeric furopyridines show almost the same σ1 affinity (Ki = 4.9-10 nM), a directed interaction of the pyridine N-atom with the receptor protein can be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbnSxnajUq-bVg90H21EOLACvtfcHk0lgxifMjljT2wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1aks7vL&md5=c5ef4fc793595e258518d9648fa24c80</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.06.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.06.073%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520sigma%2520receptor%2520affinity%2520of%2520regioisomeric%2520spirocyclic%2520furopyridines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D83%26spage%3D709%26epage%3D716%26doi%3D10.1016%2Fj.ejmech.2014.06.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Pyridine analogues of spirocyclic sigma(1) receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4277</span>– <span class="NLM_lpage">4284</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2014.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24913984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslClsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4277-4284&author=K.+Miyataauthor=G.+M%C3%B6llerauthor=D.+Schepmannauthor=B.+Wunsch&title=Pyridine+analogues+of+spirocyclic+sigma%281%29+receptor+ligands&doi=10.1016%2Fj.bmc.2014.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridine analogues of spirocyclic σ1 receptor ligands</span></div><div class="casAuthors">Miyata, Kengo; Moeller, Guido; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4277-4284</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spirocyclic benzopyrans interact with high affinity and selectivity with σ1 receptors.  Bioisosteric replacement of the benzene ring of the benzopyran substructure with the electron rich thiophene ring led to increased σ1 affinity.  Herein the synthesis and pharmacol. evaluation of electron deficient pyridine bioisosteres are reported.  Homologation of the aldehyde to afford the pyridylacetaldehyde deriv. was performed by a Wittig reaction.  Bromine lithium exchange of the bromopyridine, addn. to 1-benzylpiperidin-4-one and cyclization led to the spirocyclic pyranopyridine.  Hydrogenolytic removal of the N-benzyl moiety provided the secondary amine, which allowed the introduction of various N-substituents.  Cyclization of the hydroxy acetal with HCl led to various modifications of the substituent in 3'-position.  Generally the σ1 affinity of the pyridine derivs. is reduced compared with those of the benzene and thiophene derivs..  However, the relationships between the structure and the σ1 affinity follow the same rules as for the benzene and thiophene derivs.  The most promising σ1 ligand within this class of compds. is the pyranopyridine I with a double bond in the pyran ring revealing a Ki-value of 4.6 nM and a very high selectivity (>217-fold) over the σ2 subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8ha_Wq6zQ7Vg90H21EOLACvtfcHk0lgxifMjljT2wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslClsLY%253D&md5=4537b04de74f88ae18957cc906ba68bc</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DM%25C3%25B6ller%26aufirst%3DG.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DPyridine%2520analogues%2520of%2520spirocyclic%2520sigma%25281%2529%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4277%26epage%3D4284%26doi%3D10.1016%2Fj.bmc.2014.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knappmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Oxa-Pictet-Spengler reaction as key step in the synthesis of novel sigma receptor ligands with 2-benzopyran structure</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4045</span>– <span class="NLM_lpage">4055</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2016.06.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27396684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFenu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=4045-4055&author=I.+Knappmannauthor=D.+Schepmannauthor=B.+Wunsch&title=Oxa-Pictet-Spengler+reaction+as+key+step+in+the+synthesis+of+novel+sigma+receptor+ligands+with+2-benzopyran+structure&doi=10.1016%2Fj.bmc.2016.06.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Oxa-Pictet-Spengler reaction as key step in the synthesis of novel σ receptor ligands with 2-benzopyran structure</span></div><div class="casAuthors">Knappmann, Inga; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4045-4055</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The oxa-Pictet-Spengler reaction of Me 3-hydroxy-4-phenylbutanoate (8, I) was explored to obtain novel σ receptor ligands.  1-Acyl protected piperidone ketals 10 and 11 (II, R = Ac, Cbz) reacted with phenylethanol 8 to yield spirocyclic compds. III.  Aliph. aldehyde acetals 19 RCH(OR')2 (R' = Me, Et) provided 1,3-disubstituted 2-benzopyrans 20 (IV) with high cis-diastereoselectivity.  The intramol. oxa-Pictet-Spengler reaction of 24 (V) led to the tricyclic compd. 25 (VI).  The spirocyclic compds. 18 (VII) show high σ1 affinity (Ki 20-26 nM) and σ1/σ2 selectivity (>9-fold), when a large substituent (n-octyl, benzyl, phenylpropyl) is attached to the piperidine N-atom.  Opening of the piperidine ring to yield aminoethyl (22, 23; VIII, IX) or aminomethyl derivs. (21, X) resulted in reduced σ1 affinity and σ1/σ2 selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd2o0njHoEFbVg90H21EOLACvtfcHk0lgxifMjljT2wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFenu7zP&md5=0d1c41129607e3048f679fe3bf7ff082</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DKnappmann%26aufirst%3DI.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DOxa-Pictet-Spengler%2520reaction%2520as%2520key%2520step%2520in%2520the%2520synthesis%2520of%2520novel%2520sigma%2520receptor%2520ligands%2520with%25202-benzopyran%2520structure%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D4045%26epage%3D4055%26doi%3D10.1016%2Fj.bmc.2016.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knappmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmkuhl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Lipase-catalyzed kinetic resolution as key step in the synthesis of enantiomerically pure sigma ligands with 2-benzopyran structure</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3384</span>– <span class="NLM_lpage">3395</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.04.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2017.04.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28501431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsFens74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3384-3395&author=I.+Knappmannauthor=K.+Lehmkuhlauthor=J.+Kohlerauthor=D.+Schepmannauthor=M.+Gieraauthor=F.+Bracherauthor=B.+Wunsch&title=Lipase-catalyzed+kinetic+resolution+as+key+step+in+the+synthesis+of+enantiomerically+pure+sigma+ligands+with+2-benzopyran+structure&doi=10.1016%2Fj.bmc.2017.04.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Lipase-catalyzed kinetic resolution as key step in the synthesis of enantiomerically pure σ ligands with 2-benzopyran structure</span></div><div class="casAuthors">Knappmann, Inga; Lehmkuhl, Kirstin; Koehler, Jens; Schepmann, Dirk; Giera, Martin; Bracher, Franz; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3384-3395</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to obtain enantiomerically pure σ1 receptor ligands with a 2-benzopyran scaffold an Oxa-Pictet-Spengler reaction with the enantiomerically pure 2-phenylethanol derivs. was envisaged.  The kinetic resoln. of racemic alc. using Amano Lipase PS-C II and isopropenyl acetate in tert-Bu Me ether led to the (R)-configured alc. in 42% yield with an enantiomeric excess of 99.6%.  The (S)-configured alc. was obtained by Amano Lipase PS-C II catalyzed hydrolysis of enantiomerically enriched acetate (76.9% ee) and provided in 26% yield and 99.7% ee.  The abs. configuration of (R)-alc. was detd. by exciton coupled CD spectroscopy of the bis(bromobenzoate).  The next important step for the synthesis of 2-benzopyrans and was the Oxa-Pictet-Spengler reaction of the enantiomerically pure alcs. with piperidone ketal and chloropropionaldehyde acetal.  The conformationally restricted spirocyclic 2-benzopyrans revealed higher σ1 affinity than the more flexible aminoethyl derivs..  The (R)- and (R,R)-configured enantiomers represent the eutomers of this class of compds. with eudismic ratios of 4.8 [I (R = Bn)] and 4.5 [I (R = Ph(CH2)3)].  High σ1/σ2 selectivity (>49) was found for the most potent σ1 ligands I [R = Bn, Ph(CH2)3, cyclohexylmethyl] and II (Ki(σ1) 9-15 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqoyTv6coP-bVg90H21EOLACvtfcHk0lgxifMjljT2wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsFens74%253D&md5=b10d5e69ea47ab9d2e4107bba778e78e</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.04.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.04.042%26sid%3Dliteratum%253Aachs%26aulast%3DKnappmann%26aufirst%3DI.%26aulast%3DLehmkuhl%26aufirst%3DK.%26aulast%3DKohler%26aufirst%3DJ.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DGiera%26aufirst%3DM.%26aulast%3DBracher%26aufirst%3DF.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DLipase-catalyzed%2520kinetic%2520resolution%2520as%2520key%2520step%2520in%2520the%2520synthesis%2520of%2520enantiomerically%2520pure%2520sigma%2520ligands%2520with%25202-benzopyran%2520structure%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3384%26epage%3D3395%26doi%3D10.1016%2Fj.bmc.2017.04.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kronenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-affinity relationships of spirocyclic benzopyrans with exocyclic amino moiety</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4204</span>– <span class="NLM_lpage">4217</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00449</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00449" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1aisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4204-4217&author=E.+Kronenbergauthor=F.+Weberauthor=S.+Bruneauthor=D.+Schepmannauthor=C.+Almansaauthor=K.+Friedlandauthor=E.+Lauriniauthor=S.+Priclauthor=B.+Wunsch&title=Synthesis+and+structure-affinity+relationships+of+spirocyclic+benzopyrans+with+exocyclic+amino+moiety&doi=10.1021%2Facs.jmedchem.9b00449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Affinity Relationships of Spirocyclic Benzopyrans with Exocyclic Amino Moiety</span></div><div class="casAuthors">Kronenberg, Elisabeth; Weber, Frauke; Brune, Stefanie; Schepmann, Dirk; Almansa, Carmen; Friedland, Kristina; Laurini, Erik; Pricl, Sabrina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4204-4217</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">σ1 And/or σ2 receptors play a crucial role in pathol. conditions such as pain, neurodegenerative disorders, and cancer.  A set of spirocyclic cyclohexanes with diverse O-heterocycles and amino moieties (general structure given in text) was prepd. and pharmacol. evaluated.  In structure-activity relationships studies, the σ1 receptor affinity and σ1:σ2 selectivity were correlated with the stereochem., the kind and substitution pattern of the O-heterocycle, and the substituents at the exocyclic amino moiety. cis-configured 2-benzopyran cis-I bearing a methoxy group and a tertiary cyclohexylmethylamino moiety showed the highest σ1 affinity (Ki = 1.9 nM) of this series of compds.  In a Ca2+ influx assay, cis-I behaved as a σ1 antagonist. cis-I reveals high selectivity over σ2 and opioid receptors.  The interactions of the novel σ1 ligands were analyzed on the mol. level using the recently reported X-ray crystal structure of the σ1 receptor protein.  The protonated amino moiety forms a persistent salt bridge with E172.  The spiro[benzopyran-1,1'-cyclohexane] scaffold and the cyclohexylmethyl moiety occupy two hydrophobic pockets.  Exchange of the N-cyclohexylmethyl moiety by a benzyl group led unexpectedly to potent and selective μ-opioid receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY45Xx2BvrZ7Vg90H21EOLACvtfcHk0ljWgTYRxtuPlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1aisr0%253D&md5=685446a1457bde87e848a7b2e2b46eb4</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00449%26sid%3Dliteratum%253Aachs%26aulast%3DKronenberg%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DFriedland%26aufirst%3DK.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520structure-affinity%2520relationships%2520of%2520spirocyclic%2520benzopyrans%2520with%2520exocyclic%2520amino%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4204%26epage%3D4217%26doi%3D10.1021%2Facs.jmedchem.9b00449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergkemper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniliuc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinoso, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis, receptor affinity, and antiallodynic activity of spirocyclic sigma receptor ligands with exocyclic amino moiety</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9666</span>– <span class="NLM_lpage">9690</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSrsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9666-9690&author=M.+Bergkemperauthor=E.+Kronenbergauthor=S.+Thumauthor=F.+Borgelauthor=C.+Daniliucauthor=D.+Schepmannauthor=F.+R.+Nietoauthor=P.+Brustauthor=R.+F.+Reinosoauthor=I.+Alvarezauthor=B.+Wunsch&title=Synthesis%2C+receptor+affinity%2C+and+antiallodynic+activity+of+spirocyclic+sigma+receptor+ligands+with+exocyclic+amino+moiety&doi=10.1021%2Facs.jmedchem.8b01183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety</span></div><div class="casAuthors">Bergkemper, Melanie; Kronenberg, Elisabeth; Thum, Simone; Boergel, Frederik; Daniliuc, Constantin; Schepmann, Dirk; Nieto, Francisco Rafael; Brust, Peter; Reinoso, Raquel F.; Alvarez, Ines; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9666-9690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spiro(benzopyrancyclohexane)amines such as I and the cis- and trans-cyclohexane diastereomers of II were prepd. and tested as σ1- and σ2-receptor ligands for potential use in the treatment of allodynia.  I was the most promising σ2 receptor ligand of the compds. tested.  The cis- and trans-cyclohexane diastereomers of II possess high σ1 affinity but moderate selectivity over the σ2 subtype and showed antiallodynic activity that is stronger than that of the ref. σ1 antagonist BD-1063.  Since the antiallodynic activity of the trans-cyclohexane diastereomer of II could only be partially reversed by the σ1 agonist PRE-084, a second mechanism likely contributes to its overall antiallodynic effect; the antiallodynic effect of the cis cyclohexane diastereomer of II can be explained solely by σ1 antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvQKzsLReDQrVg90H21EOLACvtfcHk0ljWgTYRxtuPlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSrsbnP&md5=93f7d570bd3d8dfad9fea6c083cbf69d</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01183%26sid%3Dliteratum%253Aachs%26aulast%3DBergkemper%26aufirst%3DM.%26aulast%3DKronenberg%26aufirst%3DE.%26aulast%3DThum%26aufirst%3DS.%26aulast%3DBorgel%26aufirst%3DF.%26aulast%3DDaniliuc%26aufirst%3DC.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DReinoso%26aufirst%3DR.%2BF.%26aulast%3DAlvarez%26aufirst%3DI.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%252C%2520receptor%2520affinity%252C%2520and%2520antiallodynic%2520activity%2520of%2520spirocyclic%2520sigma%2520receptor%2520ligands%2520with%2520exocyclic%2520amino%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9666%26epage%3D9690%26doi%3D10.1021%2Facs.jmedchem.8b01183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherafat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alirezapour, B.</span></span> <span> </span><span class="NLM_article-title">One-pot synthesis and sigma receptor binding studies of novel spirocyclic-2,6-diketopiperazine derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2676</span>– <span class="NLM_lpage">2679</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2016.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27090556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmt1emsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2676-2679&author=M.+Ghandiauthor=F.+Sherafatauthor=M.+Sadeghzadehauthor=B.+Alirezapour&title=One-pot+synthesis+and+sigma+receptor+binding+studies+of+novel+spirocyclic-2%2C6-diketopiperazine+derivatives&doi=10.1016%2Fj.bmcl.2016.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot synthesis and sigma receptor binding studies of novel spirocyclic-2,6-diketopiperazine derivatives</span></div><div class="casAuthors">Ghandi, Mehdi; Sherafat, Fatemeh; Sadeghzadeh, Masoud; Alirezapour, Behrouz</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2676-2679</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spirocyclic-2,6-diketopiperazines I (R = H, MeO; R1 = H, Me, MeO; X = PhCH2N, CH2, t-BuCH; Y = bond, CH2) were prepd. by a one-pot four-component Ugi reaction of N-benzyl-4-piperidinone, cyclopentanone, cyclohexanone, or 4-tert-butylcyclohexanone with benzoic acid 2-R-4-R1C6H3CO2H (R = H, MeO; R1 = H, Me, MeO), cyclohexyl isocyanide, and Et glycinate hydrochloride followed by intramol. amidation in 70-88% yields.  The binding of I to σ1- and σ2-receptors was detd.; the σ1 affinities and subtype selectivities of three spirocyclic piperidine derivs. are generally comparable to those of spirocycloalkane analogs.  The σ1 affinities and subtype selectivities of spirocyclic piperidines were comparable to those of spirocycloalkane analogs; spirocyclopentanes were bound more effectively by σ2-receptors than spirocyclohexanes.  Of the compds. I, the best binding affinity and subtype selectivity was identified for I (R = H; R1 = MeO; X = PhCH2N; Y = CH2) with Ki values for σ1 and σ2 receptors of 5.9 ± 0.5 nM and 563 ± 21 nM, resp. (σ1/σ2 = 95).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWzexVq1WOUrVg90H21EOLACvtfcHk0ljWgTYRxtuPlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmt1emsLs%253D&md5=1429b80fe70990ad42dc973750d9519e</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DGhandi%26aufirst%3DM.%26aulast%3DSherafat%26aufirst%3DF.%26aulast%3DSadeghzadeh%26aufirst%3DM.%26aulast%3DAlirezapour%26aufirst%3DB.%26atitle%3DOne-pot%2520synthesis%2520and%2520sigma%2520receptor%2520binding%2520studies%2520of%2520novel%2520spirocyclic-2%252C6-diketopiperazine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2676%26epage%3D2679%26doi%3D10.1016%2Fj.bmcl.2016.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uprety, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaoa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redel-Traub, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinberg, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of spiro-2,6-dioxopiperazine and spiro-2,6-dioxopyrazine scaffolds using amino acids in a three-component reaction to generate potential sigma-1 (sigma1) receptor selective ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2018.12.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30597325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlsFSk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=241-251&author=R.+Upretyauthor=A.+Varadiauthor=A.+Allaoaauthor=G.+N.+Redel-Traubauthor=T.+C.+Palmerauthor=E.+N.+Feinbergauthor=A.+C.+Ferrisauthor=V.+S.+Pandeauthor=G.+W.+Pasternakauthor=S.+Majumdar&title=Synthesis+of+spiro-2%2C6-dioxopiperazine+and+spiro-2%2C6-dioxopyrazine+scaffolds+using+amino+acids+in+a+three-component+reaction+to+generate+potential+sigma-1+%28sigma1%29+receptor+selective+ligands&doi=10.1016%2Fj.ejmech.2018.12.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of spiro-2,6-dioxopiperazine and spiro-2,6-dioxopyrazine scaffolds using amino acids in a three-component reaction to generate potential Sigma-1 (σ1) receptor selective ligands</span></div><div class="casAuthors">Uprety, Rajendra; Varadi, Andras; Allaoa, Abdullah; Redel-Traub, Gabriel N.; Palmer, Travis C.; Feinberg, Evan N.; Ferris, Alex C.; Pande, Vijay S.; Pasternak, Gavril W.; Majumdar, Susruta</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">241-251</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design and synthesis of novel heterocycles with spiro-2,6-dioxopiperazine and spiro-2,6-pyrazine scaffolds through a three-component reaction using various amino acids, ketones and isocyanides was presented.  Screening of selected compds. over fifty CNS receptors including G-protein coupled receptors (GPCRs), ion channels, transporters and enzymes through the NIMH psychoactive drug screening program indicated that a novel spiro-2,6-dioxopyrazine scaffold, e.g., I, displayed high binding affinity at sigma-1 (σ1) receptor in the nanomolar range.  In addn., mol. docking of spiro-2,6-dioxopyrazine scaffold, e.g., I at the human σ1 receptor showed that it resides in the same binding site that was occupied by the ligand N-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP) used to obtain a crystal structure of the human sigma-1 (σ1) receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB4kaewGiLqLVg90H21EOLACvtfcHk0ljzRjJ8ofFMMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlsFSk&md5=25959562ec36b0f8a994e7fd38fa24d8</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.048%26sid%3Dliteratum%253Aachs%26aulast%3DUprety%26aufirst%3DR.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DAllaoa%26aufirst%3DA.%26aulast%3DRedel-Traub%26aufirst%3DG.%2BN.%26aulast%3DPalmer%26aufirst%3DT.%2BC.%26aulast%3DFeinberg%26aufirst%3DE.%2BN.%26aulast%3DFerris%26aufirst%3DA.%2BC.%26aulast%3DPande%26aufirst%3DV.%2BS.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DMajumdar%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520spiro-2%252C6-dioxopiperazine%2520and%2520spiro-2%252C6-dioxopyrazine%2520scaffolds%2520using%2520amino%2520acids%2520in%2520a%2520three-component%2520reaction%2520to%2520generate%2520potential%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520selective%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D241%26epage%3D251%26doi%3D10.1016%2Fj.ejmech.2018.12.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lepovitz, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span> <span> </span><span class="NLM_article-title">Diversity-oriented synthesis of bioactive azaspirocycles</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">130637</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2019.130637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.tet.2019.130637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvF2qs7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=130637&author=L.+T.+Lepovitzauthor=S.+F.+Martin&title=Diversity-oriented+synthesis+of+bioactive+azaspirocycles&doi=10.1016%2Fj.tet.2019.130637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-Oriented Synthesis of Bioactive Azaspirocycles</span></div><div class="casAuthors">Lepovitz, Lance T.; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">130637pp.</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A collection of novel azaspirocyclic β-arylethylamines was prepd. in good yield and excellent diastereoselectivity by an expedient strategy that features condensation of a cyclic ketone with an amino allylsilane and a tandem aza-Sakurai cyclization to generate several different spirocyclic N-heterocycles.  Subsequent elaboration of the spirocyclic scaffold was achieved via Pictet-Spengler cyclizations, Suzuki cross-coupling reactions, N-functionalizations, and olefin refunctionalization reactions to create a diverse library of compds., several of which have nanomolar affinity for the sigma 1 receptor and transmembrane protein 97 (TMEM97).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrCl60i0psjbVg90H21EOLACvtfcHk0ljzRjJ8ofFMMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvF2qs7rN&md5=66d43bf39a2294c2744488f71e07e0e0</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2019.130637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2019.130637%26sid%3Dliteratum%253Aachs%26aulast%3DLepovitz%26aufirst%3DL.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DDiversity-oriented%2520synthesis%2520of%2520bioactive%2520azaspirocycles%26jtitle%3DTetrahedron%26date%3D2019%26volume%3D75%26spage%3D130637%26doi%3D10.1016%2Fj.tet.2019.130637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Pozo, E.</span></span> <span> </span><span class="NLM_article-title">Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1007/s00213-009-1513-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs00213-009-1513-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19326101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Kksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2009&pages=21-33&author=J.+M.+Entrenaauthor=E.+J.+Cobosauthor=F.+R.+Nietoauthor=C.+M.+Cendanauthor=J.+M.+Baeyensauthor=E.+Del+Pozo&title=Antagonism+by+haloperidol+and+its+metabolites+of+mechanical+hypersensitivity+induced+by+intraplantar+capsaicin+in+mice%3A+role+of+sigma-1+receptors&doi=10.1007%2Fs00213-009-1513-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors</span></div><div class="casAuthors">Entrena, Jose M.; Cobos, Enrique J.; Nieto, Francisco R.; Cendan, Cruz M.; Baeyens, Jose M.; Del Pozo, Esperanza</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-33</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Rationale: We evaluated the effects of haloperidol and its metabolites on capsaicin-induced mech. hypersensitivity (allodynia) and on nociceptive pain induced by punctate mech. stimuli in mice.  Results: S.c. administration of haloperidol or its metabolites I or II (reduced haloperidol) dose-dependently reversed capsaicin-induced (1 μg, intraplantar) mech. hypersensitivity of the hind paw (stimulated with a nonpainful, 0.5-g force, punctate stimulus).  The order of potency of these drugs to induce antiallodynic effects was the order of their affinity for brain sigma-1 (σ1) receptor ([3H](+)-pentazocine-labeled).  Antiallodynic activity of haloperidol and its metabolites was dose-dependently prevented by the selective σ1 receptor agonist PRE-084, but not by naloxone.  These results suggest the involvement of σ1 receptors, but discard any role of the endogenous opioid system, on the antiallodynic effects.  Dopamine receptor antagonism also appears unlikely to be involved in these effects, since the D2/D3 receptor antagonist (-)-sulpiride, which had no affinity for σ1 receptors, showed no antiallodynic effect.  None of these drugs modified hind-paw withdrawal after a painful (4 g force) punctate mech. stimulus in noncapsaicin-sensitized animals.  As expected, the control drug gabapentin showed antiallodynic but not antinociceptive activity, whereas clonidine exhibited both activities and rofecoxib, used as neg. control, showed neither.  Conclusion: These results show that haloperidol and its metabolites I and II produce antiallodynic but not antinociceptive effects against punctate mech. stimuli and suggest that their antiallodynic effect may be due to blockade of σ1 receptors but not to dopamine receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI0AnJHWbghLVg90H21EOLACvtfcHk0ljzRjJ8ofFMMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Kksbg%253D&md5=8b2077efc615a10a83b9dcaa973deeb2</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1007%2Fs00213-009-1513-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-009-1513-8%26sid%3Dliteratum%253Aachs%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DCendan%26aufirst%3DC.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DDel%2BPozo%26aufirst%3DE.%26atitle%3DAntagonism%2520by%2520haloperidol%2520and%2520its%2520metabolites%2520of%2520mechanical%2520hypersensitivity%2520induced%2520by%2520intraplantar%2520capsaicin%2520in%2520mice%253A%2520role%2520of%2520sigma-1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D205%26spage%3D21%26epage%3D33%26doi%3D10.1007%2Fs00213-009-1513-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinciguerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giurdanella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporarello, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anfuso, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span> <span> </span><span class="NLM_article-title">Antiangiogenic effect of (±)-haloperidol metabolite II valproate ester [(±)-MRJF22] in human microvascular retinal endothelial cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9960</span>– <span class="NLM_lpage">9966</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9960-9966&author=M.+Olivieriauthor=E.+Amataauthor=S.+Vinciguerraauthor=J.+Fioritoauthor=G.+Giurdanellaauthor=F.+Dragoauthor=N.+Caporarelloauthor=O.+Prezzaventoauthor=E.+Arenaauthor=L.+Salernoauthor=A.+Rescifinaauthor=G.+Lupoauthor=C.+D.+Anfusoauthor=A.+Marrazzo&title=Antiangiogenic+effect+of+%28%C2%B1%29-haloperidol+metabolite+II+valproate+ester+%5B%28%C2%B1%29-MRJF22%5D+in+human+microvascular+retinal+endothelial+cells&doi=10.1021%2Facs.jmedchem.6b01039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells</span></div><div class="casAuthors">Olivieri, Melania; Amata, Emanuele; Vinciguerra, Shila; Fiorito, Jole; Giurdanella, Giovanni; Drago, Filippo; Caporarello, Nunzia; Prezzavento, Orazio; Arena, Emanuela; Salerno, Loredana; Rescifina, Antonio; Lupo, Gabriella; Anfuso, Carmelina Daniela; Marrazzo, Agostino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9960-9966</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(±)-MRJF22 [(±)-2], a novel prodrug of haloperidol metabolite II (sigma-1 receptor antagonist/sigma-2 receptor agonist ligand) obtained by conjugation to valproic acid (histone deacetylase inhibitor) via an ester bond, exhibits antiangiogenic activity, being able to reduce human retinal endothelial cell (HREC) viability in a comparable manner to bevacizumab.  Moreover, (±)-2 was able to significantly reduce viable cells count, endothelial cell migration, and tube formation in vascular endothelial growth factor A (VEGF-A) stimulated HREC cultures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJedDLZWd8jbVg90H21EOLACvtfcHk0liMxuvCxL4jwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77P&md5=f0a092eedd76c583f4dabaa7151774c4</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01039%26sid%3Dliteratum%253Aachs%26aulast%3DOlivieri%26aufirst%3DM.%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DVinciguerra%26aufirst%3DS.%26aulast%3DFiorito%26aufirst%3DJ.%26aulast%3DGiurdanella%26aufirst%3DG.%26aulast%3DDrago%26aufirst%3DF.%26aulast%3DCaporarello%26aufirst%3DN.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DSalerno%26aufirst%3DL.%26aulast%3DRescifina%26aufirst%3DA.%26aulast%3DLupo%26aufirst%3DG.%26aulast%3DAnfuso%26aufirst%3DC.%2BD.%26aulast%3DMarrazzo%26aufirst%3DA.%26atitle%3DAntiangiogenic%2520effect%2520of%2520%2528%25C2%25B1%2529-haloperidol%2520metabolite%2520II%2520valproate%2520ester%2520%255B%2528%25C2%25B1%2529-MRJF22%255D%2520in%2520human%2520microvascular%2520retinal%2520endothelial%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9960%26epage%3D9966%26doi%3D10.1021%2Facs.jmedchem.6b01039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichiara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittala, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span> <span> </span><span class="NLM_article-title">(+)-Methyl (1<i>R</i>,2<i>S</i>)-2-{[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropa necarboxylate [(+)-MR200] derivatives as potent and selective sigma receptor ligands: stereochemistry and pharmacological properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01584</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01584" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCktLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=372-384&author=E.+Amataauthor=A.+Rescifinaauthor=O.+Prezzaventoauthor=E.+Arenaauthor=M.+Dichiaraauthor=V.+Pittalaauthor=A.+Montilla-Garciaauthor=F.+Punzoauthor=P.+Merinoauthor=E.+J.+Cobosauthor=A.+Marrazzo&title=%28%2B%29-Methyl+%281R%2C2S%29-2-%7B%5B4-%284-chlorophenyl%29-4-hydroxypiperidin-1-yl%5Dmethyl%7D-1-phenylcyclopropa+necarboxylate+%5B%28%2B%29-MR200%5D+derivatives+as+potent+and+selective+sigma+receptor+ligands%3A+stereochemistry+and+pharmacological+properties&doi=10.1021%2Facs.jmedchem.7b01584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">(+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties</span></div><div class="casAuthors">Amata, Emanuele; Rescifina, Antonio; Prezzavento, Orazio; Arena, Emanuela; Dichiara, Maria; Pittala, Valeria; Montilla-Garcia, Angeles; Punzo, Francesco; Merino, Pedro; Cobos, Enrique J.; Marrazzo, Agostino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">372-384</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Methoxycarbonyl-1-phenyl-2-cyclopropylmethyl based derivs. [cis-(+)-MR200], [cis-(-)-MR201], and [trans-(±)-MR204], have been identified as new potent sigma (σ) receptor ligands.  In the present paper, novel enantiomerically pure analogs were synthesized and optimized for their σ receptor affinity and selectivity.  Docking studies rationalized the results obtained in the radioligand binding assay.  Abs. stereochem. was unequivocally established by X-ray anal. of a precursor as camphorsulfonyl deriv.  The most promising compd., I, showed remarkable selectivity over a panel of more than 15 receptors as well as good chem. and enzymic stability in human plasma.  An in vivo evaluation evidenced that I, in contrast to its isomers, which behave as σ1 antagonists, exhibited a σ1 agonist profile.  These data clearly demonstrated that compd. I, due to its σ1 agonist activity and favorable receptor selectivity and stability, provided an useful tool for the study of σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHc_luLz8QZLVg90H21EOLACvtfcHk0liMxuvCxL4jwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCktLzP&md5=48051bdd2674c6bb9f5da0277b26b137</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01584%26sid%3Dliteratum%253Aachs%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DRescifina%26aufirst%3DA.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DDichiara%26aufirst%3DM.%26aulast%3DPittala%26aufirst%3DV.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DPunzo%26aufirst%3DF.%26aulast%3DMerino%26aufirst%3DP.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DMarrazzo%26aufirst%3DA.%26atitle%3D%2528%252B%2529-Methyl%2520%25281R%252C2S%2529-2-%257B%255B4-%25284-chlorophenyl%2529-4-hydroxypiperidin-1-yl%255Dmethyl%257D-1-phenylcyclopropa%2520necarboxylate%2520%255B%2528%252B%2529-MR200%255D%2520derivatives%2520as%2520potent%2520and%2520selective%2520sigma%2520receptor%2520ligands%253A%2520stereochemistry%2520and%2520pharmacological%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D372%26epage%3D384%26doi%3D10.1021%2Facs.jmedchem.7b01584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokornaczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Microwave-assisted regioselective direct C-H arylation of thiazole derivatives leading to increased σ1 receptor affinity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1039/C5MD00526D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC5MD00526D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCqsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=327-331&author=A.+Kokornaczykauthor=D.+Schepmannauthor=J.+Yamaguchiauthor=K.+Itamiauthor=B.+W%C3%BCnsch&title=Microwave-assisted+regioselective+direct+C-H+arylation+of+thiazole+derivatives+leading+to+increased+%CF%831+receptor+affinity&doi=10.1039%2FC5MD00526D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave-assisted regioselective direct C-H arylation of thiazole derivatives leading to increased σ1 receptor affinity</span></div><div class="casAuthors">Kokornaczyk, Artur; Schepmann, Dirk; Yamaguchi, Junichiro; Itami, Kenichiro; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-331</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">New thiazole analogs I (R = H, 4-H3CC6H4, 5-H3CC6H4) of spirocyclic thiophenes II, which are known to show high σ1 receptor affinities, have been developed as potentially better σ1 receptor ligands.  To introduce an aryl group onto the thiazole core of I (R = 4-H3CC6H4, 5-H3CC6H4) (C4 or C5 positions), Pd-catalyzed regioselective C-H arylation reactions were used.  The Pd-catalyzed C5 arylation of I (R = H) could be considerably improved by using microwave irradn. technique.  The Pd-catalyzed C4 arylation of thiazole I (R = H) with 4-methylphenylboronic acid could be achieved in the presence of Pd(OAc)2, 1,10-phenanthroline, TEMPO, and LiBF4.  Under these conditions, the tertiary amine and the tertiary alc. were well-tolerated.  The regioselective arylation of I (R = H) led to new compds. I (R = 4-H3CC6H4, 5-H3CC6H4), with a 4-tolyl moiety in the C5- and C4-positions, displaying five to nine-fold increased σ1 affinity.  The same σ1 affinity of the regioisomeric thiazoles I (R = 4-H3CC6H4, 5-H3CC6H4) can be explained by fast rotation around the piperidine-thiazole bond.  Compared to spirocyclic thiophenes II, thiazoles I (R = H, 4-H3CC6H4, 5-H3CC6H4) are considerably more polar.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7vYHLlGs97Vg90H21EOLACvtfcHk0liMxuvCxL4jwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCqsrvK&md5=bab3d4b490ef73b85ff48c5bb816364b</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1039%2FC5MD00526D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00526D%26sid%3Dliteratum%253Aachs%26aulast%3DKokornaczyk%26aufirst%3DA.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DMicrowave-assisted%2520regioselective%2520direct%2520C-H%2520arylation%2520of%2520thiazole%2520derivatives%2520leading%2520to%2520increased%2520%25CF%25831%2520receptor%2520affinity%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D327%26epage%3D331%26doi%3D10.1039%2FC5MD00526D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokornaczyk, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Thiazole-based sigma1 receptor ligands: diversity by late-stage C-H arylation of thiazoles, structure-affinity and selectivity relationships, and molecular interactions</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fcmdc.201700166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28544475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVarsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1070-1080&author=A.+K.+Kokornaczykauthor=D.+Schepmannauthor=J.+Yamaguchiauthor=K.+Itamiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=B.+Wunsch&title=Thiazole-based+sigma1+receptor+ligands%3A+diversity+by+late-stage+C-H+arylation+of+thiazoles%2C+structure-affinity+and+selectivity+relationships%2C+and+molecular+interactions&doi=10.1002%2Fcmdc.201700166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazole-Based σ1 Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles, Structure-Affinity and Selectivity Relationships, and Mol. Interactions</span></div><div class="casAuthors">Kokornaczyk, Artur K.; Schepmann, Dirk; Yamaguchi, Junichiro; Itami, Kenichiro; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocyclic thiophene derivs. represent promising σ1 ligands with high σ1 affinity and selectivity over the σ2 subtype.  To increase ligand efficiency, the thiophene ring was replaced bioisosterically by a thiazole ring, and the pyran ring was opened.  Late-stage diversification by regioselective C-H arylation of thiazoles 9 a-c resulted in a set of 53 compds. with high diversity.  This set of compds. was analyzed with respect to σ1 affinity, σ1/σ2 selectivity, lipophilicity (logD7.4), lipophilicity-cor. ligand efficiency (LELP), and mol. target interactions.  The most promising candidates were pyridyl-substituted thiazole derivs. 33 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-3-yl)thiazole) and 34 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-4-yl)thiazole), possessing low-nanomolar σ1 affinity (Ki=1.3 and 1.9 nM), high σ1/σ2 selectivity (>1500-fold), low lipophilicity (logD7.4=1.8) and very good ligand efficiency (LELP=5.5), indicating promising pharmacodynamics and pharmacokinetics.  Mol. simulation studies, including docking and deconvolution of the free binding energy into its major components, led to decreased hydrophobic stabilization of pyridyl derivs. 33 c and 34 c, which was compensated by lower desolvation energy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH1KP3Hivs9rVg90H21EOLACvtfcHk0lhP0asvQecgBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVarsL3K&md5=5317bdafd4f74079cf90fc4d86d751fa</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700166%26sid%3Dliteratum%253Aachs%26aulast%3DKokornaczyk%26aufirst%3DA.%2BK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DThiazole-based%2520sigma1%2520receptor%2520ligands%253A%2520diversity%2520by%2520late-stage%2520C-H%2520arylation%2520of%2520thiazoles%252C%2520structure-affinity%2520and%2520selectivity%2520relationships%252C%2520and%2520molecular%2520interactions%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1070%26epage%3D1080%26doi%3D10.1002%2Fcmdc.201700166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikome, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntie-Kang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngemenya, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efange, S. M.</span></span> <span> </span><span class="NLM_article-title">4-Aroylpiperidines and 4-(alpha-hydroxyphenyl)piperidines as selective sigma-1 receptor ligands: synthesis, preliminary pharmacological evaluation and computational studies</span>. <i>Chem. Cent. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">53</span>, <span class="refDoi"> DOI: 10.1186/s13065-016-0200-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1186%2Fs13065-016-0200-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27555879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKkurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=53&author=H.+N.+Ikomeauthor=F.+Ntie-Kangauthor=M.+N.+Ngemenyaauthor=Z.+Tuauthor=R.+H.+Machauthor=S.+M.+Efange&title=4-Aroylpiperidines+and+4-%28alpha-hydroxyphenyl%29piperidines+as+selective+sigma-1+receptor+ligands%3A+synthesis%2C+preliminary+pharmacological+evaluation+and+computational+studies&doi=10.1186%2Fs13065-016-0200-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">4-aroylpiperidines and 4-(α-hydroxyphenyl)piperidines as selective sigma-1 receptor ligands: synthesis, preliminary pharmacological evaluation and computational studies</span></div><div class="casAuthors">Ikome, Hermia N.; Ntie-Kang, Fidele; Ngemenya, Moses N.; Tu, Zhude; Mach, Robert H.; Efange, Simon M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Central Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53/1-53/15</span>CODEN:
                <span class="NLM_cas:coden">CCJHA2</span>;
        ISSN:<span class="NLM_cas:issn">1752-153X</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Sigma (σ) receptors are membrane-bound proteins characterized by an unusual promiscuous ability to bind a wide variety of drugs and their high affinity for typical neuroleptic drugs, such as haloperidol, and their potential as alternative targets for antipsychotic agents.  Sigma receptors display diverse biol. activities and represent potential fruitful targets for therapeutic development in combating many human diseases.  Therefore, they present an interesting avenue for further exploration.  It was our goal to evaluate the potential of ring opened spipethiane (1) analogs as functional ligands (agonists) for σ receptors by chem. modification.  Chem. modification of the core structure of the lead compd., (1), by replacement of the sulfur atom with a carbonyl group, hydroxyl group and 3-bromobenzylamine with the simultaneous presence of 4-fluorobenzoyl replacing the spirofusion afforded novel potent sigma-1 receptor ligands 7a-f, 8a-f and 9d-e.  The sigma-1 receptor affinities of 7e, 8a and 8f were slightly lower than that of 1 and their selectivities for this receptor two to threefold greater than that of 1.  It was found that these compds. have higher selectivities for sigma-1 receptors compared to 1.  Quantitatitive structure-activity relationship studies revealed that sigma-1 binding is driven by hydrophobic interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTVi2CN-ZgibVg90H21EOLACvtfcHk0lhP0asvQecgBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKkurrP&md5=f47df06b9948f9ef8b37ef57eb5228d2</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1186%2Fs13065-016-0200-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13065-016-0200-1%26sid%3Dliteratum%253Aachs%26aulast%3DIkome%26aufirst%3DH.%2BN.%26aulast%3DNtie-Kang%26aufirst%3DF.%26aulast%3DNgemenya%26aufirst%3DM.%2BN.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DEfange%26aufirst%3DS.%2BM.%26atitle%3D4-Aroylpiperidines%2520and%25204-%2528alpha-hydroxyphenyl%2529piperidines%2520as%2520selective%2520sigma-1%2520receptor%2520ligands%253A%2520synthesis%252C%2520preliminary%2520pharmacological%2520evaluation%2520and%2520computational%2520studies%26jtitle%3DChem.%2520Cent.%2520J.%26date%3D2016%26volume%3D10%26spage%3D53%26doi%3D10.1186%2Fs13065-016-0200-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Bello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piergentili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimarelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flammini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amantini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quaglia, W.</span></span> <span> </span><span class="NLM_article-title">Novel potent <i>N</i>-methyl-d-aspartate (NMDA) receptor antagonists or sigma1 receptor ligands based on properly substituted 1,4-dioxane ring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8601</span>– <span class="NLM_lpage">8615</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01214</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01214" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Slsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8601-8615&author=A.+Bonifaziauthor=F.+Del+Belloauthor=V.+Mammoliauthor=A.+Piergentiliauthor=R.+Petrelliauthor=C.+Cimarelliauthor=M.+Pelleiauthor=D.+Schepmannauthor=B.+Wunschauthor=E.+Barocelliauthor=S.+Bertoniauthor=L.+Flamminiauthor=C.+Amantiniauthor=M.+Nabissiauthor=G.+Santoniauthor=G.+Vistoliauthor=W.+Quaglia&title=Novel+potent+N-methyl-d-aspartate+%28NMDA%29+receptor+antagonists+or+sigma1+receptor+ligands+based+on+properly+substituted+1%2C4-dioxane+ring&doi=10.1021%2Facs.jmedchem.5b01214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Potent N-Methyl-D-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring</span></div><div class="casAuthors">Bonifazi, Alessandro; Del Bello, Fabio; Mammoli, Valerio; Piergentili, Alessandro; Petrelli, Riccardo; Cimarelli, Cristina; Pellei, Maura; Schepmann, Dirk; Wunsch, Bernhard; Barocelli, Elisabetta; Bertoni, Simona; Flammini, Lisa; Amantini, Consuelo; Nabissi, Massimo; Santoni, Giorgio; Vistoli, Giulio; Quaglia, Wilma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8601-8615</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two series of 1,4-dioxanes (4-11 and 12-19) were rationally designed and prepd. to interact either with the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA) receptor or with σ1 receptors, resp.  The biol. profiles of the novel compds. were assessed using radioligand binding assays, and the compds. with the highest affinities were investigated for their functional activity.  The results were in line with the available pharmacophore models and highlighted that the 1,4-dioxane scaffold is compatible with potent antagonist activity at NMDA receptor or high affinity for σ1 receptors.  The primary amines I [R = C6H11, trans] and I [R = Ph] bearing a cyclohexyl and a Ph ring or two Ph rings in position 6, resp., were the most potent noncompetitive antagonists at the NMDA receptor with IC50 values similar to those of the dissociative anesthetic (S)-(+)-ketamine.  The 5,5-di-Ph substitution assocd. with a benzylaminomethyl moiety in position 2, as in II, favored the interaction with σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom9Lw-lUtPSLVg90H21EOLACvtfcHk0lhP0asvQecgBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Slsb%252FN&md5=0c053c67bc8f4f3449c1af2a3470df2e</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01214%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DDel%2BBello%26aufirst%3DF.%26aulast%3DMammoli%26aufirst%3DV.%26aulast%3DPiergentili%26aufirst%3DA.%26aulast%3DPetrelli%26aufirst%3DR.%26aulast%3DCimarelli%26aufirst%3DC.%26aulast%3DPellei%26aufirst%3DM.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DBertoni%26aufirst%3DS.%26aulast%3DFlammini%26aufirst%3DL.%26aulast%3DAmantini%26aufirst%3DC.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DQuaglia%26aufirst%3DW.%26atitle%3DNovel%2520potent%2520N-methyl-d-aspartate%2520%2528NMDA%2529%2520receptor%2520antagonists%2520or%2520sigma1%2520receptor%2520ligands%2520based%2520on%2520properly%2520substituted%25201%252C4-dioxane%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8601%26epage%3D8615%26doi%3D10.1021%2Facs.jmedchem.5b01214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asare-Nkansah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of conformationally restricted 1,3-dioxanes to analyze the bioactive conformation of 1,3-dioxane-based sigma1 and PCP receptor antagonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2472</span>– <span class="NLM_lpage">2481</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2017.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28320613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksFCjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2472-2481&author=S.+Asare-Nkansahauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis+of+conformationally+restricted+1%2C3-dioxanes+to+analyze+the+bioactive+conformation+of+1%2C3-dioxane-based+sigma1+and+PCP+receptor+antagonists&doi=10.1016%2Fj.bmc.2017.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of conformationally restricted 1,3-dioxanes to analyze the bioactive conformation of 1,3-dioxane-based σ1 and PCP receptor antagonists</span></div><div class="casAuthors">Asare-Nkansah, Samuel; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2472-2481</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The receptor binding profile of 2-phenyl-4-(aminoethyl)-1,3-dioxanes was dependent on the addnl. substituent in 2-position, the substituents at the amino moiety and the stereochem.  The conformationally restricted 1,3-dioxanes bearing an axially oriented Ph moiety in 2-position were prepd. and pharmacol. evaluated.  Two subsequent intramol. transacetalization reactions represented the key steps in the synthesis of the tricyclic system.  The resulting alc. I [R = OH] was transformed into amines II [X = NH2, benzylamine, dibenzylamine and dimethylamine] and III [X = NH2, benzylamine, dibenzylamine and dimethylamine] with axially (a-series) or equatorially oriented aminoethyl moiety (b-series).  The primary amines II [X = NH2] and III [X = NH2] did not interact with the PCP binding site of the NMDA receptor, which is explained by the addnl. methylene moiety between the acetalic center and the Ph moiety, the missing substituent at the acetalic position and/or a non-optimal three-dimensional arrangement of the pharmacophoric elements.  The benzylamine III [X = benzylamine] with an equatorially oriented aminoethyl moiety showed high σ1 affinity (Ki = 5.9 nM).  Compared with the conformationally flexible 1,3-dioxane, the σ1 affinity of III [X = benzylamine] is 3-fold and the σ1/σ2 selectivity was 5-fold increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkYGJ8bTyTubVg90H21EOLACvtfcHk0ljiB7pQ7fkMdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksFCjtbs%253D&md5=6e6b3e1d2b8fedd11339c308116d8c3e</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DAsare-Nkansah%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520conformationally%2520restricted%25201%252C3-dioxanes%2520to%2520analyze%2520the%2520bioactive%2520conformation%2520of%25201%252C3-dioxane-based%2520sigma1%2520and%2520PCP%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D2472%26epage%3D2481%26doi%3D10.1016%2Fj.bmc.2017.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strydom, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greyling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">V. Dyk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malan, S. F.</span></span> <span> </span><span class="NLM_article-title">Hexacyclododecylamines with sigma-1 receptor affinity and calcium channel modulating ability</span>. <i>Open Med. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.2174/1874104501913010029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F1874104501913010029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWqsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=29-39&author=J.+Joubertauthor=N.+Strydomauthor=W.+J.+Geldenhuysauthor=Y.+Greylingauthor=S.+V.+Dykauthor=S.+F.+Malan&title=Hexacyclododecylamines+with+sigma-1+receptor+affinity+and+calcium+channel+modulating+ability&doi=10.2174%2F1874104501913010029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Hexacyclododecylamines with sigma-1 receptor affinity and calcium channel modulating ability</span></div><div class="casAuthors">Joubert, Jacques; Strydom, Natasha; Geldenhuys, Werner J.; Greyling, Yolande; Dyk, Sandra V.; Malan, Sarel F.</div><div class="citationInfo"><span class="NLM_cas:title">Open Medicinal Chemistry Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">OMCJB6</span>;
        ISSN:<span class="NLM_cas:issn">1874-1045</span>.
    
            (<span class="NLM_cas:orgname">Bentham Open</span>)
        </div><div class="casAbstract">Introduction: Recent research points to the Sigma Receptor (σR) as a possible neuromodulatory system with multifunctional action and σ1Rs have been suggested as a drug target for a no. of CNS conditions.  Hexacyclododecylamines have shown σ1R activity and provide an advantageous scaffold for drug design that can improve the blood-brain barrier permeability of privileged structures.  Methods and Materials: A series of oxa and aza hexaxcyclododecylamines were synthesized and evaluated for sigma 1 receptor activity and voltage gated calcium channel blocking ability to det. the effect of inclusion of amine contg. heterocycles.  Results & Discussion: The compds. had promising σ1R activities (Ki = 0.067- 11.86 μM) with the aza hexacyclododecylamines 12, 24 and 27 showing some of the highest affinities (Ki = 0.067 μM, 0.215 μM and 0.496 μM resp.).  This confirms, as obsd. in previous studies, that the aza compds. are more favorable for σ1R binding than their oxa counterparts.  The addn. of the amine heterocycle showed affinities similar to that of related structures with only two lipophilic binding regions.  This indicates that the inclusion of an amine heterocycle into these structures is a viable option in the design of new σ1R ligands.  Conclusion: The σ1R activity and potential effect on other receptor classes and calcium channels could prove beneficial in pharmacol. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWB0dLMmX7UrVg90H21EOLACvtfcHk0ljiB7pQ7fkMdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWqsr3O&md5=40736af7853100e4e1d6a9e7d58df777</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.2174%2F1874104501913010029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874104501913010029%26sid%3Dliteratum%253Aachs%26aulast%3DJoubert%26aufirst%3DJ.%26aulast%3DStrydom%26aufirst%3DN.%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DGreyling%26aufirst%3DY.%26aulast%3DV.%2BDyk%26aufirst%3DS.%26aulast%3DMalan%26aufirst%3DS.%2BF.%26atitle%3DHexacyclododecylamines%2520with%2520sigma-1%2520receptor%2520affinity%2520and%2520calcium%2520channel%2520modulating%2520ability%26jtitle%3DOpen%2520Med.%2520Chem.%2520J.%26date%3D2019%26volume%3D13%26spage%3D29%26epage%3D39%26doi%3D10.2174%2F1874104501913010029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aube, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span> <span> </span><span class="NLM_article-title">Decahydrobenzoquinolin-5-one sigma receptor ligands: divergent development of both sigma 1 and sigma 2 receptor selective examples</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5689</span>– <span class="NLM_lpage">5694</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2016.10.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27839919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5689-5694&author=M.+C.+McLeodauthor=J.+Aubeauthor=K.+J.+Frankowski&title=Decahydrobenzoquinolin-5-one+sigma+receptor+ligands%3A+divergent+development+of+both+sigma+1+and+sigma+2+receptor+selective+examples&doi=10.1016%2Fj.bmcl.2016.10.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples</span></div><div class="casAuthors">McLeod, Michael C.; Aube, Jeffrey; Frankowski, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5689-5694</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Analogs of the decahydrobenzoquinolin-5-one class of sigma (σ) receptor ligands were used to probe the structure-activity relationship trends for this recently discovered series of σ ligands.  In all, 29 representatives were tested for σ and opioid receptor affinity, leading to the identification of compds. possessing improved σ1 selectivity and, for the first time in this series, examples possessing preferential σ2 affinity.  Several structural features assocd. with these selectivity trends have been identified.  Two analogs of improved selectivity were evaluated in a binding panel of 43 CNS-relevant targets to confirm their sigma receptor preference.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3DbJ3TPJurVg90H21EOLACvtfcHk0ljiB7pQ7fkMdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3L&md5=c71a5ddb62936d09ef826ce9c8628f28</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.065%26sid%3Dliteratum%253Aachs%26aulast%3DMcLeod%26aufirst%3DM.%2BC.%26aulast%3DAube%26aufirst%3DJ.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26atitle%3DDecahydrobenzoquinolin-5-one%2520sigma%2520receptor%2520ligands%253A%2520divergent%2520development%2520of%2520both%2520sigma%25201%2520and%2520sigma%25202%2520receptor%2520selective%2520examples%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5689%26epage%3D5694%26doi%3D10.1016%2Fj.bmcl.2016.10.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topczewski, J. J.</span></span> <span> </span><span class="NLM_article-title">3-Amino-chromanes and tetrahydroquinolines as selective 5-HT2B, 5-HT7, or sigma 1 receptor ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1436</span>– <span class="NLM_lpage">1442</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00225</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00225" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVent77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1436-1442&author=M.+R.+Porterauthor=H.+Xiaoauthor=J.+Wangauthor=S.+B.+Smithauthor=J.+J.+Topczewski&title=3-Amino-chromanes+and+tetrahydroquinolines+as+selective+5-HT2B%2C+5-HT7%2C+or+sigma+1+receptor+ligands&doi=10.1021%2Facsmedchemlett.9b00225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands</span></div><div class="casAuthors">Porter, Matthew R.; Xiao, Haiyan; Wang, Jing; Smith, Sylvia B.; Topczewski, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1436-1442</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phenethylamine backbone is a privileged substructure found in a wide variety of G protein-coupled receptor (GPCR) ligands.  This includes both endogenous neurotransmitters and active pharmaceutical agents.  More than 20 structurally unique heterocyclic phenethylamine derivs. were broadly evaluated for GPCR affinity.  Selective ligands for the 5-HT2B, 5-HT7, and σ1 receptors were identified, each with low nanomolar binding affinities.  The σ1 receptor affinity was supported in a cellular assay that provided evidence for increased cell survival under oxidative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0d2zLDIyGCrVg90H21EOLACvtfcHk0lj2xyR0-Wk3uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVent77M&md5=9c51129feafc5b64c80813f98a6107c1</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00225%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DM.%2BR.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%2BB.%26aulast%3DTopczewski%26aufirst%3DJ.%2BJ.%26atitle%3D3-Amino-chromanes%2520and%2520tetrahydroquinolines%2520as%2520selective%25205-HT2B%252C%25205-HT7%252C%2520or%2520sigma%25201%2520receptor%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1436%26epage%3D1442%26doi%3D10.1021%2Facsmedchemlett.9b00225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">From alpha4beta2 nicotinic ligands to the discovery of sigma1 receptor ligands: pharmacophore analysis and rational design</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1058</span>, <span class="refDoi"> DOI: 10.1021/ml3002715</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3002715" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1054-1058&author=L.+F.+Yuauthor=H.+K.+Zhangauthor=H.+Gunosewoyoauthor=A.+P.+Kozikowski&title=From+alpha4beta2+nicotinic+ligands+to+the+discovery+of+sigma1+receptor+ligands%3A+pharmacophore+analysis+and+rational+design&doi=10.1021%2Fml3002715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design</span></div><div class="casAuthors">Yu, Li-Fang; Zhang, Han-Kun; Gunosewoyo, Hendra; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1054-1058</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Comparative analyses of the pharmacophoric elements required for σ1 and nicotinic ligands led to the identification of a potent and selective σ1 ligand (15, I).  Compd. 15 displayed high selectivity for the σ1 receptor (Ki, σ1 = 4.1 nM; Ki, σ2 = 1312 nM) with moderate binding affinity for the DAT (Ki = 373 nM) and NET (Ki = 203 nM) in the PDSP broad screening panel of common CNS neurotransmitter transporters and receptors.  The key finding in this present work is that a subtle structural modification could be used as a tool to switch a ligand's selectivity between nAChRs and sigma receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp00SphSwYKLrVg90H21EOLACvtfcHk0lj2xyR0-Wk3uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtr3K&md5=908dc6a13498beb6e751249b33d35e71</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Fml3002715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3002715%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DH.%2BK.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DFrom%2520alpha4beta2%2520nicotinic%2520ligands%2520to%2520the%2520discovery%2520of%2520sigma1%2520receptor%2520ligands%253A%2520pharmacophore%2520analysis%2520and%2520rational%2520design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D1054%26epage%3D1058%26doi%3D10.1021%2Fml3002715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span> <span> </span><span class="NLM_article-title">Development of novel alkoxyisoxazoles as sigma-1 receptor antagonists with antinociceptive efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6329</span>– <span class="NLM_lpage">6343</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00571</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00571" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFyntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6329-6343&author=H.+Sunauthor=M.+Shiauthor=W.+Zhangauthor=Y.+M.+Zhengauthor=Y.+Z.+Xuauthor=J.+J.+Shiauthor=T.+Liuauthor=H.+Gunosewoyoauthor=T.+Pangauthor=Z.+B.+Gaoauthor=F.+Yangauthor=J.+Tangauthor=L.+F.+Yu&title=Development+of+novel+alkoxyisoxazoles+as+sigma-1+receptor+antagonists+with+antinociceptive+efficacy&doi=10.1021%2Facs.jmedchem.6b00571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Development of novel alkoxyisoxazoles as sigma-1 receptor antagonists with antinociceptive efficacy</span></div><div class="casAuthors">Sun, Hao; Shi, Min; Zhang, Wei; Zheng, Yue-Ming; Xu, Ya-Zhou; Shi, Jun-Jie; Liu, Ting; Gunosewoyo, Hendra; Pang, Tao; Gao, Zhao-Bing; Yang, Fan; Tang, Jie; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6329-6343</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of sigma (σ) receptor ligands based on an alkoxyisoxazole scaffold has been designed and synthesized.  Preliminary receptor binding assays identified highly potent (Ki < 1 nM) and selective σ1 ligands devoid of binding interactions with the monoamine transporters DAT, NET, and SERT.  In particular, compd. I was shown to possess significant antinociceptive activity in the mouse formalin-induced inflammation pain model when administered i.p. at 40 and 80 mg/kg.  Initial pharmacokinetics evaluation indicated an excellent brain exposure following oral dosing in mice, suggesting that further investigation into the use of alkoxyisoxazoles as σ1 ligands for antinociception is warranted.  This study supports the notion that selective σ1 antagonism could be a useful strategy in the development of novel antipain therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHMyTThgBAs7Vg90H21EOLACvtfcHk0lj2xyR0-Wk3uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFyntb4%253D&md5=ec9ef2824ddeaef099b4326025130d09</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00571%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DY.%2BM.%26aulast%3DXu%26aufirst%3DY.%2BZ.%26aulast%3DShi%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DZ.%2BB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DL.%2BF.%26atitle%3DDevelopment%2520of%2520novel%2520alkoxyisoxazoles%2520as%2520sigma-1%2520receptor%2520antagonists%2520with%2520antinociceptive%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6329%26epage%3D6343%26doi%3D10.1021%2Facs.jmedchem.6b00571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.-F.</span></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i>-cyclobutylaminoethoxyisoxazole derivatives as novel sigma-1 receptor ligands with neurite outgrowth efficacy in cells</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">7080</span>– <span class="NLM_lpage">7088</span>, <span class="refDoi"> DOI: 10.1039/C8RA00072G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC8RA00072G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=7080-7088&author=H.+Sunauthor=Y.-J.+Wangauthor=W.-W.+Shiauthor=F.+Yangauthor=J.+Tangauthor=T.+Pangauthor=L.-F.+Yu&title=Discovery+of+N-cyclobutylaminoethoxyisoxazole+derivatives+as+novel+sigma-1+receptor+ligands+with+neurite+outgrowth+efficacy+in+cells&doi=10.1039%2FC8RA00072G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-cyclobutylaminoethoxyisoxazole derivatives as novel sigma-1 receptor ligands with neurite outgrowth efficacy in cells</span></div><div class="casAuthors">Sun, Hao; Wang, Yun-Jie; Shi, Wen-Wen; Yang, Fan; Tang, Jie; Pang, Tao; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7080-7088</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Herein we reported a series of 14 novel derivs. based on the N-cyclobutylaminoethoxyisoxazole scaffold.  In vitro binding studies of these compds. demonstrated their low nanomolar to subnanomolar potencies as σ1 receptor ligands, with moderate to excellent selectivity over the σ2 receptor as represented by compds. 17-30.  The majority of the derivs. scored high (>4.7) in the CNS MPO appraisal system, indicating their high likelihood in penetrating the blood-brain barrier.  A no. of these compds. exhibited significant neurite outgrowth efficacy in N1E-115 neuronal cells and displayed excellent selectivity for σ1 receptors over the selected endogenous neurotransmitter transporters, such as DAT, NET and SERT.  Among the mini-series, compd. 28 (Ki σ1 = 0.2 nM, Ki σ2 = 198 nM, CNS MPO score = 5.4) emerged as a promising selective σ1 receptor ligand that warrants its further evaluation as a potential therapeutic for neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiYUOZSg4iE7Vg90H21EOLACvtfcHk0lj2ebIAyY-79w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSlsrw%253D&md5=acccca6c662001d63d4e6d6872608a76</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1039%2FC8RA00072G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8RA00072G%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DShi%26aufirst%3DW.-W.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DL.-F.%26atitle%3DDiscovery%2520of%2520N-cyclobutylaminoethoxyisoxazole%2520derivatives%2520as%2520novel%2520sigma-1%2520receptor%2520ligands%2520with%2520neurite%2520outgrowth%2520efficacy%2520in%2520cells%26jtitle%3DRSC%2520Adv.%26date%3D2018%26volume%3D8%26spage%3D7080%26epage%3D7088%26doi%3D10.1039%2FC8RA00072G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toussaint, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousset, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemard, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 ligands: Tic-hydantoin as a key pharmacophore</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2009.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2009.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19875205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2ju7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=256-263&author=M.+Toussaintauthor=D.+Moussetauthor=C.+Foulonauthor=U.+Jacquemardauthor=C.+Vaccherauthor=P.+Melnyk&title=Sigma-1+ligands%3A+Tic-hydantoin+as+a+key+pharmacophore&doi=10.1016%2Fj.ejmech.2009.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 ligands: Tic-hydantoin as a key pharmacophore</span></div><div class="casAuthors">Toussaint, Marion; Mousset, Deborah; Foulon, Catherine; Jacquemard, Ulrich; Vaccher, Claude; Melnyk, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">256-263</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sigma-1 receptors are involved in numerous pathol. dysfunctions and the synthesis of selective ligands is of interest.  The authors identified a fused tetrahydroisoquinoline-hydantoin (Tic-hydantoin) structure with high affinity and selectivity for these receptors.  They report here their efforts towards the pharmacomodulation of this substructure, the synthesis of 9 analogs, e.g., I (R = H, Cl, I), with stereochem. inversion, opening of isoquinoline ring, removal of isoquinoline nitrogen, replacement of isoquinoline by pyridine, of Tic-hydantoin moiety by quinazolinedione heterocycle.  All these analogs provided a loss in the affinity for the sigma-1 receptor.  The present work underlines the real importance of the Tic-hydantoin moiety for the obtainment of high affinity ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZHp1sO6otxLVg90H21EOLACvtfcHk0lj2ebIAyY-79w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2ju7vL&md5=c38f1c0fa851af2eac0e20d55c021c09</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DToussaint%26aufirst%3DM.%26aulast%3DMousset%26aufirst%3DD.%26aulast%3DFoulon%26aufirst%3DC.%26aulast%3DJacquemard%26aufirst%3DU.%26aulast%3DVaccher%26aufirst%3DC.%26aulast%3DMelnyk%26aufirst%3DP.%26atitle%3DSigma-1%2520ligands%253A%2520Tic-hydantoin%2520as%2520a%2520key%2520pharmacophore%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D256%26epage%3D263%26doi%3D10.1016%2Fj.ejmech.2009.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnier-Marechal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larchanche, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Broc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, P.</span></span> <span> </span><span class="NLM_article-title">Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.10.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25462240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOqtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=198-206&author=M.+Donnier-Marechalauthor=P.+E.+Larchancheauthor=D.+Le+Brocauthor=C.+Furmanauthor=P.+Caratoauthor=P.+Melnyk&title=Carboline-+and+phenothiazine-derivated+heterocycles+as+potent+SIGMA-1+protein+ligands&doi=10.1016%2Fj.ejmech.2014.10.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Carboline and phenothiazine derivatives as potent SIGMA-1 protein ligands</span></div><div class="casAuthors">Donnier-Marechal, Marion; Larchanche, Paul-Emmanuel; Le Broc, Delphine; Furman, Christophe; Carato, Pascal; Melnyk, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">198-206</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sigma 1 receptors are assocd. with neurodegenerative and psychiatric disorders.  These receptors, via their chaperoning functions that counteract endoplasmic reticulum stress and block neurodegeneration, may serve as a target for a new generation of antidepressants or neuroprotective agents.  The involvement of these receptors has also been obsd. in neuropathic pain and cancer.  Only a few ligands, such as Igmesine and Anavex 2-73, have been involved in clin. trials.  Thus the development of sigma 1 ligands is of interest to a new generation of drugs.  Previous work in the lab. underlined the potency of benzannulated bicyclic compds. as interesting ligands.  Herein the work was extended to a series of novel tricyclic compds.  Carboline and phenothiazine derivs. were designed and synthesized.  In vitro competition binding assays for sigma 1 and 2 receptors showed that most of them have high affinity for sigma 1 receptor (Ki = 2.5-18 nM), and selectivity toward sigma 2 receptor, without cytotoxic effects on SY5Y cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm1NcJb9IIs7Vg90H21EOLACvtfcHk0lj2ebIAyY-79w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOqtb7F&md5=e53f5f17f8baa47cbc36531b7d3bb34f</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.053%26sid%3Dliteratum%253Aachs%26aulast%3DDonnier-Marechal%26aufirst%3DM.%26aulast%3DLarchanche%26aufirst%3DP.%2BE.%26aulast%3DLe%2BBroc%26aufirst%3DD.%26aulast%3DFurman%26aufirst%3DC.%26aulast%3DCarato%26aufirst%3DP.%26aulast%3DMelnyk%26aufirst%3DP.%26atitle%3DCarboline-%2520and%2520phenothiazine-derivated%2520heterocycles%2520as%2520potent%2520SIGMA-1%2520protein%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D198%26epage%3D206%26doi%3D10.1016%2Fj.ejmech.2014.10.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnier-Marechal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Broc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of benzannulated derivatives as potent and selective sigma-1 protein ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25602932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVertrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=575-582&author=M.+Donnier-Marechalauthor=P.+Caratoauthor=D.+Le+Brocauthor=C.+Furmanauthor=P.+Melnyk&title=Synthesis+and+pharmacological+evaluation+of+benzannulated+derivatives+as+potent+and+selective+sigma-1+protein+ligands&doi=10.1016%2Fj.ejmech.2014.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of benzannulated derivatives as potent and selective sigma-1 protein ligands</span></div><div class="casAuthors">Donnier-Marechal, Marion; Carato, Pascal; Le Broc, Delphine; Furman, Christophe; Melnyk, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">575-582</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The σ1 proteins are considered to be a new class of target structures for several central nervous system disorders, including depression, anxiety, psychosis, and Parkinson's and Alzheimer's diseases.  Recently, the involvement of these receptors in neuropathic pain and cancer also was obsd.  So far, only a few ligands are in clin. trials.  In a continuation of the authors' previous studies on the development of σ1 ligands, a new series of benzannulated heterocycles was designed and synthesized.  In vitro competition binding assays showed that many of them possessed high σ1 receptor affinity (Ki = 0.6-10.3 nM), and good σ2/σ1 subtype selectivity, without cytotoxic effects on SY5Y cells (human neuroblastoma cell line).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqysWvGfSMtqrVg90H21EOLACvtfcHk0li2xq1n0A6u7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVertrc%253D&md5=cf877e45fcf78478d55919ae3d1bced5</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DDonnier-Marechal%26aufirst%3DM.%26aulast%3DCarato%26aufirst%3DP.%26aulast%3DLe%2BBroc%26aufirst%3DD.%26aulast%3DFurman%26aufirst%3DC.%26aulast%3DMelnyk%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520benzannulated%2520derivatives%2520as%2520potent%2520and%2520selective%2520sigma-1%2520protein%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D575%26epage%3D582%26doi%3D10.1016%2Fj.ejmech.2014.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnier-Marechal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larchanche, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulahjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxombre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermersch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">964</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2017.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28756263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GkurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=964-978&author=M.+Donnier-Marechalauthor=P.+Caratoauthor=P.+E.+Larchancheauthor=S.+Ravezauthor=R.+Boulahjarauthor=A.+Barczykauthor=B.+Oxombreauthor=P.+Vermerschauthor=P.+Melnyk&title=Synthesis+and+pharmacological+evaluation+of+benzamide+derivatives+as+potent+and+selective+sigma-1+protein+ligands&doi=10.1016%2Fj.ejmech.2017.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligands</span></div><div class="casAuthors">Donnier-Marechal, Marion; Carato, Pascal; Larchanche, Paul-Emmanuel; Ravez, Severine; Boulahjar, Rajaa; Barczyk, Amelie; Oxombre, Benedicte; Vermersch, Patrick; Melnyk, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">964-978</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel N-(aminoalkyl)benzamide derivs. such as I [m = 2, 3; R1 = Me; R2 = Bn, (CH2)2C6H4; R1R2 = (CH2)4, (CH2)2O(CH2)2, (CH2)2NMe(CH2)2, etc.; R3 = H, 4-n-Bu, 4-Cl, etc.] and N-benzyl-N-methyl-propan-1-amine derivs. II [X = CH2NH, SO2NH, NHC(O)] was designed, synthesized and pharmacol. evaluated.  In vitro competition binding assays against sigma proteins (sigma-1 S1R and sigma-2 S2R) revealed that most of them conferred S2R/S1R selectivity toward without cytotoxic effects on SY5Y cells, esp. with compds. I [m = 2, 3; R1 = Me; R2 = Bn].  Some selected compds. were also evaluated for their agonist and antagonist activities on a panel of 40 receptors and results showed the importance of the nature and the position with halogeno atom on the benzamide scaffold, the length chain and also the contribution of the hydrophobic part on the amine group.  Among them, compds. I [m = 2, 3; R1 = Me; R2 = Bn; R3 = 4-Cl, 4-CN, 4-NO2] showed excellent affinity for S1R (Ki = 1.2-3.6 nM), selectivity for S2R (Ki up to 1400 nM) and high selectivity index (IC50(SY5Y)/Ki(S1R) ratio from 28/000 to 83/000).  Furthermore, these compds. I and II presented an excellent safety profile over 40 other receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2VybgDKUtbVg90H21EOLACvtfcHk0li2xq1n0A6u7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GkurnE&md5=6dd003ecd4f63615b8fbf3a68e2445c9</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DDonnier-Marechal%26aufirst%3DM.%26aulast%3DCarato%26aufirst%3DP.%26aulast%3DLarchanche%26aufirst%3DP.%2BE.%26aulast%3DRavez%26aufirst%3DS.%26aulast%3DBoulahjar%26aufirst%3DR.%26aulast%3DBarczyk%26aufirst%3DA.%26aulast%3DOxombre%26aufirst%3DB.%26aulast%3DVermersch%26aufirst%3DP.%26aulast%3DMelnyk%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520benzamide%2520derivatives%2520as%2520potent%2520and%2520selective%2520sigma-1%2520protein%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D964%26epage%3D978%26doi%3D10.1016%2Fj.ejmech.2017.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span> <span> </span><span class="NLM_article-title">Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2016.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27366902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSgu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=712-726&author=D.+Zampieriauthor=L.+Vioauthor=M.+Fermegliaauthor=S.+Priclauthor=B.+Wunschauthor=D.+Schepmannauthor=M.+Romanoauthor=M.+G.+Mamoloauthor=E.+Laurini&title=Computer-assisted+design%2C+synthesis%2C+binding+and+cytotoxicity+assessments+of+new+1-%284-%28aryl%28methyl%29amino%29butyl%29-heterocyclic+sigma+1+ligands&doi=10.1016%2Fj.ejmech.2016.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands</span></div><div class="casAuthors">Zampieri, Daniele; Vio, Luciano; Fermeglia, Maurizio; Pricl, Sabrina; Wunsch, Bernhard; Schepmann, Dirk; Romano, Maurizio; Mamolo, Maria Grazia; Laurini, Erik</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">712-726</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work a blend of computational and synthetic techniques were applied with the aim to design, synthesize, and characterize new σ1 receptor (σ1R) ligands.  Starting from the structure of previously reported, high-affinity benzoxazolone-based σ1 ligands, the three-dimensional homol. model of the σ1R was exploited for retrieving the mol. determinants to fulfill the optimal pharmacophore requirements.  Accordingly, the benzoxazolone moiety was replaced by other heterocyclic scaffolds, the relevant conformational space in the σ1R binding cavity was explored, and the effect on σ1R binding affinity was ultimately assessed.  Next, the compds. designed in silico were synthesized, and their affinity and selectivity toward σ1 and σ2 receptors were tested.  Finally, a representative series of best σ1R binders were assayed for cytotoxic activity on the SH-SY5Y human neuroblastoma cell line.  Specifically, the new 4-phenyloxazolidin-2-one derivs. (i.e., (R)- and (S)-3-(4-((4-chlorobenzyl)-(methyl)-amino)-butyl)-4-phenyl-oxazolidin-2-one) emerged as potential leads for further development as σ1R agents, as they were found endowed with the highest σ1R affinity (Kiσ1 values in the range 0.95-9.3 nM), and showed minimal cytotoxic levels exhibited in the selected, cell-based test, in line with a σ1R agonist behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGpvF0Y7uR7Vg90H21EOLACvtfcHk0li2xq1n0A6u7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSgu77K&md5=1fae4fb45c6c9807766ed6b3573b5e3d</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DLaurini%26aufirst%3DE.%26atitle%3DComputer-assisted%2520design%252C%2520synthesis%252C%2520binding%2520and%2520cytotoxicity%2520assessments%2520of%2520new%25201-%25284-%2528aryl%2528methyl%2529amino%2529butyl%2529-heterocyclic%2520sigma%25201%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D712%26epage%3D726%26doi%3D10.1016%2Fj.ejmech.2016.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based sigma1 receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24996139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1aks7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=526-533&author=E.+Lauriniauthor=D.+Harelauthor=D.+Marsonauthor=D.+Schepmannauthor=T.+J.+Schmidtauthor=S.+Priclauthor=B.+Wunsch&title=Identification%2C+pharmacological+evaluation+and+binding+mode+analysis+of+novel+chromene+and+chromane+based+sigma1+receptor+ligands&doi=10.1016%2Fj.ejmech.2014.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands</span></div><div class="casAuthors">Laurini, Erik; Harel, Dipak; Marson, Domenico; Schepmann, Dirk; Schmidt, Thomas J.; Pricl, Sabrina; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">526-533</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A set of aminoethyl substituted chromenes 3 and chromanes 4, originally developed as antiprotozoal drugs was evaluated as novel types of σ1 receptor ligands.  Anal. of SAR showed that chromenes 3 have a higher σ1 affinity than chromanes 4.  A distance of four bond lengths between the basic amino moiety and the Ph ring (3c), an alicyclic N-substituent such as the cyclohexylmethyl moiety (3l), and methylation of the secondary amine to afford a tertiary amine (3n) result in very high σ1 affinity and selectivity over the σ2 subtype.  Compds. 3a-n and 4a-e were docked into the putative binding site of the σ1 receptor model and the relevant binding mode was analyzed and scored.  Specifically, for the best σ1 ligand 3n, a salt bridge between Asp126 and the protonated amino group, an H-bond between the receptor backbone NH group (Ala122-Glu123) and the methoxy moiety of 3n, a lipophilic protein cavity encasing the chromene ring, and a T-shaped π-π stacking between the indole ring of Trp121 and the Ph ring of 3n represent the most important ligand/protein stabilizing interactions.  The binding pose of 3n was compared with the binding poses of the non-methylated chromene 3c, the satd. chromane 4c, and the N-cyclohexylmethyl deriv. 3l.  The contribution of the single amino acids to the overall free binding enthalpy was analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWhkbKyV7MDrVg90H21EOLACvtfcHk0lhBGIHFcM-zZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1aks7vM&md5=9038e0e68b27b0618d7a6bf77a8e2035</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DHarel%26aufirst%3DD.%26aulast%3DMarson%26aufirst%3DD.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DSchmidt%26aufirst%3DT.%2BJ.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DIdentification%252C%2520pharmacological%2520evaluation%2520and%2520binding%2520mode%2520analysis%2520of%2520novel%2520chromene%2520and%2520chromane%2520based%2520sigma1%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D83%26spage%3D526%26epage%3D533%26doi%3D10.1016%2Fj.ejmech.2014.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyamu, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiltz, G. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel class of potent and selective tetrahydroindazole-based sigma-1 receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1824</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.03.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2019.03.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30904383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1egsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1824-1835&author=I.+D.+Iyamuauthor=W.+Lvauthor=N.+Malikauthor=R.+K.+Mishraauthor=G.+E.+Schiltz&title=Discovery+of+a+novel+class+of+potent+and+selective+tetrahydroindazole-based+sigma-1+receptor+ligands&doi=10.1016%2Fj.bmc.2019.03.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel class of potent and selective tetrahydroindazole-based sigma-1 receptor ligands</span></div><div class="casAuthors">Iyamu, Iredia D.; Lv, Wei; Malik, Neha; Mishra, Rama K.; Schiltz, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1824-1835</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 and sigma-2 receptors have been shown to play important roles in CNS diseases, cancer, and other disorders.  These findings suggest that targeting these proteins with small-mol. modulators may be of important therapeutic value.  Here we report the development of a new class of tetrahydroindazoles that are highly potent and selective ligands for sigma-1.  Mol. modeling was used to rationalize the obsd. structure-activity relationships and identify key interactions responsible for increased potency of the optimized compds.  Assays for soly. and microsomal stability showed this series possesses favorable characteristics and is amenable to further therapeutic development.  The compds. described herein will be useful in the development of new chem. probes for sigma-1 and to aid in future work therapeutically targeting this protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr89UFpukY567Vg90H21EOLACvtfcHk0lhBGIHFcM-zZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1egsbg%253D&md5=6de5b22c574c4dc707ff3b7a16799bcf</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.03.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.03.030%26sid%3Dliteratum%253Aachs%26aulast%3DIyamu%26aufirst%3DI.%2BD.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DMalik%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DSchiltz%26aufirst%3DG.%2BE.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520potent%2520and%2520selective%2520tetrahydroindazole-based%2520sigma-1%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1824%26epage%3D1835%26doi%3D10.1016%2Fj.bmc.2019.03.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+modulation+of+class+A+GPCRs%3A+targets%2C+agents%2C+and+emerging+concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0lhBGIHFcM-zZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520modulation%2520of%2520class%2520A%2520GPCRs%253A%2520targets%252C%2520agents%252C%2520and%2520emerging%2520concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vavers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvejniece, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambrova, M.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of sigma-1 receptor: a review</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">223</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffphar.2019.00223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30941035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGns7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=223&author=E.+Vaversauthor=L.+Zvejnieceauthor=T.+Mauriceauthor=M.+Dambrova&title=Allosteric+modulators+of+sigma-1+receptor%3A+a+review&doi=10.3389%2Ffphar.2019.00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulators of sigma-1 receptor: a review</span></div><div class="casAuthors">Vavers, Edijs; Zvejniece, Liga; Maurice, Tangui; Dambrova, Maija</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">223</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Allosteric modulators of sigma-1 receptor (Sig1R) are described as compds. that can increase the activity of some Sig1R ligands that compete with (+)-pentazocine, one of the classic prototypical ligands that binds to the orthosteric Sig1R binding site.  Sig1R is an endoplasmic reticulum membrane protein that, in addn. to its promiscuous high-affinity ligand binding, has been shown to have chaperone activity.  Different exptl. approaches have been used to describe and validate the activity of allosteric modulators of Sig1R.  Sig1R-modulatory activity was first found for phenytoin, an anticonvulsant drug that primarily acts by blocking the voltage-gated sodium channels.  Accumulating evidence suggests that allosteric Sig1R modulators affect processes involved in the pathophysiol. of depression, memory and cognition disorders as well as convulsions.  This review will focus on the description of selective and non-selective allosteric modulators of Sig1R, including mol. structure properties and pharmacol. activity both in vitro and in vivo, with the aim of providing the latest overview from compd. discovery approaches to eventual clin. applications.  In this review, the possible mechanisms of action will be discussed, and future challenges in the development of novel compds. will be addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdr0ABFjLtSLVg90H21EOLACvtfcHk0ligXAJYBXqWKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGns7nL&md5=1b87ec1c67abe315b40134b80b4aa90f</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00223%26sid%3Dliteratum%253Aachs%26aulast%3DVavers%26aufirst%3DE.%26aulast%3DZvejniece%26aufirst%3DL.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDambrova%26aufirst%3DM.%26atitle%3DAllosteric%2520modulators%2520of%2520sigma-1%2520receptor%253A%2520a%2520review%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D223%26doi%3D10.3389%2Ffphar.2019.00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craviso, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span> <span> </span><span class="NLM_article-title">High-affinity dextromethorphan binding sites in guinea pig brain. II. Competition experiments</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">640</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=6865909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL3sXktFKntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=629-640&author=G.+L.+Cravisoauthor=J.+M.+Musacchio&title=High-affinity+dextromethorphan+binding+sites+in+guinea+pig+brain.+II.+Competition+experiments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity dextromethorphan binding sites in guinea pig brain.  II.  Competition experiments</span></div><div class="casAuthors">Craviso, Gale L.; Musacchio, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-40</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Binding of dextromethorphan (DM)(I)  [125-71-3] to guinea pig brain is stereoselective, since levomethorphan  [125-70-2] is 20 times weaker than DM in competing for DM sites.  In general, opiate agonists and antagonists as well as their corresponding dextrorotatory isomers are weak competitors for tritiated dextromethorphan ([3H]DM) binding sites and display IC50 values in the micromolar range.  In contrast, several nonnarcotic, centrally acting antitussives are inhibitory in the nanomolar range (IC50 values for caramiphen  [77-22-5], carbetapentane  [77-23-6], dimethoxanate  [477-93-0], and pipazethate  [2167-85-3] are 25, 9, 41, and 190 nM, resp.).  Other antitussives, such as levopropoxyphene  [2338-37-6], chlophedianol  [791-35-5], and fominoben  [18053-31-1], have poor affinity for DM sites whereas the antitussive noscapine  [128-62-1] enhances DM binding by increasing the affinity of DM for its central binding sites.  Addnl. competition studies indicate that there is no correlation of DM binding with any of the known or putative neurotransmitters in the central nervous system.  DM binding is also not related to tricyclic antidepressant binding sites or biogenic amine uptake sites.  However, certain phenothiazine neuroleptics and typical and atypical antidepressants inhibit binding with IC50 values in the nanomolar range.  Moreover, the anticonvulsant drug diphenylhydantoin  [57-41-0] enhances DM binding in a manner similar to that of noscapine.  Preliminary expts. utilizing acid exts. of brain have not demonstrated the presence of an endogenous ligand for DM sites.  The binding characteristics of DM sites studied in rat and mouse brain indicate that the relative potencies of several antitussives to inhibit specific DM binding vary according to species.  High-affinity, saturable, and stereoselective [3H]DM binding sites are present in liver homogenates, but several differences were n found for these peripheral binding sites and those described for brain.  Although the nature of central DM binding sites is not known, the potent interaction of several classes of centrally acting antitussives with DM sites suggests that they may be related to the mechanism of action of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXo7IRZP6ldLVg90H21EOLACvtfcHk0ligXAJYBXqWKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXktFKntrc%253D&md5=613b43e28c91ab1f427c5aa7ce2facd1</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCraviso%26aufirst%3DG.%2BL.%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26atitle%3DHigh-affinity%2520dextromethorphan%2520binding%2520sites%2520in%2520guinea%2520pig%2520brain.%2520II.%2520Competition%2520experiments%26jtitle%3DMol.%2520Pharmacol.%26date%3D1983%26volume%3D23%26spage%3D629%26epage%3D640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paturzo, J. J.</span></span> <span> </span><span class="NLM_article-title">Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[<sup>3</sup>H]3-(−3-hydroxyphenyl)-<i>N</i>-(1-propyl)piperidine</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=2536463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL1MXhsVOlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1989&pages=1-5&author=J.+M.+Musacchioauthor=M.+Kleinauthor=J.+J.+Paturzo&title=Effects+of+dextromethorphan+site+ligands+and+allosteric+modifiers+on+the+binding+of+%28%2B%29-%5B3H%5D3-%28%E2%88%923-hydroxyphenyl%29-N-%281-propyl%29piperidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine</span></div><div class="casAuthors">Musacchio, Jose M.; Klein, Martine; Paturzo, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Equil. binding anal. demonstrated that (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine [(+)-[3H]3-PPP] binds in guinea pig brain homogenates to high and low affinity sites with Kd values of 25 nM and 0.9 μM, resp.  Competition studies with dextromethorphan (DM) site ligands and other drugs against (+)-[3H]3-PPP demonstrated that their Ki values and rank order of potency are identical to those found previously against [3H] DM.  Most significant, ropizine produced a concn-dependent increase in the binding of (+)-[3H]3-PPP, with an inhibitory component at high concns., as described previously for [3H]DM.  Similarly, phenytoin increased the binding of (+)-[3H]3-PPP in the same fashion as that of [3H]DM.  Computer-assisted anal. of equil. binding of (+)-[3H]3-PPP in the presence of 10 μM ropizine demonstrated that the binding increase produced is due to a 3-fold increase in the affinity for (+)-[3H]3-PPP.  These results, and previous finding that σ ligands inhibit [3H] DM binding with a rank order of potency similar to that for sites labeled with (+)-[3H]3-PPP or (+)-[3H]SKF10,047 strongly suggest that σ ligands bind to the high affinity DM site.  These findings, and the inability of DM and other antitussives to produce psychotomimetic side effects, suggest that the high affinity DM sites can mediate only the nonpsychotomimetic effects of σ ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsH901CqfnKLVg90H21EOLACvtfcHk0ligXAJYBXqWKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhsVOlsLo%253D&md5=ba18c7810eb4da7a5a37701f7aecfa58</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DPaturzo%26aufirst%3DJ.%2BJ.%26atitle%3DEffects%2520of%2520dextromethorphan%2520site%2520ligands%2520and%2520allosteric%2520modifiers%2520on%2520the%2520binding%2520of%2520%2528%252B%2529-%255B3H%255D3-%2528%25E2%2588%25923-hydroxyphenyl%2529-N-%25281-propyl%2529piperidine%26jtitle%3DMol.%2520Pharmacol.%26date%3D1989%26volume%3D35%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">SKF83959 is a potent allosteric modulator of sigma-1 receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1124/mol.112.083840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fmol.112.083840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23295385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVCrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=577-586&author=L.+Guoauthor=J.+Zhaoauthor=G.+Jinauthor=B.+Zhaoauthor=G.+Wangauthor=A.+Zhangauthor=X.+Zhen&title=SKF83959+is+a+potent+allosteric+modulator+of+sigma-1+receptor&doi=10.1124%2Fmol.112.083840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">SKF83959 is a potent allosteric modulator of sigma-1 receptor</span></div><div class="casAuthors">Guo, Lin; Zhao, Jianghao; Jin, Guozhang; Zhao, Bin; Wang, Guanghui; Zhang, Ao; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-586</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">SKF83959 (3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine), an atypical dopamine receptor-1 (D1 receptor) agonist, has shown many D1 receptor-independent effects, such as neuroprotection, blockade of Na+ channel, and promotion of spontaneous glutamate release, which resemble the effects of the sigma-1 receptor activation.  In the present work, we explored the potential modulation of SKF83959 on the sigma-1 receptor.  The results indicated that SKF83959 dramatically promoted the binding of 3H(+)-pentazocine (a selective sigma-1 receptor agonist) to the sigma-1 receptor in brain and liver tissues but produced no effect on 3H-progesterone binding (a sigma-1 receptor antagonist).  The satn. assay and the dissocn. kinetics assay confirmed the allosteric effect.  We further demonstrated that the SKF83959 analogs, such as SCH22390 [(R)-(1)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride] and SKF38393 [(+/-)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrobromide], also showed the similar allosteric effect on the sigma-1 receptor in the liver tissue but not in the brain tissue.  Moreover, all three tested chems. elicited no significant effect on 3H-1,3-di(2-tolyl)-guanidine (3H-DTG) binding to the sigma-2 receptor.  The present data uncovered a new role of SKF83959 and its analogs on the sigma-1 receptor, which, in turn, may reveal the underlying mechanism for the D1 receptor-independent effect of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLPGE6uCA_2bVg90H21EOLACvtfcHk0ligXAJYBXqWKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVCrur8%253D&md5=75fee11a994695b5065c7946c6a23226</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.083840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.083840%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DSKF83959%2520is%2520a%2520potent%2520allosteric%2520modulator%2520of%2520sigma-1%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D577%26epage%3D586%26doi%3D10.1124%2Fmol.112.083840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santiago, L. J.</span></span> <span> </span><span class="NLM_article-title">High affinity dextromethorphan binding sites in guinea pig brain: further characterization and allosteric interactions</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">431</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=3183944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL1MXhvVCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1988&pages=424-431&author=J.+M.+Musacchioauthor=M.+Kleinauthor=L.+J.+Santiago&title=High+affinity+dextromethorphan+binding+sites+in+guinea+pig+brain%3A+further+characterization+and+allosteric+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">High affinity dextromethorphan binding sites in guinea pig brain:  further characterization and allosteric interactions</span></div><div class="casAuthors">Musacchio, Jose M.; Klein, Martine; Santiago, Lucia J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">424-31</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Dextromethorphan (DN), a non-narcotic antitussive with anticonvulsant activity, binds to high (Kd, 57 nM)- and low-affinity sites (Kd, 24 μM) in the guinea pig brain.  This work, done at physiol. pH, expands previous results obtained at pH 8.3.  Phenytoin (PHT) produces an allosteric increase in the binding of [3H]DM, which is more marked than that reported previously: PHT (100 μM,) at pH 7.4, increased the binding affinity of [3H] DM to brain homogenates 4-fold, without changing the concn. of DM sites.  Ropizine (SC-13504) an anticonvulsant benzhydryl piperazine, also produced a marked concn.-dependent increase in the binding of [3H]DM, which is mediated by a decrease in the dissocn. rate of [3H]DM.  The effects of ropizine are fully apparent at 10 μM, 10-fold lower than those of PHT.  The effects of PHT and ropizine show that the affinity of the DM sites can be increased by other ligands, suggesting that these sites are located on macromols. that can exist in at least 2 conformational states.  [3H]DM also binds to peripheral tissues, but the brain displays the highest affinity.  Besides, the central and peripheral sites are different as detd. by competition studies with caramiphen and carbetapentane, which are DM site ligands with antitussive and anticonvulsant activity.  The results reported are consistent with the hypothesis that the high-affinity DM binding sites mediate antitussive and anticonvulsant activity when occupied by the appropriate ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkMuLF6ry25LVg90H21EOLACvtfcHk0lgu4r1VLQ4jdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhvVCmuw%253D%253D&md5=8e90e55e69aa92b4fca3614ed3a284fd</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DSantiago%26aufirst%3DL.%2BJ.%26atitle%3DHigh%2520affinity%2520dextromethorphan%2520binding%2520sites%2520in%2520guinea%2520pig%2520brain%253A%2520further%2520characterization%2520and%2520allosteric%2520interactions%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1988%26volume%3D247%26spage%3D424%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malykh, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadaie, M. R.</span></span> <span> </span><span class="NLM_article-title">Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.2165/11319230-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2165%2F11319230-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20166767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFOnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=287-312&author=A.+G.+Malykhauthor=M.+R.+Sadaie&title=Piracetam+and+piracetam-like+drugs%3A+from+basic+science+to+novel+clinical+applications+to+CNS+disorders&doi=10.2165%2F11319230-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders</span></div><div class="casAuthors">Malykh, Andrei G.; Sadaie, M. Reza</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-312</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  There is an increasing interest in nootropic drugs for the treatment of CNS disorders.  Since the last meta-anal. of the clin. efficacy of piracetam, more information has accumulated.  The primary objective of this systematic survey is to evaluate the clin. outcomes as well as the scientific literature relating to the pharmacol., pharmacokinetics/pharmacodynamics, mechanism of action, dosing, toxicol. and adverse effects of marketed and investigational drugs.  The major focus of the literature search was on articles demonstrating evidence-based clin. investigations during the past 10 years for the following therapeutic categories of CNS disorders: (i) cognition/memory; (ii) epilepsy and seizure; (iii) neurodegenerative diseases; (iv) stroke/ischemia; and (v) stress and anxiety.  In this article, piracetam-like compds. are divided into three subgroups based on their chem. structures, known efficacy and intended clin. uses.  Subgroup 1 drugs include piracetam, oxiracetam, aniracetam, pramiracetam and phenylpiracetam, which have been used in humans and some of which are available as dietary supplements.  Of these, oxiracetam and aniracetam are no longer in clin. use.  Pramiracetam reportedly improved cognitive deficits assocd. with traumatic brain injuries.  Although piracetam exhibited no long-term benefits for the treatment of mild cognitive impairments, recent studies demonstrated its neuroprotective effect when used during coronary bypass surgery.  It was also effective in the treatment of cognitive disorders of cerebrovascular and traumatic origins; however, its overall effect on lowering depression and anxiety was higher than improving memory.  As add-on therapy, it appears to benefit individuals with myoclonus epilepsy and tardive dyskinesia.  Phenylpiracetam is more potent than piracetam and is used for a wider range of indications.  In combination with a vasodilator drug, piracetam appeared to have an additive beneficial effect on various cognitive disabilities.  Subgroup 2 drugs include levetiracetam, seletracetam and brivaracetam, which demonstrate antiepileptic activity, although their cognitive effects are unclear.  Subgroup 3 includes piracetam derivs. with unknown clin. efficacies, and of these nefiracetam failed to improve cognition in post-stroke patients and rolipram is currently in clin. trials as an antidepressant.  The remaining compds. of this subgroup are at various preclin. stages of research.  The modes of action of piracetam and most of its derivs. remain an enigma.  Differential effects on subtypes of glutamate receptors, but not the GABAergic actions, have been implicated.  Piracetam seems to activate calcium influx into neuronal cells; however, this function is questionable in the light of findings that a persistent calcium inflow may have deleterious impact on neuronal cells.  Although subgroup 2 compds. act via binding to another neuronal receptor (synaptic vesicle 2A), some of the subgroup 3 compds., such as nefiracetam, are similar to those of subgroup 1.  Based on calcns. of the efficacy rates, our assessments indicate notable improvements in clin. outcomes with some of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoATfClrTw8t7Vg90H21EOLACvtfcHk0lgu4r1VLQ4jdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFOnu7g%253D&md5=67c0bc575dc0ac3b48c399593f5656ac</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.2165%2F11319230-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11319230-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DMalykh%26aufirst%3DA.%2BG.%26aulast%3DSadaie%26aufirst%3DM.%2BR.%26atitle%3DPiracetam%2520and%2520piracetam-like%2520drugs%253A%2520from%2520basic%2520science%2520to%2520novel%2520clinical%2520applications%2520to%2520CNS%2520disorders%26jtitle%3DDrugs%26date%3D2010%26volume%3D70%26spage%3D287%26epage%3D312%26doi%3D10.2165%2F11319230-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veinberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvejniece, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilskersts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vavers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liepinsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyakov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishnev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznecovs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vikainis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponomaryov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambrova, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2764</span>– <span class="NLM_lpage">2771</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2013.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23582449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVWgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2764-2771&author=G.+Veinbergauthor=M.+Voronaauthor=L.+Zvejnieceauthor=R.+Vilskerstsauthor=E.+Vaversauthor=E.+Liepinshauthor=H.+Kazokaauthor=S.+Belyakovauthor=A.+Mishnevauthor=J.+Kuznecovsauthor=S.+Vikainisauthor=N.+Orlovaauthor=A.+Lebedevauthor=Y.+Ponomaryovauthor=M.+Dambrova&title=Synthesis+and+biological+evaluation+of+2-%285-methyl-4-phenyl-2-oxopyrrolidin-1-yl%29-acetamide+stereoisomers+as+novel+positive+allosteric+modulators+of+sigma-1+receptor&doi=10.1016%2Fj.bmc.2013.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor</span></div><div class="casAuthors">Veinberg, Grigory; Vorona, Maxim; Zvejniece, Liga; Vilskersts, Reinis; Vavers, Edijs; Liepinsh, Edvards; Kazoka, Helena; Belyakov, Sergey; Mishnev, Anatoly; Kuznecovs, Jevgenijs; Vikainis, Sergejs; Orlova, Natalja; Lebedev, Anton; Ponomaryov, Yuri; Dambrova, Maija</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2764-2771</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel pos. allosteric modulators of sigma-1 receptor represented by 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide enantiomers I were synthesized using an asym. Michael addn. of 2-nitroprop-1-enylbenzene to di-Et malonate.  Following the chromatog. sepn. of the Me erythro- and threo-4-nitro-3R- and 3S-phenylpentanoate diastereoisomers, target compds. were obtained by their reductive cyclization into 5-methyl-4-phenylpyrrolidin-2-one enantiomers and the attachment of the acetamide group to the heterocyclic nitrogen.  Expts. with elec. stimulated rat vas deference contractions induced by the PRE-084, an agonist of sigma-1 receptor, showed that (4R,5S)- and (4R,5R)-2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamides with an R-configuration at the C-4 chiral center in the 2-pyrrolidone ring were more effective pos. allosteric modulators of sigma-1 receptor than were their optical antipodes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj9i0QUZ1gs7Vg90H21EOLACvtfcHk0lgu4r1VLQ4jdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVWgs70%253D&md5=05a11b153e7a0e928df4e4b6962c4133</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DVeinberg%26aufirst%3DG.%26aulast%3DVorona%26aufirst%3DM.%26aulast%3DZvejniece%26aufirst%3DL.%26aulast%3DVilskersts%26aufirst%3DR.%26aulast%3DVavers%26aufirst%3DE.%26aulast%3DLiepinsh%26aufirst%3DE.%26aulast%3DKazoka%26aufirst%3DH.%26aulast%3DBelyakov%26aufirst%3DS.%26aulast%3DMishnev%26aufirst%3DA.%26aulast%3DKuznecovs%26aufirst%3DJ.%26aulast%3DVikainis%26aufirst%3DS.%26aulast%3DOrlova%26aufirst%3DN.%26aulast%3DLebedev%26aufirst%3DA.%26aulast%3DPonomaryov%26aufirst%3DY.%26aulast%3DDambrova%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-%25285-methyl-4-phenyl-2-oxopyrrolidin-1-yl%2529-acetamide%2520stereoisomers%2520as%2520novel%2520positive%2520allosteric%2520modulators%2520of%2520sigma-1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2764%26epage%3D2771%26doi%3D10.1016%2Fj.bmc.2013.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zvejniece, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vavers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svalbe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilskersts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domracheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veinberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misane, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stonans, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalvinsh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambrova, M.</span></span> <span> </span><span class="NLM_article-title">The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1111/bph.12506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fbph.12506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24490863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFWqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=761-771&author=L.+Zvejnieceauthor=E.+Vaversauthor=B.+Svalbeauthor=R.+Vilskerstsauthor=I.+Domrachevaauthor=M.+Voronaauthor=G.+Veinbergauthor=I.+Misaneauthor=I.+Stonansauthor=I.+Kalvinshauthor=M.+Dambrova&title=The+cognition-enhancing+activity+of+E1R%2C+a+novel+positive+allosteric+modulator+of+sigma-1+receptors&doi=10.1111%2Fbph.12506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors</span></div><div class="casAuthors">Zvejniece, L.; Vavers, E.; Svalbe, B.; Vilskersts, R.; Domracheva, I.; Vorona, M.; Veinberg, G.; Misane, I.; Stonans, I.; Kalvinsh, I.; Dambrova, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">761-771</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Here, we describe the in vitro and in vivo effects of (4R,5S)-2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide (E1R), a novel pos. allosteric modulator of sigma-1 receptors.  Exptl. Approach : E1R was tested for sigma receptor binding activity in a [3H](+)-pentazocine assay, in bradykinin (BK)-induced intracellular Ca2+ concn. ([Ca2+]i) assays and in an elec. stimulated rat vas deferens model.  E1R's effects on cognitive function were tested using passive avoidance (PA) and Y-maze tests in mice.  A selective sigma-1 receptor antagonist (NE-100), was used to study the involvement of the sigma-1 receptor in the effects of E1R.  The open-field test was used to detect the effects of E1R on locomotion.  Key Results : Pretreatment with E1R enhanced the selective sigma-1 receptor agonist PRE-084's stimulating effect during a model study employing elec. stimulated rat vasa deferentia and an assay measuring the BK-induced [Ca2+]i increase.  Pretreatment with E1R facilitated PA retention in a dose-related manner.  Furthermore, E1R alleviated the scopolamine-induced cognitive impairment during the PA and Y-maze tests in mice.  The in vivo and in vitro effects of E1R were blocked by treatment with the selective sigma-1 receptor antagonist NE-100.  E1R did not affect locomotor activity.  Conclusion and Implications : E1R is a novel 4,5-disubstituted deriv. of piracetam that enhances cognition and demonstrates efficacy against scopolamine-induced cholinergic dysfunction in mice.  These effects are attributed to its pos. modulatory action on the sigma-1 receptor and this activity may be relevant when developing new drugs for treating cognitive symptoms related to neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC_B_s0roD07Vg90H21EOLACvtfcHk0lgaeugy4sg5eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFWqtA%253D%253D&md5=16177e5a4ebd9dfad1950ce26aaee874</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1111%2Fbph.12506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12506%26sid%3Dliteratum%253Aachs%26aulast%3DZvejniece%26aufirst%3DL.%26aulast%3DVavers%26aufirst%3DE.%26aulast%3DSvalbe%26aufirst%3DB.%26aulast%3DVilskersts%26aufirst%3DR.%26aulast%3DDomracheva%26aufirst%3DI.%26aulast%3DVorona%26aufirst%3DM.%26aulast%3DVeinberg%26aufirst%3DG.%26aulast%3DMisane%26aufirst%3DI.%26aulast%3DStonans%26aufirst%3DI.%26aulast%3DKalvinsh%26aufirst%3DI.%26aulast%3DDambrova%26aufirst%3DM.%26atitle%3DThe%2520cognition-enhancing%2520activity%2520of%2520E1R%252C%2520a%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520sigma-1%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D761%26epage%3D771%26doi%3D10.1111%2Fbph.12506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vavers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svalbe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauberte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stonans, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misane, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambrova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvejniece, L.</span></span> <span> </span><span class="NLM_article-title">The activity of selective sigma-1 receptor ligands in seizure models in vivo</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2017.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbr.2017.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28389336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2017&pages=13-18&author=E.+Vaversauthor=B.+Svalbeauthor=L.+Lauberteauthor=I.+Stonansauthor=I.+Misaneauthor=M.+Dambrovaauthor=L.+Zvejniece&title=The+activity+of+selective+sigma-1+receptor+ligands+in+seizure+models+in+vivo&doi=10.1016%2Fj.bbr.2017.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">The activity of selective sigma-1 receptor ligands in seizure models in vivo</span></div><div class="casAuthors">Vavers, Edijs; Svalbe, Baiba; Lauberte, Lasma; Stonans, Ilmars; Misane, Ilga; Dambrova, Maija; Zvejniece, Liga</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-18</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma-1 receptor (Sig1R) is a ligand-regulated protein which, since its discovery, has been widely studied as a novel target to treat neurol. disorders, including seizures.  However, the roles and mechanisms of Sig1R in the regulation of seizures are not fully understood.  The aim of the present study was to test and compare effects of often used selective Sig1R ligands in models of exptl. induced seizures.  The anti-seizure activities and interactions of selective Sig1R agonist PRE-084, selective Sig1R antagonist NE-100 and novel pos. allosteric Sig1R modulator E1R were evaluated in pentylenetetrazol (PTZ) and (+)-bicuculline (BIC)-induced seizure models in mice.  Sig1R antagonist NE-100 at a dose of 25 mg/kg demonstrated pro-convulsive activity on PTZ-induced seizures.  Agonist PRE-084 did not change the thresholds of chemoconvulsant-induced seizures.  Pos. allosteric modulator E1R at a dose of 50 mg/kg showed anti-convulsive effects on PTZ- and BIC-induced clonic and tonic seizures.  The anti-seizure activity of E1R was blocked by NE-100.  Surprisingly, NE-100 at a dose of 50 mg/kg induced convulsions, but E1R significantly alleviated the convulsive behavior induced by NE-100.  In conclusion, the selective Sig1R antagonist NE-100 induced seizures that could be partially attenuated by pos. allosteric Sig1R modulator.  Our results confirm that Sig1R could be a novel mol. target for new anti-convulsive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeOFzQ4WCPN7Vg90H21EOLACvtfcHk0lgaeugy4sg5eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFCisr0%253D&md5=30018fac502e22da158ad722b8cf689c</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2017.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2017.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DVavers%26aufirst%3DE.%26aulast%3DSvalbe%26aufirst%3DB.%26aulast%3DLauberte%26aufirst%3DL.%26aulast%3DStonans%26aufirst%3DI.%26aulast%3DMisane%26aufirst%3DI.%26aulast%3DDambrova%26aufirst%3DM.%26aulast%3DZvejniece%26aufirst%3DL.%26atitle%3DThe%2520activity%2520of%2520selective%2520sigma-1%2520receptor%2520ligands%2520in%2520seizure%2520models%2520in%2520vivo%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2017%26volume%3D328%26spage%3D13%26epage%3D18%26doi%3D10.1016%2Fj.bbr.2017.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span> <span> </span><span class="NLM_article-title">SKF83959 has protective effects in the scopolamine model of dementia</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1248/bpb.b17-00877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1248%2Fbpb.b17-00877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29491219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWhsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=427-434&author=G.+Shengauthor=J.+Zhangauthor=S.+Gaoauthor=Y.+Guauthor=B.+Jiangauthor=Q.+Gao&title=SKF83959+has+protective+effects+in+the+scopolamine+model+of+dementia&doi=10.1248%2Fbpb.b17-00877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">SKF83959 has protective effects in the scopolamine model of dementia</span></div><div class="casAuthors">Sheng, Gaofeng; Zhang, Jinlin; Gao, Shengfeng; Gu, Yuanyuan; Jiang, Bo; Gao, Qiufang</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-434</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Patients with Alzheimer's disease (AD) always have cognitive impairments.  In this study we investigated whether 6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine (SKF83959) has improvements on cognitive dysfunction.  The scopolamine model of dementia was used to investigate the anti-amnesic activities of SKF83959, and then, Western blotting and pharmacol. inhibitor were used to assay the anti-amnesic mechanisms of SKF83959.  It was found that SKF83959 administration significantly improved the scopolamine-induced memory impairments in the passive avoidance task, Y-maze test, and Morris water maze task.  Moreover, SKF83959 treatment significantly antagonized the down-regulating effects of scopolamine on brain-derived neurotrophic factor (BDNF) signaling cascade in the hippocampus, but not cortex.  Importantly, the usage of K252a, a selective inhibitor of tyrosine kinase B (TrkB), significantly attenuated the protective effects of SKF83959 in the scopolamine model.  Collectively, this study shows that SKF83959 has beneficial effects in the scopolamine model of dementia by modulation of hippocampal BDNF signaling, implying a novel and potential therapeutic agent for treating dementia in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM1lahHSV9UbVg90H21EOLACvtfcHk0lj5axSamsnhZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWhsbvI&md5=d3588ebff447cff7be6effd068e353eb</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b17-00877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b17-00877%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DSKF83959%2520has%2520protective%2520effects%2520in%2520the%2520scopolamine%2520model%2520of%2520dementia%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2018%26volume%3D41%26spage%3D427%26epage%3D434%26doi%3D10.1248%2Fbpb.b17-00877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of sigma-1 receptors elicits anti-seizure activities</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">4052</span>– <span class="NLM_lpage">4065</span>, <span class="refDoi"> DOI: 10.1111/bph.13195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fbph.13195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25989224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=4052-4065&author=L.+Guoauthor=Y.+Chenauthor=R.+Zhaoauthor=G.+Wangauthor=E.+Friedmanauthor=A.+Zhangauthor=X.+Zhen&title=Allosteric+modulation+of+sigma-1+receptors+elicits+anti-seizure+activities&doi=10.1111%2Fbph.13195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of sigma-1 receptors elicits anti-seizure activities</span></div><div class="casAuthors">Guo, Lin; Chen, Yanke; Zhao, Rui; Wang, Guanghui; Friedman, Eitan; Zhang, Ao; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4052-4065</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Application of orthosteric sigma-1 receptor agonists as anti-seizure drugs has been hindered by questionable efficacy and potential adverse effects.  Here, we have investigated the anti-seizure effects of the novel and potent allosteric modulator of sigma-1 receptors, SKF83959 and its deriv. SOMCL-668 (3-methyl-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol).  Exptl. Approach : The anti-seizure effects of SKF83959 were investigated in three mouse models, maximal electroshock seizures, pentylenetetrazole-induced convulsions and kainic acid-induced 'status epilepticus'.  Also, in rats, the cortical epileptiform activity induced by topical application of picrotoxin was recorded in electrocorticograms.  In rat hippocampal brain slices, effects of the drugs on the high potassium-evoked epileptiform local field potentials were studied.  Anti-seizure activities of SOMCL-668, a newly developed sigma-1 receptor selective allosteric modulator, were also investigated.  Key Results : SKF83959 (20, 40 mg·kg-1) exhibited anti -seizure activity in the three mouse models and reduced the cortical epileptiform activity without alteration of spontaneous motor activity and motor coordination.  These effects were blocked by the sigma-1 receptor antagonist BD1047, but not the dopamine D1 receptor antagonist SCH23390.  SKF83959 alone did not directly inhibit the epileptiform firing of CA3 neurons induced by high potassium in hippocampal slices, but did potentiate inhibition by the orthosteric sigma-1 receptor agonist SKF10047.  Lastly, a selective sigma-1 receptor allosteric modulator SOMCL-668, which does not bind to dopamine receptors, exerted similar anti-seizure activities.  Conclusions and Implications : SKF83959 and SOMCL-668 displayed anti-seizure activities, indicating that allosteric modulation of sigma-1 receptors may provide a novel approach for discovering new anti-seizure drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdZQgIVi8TZbVg90H21EOLACvtfcHk0lj5axSamsnhZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurnJ&md5=e15ae86b8e6af8a7cb3ca3846b77d3e8</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1111%2Fbph.13195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13195%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DAllosteric%2520modulation%2520of%2520sigma-1%2520receptors%2520elicits%2520anti-seizure%2520activities%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D4052%26epage%3D4065%26doi%3D10.1111%2Fbph.13195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virgili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as dual mu-opioid receptor agonists and sigma1 receptor antagonists for the treatment of pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01256</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2nur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2434-2454&author=M.+Garciaauthor=M.+Virgiliauthor=M.+Alonsoauthor=C.+Alegretauthor=B.+Fernandezauthor=A.+Portauthor=R.+Pascualauthor=X.+Monroyauthor=A.+Vidal-Torresauthor=M.+T.+Serafiniauthor=J.+M.+Velaauthor=C.+Almansa&title=4-Aryl-1-oxa-4%2C9-diazaspiro%5B5.5%5Dundecane+derivatives+as+dual+mu-opioid+receptor+agonists+and+sigma1+receptor+antagonists+for+the+treatment+of+pain&doi=10.1021%2Facs.jmedchem.9b01256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as dual μ-opioid receptor agonists and σ1 receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Garcia, Monica; Virgili, Marina; Alonso, Monica; Alegret, Carles; Fernandez, Begona; Port, Adriana; Pascual, Rosalia; Monroy, Xavier; Vidal-Torres, Alba; Serafini, Maria-Teresa; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2434-2454</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivs. as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are reported.  The different positions of the central scaffold, designed using a merging strategy of both targets pharmacophores, were explored using a versatile synthetic approach.  Phenethyl derivs. in position 9, substituted pyridyl moieties in position 4 and small alkyl groups in position 2 provided the best profiles.  One of the best compds., I, showed a balanced dual profile (i.e. MOR agonism and sigma antagonism) and potent analgesic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice.  Contrary to oxycodone, as expected from the addn. of σ1R antagonism, I showed local, peripheral activity in this test, which was reversed by the σ1R agonist PRE-084.  At equianalgesic doses, I showed less constipation than oxycodone, providing evidence that dual MOR agonism and σ1R antagonism may be a useful strategy for obtaining potent and safer analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_96WgxDmIbVg90H21EOLACvtfcHk0liE4KB1wRz9jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2nur3M&md5=6ff458638f9069ade1ccca8adabebb9a</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01256%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DM.%26aulast%3DVirgili%26aufirst%3DM.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DAlegret%26aufirst%3DC.%26aulast%3DFernandez%26aufirst%3DB.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3DSerafini%26aufirst%3DM.%2BT.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3D4-Aryl-1-oxa-4%252C9-diazaspiro%255B5.5%255Dundecane%2520derivatives%2520as%2520dual%2520mu-opioid%2520receptor%2520agonists%2520and%2520sigma1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2434%26epage%3D2454%26doi%3D10.1021%2Facs.jmedchem.9b01256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">112144</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2020.112144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=32087465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1KqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2020&pages=112144&author=J.+Xiongauthor=J.+Jinauthor=L.+Gaoauthor=C.+Haoauthor=X.+Liuauthor=B.+F.+Liuauthor=Y.+Chenauthor=G.+Zhang&title=Piperidine+propionamide+as+a+scaffold+for+potent+sigma-1+receptor+antagonists+and+mu+opioid+receptor+agonists+for+treating+neuropathic+pain&doi=10.1016%2Fj.ejmech.2020.112144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain</span></div><div class="casAuthors">Xiong, Jiaying; Jin, Jian; Gao, Lanchang; Hao, Chao; Liu, Xin; Liu, Bi-Feng; Chen, Yin; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112144pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of piperidine propionamide derivs. as potent sigma-1 (σ1) receptor antagonists and mu (μ) opioid receptor agonists, and measured their affinity for σ1 and μ receptors in-vitro through binding assays was designed and synthesized .  The basic scaffold of the new compds. contained a 4-substituted piperidine ring and N-aryl propionamide.  Compd. N-(2-(4-(4-fluorobenzyl)piperidin-1-yl)ethyl)-N-(4-methoxyphenyl)propionamide, showed the highest affinity for σ1 receptor (Ki σ1 = 1.86 nM) and μ receptor (Ki μ = 2.1 nM).  It exhibited potent analgesic activity in the formalin test (ED50 = 15.1 ± 1.67 mg/kg) and has equiv. analgesic effects to S1RA (σ1 antagonist) in a CCI model.  Therefore, Compd. N-(2-(4-(4-fluorobenzyl)piperidin-1-yl)ethyl)-N-(4-methoxyphenyl)propionamide, which has mixed σ1/μ receptor profiles, was a potential candidate for treating neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorVklStH7JO7Vg90H21EOLACvtfcHk0liE4KB1wRz9jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1KqsLs%253D&md5=d7563536f3b04ef267b2fa1c0a67af4b</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112144%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DPiperidine%2520propionamide%2520as%2520a%2520scaffold%2520for%2520potent%2520sigma-1%2520receptor%2520antagonists%2520and%2520mu%2520opioid%2520receptor%2520agonists%2520for%2520treating%2520neuropathic%2520pain%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D191%26spage%3D112144%26doi%3D10.1016%2Fj.ejmech.2020.112144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Garcia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Franco, M. I.</span></span> <span> </span><span class="NLM_article-title">New neurogenic lipoic-based hybrids as innovative Alzheimer’s drugs with sigma-1 agonism and beta-secretase inhibition</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1191</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.4155/fmc-2016-0036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.4155%2Ffmc-2016-0036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27402296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gitb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1191-1207&author=M.+Estradaauthor=C.+Perezauthor=E.+Sorianoauthor=E.+Lauriniauthor=M.+Romanoauthor=S.+Priclauthor=J.+A.+Morales-Garciaauthor=A.+Perez-Castilloauthor=M.+I.+Rodriguez-Franco&title=New+neurogenic+lipoic-based+hybrids+as+innovative+Alzheimer%E2%80%99s+drugs+with+sigma-1+agonism+and+beta-secretase+inhibition&doi=10.4155%2Ffmc-2016-0036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition</span></div><div class="casAuthors">Estrada, Martin; Perez, Concepcion; Soriano, Elena; Laurini, Erik; Romano, Maurizio; Pricl, Sabrina; Morales-Garcia, Jose A.; Perez-Castillo, Ana; Rodriguez-Franco, Maria Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1191-1207</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Neurogenic agents emerge as innovative drugs for the treatment of Alzheimer's disease (AD), whose pathol. complexity suggests strengthening research in the multi-target directed ligands strategy.  Results: By combining the lipoic acid structure with N-benzylpiperidine or N,N-dibenzyl(N-methyl)amine fragments, new multi-target directed ligands were obtained that act at three relevant targets in AD: σ-1 receptor (σ1R), β-secretase-1 (BACE1) and acetylcholinesterase (AChE).  Moreover, they show potent neurogenic properties, good antioxidant capacity and favorable CNS permeability.  Mol. modeling studies on AChE, σ1R and BACE1 highlight relevant drug-protein interactions that may contribute to the development of new disease-modifying drugs.  Conclusion: New lipoic-based σ1 agonists endowed with neurogenic, antioxidant, cholinergic and amyloid β-peptide-reducing properties have been discovered for the potential treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_JgBqiAyiQ7Vg90H21EOLACvtfcHk0lgB2IT023X6fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gitb3P&md5=e72c02533e11501f236a9448956d0d12</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0036%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DMorales-Garcia%26aufirst%3DJ.%2BA.%26aulast%3DPerez-Castillo%26aufirst%3DA.%26aulast%3DRodriguez-Franco%26aufirst%3DM.%2BI.%26atitle%3DNew%2520neurogenic%2520lipoic-based%2520hybrids%2520as%2520innovative%2520Alzheimer%25E2%2580%2599s%2520drugs%2520with%2520sigma-1%2520agonism%2520and%2520beta-secretase%2520inhibition%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D1191%26epage%3D1207%26doi%3D10.4155%2Ffmc-2016-0036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Samuel Obeng, Takato Hiranita, Francisco León, Lance R. McMahon, <span class="NLM_string-name hlFld-ContribAuthor">Christopher R. McCurdy</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6523-6548. <a href="https://doi.org/10.1021/acs.jmedchem.1c00028" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00028%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BApproaches%25252C%252BDrug%252BCandidates%25252C%252Band%252BTargets%252Bin%252BPain%252BDrug%252BDiscovery%26aulast%3DObeng%26aufirst%3DSamuel%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D07012021%26date%3D06052021%26volume%3D64%26issue%3D10%26spage%3D6523%26epage%3D6548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Zhuang</span>, <span class="hlFld-ContribAuthor ">Jiaying  Xiong</span>, <span class="hlFld-ContribAuthor ">Shuaishuai  Hao</span>, <span class="hlFld-ContribAuthor ">Wei  Du</span>, <span class="hlFld-ContribAuthor ">Zhenming  Liu</span>, <span class="hlFld-ContribAuthor ">Bifeng  Liu</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhang</span>, <span class="hlFld-ContribAuthor ">Yin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional μ opioid and σ1 receptor ligands as novel analgesics with reduced side effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113658. <a href="https://doi.org/10.1016/j.ejmech.2021.113658" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113658%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBifunctional%252B%2525CE%2525BC%252Bopioid%252Band%252B%2525CF%2525831%252Breceptor%252Bligands%252Bas%252Bnovel%252Banalgesics%252Bwith%252Breduced%252Bside%252Beffects%26aulast%3DZhuang%26aufirst%3DTao%26date%3D2021%26volume%3D223%26spage%3D113658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Szabolcs  Dvorácskó</span>, <span class="hlFld-ContribAuthor ">László  Lázár</span>, <span class="hlFld-ContribAuthor ">Ferenc  Fülöp</span>, <span class="hlFld-ContribAuthor ">Márta  Palkó</span>, <span class="hlFld-ContribAuthor ">Zita  Zalán</span>, <span class="hlFld-ContribAuthor ">Botond  Penke</span>, <span class="hlFld-ContribAuthor ">Lívia  Fülöp</span>, <span class="hlFld-ContribAuthor ">Csaba  Tömböly</span>, <span class="hlFld-ContribAuthor ">Ferenc  Bogár</span>. </span><span class="cited-content_cbyCitation_article-title">Novel High Affinity Sigma-1 Receptor Ligands from Minimal Ensemble Docking-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (15)
                                     , 8112. <a href="https://doi.org/10.3390/ijms22158112" title="DOI URL">https://doi.org/10.3390/ijms22158112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22158112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22158112%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DNovel%252BHigh%252BAffinity%252BSigma-1%252BReceptor%252BLigands%252Bfrom%252BMinimal%252BEnsemble%252BDocking-Based%252BVirtual%252BScreening%26aulast%3DDvor%25C3%25A1csk%25C3%25B3%26aufirst%3DSzabolcs%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D15%26spage%3D8112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Guo</span>, <span class="hlFld-ContribAuthor ">Tianyu  Gao</span>, <span class="hlFld-ContribAuthor ">Ce  Gao</span>, <span class="hlFld-ContribAuthor ">Xiaoxia  Jia</span>, <span class="hlFld-ContribAuthor ">Jing  Ni</span>, <span class="hlFld-ContribAuthor ">Chaojun  Han</span>, <span class="hlFld-ContribAuthor ">Yun  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Stimulation of astrocytic sigma-1 receptor is sufficient to ameliorate inflammation- induced depression. </span><span class="cited-content_cbyCitation_journal-name">Behavioural Brain Research</span><span> <strong>2021,</strong> <em>410 </em>, 113344. <a href="https://doi.org/10.1016/j.bbr.2021.113344" title="DOI URL">https://doi.org/10.1016/j.bbr.2021.113344</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbr.2021.113344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbr.2021.113344%26sid%3Dliteratum%253Aachs%26jtitle%3DBehavioural%2520Brain%2520Research%26atitle%3DStimulation%252Bof%252Bastrocytic%252Bsigma-1%252Breceptor%252Bis%252Bsufficient%252Bto%252Bameliorate%252Binflammation-%252Binduced%252Bdepression%26aulast%3DGuo%26aufirst%3DLin%26date%3D2021%26volume%3D410%26spage%3D113344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vladimir  Zhemkov</span>, <span class="hlFld-ContribAuthor ">Michal  Geva</span>, <span class="hlFld-ContribAuthor ">Michael R.  Hayden</span>, <span class="hlFld-ContribAuthor ">Ilya  Bezprozvanny</span>. </span><span class="cited-content_cbyCitation_article-title">Sigma-1 Receptor (S1R) Interaction with Cholesterol: Mechanisms of S1R Activation and Its Role in Neurodegenerative Diseases. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (8)
                                     , 4082. <a href="https://doi.org/10.3390/ijms22084082" title="DOI URL">https://doi.org/10.3390/ijms22084082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22084082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22084082%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DSigma-1%252BReceptor%252B%252528S1R%252529%252BInteraction%252Bwith%252BCholesterol%25253A%252BMechanisms%252Bof%252BS1R%252BActivation%252Band%252BIts%252BRole%252Bin%252BNeurodegenerative%252BDiseases%26aulast%3DZhemkov%26aufirst%3DVladimir%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D8%26spage%3D4082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Number of papers published between 1994 and 2019 according to the recent PubMed search using “<i>Sigma-1</i>” as the keyword.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Major milestones in the history of sigma-1 receptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Homotrimer and protomer structure of the σ<sub>1</sub> receptor (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a>). (B) Overlays of the cocrystal structures of the σ<sub>1</sub> receptor bound to the antagonist PD144418 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a>, brown) and the agonist (+)-pentazocine (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK1">6DK1</a>, green). Residues are colored in gray.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic summary of the functions and protein interactions of sigma-1 as a receptor chaperone in physiological and pathophysiological conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Selective sigma-1 receptor ligands in human clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic presentation of the sigma-1 receptor pharmacophores (Glennon’s model).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Ether modifications of SA4503.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. SA4503 derivatives with monocyclic piperazine or homopiperazine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. SA4503 derivatives with monocyclic piperidine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. SA4503 derivatives with fused and bridged ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Biaryl modifications of S1RA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Monoaryl S1RA derivatives</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Spirocyclic benzofuran and benzopyran derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Spirocyclic sigma-1 ligands synthesized by multicomponent reactions or diversity-oriented synthesis strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Spiro ring opened arylpiperidine derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Spiro ring opened monocyclic piperidine derivatives</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Polycyclic sigma-1 ligands</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Acyclic amines as sigma-1 ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/medium/jm0c01192_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Sigma-1 receptor allosteric modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01192/20201218/images/large/jm0c01192_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01192&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 210 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor chaperone as an inter-organelle signaling modulator</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2010.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.tips.2010.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20869780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGisbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=557-566&author=T.+P.+Suauthor=T.+Hayashiauthor=T.+Mauriceauthor=S.+Buchauthor=A.+E.+Ruoho&title=The+sigma-1+receptor+chaperone+as+an+inter-organelle+signaling+modulator&doi=10.1016%2Fj.tips.2010.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor chaperone as an inter-organelle signaling modulator</span></div><div class="casAuthors">Su, Tsung-Ping; Hayashi, Teruo; Maurice, Tangui; Buch, Shilpa; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">557-566</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inter-organelle signaling plays important roles in many physiol. functions.  Endoplasmic reticulum (ER)-mitochondrion signaling affects intramitochondrial calcium (Ca2+) homeostasis and cellular bioenergetics.  ER-nucleus signaling attenuates ER stress.  ER-plasma membrane signaling regulates cytosolic Ca2+ homeostasis and ER-mitochondrion-plasma membrane signaling regulates hippocampal dendritic spine formation.  Here, we propose that the sigma-1 receptor (Sig-1R), an ER chaperone protein, acts as an inter-organelle signaling modulator.  Sig-1Rs normally reside at the ER-mitochondrion contact called the MAM (mitochondrion-assocd. ER membrane), where Sig-1Rs regulate ER-mitochondrion signaling and ER-nucleus crosstalk.  When cells are stimulated by ligands or undergo prolonged stress, Sig-1Rs translocate from the MAM to the ER reticular network and plasmalemma/plasma membrane to regulate a variety of functional proteins, including ion channels, receptors and kinases.  Thus, the Sig-1R serves as an inter-organelle signaling modulator locally at the MAM and remotely at the plasmalemma/plasma membrane.  Many pharmacol./physiol. effects of Sig-1Rs might relate to this unique action of Sig-1Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqgD87pznGvLVg90H21EOLACvtfcHk0lg-5Lm73L_KhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGisbbE&md5=a768850c77087ebf6732c0d57577f111</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2010.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2010.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DBuch%26aufirst%3DS.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DThe%2520sigma-1%2520receptor%2520chaperone%2520as%2520an%2520inter-organelle%2520signaling%2520modulator%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2010%26volume%3D31%26spage%3D557%26epage%3D566%26doi%3D10.1016%2Fj.tips.2010.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christ, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huesmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behl, C.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">211</span>, <span class="refDoi"> DOI: 10.3390/cells8030211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3390%2Fcells8030211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKnsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=211&author=M.+G.+Christauthor=H.+Huesmannauthor=H.+Nagelauthor=A.+Kernauthor=C.+Behl&title=Sigma-1+receptor+activation+induces+autophagy+and+increases+proteostasis+capacity+in+vitro+and+in+vivo&doi=10.3390%2Fcells8030211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo</span></div><div class="casAuthors">Christ, Maximilian G.; Huesmann, Heike; Nagel, Heike; Kern, Andreas; Behl, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Dysfunction of autophagy and disturbed protein homeostasis are linked to the pathogenesis of human neurodegenerative diseases and the modulation of autophagy as the protein clearance process has become one key pharmacol. target.  Due to the role of sigma-1 receptors (Sig-1R) in learning and memory, and the described pleiotropic neuroprotective effects in various exptl. paradigms, Sig-1R activation is recognized as one potential approach for prevention and therapy of neurodegeneration and, interestingly, in amyotrophic lateral sclerosis assocd. with mutated Sig-1R, autophagy is disturbed.  Here we analyzed the effects of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73), a muscarinic receptor ligand and Sig-1R agonist, on autophagy and proteostasis.  We describe, at the mol. level, for the first time, that pharmacol. Sig-1R activation a) enhances the autophagic flux in human cells and in Caenorhabditis elegans and b) increases proteostasis capacity, ultimately ameliorating paralysis caused by protein aggregation in C. elegans.  ANAVEX2-73 is already in clin. investigation for the treatment of Alzheimer's disease, and the novel activities of this compd. on autophagy and proteostasis described here may have consequences for the use and further development of the Sig-1R as a drug target in the future.  Moreover, our study defines the Sig-1R as an upstream modulator of canonical autophagy, which may have further implications for various conditions with dysfunctional autophagy, besides neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmdn1zzN_AnLVg90H21EOLACvtfcHk0lg-5Lm73L_KhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKnsr%252FP&md5=d2aa7fdfe7eb6b828859dd20d1cf613f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3390%2Fcells8030211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8030211%26sid%3Dliteratum%253Aachs%26aulast%3DChrist%26aufirst%3DM.%2BG.%26aulast%3DHuesmann%26aufirst%3DH.%26aulast%3DNagel%26aufirst%3DH.%26aulast%3DKern%26aufirst%3DA.%26aulast%3DBehl%26aufirst%3DC.%26atitle%3DSigma-1%2520receptor%2520activation%2520induces%2520autophagy%2520and%2520increases%2520proteostasis%2520capacity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D211%26doi%3D10.3390%2Fcells8030211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goguadze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuravliova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikeladze, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor agonists induce oxidative stress in mitochondria and enhance complex I activity in physiological condition but protect against pathological oxidative stress</span>. <i>Neurotoxic. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1007/s12640-017-9838-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs12640-017-9838-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29127580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSrsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=1-18&author=N.+Goguadzeauthor=E.+Zhuravliovaauthor=D.+Morinauthor=D.+Mikeladzeauthor=T.+Maurice&title=Sigma-1+receptor+agonists+induce+oxidative+stress+in+mitochondria+and+enhance+complex+I+activity+in+physiological+condition+but+protect+against+pathological+oxidative+stress&doi=10.1007%2Fs12640-017-9838-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress</span></div><div class="casAuthors">Goguadze, Nino; Zhuravliova, Elene; Morin, Didier; Mikeladze, Davit; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-18</span>CODEN:
                <span class="NLM_cas:coden">NURRFI</span>;
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The sigma1 receptor (σ1R) is a chaperone protein residing at mitochondria-assocd. endoplasmic reticulum (ER) membranes (MAMs), where it modulates Ca2+ exchange between the ER and mitochondria by interacting with inositol-1,4,5 trisphosphate receptors (IP3Rs).  The σ1R is highly expressed in the central nervous system and its activation stimulates neuromodulation and neuroprotection, for instance in Alzheimer's disease (AD) models in vitro and in vivo. σ1R effects on mitochondria pathophysiol. and the downstream signaling are still not fully understood.  We here evaluated the impacts of σ1R ligands in mouse mitochondria prepns. on reactive oxygen species (ROS) prodn., mitochondrial respiration, and complex activities, in physiol. condition and after direct application of amyloid Aβ1-42 peptide. σ1R agonists (2-(4-morpholinethyl)-1-phenylcyclohexanecarboxylate hydrochloride (PRE-084), tetrahydro-N,N-dimethyl-5,5-diphenyl-3-furanmethanamine (ANAVEX1-41, AN1-41), (S)-1-(2,8-dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one (ANAVEX3-71, AN3-71), dehydroepiandrosterone-3 sulfate (DHEA), donepezil) increased mitochondrial ROS in a σ1R antagonist-sensitive manner but decreased Aβ1-42-induced increase in ROS. σ1R ligands (agonists or antagonists) did not impact respiration but attenuated Aβ1-42-induced alteration. σ1R agonists (PRE-084, AN1-41, tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AN2-73), AN3-71) increased complex I activity, in a Ca2+-dependent and σ1R antagonist-sensitive manner. σ1R ligands failed to affect complex II, III, and IV activities.  The increase in complex I activity explain the σ1R-induced increase in ROS since ligands failed to affect other sources of ROS accumulation in mitochondria and homogenates, namely NADPH oxidase (NOX) and superoxide dismutase (SOD) activities.  Furthermore, Aβ1-42 significantly decreased the activity of complexes I and IV and σ1R agonists attenuated the Aβ1-42-induced complex I and IV dysfunctions. σ1R activity in mitochondria therefore results in a Ying-Yang effect, by triggering moderate ROS increase acting as a physiol. signal and promoting a marked anti-oxidant effect in pathol. (Aβ) conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnPQT4YFFSzbVg90H21EOLACvtfcHk0lhuwL94_EpITA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSrsLnI&md5=765cb6c0c43cf8bea84bb3087a1e5ad6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs12640-017-9838-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12640-017-9838-2%26sid%3Dliteratum%253Aachs%26aulast%3DGoguadze%26aufirst%3DN.%26aulast%3DZhuravliova%26aufirst%3DE.%26aulast%3DMorin%26aufirst%3DD.%26aulast%3DMikeladze%26aufirst%3DD.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DSigma-1%2520receptor%2520agonists%2520induce%2520oxidative%2520stress%2520in%2520mitochondria%2520and%2520enhance%2520complex%2520I%2520activity%2520in%2520physiological%2520condition%2520but%2520protect%2520against%2520pathological%2520oxidative%2520stress%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2019%26volume%3D35%26spage%3D1%26epage%3D18%26doi%3D10.1007%2Fs12640-017-9838-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Marissal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medard, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzedine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrast, R.</span></span> <span> </span><span class="NLM_article-title">Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1093/brain/awv008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1093%2Fbrain%2Fawv008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25678561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC2MrltFyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2015&pages=875-890&author=N.+Bernard-Marissalauthor=J.+J.+Medardauthor=H.+Azzedineauthor=R.+Chrast&title=Dysfunction+in+endoplasmic+reticulum-mitochondria+crosstalk+underlies+SIGMAR1+loss+of+function+mediated+motor+neuron+degeneration&doi=10.1093%2Fbrain%2Fawv008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration</span></div><div class="casAuthors">Bernard-Marissal Nathalie; Medard Jean-Jacques; Azzedine Hamid; Chrast Roman</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">Pt 4</span>),
    <span class="NLM_cas:pages">875-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutations in Sigma 1 receptor (SIGMAR1) have been previously identified in patients with amyotrophic lateral sclerosis and disruption of Sigmar1 in mouse leads to locomotor deficits.  However, cellular mechanisms underlying motor phenotypes in human and mouse with disturbed SIGMAR1 function have not been described so far.  Here we used a combination of in vivo and in vitro approaches to investigate the role of SIGMAR1 in motor neuron biology.  Characterization of Sigmar1(-/-) mice revealed that affected animals display locomotor deficits associated with muscle weakness, axonal degeneration and motor neuron loss.  Using primary motor neuron cultures, we observed that pharmacological or genetic inactivation of SIGMAR1 led to motor neuron axonal degeneration followed by cell death.  Disruption of SIGMAR1 function in motor neurons disturbed endoplasmic reticulum-mitochondria contacts, affected intracellular calcium signalling and was accompanied by activation of endoplasmic reticulum stress and defects in mitochondrial dynamics and transport.  These defects were not observed in cultured sensory neurons, highlighting the exacerbated sensitivity of motor neurons to SIGMAR1 function.  Interestingly, the inhibition of mitochondrial fission was sufficient to induce mitochondria axonal transport defects as well as axonal degeneration similar to the changes observed after SIGMAR1 inactivation or loss.  Intracellular calcium scavenging and endoplasmic reticulum stress inhibition were able to restore mitochondrial function and consequently prevent motor neuron degeneration.  These results uncover the cellular mechanisms underlying motor neuron degeneration mediated by loss of SIGMAR1 function and provide therapeutically relevant insight into motor neuronal diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhjJvMF5NoGgpJitSxOdIlfW6udTcc2ebhF-vLKSTiH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrltFyjsw%253D%253D&md5=a9d9cbc7790f896feeb4c5fad68606e8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawv008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawv008%26sid%3Dliteratum%253Aachs%26aulast%3DBernard-Marissal%26aufirst%3DN.%26aulast%3DMedard%26aufirst%3DJ.%2BJ.%26aulast%3DAzzedine%26aufirst%3DH.%26aulast%3DChrast%26aufirst%3DR.%26atitle%3DDysfunction%2520in%2520endoplasmic%2520reticulum-mitochondria%2520crosstalk%2520underlies%2520SIGMAR1%2520loss%2520of%2520function%2520mediated%2520motor%2520neuron%2520degeneration%26jtitle%3DBrain%26date%3D2015%26volume%3D138%26spage%3D875%26epage%3D890%26doi%3D10.1093%2Fbrain%2Fawv008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canizares, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubero, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Segura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span> <span> </span><span class="NLM_article-title">Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice</span>. <i>Mol. Pain</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi"> DOI: 10.1186/1744-8069-10-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1186%2F1744-8069-10-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24517272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12ms7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=11&author=F.+R.+Nietoauthor=C.+M.+Cendanauthor=F.+J.+Canizaresauthor=M.+A.+Cuberoauthor=J.+M.+Velaauthor=E.+Fernandez-Seguraauthor=J.+M.+Baeyens&title=Genetic+inactivation+and+pharmacological+blockade+of+sigma-1+receptors+prevent+paclitaxel-induced+sensory-nerve+mitochondrial+abnormalities+and+neuropathic+pain+in+mice&doi=10.1186%2F1744-8069-10-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice</span></div><div class="casAuthors">Nieto, Francisco R.; Cendan, Cruz M.; Canizares, Francisco J.; Cubero, Maria A.; Vela, Jose M.; Fernandez-Segura, Eduardo; Baeyens, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pain</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11/1-11/12, 12</span>CODEN:
                <span class="NLM_cas:coden">MPOAC5</span>;
        ISSN:<span class="NLM_cas:issn">1744-8069</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Paclitaxel, a widely-used antineoplastic drug, produces a painful peripheral neuropathy that in rodents is assocd. with peripheral-nerve mitochondrial alterations.  The sigma-1 receptor (σ1R) is a ligand-regulated mol. chaperone involved in mitochondrial calcium homeostasis and pain hypersensitivity.  This receptor plays a key role in paclitaxel-induced neuropathic pain, but it is not known whether it also modulates mitochondrial abnormalities.  In this study, we used a mouse model of paclitaxel-induced neuropathic pain to test the involvement of the σ1R in the mitochondrial abnormalities assocd. with paclitaxel, by using genetic (σ1R knockout mice) and pharmacol. (σ1R antagonist) approaches.  Results: Paclitaxel administration to wild-type (WT) mice produced cold- and mech.-allodynia, and an increase in the frequency of swollen and vacuolated mitochondria in myelinated A-fibers, but not in C-fibers, of the saphenous nerve.  Behavioral and mitochondrial alterations were marked at 10 days after paclitaxel-administration and had resolved at day 28.  In contrast, paclitaxel treatment did not induce allodynia or mitochondrial abnormalities in σ1R knockout mice.  Moreover, the prophylactic treatment of WT mice with BD-1063 also prevented the neuropathic pain and mitochondrial abnormalities induced by paclitaxel.  Conclusions: These results suggest that activation of the σ1R is necessary for development of the sensory nerve mitochondrial damage and neuropathic pain produced by paclitaxel.  Therefore, σ1R antagonists might have therapeutic value for the prevention of paclitaxel-induced neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7RZewhZNEx7Vg90H21EOLACvtfcHk0lhuwL94_EpITA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12ms7rP&md5=2e3d7a755bd25fc4bc80d172e71dee57</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2F1744-8069-10-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1744-8069-10-11%26sid%3Dliteratum%253Aachs%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DCendan%26aufirst%3DC.%2BM.%26aulast%3DCanizares%26aufirst%3DF.%2BJ.%26aulast%3DCubero%26aufirst%3DM.%2BA.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DFernandez-Segura%26aufirst%3DE.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26atitle%3DGenetic%2520inactivation%2520and%2520pharmacological%2520blockade%2520of%2520sigma-1%2520receptors%2520prevent%2520paclitaxel-induced%2520sensory-nerve%2520mitochondrial%2520abnormalities%2520and%2520neuropathic%2520pain%2520in%2520mice%26jtitle%3DMol.%2520Pain%26date%3D2014%26volume%3D10%26spage%3D11%26doi%3D10.1186%2F1744-8069-10-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eades, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppler, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, P. E.</span></span> <span> </span><span class="NLM_article-title">The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=945347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaE28XltlOhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=1976&pages=517-532&author=W.+R.+Martinauthor=C.+G.+Eadesauthor=J.+A.+Thompsonauthor=R.+E.+Hupplerauthor=P.+E.+Gilbert&title=The+effects+of+morphine-+and+nalorphine-+like+drugs+in+the+nondependent+and+morphine-dependent+chronic+spinal+dog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog</span></div><div class="casAuthors">Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">517-32</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Three different syndromes produced by congeners of morphine sulfate (I sulfate) [64-31-3] were identified in the nondependent chronic spinal dog.  These syndromes were attributed to interaction of agonists with three distinguishable receptors (μ, κ and σ).  I was the prototype agonist for the μ receptor, ketocyclazocine lactate [59985-33-0] for the κ receptor and SKF-10,047 lactate [59985-34-1] for the σ receptor.  The I syndrome (μ) in the dog was characterized by miosis, bradycardia, hypothermia, a general depression of the nociceptive responses and indifferences to environmental stimuli.  Ketocyclazocine (κ) constricted pupils, depressed the flexor reflex and produced sedation but did not markedly alter pulse rate or the skin twitch reflex.  SKF-10,047 (σ) caused mydriasis, tachypnea, tachycardia and mania.  The effects of these three drugs was antagonized by the pure antagonist naltrexone-HCl, indicating that they are agonists.  Further, chronic administration of I, ketocyclazocine and SKF-10,047 induced tolerance to their agonistic effects.  I suppressed abstinence in I-dependent dogs while ketocyclazocine did not.  Ketocyclazocine at best pptd. only a liminal abstinence syndrome in the I-dependent dog, indicating that it had little affinity for the I receptor.  Ketocyclazocine thus appears to be a selective agonist at the κ receptor.  Buprenorphine-HCl [53152-21-9] was a partial agonist of the μ type which both suppressed and pptd. abstinence in the I-dependent dog while I and d-propoxyphene-HCl [1639-60-7] were stronger agonists.  Apomorphine-HCl [314-19-2] and SKF-10,047 produced similar pharmacol. effects suggesting that σ activity may involve a dopaminergic mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6rgyf41iRTbVg90H21EOLACvtfcHk0lgf6IM1OCAxxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XltlOhurw%253D&md5=ca7c637f336ac9ecc2c3bb040dbcdbee</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DW.%2BR.%26aulast%3DEades%26aufirst%3DC.%2BG.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DHuppler%26aufirst%3DR.%2BE.%26aulast%3DGilbert%26aufirst%3DP.%2BE.%26atitle%3DThe%2520effects%2520of%2520morphine-%2520and%2520nalorphine-%2520like%2520drugs%2520in%2520the%2520nondependent%2520and%2520morphine-dependent%2520chronic%2520spinal%2520dog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1976%26volume%3D197%26spage%3D517%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Evidence for sigma opioid receptor: binding of [<sup>3</sup>H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>223</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=6290634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL3sXksV0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=1982&pages=284-290&author=T.+P.+Su&title=Evidence+for+sigma+opioid+receptor%3A+binding+of+%5B3H%5DSKF-10047+to+etorphine-inaccessible+sites+in+guinea-pig+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for sigma opioid receptor:  binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea pig brain</span></div><div class="casAuthors">Su, Tsung Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-90</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">A portion of the specific binding of tritiated dl-SKF-10047  [7313-95-3] to the guinea-pig brain suspension of the particulate fraction was not inhibited by the strong narcotic analgesic l-etorphine.  The binding properties of these etorphine-inaccessible (EI) sites were examd.  The specific binding of [3H]SKF-10047 to the EI sites was saturable.  Scatchard anal. of the satn. curve revealed a single class of binding sites with apparent Kd of 252 nM and an estd. Bmax of 663 fmol/mg of protein.  The EI binding was reduced by heat treatment, trypsin digestion and phospholipase C digestion.  The presence of Na+ slightly increased specific EI binding.  Li increased the EI binding by about 38% at the optimal concn. of 1 mM.  Divalent cations such as Mg2+, Ca2+ and Mn2+ reduced EI binding.  Morphine-like drugs such as l-morphine  [57-27-2], levorphanol  [77-07-6] and naltrexone  [16590-41-3] were poor inhibitors for the EI binding, whereas opioid derivs. such as dl-pentazocine  [359-83-1], dextrallorphan  [5822-43-5], dl-cyclazocine  [63903-61-7], SKF-10047 and dextrorphan  [125-73-5] were potent inhibitors.  Nonopioid drugs such as haloperidol  [52-86-8], imipramine  [50-49-7], pimozide  [2062-78-4] and dl-propranolol  [525-66-6] were also potent inhibitors of the EI binding.  Distribution of the EI sites in brain was different from that of the μ receptor: highest concn. of EI sites was found in brainstem, midbrain and cerebellum, whereas lower concns. were found in striatum and cortex.  Apparently, EI sites are not μ receptors but may represent σ receptors in the central nervous system, mediating psychotomimetic effects of several opioids and other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ7zMdhq6AbVg90H21EOLACvtfcHk0lgf6IM1OCAxxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXksV0%253D&md5=d5710578a9c7cdaaba979289cb753e01</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DEvidence%2520for%2520sigma%2520opioid%2520receptor%253A%2520binding%2520of%2520%255B3H%255DSKF-10047%2520to%2520etorphine-inaccessible%2520sites%2520in%2520guinea-pig%2520brain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1982%26volume%3D223%26spage%3D284%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. L.</span></span> <span> </span><span class="NLM_article-title">Stereoisomers of [<sup>3</sup>H]-<i>N</i>-allylnormetazocine bind to different sites in mouse brain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">544</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=6094791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL2MXhtVKjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1984&pages=539-544&author=B.+R.+Martinauthor=J.+S.+Katzenauthor=J.+A.+Woodsauthor=H.+L.+Tripathiauthor=L.+S.+Harrisauthor=E.+L.+May&title=Stereoisomers+of+%5B3H%5D-N-allylnormetazocine+bind+to+different+sites+in+mouse+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain</span></div><div class="casAuthors">Martin, Billy R.; Katzen, Judith S.; Woods, Judith A.; Tripathi, Hem L.; Harris, Louis S.; May, Everette L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">539-44</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The 3H-labeled (+)-  [58640-82-7] and (-)-  [14198-28-8] isomers of N-allylnormetazocine (NANM) were synthesized and evaluated for binding to mouse brain membranes.  Scatchard anal. of the saturable binding of (-)-[3H]NANM suggested a single class of binding sites with an apparent dissocn. const. KD of 2.1 nM and an estd. max. binding of 197 fmol/mg protein.  Increasing the concn. of Na+, K+, Mn2+, or Ca2+ decreased (-)-[3H]NANM specific binding.  (-)-[3H]NANM apparently binds to the μ opiate receptor in that (-)-isomers, but not the (+)-isomers, of N-cis-3-chloroallylnormetazocine, N-propynylnormetazocine, pentazocine, cyclazocine, naloxone, phenazocine, and morphine competed for binding.  The (-)-isomers of ethyloxocyclazocine and oxocyclazocine and NIH 9101  [57287-02-2] also displaced (-)-[3H]NANM binding which suggested κ activity in addn. to μ activity.  Phencyclidine  [77-10-1] and its analogs did not bind to the (-)-[3H]NANM site.  Scatchard anal. of saturable binding of (+)-[3H]NANM also revealed a homogeneous population of binding sites with apparent KD of 12 nM and an estd. max. binding of 360 fmol/mg protein.  This binding site was unaffected by increasing concns. of Na+ and K+, but binding was decreased by high concns. of Mn2+ and Ca2+.  The (+)-isomers of the benzomorphans N-cis-3-chloroallylnormetazocine, phenazocine, pentazocine, and cyclazocine effectively displaced (+)-[3H]NANM binding.  In addn., the (+)-isomers of osocyclazocine and ethyloxocyclazocine, as well as dextrorphan  [125-73-5], a (+)-morphinan, bound to the (+)-[3H]NANM site.  The (-)-isomers of μ agonist/antagonists and κ agonists competed poorly, or not at all, for the (+)-[3H]NANM site, whereas phencyclidine and related compds. exhibited a low affinity for this site.  Thus, the isomers of NANM bind to 2 distinct sites in mouse brain membranes, suggesting a heterogeneity of actions of the putative σ agonist (±)-NANM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAQjOmoHWNRbVg90H21EOLACvtfcHk0lgf6IM1OCAxxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXhtVKjtLc%253D&md5=37f85af241ade71eefc44545d8b0f3a9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DKatzen%26aufirst%3DJ.%2BS.%26aulast%3DWoods%26aufirst%3DJ.%2BA.%26aulast%3DTripathi%26aufirst%3DH.%2BL.%26aulast%3DHarris%26aufirst%3DL.%2BS.%26aulast%3DMay%26aufirst%3DE.%2BL.%26atitle%3DStereoisomers%2520of%2520%255B3H%255D-N-allylnormetazocine%2520bind%2520to%2520different%2520sites%2520in%2520mouse%2520brain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1984%26volume%3D231%26spage%3D539%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaupel, D. B.</span></span> <span> </span><span class="NLM_article-title">Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(83)90297-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2F0014-2999%2883%2990297-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=6313397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL3sXlvVOmurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1983&pages=269-274&author=D.+B.+Vaupel&title=Naltrexone+fails+to+antagonize+the+sigma+effects+of+PCP+and+SKF+10%2C047+in+the+dog&doi=10.1016%2F0014-2999%2883%2990297-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Naltrexone fails to antagonize the σ effects of PCP and SKF 10,047 in the dog</span></div><div class="casAuthors">Vaupel, D. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">269-74</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">SKF 10047 (N-allylnormetazocine)(I)  [14198-28-8] a benzomorphan narcotic antagonist, and the arylcyclohexylamine anesthetic phencyclidine (PCP)(II)  [77-10-1] produced similar reflex, autonomic and behavioral effects in the chronic spinal dog which were not antagonized by naltrexone pretreatment.  Naltrexone prevented the effects of morphine.  Apparently, the acute effects of phencyclidine and SKF 10,047 are alike and that their principal mechanism of action does not involve opiate activity of the morphine type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorcABIoaRnvLVg90H21EOLACvtfcHk0ljjEJ2kBDXpeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlvVOmurs%253D&md5=b14cdb8ad58619f5170d009b005c6a34</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2883%2990297-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252883%252990297-2%26sid%3Dliteratum%253Aachs%26aulast%3DVaupel%26aufirst%3DD.%2BB.%26atitle%3DNaltrexone%2520fails%2520to%2520antagonize%2520the%2520sigma%2520effects%2520of%2520PCP%2520and%2520SKF%252010%252C047%2520in%2520the%2520dog%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1983%26volume%3D92%26spage%3D269%26epage%3D274%26doi%3D10.1016%2F0014-2999%2883%2990297-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor ligands: neurobiological effects</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.2174/0929867322666150114163607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F0929867322666150114163607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25620095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=989-1003&author=L.+Guoauthor=X.+Zhen&title=Sigma-2+receptor+ligands%3A+neurobiological+effects&doi=10.2174%2F0929867322666150114163607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 Receptor Ligands: Neurobiological Effects</span></div><div class="casAuthors">Guo, Lin; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">989-1003</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Sigma-2 receptor is a widely distributed protein, which can modulate cell proliferation and involved in the pathogenesis of tumor.  Photoaffinity labeling techniques testified that its mol. size is about 18 kDa.  Recent studies indicated that sigma-2 receptor modulates the cytosolic Ca2+ concn., dopaminergic transmission, and cocaine-induced addiction behavior.  Some sigma-2 receptor ligands (ditolylguanidine, afobazole, etc) display the neuroprotective effect.  Although sigma-2 receptor hasn't been cloned, tens of sigma-2 receptor ligands, which demonstrate high affinity and selectivity, have been identified in the past decade.  In this review, we mainly focus on these series of selective sigma-2 receptor ligands, their neuropsychol. effects, and mol. probes for tracing sigma-2 receptors in central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrATDnlV7WgQbVg90H21EOLACvtfcHk0ljjEJ2kBDXpeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslCnsLs%253D&md5=bf46a950d9559199eb858f5381271167</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150114163607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150114163607%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DSigma-2%2520receptor%2520ligands%253A%2520neurobiological%2520effects%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D989%26epage%3D1003%26doi%3D10.2174%2F0929867322666150114163607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quirion, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itzhak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junien, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. P.</span></span> <span> </span><span class="NLM_article-title">A proposal for the classification of sigma binding sites</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/0165-6147(92)90030-A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2F0165-6147%2892%2990030-A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1315463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADyaK383ksFGrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1992&pages=85-86&author=R.+Quirionauthor=W.+D.+Bowenauthor=Y.+Itzhakauthor=J.+L.+Junienauthor=J.+M.+Musacchioauthor=R.+B.+Rothmanauthor=T.-P.+Suauthor=S.+W.+Tamauthor=D.+P.+Taylor&title=A+proposal+for+the+classification+of+sigma+binding+sites&doi=10.1016%2F0165-6147%2892%2990030-A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A proposal for the classification of sigma binding sites</span></div><div class="casAuthors">Quirion R; Bowen W D; Itzhak Y; Junien J L; Musacchio J M; Rothman R B; Su T P; Tam S W; Taylor D P</div><div class="citationInfo"><span class="NLM_cas:title">Trends in pharmacological sciences</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">85-6</span>
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9QiJWG_oOy3p3bfzSLaX5fW6udTcc2eZLjqGjQhBlBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK383ksFGrsQ%253D%253D&md5=bdbde1d04c3c3e627e4ff512102ddf5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0165-6147%2892%2990030-A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-6147%252892%252990030-A%26sid%3Dliteratum%253Aachs%26aulast%3DQuirion%26aufirst%3DR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DItzhak%26aufirst%3DY.%26aulast%3DJunien%26aufirst%3DJ.%2BL.%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DSu%26aufirst%3DT.-P.%26aulast%3DTam%26aufirst%3DS.%2BW.%26aulast%3DTaylor%26aufirst%3DD.%2BP.%26atitle%3DA%2520proposal%2520for%2520the%2520classification%2520of%2520sigma%2520binding%2520sites%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1992%26volume%3D13%26spage%3D85%26epage%3D86%26doi%3D10.1016%2F0165-6147%2892%2990030-A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">The molecular function of sigma receptors: past, present, and future</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2019.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.tips.2019.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31387763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeqs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=636-654&author=H.+R.+Schmidtauthor=A.+C.+Kruse&title=The+molecular+function+of+sigma+receptors%3A+past%2C+present%2C+and+future&doi=10.1016%2Fj.tips.2019.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Function of σ Receptors: Past, Present, and Future</span></div><div class="casAuthors">Schmidt, Hayden R.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">636-654</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The σ1 and σ2 receptors are enigmatic proteins that have attracted attention for decades due to the chem. diversity and therapeutic potential of their ligands.  However, despite ongoing clin. trials with σ receptor ligands for multiple conditions, relatively little is known regarding the mol. function of these receptors.  In this review, we revisit past research on σ receptors and discuss the interpretation of these data in light of recent developments.  We provide a synthesis of emerging structural and genetic data on the σ1 receptor and discuss the recent cloning of the σ2 receptor.  Finally, we discuss the major questions that remain in the study of σ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonQzGSQdFecbVg90H21EOLACvtfcHk0ljjEJ2kBDXpeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeqs7bJ&md5=03896ad7b332beb873ad3fbc32c96423</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DThe%2520molecular%2520function%2520of%2520sigma%2520receptors%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26spage%3D636%26epage%3D654%26doi%3D10.1016%2Fj.tips.2019.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flandorfer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossmann, H.</span></span> <span> </span><span class="NLM_article-title">Purification, molecular cloning, and expression of the mammalian sigma1-binding site</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">8072</span>– <span class="NLM_lpage">8077</span>, <span class="refDoi"> DOI: 10.1073/pnas.93.15.8072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1073%2Fpnas.93.15.8072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=8755605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK28XksFSqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=8072-8077&author=M.+Hannerauthor=F.+F.+Moebiusauthor=A.+Flandorferauthor=H.+G.+Knausauthor=J.+Striessnigauthor=E.+Kempnerauthor=H.+Glossmann&title=Purification%2C+molecular+cloning%2C+and+expression+of+the+mammalian+sigma1-binding+site&doi=10.1073%2Fpnas.93.15.8072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Purification, molecular cloning, and expression of the mammalian sigma1-binding site</span></div><div class="casAuthors">Hanner, Markus; Moebius, Fabian F.; Flandorfer, Astrid; Knaus, Hans-Guenther; Striessnig, Joerg; Kempner, Ellis; Glossman, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8072-8077</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sigma-ligands comprise several chem. unrelated drugs such as haloperidol, pentazocine, and ditolylguanidine, which bind to a family of low mol. mass proteins in the endoplasmic reticulum.  These so-called sigma-receptors are believed to mediate various pharmacol. effects of sigma-ligands by as yet unknown mechanisms.  Based on their opposite enantioselectivity for benzomorphans and different mol. masses, two subtypes are differentiated.  We purified the sigma1-binding site as a single 30-kDa protein from guinea pig liver employing the benzomorphan (+)[3H]pentazocine and the aryladize (-)[3H]azidopamil as specific probes.  The purified (+)[3H]pentazocine-binding protein retained its high affinity for haloperidol, pentazocine, and ditolylguanidine.  Partial amino acid sequence obtained after trypsinolysis revealed no homol. to known proteins.  Radiation inactivation of the pentazocine-labeled sigma1-binding site yielded a mol. mass of 24 kDa.  The corresponding cDNA was cloned using degenerate oligonucleotides and cDNA library screening.  Its open reading frame encoded a 25.3-kDa protein with at least one putative transmembrane segment.  The protein expressed in yeast cells transformed with the cDNA showed the pharmacol. characteristics of the brain and liver sigma1-binding site.  The deduced amino acid sequence was structurally unrelated to known mammalian proteins but it shared homol. with fungal proteins involved in sterol synthesis.  Northern blots showed high densities of the sigma1-binding site mRNA in sterol-producing tissues.  This is also in agreement with the known ability of sigma1-binding sites to interact with steroids, such as progesterone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3kp2l6ZPKdrVg90H21EOLACvtfcHk0lhaZIVSX3bn4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFSqsr8%253D&md5=01c7d3bbab83dd5d18531845213bf267</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.15.8072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.15.8072%26sid%3Dliteratum%253Aachs%26aulast%3DHanner%26aufirst%3DM.%26aulast%3DMoebius%26aufirst%3DF.%2BF.%26aulast%3DFlandorfer%26aufirst%3DA.%26aulast%3DKnaus%26aufirst%3DH.%2BG.%26aulast%3DStriessnig%26aufirst%3DJ.%26aulast%3DKempner%26aufirst%3DE.%26aulast%3DGlossmann%26aufirst%3DH.%26atitle%3DPurification%252C%2520molecular%2520cloning%252C%2520and%2520expression%2520of%2520the%2520mammalian%2520sigma1-binding%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D8072%26epage%3D8077%26doi%3D10.1073%2Fpnas.93.15.8072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kekuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibach, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1996.1842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1006%2Fbbrc.1996.1842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=8954936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK28Xns1ehtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=1996&pages=553-558&author=R.+Kekudaauthor=P.+D.+Prasadauthor=Y.+J.+Feiauthor=F.+H.+Leibachauthor=V.+Ganapathy&title=Cloning+and+functional+expression+of+the+human+type+1+sigma+receptor+%28hSigmaR1%29&doi=10.1006%2Fbbrc.1996.1842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1)</span></div><div class="casAuthors">Kekuda, Ramesh; Prasad, Puttur D.; Fei, You-Jun; Leibach, Frederich H.; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">553-558</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">We have isolated a cDNA clone from a human placental choriocarcinoma cell (JAR) cDNA library which codes for a functional type 1 sigma receptor.  An RT-PCR product obtained from guinea pig kidney mRNA using primers specific for the guineas pig sigma receptor cDNA was used to screen the cDNA library.  The hSigmaR1 cDNA predicts a protein of 223 amino acids with a single putative transmembrane domain.  The amino acid sequence exhibits 93% identity with the guinea pig sigma receptor.  When functionally expressed in HeLa cells, the hSigmaR1 cDNA enhances the binding of [3H]-haloperidol, a sigma receptor ligand, to the HeLa cell membranes.  The inhibitor specificity of the cloned hSigmaR1 indicates that it is the type 1 sigma receptor.  Several human tissues, including placenta, liver, and brain, and several human cell lines express the SigmaR1 mRNA (1.7 kb) to a variable extent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSSxDn_6je4bVg90H21EOLACvtfcHk0lhaZIVSX3bn4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xns1ehtrw%253D&md5=8a128351bb8a55e5b3fc3dd31d879b90</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1996.1842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1996.1842%26sid%3Dliteratum%253Aachs%26aulast%3DKekuda%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DFei%26aufirst%3DY.%2BJ.%26aulast%3DLeibach%26aufirst%3DF.%2BH.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DCloning%2520and%2520functional%2520expression%2520of%2520the%2520human%2520type%25201%2520sigma%2520receptor%2520%2528hSigmaR1%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1996%26volume%3D229%26spage%3D553%26epage%3D558%26doi%3D10.1006%2Fbbrc.1996.1842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Identification of the gene that codes for the sigma2 receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7165</span>, <span class="refDoi"> DOI: 10.1073/pnas.1705154114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1073%2Fpnas.1705154114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28559337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=7160-7165&author=A.+Alonauthor=H.+R.+Schmidtauthor=M.+D.+Woodauthor=J.+J.+Sahnauthor=S.+F.+Martinauthor=A.+C.+Kruse&title=Identification+of+the+gene+that+codes+for+the+sigma2+receptor&doi=10.1073%2Fpnas.1705154114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the gene that codes for the σ2 receptor</span></div><div class="casAuthors">Alon, Assaf; Schmidt, Hayden R.; Wood, Michael D.; Sahn, James J.; Martin, Stephen F.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7160-7165</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The σ2 receptor is an enigmatic protein that has attracted significant attention because of its involvement in diseases as diverse as cancer and neurol. disorders.  Unlike virtually all other receptors of medical interest, it has eluded mol. cloning since its discovery, and the gene that codes for the receptor remains unknown, precluding the use of modern biol. methods to study its function.  Using a chem. biol. approach, we purified the σ2 receptor from tissue, revealing its identity as TMEM97, an endoplasmic reticulum-resident transmembrane protein that regulates the sterol transporter NPC1.  We show that TMEM97 possesses the full suite of mol. properties that define the σ2 receptor, and we identify Asp29 and Asp56 as essential for ligand recognition.  Cloning the σ2 receptor resolves a longstanding mystery and will enable therapeutic targeting of this potential drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoAS9Q6KtY7Vg90H21EOLACvtfcHk0lhaZIVSX3bn4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D&md5=71d3c246ebe6ac84c33980b97cb9889c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1705154114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1705154114%26sid%3Dliteratum%253Aachs%26aulast%3DAlon%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DIdentification%2520of%2520the%2520gene%2520that%2520codes%2520for%2520the%2520sigma2%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D7160%26epage%3D7165%26doi%3D10.1073%2Fpnas.1705154114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guitart, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montoliu, L.</span></span> <span> </span><span class="NLM_article-title">Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2188</span>– <span class="NLM_lpage">2196</span>, <span class="refDoi"> DOI: 10.1046/j.1460-9568.2003.02950.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1046%2Fj.1460-9568.2003.02950.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=14622179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BD3srksVWgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=2188-2196&author=F.+Langaauthor=X.+Codonyauthor=V.+Tovarauthor=A.+Lavadoauthor=E.+Gimenezauthor=P.+Cozarauthor=M.+Canteroauthor=A.+Dordalauthor=E.+Hernandezauthor=R.+Perezauthor=X.+Monroyauthor=D.+Zamanilloauthor=X.+Guitartauthor=L.+Montoliu&title=Generation+and+phenotypic+analysis+of+sigma+receptor+type+I+%28sigma+1%29+knockout+mice&doi=10.1046%2Fj.1460-9568.2003.02950.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice</span></div><div class="casAuthors">Langa Francina; Codony Xavier; Tovar Victoria; Lavado Alfonso; Gimenez Estela; Cozar Patricia; Cantero Marta; Dordal Albert; Hernandez Enric; Perez Raquel; Monroy Xavier; Zamanillo Daniel; Guitart Xavier; Montoliu Lluis</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2188-96</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Sigma (sigma) sites are a type of nonopiate receptor whose role has been associated with several behaviours, including anxiety, depression, analgesia, learning processes and psychosis.  Although there are several known sigma receptor types, only the type I receptor (sigma 1) has been cloned.  To uncover the in vivo relevance of sigma-receptors, we have generated knockout mice for sigma 1.  Despite the broad expression pattern found for the sigma 1-gene, homozygous mutant mice are viable, fertile and do not display any overt phenotype, compared with their wild-type litter-mates, in mixed genetic backgrounds.  However, a significant decrease in the hypermotility response has been measured in knockout mice upon challenge with (+)SKF-10 047, in agreement with the involvement of sigma 1-receptors in the induction of psychostimulant actions.  The activity of sigma 2-receptors seems to be unaffected in sigma 1-mutant mice.  These knockout mice could contribute to better understand the in vivo role of sigma-receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8ySfPf0Y6GEEksK8CslK8fW6udTcc2eaz98Kkb2ViYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srksVWgsg%253D%253D&md5=eb1171c29ecada32dca53fe0effd3f01</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1046%2Fj.1460-9568.2003.02950.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1460-9568.2003.02950.x%26sid%3Dliteratum%253Aachs%26aulast%3DLanga%26aufirst%3DF.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DTovar%26aufirst%3DV.%26aulast%3DLavado%26aufirst%3DA.%26aulast%3DGimenez%26aufirst%3DE.%26aulast%3DCozar%26aufirst%3DP.%26aulast%3DCantero%26aufirst%3DM.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DE.%26aulast%3DPerez%26aufirst%3DR.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DGuitart%26aufirst%3DX.%26aulast%3DMontoliu%26aufirst%3DL.%26atitle%3DGeneration%2520and%2520phenotypic%2520analysis%2520of%2520sigma%2520receptor%2520type%2520I%2520%2528sigma%25201%2529%2520knockout%2520mice%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2003%26volume%3D18%26spage%3D2188%26epage%3D2196%26doi%3D10.1046%2Fj.1460-9568.2003.02950.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">596</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.08.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.cell.2007.08.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=17981125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWitrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=596-610&author=T.+Hayashiauthor=T.+P.+Su&title=Sigma-1+receptor+chaperones+at+the+ER-mitochondrion+interface+regulate+Ca%282%2B%29+signaling+and+cell+survival&doi=10.1016%2Fj.cell.2007.08.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival</span></div><div class="casAuthors">Hayashi, Teruo; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">596-610</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Communication between the endoplasmic reticulum (ER) and mitochondrion is important for bioenergetics and cellular survival.  The ER supplies Ca2+ directly to mitochondria via inositol 1,4,5-trisphosphate receptors (IP3Rs) at close contacts between the two organelles referred to as mitochondrion-assocd. ER membrane (MAM).  We found here that the ER protein sigma-1 receptor (Sig-1R), which is implicated in neuroprotection, carcinogenesis, and neuroplasticity, is a Ca2+-sensitive and ligand-operated receptor chaperone at MAM.  Normally, Sig-1Rs form a complex at MAM with another chaperone, BiP.  Upon ER Ca2+ depletion or via ligand stimulation, Sig-1Rs dissoc. from BiP, leading to a prolonged Ca2+ signaling into mitochondria via IP3Rs.  Sig-1Rs can translocate under chronic ER stress.  Increasing Sig-1Rs in cells counteracts ER stress response, whereas decreasing them enhances apoptosis.  These results reveal that the orchestrated ER chaperone machinery at MAM, by sensing ER Ca2+ concns., regulates ER-mitochondrial interorganellar Ca2+ signaling and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFqHhdVumdO7Vg90H21EOLACvtfcHk0ljWJ6arMWZCSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWitrzK&md5=7bb4e806d7ad895f9ed1a8c4f7eb7f6c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DSigma-1%2520receptor%2520chaperones%2520at%2520the%2520ER-mitochondrion%2520interface%2520regulate%2520Ca%25282%252B%2529%2520signaling%2520and%2520cell%2520survival%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D596%26epage%3D610%26doi%3D10.1016%2Fj.cell.2007.08.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faccenda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catterall, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spedding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmar, A. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The concise guide to pharmacology 2013/14: overview</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1111/bph.12444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fbph.12444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24528237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeqtLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=1449-1458&author=S.+P.+Alexanderauthor=H.+E.+Bensonauthor=E.+Faccendaauthor=A.+J.+Pawsonauthor=J.+L.+Sharmanauthor=J.+C.+McGrathauthor=W.+A.+Catterallauthor=M.+Speddingauthor=J.+A.+Petersauthor=A.+J.+Harmar&title=The+concise+guide+to+pharmacology+2013%2F14%3A+overview&doi=10.1111%2Fbph.12444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Concise Guide to PHARMACOLOGY 2013/14: Overview</span></div><div class="casAuthors">Alexander, Stephen P. H.; Benson, Helen E.; Faccenda, Elena; Pawson, Adam J.; Sharman, Joanna L.; McGrath, John C.; Catterall, William A.; Spedding, Michael; Peters, John A.; Harmar, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1449-1458</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The Concise Guide to PHARMACOl. 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacol., plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacol.org), which provides more detailed views of target and ligand properties from the IUPHAR database.  The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.12444/full.  This compilation of the major pharmacol. targets is divided into seven areas of focus: G protein-coupled receptors, ligand-gated ion channels, ion channels, catalytic receptors, nuclear hormone receptors, transporters and enzymes.  These are presented with nomenclature guidance and summary information on the best available pharmacol. tools, alongside key refs. and suggestions for further reading.  A new landscape format has easy to use tables comparing related targets.  It is a condensed version of material contemporary to late 2013, which is presented in greater detail and constantly updated on the website www.guidetopharmacol.org, superseding data presented in previous Guides to Receptors & Channels.  It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate.  It consolidates information previously curated and displayed sep. in IUPHAR-DB and GRAC and provides a permanent, citable, point-in-time record that will survive database updates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY6GzsPrSnGLVg90H21EOLACvtfcHk0ljWJ6arMWZCSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeqtLvM&md5=c52bfad1955f4967940f62215bde6c4a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fbph.12444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12444%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DS.%2BP.%26aulast%3DBenson%26aufirst%3DH.%2BE.%26aulast%3DFaccenda%26aufirst%3DE.%26aulast%3DPawson%26aufirst%3DA.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BL.%26aulast%3DMcGrath%26aufirst%3DJ.%2BC.%26aulast%3DCatterall%26aufirst%3DW.%2BA.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DHarmar%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520concise%2520guide%2520to%2520pharmacology%25202013%252F14%253A%2520overview%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D1449%26epage%3D1458%26doi%3D10.1111%2Fbph.12444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurpinar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human sigma1 receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1038/nature17391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fnature17391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27042935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=527-530&author=H.+R.+Schmidtauthor=S.+Zhengauthor=E.+Gurpinarauthor=A.+Koehlauthor=A.+Manglikauthor=A.+C.+Kruse&title=Crystal+structure+of+the+human+sigma1+receptor&doi=10.1038%2Fnature17391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human σ1 receptor</span></div><div class="casAuthors">Schmidt, Hayden R.; Zheng, Sanduo; Gurpinar, Esin; Koehl, Antoine; Manglik, Aashish; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7600</span>),
    <span class="NLM_cas:pages">527-530</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human σ1 receptor is an enigmatic endoplasmic reticulum (ER)-resident transmembrane protein implicated in a variety of disorders including depression, drug addiction, and neuropathic pain.  Recently, an addnl. connection to amyotrophic lateral sclerosis has emerged from studies of human genetics and mouse models.  Unlike many transmembrane receptors that belong to large, extensively studied families such as G-protein-coupled receptors or ligand-gated ion channels, the σ1 receptor is an evolutionary isolate with no discernible similarity to any other human protein.  Despite its increasingly clear importance in human physiol. and disease, the mol. architecture of the σ1 receptor and its regulation by drug-like compds. remain poorly defined.  Here, the authors report crystal structures of the human σ1 receptor in complex with 2 chem. divergent ligands, PD 144418 and 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP).  The structures revealed a trimeric architecture with a single transmembrane domain in each protomer.  The C-terminal domain of the receptor showed an extensive flat, hydrophobic membrane-proximal surface, suggesting an intimate assocn. with the cytosolic surface of the ER membrane in cells.  This domain included a cupin-like β-barrel with the ligand-binding site buried at its center.  This large, hydrophobic ligand-binding cavity showed remarkable plasticity in ligand recognition, binding the 2 ligands in similar positions despite dissimilar chem. structures.  Taken together, these results revealed the overall architecture, oligomerization state, and mol. basis for ligand recognition by this important but poorly understood protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokQBAf03Pml7Vg90H21EOLACvtfcHk0ljx_tPK2SM2tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D&md5=fb6df7814060fbd05ba41261ad1061f5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature17391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17391%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DGurpinar%26aufirst%3DE.%26aulast%3DKoehl%26aufirst%3DA.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520sigma1%2520receptor%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D527%26epage%3D530%26doi%3D10.1038%2Fnature17391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for sigma1 receptor ligand recognition</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0137-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fs41594-018-0137-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30291362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=981-987&author=H.+R.+Schmidtauthor=R.+M.+Betzauthor=R.+O.+Drorauthor=A.+C.+Kruse&title=Structural+basis+for+sigma1+receptor+ligand+recognition&doi=10.1038%2Fs41594-018-0137-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for σ1 receptor ligand recognition</span></div><div class="casAuthors">Schmidt, Hayden R.; Betz, Robin M.; Dror, Ron O.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-987</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The s1 receptor is a poorly understood membrane protein expressed throughout the human body.  Ligands targeting the s1 receptor are in clin. trials for treatment of Alzheimer's disease, ischemic stroke, and neuropathic pain.  However, relatively little is known regarding the s1 receptor's mol. function.  Here, we present crystal structures of human s1 receptor bound to the antagonists haloperidol and NE-100, and the agonist (+)-pentazocine, at crystallog. resolns. of 3.1 Å, 2.9 Å, and 3.1 Å, resp.  These structures reveal a unique binding pose for the agonist.  The structures and accompanying mol. dynamics (MD) simulations identify agonist-induced structural rearrangements in the receptor.  Addnl., we show that ligand binding to s1 is a multistep process that is rate limited by receptor conformational change.  We used MD simulations to reconstruct a ligand binding pathway involving two major conformational changes.  These data provide a framework for understanding the mol. basis for s1 agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ2dgVTV70vbVg90H21EOLACvtfcHk0ljx_tPK2SM2tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM&md5=d12d12aecbd89684824975977ec03e4b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0137-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0137-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DStructural%2520basis%2520for%2520sigma1%2520receptor%2520ligand%2520recognition%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D981%26epage%3D987%26doi%3D10.1038%2Fs41594-018-0137-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhemkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraskovskaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">862</span>, <span class="refDoi"> DOI: 10.3389/fnins.2019.00862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffnins.2019.00862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31551669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=862&author=D.+A.+Ryskampauthor=S.+Korbanauthor=V.+Zhemkovauthor=N.+Kraskovskayaauthor=I.+Bezprozvanny&title=Neuronal+sigma-1+receptors%3A+signaling+functions+and+protective+roles+in+neurodegenerative+diseases&doi=10.3389%2Ffnins.2019.00862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span></div><div class="casAuthors">Ryskamp Daniel A; Zhemkov Vladimir; Bezprozvanny Ilya; Korban Svetlana; Kraskovskaya Nina; Bezprozvanny Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">862</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer's (AD) and Huntington's diseases (HD).  S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic; yet, relatively little is known regarding the exact mechanisms of receptor functioning at the molecular level.  This review summarizes therapeutically relevant mechanisms by which S1R modulates neurophysiology and implements neuroprotective functions in neurodegenerative diseases.  These mechanisms are diverse due to the fact that S1R can bind to and modulate a large range of client proteins, including many ion channels in both ER and plasma membranes.  We summarize the effect of S1R on its interaction partners and consider some of the cell type- and disease-specific aspects of these actions.  Besides direct protein interactions in the endoplasmic reticulum, S1R is likely to function at the cellular/interorganellar level by altering the activity of several plasmalemmal ion channels through control of trafficking, which may help to reduce excitotoxicity.  Moreover, S1R is situated in lipid rafts where it binds cholesterol and regulates lipid and protein trafficking and calcium flux at the mitochondrial-associated membrane (MAM) domain.  This may have important implications for MAM stability and function in neurodegenerative diseases as well as cellular bioenergetics.  We also summarize the structural and biochemical features of S1R proposed to underlie its activity.  In conclusion, S1R is incredibly versatile in its ability to foster neuronal homeostasis in the context of several neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnXmondofHvmyYR5VtavbzfW6udTcc2ea5Q1p5WxUUnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D&md5=b8a65774a44e82a94e5049247c993883</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2019.00862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2019.00862%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%2BA.%26aulast%3DKorban%26aufirst%3DS.%26aulast%3DZhemkov%26aufirst%3DV.%26aulast%3DKraskovskaya%26aufirst%3DN.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DNeuronal%2520sigma-1%2520receptors%253A%2520signaling%2520functions%2520and%2520protective%2520roles%2520in%2520neurodegenerative%2520diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D862%26doi%3D10.3389%2Ffnins.2019.00862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, J. H.</span></span> <span> </span><span class="NLM_article-title">Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1126/science.2832949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1126%2Fscience.2832949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=2832949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL1cXhvVShsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=1988&pages=219-221&author=T.+P.+Suauthor=E.+D.+Londonauthor=J.+H.+Jaffe&title=Steroid+binding+at+sigma+receptors+suggests+a+link+between+endocrine%2C+nervous%2C+and+immune+systems&doi=10.1126%2Fscience.2832949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Steroid binding at σ receptors suggests a link between endocrine, nervous, and immune systems</span></div><div class="casAuthors">Su, Tsung Ping; London, Edythe D.; Jaffe, Jerome H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">4849</span>),
    <span class="NLM_cas:pages">219-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review, with 27 refs., which shows that steroids are naturally occurring ligands for σ receptors.  These sites may mediate some aspects of steroid-induced mental disturbances and alterations in immune functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ8c6ri5jc4LVg90H21EOLACvtfcHk0liMA3YI1AmOtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhvVShsrk%253D&md5=7bea36e8c31598c9652d93b991c71ef4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscience.2832949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2832949%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DLondon%26aufirst%3DE.%2BD.%26aulast%3DJaffe%26aufirst%3DJ.%2BH.%26atitle%3DSteroid%2520binding%2520at%2520sigma%2520receptors%2520suggests%2520a%2520link%2520between%2520endocrine%252C%2520nervous%252C%2520and%2520immune%2520systems%26jtitle%3DScience%26date%3D1988%26volume%3D240%26spage%3D219%26epage%3D221%26doi%3D10.1126%2Fscience.2832949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontanilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzi, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">The hallucinogen <i>N</i>,<i>N</i>-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">934</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1126/science.1166127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1126%2Fscience.1166127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19213917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslSgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2009&pages=934-937&author=D.+Fontanillaauthor=M.+Johannessenauthor=A.+R.+Hajipourauthor=N.+V.+Cozziauthor=M.+B.+Jacksonauthor=A.+E.+Ruoho&title=The+hallucinogen+N%2CN-dimethyltryptamine+%28DMT%29+is+an+endogenous+sigma-1+receptor+regulator&doi=10.1126%2Fscience.1166127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator</span></div><div class="casAuthors">Fontanilla, Dominique; Johannessen, Molly; Hajipour, Abdol R.; Cozzi, Nicholas V.; Jackson, Meyer B.; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">5916</span>),
    <span class="NLM_cas:pages">934-937</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The sigma-1 receptor is widely distributed in the central nervous system and periphery.  Originally mischaracterized as an opioid receptor, the sigma-1 receptor binds a vast no. of synthetic compds. but does not bind opioid peptides; it is currently considered an orphan receptor.  The sigma-1 receptor pharmacophore includes an alkylamine core, also found in the endogenous compd. N,N-dimethyltryptamine (DMT).  DMT acts as a hallucinogen, but its receptor target has been unclear.  DMT bound to sigma-1 receptors and inhibited voltage-gated sodium ion (Na+) channels in both native cardiac myocytes and heterologous cells that express sigma-1 receptors.  DMT induced hypermobility in wild-type mice but not in sigma-1 receptor knockout mice.  These biochem., physiol., and behavioral expts. indicate that DMT is an endogenous agonist for the sigma-1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAp8p0wmc1wLVg90H21EOLACvtfcHk0liMA3YI1AmOtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslSgsbw%253D&md5=480f24607d42dbe5c5fcd9cdc8ee5e5c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscience.1166127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1166127%26sid%3Dliteratum%253Aachs%26aulast%3DFontanilla%26aufirst%3DD.%26aulast%3DJohannessen%26aufirst%3DM.%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DCozzi%26aufirst%3DN.%2BV.%26aulast%3DJackson%26aufirst%3DM.%2BB.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DThe%2520hallucinogen%2520N%252CN-dimethyltryptamine%2520%2528DMT%2529%2520is%2520an%2520endogenous%2520sigma-1%2520receptor%2520regulator%26jtitle%3DScience%26date%3D2009%26volume%3D323%26spage%3D934%26epage%3D937%26doi%3D10.1126%2Fscience.1166127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">The sigma1 receptor interacts with <i>N</i>-alkyl amines and endogenous sphingolipids</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>609</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2009.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejphar.2009.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19285059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslyhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=609&publication_year=2009&pages=19-26&author=S.+Ramachandranauthor=U.+B.+Chuauthor=T.+A.+Mavlyutovauthor=A.+Palauthor=S.+Pyneauthor=A.+E.+Ruoho&title=The+sigma1+receptor+interacts+with+N-alkyl+amines+and+endogenous+sphingolipids&doi=10.1016%2Fj.ejphar.2009.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids</span></div><div class="casAuthors">Ramachandran, Subramaniam; Chu, Uyen B.; Mavlyutov, Timur A.; Pal, Arindam; Pyne, Susan; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">609</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma1 receptor is distinguished for its ability to bind various pharmacol. agents including drugs of abuse such as cocaine and methamphetamine.  Some endogenous ligands have been identified as putative sigma1 receptor regulators.  High affinity ligands for the sigma1 receptor contain a nitrogen atom connected to long alkyl chains.  It was found that long alkyl chain primary amines including endogenous amines belonging to the sphingolipid family such as D-erythro-sphingosine and sphinganine bind with considerable affinity to the sigma1 receptor but not to the sigma2 receptor.  The binding of D-erythro-sphingosine to the sigma1 receptor appears to be competitive in nature as assessed against the radioligand [3H]-(+)-pentazocine.  Interestingly, the well studied sphingolipid mediator sphingosine-1 phosphate did not bind to the sigma1 or the sigma2 receptor.  Sphingosine is converted to sphingosine-1 phosphate by a family of sphingosine kinases that regulate the relative levels of these two bioactive lipids in the cell.  The selective binding of sphingosine but not sphingosine-1 phosphate to the sigma1 receptor suggests a mechanism for regulation of sigma1 receptor activity by the sphingosine kinase.  This hypothetical model was successfully reconstituted in HEK-293 cells over-expressing both the sigma1 receptor and sphingosine kinase-1.  The data presented here strongly supports sphingosine as an endogenous modulator of the sigma1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqlBCB_WLlKrVg90H21EOLACvtfcHk0liMA3YI1AmOtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslyhtrw%253D&md5=346fe65ca526c85856fd6f836f966b8b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2009.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2009.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DU.%2BB.%26aulast%3DMavlyutov%26aufirst%3DT.%2BA.%26aulast%3DPal%26aufirst%3DA.%26aulast%3DPyne%26aufirst%3DS.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DThe%2520sigma1%2520receptor%2520interacts%2520with%2520N-alkyl%2520amines%2520and%2520endogenous%2520sphingolipids%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D609%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.ejphar.2009.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, M.</span></span> <span> </span><span class="NLM_article-title">Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1124/mol.109.062539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fmol.109.062539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20053954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2010&pages=517-528&author=T.+Hayashiauthor=M.+Fujimoto&title=Detergent-resistant+microdomains+determine+the+localization+of+sigma-1+receptors+to+the+endoplasmic+reticulum-mitochondria+junction&doi=10.1124%2Fmol.109.062539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Detergent-resistant microdomains determine the localization of σ-1 receptors to the endoplasmic reticulum-mitochondria junction</span></div><div class="casAuthors">Hayashi, Teruo; Fujimoto, Michiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">σ-1 Receptors (Sig-1Rs) that bind diverse synthetic and endogenous compds. have been implicated in the pathophysiol. of several human diseases such as drug addiction, depression, neurodegenerative disorders, pain-related disorders, and cancer.  Sig-1Rs were identified recently as novel ligand-operated mol. chaperones.  Although Sig-1Rs are predominantly expressed at endoplasmic reticulum (ER) subdomains apposing mitochondria [i.e., the mitochondria-assocd. ER membrane (MAM)], they dynamically change the cellular distribution, thus regulating both MAM-specific and plasma membrane proteins.  However, what dets. the location of Sig-1R at the MAM and how the receptor translocation is initiated is unknown.  Here we report that the detergent-resistant membranes (DRMs) play an important role in anchoring Sig-1Rs to the MAM.  The MAM, which is highly capable of accumulating ceramides, is enriched with both cholesterol and simple sphingolipids, thus forming Triton X-114-resistant DRMs.  Sig-1Rs assoc. with MAM-derived DRMs but not with those from microsomes.  A lipid overlay assay found that solubilized Sig-1Rs preferentially assoc. with simple sphingolipids such as ceramides.  Disrupting DRMs by lowering cholesterol or inhibiting de novo synthesis of ceramides at the ER largely decreases Sig-1R at DRMs and causes translocation of Sig-1R from the MAM to ER cisternae.  These findings suggest that the MAM, bearing cholesterol and ceramide-enriched microdomains at the ER, may use the microdomains to anchor Sig-1Rs to the location; thus, it serves to stage Sig-1R at ER-mitochondria junctions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZYY_eReHQzbVg90H21EOLACvtfcHk0liMA3YI1AmOtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyktbY%253D&md5=f36cef4c5a43f799cf7fbdef27bb968f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.062539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.062539%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DM.%26atitle%3DDetergent-resistant%2520microdomains%2520determine%2520the%2520localization%2520of%2520sigma-1%2520receptors%2520to%2520the%2520endoplasmic%2520reticulum-mitochondria%2520junction%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D77%26spage%3D517%26epage%3D528%26doi%3D10.1124%2Fmol.109.062539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. Y.</span></span> <span> </span><span class="NLM_article-title">A role for sigma receptors in stimulant self administration and addiction</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">914</span>, <span class="refDoi"> DOI: 10.3390/ph4060880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3390%2Fph4060880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21904468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVWgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=880-914&author=J.+L.+Katzauthor=T.+P.+Suauthor=T.+Hiranitaauthor=T.+Hayashiauthor=G.+Tandaauthor=T.+Kopajticauthor=S.+Y.+Tsai&title=A+role+for+sigma+receptors+in+stimulant+self+administration+and+addiction&doi=10.3390%2Fph4060880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A role for sigma receptors in stimulant self administration and addiction</span></div><div class="casAuthors">Katz, Jonathan L.; Su, Tsung-Ping; Hiranita, Takato; Hayashi, Teruo; Tanda, Gianluigi; Kopajtic, Theresa; Tsai, Shang-Yi</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">880-914</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Sigma1 receptors (σ1Rs) represent a structurally unique class of intracellular proteins that function as chaperones.  σ1Rs translocate from the mitochondria-assocd. membrane to the cell nucleus or cell membrane, and through protein-protein interactions influence several targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins.  Several studies have demonstrated that σR antagonists block stimulant-induced behavioral effects, including ambulatory activity, sensitization, and acute toxicities.  Curiously, the effects of stimulants have been blocked by σR antagonists tested under place-conditioning but not self-administration procedures, indicating fundamental differences in the mechanisms underlying these two effects.  The self administration of σR agonists has been found in subjects previously trained to self administer cocaine.  The reinforcing effects of the σR agonists were blocked by σR antagonists.  Addnl., σR agonists were found to increase dopamine concns. in the nucleus accumbens shell, a brain region considered important for the reinforcing effects of abused drugs.  Although the effects of the σR agonist, DTG, on dopamine were obtained at doses that approximated those that maintained self administration behavior those of another agonist, PRE-084 required higher doses.  The effects of DTG were antagonized by non-selective or a preferential σ2R antagonist but not by a preferential σ1R antagonist.  The effects of PRE-084 on dopamine were insensitive to σR antagonists.  The data suggest that the self administration of σR agonists is independent of dopamine and the findings are discussed in light of a hypothesis that cocaine has both intracellular actions mediated by σRs, as well as extracellular actions mediated through conventionally studied mechanisms.  The co-activation and potential interactions among these mechanisms, in particular those involving the intracellular chaperone σRs, may lead to the pernicious addictive effects of stimulant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-C58BXc2OEbVg90H21EOLACvtfcHk0ljh9QM7dKq4Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVWgt7o%253D&md5=91e115c03c04656ead69abe04c02eb2e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3390%2Fph4060880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph4060880%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DTsai%26aufirst%3DS.%2BY.%26atitle%3DA%2520role%2520for%2520sigma%2520receptors%2520in%2520stimulant%2520self%2520administration%2520and%2520addiction%26jtitle%3DPharmaceuticals%26date%3D2011%26volume%3D4%26spage%3D880%26epage%3D914%26doi%3D10.3390%2Fph4060880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, S. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitlock, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, P.</span></span> <span> </span><span class="NLM_article-title">Differential localization of three distinct binding sites for sigma receptor ligands in rat spleen</span>. <i>J. Neuroimmunol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/S0165-5728(96)00140-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS0165-5728%2896%2900140-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=9003244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1Ois7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1997&pages=45-58&author=S.+A.+Wolfeauthor=B.+K.+Haauthor=B.+B.+Whitlockauthor=P.+Saini&title=Differential+localization+of+three+distinct+binding+sites+for+sigma+receptor+ligands+in+rat+spleen&doi=10.1016%2FS0165-5728%2896%2900140-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Differential localization of three distinct binding sites for sigma receptor ligands in rat spleen</span></div><div class="casAuthors">Wolfe, Seth A., Jr.; Keun Ha, Byeong; Whitlock, Ben B.; Saini, Priya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-58</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In vitro receptor autoradiog. was used to localize σ1 receptors, σ2 receptors, and novel haloperidol/DTG-inaccessible sites for sigma and opiate ligands in rat spleen.  Sigma-1 receptors were present throughout the spleen, but were most concd. in the T cell zones.  Binding under σ2 receptor-selective' conditions was 70% nonspecific, and σ2 receptors could not be detected.  Haloperidol/DTG-inaccessible sites had a coarse, punctate distribution in the red pulp and marginal zones of the white pulp.  This anatomical localization suggests types of cells and functions that should be examd. for modulation by sigma receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIocw7I4Y6j7Vg90H21EOLACvtfcHk0ljh9QM7dKq4Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1Ois7k%253D&md5=d850f70f54fc4172039bf5a51eb5b808</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0165-5728%2896%2900140-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-5728%252896%252900140-3%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DS.%2BA.%26aulast%3DHa%26aufirst%3DB.%2BK.%26aulast%3DWhitlock%26aufirst%3DB.%2BB.%26aulast%3DSaini%26aufirst%3DP.%26atitle%3DDifferential%2520localization%2520of%2520three%2520distinct%2520binding%2520sites%2520for%2520sigma%2520receptor%2520ligands%2520in%2520rat%2520spleen%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D1997%26volume%3D72%26spage%3D45%26epage%3D58%26doi%3D10.1016%2FS0165-5728%2896%2900140-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermack, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debonnel, G.</span></span> <span> </span><span class="NLM_article-title">The role of sigma receptors in depression</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1254/jphs.CRJ04005X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1254%2Fjphs.CRJ04005X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=15750289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVGjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=317-336&author=J.+E.+Bermackauthor=G.+Debonnel&title=The+role+of+sigma+receptors+in+depression&doi=10.1254%2Fjphs.CRJ04005X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The role of sigma receptors in depression</span></div><div class="casAuthors">Bermack, Jordanna E.; Debonnel, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-336</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">A review.  Behavioral models used to test potential antidepressants have shown that ligands that bind to sigma receptors possess "antidepressant-like" properties.  The focus of this review is to discuss the literature concerning sigma receptors and their ligands, with respect to their antidepressants properties.  In addn. to the behavioral data, we discuss electrophysiol. and biochem. models demonstrating sigma receptors' ability to modulate important factors in the pathophysiol. of depression and/or the mechanisms of action of antidepressants such as the serotonergic neurotransmission in the dorsal raphe nucleus (DRN) and the glutamatergic transmission in the hippocampus.  We also discuss the significance of these two systems in the mechanism of action of antidepressants.  Sigma ligands have potential as antidepressant medications with a fast onset of action as they produce a rapid modulation of the serotonergic system in the DRN and the glutamatergic transmission in the hippocampus.  As these effects of sigma ligands may produce antidepressant properties by completely novel mechanisms of action, they may provide an alternative to the antidepressants currently available and may prove to be beneficial for treatment-resistant depressed patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTc8adYlmpSrVg90H21EOLACvtfcHk0ljh9QM7dKq4Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVGjtL4%253D&md5=1cdda174b9b1e5087118ae49526b3eb0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1254%2Fjphs.CRJ04005X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.CRJ04005X%26sid%3Dliteratum%253Aachs%26aulast%3DBermack%26aufirst%3DJ.%2BE.%26aulast%3DDebonnel%26aufirst%3DG.%26atitle%3DThe%2520role%2520of%2520sigma%2520receptors%2520in%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D97%26spage%3D317%26epage%3D336%26doi%3D10.1254%2Fjphs.CRJ04005X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucke-Wold, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptors and neurodegenerative diseases: towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>964</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-50174-1_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2F978-3-319-50174-1_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28315269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFegsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=964&publication_year=2017&pages=133-152&author=L.+Nguyenauthor=B.+P.+Lucke-Woldauthor=S.+Mookerjeeauthor=N.+Kaushalauthor=R.+R.+Matsumoto&title=Sigma-1+receptors+and+neurodegenerative+diseases%3A+towards+a+hypothesis+of+sigma-1+receptors+as+amplifiers+of+neurodegeneration+and+neuroprotection&doi=10.1007%2F978-3-319-50174-1_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptors and neurodegenerative diseases: towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection</span></div><div class="casAuthors">Nguyen, Linda; Lucke-Wold, Brandon P.; Mookerjee, Shona; Kaushal, Nidhi; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">964</span>
        (<span class="NLM_cas:issue">Sigma Receptors: Their Role in Disease and as Therapeutic Targets</span>),
    <span class="NLM_cas:pages">133-152</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Sigma-1 receptors are mol. chaperones that may act as pathol. mediators and targets for novel therapeutic applications in neurodegenerative diseases.  Accumulating evidence indicates that sigma-1 ligands can either directly or indirectly modulate multiple neurodegenerative processes, including excitotoxicity, calcium dysregulation, mitochondrial and endoplasmic reticulum dysfunction, inflammation, and astrogliosis.  In addn., sigma-1 ligands may act as disease-modifying agents in the treatment for central nervous system (CNS) diseases by promoting the activity of neurotrophic factors and neural plasticity.  Here, we summarize their neuroprotective and neurorestorative effects in different animal models of acute brain injury and chronic neurodegenerative diseases, and highlight their potential role in mitigating disease.  Notably, current data suggest that sigma-1 receptor dysfunction worsens disease progression, whereas enhancement amplifies pre-existing functional mechanisms of neuroprotection and/or restoration to slow disease progression.  Collectively, the data support a model of the sigma-1 receptor as an amplifier of intracellular signaling, and suggest future clin. applications of sigma-1 ligands as part of multi-therapy approaches to treat neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO4KO0RLJ4fLVg90H21EOLACvtfcHk0ljSIJFW07c9sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFegsLfN&md5=72a736369a3912dd64fa1913ec00d3fb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-50174-1_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-50174-1_10%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DLucke-Wold%26aufirst%3DB.%2BP.%26aulast%3DMookerjee%26aufirst%3DS.%26aulast%3DKaushal%26aufirst%3DN.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSigma-1%2520receptors%2520and%2520neurodegenerative%2520diseases%253A%2520towards%2520a%2520hypothesis%2520of%2520sigma-1%2520receptors%2520as%2520amplifiers%2520of%2520neurodegeneration%2520and%2520neuroprotection%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D964%26spage%3D133%26epage%3D152%26doi%3D10.1007%2F978-3-319-50174-1_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucke-Wold, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavendish, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scandinaro, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Role of sigma-1 receptors in neurodegenerative diseases</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.jphs.2014.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jphs.2014.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25704014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XislaksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=17-29&author=L.+Nguyenauthor=B.+P.+Lucke-Woldauthor=S.+A.+Mookerjeeauthor=J.+Z.+Cavendishauthor=M.+J.+Robsonauthor=A.+L.+Scandinaroauthor=R.+R.+Matsumoto&title=Role+of+sigma-1+receptors+in+neurodegenerative+diseases&doi=10.1016%2Fj.jphs.2014.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Role of sigma-1 receptors in neurodegenerative diseases</span></div><div class="casAuthors">Nguyen, Linda; Lucke-Wold, Brandon P.; Mookerjee, Shona A.; Cavendish, John Z.; Robson, Matthew J.; Scandinaro, Anna L.; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-29</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neurodegenerative diseases with distinct genetic etiologies and pathol. phenotypes appear to share common mechanisms of neuronal cellular dysfunction, including excitotoxicity, calcium dysregulation, oxidative damage, ER stress and mitochondrial dysfunction.  Glial cells, including microglia and astrocytes, play an increasingly recognized role in both the promotion and prevention of neurodegeneration.  Sigma receptors, particularly the sigma-1 receptor subtype, which are expressed in both neurons and glia of multiple regions within the central nervous system, are a unique class of intracellular proteins that can modulate many biol. mechanisms assocd. with neurodegeneration.  These receptors therefore represent compelling putative targets for pharmacol. treating neurodegenerative disorders.  In this review, we provide an overview of the biol. mechanisms frequently assocd. with neurodegeneration, and discuss how sigma-1 receptors may alter these mechanisms to preserve or restore neuronal function.  In addn., we speculate on their therapeutic potential in the treatment of various neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdBzbVUAlU9rVg90H21EOLACvtfcHk0ljSIJFW07c9sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XislaksLY%253D&md5=1aa1ab1a9eb49ef2d69eef975a568a2d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jphs.2014.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jphs.2014.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DLucke-Wold%26aufirst%3DB.%2BP.%26aulast%3DMookerjee%26aufirst%3DS.%2BA.%26aulast%3DCavendish%26aufirst%3DJ.%2BZ.%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DScandinaro%26aufirst%3DA.%2BL.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DRole%2520of%2520sigma-1%2520receptors%2520in%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D127%26spage%3D17%26epage%3D29%26doi%3D10.1016%2Fj.jphs.2014.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieloch, T.</span></span> <span> </span><span class="NLM_article-title">The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.jphs.2014.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jphs.2014.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25704015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislalu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=30-35&author=K.+Ruscherauthor=T.+Wieloch&title=The+involvement+of+the+sigma-1+receptor+in+neurodegeneration+and+neurorestoration&doi=10.1016%2Fj.jphs.2014.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration</span></div><div class="casAuthors">Ruscher, Karsten; Wieloch, Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-35</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor (Sig-1R) is a single 25 kD polypeptide and a chaperone protein immersed in lipid rafts of the endoplasmic reticulum (ER) where it interacts with mitochondria at the mitochondria-assocd. ER membrane domain (MAM).  Upon activation, the Sig-1R binds to the inositol trisphosphate receptor (IP3R), and modulates cellular calcium (Ca2+) homeostasis.  Also, the activated Sig-1R modulates plasma membrane receptor and ion channel functions, and may regulate cellular excitability.  Further, the Sig-1R promotes trafficking of lipids and proteins essential for neurotransmission, cell growth and motility.  Activation of the Sig-1R provides neuroprotection and is neurorestorative in cellular and animal models of neurodegenerative diseases and brain ischemia.  Neuroprotection appears to be due to inhibition of cellular Ca2+ toxicity and/or inflammation, and neurorestoration may include balancing abberant neurotransmission or stimulation of synaptogenesis, thus remodelling brain connectivity.  Single nucleotide polymorphisms and mutations of the SIGMAR1 gene worsen outcome in Alzheimer's disease and myotrophic lateral sclerosis supporting a role of Sig-1R in neurodegenerative disease.  The combined neuroprotective and neurorestorative actions of the Sig-1R, provide a broad therapeutic time window of Sig-1R agonists.  The Sig-1R is therefore a strong therapeutic target for the development of new treatments for neurodegenerative diseases and stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8YOx7k1TXx7Vg90H21EOLACvtfcHk0ljSIJFW07c9sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislalu7c%253D&md5=7c18045bd413a002427b9e7f9abbecf1</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jphs.2014.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jphs.2014.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DRuscher%26aufirst%3DK.%26aulast%3DWieloch%26aufirst%3DT.%26atitle%3DThe%2520involvement%2520of%2520the%2520sigma-1%2520receptor%2520in%2520neurodegeneration%2520and%2520neurorestoration%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D127%26spage%3D30%26epage%3D35%26doi%3D10.1016%2Fj.jphs.2014.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor-modulated neuroinflammation in neurological diseases</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">314</span>, <span class="refDoi"> DOI: 10.3389/fncel.2018.00314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffncel.2018.00314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30294261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=314&author=J.+Jiaauthor=J.+Chengauthor=C.+Wangauthor=X.+Zhen&title=Sigma-1+receptor-modulated+neuroinflammation+in+neurological+diseases&doi=10.3389%2Ffncel.2018.00314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor-modulated neuroinflammation in neurological diseases</span></div><div class="casAuthors">Jia, Jia; Cheng, Jian; Wang, Cheng; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">314</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A large body of evidence indicates that sigma-1 receptors (Sig-1R) are important drug targets for a no. of neuropsychiatric disorders.  Sig-1Rs are enriched in central nervous system (CNS).  In addn. to neurons, both cerebral microglia and astrocytes express Sig-1Rs.  Activation of Sig-1Rs is known to elicit potent neuroprotective effects and promote neuronal survival via multiple mechanisms, including promoting mitochondrial functions, decreasing oxidative stress and regulating neuroimmnol. functions.  In this review article, we focus on the emerging role of Sig-1Rs in regulating neuroinflammation and discuss the recent advances on the Sig-1R-modulating neuroinflammation in the pathophysiol. and therapy of neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6jkx0g1TjobVg90H21EOLACvtfcHk0lhu0nzfgDzqwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7nM&md5=265ed5482d3ee53c3e7b6a8541d81221</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2018.00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2018.00314%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DSigma-1%2520receptor-modulated%2520neuroinflammation%2520in%2520neurological%2520diseases%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2018%26volume%3D12%26spage%3D314%26doi%3D10.3389%2Ffncel.2018.00314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhasz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakaski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janka, Z.</span></span> <span> </span><span class="NLM_article-title">Association between a variant of the sigma-1 receptor gene and Alzheimer’s disease</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>517</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2012.04.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neulet.2012.04.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22561649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFKlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=517&publication_year=2012&pages=136-139&author=A.+Feherauthor=A.+Juhaszauthor=A.+Laszloauthor=J.+Kalmanauthor=M.+Pakaskiauthor=J.+Kalmanauthor=Z.+Janka&title=Association+between+a+variant+of+the+sigma-1+receptor+gene+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neulet.2012.04.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Association between a variant of the sigma-1 receptor gene and Alzheimer's disease</span></div><div class="casAuthors">Feher, Agnes; Juhasz, Anna; Laszlo, Anna; Kalman, Janos; Pakaski, Magdolna; Janka, Zoltan</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">517</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-139</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a progressive neurodegenerative disorder with complex etiol. and strong genetic predisposition.  A no. of investigations support the possible involvement of sigma non-opioid intracellular receptor 1 (SIGMAR1) in the pathophysiol. of AD.  We aimed to investigate the assocn. between SIGMAR1 polymorphisms and late-onset AD, therefore we genotyped rs1799729 (GC-241-240TT) and rs1800866 (Q2P) in 322 Hungarian late-onset AD patients and 250 ethnically matched, elderly control individuals.  The investigated polymorphisms were in nearly complete linkage disequil. resulting in the GC-Q and TT-P predominant haplotypes that were subjected to the statistical analyses.  Our data demonstrates an assocn. between the SIGMAR1 TT-P variant and the risk for developing AD (p = 0.019), and a potential modest interaction effect (p = 0.058) of the co-presence of the TT-P haplotype with apolipoprotein E4 allele on the risk for AD.  Based on this mild significance, we could not fully support the hypothesis that TT-P haplotype in interaction with APOE E4 allele confers risk for developing AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwEWSD-BqIcrVg90H21EOLACvtfcHk0lhu0nzfgDzqwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFKlurg%253D&md5=2affc9e415ba1214d3a32d1558a015c4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2012.04.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2012.04.046%26sid%3Dliteratum%253Aachs%26aulast%3DFeher%26aufirst%3DA.%26aulast%3DJuhasz%26aufirst%3DA.%26aulast%3DLaszlo%26aufirst%3DA.%26aulast%3DKalman%26aufirst%3DJ.%26aulast%3DPakaski%26aufirst%3DM.%26aulast%3DKalman%26aufirst%3DJ.%26aulast%3DJanka%26aufirst%3DZ.%26atitle%3DAssociation%2520between%2520a%2520variant%2520of%2520the%2520sigma-1%2520receptor%2520gene%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D2012%26volume%3D517%26spage%3D136%26epage%3D139%26doi%3D10.1016%2Fj.neulet.2012.04.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson-Stone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallupp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. D.</span></span> <span> </span><span class="NLM_article-title">Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer’s disease</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.2174/156720511797633232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F156720511797633232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21605063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWhsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=765-770&author=Y.+Huangauthor=L.+Zhengauthor=G.+Hallidayauthor=C.+Dobson-Stoneauthor=Y.+Wangauthor=H.+D.+Tangauthor=L.+Caoauthor=Y.+L.+Dengauthor=G.+Wangauthor=Y.+M.+Zhangauthor=J.+H.+Wangauthor=M.+Halluppauthor=J.+Kwokauthor=S.+D.+Chen&title=Genetic+polymorphisms+in+sigma-1+receptor+and+apolipoprotein+E+interact+to+influence+the+severity+of+Alzheimer%E2%80%99s+disease&doi=10.2174%2F156720511797633232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease</span></div><div class="casAuthors">Huang, Yue; Zheng, Lan; Halliday, Glenda; Dobson-Stone, Carol; Wang, Ying; Tang, Hui-Dong; Cao, Li; Deng, Yu-Lei; Wang, Gang; Zhang, Yu-Mei; Wang, Jian-Hua; Hallupp, Marianne; Kwok, John; Chen, Sheng-Di</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">765-770</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Apolipoprotein E (APOE) ε4 allele and sigma-1 receptor (SIGMAR1) c.5C (Q2P) polymorphisms were acknowledged as risk factors for developing Alzheimer's disease (AD).  However, whether these polymorphisms influence the disease process is unclear.  Therefore, 2 cohorts with a clin. diagnosis of AD were recruited, a postmortem confirmed Australian cohort (82 cases) from the Australian Brain Bank Network, and a Chinese cohort with detailed clin. assessments recruited through an epidemiol. study in Shanghai and through the neurol. department outpatients clinic of Shanghai Ruijin Hospital (330 cases).  SIGMAR1 Q2P and APOE genotyping was performed on all cases.  Dementia severity in the Chinese cohort was assessed using MMSE scores, and the stages of senile plaques and neurofibrillary tangles (NFT) assessed in the Australian cohort.  Assocns. between SIGMAR1 Q2P and APOE genotypes and disease severity were assessed using SPSS.  Results confirmed that APOE ε4 allele assocd. with increased NFT stages and cognitive decline, with carriers with one APOE ε2 or ε3 allele often having better clin. outcomes compared to carriers with none or 2 ε2 or ε3 alleles resp.  SIGMAR1 c.5C polymorphism alone did not assoc. with MMSE score variability in Chinese or with pathol. stages in Caucasians.  However, the assocn. studies revealed a significant genetic interaction between the APOE ε4 allele and SIGMAR1 2P carriers in both populations, i.e., in APOE non ε4 allele carriers, SIGMAR1 2P variant had increased cognitive dysfunction and more advanced stages of NFT.  The authors' data demonstrate that SIGMAR1 and APOE interact to influence AD severity across ethnic populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Qk9dxRhwMbVg90H21EOLACvtfcHk0lhu0nzfgDzqwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWhsrvO&md5=e5ad2ebca7fd1cea4cda742e1cc65792</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F156720511797633232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720511797633232%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DHalliday%26aufirst%3DG.%26aulast%3DDobson-Stone%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DH.%2BD.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DHallupp%26aufirst%3DM.%26aulast%3DKwok%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%2BD.%26atitle%3DGenetic%2520polymorphisms%2520in%2520sigma-1%2520receptor%2520and%2520apolipoprotein%2520E%2520interact%2520to%2520influence%2520the%2520severity%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2011%26volume%3D8%26spage%3D765%26epage%3D770%26doi%3D10.2174%2F156720511797633232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span> <span> </span><span class="NLM_article-title">Low density of sigma1 receptors in early Alzheimer’s disease</span>. <i>Ann. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1007/s12149-007-0094-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs12149-007-0094-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18498028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1yntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=151-156&author=M.+Mishinaauthor=M.+Ohyamaauthor=K.+Ishiiauthor=S.+Kitamuraauthor=Y.+Kimuraauthor=K.+Odaauthor=K.+Kawamuraauthor=T.+Sasakiauthor=S.+Kobayashiauthor=Y.+Katayamaauthor=K.+Ishiwata&title=Low+density+of+sigma1+receptors+in+early+Alzheimer%E2%80%99s+disease&doi=10.1007%2Fs12149-007-0094-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Low density of sigma1 receptors in early Alzheimer's disease</span></div><div class="casAuthors">Mishina, Masahiro; Ohyama, Masashi; Ishii, Kenji; Kitamura, Shin; Kimura, Yuichi; Oda, Kei-ichi; Kawamura, Kazunori; Sasaki, Toru; Kobayashi, Shiro; Katayama, Yasuo; Ishiwata, Kiichi</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-156</span>CODEN:
                <span class="NLM_cas:coden">ANMEEX</span>;
        ISSN:<span class="NLM_cas:issn">0914-7187</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">Objective: The sigma1 receptor is considered to be involved in cognitive function.  A postmortem study reported that the sigma1 receptors were reduced in the hippocampus in Alzheimer's disease (AD).  However, in vivo imaging of sigma1 receptors in the brain of AD patients has not been reported.  The aim of this study is to investigate the mapping of sigma1 receptors in AD using [11C]SA4503 positron emission tomog. (PET).  Methods: We studied five AD patients and seven elderly volunteers.  A dynamic series of decay-cor. PET data acquisition was performed for 90 min starting at the time of the injection of 500 MBq of [11C]SA4503.  A two-tissue three-compartment model was used to est. K1 k2, k3, k4, and the delay between metabolite-cor. plasma and tissue time activity using a Gauss-Newton algorithm.  The ratio of k3 to k4 was computed as the binding potential (BP), which is linearly related to the d. of sigma1 receptors.  Unpaired t tests were used to compare K1 and BP in patients with AD and normal subjects.  Results: As compared with normals, BP in the AD was significantly lower in the frontal, temporal, and occipital lobe, cerebellum and thalamus, whereas K1 was significantly lower in the parietal lobe.  Conclusions: [11C]SA4503 PET can demonstrate that the d. of cerebral and cerebellar sigma1 receptors is reduced in early AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC4SpMfV0TfrVg90H21EOLACvtfcHk0liTsioAZOwSiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1yntb8%253D&md5=31fd013a70d4b4c4df83ddca47d7e0d7</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs12149-007-0094-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12149-007-0094-z%26sid%3Dliteratum%253Aachs%26aulast%3DMishina%26aufirst%3DM.%26aulast%3DOhyama%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DY.%26aulast%3DIshiwata%26aufirst%3DK.%26atitle%3DLow%2520density%2520of%2520sigma1%2520receptors%2520in%2520early%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAnn.%2520Nucl.%2520Med.%26date%3D2008%26volume%3D22%26spage%3D151%26epage%3D156%26doi%3D10.1007%2Fs12149-007-0094-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rammes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Pridopidine stabilizes mushroom spines in mouse models of Alzheimer’s disease by acting on the sigma-1 receptor</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2018.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.nbd.2018.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30594810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=489-504&author=D.+Ryskampauthor=L.+Wuauthor=J.+Wuauthor=D.+Kimauthor=G.+Rammesauthor=M.+Gevaauthor=M.+Haydenauthor=I.+Bezprozvanny&title=Pridopidine+stabilizes+mushroom+spines+in+mouse+models+of+Alzheimer%E2%80%99s+disease+by+acting+on+the+sigma-1+receptor&doi=10.1016%2Fj.nbd.2018.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor</span></div><div class="casAuthors">Ryskamp, Daniel; Wu, Lili; Wu, Jun; Kim, Dabin; Rammes, Gerhard; Geva, Michal; Hayden, Michael; Bezprozvanny, Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">489-504</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There is evidence that cognitive decline in Alzheimer's disease (AD) results from deficiencies in synaptic communication (e.g., loss of mushroom-shaped 'memory spines') and neurodegenerative processes.  This might be treated with sigma-1 receptor (S1R) agonists, which are broadly neuroprotective and modulate synaptic plasticity.  For example, we previously found that the mixed muscarinic/S1R agonist AF710B prevents mushroom spine loss in hippocampal cultures from APP knock-in (APP-KI) and presenilin-1-M146 V knock-in (PS1-KI) mice.  We also found that the "dopaminergic stabilizer" pridopidine (structurally similar to the S1R agonist R(+)-3-PPP), is a high-affinity S1R agonist and is synaptoprotective in a mouse model of Huntington disease.  Here we tested whether pridopidine and R(+)-3-PPP are synaptoprotective in models of AD and whether this requires S1R.  We also examd. the effects of pridopidine on long-term potentiation (LTP), endoplasmic reticulum calcium and neuronal store-operated calcium entry (nSOC) in spines, all of which are dysregulated in AD, contributing to synaptic pathol.  We report here that pridopidine and 3-PPP protect mushroom spines from Aβ42 oligomer toxicity in primary WT hippocampal cultures from mice.  Pridopidine also reversed LTP defects in hippocampal slices resulting from application of Aβ42 oligomers.  Pridopidine and 3-PPP rescued mushroom spines in hippocampal cultures from APP-KI and PS1-KI mice.  S1R knockdown from lenti-viral shRNA expression destabilized WT mushroom spines and prevented the synaptoprotective effects of pridopidine in PS1-KI cultures.  Knockout of PS1/2 destabilized mushroom spines and pridopidine was unable to prevent this.  Pridopidine lowered endoplasmic reticulum calcium levels in WT, PS1-KO, PS1-KI and PS2 KO neurons, but not in PS1/2 KO neurons.  S1R was required for pridopidine to enhance spine nSOC in PS1-KI neurons.  Pridopidine was unable to rescue PS1-KI mushroom spines during pharmacol. or genetic inhibition of nSOC.  Oral pridopidine treatment rescued mushroom spines in vivo in aged PS1-KI-GFP mice.  Pridopidine stabilizes mushroom spines in mouse models of AD and this requires S1R, endoplasmic reticulum calcium leakage through PS1/2 and nSOC.  Thus, pridopidine may be useful to explore for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZa0vjyeC-9rVg90H21EOLACvtfcHk0liTsioAZOwSiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFCrsg%253D%253D&md5=70e9a25da577b8469533fda8b9316348</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2018.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2018.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DRammes%26aufirst%3DG.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DPridopidine%2520stabilizes%2520mushroom%2520spines%2520in%2520mouse%2520models%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520by%2520acting%2520on%2520the%2520sigma-1%2520receptor%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2019%26volume%3D124%26spage%3D489%26epage%3D504%26doi%3D10.1016%2Fj.nbd.2018.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strehaiano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duhr, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevallier, N.</span></span> <span> </span><span class="NLM_article-title">Amyloid toxicity is enhanced after pharmacological or genetic invalidation of the sigma1 receptor</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2017.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbr.2017.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29129596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSiu7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2018&pages=1-10&author=T.+Mauriceauthor=M.+Strehaianoauthor=F.+Duhrauthor=N.+Chevallier&title=Amyloid+toxicity+is+enhanced+after+pharmacological+or+genetic+invalidation+of+the+sigma1+receptor&doi=10.1016%2Fj.bbr.2017.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid toxicity is enhanced after pharmacological or genetic invalidation of the σ1 receptor</span></div><div class="casAuthors">Maurice, Tangui; Strehaiano, Manon; Duhr, Fanny; Chevallier, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor (S1R) is a mol. chaperone which activity modulates several intracellular signals including calcium mobilization at mitochondria-assocd. endoplasmic reticulum membranes.  S1R agonists are potent neuroprotectants against neurodegenerative insults and particularly in rodent models of Alzheimer's disease (AD).  We here analyzed whether S1R inactivation modifies vulnerability to amyloid toxicity in AD models.  Two strategies were used: (1) amyloid β[25-35] (Aβ25-35) peptide (1, 3, 9 nmol) was injected intracerebroventricularly in mice treated repeatedly with the S1R antagonist NE-100 or in S1RKO mice, and (2) WT, APPSweInd, S1RKO, and APPSweInd/S1RKO mice were created and female littermates analyzed at 8 mo of age.  Learning deficits, oxidative stress, Bax level and BDNF content in the hippocampus were analyzed.  Aβ25-35 induced learning impairment, oxidative stress, Bax induction and BDNF alteration at lower dose in NE-100-treated mice or S1RKO mice as compared to WT animals.  The extent of learning deficits and biochem. alterations were also higher in APPSweInd/S1RKO mice as compared to WT, APPSweInd, and S1RKO animals.  S1R inactivation or altered S1R expression augmented the pathol. status in pharmacol. and genetic AD mouse models.  These observations, in relation with the well-known protective effects of S1R agonists, are coherent with a role of signal amplifier in neurodegeneration and neuroprotection proposed for S1R in AD and related neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcOulohjzwbbVg90H21EOLACvtfcHk0liTsioAZOwSiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSiu7zM&md5=3fb7d4e21f964fa32d9d33733e59a39f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2017.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2017.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DStrehaiano%26aufirst%3DM.%26aulast%3DDuhr%26aufirst%3DF.%26aulast%3DChevallier%26aufirst%3DN.%26atitle%3DAmyloid%2520toxicity%2520is%2520enhanced%2520after%2520pharmacological%2520or%2520genetic%2520invalidation%2520of%2520the%2520sigma1%2520receptor%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2018%26volume%3D339%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.bbr.2017.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Waarde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybczynska, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsinga, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijholt, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luiten, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierckx, R. A.</span></span> <span> </span><span class="NLM_article-title">The cholinergic system, sigma-1 receptors and cognition</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>221</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2009.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbr.2009.12.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20060423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFClu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=221&publication_year=2011&pages=543-554&author=A.+van%0AWaardeauthor=N.+K.+Ramakrishnanauthor=A.+A.+Rybczynskaauthor=P.+H.+Elsingaauthor=K.+Ishiwataauthor=I.+M.+Nijholtauthor=P.+G.+Luitenauthor=R.+A.+Dierckx&title=The+cholinergic+system%2C+sigma-1+receptors+and+cognition&doi=10.1016%2Fj.bbr.2009.12.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The cholinergic system, sigma-1 receptors and cognition</span></div><div class="casAuthors">van Waarde, Aren; Ramakrishnan, Nisha K.; Rybczynska, Anna A.; Elsinga, Philip H.; Ishiwata, Kiichi; Nijholt, Ingrid M.; Luiten, Paul G. M.; Dierckx, Rudi A.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">221</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">543-554</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article provides an overview of present knowledge regarding the relationship between the cholinergic system and sigma-1 receptors, and discusses potential applications of sigma-1 receptor agonists in the treatment of memory deficits and cognitive disorders.  Sigma-1 receptors, initially considered as a subtype of the opioid family, are unique ligand-regulated mol. chaperones in the endoplasmatic reticulum playing a modulatory role in intracellular calcium signaling and in the activity of several neurotransmitter systems, particularly the cholinergic and glutamatergic pathways.  Several central nervous system (CNS) drugs show high to moderate affinities for sigma-1 receptors, including acetylcholinesterase inhibitors (donepezil), antipsychotics (haloperidol, rimcazole), selective serotonin reuptake inhibitors (fluvoxamine, sertraline) and monoamine oxidase inhibitors (clorgyline).  These compds. can influence cognitive functions both via their primary targets and by activating sigma-1 receptors in the CNS.  Sigma-1 agonists show powerful anti-amnesic and neuroprotective effects in a large variety of animal models of cognitive dysfunction involving, among others (i) pharmacol. target blockade (with muscarinic or NMDA receptor antagonists or p-chloroamphetamine); (ii) selective lesioning of cholinergic neurons; (iii) CNS administration of β-amyloid peptides; (iv) aging-induced memory loss, both in normal and senescent-accelerated rodents; (v) neurodegeneration induced by toxic compds. (CO, trimethyltin, cocaine), and (vi) prenatal restraint stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYOwSZZsWJLVg90H21EOLACvtfcHk0lj1PhP7cb5DlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFClu7Y%253D&md5=ef059d9c2c5efa713f80c7a280c379ad</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2009.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2009.12.043%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BWaarde%26aufirst%3DA.%26aulast%3DRamakrishnan%26aufirst%3DN.%2BK.%26aulast%3DRybczynska%26aufirst%3DA.%2BA.%26aulast%3DElsinga%26aufirst%3DP.%2BH.%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DNijholt%26aufirst%3DI.%2BM.%26aulast%3DLuiten%26aufirst%3DP.%2BG.%26aulast%3DDierckx%26aufirst%3DR.%2BA.%26atitle%3DThe%2520cholinergic%2520system%252C%2520sigma-1%2520receptors%2520and%2520cognition%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2011%26volume%3D221%26spage%3D543%26epage%3D554%26doi%3D10.1016%2Fj.bbr.2009.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.560837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1517%2F14728222.2011.560837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21375464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksV2mu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=557-577&author=T.+Hayashiauthor=S.+Y.+Tsaiauthor=T.+Moriauthor=M.+Fujimotoauthor=T.+P.+Su&title=Targeting+ligand-operated+chaperone+sigma-1+receptors+in+the+treatment+of+neuropsychiatric+disorders&doi=10.1517%2F14728222.2011.560837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders</span></div><div class="casAuthors">Hayashi, Teruo; Tsai, Shang-Yi; Mori, Tomohisa; Fujimoto, Michiko; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">557-577</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Current drugs for the treatment of psychiatric or neurodegenerative disorders have limitations.  Psychotherapeutic drugs such as typical and atypical antipsychotics, tricyclic antidepressants and selective monoamine reuptake inhibitors, aim to normalize the hyper- or hypo-neurotransmission of monoaminergic systems.  Despite their contribution to the outcomes of psychiatric patients, these agents often exert severe side effects and require chronic treatments to promote amelioration of symptoms.  Drugs available for the treatment of neurodegenerative disorders are severely limited.Areas covered: Recent evidence that has shed light on sigma-1 receptor ligands, which may serve as a new class of antidepressants or neuroprotective agents.  Sigma-1 receptors are novel ligand-operated mol. chaperones regulating signal transduction, ER stress, cellular redox, cellular survival and synaptogenesis.  Selective sigma-1 receptor ligands exert rapid antidepressant-like, anxiolytic, antinociceptive and robust neuroprotective actions in preclin. studies.  Recent studies that suggest that reactive oxygen species might play a role as signal integrators downstream of Sig-1Rs are also covered.Expert opinion: The advances in sigma receptor research in the last decade have begun to elucidate the intracellular signal cascades upstream and downstream of sigma-1 receptors.  The novel ligand-operated properties of the sigma-1 receptor chaperone may enable interventions by which stress-related cellular systems can be pharmacol. controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocF6RNqv-abLVg90H21EOLACvtfcHk0lj1PhP7cb5DlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksV2mu7s%253D&md5=ec71b2f1add05e37b3273b3070dfdb84</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.560837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.560837%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DTsai%26aufirst%3DS.%2BY.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DTargeting%2520ligand-operated%2520chaperone%2520sigma-1%2520receptors%2520in%2520the%2520treatment%2520of%2520neuropsychiatric%2520disorders%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D557%26epage%3D577%26doi%3D10.1517%2F14728222.2011.560837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, R.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>578</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.2006.116178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1113%2Fjphysiol.2006.116178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=17068104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1Smsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=578&publication_year=2007&pages=143-157&author=M.+Martinaauthor=M.+E.+Turcotteauthor=S.+Halmanauthor=R.+Bergeron&title=The+sigma-1+receptor+modulates+NMDA+receptor+synaptic+transmission+and+plasticity+via+SK+channels+in+rat+hippocampus&doi=10.1113%2Fjphysiol.2006.116178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus</span></div><div class="casAuthors">Martina Marzia; Turcotte Marie-Eve B; Halman Samantha; Bergeron Richard</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">578</span>
        (<span class="NLM_cas:issue">Pt 1</span>),
    <span class="NLM_cas:pages">143-57</span>
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">The sigma receptor (sigmaR), once considered a subtype of the opioid receptor, is now described as a distinct pharmacological entity.  Modulation of N-methyl-D-aspartate receptor (NMDAR) functions by sigmaR-1 ligands is well documented; however, its mechanism is not fully understood.  Using patch-clamp whole-cell recordings in CA1 pyramidal cells of rat hippocampus and (+)pentazocine, a high-affinity sigmaR-1 agonist, we found that sigmaR-1 activation potentiates NMDAR responses and long-term potentiation (LTP) by preventing a small conductance Ca2+-activated K+ current (SK channels), known to shunt NMDAR responses, to open.  Therefore, the block of SK channels and the resulting increased Ca2+ influx through the NMDAR enhances NMDAR responses and LTP.  These results emphasize the importance of the sigmaR-1 as postsynaptic regulator of synaptic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQu6zsw05NSA7YtC3U5jeOifW6udTcc2eZZZnKlj06j9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1Smsg%253D%253D&md5=a2add2be7909667c437f77bae985ea61</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2006.116178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2006.116178%26sid%3Dliteratum%253Aachs%26aulast%3DMartina%26aufirst%3DM.%26aulast%3DTurcotte%26aufirst%3DM.%2BE.%26aulast%3DHalman%26aufirst%3DS.%26aulast%3DBergeron%26aufirst%3DR.%26atitle%3DThe%2520sigma-1%2520receptor%2520modulates%2520NMDA%2520receptor%2520synaptic%2520transmission%2520and%2520plasticity%2520via%2520SK%2520channels%2520in%2520rat%2520hippocampus%26jtitle%3DJ.%2520Physiol.%26date%3D2007%26volume%3D578%26spage%3D143%26epage%3D157%26doi%3D10.1113%2Fjphysiol.2006.116178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pabba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlskog, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biscaro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassrallah, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngsee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beique, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, R.</span></span> <span> </span><span class="NLM_article-title">NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">11325</span>– <span class="NLM_lpage">11338</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0458-14.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1523%2FJNEUROSCI.0458-14.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25143613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=11325-11338&author=M.+Pabbaauthor=A.+Y.+Wongauthor=N.+Ahlskogauthor=E.+Hristovaauthor=D.+Biscaroauthor=W.+Nassrallahauthor=J.+K.+Ngseeauthor=M.+Snyderauthor=J.+C.+Beiqueauthor=R.+Bergeron&title=NMDA+receptors+are+upregulated+and+trafficked+to+the+plasma+membrane+after+sigma-1+receptor+activation+in+the+rat+hippocampus&doi=10.1523%2FJNEUROSCI.0458-14.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus</span></div><div class="casAuthors">Pabba, Mohan; Wong, Adrian Y. C.; Ahlskog, Nina; Hristova, Elitza; Biscaro, Dante; Nassrallah, Wissam; Ngsee, Johnny K.; Snyder, Melissa; Beique, Jean-Claude; Bergeron, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">11325-11338, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Sigma-1 receptors (σ-1Rs) are endoplasmic reticulum resident chaperone proteins implicated in many physiol. and pathol. processes in the CNS.  A striking feature of σ-1Rs is their ability to interact and modulate a large no. of voltage- and ligand-gated ion channels at the plasma membrane.  We have reported previously that agonists for σ-1Rs potentiate NMDA receptor (NMDAR) currents, although the mechanism by which this occurs is still unclear.  In this study, we show that in vivo administration of the selective σ-1R agonists (+)-SKF 10,047 [2S-(2α,6α,11R*]-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(2-propenyl)-2,6-methano-3-benzazocin-8-ol hydrochloride (N-allylnormetazocine) hydrochloride), PRE-084 (2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate hydrochloride), and (+)-pentazocine increases the expression of GluN2A and GluN2B subunits, as well as postsynaptic d. protein 95 in the rat hippocampus.  We also demonstrate that σ-1R activation leads to an increased interaction between GluN2 subunits and σ-1Rs and mediates trafficking of NMDARs to the cell surface.  These results suggest that σ-1R may play an important role in NMDAR-mediated functions, such as learning and memory.  It also opens new avenues for addnl. studies into a multitude of pathol. conditions in which NMDARs are involved, including schizophrenia, dementia, and stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHT-QqvmMZ-7Vg90H21EOLACvtfcHk0lir4cNHc4Qgjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjtb%252FO&md5=c12aab696738fe1960e39b098366cbe6</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0458-14.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0458-14.2014%26sid%3Dliteratum%253Aachs%26aulast%3DPabba%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DA.%2BY.%26aulast%3DAhlskog%26aufirst%3DN.%26aulast%3DHristova%26aufirst%3DE.%26aulast%3DBiscaro%26aufirst%3DD.%26aulast%3DNassrallah%26aufirst%3DW.%26aulast%3DNgsee%26aufirst%3DJ.%2BK.%26aulast%3DSnyder%26aufirst%3DM.%26aulast%3DBeique%26aufirst%3DJ.%2BC.%26aulast%3DBergeron%26aufirst%3DR.%26atitle%3DNMDA%2520receptors%2520are%2520upregulated%2520and%2520trafficked%2520to%2520the%2520plasma%2520membrane%2520after%2520sigma-1%2520receptor%2520activation%2520in%2520the%2520rat%2520hippocampus%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D11325%26epage%3D11338%26doi%3D10.1523%2FJNEUROSCI.0458-14.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herreman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Role of presenilins in neuronal calcium homeostasis</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">8566</span>– <span class="NLM_lpage">8580</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1554-10.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1523%2FJNEUROSCI.1554-10.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20573903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Knur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=8566-8580&author=H.+Zhangauthor=S.+Sunauthor=A.+Herremanauthor=B.+De+Strooperauthor=I.+Bezprozvanny&title=Role+of+presenilins+in+neuronal+calcium+homeostasis&doi=10.1523%2FJNEUROSCI.1554-10.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Role of presenilins in neuronal calcium homeostasis</span></div><div class="casAuthors">Zhang, Hua; Sun, Suya; Herreman, An; De Strooper, Bart; Bezprozvanny, Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">8566-8580</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder.  Familial AD (FAD) mutations in presenilins have been linked to calcium (Ca2+) signaling abnormalities.  To explain these results, we previously proposed that presenilins function as endoplasmic reticulum (ER) passive Ca2+ leak channels.  To directly investigate the role of presenilins in neuronal ER Ca2+ homeostasis, we here performed a series of Ca2+ imaging expts. with primary neuronal cultures from conditional presenilin double-knock-out mice (PS1dTAG/dTAG, PS2-/-) and from triple-transgenic AD mice (KI-PS1M146V, Thy1-APPKM670/671NL, Thy1-tauP301L).  Obtained results provided addnl. support to the hypothesis that presenilins function as ER Ca2+ leak channels in neurons.  Interestingly, we discovered that presenilins play a major role in ER Ca2+ leak function in hippocampal but not in striatal neurons.  We further discovered that, in hippocampal neurons, loss of presenilin-mediated ER Ca2+ leak function was compensated by an increase in expression and function of ryanodine receptors (RyanRs).  Long-term feeding of the RyanR inhibitor dantrolene to amyloid precursor protein-presenilin-1 mice (Thy1-APPKM670/671NL, Thy1-PS1L166P) resulted in an increased amyloid load, loss of synaptic markers, and neuronal atrophy in hippocampal and cortical regions.  These results indicate that disruption of ER Ca2+ leak function of presenilins may play an important role in AD pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcprlFcryprbVg90H21EOLACvtfcHk0lir4cNHc4Qgjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Knur0%253D&md5=35b43ca2c8664b2faf9beac06ac3991a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1554-10.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1554-10.2010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DHerreman%26aufirst%3DA.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DRole%2520of%2520presenilins%2520in%2520neuronal%2520calcium%2520homeostasis%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D8566%26epage%3D8580%26doi%3D10.1523%2FJNEUROSCI.1554-10.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beglopoulos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Hippocampal spatial memory impairments caused by the familial Alzheimer’s disease-linked presenilin 1 M146V mutation</span>. <i>Neurodegener. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1159/000086426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1159%2F000086426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16908998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFSns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=6-15&author=X.+Sunauthor=V.+Beglopoulosauthor=M.+P.+Mattsonauthor=J.+Shen&title=Hippocampal+spatial+memory+impairments+caused+by+the+familial+Alzheimer%E2%80%99s+disease-linked+presenilin+1+M146V+mutation&doi=10.1159%2F000086426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Hippocampal spatial memory impairments caused by the familial Alzheimer's disease-linked presenilin 1 M146V mutation</span></div><div class="casAuthors">Sun, Xiaoyan; Beglopoulos, Vassilios; Mattson, Mark P.; Shen, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-15</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Mutations in presenilins (PS) 1 and 2 are the major cause of familial Alzheimer's disease.  Conditional inactivation of PS1 in the mouse postnatal forebrain leads to mild deficits in spatial learning and memory, whereas inactivation of both PS1 and PS2 results in severe memory and synaptic plasticity impairments, followed by progressive and substantial neurodegeneration.  Here we investigate the effect of a familial Alzheimer's disease-linked PS1 missense mutation using knock-in (KI) mice, in which the wild-type PS1 allele is replaced with the M146V mutant allele.  In the Morris water maze task,PS1 KI mice at 3 mo of age exhibit reduced quadrant occupancy and platform crossing in the probe trial after 6 days of training, though their performance was normal in the probe trial after 12 days of training.  By the age of 9 mo, even after 12 days of training,PS1 homozygous KI mice still exhibit reduced platform crossing in the post-training probe trial.  ELISA anal. revealed a selective increase in cortical levels of β-amyloid 42 in PS1 KI mice, whereas prodn. of β-amyloid 40 was normal.  Histol. and quant. real-time RT-PCR analyses showed normal gross hippocampal morphol. and unaltered expression of three genes involved in inflammatory responses in PS1 KI mice.  These results show hippocampal spatial memory impairments caused by the PS1 M146V mutation and age-related deterioration of the memory impairment, suggesting that PS1 KI mice are a valuable model system for the study of memory loss in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1rkdLKmgaL7Vg90H21EOLACvtfcHk0lir4cNHc4Qgjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFSns7w%253D&md5=7980c416e696f59cd38da7184f7b8dbc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1159%2F000086426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000086426%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DBeglopoulos%26aufirst%3DV.%26aulast%3DMattson%26aufirst%3DM.%2BP.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DHippocampal%2520spatial%2520memory%2520impairments%2520caused%2520by%2520the%2520familial%2520Alzheimer%25E2%2580%2599s%2520disease-linked%2520presenilin%25201%2520M146V%2520mutation%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2005%26volume%3D2%26spage%3D6%26epage%3D15%26doi%3D10.1159%2F000086426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Ner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandeis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahum, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershonov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFerla, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, R.</span></span> <span> </span><span class="NLM_article-title">AF710B, a novel M1/sigma1 agonist with therapeutic efficacy in animal models of Alzheimer’s disease</span>. <i>Neurodegener. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1159/000440864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1159%2F000440864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=26606130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFSgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=95-110&author=A.+Fisherauthor=I.+Bezprozvannyauthor=L.+Wuauthor=D.+A.+Ryskampauthor=N.+Bar-Nerauthor=N.+Natanauthor=R.+Brandeisauthor=H.+Elkonauthor=V.+Nahumauthor=E.+Gershonovauthor=F.+M.+LaFerlaauthor=R.+Medeiros&title=AF710B%2C+a+novel+M1%2Fsigma1+agonist+with+therapeutic+efficacy+in+animal+models+of+Alzheimer%E2%80%99s+disease&doi=10.1159%2F000440864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease</span></div><div class="casAuthors">Fisher, Abraham; Bezprozvanny, Ilya; Wu, Lili; Ryskamp, Daniel A.; Bar-Ner, Nira; Natan, Niva; Brandeis, Rachel; Elkon, Hanoch; Nahum, Victoria; Gershonov, Eitan; La Ferla, Frank M.; Medeiros, Rodrigo</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">95-110</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and potential disease modifiers.  We now report on a novel compd., AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist.  AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concns. of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB).  AF710B (1-30 μg/kg, p.o.) was a potent and safe cognitive enhancer in rats treated with the M1 antagonist trihexyphenidyl (passive avoidance impairment).  These effects of AF710B involve σ1 receptor activation.  In agreement with its antiamnesic properties, AF710B (at 30 nM), via activation of M1 and a possible involvement of σ1 receptors, rescued mushroom synapse loss in PS1-KI and APP-KI neuronal cultures, while AF267B (1 μM) was less potent in PS1-KI and ineffective in APP-KI models, resp.  In female 3xTg-AD mice, AF710B (10 μg/kg, i.p./daily/2 mo) (i) mitigated cognitive impairments in the Morris water maze; (ii) decreased BACE1, GSK3β activity, p25/CDK5, neuroinflammation, sol. and insol. Aβ40, Aβ42, plaques and tau pathologies.  AF710B differs from conventional σ1 and M1 muscarinic (orthosteric, allosteric or bitopic) agonists.  These results highlight AF710B as a potential treatment for Alzheimer's disease (e.g. improving cognitive deficits, synaptic loss, amyloid and tau pathologies, and neuroinflammation) with a superior profile over a plethora of other therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTz3y9CSkTfbVg90H21EOLACvtfcHk0lir4cNHc4Qgjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFSgur4%253D&md5=f309d08291b52ef002413ad48eba1acc</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1159%2F000440864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000440864%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DA.%26aulast%3DBezprozvanny%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DRyskamp%26aufirst%3DD.%2BA.%26aulast%3DBar-Ner%26aufirst%3DN.%26aulast%3DNatan%26aufirst%3DN.%26aulast%3DBrandeis%26aufirst%3DR.%26aulast%3DElkon%26aufirst%3DH.%26aulast%3DNahum%26aufirst%3DV.%26aulast%3DGershonov%26aufirst%3DE.%26aulast%3DLaFerla%26aufirst%3DF.%2BM.%26aulast%3DMedeiros%26aufirst%3DR.%26atitle%3DAF710B%252C%2520a%2520novel%2520M1%252Fsigma1%2520agonist%2520with%2520therapeutic%2520efficacy%2520in%2520animal%2520models%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2016%26volume%3D16%26spage%3D95%26epage%3D110%26doi%3D10.1159%2F000440864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francardo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieloch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissbrandt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, M. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1998</span>– <span class="NLM_lpage">2014</span>, <span class="refDoi"> DOI: 10.1093/brain/awu107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1093%2Fbrain%2Fawu107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24755275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC2cnlslOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2014&pages=1998-2014&author=V.+Francardoauthor=F.+Bezauthor=T.+Wielochauthor=H.+Nissbrandtauthor=K.+Ruscherauthor=M.+A.+Cenci&title=Pharmacological+stimulation+of+sigma-1+receptors+has+neurorestorative+effects+in+experimental+parkinsonism&doi=10.1093%2Fbrain%2Fawu107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism</span></div><div class="casAuthors">Francardo Veronica; Bez Francesco; Cenci M Angela; Wieloch Tadeusz; Ruscher Karsten; Nissbrandt Hans</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">Pt 7</span>),
    <span class="NLM_cas:pages">1998-2014</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The sigma-1 receptor, an endoplasmic reticulum-associated molecular chaperone, is attracting great interest as a potential target for neuroprotective treatments.  We provide the first evidence that pharmacological modulation of this protein produces functional neurorestoration in experimental parkinsonism.  Mice with intrastriatal 6-hydroxydopamine lesions were treated daily with the selective sigma-1 receptor agonist, PRE-084, for 5 weeks.  At the dose of 0.3 mg/kg/day, PRE-084 produced a gradual and significant improvement of spontaneous forelimb use.  The behavioural recovery was paralleled by an increased density of dopaminergic fibres in the most denervated striatal regions, by a modest recovery of dopamine levels, and by an upregulation of neurotrophic factors (BDNF and GDNF) and their downstream effector pathways (extracellular signal regulated kinases 1/2 and Akt).  No treatment-induced behavioural-histological restoration occurred in sigma-1 receptor knockout mice subjected to 6-hydroxydopamine lesions and treated with PRE-084.  Immunoreactivity for the sigma-1 receptor protein was evident in both astrocytes and neurons in the substantia nigra and the striatum, and its intracellular distribution was modulated by PRE-084 (the treatment resulted in a wider intracellular distribution of the protein).  Our results suggest that sigma-1 receptor regulates endogenous defence and plasticity mechanisms in experimental parkinsonism.  Boosting the activity of this protein may have disease-modifying effects in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnve9PDTl05D0SWnHPWbmmfW6udTcc2eY-WLwDs0wfx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnlslOruw%253D%253D&md5=9beba8f569133d7d32a9c7c52f2ff533</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawu107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawu107%26sid%3Dliteratum%253Aachs%26aulast%3DFrancardo%26aufirst%3DV.%26aulast%3DBez%26aufirst%3DF.%26aulast%3DWieloch%26aufirst%3DT.%26aulast%3DNissbrandt%26aufirst%3DH.%26aulast%3DRuscher%26aufirst%3DK.%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DPharmacological%2520stimulation%2520of%2520sigma-1%2520receptors%2520has%2520neurorestorative%2520effects%2520in%2520experimental%2520parkinsonism%26jtitle%3DBrain%26date%3D2014%26volume%3D137%26spage%3D1998%26epage%3D2014%26doi%3D10.1093%2Fbrain%2Fawu107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakayori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, Y.</span></span> <span> </span><span class="NLM_article-title">Function of sigma1 receptors in Parkinson’s disease</span>. <i>Acta Neurol. Scand.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0404.2005.00432.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fj.1600-0404.2005.00432.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16008536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Crtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2005&pages=103-107&author=M.+Mishinaauthor=K.+Ishiwataauthor=K.+Ishiiauthor=S.+Kitamuraauthor=Y.+Kimuraauthor=K.+Kawamuraauthor=K.+Odaauthor=T.+Sasakiauthor=O.+Sakayoriauthor=M.+Hamamotoauthor=S.+Kobayashiauthor=Y.+Katayama&title=Function+of+sigma1+receptors+in+Parkinson%E2%80%99s+disease&doi=10.1111%2Fj.1600-0404.2005.00432.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Function of sigma1 receptors in Parkinson's disease</span></div><div class="casAuthors">Mishina, M.; Ishiwata, K.; Ishii, K.; Kitamura, S.; Kimura, Y.; Kawamura, K.; Oda, K.; Sasaki, T.; Sakayori, O.; Hamamoto, M.; Kobayashi, S.; Katayama, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neurologica Scandinavica</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-107</span>CODEN:
                <span class="NLM_cas:coden">ANRSAS</span>;
        ISSN:<span class="NLM_cas:issn">0001-6314</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Objective: The objective of this study was to investigate the mapping of sigma1 receptors in Parkinson's disease (PD) using [11C]SA4503 and positron emission tomog. (PET), and to assess whether sigma1 receptors are involved in the damaged dopaminergic system in PD patients.  Materials and methods: We studied seven normal volunteers and six PD patients.  The low d. of dopamine transporters and the normal or high d. of dopamine receptors were confirmed in the putamen of all patients using [11C]CFT and [11C]RAC PET.  A dynamic series of PET data acquisition was performed with arterial blood sampling.  We computed the binding potential (BP) of [11C]SA4503.  Results: In PD patients, the BP was significantly lower on the more affected than the less affected side of the anterior putamen, although there was no significant difference with respect to the BP between patients and controls.  Conclusions: Release of dopamine is reduced asym. in the putamen of early PD.  [11C]SA4503 PET is an indicator of presynaptic dopaminergic damage in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHGDd-UqykhrVg90H21EOLACvtfcHk0liyMH5IVflYoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Crtbc%253D&md5=674dec4286720f7d8dfc54d4d168d5ec</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0404.2005.00432.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0404.2005.00432.x%26sid%3Dliteratum%253Aachs%26aulast%3DMishina%26aufirst%3DM.%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DSakayori%26aufirst%3DO.%26aulast%3DHamamoto%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DY.%26atitle%3DFunction%2520of%2520sigma1%2520receptors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DActa%2520Neurol.%2520Scand.%26date%3D2005%26volume%3D112%26spage%3D103%26epage%3D107%26doi%3D10.1111%2Fj.1600-0404.2005.00432.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor knockout increases alpha-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2017.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neurobiolaging.2017.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28870519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2ltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2017&pages=171-183&author=J.+Hongauthor=L.+Wangauthor=T.+Zhangauthor=B.+Zhangauthor=L.+Chen&title=Sigma-1+receptor+knockout+increases+alpha-synuclein+aggregation+and+phosphorylation+with+loss+of+dopaminergic+neurons+in+substantia+nigra&doi=10.1016%2Fj.neurobiolaging.2017.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor knockout increases α-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra</span></div><div class="casAuthors">Hong, Juan; Wang, Ling; Zhang, Tingting; Zhang, Baofeng; Chen, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171-183</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sigma-1 receptor (σ1R) is expressed in dopaminergic neurons of substantia nigra.  Here, we show that σ1R knockout (σ1R-/-) mice, at age 6-12 mo, appeared with age-related loss of dopaminergic neurons and decline of motor coordination.  Levels of α-synuclein (αSyn) oligomers and fibrillar αSyn in substantia nigra of σ1R-/- mice were age-dependently increased without the changes in αSyn monomers.  The phosphorylation of αSyn monomers or oligomers in dopaminergic neurons was enhanced in σ1R-/- mice.  Levels of phosphorylated eIF2a and C/EBP homologous protein expression were elevated in σ1R-/- mice with decline of proteasome activity.  Inhibition of endoplasmic reticulum stress by salubrinal recovered the αSyn phosphorylation and proteasome activity and prevented early oligomerization of αSyn in σ1R-/- mice.  Rifampicin reduced the late increase of αSyn oligomers in σ1R-/- mice.  Rifampicin or salubrinal could reduce the loss of dopaminergic neurons in σ1R-/- mice and improved their motor coordination.  The results indicate that the σ1R deficiency through enhanced aggregation and phosphorylation of αSyn causes the loss of dopaminergic neurons leading to the decline of motor coordination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowE7N9mIPRP7Vg90H21EOLACvtfcHk0ljhh-QvRiQ15w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2ltLnL&md5=77edf6dab969d045ef7118ae85a600a3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2017.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2017.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSigma-1%2520receptor%2520knockout%2520increases%2520alpha-synuclein%2520aggregation%2520and%2520phosphorylation%2520with%2520loss%2520of%2520dopaminergic%2520neurons%2520in%2520substantia%2520nigra%26jtitle%3DNeurobiol.%2520Aging%26date%3D2017%26volume%3D59%26spage%3D171%26epage%3D183%26doi%3D10.1016%2Fj.neurobiolaging.2017.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Compromising sigma-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-kappaB/Bcl-2-dependent mechanism: potential relevance to Parkinson’s disease</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.190868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.111.190868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22399814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=663-671&author=T.+Moriauthor=T.+Hayashiauthor=T.+P.+Su&title=Compromising+sigma-1+receptors+at+the+endoplasmic+reticulum+render+cytotoxicity+to+physiologically+relevant+concentrations+of+dopamine+in+a+nuclear+factor-kappaB%2FBcl-2-dependent+mechanism%3A+potential+relevance+to+Parkinson%E2%80%99s+disease&doi=10.1124%2Fjpet.111.190868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Compromising σ-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-κB/Bcl-2-dependent mechanism: potential relevance to Parkinson's disease</span></div><div class="casAuthors">Mori, Tomohisa; Hayashi, Teruo; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">663-671</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The endoplasmic reticulum (ER) chaperone σ-1 receptor (Sig-1R) is cytoprotective against ER stress-induced apoptosis.  The level of Sig-1Rs in the brain was reported to be lower in early parkinsonian patients.  Because dopamine (DA) toxicity is well known to be involved in the etiol. of Parkinson's disease, we tested in this study whether a relationship might exist between Sig-1Rs and DA-induced cytotoxicity in a cellular model by using Chinese hamster ovary (CHO) cells.  DA in physiol. concns. (e.g., lower than 10 μM) does not cause apoptosis.  However, the same concns. of DA cause apoptosis in Sig-1R knockdown CHO cells.  In search of a mechanistic explanation, we found that unfolded protein response is not involved.  Rather, the level of protective protein Bcl-2 is critically involved in this DA/Sig-1R knockdown-induced apoptosis.  Specifically, the DA/Sig-1R knockdown causes a synergistic proteasomal conversion of nuclear factor κB (NF-κB) p105 to the active form of p50, which is known to down-regulate the transcription of Bcl-2.  It is noteworthy that the DA/Sig-1R knockdown-induced apoptosis is blocked by the overexpression of Bcl-2.  Our results therefore indicate that DA is involved in the activation of NF-κB and suggest that endogenous Sig-1Rs are tonically inhibiting the proteasomal conversion/activation of NF-κB caused by physiol. relevant concns. of DA that would otherwise cause apoptosis.  Thus, Sig-1Rs and assocd. ligands may represent new therapeutic targets for the treatment of parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsgrWkRvcZ7Vg90H21EOLACvtfcHk0ljhh-QvRiQ15w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWlt7c%253D&md5=dc5fe9352b05306ab0d736079f375c75</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.190868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.190868%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DCompromising%2520sigma-1%2520receptors%2520at%2520the%2520endoplasmic%2520reticulum%2520render%2520cytotoxicity%2520to%2520physiologically%2520relevant%2520concentrations%2520of%2520dopamine%2520in%2520a%2520nuclear%2520factor-kappaB%252FBcl-2-dependent%2520mechanism%253A%2520potential%2520relevance%2520to%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D663%26epage%3D671%26doi%3D10.1124%2Fjpet.111.190868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span> <span> </span><span class="NLM_article-title">Trends in sigma-1 receptor research: a 25-year bibliometric analysis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">564</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffphar.2019.00564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31178733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BB3M3kslejtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=564&author=L.+Romeroauthor=E.+Portillo-Salido&title=Trends+in+sigma-1+receptor+research%3A+a+25-year+bibliometric+analysis&doi=10.3389%2Ffphar.2019.00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in Sigma-1 Receptor Research: A 25-Year Bibliometric Analysis</span></div><div class="casAuthors">Romero Luz; Portillo-Salido Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">564</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Purpose: There are previous reviews focused on Sigma-1 receptor but no bibliometric studies examining this field as a whole.  This article aims to present a global view of Sigma-1 receptor research and its intellectual structure.  Methods: We used bibliometric indicators of a basic nature as well as techniques for the visualization and analysis of networks of scientific information extracted from Scopus database.  Results: In total, 1,102 articles from 1992 to 2017 were identified.  The growth in the production of articles is not constant over time, with periods of stagnation of approximately 5 years.  Only 247 authors have five or more publications.  The authors appear grouped in relatively independent clusters, thus suggesting a low level of collaborations between those dedicated to the Sigma-1 receptor.  The United States was the country with the highest production followed by Japan and Germany.  Spain, Japan, and Italy showed the highest per million inhabitants ratio.  The highest citation/article ratio was reached in France, United States, and Canada.  The leading institutions were the University of Munster, the National Institutes of Health, ESTEVE, and INSERM.  The top authors in number of publications were Wunsch-B, Schepmann-D, and Maurice-T.  Hayashi-T, Su-TP and Bowen-WD showed the highest citations per article.  The article by Hayashi-T and Su-TP in Cell (2007) describing the Sigma-1 receptor as a chaperone protein is the top cited reference.  Cluster labeling from author co-citation analysis shows that research has been focused on specific diseases such as addiction, neuroprotection and neurodegenerative diseases, psychiatric disorders, and pain.  High-frequency terms in author keywords suggest that the research efforts in some areas such as neuroimaging, cocaine addiction or psychiatric disorders have declined over time, while others such as neurodegenerative diseases or pain are currently most popular.  Perspective: A greater involvement of the scientific community, with an increase in the scientific production related to Sigma-1, is desirable.  Additional boost needed to improve research performance is likely to come from combining data from different laboratories to overcome the limitations of individual approaches.  The resulting maps are a useful and attractive tool for the Sigma-1 receptor research community, as they reveal the main lines of exploration at a glance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX1yhwJRUF1Ptos8R3JUhXfW6udTcc2eaAKCBTjIIXSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3kslejtw%253D%253D&md5=d8094c2a7c2f0fb53d0ca183e59fc059</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00564%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26atitle%3DTrends%2520in%2520sigma-1%2520receptor%2520research%253A%2520a%252025-year%2520bibliometric%2520analysis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D564%26doi%3D10.3389%2Ffphar.2019.00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugarolas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguinaga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e61245</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0061245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1371%2Fjournal.pone.0061245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23637801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=G.+Navarroauthor=E.+Morenoauthor=J.+Bonaventuraauthor=M.+Brugarolasauthor=D.+Farreauthor=D.+Aguinagaauthor=J.+Mallolauthor=A.+Cortesauthor=V.+Casadoauthor=C.+Lluisauthor=S.+Ferreauthor=R.+Francoauthor=E.+Canelaauthor=P.+J.+McCormick&title=Cocaine+inhibits+dopamine+D2+receptor+signaling+via+sigma-1-D2+receptor+heteromers&doi=10.1371%2Fjournal.pone.0061245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers</span></div><div class="casAuthors">Navarro, Gemma; Moreno, Estefania; Bonaventura, Jordi; Brugarolas, Marc; Farre, Daniel; Aguinaga, David; Mallol, Josefa; Cortes, Antoni; Casado, Vicent; Lluis, Carmen; Ferre, Sergi; Franco, Rafael; Canela, Enric; McCormick, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e61245</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Under normal conditions the brain maintains a delicate balance between inputs of reward seeking controlled by neurons contg. the D1-like family of dopamine receptors and inputs of aversion coming from neurons contg. the D2-like family of dopamine receptors.  Cocaine is able to subvert these balanced inputs by altering the cell signaling of these two pathways such that D1 reward seeking pathway dominates.  Here, we provide an explanation at the cellular and biochem. level how cocaine may achieve this.  Exploring the effect of cocaine on dopamine D2 receptors function, we present evidence of σ1 receptor mol. and functional interaction with dopamine D2 receptors.  Using biophys., biochem. and cell biol. approaches, we discovered that D2 receptors (the long isoform of the D2 receptor) can complex with σ1 receptors, a result that is specific to D2 receptors, as D3 and D4 receptors did not form heteromers.  We demonstrate that the σ1-D2 receptor heteromers consist of higher order oligomers, are found in mouse striatum and that cocaine, by binding to σ1-D2 receptor heteromers, inhibits downstream signaling in both cultured cells and in mouse striatum.  In contrast, in striatum from σ1 knockout animals these complexes are not found and this inhibition is not seen.  Taken together, these data illuminate the mechanism by which the initial exposure to cocaine can inhibit signaling via D2 receptor contg. neurons, destabilizing the delicate signaling balance influencing drug seeking that emanates from the D1 and D2 receptor contg. neurons in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR4PjTJlFvzLVg90H21EOLACvtfcHk0li7dH0NuqG_CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFaqs7g%253D&md5=61bcdce4f07ad8dc8582c3d1b692359d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0061245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0061245%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DBonaventura%26aufirst%3DJ.%26aulast%3DBrugarolas%26aufirst%3DM.%26aulast%3DFarre%26aufirst%3DD.%26aulast%3DAguinaga%26aufirst%3DD.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DCasado%26aufirst%3DV.%26aulast%3DLluis%26aufirst%3DC.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DCanela%26aufirst%3DE.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DCocaine%2520inhibits%2520dopamine%2520D2%2520receptor%2520signaling%2520via%2520sigma-1-D2%2520receptor%2520heteromers%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0061245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Delgado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell-Vilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medrano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine disrupts histamine H<sub>3</sub> receptor modulation of dopamine D<sub>1</sub> receptor signaling: sigma1-D<sub>1</sub>-H<sub>3</sub> receptor complexes as key targets for reducing cocaine’s effects</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3545</span>– <span class="NLM_lpage">3558</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4147-13.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1523%2FJNEUROSCI.4147-13.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24599455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1ajtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=3545-3558&author=E.+Morenoauthor=D.+Moreno-Delgadoauthor=G.+Navarroauthor=H.+M.+Hoffmannauthor=S.+Fuentesauthor=S.+Rosell-Vilarauthor=P.+Gasperiniauthor=M.+Rodriguez-Ruizauthor=M.+Medranoauthor=J.+Mallolauthor=A.+Cortesauthor=V.+Casadoauthor=C.+Lluisauthor=S.+Ferreauthor=J.+Ortizauthor=E.+Canelaauthor=P.+J.+McCormick&title=Cocaine+disrupts+histamine+H3+receptor+modulation+of+dopamine+D1+receptor+signaling%3A+sigma1-D1-H3+receptor+complexes+as+key+targets+for+reducing+cocaine%E2%80%99s+effects&doi=10.1523%2FJNEUROSCI.4147-13.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine's effects</span></div><div class="casAuthors">Moreno, Estefania; Moreno-Delgado, David; Navarro, Gemma; Hoffmann, Hanne M.; Fuentes, Silvia; Rosell-Vilar, Santi; Gasperini, Paola; Rodriguez-Ruiz, Mar; Medrano, Mireia; Mallol, Josefa; Cortes, Antoni; Casado, Vicent; Lluis, Carme; Ferre, Sergi; Ortiz, Jordi; Canela, Enric; McCormick, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3545-3558</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The general effects of cocaine are not well understood at the mol. level.  What is known is that the dopamine D1 receptor plays an important role.  Here we show that a key mechanism may be cocaine's blockade of the histamine H3 receptor-mediated inhibition of D1 receptor function.  This blockade requires the σ1 receptor and occurs upon cocaine binding to σ1-D1-H3 receptor complexes.  The cocaine-mediated disruption leaves an uninhibited D1 receptor that activates Gs, freely recruits β-arrestin, increases p-ERK 1/2 levels, and induces cell death when over activated.  Using in vitro assays with transfected cells and in ex vivo expts. using both rats acutely treated or self-administered with cocaine along with mice depleted of σ1 receptor, we show that blockade of σ1 receptor by an antagonist restores the protective H3 receptor-mediated brake on D1 receptor signaling and prevents the cell death from elevated D1 receptor signaling.  These findings suggest that a combination therapy of σ1R antagonists with H3 receptor agonists could serve to reduce some effects of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ARavI4E7T7Vg90H21EOLACvtfcHk0li7dH0NuqG_CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1ajtrc%253D&md5=6aea1fdccecd4373e3a36ecea9e5d9dd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4147-13.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4147-13.2014%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DMoreno-Delgado%26aufirst%3DD.%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DH.%2BM.%26aulast%3DFuentes%26aufirst%3DS.%26aulast%3DRosell-Vilar%26aufirst%3DS.%26aulast%3DGasperini%26aufirst%3DP.%26aulast%3DRodriguez-Ruiz%26aufirst%3DM.%26aulast%3DMedrano%26aufirst%3DM.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DCasado%26aufirst%3DV.%26aulast%3DLluis%26aufirst%3DC.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DOrtiz%26aufirst%3DJ.%26aulast%3DCanela%26aufirst%3DE.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DCocaine%2520disrupts%2520histamine%2520H3%2520receptor%2520modulation%2520of%2520dopamine%2520D1%2520receptor%2520signaling%253A%2520sigma1-D1-H3%2520receptor%2520complexes%2520as%2520key%2520targets%2520for%2520reducing%2520cocaine%25E2%2580%2599s%2520effects%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D3545%26epage%3D3558%26doi%3D10.1523%2FJNEUROSCI.4147-13.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbny, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaitoun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziskind-Conhaim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Lack of sigma-1 receptor exacerbates ALS progression in mice</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2013.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuroscience.2013.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23458708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=2013&pages=129-134&author=T.+A.+Mavlyutovauthor=M.+L.+Epsteinauthor=Y.+I.+Verbnyauthor=M.+S.+Huertaauthor=I.+Zaitounauthor=L.+Ziskind-Conhaimauthor=A.+E.+Ruoho&title=Lack+of+sigma-1+receptor+exacerbates+ALS+progression+in+mice&doi=10.1016%2Fj.neuroscience.2013.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of sigma-1 receptor exacerbates ALS progression in mice</span></div><div class="casAuthors">Mavlyutov, T. A.; Epstein, M. L.; Verbny, Y. I.; Huerta, M. S.; Zaitoun, I.; Ziskind-Conhaim, L.; Ruoho, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-134</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The function of the sigma-1 receptor (S1R) has been implicated in modulating the activity of various ion channels.  In the CNS S1R is enriched in cholinergic postsynaptic densities in spinal cord motoneurons (MNs).  Mutations in S1R have been found in familial cases of amyotrophic lateral sclerosis (ALS).  In this study we show that a knockout of S1R in the SOD1*G93A mouse model of ALS significantly reduces longevity (end stage).  Electrophysiol. expts. demonstrate that MN of mice lacking S1R exhibit increased excitability.  Taken together the data suggest the S1R acts as a brake on excitability, an effect that might enhance longevity in an ALS mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdrWA4qm3FVLVg90H21EOLACvtfcHk0li7dH0NuqG_CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCrsLs%253D&md5=dfeed9f2618149f5976306e84dd09602</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2013.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2013.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DMavlyutov%26aufirst%3DT.%2BA.%26aulast%3DEpstein%26aufirst%3DM.%2BL.%26aulast%3DVerbny%26aufirst%3DY.%2BI.%26aulast%3DHuerta%26aufirst%3DM.%2BS.%26aulast%3DZaitoun%26aufirst%3DI.%26aulast%3DZiskind-Conhaim%26aufirst%3DL.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DLack%2520of%2520sigma-1%2520receptor%2520exacerbates%2520ALS%2520progression%2520in%2520mice%26jtitle%3DNeuroscience%26date%3D2013%26volume%3D240%26spage%3D129%26epage%3D134%26doi%3D10.1016%2Fj.neuroscience.2013.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luty, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson-Stone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loy, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coupland, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlstrom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchorzewska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruszak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcikowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panegyres, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zekanowski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span> <span> </span><span class="NLM_article-title">Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1002/ana.22274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fana.22274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21031579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOnsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2010&pages=639-649&author=A.+A.+Lutyauthor=J.+B.+Kwokauthor=C.+Dobson-Stoneauthor=C.+T.+Loyauthor=K.+G.+Couplandauthor=H.+Karlstromauthor=T.+Sobowauthor=J.+Tchorzewskaauthor=A.+Maruszakauthor=M.+Barcikowskaauthor=P.+K.+Panegyresauthor=C.+Zekanowskiauthor=W.+S.+Brooksauthor=K.+L.+Williamsauthor=I.+P.+Blairauthor=K.+A.+Matherauthor=P.+S.+Sachdevauthor=G.+M.+Hallidayauthor=P.+R.+Schofield&title=Sigma+nonopioid+intracellular+receptor+1+mutations+cause+frontotemporal+lobar+degeneration-motor+neuron+disease&doi=10.1002%2Fana.22274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease</span></div><div class="casAuthors">Luty, Agnes A.; Kwok, John B. J.; Dobson-Stone, Carol; Loy, Clement T.; Coupland, Kirsten G.; Karlstrom, Helena; Sobow, Tomasz; Tchorzewska, Joanna; Maruszak, Aleksandra; Barcikowska, Maria; Panegyres, Peter K.; Zekanowski, Cezary; Brooks, William S.; Williams, Kelly L.; Blair, Ian P.; Mather, Karen A.; Sachdev, Perminder S.; Halliday, Glenda M.; Schofield, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-649</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Frontotemporal lobar degeneration (FTLD) is the most common cause of early-onset dementia.  Pathol. ubiquitinated inclusion bodies obsd. in FTLD and motor neuron disease (MND) comprise transactivating response element (TAR) DNA binding protein (TDP-43) and/or fused in sarcoma (FUS) protein.  Our objective was to identify the causative gene in an FTLD-MND pedigree with no mutations in known dementia genes.  Methods: A mutation screen of candidate genes, luciferase assays, and quant. polymerase chain reaction (PCR) was performed to identify the biol. role of the putative mutation.  Neuropathol. characterization of affected individuals and western blot studies of cell lines were performed to identify the pathol. mechanism of the mutation.  Results: We identified a nonpolymorphic mutation (c.672*51G>T) in the 3'-untranslated region (UTR) of the Sigma nonopioid intracellular receptor 1 (SIGMAR1) gene in affected individuals from the FTLD-MND pedigree.  The c.672*51G>T mutation increased gene expression by 1.4-fold, corresponding with a significant 1.5-fold to 2-fold change in the SIGMAR1 transcript or Sigma-1 protein in lymphocyte or brain tissue.  Brains of SIGMAR1 mutation carriers displayed a unique pathol. with cytoplasmic inclusions immunopos. for either TDP-43 or FUS but not Sigma-1.  Overexpression of SIGMAR1 shunted TDP-43 and FUS from the nucleus to the cytoplasm by 2.3-fold and 5.2-fold, resp.  Treatment of cells with Sigma-1 ligands significantly altered translocation of TDP-43 by up to 2-fold.  Interpretation: SIGMAR1 is a causative gene for familial FTLD-MND with a unique neuropathol. that differs from other FTLD and MND cases.  Our findings also suggest Sigma-1 drugs as potential treatments for the TDP-43/FUS proteinopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLlsN4nYXas7Vg90H21EOLACvtfcHk0lhsbyCakOs1sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOnsrbM&md5=910ad11aa17d829a5d241efd932e96a6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fana.22274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22274%26sid%3Dliteratum%253Aachs%26aulast%3DLuty%26aufirst%3DA.%2BA.%26aulast%3DKwok%26aufirst%3DJ.%2BB.%26aulast%3DDobson-Stone%26aufirst%3DC.%26aulast%3DLoy%26aufirst%3DC.%2BT.%26aulast%3DCoupland%26aufirst%3DK.%2BG.%26aulast%3DKarlstrom%26aufirst%3DH.%26aulast%3DSobow%26aufirst%3DT.%26aulast%3DTchorzewska%26aufirst%3DJ.%26aulast%3DMaruszak%26aufirst%3DA.%26aulast%3DBarcikowska%26aufirst%3DM.%26aulast%3DPanegyres%26aufirst%3DP.%2BK.%26aulast%3DZekanowski%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DW.%2BS.%26aulast%3DWilliams%26aufirst%3DK.%2BL.%26aulast%3DBlair%26aufirst%3DI.%2BP.%26aulast%3DMather%26aufirst%3DK.%2BA.%26aulast%3DSachdev%26aufirst%3DP.%2BS.%26aulast%3DHalliday%26aufirst%3DG.%2BM.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26atitle%3DSigma%2520nonopioid%2520intracellular%2520receptor%25201%2520mutations%2520cause%2520frontotemporal%2520lobar%2520degeneration-motor%2520neuron%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2010%26volume%3D68%26spage%3D639%26epage%3D649%26doi%3D10.1002%2Fana.22274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Saif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mohanna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlega, S.</span></span> <span> </span><span class="NLM_article-title">A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1002/ana.22534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fana.22534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21842496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1CqurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=913-919&author=A.+Al-Saifauthor=F.+Al-Mohannaauthor=S.+Bohlega&title=A+mutation+in+sigma-1+receptor+causes+juvenile+amyotrophic+lateral+sclerosis&doi=10.1002%2Fana.22534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis</span></div><div class="casAuthors">Al-Saif, Amr; Al-Mohanna, Futwan; Bohlega, Saeed</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">913-919</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by loss of motor neurons in the brain and spinal cord, leading to muscle weakness and eventually death from respiratory failure.  ALS is familial in about 10% of cases, with SOD1 mutations accounting for 20% of familial cases.  Here we describe a consanguineous family segregating juvenile ALS in an autosomal recessive pattern and describe the genetic variant responsible for the disorder.  Methods: We performed homozygosity mapping and direct sequencing to detect the genetic variant and tested the effect of this variant on a motor neuron-like cell line model (NSC34) expressing the wild-type or mutant gene.  Results: We identified a shared homozygosity region in affected individuals that spans ∼120kbp on chromosome 9p13.3 contg. 9 RefSeq genes.  Sequencing the SIGMAR1 gene revealed a mutation affecting a highly conserved amino acid located in the transmembrane domain of the encoded protein, sigma-1 receptor.  The mutated protein showed an aberrant subcellular distribution in NSC34 cells.  Furthermore, cells expressing the mutant protein were less resistant to apoptosis induced by endoplasmic reticulum stress.  Interpretation: Sigma-1 receptors are known to have neuroprotective properties, and recently Sigmar1 knockout mice have been described to have motor deficiency.  Our findings emphasize the role of sigma-1 receptors in motor neuron function and disease.  ANN NEUROL 2011;.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBYWm6mJA60LVg90H21EOLACvtfcHk0lhsbyCakOs1sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1CqurfI&md5=ca3b6746092861e44b37088f3c4f86ea</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fana.22534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22534%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Saif%26aufirst%3DA.%26aulast%3DAl-Mohanna%26aufirst%3DF.%26aulast%3DBohlega%26aufirst%3DS.%26atitle%3DA%2520mutation%2520in%2520sigma-1%2520receptor%2520causes%2520juvenile%2520amyotrophic%2520lateral%2520sclerosis%26jtitle%3DAnn.%2520Neurol.%26date%3D2011%26volume%3D70%26spage%3D913%26epage%3D919%26doi%3D10.1002%2Fana.22534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prause, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnizler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushuven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchkremer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troost, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, J.</span></span> <span> </span><span class="NLM_article-title">Altered localization, abnormal modification and loss of function of sigma receptor-1 in amyotrophic lateral sclerosis</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1581</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddt008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1093%2Fhmg%2Fddt008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23314020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFWhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1581-1600&author=J.+Prauseauthor=A.+Goswamiauthor=I.+Katonaauthor=A.+Roosauthor=M.+Schnizlerauthor=E.+Bushuvenauthor=A.+Dreierauthor=S.+Buchkremerauthor=S.+Johannauthor=C.+Beyerauthor=M.+Deschauerauthor=D.+Troostauthor=J.+Weis&title=Altered+localization%2C+abnormal+modification+and+loss+of+function+of+sigma+receptor-1+in+amyotrophic+lateral+sclerosis&doi=10.1093%2Fhmg%2Fddt008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Altered localization, abnormal modification and loss of function of Sigma receptor-1 in amyotrophic lateral sclerosis</span></div><div class="casAuthors">Prause, J.; Goswami, A.; Katona, I.; Roos, A.; Schnizler, M.; Bushuven, E.; Dreier, A.; Buchkremer, S.; Johann, S.; Beyer, C.; Deschauer, M.; Troost, D.; Weis, J.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1581-1600</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Intracellular accumulations of mutant, misfolded proteins are major pathol. hallmarks of amyotrophic lateral sclerosis (ALS) and related disorders.  Recently, mutations in Sigma receptor 1 (SigR1) have been found to cause a form of ALS and frontotemporal lobar degeneration (FTLD).  Our goal was to pinpoint alterations and modifications of SigR1 in ALS and to det. how these changes contribute to the pathogenesis of ALS.  In the present study, we found that levels of the SigR1 protein were reduced in lumbar ALS patient spinal cord.  SigR1 was abnormally accumulated in enlarged C-terminals and endoplasmic reticulum (ER) structures of alpha motor neurons.  These accumulations co-localized with the 20s proteasome subunit.  SigR1 accumulations were also obsd. in SOD1 transgenic mice, cultured ALS-8 patient's fibroblasts with the P56S-VAPB mutation and in neuronal cell culture models.  Along with the accumulation of SigR1 and several other proteins involved in protein quality control, severe disturbances in the unfolded protein response and impairment of protein degrdn. pathways were detected in the above-mentioned cell culture systems.  Furthermore, shRNA knockdown of SigR1 lead to deranged calcium signaling and caused abnormalities in ER and Golgi structures in cultured NSC-34 cells.  Finally, pharmacol. activation of SigR1 induced the clearance of mutant protein aggregates in these cells.  Our results support the notion that SigR1 is abnormally modified and contributes to the pathogenesis of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCFL_fGrhAaLVg90H21EOLACvtfcHk0lhsbyCakOs1sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFWhs7g%253D&md5=92be0eece152502d0d2e1c708eead883</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddt008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddt008%26sid%3Dliteratum%253Aachs%26aulast%3DPrause%26aufirst%3DJ.%26aulast%3DGoswami%26aufirst%3DA.%26aulast%3DKatona%26aufirst%3DI.%26aulast%3DRoos%26aufirst%3DA.%26aulast%3DSchnizler%26aufirst%3DM.%26aulast%3DBushuven%26aufirst%3DE.%26aulast%3DDreier%26aufirst%3DA.%26aulast%3DBuchkremer%26aufirst%3DS.%26aulast%3DJohann%26aufirst%3DS.%26aulast%3DBeyer%26aufirst%3DC.%26aulast%3DDeschauer%26aufirst%3DM.%26aulast%3DTroost%26aufirst%3DD.%26aulast%3DWeis%26aufirst%3DJ.%26atitle%3DAltered%2520localization%252C%2520abnormal%2520modification%2520and%2520loss%2520of%2520function%2520of%2520sigma%2520receptor-1%2520in%2520amyotrophic%2520lateral%2520sclerosis%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2013%26volume%3D22%26spage%3D1581%26epage%3D1600%26doi%3D10.1093%2Fhmg%2Fddt008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Role of the sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS)</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.jphs.2014.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jphs.2014.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25704013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislaksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=10-16&author=T.+A.+Mavlyutovauthor=L.+W.+Guoauthor=M.+L.+Epsteinauthor=A.+E.+Ruoho&title=Role+of+the+sigma-1+receptor+in+Amyotrophic+Lateral+Sclerosis+%28ALS%29&doi=10.1016%2Fj.jphs.2014.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS)</span></div><div class="casAuthors">Mavlyutov, Timur A.; Guo, Lian-Wang; Epstein, Miles L.; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-16</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease affecting spinal cord motoneurons (MN) with an associative connection to Frontotemporal Lobar Dementia (FTLD).  The endoplasmic reticulum (ER) bound Sigma-1 Receptor (S1R) chaperone protein localizes to specialized ER cisternae within 10 nm of the plasma membrane in spinal cord ventral horn cholinergic post synaptic C-terminals.  Removal of the S1R gene in the Superoxide Dismutase-1 (SOD-1) mouse model of ALS exacerbated the neurodegenerative condition and resulted in a significantly reduced longevity when compared to the SOD-1/S1R wild type (WT) mouse.  The proposed amelioration of the ALS phenotype by the S1R is likely due to a "brake" on excitation of the MN as evidenced by a redn. in action potential generation in the MN of the WT when compared to the S1R KO mouse MN.  Although the precise signal transduction pathway(s) regulated by the S1R in the MN has/have not been elucidated at present, it is likely that direct or indirect functional interactions occur between the S1R in the ER cisternae with voltage gated potassium channels and/or with muscarinic M2 receptor signaling in the post synaptic plasma membrane.  Possible mechanisms for regulation of MN excitability by S1R are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbysHgXVhmt7Vg90H21EOLACvtfcHk0ljYhjpeFlW32w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislaksbs%253D&md5=cd83eb6b7497ce9049cb1a85e75fe744</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.jphs.2014.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jphs.2014.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DMavlyutov%26aufirst%3DT.%2BA.%26aulast%3DGuo%26aufirst%3DL.%2BW.%26aulast%3DEpstein%26aufirst%3DM.%2BL.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DRole%2520of%2520the%2520sigma-1%2520receptor%2520in%2520Amyotrophic%2520Lateral%2520Sclerosis%2520%2528ALS%2529%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D127%26spage%3D10%26epage%3D16%26doi%3D10.1016%2Fj.jphs.2014.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Lenis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, C.</span></span> <span> </span><span class="NLM_article-title">Selective sigma receptor agonist 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2009.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuroscience.2009.03.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19345724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvFymu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2009&pages=31-38&author=M.+S.+Guzman-Lenisauthor=X.+Navarroauthor=C.+Casas&title=Selective+sigma+receptor+agonist+2-%284-morpholinethyl%291-phenylcyclohexanecarboxylate+%28PRE084%29+promotes+neuroprotection+and+neurite+elongation+through+protein+kinase+C+%28PKC%29+signaling+on+motoneurons&doi=10.1016%2Fj.neuroscience.2009.03.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Selective sigma receptor agonist 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons</span></div><div class="casAuthors">Guzman-Lenis, M.-S.; Navarro, X.; Casas, C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-38</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neuronal loss and interruption of axonal pathways occur after spinal cord injury.  This is initiated by the mech. damage and propagated by secondary events that include the fast rise of glutamate concn. and the subsequent over-activation of glutamate receptors, triggering noxious processes to the cell.  Excitotoxic processes are also obsd. in degenerative diseases that involve motoneuron loss.  Sigma-1 receptors (Sig-1Rs) are expressed in the CNS and their ligands have been shown to prevent neuronal death assocd. to glutamate toxicity.  In the present study, we used organotypic cultures of spinal cord slices and dorsal root ganglia (DRG) explants from 7-8 days old postnatal rats to assess whether the agonist of the Sig-1R, 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084), protects the spinal cord against glutamate excitotoxicity and promotes neurite elongation.  The results showed that PRE084 exerted a bell-shape dose-dependent protective response of the motoneurons, with a significant neuroprotection obtained with 10 μM PRE084.  PRE084 also caused an increase in the length of neurites in both motoneurons and neurons in DRG explants.  Both effects were abrogated with the addn. of BD 1063, an antagonist of Sig-1R, and the use of chelerythrine, a protein kinase C (PKC) pan-inhibitor indicating that PKC is implicated in the obsd. effects.  These results suggest the use of PRE084 as a neuroprotective agent for spinal cord damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps_4sw8EYDA7Vg90H21EOLACvtfcHk0ljYhjpeFlW32w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvFymu7w%253D&md5=aab657c16e7163f8c5e344765a2c00d8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2009.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2009.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DGuzman-Lenis%26aufirst%3DM.%2BS.%26aulast%3DNavarro%26aufirst%3DX.%26aulast%3DCasas%26aufirst%3DC.%26atitle%3DSelective%2520sigma%2520receptor%2520agonist%25202-%25284-morpholinethyl%25291-phenylcyclohexanecarboxylate%2520%2528PRE084%2529%2520promotes%2520neuroprotection%2520and%2520neurite%2520elongation%2520through%2520protein%2520kinase%2520C%2520%2528PKC%2529%2520signaling%2520on%2520motoneurons%26jtitle%3DNeuroscience%26date%3D2009%26volume%3D162%26spage%3D31%26epage%3D38%26doi%3D10.1016%2Fj.neuroscience.2009.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual-Font, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fores, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor agonist 2-(4-morpholinethyl)1 phenylcyclohexanecarboxylate (PRE084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury</span>. <i>J. Neurotrauma</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1089/neu.2010.1674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1089%2Fneu.2010.1674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21332255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC3MvpvVegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=831-840&author=C.+Penasauthor=A.+Pascual-Fontauthor=R.+Mancusoauthor=J.+Foresauthor=C.+Casasauthor=X.+Navarro&title=Sigma+receptor+agonist+2-%284-morpholinethyl%291+phenylcyclohexanecarboxylate+%28PRE084%29+increases+GDNF+and+BiP+expression+and+promotes+neuroprotection+after+root+avulsion+injury&doi=10.1089%2Fneu.2010.1674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptor agonist 2-(4-morpholinethyl)1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury</span></div><div class="casAuthors">Penas Clara; Pascual-Font Aran; Mancuso Renzo; Fores Joaquim; Casas Caty; Navarro Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurotrauma</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">831-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spinal root avulsion leads to a progressive loss of axotomized motoneurons (MNs).  Nowadays, there is no effective treatment to prolong MN survival that could permit recovery as a result of delayed surgical repair.  Administration of Sigma-1 receptor (Sig-1R) ligands has been reported to promote beneficial effects after several types of neural injury.  In order to shed light of whether Sig-1R ligands could promote MN survival after root avulsion, L4-L5 spinal roots were unilaterally avulsed in adult rats and the Sig-1R agonist Pre084 was administered at different doses.  The ventral spinal cords of the animals were studied from 3 to 21 days post-operation (DPO) by using histological, immunohistochemical, and Western blot techniques.  Daily treatment with 0.25 mg/kg Pre084 significantly promoted MN survival (68% vs 43% in untreated rats) at 21 DPO, an effect that was antagonized by coadministration of BD1063, an antagonist of Sig-1R.  There was a reduction in astroglial- associated immunoreactivity in rats treated with Pre084.  Moreover, Pre084 produced an increase in the Sig-1R co-chaperone BiP within MNs, and an increase of GDNF expression by astrocytes in the ventral horn early after injury.  Although the mechanisms promoting MN survival by Pre084 remain unclear, we hypothesize that it is mediated at least in part through the increase in these cytoprotective factors.  Therefore, early application of Sig-1R agonist appears to be a promising therapy to improve MN survival after root avulsion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZdy7tFHm5d8NIRw0GKUoEfW6udTcc2eZEQySGlyOFt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvpvVegsQ%253D%253D&md5=b437f44edb0c64ca843031cf3d864ab6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1089%2Fneu.2010.1674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fneu.2010.1674%26sid%3Dliteratum%253Aachs%26aulast%3DPenas%26aufirst%3DC.%26aulast%3DPascual-Font%26aufirst%3DA.%26aulast%3DMancuso%26aufirst%3DR.%26aulast%3DFores%26aufirst%3DJ.%26aulast%3DCasas%26aufirst%3DC.%26aulast%3DNavarro%26aufirst%3DX.%26atitle%3DSigma%2520receptor%2520agonist%25202-%25284-morpholinethyl%25291%2520phenylcyclohexanecarboxylate%2520%2528PRE084%2529%2520increases%2520GDNF%2520and%2520BiP%2520expression%2520and%2520promotes%2520neuroprotection%2520after%2520root%2520avulsion%2520injury%26jtitle%3DJ.%2520Neurotrauma%26date%3D2011%26volume%3D28%26spage%3D831%26epage%3D840%26doi%3D10.1089%2Fneu.2010.1674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span> <span> </span><span class="NLM_article-title">Sigma-1R agonist improves motor function and motoneuron survival in ALS mice</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1007/s13311-012-0140-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs13311-012-0140-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22935988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqtbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=814-826&author=R.+Mancusoauthor=S.+Olivanauthor=A.+Randoauthor=C.+Casasauthor=R.+Ostaauthor=X.+Navarro&title=Sigma-1R+agonist+improves+motor+function+and+motoneuron+survival+in+ALS+mice&doi=10.1007%2Fs13311-012-0140-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice</span></div><div class="casAuthors">Mancuso, Renzo; Olivan, Sara; Rando, Amaya; Casas, Caty; Osta, Rosario; Navarro, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">814-826</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by progressive weakness, muscle atrophy, and paralysis due to the loss of upper and lower motoneurons (MNs).  Sigma-1 receptor (sigma-1R) activation promotes neuroprotection after ischemic and traumatic injuries to the central nervous system.  We recently reported that sigma-1R agonist (PRE-084) improves the survival of MNs after root avulsion injury in rats.  Moreover, a mutation of the sigma-1R leading to frontotemporal lobar degeneration/amyotrophic lateral sclerosis (ALS) was recently described in human patients.  In the present study, we analyzed the potential therapeutic effect of the sigma-1R agonist (PRE-084) in the SOD1G93A mouse model of ALS.  Mice were daily administered with PRE-084 (0.25 mg/kg) from 8 to 16 wk of age.  Functional outcome was assessed by electrophysiol. tests and computerized anal. of locomotion.  Histol., immunohistochem. analyses and Western blot of the spinal cord were performed.  PRE-084 administration from 8 wk of age improved the function of MNs, which was manifested by maintenance of the amplitude of muscle action potentials and locomotor behavior, and preserved neuromuscular connections and MNs in the spinal cord.  Moreover, it extended survival in both female and male mice by more than 15 %.  Delayed administration of PRE-084 from 12 wk of age also significantly improved functional outcome and preservation of the MNs.  There was an induction of protein kinase C-specific phosphorylation of the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor in SOD1G93A animals, and a redn. of the microglial reactivity compared with untreated mice.  PRE-084 exerts a dual therapeutic contribution, modulating NMDA Ca2+ influx to protect MNs, and the microglial reactivity to ameliorate the MN environment.  In conclusion, sigma-1R agonists, such as PRE-084, may be promising candidates for a therapeutical strategy of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo752Zuu4G6tbVg90H21EOLACvtfcHk0lhhruAA-gR1HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqtbnO&md5=d058d70a447dbc778d0bec822a01225b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs13311-012-0140-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-012-0140-y%26sid%3Dliteratum%253Aachs%26aulast%3DMancuso%26aufirst%3DR.%26aulast%3DOlivan%26aufirst%3DS.%26aulast%3DRando%26aufirst%3DA.%26aulast%3DCasas%26aufirst%3DC.%26aulast%3DOsta%26aufirst%3DR.%26aulast%3DNavarro%26aufirst%3DX.%26atitle%3DSigma-1R%2520agonist%2520improves%2520motor%2520function%2520and%2520motoneuron%2520survival%2520in%2520ALS%2520mice%26jtitle%3DNeurotherapeutics%26date%3D2012%26volume%3D9%26spage%3D814%26epage%3D826%26doi%3D10.1007%2Fs13311-012-0140-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peviani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvaneschi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bontempi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, D.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of the sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">218</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2013.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.nbd.2013.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24141020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlarsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2014&pages=218-232&author=M.+Pevianiauthor=E.+Salvaneschiauthor=L.+Bontempiauthor=A.+Peteseauthor=A.+Manzoauthor=D.+Rossiauthor=M.+Salmonaauthor=S.+Collinaauthor=P.+Biginiauthor=D.+Curti&title=Neuroprotective+effects+of+the+sigma-1+receptor+%28S1R%29+agonist+PRE-084%2C+in+a+mouse+model+of+motor+neuron+disease+not+linked+to+SOD1+mutation&doi=10.1016%2Fj.nbd.2013.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation</span></div><div class="casAuthors">Peviani, Marco; Salvaneschi, Eleonora; Bontempi, Leonardo; Petese, Alessandro; Manzo, Antonio; Rossi, Daniela; Salmona, Mario; Collina, Simona; Bigini, Paolo; Curti, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">218-232</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The identification of novel mol. targets crucially involved in motor neuron degeneration/survival is a necessary step for the development of hopefully more effective therapeutic strategies for amyotrophic lateral sclerosis (ALS) patients.  In this view, S1R, an endoplasmic reticulum (ER)-resident receptor with chaperone-like activity, has recently attracted great interest.  S1R is involved in several processes leading to acute and chronic neurodegeneration, including ALS pathol.  Treatment with the S1R agonist PRE-084 improves locomotor function and motor neuron survival in presymptomatic and early symptomatic mutant SOD1-G93A ALS mice.  Here, we tested the efficacy of PRE-084 in a model of spontaneous motor neuron degeneration, the wobbler mouse (wr) as a proof of concept that S1R may be regarded as a key therapeutic target also for ALS cases not linked to SOD1 mutation.  Increased staining for S1R was detectable in morphol. spared cervical spinal cord motor neurons of wr mice both at early (6th week) and late (12th week) phases of clin. progression.  S1R signal was also detectable in hypertrophic astrocytes and reactive microglia of wr mice.  Chronic treatment with PRE-084 (three times a week, for 8 wk), starting at symptom onset, significantly increased the levels of BDNF in the gray matter, improved motor neuron survival and ameliorated paw abnormality and grip strength performance.  In addn., the treatment significantly reduced the no. of reactive astrocytes whereas, that of CD11b + microglial cells was increased.  A deeper evaluation of microglial markers revealed significant increased no. of cells pos. for the pan-macrophage marker CD68 and of CD206 + cells, involved in tissue restoration, in the white matter of PRE-084-treated mice.  The mRNA levels of TNF-α and IL-1β were not affected by PRE-084 treatment.  Thus, our results support pharmacol. manipulation of S1R as a promising strategy to cure ALS and point to increased availability of growth factors and modulation of astrocytosis and of macrophage/microglia as part of the mechanisms involved in S1R-mediated neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5m02NQMRO7Vg90H21EOLACvtfcHk0lhhruAA-gR1HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlarsA%253D%253D&md5=af372183f209c89a30a6c63ab24a0c3a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2013.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2013.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeviani%26aufirst%3DM.%26aulast%3DSalvaneschi%26aufirst%3DE.%26aulast%3DBontempi%26aufirst%3DL.%26aulast%3DPetese%26aufirst%3DA.%26aulast%3DManzo%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DSalmona%26aufirst%3DM.%26aulast%3DCollina%26aufirst%3DS.%26aulast%3DBigini%26aufirst%3DP.%26aulast%3DCurti%26aufirst%3DD.%26atitle%3DNeuroprotective%2520effects%2520of%2520the%2520sigma-1%2520receptor%2520%2528S1R%2529%2520agonist%2520PRE-084%252C%2520in%2520a%2520mouse%2520model%2520of%2520motor%2520neuron%2520disease%2520not%2520linked%2520to%2520SOD1%2520mutation%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2014%26volume%3D62%26spage%3D218%26epage%3D232%26doi%3D10.1016%2Fj.nbd.2013.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span> <span> </span><span class="NLM_article-title">An increase of sigma-1 receptor in the penumbra neuron after acute ischemic stroke</span>. <i>J. Stroke Cerebrovasc. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1981</span>– <span class="NLM_lpage">1987</span>, <span class="refDoi"> DOI: 10.1016/j.jstrokecerebrovasdis.2017.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jstrokecerebrovasdis.2017.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28687423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlsFChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=1981-1987&author=X.+Zhangauthor=F.+Wuauthor=Y.+Jiaoauthor=T.+Tangauthor=L.+Yangauthor=C.+Luauthor=Y.+Zhangauthor=Y.+Zhangauthor=Y.+Baiauthor=J.+Chaoauthor=G.+Tengauthor=H.+Yao&title=An+increase+of+sigma-1+receptor+in+the+penumbra+neuron+after+acute+ischemic+stroke&doi=10.1016%2Fj.jstrokecerebrovasdis.2017.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">An Increase of Sigma-1 Receptor in the Penumbra Neuron after Acute Ischemic Stroke</span></div><div class="casAuthors">Zhang Xiaotian; Yang Li; Zhang Yanhong; Zhang Yuan; Bai Ying; Wu Fangfang; Jiao Yun; Tang Tianyu; Lu Chunqiang; Teng Gaojun; Chao Jie; Yao Honghong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1981-1987</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Penumbra salvage from infarction by early reperfusion within the time window is the target of acute ischemic stroke therapies.  Although the penumbral imaging is potently usable in clinic trial, additional work needs to be performed to advancing the field with better-defined, evaluated, and validated imaging measures.  METHODS:  Mice were subjected to permanent stroke by right middle cerebral artery (MCA) occlusion.  Multimodel magnetic resonance imaging (MRI) method was assessed to define the penumbra as that brain region in which the perfusion and diffusion-weighted MR images are mismatched (perfusion-weighted imaging [PWI]-diffusion-weighted imaging [DWI] mismatch).  MRI measurements were performed at 1 hour after MCA occlusion (MCAO).  Sigma-1 receptor expression was assessed by immunoblotting and immunostaining in PWI-DWI-defined penumbra and core compared with sham or contralateral slice.  Penumbral sigma-1 receptor identified the correlation with the neuron, astrocyte, and microglia by immuno-colocalization.  RESULTS:  Sigma-1 receptor was significantly upregulated in penumbra or peri-infarct compared with sham and core tissue at 1 hour and 24 hours after MCAO.  There was a colocalization of sigma-1 receptor and neuron in penumbra at 1 hour after stroke.  Sigma-1 receptor is specifically increased in ischemic penumbral neuron at 1 hour after MCAO.  CONCLUSIONS:  Sigma-1 receptor may act as an endogenous marker of penumbra after acute ischemic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOuudjsPZ3sTslzEEsg76ufW6udTcc2ebzsE7YymbYiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlsFChug%253D%253D&md5=338df0841468b4f15eba0a7423eb9315</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.jstrokecerebrovasdis.2017.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jstrokecerebrovasdis.2017.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DTeng%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DH.%26atitle%3DAn%2520increase%2520of%2520sigma-1%2520receptor%2520in%2520the%2520penumbra%2520neuron%2520after%2520acute%2520ischemic%2520stroke%26jtitle%3DJ.%2520Stroke%2520Cerebrovasc.%2520Dis.%26date%3D2017%26volume%3D26%26spage%3D1981%26epage%3D1987%26doi%3D10.1016%2Fj.jstrokecerebrovasdis.2017.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hazell, A. S.</span></span> <span> </span><span class="NLM_article-title">Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/j.neuint.2007.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuint.2007.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=17576023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVKmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=941-953&author=A.+S.+Hazell&title=Excitotoxic+mechanisms+in+stroke%3A+an+update+of+concepts+and+treatment+strategies&doi=10.1016%2Fj.neuint.2007.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Excitotoxic mechanisms in stroke: An update of concepts and treatment strategies</span></div><div class="casAuthors">Hazell, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">941-953</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cerebral damage as a consequence of glutamate-mediated excitotoxicity represents a major consequence of stroke.  However, the development of effective clin. treatments for this potentially devastating condition was largely unsuccessful to date, despite promising basic research.  This review will focus on the latest advances in the understanding of the excitotoxic process including the release of glutamate as a neurotransmitter and the potential contribution of complexins, the important role of astrocytes, including its involvement in glutamate uptake, alterations in glutamate transporter levels, reversed glutamate uptake, and the vesicular release of glutamate.  Recent progress in the understanding of the involvement of excitotoxicity in white matter injury following ischemic insults is also discussed, as is oxidative stress and ischemic tolerance, along with an update on the use of treatment strategies with potential therapeutic benefit including stimulation of neurogenesis.  Such key issues are at the heart of future interventions directed at limiting the extent of the excitotoxic process, and remain a viable consideration for effective stroke management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAOOx_KUQIVLVg90H21EOLACvtfcHk0lh40Tfd4ENu0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVKmsLo%253D&md5=3cce1e63a63a64fa0ae8bcd5e3c6c658</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2007.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2007.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DHazell%26aufirst%3DA.%2BS.%26atitle%3DExcitotoxic%2520mechanisms%2520in%2520stroke%253A%2520an%2520update%2520of%2520concepts%2520and%2520treatment%2520strategies%26jtitle%3DNeurochem.%2520Int.%26date%3D2007%26volume%3D50%26spage%3D941%26epage%3D953%26doi%3D10.1016%2Fj.neuint.2007.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Yebenes, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landwehrmeyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squitieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saft, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnet, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sword, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rembratt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedroff, J.</span></span> <span> </span><span class="NLM_article-title">Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(11)70233-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS1474-4422%2811%2970233-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22071279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2gsbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1049-1057&author=J.+G.+de%0AYebenesauthor=B.+Landwehrmeyerauthor=F.+Squitieriauthor=R.+Reilmannauthor=A.+Rosserauthor=R.+A.+Barkerauthor=C.+Saftauthor=M.+K.+Magnetauthor=A.+Swordauthor=A.+Rembrattauthor=J.+Tedroff&title=Pridopidine+for+the+treatment+of+motor+function+in+patients+with+Huntington%E2%80%99s+disease+%28MermaiHD%29%3A+a+phase+3%2C+randomised%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS1474-4422%2811%2970233-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial</span></div><div class="casAuthors">de Yebenes, Justo Garcia; Landwehrmeyer, Bernhard; Squitieri, Ferdinando; Reilmann, Ralf; Rosser, Anne; Barker, Roger A.; Saft, Carsten; Magnet, Markus K.; Sword, Alastair; Rembratt, Asa; Tedroff, Joakim</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1049-1057</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Huntington's disease is a progressive neurodegenerative disorder, characterised by motor, cognitive, and behavioral deficits.  Pridopidine belongs to a new class of compds. known as dopaminergic stabilizers, and results from a small phase 2 study in patients with Huntington's disease suggested that this drug might improve voluntary motor function.  We aimed to assess further the effects of pridopidine in patients with Huntington's disease.  We undertook a 6 mo, randomised, double-blind, placebo-controlled trial to assess the efficacy of pridopidine in the treatment of motor deficits in patients with Huntington's disease.  Our primary endpoint was change in the modified motor score (mMS; derived from the unified Huntington's disease rating scale) at 26 wk.  We recruited patients with Huntington's disease from 32 European centers; patients were aged 30 years or older and had an mMS of 10 points or greater at baseline.  Patients were randomly assigned (1:1:1) to receive placebo, 45 mg per day pridopidine, or 90 mg per day pridopidine by use of centralised computer-generated codes.  Patients and investigators were masked to treatment assignment.  We also assessed the safety and tolerability profile of pridopidine.  For our primary anal., all patients were eligible for inclusion in our full anal. set, in which we used the last observation carried forward method for missing values.  We used an anal. of covariance model and the Bonferroni method to adjust for multiple comparisons.  We used a prespecified per-protocol population as our sensitivity anal.  The α level was 0.025 for our primary anal. and 0.05 overall.  This trial is registered with ClinicalTrials.gov, no. NCT00665223.  At 26 wk, in our full anal. set the difference in mean mMS was -0.99 points (97.5% CI -2.08 to 0.10, p = 0.042) in patients who received 90 mg per day pridopidine (n = 145) vs. those who received placebo (n = 144), and -0.36 points (-1.44 to 0.72, p = 0.456) in those who received 45 mg per day pridopidine (n = 148) vs. those who received placebo.  At the 90 mg per day dose, in our per-protocol population (n = 114), the redn. in the mMS was of -1.29 points (-2.47 to -0.12; p = 0.014) compared with placebo (n = 120).  We did not identify any changes in non-motor endpoints at either dose.  Pridopidine was well tolerated and had an adverse event profile similar to that of placebo.  This study did not provide evidence of efficacy as measured by the mMS, but a potential effect of pridopidine on the motor phenotype of Huntington's disease merits further investigation.  Pridopidine up to 90 mg per day was well tolerated in patients with Huntington's disease.  Funding: NeuroSearch A/S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVDXQbNRAMqLVg90H21EOLACvtfcHk0lh40Tfd4ENu0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2gsbrO&md5=ed31da6ccaad5c90745d35aacbbb6f4a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2811%2970233-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252811%252970233-2%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BYebenes%26aufirst%3DJ.%2BG.%26aulast%3DLandwehrmeyer%26aufirst%3DB.%26aulast%3DSquitieri%26aufirst%3DF.%26aulast%3DReilmann%26aufirst%3DR.%26aulast%3DRosser%26aufirst%3DA.%26aulast%3DBarker%26aufirst%3DR.%2BA.%26aulast%3DSaft%26aufirst%3DC.%26aulast%3DMagnet%26aufirst%3DM.%2BK.%26aulast%3DSword%26aufirst%3DA.%26aulast%3DRembratt%26aufirst%3DA.%26aulast%3DTedroff%26aufirst%3DJ.%26atitle%3DPridopidine%2520for%2520the%2520treatment%2520of%2520motor%2520function%2520in%2520patients%2520with%2520Huntington%25E2%2580%2599s%2520disease%2520%2528MermaiHD%2529%253A%2520a%2520phase%25203%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%2520Neurol.%26date%3D2011%26volume%3D10%26spage%3D1049%26epage%3D1057%26doi%3D10.1016%2FS1474-4422%2811%2970233-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katnik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennypacker, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1365</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.107557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.106.107557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16988055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2006&pages=1355-1365&author=C.+Katnikauthor=W.+R.+Guerreroauthor=K.+R.+Pennypackerauthor=Y.+Herreraauthor=J.+Cuevas&title=Sigma-1+receptor+activation+prevents+intracellular+calcium+dysregulation+in+cortical+neurons+during+in+vitro+ischemia&doi=10.1124%2Fjpet.106.107557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia</span></div><div class="casAuthors">Katnik, Christopher; Guerrero, Waldo R.; Pennypacker, Keith R.; Herrera, Yelenis; Cuevas, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1355-1365</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sigma receptors are putative targets for neuroprotection following ischemia; however, little is known on their mechanism of action.  One of the key components in the demise of neurons following ischemic injury is the disruption of intracellular calcium homeostasis.  Fluorometric calcium imaging was used to examine the effects of sigma receptor activation on changes in intracellular calcium concns. ([Ca2+]i) evoked by in vitro ischemia in cultured cortical neurons from embryonic rats.  The sigma receptor agonist, 1,3-di-o-tolyl-guanidine (DTG), was shown to depress [Ca2+]i elevations obsd. in response to ischemia induced by sodium azide and glucose deprivation.  Two sigma receptor antagonists, metaphit and BD-1047, were shown to blunt the ability of DTG to inhibit ischemia-evoked increases in [Ca2+]i, revealing that the effects are mediated by activation of sigma receptors and not via the actions of DTG on nonspecific targets such as N-methyl-D-aspartate receptors.  DTG inhibition of ischemia-induced increases in [Ca2+]i was mimicked by the σ-1 receptor-selective agonists, carbetapentane, (+)-pentazocine and PRE-084 [2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate hydrochloride], but not by the sigma-2-selective agonist, ibogaine, showing that activation of sigma-1 receptors is responsible for the effects.  In contrast, DTG, carbetapentane, and ibogaine blocked spontaneous, synchronous calcium transients obsd. in our prepn. at concns. consistent with sigma receptor-mediated effects, indicating that both sigma-1 and sigma-2 receptors regulate events that affect [Ca2+]i in cortical neurons.  Our studies show that activation of sigma receptors can ameliorate [Ca2+]i dysregulation assocd. with ischemia in cortical neurons and, thus, identify one of the mechanisms by which these receptors may exert their neuroprotective properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUF4Cm8IUXC7Vg90H21EOLACvtfcHk0lh40Tfd4ENu0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltLrN&md5=56403735f0ab724612afb2746fd8d07f</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.107557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.107557%26sid%3Dliteratum%253Aachs%26aulast%3DKatnik%26aufirst%3DC.%26aulast%3DGuerrero%26aufirst%3DW.%2BR.%26aulast%3DPennypacker%26aufirst%3DK.%2BR.%26aulast%3DHerrera%26aufirst%3DY.%26aulast%3DCuevas%26aufirst%3DJ.%26atitle%3DSigma-1%2520receptor%2520activation%2520prevents%2520intracellular%2520calcium%2520dysregulation%2520in%2520cortical%2520neurons%2520during%2520in%2520vitro%2520ischemia%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D319%26spage%3D1355%26epage%3D1365%26doi%3D10.1124%2Fjpet.106.107557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, P.</span></span> <span> </span><span class="NLM_article-title">Sigma-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1016/0304-3940(90)90139-Z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2F0304-3940%2890%2990139-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1963213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK3MXjslE%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1990&pages=169-174&author=D.+Lobnerauthor=P.+Lipton&title=Sigma-ligands+and+non-competitive+NMDA+antagonists+inhibit+glutamate+release+during+cerebral+ischemia&doi=10.1016%2F0304-3940%2890%2990139-Z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">σ-Ligands and noncompetitive NMDA antagonists inhibit glutamate release during cerebral ischemia</span></div><div class="casAuthors">Lobner, Doug; Lipton, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">169-74</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    </div><div class="casAbstract">Release of glutamate from brain cells is increased during ischemia and is thought to be involved in ischemic damage.  In rat hippocampal slices the release of glutamate during in vitro ischemia (anoxia without glucose) is shown to be blocked by two groups of compds.: non-competitive N-methyl-D-aspartate (NMDA) antagonists and sigma ligands.  The effects are selective for the ischemic glutamate release, which is independent of extracellular Ca2+.  High K+, Ca2+ dependent, induced release of glutamate is not inhibited.  NMDA receptor blockade normally does not prevent ischemic transmission damage in the rat hippocampal slice.  However, when ischemic glutamate release is attenuated, NMDA receptor antagonists do prevent the damage.  This indicates that high levels of glutamate may cause damage via non-NMDA as well as NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWQFtVXDOwZ7Vg90H21EOLACvtfcHk0ljYNmbxsVSv7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXjslE%253D&md5=d763713e9146fd59bf60c15d63db8850</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0304-3940%2890%2990139-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3940%252890%252990139-Z%26sid%3Dliteratum%253Aachs%26aulast%3DLobner%26aufirst%3DD.%26aulast%3DLipton%26aufirst%3DP.%26atitle%3DSigma-ligands%2520and%2520non-competitive%2520NMDA%2520antagonists%2520inhibit%2520glutamate%2520release%2520during%2520cerebral%2520ischemia%26jtitle%3DNeurosci.%2520Lett.%26date%3D1990%26volume%3D117%26spage%3D169%26epage%3D174%26doi%3D10.1016%2F0304-3940%2890%2990139-Z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ajmo, C. T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernon, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennypacker, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, J.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor activation reduces infarct size at 24 h after permanent middle cerebral artery occlusion in rats</span>. <i>Curr. Neurovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.2174/156720206776875849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F156720206776875849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16719792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Ors74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=89-98&author=C.+T.+Ajmoauthor=D.+O.+Vernonauthor=L.+Collierauthor=K.+R.+Pennypackerauthor=J.+Cuevas&title=Sigma+receptor+activation+reduces+infarct+size+at+24+h+after+permanent+middle+cerebral+artery+occlusion+in+rats&doi=10.2174%2F156720206776875849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptor activation reduces infract size at 24 hours after permanent middle cerebral artery occlusion in rats</span></div><div class="casAuthors">Ajmo, Craig T., Jr.; Vernon, Dionne O. L.; Collier, Lisa; Pennypacker, Keith R.; Cuevas, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Current Neurovascular Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">CNRUAM</span>;
        ISSN:<span class="NLM_cas:issn">1567-2026</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The only available treatment for embolic stroke is recombinant tissue plasminogen activator, which must be administered within three hours of stroke onset.  We examd. the effects of 1,3-di-o-tolyguanidine (DTG), a high affinity sigma receptor agonist, as a potential treatment for decreasing infarct area at delayed time points.  Rats were subjected to permanent embolic middle cerebral artery occlusion (MCAO) and allowed to recover before receiving s.c. injections of 15 mg/kg of DTG at 24, 48, and 72 h.  At 96 h the rats were euthanized, and brains harvested and sectioned.  Infarct areas were quantified at the level of the cortical/striatal and cortical/hippocampal regions in control (MCAO-only) and DTG treated animals using a marker for neurodegeneration, Fluoro-Jade.  DTG treatment significantly reduced infarct area in both cortical/striatal and cortical/hippocampal regions by >80%, relative to control rats.  These findings were confirmed by immunohistochem. expts. using the neuronal marker, mouse anti-neuronal nuclei monoclonal antibody (NeuN), which showed that application of DTG significantly increased the no. of viable neurons in these regions.  Furthermore, DTG blocked the inflammatory response evoked by MCAO, as indicated by decreases in the no. of reactive astrocytes and activated microglia/macrophages detected by immunostaining for glial fibrillary acidic protein (GFAP) and binding of isolectin IB4, resp.  Thus, our results demonstrate that the sigma receptor-selective agonist, DTG, can enhance neuronal survival when administered 24 h after an ischemic stroke.  In addn., the efficacy of sigma receptors for stroke treatment at delayed time points is likely the result of combined neuroprotective and anti-inflammatory properties of these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8VrhYX_Dt5LVg90H21EOLACvtfcHk0ljYNmbxsVSv7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Ors74%253D&md5=2e9a6d25b30ba69fed8d9626f48aa5ea</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.2174%2F156720206776875849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156720206776875849%26sid%3Dliteratum%253Aachs%26aulast%3DAjmo%26aufirst%3DC.%2BT.%26aulast%3DVernon%26aufirst%3DD.%2BO.%26aulast%3DCollier%26aufirst%3DL.%26aulast%3DPennypacker%26aufirst%3DK.%2BR.%26aulast%3DCuevas%26aufirst%3DJ.%26atitle%3DSigma%2520receptor%2520activation%2520reduces%2520infarct%2520size%2520at%252024%2520h%2520after%2520permanent%2520middle%2520cerebral%2520artery%2520occlusion%2520in%2520rats%26jtitle%3DCurr.%2520Neurovasc.%2520Res.%26date%3D2006%26volume%3D3%26spage%3D89%26epage%3D98%26doi%3D10.2174%2F156720206776875849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katnik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behensky, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasny, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seredenin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAleer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, J.</span></span> <span> </span><span class="NLM_article-title">Treatment with afobazole at delayed time points following ischemic stroke improves long-term functional and histological outcomes</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2013.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.nbd.2013.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24141021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2014&pages=354-364&author=C.+Katnikauthor=A.+Garciaauthor=A.+A.+Behenskyauthor=I.+E.+Yasnyauthor=A.+M.+Shusterauthor=S.+B.+Seredeninauthor=A.+V.+Petrovauthor=S.+Seifuauthor=J.+McAleerauthor=A.+Willingauthor=J.+Cuevas&title=Treatment+with+afobazole+at+delayed+time+points+following+ischemic+stroke+improves+long-term+functional+and+histological+outcomes&doi=10.1016%2Fj.nbd.2013.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with afobazole at delayed time points following ischemic stroke improves long-term functional and histological outcomes</span></div><div class="casAuthors">Katnik, C.; Garcia, A.; Behensky, A. A.; Yasny, I. E.; Shuster, A. M.; Seredenin, S. B.; Petrov, A. V.; Seifu, S.; McAleer, J.; Willing, A.; Cuevas, J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">354-364</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There is currently a significant lack of therapeutic options for acute ischemic stroke, and no drug has been approved for treating patients at delayed time points (≥ 6 h post-stroke).  Afobazole, an anxiolytic currently used clin. in Russia, has been shown to reduce neuronal and glial cell injury in vitro following ischemia.  Expts. using the permanent middle cerebral artery occlusion (MCAO) rat model were carried out to det. if afobazole can reduce ischemic stroke damage in vivo and expand the therapeutic window for stroke treatment.  Post-stroke (24 h) application of afobazole (0.3-3 mg/kg) significantly decreased infarct vol. at 96 h post-surgery, as detd. by Fluoro-Jade and NeuN staining of brain sections.  Moreover, afobazole helped preserve both the levels and normal histol. distribution of myelin basic protein, indicating a redn. in white matter injury.  A time-dependence study showed that either pre-treatment or treatment started 6 to 48 h post-stroke with the drug yields improved outcomes at 96 h.  The decrease in infarct vol. produced by afobazole was blocked by the application of either a σ-1 (BD 1063, 30 mg/kg) or a σ-2 (SM-21, 1 mg/kg) antagonist, indicating that both receptor subtypes are involved in the effects of afobazole.  Treatment with afobazole starting at 24 h post-stroke resulted in enhanced survival one month following surgery.  Behavioral testing of animals 28-32 days post-surgery using the elevated body swing and forelimb grip-strength tests revealed that treatment with afobazole starting 24 h post-stroke significantly reduces behavioral deficits caused by ischemic stroke.  The increase in survival and improved functional outcomes are accompanied by a redn. in infarct vol., as detd. by thionin staining of brain sections.  Taken together, our data support the use of afobazole as a post-stroke pharmacol. agent to expand the current therapeutic window.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEZe5ZFCdkQrVg90H21EOLACvtfcHk0ljYNmbxsVSv7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlemsg%253D%253D&md5=39491a39c38c4e39c1a39a1f5c15e4b7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2013.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2013.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DKatnik%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DBehensky%26aufirst%3DA.%2BA.%26aulast%3DYasny%26aufirst%3DI.%2BE.%26aulast%3DShuster%26aufirst%3DA.%2BM.%26aulast%3DSeredenin%26aufirst%3DS.%2BB.%26aulast%3DPetrov%26aufirst%3DA.%2BV.%26aulast%3DSeifu%26aufirst%3DS.%26aulast%3DMcAleer%26aufirst%3DJ.%26aulast%3DWilling%26aufirst%3DA.%26aulast%3DCuevas%26aufirst%3DJ.%26atitle%3DTreatment%2520with%2520afobazole%2520at%2520delayed%2520time%2520points%2520following%2520ischemic%2520stroke%2520improves%2520long-term%2520functional%2520and%2520histological%2520outcomes%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2014%26volume%3D62%26spage%3D354%26epage%3D364%26doi%3D10.1016%2Fj.nbd.2013.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allahtavakoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarrott, B.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2011.03.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.brainresbull.2011.03.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21453760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=219-224&author=M.+Allahtavakoliauthor=B.+Jarrott&title=Sigma-1+receptor+ligand+PRE-084+reduced+infarct+volume%2C+neurological+deficits%2C+pro-inflammatory+cytokines+and+enhanced+anti-inflammatory+cytokines+after+embolic+stroke+in+rats&doi=10.1016%2Fj.brainresbull.2011.03.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats</span></div><div class="casAuthors">Allahtavakoli, Mohammad; Jarrott, Bevyn</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">219-224</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma receptor agonists have been found to provide potent neuroprotection in rats and mice.  This neuroprotection is thought to be mediated through anti-excitotoxic mechanisms.  Neuroprotective and immune modulatory effects of sigma ligands have not been investigated in embolic stroke.  In the present study, rats were subjected to embolic stroke or sham stroke and were treated with the sigma-1 receptor agonist PRE-084 (5 mg/kg i.p.) or saline vehicle 3 and 24 h after stroke.  Infarct vol. and behavioral tests were conducted, and cytokine levels (ILs-1α and β, IL-2, IL-4, IL-6, IL-10, GM-CSF and TNF-α) were detd. in ischemic and non-ischemic cortices.  Axonal damage was detd. using the pNF-H ELISA assay.  Treatment with PRE-084 afforded neuroprotection following embolic stroke as evidenced by significantly reduced infarct vol. and improved behavioral outcome.  Remarkably, treatment with PRE-084 reduced levels of pro-inflammatory cytokines and enhanced anti-inflammatory cytokines.  Levels of pNF-H were lower in rats treated with PRE-084 suggesting reduced axonal damage but this finding did not reach statistical significance.  The findings of the present study suggest that part of the neuroprotective effects of sigma-1 receptor agonists may be mediated through a dual effect on cytokine release following stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobFI49nXcFRbVg90H21EOLACvtfcHk0lhtMDSwdHwnvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFCrsbk%253D&md5=9388655859dcffdd21437099d07798d3</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2011.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2011.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DAllahtavakoli%26aufirst%3DM.%26aulast%3DJarrott%26aufirst%3DB.%26atitle%3DSigma-1%2520receptor%2520ligand%2520PRE-084%2520reduced%2520infarct%2520volume%252C%2520neurological%2520deficits%252C%2520pro-inflammatory%2520cytokines%2520and%2520enhanced%2520anti-inflammatory%2520cytokines%2520after%2520embolic%2520stroke%2520in%2520rats%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2011%26volume%3D85%26spage%3D219%26epage%3D224%26doi%3D10.1016%2Fj.brainresbull.2011.03.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamloo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickhag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladunga, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisselsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toresson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruslim-Litrus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urfer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieloch, T.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1093/brain/awq367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1093%2Fbrain%2Fawq367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21278085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BC3M3itVGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2011&pages=732-746&author=K.+Ruscherauthor=M.+Shamlooauthor=M.+Rickhagauthor=I.+Ladungaauthor=L.+Sorianoauthor=L.+Gisselssonauthor=H.+Toressonauthor=L.+Ruslim-Litrusauthor=D.+Oksenbergauthor=R.+Urferauthor=B.+B.+Johanssonauthor=K.+Nikolichauthor=T.+Wieloch&title=The+sigma-1+receptor+enhances+brain+plasticity+and+functional+recovery+after+experimental+stroke&doi=10.1093%2Fbrain%2Fawq367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke</span></div><div class="casAuthors">Ruscher Karsten; Shamloo Mehrdad; Rickhag Mattias; Ladunga Istvan; Soriano Liza; Gisselsson Lennart; Toresson Hakan; Ruslim-Litrus Lily; Oksenberg Donna; Urfer Roman; Johansson Barbro B; Nikolich Karoly; Wieloch Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">Pt 3</span>),
    <span class="NLM_cas:pages">732-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Stroke leads to brain damage with subsequent slow and incomplete recovery of lost brain functions.  Enriched housing of stroke-injured rats provides multi-modal sensorimotor stimulation, which improves recovery, although the specific mechanisms involved have not been identified.  In rats housed in an enriched environment for two weeks after permanent middle cerebral artery occlusion, we found increased sigma-1 receptor expression in peri-infarct areas.  Treatment of rats subjected to permanent or transient middle cerebral artery occlusion with 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride, an agonist of the sigma-1 receptor, starting two days after injury, enhanced the recovery of lost sensorimotor function without decreasing infarct size.  The sigma-1 receptor was found in the galactocerebroside enriched membrane microdomains of reactive astrocytes and in neurons.  Sigma-1 receptor activation increased the levels of the synaptic protein neurabin and neurexin in membrane rafts in the peri-infarct area, while sigma-1 receptor silencing prevented sigma-1 receptor-mediated neurite outgrowth in primary cortical neuronal cultures.  In astrocytic cultures, oxygen and glucose deprivation induced sigma-1 receptor expression and actin dependent membrane raft formation, the latter blocked by sigma-1 receptor small interfering RNA silencing and pharmacological inhibition.  We conclude that sigma-1 receptor activation stimulates recovery after stroke by enhancing cellular transport of biomolecules required for brain repair, thereby stimulating brain plasticity.  Pharmacological targeting of the sigma-1 receptor provides new opportunities for stroke treatment beyond the therapeutic window of neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3TsV5rFaPgP69nzq6467DfW6udTcc2eY1GQlhhGNUXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3itVGksg%253D%253D&md5=d336b50f51488568b4fb6d2f72d794ec</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawq367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawq367%26sid%3Dliteratum%253Aachs%26aulast%3DRuscher%26aufirst%3DK.%26aulast%3DShamloo%26aufirst%3DM.%26aulast%3DRickhag%26aufirst%3DM.%26aulast%3DLadunga%26aufirst%3DI.%26aulast%3DSoriano%26aufirst%3DL.%26aulast%3DGisselsson%26aufirst%3DL.%26aulast%3DToresson%26aufirst%3DH.%26aulast%3DRuslim-Litrus%26aufirst%3DL.%26aulast%3DOksenberg%26aufirst%3DD.%26aulast%3DUrfer%26aufirst%3DR.%26aulast%3DJohansson%26aufirst%3DB.%2BB.%26aulast%3DNikolich%26aufirst%3DK.%26aulast%3DWieloch%26aufirst%3DT.%26atitle%3DThe%2520sigma-1%2520receptor%2520enhances%2520brain%2520plasticity%2520and%2520functional%2520recovery%2520after%2520experimental%2520stroke%26jtitle%3DBrain%26date%3D2011%26volume%3D134%26spage%3D732%26epage%3D746%26doi%3D10.1093%2Fbrain%2Fawq367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Blazquez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozo-Rodrigalvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzon, J.</span></span> <span> </span><span class="NLM_article-title">The sigma-1 receptor antagonist, S1RA, reduces stroke damage, ameliorates post-stroke neurological deficits and suppresses the overexpression of MMP-9</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4940</span>– <span class="NLM_lpage">4951</span>, <span class="refDoi"> DOI: 10.1007/s12035-017-0697-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs12035-017-0697-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28779350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yhs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2018&pages=4940-4951&author=P.+Sanchez-Blazquezauthor=A.+Pozo-Rodrigalvarezauthor=M.+Merlosauthor=J.+Garzon&title=The+sigma-1+receptor+antagonist%2C+S1RA%2C+reduces+stroke+damage%2C+ameliorates+post-stroke+neurological+deficits+and+suppresses+the+overexpression+of+MMP-9&doi=10.1007%2Fs12035-017-0697-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor antagonist, s1ra, reduces stroke damage, ameliorates post-stroke neurological deficits and suppresses the overexpression of mmp-9</span></div><div class="casAuthors">Sanchez-Blazquez, Pilar; Pozo-Rodrigalvarez, Andrea; Merlos, Manuel; Garzon, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">4940-4951</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">The glutamate N-methyl-D-aspartate receptor (NMDAR) plays an essential role in the excitotoxic neural damage that follows ischemic stroke.  Because the sigma-1 receptor (σ1R) can regulate NMDAR transmission, exogenous and putative endogenous regulators of σ1R have been investigated using animal models of ischemic stroke.  As both agonists and antagonists provide some neural protection, the selective involvement of σ1Rs in these effects has been questioned.  The availability of S1RA (E-52862/MR309), a highly selective σ1R antagonist, prompted us to explore its therapeutic potential in an animal model of focal cerebral ischemia.  Mice were subjected to right middle cerebral artery occlusion (MCAO), and post-ischemic infarct vol. and neurol. deficits were detd. across a range of intervals after the stroke-inducing surgery.  Intracerebroventricular or i.v. treatment with S1RA significantly reduced the cerebral infarct size and neurol. deficits caused by permanent MCAO (pMCAO).  Compared with the control/sham-operated mice, the neuroprotective effects of S1RA were obsd. when delivered up to 5 h prior to surgery and 3 h after ischemic onset.  Interestingly, neither mice with the genetic deletion of σ1R nor wild-type mice that were pre-treated with the σ1R agonist PRE084 showed beneficial effects after S1RA administration with regard to stroke infarction.  S1RA-treated mice showed faster behavioral recovery from stroke; this finding complements the significant decreases in matrix metalloproteinase-9 (MMP-9) expression and reactive astrogliosis surrounding the infarcted cortex.  Our data indicate that S1RA, via σ1R, holds promising potential for clin. application as a therapeutic agent for ischemic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZUGbqL3A9JrVg90H21EOLACvtfcHk0lhtMDSwdHwnvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yhs7jP&md5=44394f0ed6fa849eb5cfe1e46c492535</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs12035-017-0697-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-017-0697-x%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Blazquez%26aufirst%3DP.%26aulast%3DPozo-Rodrigalvarez%26aufirst%3DA.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DGarzon%26aufirst%3DJ.%26atitle%3DThe%2520sigma-1%2520receptor%2520antagonist%252C%2520S1RA%252C%2520reduces%2520stroke%2520damage%252C%2520ameliorates%2520post-stroke%2520neurological%2520deficits%2520and%2520suppresses%2520the%2520overexpression%2520of%2520MMP-9%26jtitle%3DMol.%2520Neurobiol.%26date%3D2018%26volume%3D55%26spage%3D4940%26epage%3D4951%26doi%3D10.1007%2Fs12035-017-0697-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fishback, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Sigma receptors: potential targets for a new class of antidepressant drug</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2010.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.pharmthera.2010.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20438757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosV2htro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=271-282&author=J.+A.+Fishbackauthor=M.+J.+Robsonauthor=Y.+T.+Xuauthor=R.+R.+Matsumoto&title=Sigma+receptors%3A+potential+targets+for+a+new+class+of+antidepressant+drug&doi=10.1016%2Fj.pharmthera.2010.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptors: Potential targets for a new class of antidepressant drug</span></div><div class="casAuthors">Fishback, James A.; Robson, Matthew J.; Xu, Yan-Tong; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-282</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Despite the widespread and devastating impact of depression on society, our current understanding of its pathogenesis is limited.  Likewise, existing treatments are inadequate, providing relief to only a subset of people suffering from depression.  The search for more effective antidepressant drugs includes the investigation of new mol. targets.  Among them, current data suggests that sigma receptors are involved in multiple processes effecting antidepressant-like actions in vivo and in vitro.  This review summarizes accumulated evidence supporting a role for sigma receptors in antidepressant effects and provides a conceptual framework for delineating their potential roles over the course of antidepressant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLgoPQq-jsCbVg90H21EOLACvtfcHk0lhR5LU_PUf9Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosV2htro%253D&md5=8bc10680890e356f82ccd21b7885e9db</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DFishback%26aufirst%3DJ.%2BA.%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DXu%26aufirst%3DY.%2BT.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSigma%2520receptors%253A%2520potential%2520targets%2520for%2520a%2520new%2520class%2520of%2520antidepressant%2520drug%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D127%26spage%3D271%26epage%3D282%26doi%3D10.1016%2Fj.pharmthera.2010.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevallier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacological interaction with the sigma1 (sigma1)-receptor in the acute behavioral effects of antidepressants</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1254/jphs.10191FP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1254%2Fjphs.10191FP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21427517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2011&pages=279-292&author=V.+Villardauthor=J.+Meunierauthor=N.+Chevallierauthor=T.+Maurice&title=Pharmacological+interaction+with+the+sigma1+%28sigma1%29-receptor+in+the+acute+behavioral+effects+of+antidepressants&doi=10.1254%2Fjphs.10191FP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological interaction with the σ1-receptor in the acute behavioral effects of antidepressants</span></div><div class="casAuthors">Villard, Vanessa; Meunier, Johann; Chevallier, Nathalie; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-292</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">Selective agonists of the sigma-1 σ1-ligand-operated chaperone protein, like igmesine or PRE-084, are antidepressants in preclin. depression models.  σ1-Protein activation may contribute to the antidepressant efficacy of drugs known to act as selective serotonin-reuptake inhibitors (SSRI) or noradrenaline reuptake inhibitors through direct or indirect involvement of the σ1-receptor in the drug effect.  We here compared antidepressant effects in two behavioral procedures, the forced swimming test (FST) and conditioned fear stress (CFS).  The involvement of the σ1-receptor was examd. using a co-treatment with the σ1-antagonist BD1047 or using σ1-knockout (KO) mice.  Igmesine but not PRE-084 decreased FST immobility.  The SSRI fluoxetine and sertraline, but not fluvoxamine, and the tricyclic antidepressants imipramine, desipramine, and amitriptyline were also effective.  Only the effect of igmesine was blocked by BD1047 or in σ1-KO mice.  Igmesine, PRE-084, fluvoxamine, and sertraline decreased the CFS immobility in a BD1047- and σ1-KO-sensitive manner.  Among tricyclics, only amitriptyline was effective and its effect was unaffected by BD1047 or in σ1-KO mice.  The behavioral effects induced by mixed σ1-receptor/SSRI antidepressants, like fluvoxamine or sertraline, may therefore involve a non-selective action at both targets.  Moreover, the CFS appears to more reliably uncover a σ1 pharmacol. component in antidepressant screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruQxCYdwY51LVg90H21EOLACvtfcHk0lhR5LU_PUf9Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOktr4%253D&md5=06dbe2071d402573e5b0ed24ea776f14</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1254%2Fjphs.10191FP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.10191FP%26sid%3Dliteratum%253Aachs%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DChevallier%26aufirst%3DN.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DPharmacological%2520interaction%2520with%2520the%2520sigma1%2520%2528sigma1%2529-receptor%2520in%2520the%2520acute%2520behavioral%2520effects%2520of%2520antidepressants%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D115%26spage%3D279%26epage%3D292%26doi%3D10.1254%2Fjphs.10191FP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faherty, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harkin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, B. E.</span></span> <span> </span><span class="NLM_article-title">The functional sensitisation of sigma receptors following chronic selective serotonin reuptake inhibitor treatment</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(98)00041-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS0014-2999%2898%2900041-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=9617747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK1cXitVKit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=1998&pages=15-21&author=C.+J.+Fahertyauthor=A.+J.+Harkinauthor=B.+E.+Leonard&title=The+functional+sensitisation+of+sigma+receptors+following+chronic+selective+serotonin+reuptake+inhibitor+treatment&doi=10.1016%2FS0014-2999%2898%2900041-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The functional sensitization of sigma receptors following chronic selective serotonin reuptake inhibitor treatment</span></div><div class="casAuthors">Faherty, Ciaran J.; Harkin, Andrew J.; Leonard, Brian E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The purpose of the present study was to investigate the potential impairment of normal motor function following chronic selective serotonin reuptake inhibitor treatment that may result from sensitization of σ receptors.  Rats were chronically treated with either sertraline, citalopram, paroxetine or fluvoxamine and a selective σ receptor ligand, di-o-tolylguanidine (DTG), for 28 days.  All animals then received an acute intra-rubral injection of either DTG or saline.  Following the direct injection of DTG into the red nucleus, rats chronically treated with DTG exhibit a maximal behavioral response characterized as a pronounced dystonia.  Animals chronically treated with sertraline and citalopram elicited a response similar to that of control animals following the acute DTG challenge, whereas chronic treatment with paroxetine and fluvoxamine significantly decreased and increased the dystonic response, resp.  Facial spasticity and vacuous chewing movements were assocd. with, and reflected the extent of, the DTG-induced dystonia.  Changes in regional biogenic amine concns. were also detd.  The concns. of serotonin and noradrenaline were detd. in the brain stem and cerebellum following the intra-rubral injection of either saline or DTG in animals that had been chronically treated with a selective serotonin reuptake inhibitor or DTG.  There was a significant increase in serotonin concn. in the brainstem as a result of chronic DTG and fluvoxamine treatments.  The increase in serotonin correlated with the reported potentiation of dystonia in animals that received 28 days treatment with these drugs.  The potentiation of dystonia following chronic DTG and fluvoxamine treatments suggests that these drugs sensitize the σ2 receptors, an effect that does not appear to be shared by citalopram, sertraline or paroxetine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokq65Pu3jG-7Vg90H21EOLACvtfcHk0lhR5LU_PUf9Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVKit70%253D&md5=e1b3f3ddee1db510ee8e6ac414c55a4b</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2898%2900041-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252898%252900041-7%26sid%3Dliteratum%253Aachs%26aulast%3DFaherty%26aufirst%3DC.%2BJ.%26aulast%3DHarkin%26aufirst%3DA.%2BJ.%26aulast%3DLeonard%26aufirst%3DB.%2BE.%26atitle%3DThe%2520functional%2520sensitisation%2520of%2520sigma%2520receptors%2520following%2520chronic%2520selective%2520serotonin%2520reuptake%2520inhibitor%2520treatment%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D346%26spage%3D15%26epage%3D21%26doi%3D10.1016%2FS0014-2999%2898%2900041-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parylak, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorrilla, E. P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor knockout mice display a depressive-like phenotype</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2008.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbr.2008.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19100292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFGqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2009&pages=472-476&author=V.+Sabinoauthor=P.+Cottoneauthor=S.+L.+Parylakauthor=L.+Steardoauthor=E.+P.+Zorrilla&title=Sigma-1+receptor+knockout+mice+display+a+depressive-like+phenotype&doi=10.1016%2Fj.bbr.2008.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor knockout mice display a depressive-like phenotype</span></div><div class="casAuthors">Sabino, Valentina; Cottone, Pietro; Parylak, Sarah L.; Steardo, Luca; Zorrilla, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">472-476</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Activation of sigma-1 receptors (Sig-1R) reportedly has antidepressant-like action.  Limited data suggest that Sig-1Rs also modulate anxiety-related behaviors.  The present expts. measured depressive-like, anxiety-like and motor behavior in Sig-1R knockout mice and their wildtype littermates.  Sig-1R knockout mutants showed increased immobility in the forced swimming test, a depressive-like phenotype, but normal anxiety-like behavior in the elevated plus-maze and light/dark box tests and normal locomotor activity.  The results further suggest that Sig-1Rs inversely modulate depressive-like behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOL-G59QQprVg90H21EOLACvtfcHk0lgCINlME0ax7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFGqs7c%253D&md5=a0c344f5de45c63439b50ab7b77ea8e5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2008.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2008.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DSabino%26aufirst%3DV.%26aulast%3DCottone%26aufirst%3DP.%26aulast%3DParylak%26aufirst%3DS.%2BL.%26aulast%3DSteardo%26aufirst%3DL.%26aulast%3DZorrilla%26aufirst%3DE.%2BP.%26atitle%3DSigma-1%2520receptor%2520knockout%2520mice%2520display%2520a%2520depressive-like%2520phenotype%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2009%26volume%3D198%26spage%3D472%26epage%3D476%26doi%3D10.1016%2Fj.bbr.2008.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skuza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoz, Z.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like effect of PRE-084, a selective sigma1 receptor agonist, in Albino Swiss and C57BL/6J mice</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1183</span>, <span class="refDoi"> DOI: 10.1016/S1734-1140(09)70181-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS1734-1140%2809%2970181-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20081254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Ggtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1179-1183&author=G.+Skuzaauthor=Z.+Rogoz&title=Antidepressant-like+effect+of+PRE-084%2C+a+selective+sigma1+receptor+agonist%2C+in+Albino+Swiss+and+C57BL%2F6J+mice&doi=10.1016%2FS1734-1140%2809%2970181-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-like effect of PRE-084, a selective σ1 receptor agonist, in Albino Swiss and C57BL/6J mice</span></div><div class="casAuthors">Skuza, Grazyna; Rogoz, Zofia</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1179-1183</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">1734-1140</span>.
    
            (<span class="NLM_cas:orgname">Polish Academy of Sciences, Institute of Pharmacology</span>)
        </div><div class="casAbstract">PRE-084, a selective a receptor agonist, exhibited an antidepressant-like effect in the forced swim test (FST) in Albino Swiss and C57BL/6J mice.  This effect was counteracted by BD 1047 (5 and 10 mg/kg) but not by SM-21 (3 and 10 mg/kg), which are σ1- and σ2-receptor antagonists, resp.  The results indicated that PRE-084 has an antidepressant-like effect in C57BL/6J and, to a lesser extent, in Albino Swiss mice.  These results support the idea that σ1-receptors, but not σ2-receptors, contribute to the mechanism of antidepressant activity of σ agonists in FST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHrd8gw1CyRrVg90H21EOLACvtfcHk0lgCINlME0ax7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Ggtbg%253D&md5=84aed69e8c3b1a8433c6a4c95d445ac8</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2FS1734-1140%2809%2970181-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1734-1140%252809%252970181-1%26sid%3Dliteratum%253Aachs%26aulast%3DSkuza%26aufirst%3DG.%26aulast%3DRogoz%26aufirst%3DZ.%26atitle%3DAntidepressant-like%2520effect%2520of%2520PRE-084%252C%2520a%2520selective%2520sigma1%2520receptor%2520agonist%252C%2520in%2520Albino%2520Swiss%2520and%2520C57BL%252F6J%2520mice%26jtitle%3DPharmacol.%2520Rep.%26date%3D2009%26volume%3D61%26spage%3D1179%26epage%3D1183%26doi%3D10.1016%2FS1734-1140%2809%2970181-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsunekawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senzaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabeshima, T.</span></span> <span> </span><span class="NLM_article-title">Role of <i>N</i>-methyl-<i>D</i>-aspartate receptors in antidepressant-like effects of sigma 1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA-4503) in olfactory bulbectomized rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.124685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.107.124685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=17556637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslKrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=1305-1314&author=D.+Wangauthor=Y.+Nodaauthor=H.+Tsunekawaauthor=Y.+Zhouauthor=M.+Miyazakiauthor=K.+Senzakiauthor=A.+Nittaauthor=T.+Nabeshima&title=Role+of+N-methyl-D-aspartate+receptors+in+antidepressant-like+effects+of+sigma+1+receptor+agonist+1-%283%2C4-dimethoxyphenethyl%29-4-%283-phenylpropyl%29piperazine+dihydrochloride+%28SA-4503%29+in+olfactory+bulbectomized+rats&doi=10.1124%2Fjpet.107.124685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Role of N-methyl-D-aspartate receptors in antidepressant-like effects of σ1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA-4503) in olfactory bulbectomized rats</span></div><div class="casAuthors">Wang, Dayong; Noda, Yukihiro; Tsunekawa, Hiroko; Zhou, Yuan; Miyazaki, Masayuki; Senzaki, Koji; Nitta, Atsumi; Nabeshima, Toshitaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1305-1314</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In the present study, we aimed to investigate the role of N-methyl-D-aspartate (NMDA) receptors in the antidepressant-like effects of a σ1 receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA-4503), in the olfactory bulbectomized (OB) rat model of depression.  A symptomatol.-based behavioral investigation was made by reconstructing in OB rats the symptoms of depression, such as psychomotor agitation, loss of interest, and cognitive dysfunction, using a typical antidepressant, desipramine, as a pos. control.  Repeated treatment with SA-4503 ameliorated the behavioral deficits in OB rats resembling depression symptoms in the open-field test, sexual behavior test, and cued and contextual fear-conditioning test.  SA-4503 displayed advantages over desipramine in the sexual behavior test.  SA-4503 also reversed the decrease in the protein expression of NMDA receptor subunit (NR)1, but not NR2A or NR2B, in the prefrontal cortex, hippocampus, and amygdala of OB rats.  The behavioral and neurochem. effects of SA-4503 were blocked by combined treatment with a specific σ1 receptor antagonist, N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride (NE-100).  Furthermore, the effects of SA-4503 on the performance of OB rats in the behavioral tests were abrogated by acute treatment with an NMDA receptor antagonist, (-)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801).  The present study indicated for the first time that the σ1 receptor agonist SA-4503 may have effects on depressive symptoms such as agitation, loss of interest, and impaired cognition, which are mediated by NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq77Az-VXFvtLVg90H21EOLACvtfcHk0li28zflLcXZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslKrtLs%253D&md5=4c619f3b2a1b6870aa8f2ef92bfe3aa6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.124685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.124685%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DNoda%26aufirst%3DY.%26aulast%3DTsunekawa%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DSenzaki%26aufirst%3DK.%26aulast%3DNitta%26aufirst%3DA.%26aulast%3DNabeshima%26aufirst%3DT.%26atitle%3DRole%2520of%2520N-methyl-D-aspartate%2520receptors%2520in%2520antidepressant-like%2520effects%2520of%2520sigma%25201%2520receptor%2520agonist%25201-%25283%252C4-dimethoxyphenethyl%2529-4-%25283-phenylpropyl%2529piperazine%2520dihydrochloride%2520%2528SA-4503%2529%2520in%2520olfactory%2520bulbectomized%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D1305%26epage%3D1314%26doi%3D10.1124%2Fjpet.107.124685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi-Utsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakaki, T.</span></span> <span> </span><span class="NLM_article-title">Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>440</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2008.05.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neulet.2008.05.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18547721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Slu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2008&pages=19-22&author=K.+Kikuchi-Utsumiauthor=T.+Nakaki&title=Chronic+treatment+with+a+selective+ligand+for+the+sigma-1+receptor+chaperone%2C+SA4503%2C+up-regulates+BDNF+protein+levels+in+the+rat+hippocampus&doi=10.1016%2Fj.neulet.2008.05.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus</span></div><div class="casAuthors">Kikuchi-Utsumi, Kazue; Nakaki, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-22</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Numerous studies have shown the sigma-1 receptor chaperone (previously designated as the sigma-1 receptor) to play an important role in various neuronal functions, and selective ligands for sigma-1 receptor chaperone have been found to have therapeutic potential in certain psychiatric disorders and some forms of neuronal damage.  Brain-derived neurotrophic factor (BDNF) is postulated to be related to the pharmacol. action of sigma ligands, though the functional interaction between sigma-1 receptor chaperone ligands and BDNF remains to be clarified.  This study was undertaken to investigate whether or not administration of SA4503, a selective ligand for sigma-1 receptor chaperone, affects BDNF levels in several regions of the rat brain.  Rats were injected with SA4503 (0.3, 1 and 3 mg/(kg day), i.p.) once or repeatedly for 2 or 4 wk.  BDNF protein levels were estd. by Western blot anal. in the striatum, midbrain, frontal cortex, hippocampus and thalamus.  A single injection of SA4503 did not change BDNF protein levels, while chronic injection for 2 or 4 wk tended to increase BDNF levels in the hippocampus.  In particular, 1 mg/kg of SA4503 daily for 2 wk led to a statistically significant, i.e. twofold, increase in the BDNF protein level in the hippocampus.  On the other hand, the TrkB receptor, a primary receptor for BDNF, exists in truncated and full-length isoforms, hippocampal levels of which were unaffected by SA4503 treatments.  Our findings indicate that chronic administration of SA4503 may regulate region-specific BDNF functions in the rat brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUJt-rR0sYFrVg90H21EOLACvtfcHk0li28zflLcXZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Slu7g%253D&md5=4b246e8f3bf935ba5e4baf277e1f8c39</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2008.05.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2008.05.055%26sid%3Dliteratum%253Aachs%26aulast%3DKikuchi-Utsumi%26aufirst%3DK.%26aulast%3DNakaki%26aufirst%3DT.%26atitle%3DChronic%2520treatment%2520with%2520a%2520selective%2520ligand%2520for%2520the%2520sigma-1%2520receptor%2520chaperone%252C%2520SA4503%252C%2520up-regulates%2520BDNF%2520protein%2520levels%2520in%2520the%2520rat%2520hippocampus%26jtitle%3DNeurosci.%2520Lett.%26date%3D2008%26volume%3D440%26spage%3D19%26epage%3D22%26doi%3D10.1016%2Fj.neulet.2008.05.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X. C.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of sigma-1 receptors elicits rapid antidepressant activity</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1111/cns.12502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fcns.12502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=26854125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVentLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=368-377&author=Y.+Wangauthor=L.+Guoauthor=H.+F.+Jiangauthor=L.+T.+Zhengauthor=A.+Zhangauthor=X.+C.+Zhen&title=Allosteric+modulation+of+sigma-1+receptors+elicits+rapid+antidepressant+activity&doi=10.1111%2Fcns.12502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Sigma-1 Receptors Elicits Rapid Antidepressant Activity</span></div><div class="casAuthors">Wang, Yun; Guo, Lin; Jiang, Hua-Feng; Zheng, Long-Tai; Zhang, Ao; Zhen, Xue-Chu</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">368-377</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Aims : Sigma-1 receptors are involved in the pathophysiol. process of several neuropsychiatric diseases such as epilepsy, depression.  Allosteric modulation represents an important mechanism for receptor functional regulation.  In this study, we examd. antidepressant activity of the latest identified novel and selective allosteric modulator of sigma-1 receptor 3-methyl-phenyl-2, 3, 4, 5-tetrahydro-1H-benzo[d]azepin-7-ol (SOMCL-668).  Methods and Results : A single administration of SOMCL-668 decreased the immobility time in the forced swimming test (FST) and tailing suspended test in mice, which were abolished by pretreatment of sigma-1 receptor antagonist BD1047.  In the chronic unpredicted mild stress (CUMS) model, chronic application of SOMCL-668 rapidly ameliorated anhedonia-like behavior (within a week), accompanying with the enhanced expression of brain-derived neurotrophic factor (BDNF) and phosphorylation of glycogen synthase kinase 3β (GSK3β) (Ser-9) in the hippocampus.  SOMCL-668 also rapidly promoted the phosphorylation of GSK3β (Ser-9) in an allosteric manner in vitro.  In the cultured primary neurons, SOMCL-668 enhanced the sigma-1 receptor agonist-induced neurite outgrowth and the secretion of BDNF.  Conclusion : SOMCL-668, a novel allosteric modulator of sigma-1 receptors, elicits a potent and rapid acting antidepressant effect.  The present data provide the first evidence that allosteric modulation of sigma-1 receptors may represent a new approach for antidepressant drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCiQyRvtg11bVg90H21EOLACvtfcHk0li28zflLcXZCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVentLo%253D&md5=feb669192dd6113e0d9f93fa5c6bc3f4</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fcns.12502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcns.12502%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%2BF.%26aulast%3DZheng%26aufirst%3DL.%2BT.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DX.%2BC.%26atitle%3DAllosteric%2520modulation%2520of%2520sigma-1%2520receptors%2520elicits%2520rapid%2520antidepressant%2520activity%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2016%26volume%3D22%26spage%3D368%26epage%3D377%26doi%3D10.1111%2Fcns.12502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anoal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/S0306-4522(00)00014-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS0306-4522%2800%2900014-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10771347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFGhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=155-170&author=G.+Alonsoauthor=V.+Phanauthor=I.+Guillemainauthor=M.+Saunierauthor=A.+Legrandauthor=M.+Anoalauthor=T.+Maurice&title=Immunocytochemical+localization+of+the+sigma%281%29+receptor+in+the+adult+rat+central+nervous+system&doi=10.1016%2FS0306-4522%2800%2900014-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system</span></div><div class="casAuthors">Alonso, G.; Phan, V.-L.; Guillemain, I.; Saunier, M.; Legrand, A.; Anoal, M.; Maurice, T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-170</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">To characterize the localization of the sigma1 receptor in the adult rat central nervous system, a polyclonal antibody was raised against a 20 amino acid peptide, corresponding to the fragment 143-162 of the cloned sigma1 receptor protein.  Throughout the rostrocaudal regions of the central nervous system extending from the olfactory bulb to the spinal cord, intense to moderate immunostaining was found to be assocd. with: (i) ependymocytes bordering the entire ventricular system, and (ii) neuron-like structures located within the parenchyma.  Double fluorescence studies confirmed that, throughout the parenchyma, sigma1 receptor-immunostaining was essentially assocd. with neuronal structures immunostained for the neuronal marker βIII-tubulin.  In all rats examd., high levels of immunostaining were always assocd. with neurons located within specific regions including the granular layer of the olfactory bulb, various hypothalamic nuclei, the septum, the central gray, motor nuclei of the hindbrain and the dorsal horn of the spinal cord.  In contrast, only faint immunostaining was assocd. with neurons located in the caudate-putamen and the cerebellum.  Electron microscope studies indicated that sigma1 receptor immunostaining was mostly assocd. with neuronal perikarya and dendrites, where it was localized to the limiting plasma membrane, the membrane of mitochondria and of some cisternae of the endoplasmic reticulum.  At the level of synaptic contacts, intense immunostaining was assocd. with postsynaptic structures including the postsynaptic thickening and some polymorphous vesicles, whereas the presynaptic axons were devoid of immunostaining.  These data indicate that the sigma1 receptor antibody prepd. here, represents a promising tool for further investigating the role of σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsAacDelSDfbVg90H21EOLACvtfcHk0ljDnzgqUzfTqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFGhurg%253D&md5=2df1ba6a60488364ad458069e059354d</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2800%2900014-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252800%252900014-2%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DG.%26aulast%3DPhan%26aufirst%3DV.%26aulast%3DGuillemain%26aufirst%3DI.%26aulast%3DSaunier%26aufirst%3DM.%26aulast%3DLegrand%26aufirst%3DA.%26aulast%3DAnoal%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DImmunocytochemical%2520localization%2520of%2520the%2520sigma%25281%2529%2520receptor%2520in%2520the%2520adult%2520rat%2520central%2520nervous%2520system%26jtitle%3DNeuroscience%26date%3D2000%26volume%3D97%26spage%3D155%26epage%3D170%26doi%3D10.1016%2FS0306-4522%2800%2900014-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of sigma-1 receptors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.pharmthera.2009.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19619582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGktLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2009&pages=195-206&author=T.+Mauriceauthor=T.+P.+Su&title=The+pharmacology+of+sigma-1+receptors&doi=10.1016%2Fj.pharmthera.2009.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of sigma-1 receptors</span></div><div class="casAuthors">Maurice, Tangui; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Originally considered an enigmatic protein, the sigma-1 receptor has recently been identified as a unique ligand-regulated mol. chaperone in the endoplasmic reticulum of cells.  This discovery causes us to look back at the many proposed roles of this receptor, even before its mol. function was identified, in many diseases such as methamphetamine or cocaine addiction, amnesia, pain, depression, Alzheimer's disease, stroke, retinal neuroprotection, HIV infection, and cancer.  In this review, we examine the reports that have clearly shown an agonist-antagonist relationship regarding sigma-1 receptors in models of those diseases and also review the relatively known mechanisms of action of sigma-1 receptors in an attempt to spur the speculation of readers on how the sigma-1 receptor at the endoplasmic reticulum might relate to so many diseases.  We found that the most prominent action of sigma-1 receptors in biol. systems including cell lines, primary cultures, and animals is the regulation and modulation of voltage-regulated and ligand-gated ion channels, including Ca2+-, K+-, Na+, Cl-, and SK channels, and NMDA and IP3 receptors.  We found that the final output of the action of sigma-1 receptor agonists is to inhibit all above-mentioned voltage-gated ion channels, while they potentiate ligand-gated channels.  The inhibition or potentiation induced by agonists is blocked by sigma-1 receptor antagonists.  Other mechanisms of action of sigma-1 receptors, and to some extent those of sigma-2 receptors, were also considered.  We conclude that the sigma-1 and sigma-2 receptors represent potential fruitful targets for therapeutic developments in combating many human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4d_UAy6J4KbVg90H21EOLACvtfcHk0ljDnzgqUzfTqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGktLnM&md5=7b5e251decc29edef42ffef1d65dd487</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DThe%2520pharmacology%2520of%2520sigma-1%2520receptors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D124%26spage%3D195%26epage%3D206%26doi%3D10.1016%2Fj.pharmthera.2009.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artacho-Cordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of peripheral mu-opioid analgesia by sigma1 receptors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.208272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.113.208272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24155346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=32-45&author=C.+Sanchez-Fernandezauthor=A.+Montilla-Garciaauthor=R.+Gonzalez-Canoauthor=F.+R.+Nietoauthor=L.+Romeroauthor=A.+Artacho-Cordonauthor=R.+Montesauthor=B.+Fernandez-Pastorauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=J.+M.+Entrenaauthor=E.+J.+Cobos&title=Modulation+of+peripheral+mu-opioid+analgesia+by+sigma1+receptors&doi=10.1124%2Fjpet.113.208272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of peripheral μ-opioid analgesia by σ1 receptors</span></div><div class="casAuthors">Sanchez-Fernandez, Cristina; Montilla-Garcia, Angeles; Gonzalez-Cano, Rafael; Nieto, Francisco Rafael; Romero, Lucia; Artacho-Cordon, Antonia; Montes, Rosa; Fernandez-Pastor, Begona; Merlos, Manuel; Baeyens, Jose Manuel; Entrena, Jose Manuel; Cobos, Enrique Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the effects of σ1-receptor inhibition on μ-opioid-induced mech. antinociception and constipation. σ1-Knockout mice exhibited marked mech. antinociception in response to several μ-opioid analgesics (fentanyl, oxycodone, morphine, buprenorphine, and tramadol) at systemic (s.c.) doses that were inactive in wild-type mice and even unmasked the antinociceptive effects of the peripheral μ-opioid agonist loperamide.  Likewise, systemic (s.c.) or local (intraplantar) treatment of wild-type mice with the selective σ1 antagonists BD-1063 [1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihydrochloride] or S1RA [4-[2-[[5-methyl-1-(2-naphthalenyl)1H-pyrazol-3-yl]oxy]ethyl] morpholine hydrochloride] potentiated μ-opioid antinociception; these effects were fully reversed by the σ1 agonist PRE-084 [2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate) hydrochloride], showing the selectivity of the pharmacol. approach.  The μ-opioid antinociception potentiated by σ1 inhibition (by σ1-receptor knockout or σ1-pharmacol. antagonism) was more sensitive to the peripherally restricted opioid antagonist naloxone methiodide than opioid antinociception under normal conditions, indicating a key role for peripheral opioid receptors in the enhanced antinociception.  Direct interaction between the opioid drugs and σ1 receptor cannot account for our results, since the former lacked affinity for σ1 receptors (labeled with [3H](+)-pentazocine).  A peripheral role for σ1 receptors was also supported by their higher d. (Western blot results) in peripheral nervous tissue (dorsal root ganglia) than in several central areas involved in opioid antinociception (dorsal spinal cord, basolateral amygdala, periaqueductal gray, and rostroventral medulla).  In contrast to its effects on nociception, σ1-receptor inhibition did not alter fentanyl- or loperamide-induced constipation, a peripherally mediated nonanalgesic opioid effect.  Therefore, σ1-receptor inhibition may be used as a systemic or local adjuvant to enhance peripheral μ-opioid analgesia without affecting opioid-induced constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXDUF69QHTL7Vg90H21EOLACvtfcHk0ljDnzgqUzfTqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju74%253D&md5=3448ecaf8c215210a48a8413b89db2a5</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208272%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DGonzalez-Cano%26aufirst%3DR.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DArtacho-Cordon%26aufirst%3DA.%26aulast%3DMontes%26aufirst%3DR.%26aulast%3DFernandez-Pastor%26aufirst%3DB.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DModulation%2520of%2520peripheral%2520mu-opioid%2520analgesia%2520by%2520sigma1%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D32%26epage%3D45%26doi%3D10.1124%2Fjpet.113.208272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roh, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span> <span> </span><span class="NLM_article-title">Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1097/ALN.0b013e3181895a83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1097%2FALN.0b013e3181895a83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18946301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Oks7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2008&pages=879-889&author=D.+H.+Rohauthor=H.+W.+Kimauthor=S.+Y.+Yoonauthor=H.+S.+Seoauthor=Y.+B.+Kwonauthor=K.+W.+Kimauthor=H.+J.+Hanauthor=A.+J.+Beitzauthor=H.+S.+Naauthor=J.+H.+Lee&title=Intrathecal+injection+of+the+sigma%281%29+receptor+antagonist+BD1047+blocks+both+mechanical+allodynia+and+increases+in+spinal+NR1+expression+during+the+induction+phase+of+rodent+neuropathic+pain&doi=10.1097%2FALN.0b013e3181895a83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Intrathecal Injection of the varsigma1 Receptor Antagonist BD1047 Blocks Both Mechanical Allodynia and Increases in Spinal NR1 Expression during the Induction Phase of Rodent Neuropathic Pain</span></div><div class="casAuthors">Roh, Dae-Hyun; Kim, Hyun-Woo; Yoon, Seo-Yeon; Seo, Hyoung-Sig; Kwon, Young-Bae; Kim, Kee-Won; Han, Ho-Jae; Beitz, Alvin J.; Na, Heung-Sik; Lee, Jang-Hern</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">879-889</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Selective blockade of spinal varsigm receptors (Sig-1R) suppresses nociceptive behaviors in the mouse formalin test.  The current study was designed to verify whether intrathecal Sig-1R antagonists can also suppress chronic neuropathic pain.  Neuropathic pain was produced by chronic constriction injury (CCI) of the right sciatic nerve in rats.  The Sig-1R antagonist BD1047 was administered intrathecally twice daily from postoperative days 0 to 5 (induction phase of neuropathic pain) or from days 15 to 20 (maintenance phase).  Western blot and immunohistochem. were performed to det. changes in Sig-1R expression and to examine the effect of BD1047 on N-methyl-d-aspartate receptor subunit 1 expression and phosphorylation in spinal cord dorsal horn from neuropathic rats.  BD1047 administered on postoperative days 0-5 significantly attenuated CCI-induced mech. allodynia, but not thermal hyperalgesia, and this suppression was blocked by intrathecal administration of the Sig-1R agonist PRE084.  In contrast, BD1047 treatment during the maintenance phase of neuropathic pain had no effect on mech. allodynia.  Sig-1R expression significantly increased in the ipsilateral spinal cord dorsal horn from days 1 to 3 after CCI.  Importantly, BD1047 (30 nmol) administered intrathecally during the induction, but not the maintenance phase, blocked the CCI-induced increase in N-methyl-d-aspartate receptor subunit 1 expression and phosphorylation.  These results demonstrate that spinal Sig-1Rs play a crit. role in both the induction of mech. allodynia and the activation of spinal N-methyl-d-aspartate receptors in CCI rats and suggest a potential therapeutic role for the use of Sig-1R antagonists in the clin. management of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxfKToM8cePbVg90H21EOLACvtfcHk0ljZX5Z7ldxDig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Oks7fE&md5=aabc720d7c9d15df821d2442bf7586a9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1097%2FALN.0b013e3181895a83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0b013e3181895a83%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DYoon%26aufirst%3DS.%2BY.%26aulast%3DSeo%26aufirst%3DH.%2BS.%26aulast%3DKwon%26aufirst%3DY.%2BB.%26aulast%3DKim%26aufirst%3DK.%2BW.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26aulast%3DBeitz%26aufirst%3DA.%2BJ.%26aulast%3DNa%26aufirst%3DH.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26atitle%3DIntrathecal%2520injection%2520of%2520the%2520sigma%25281%2529%2520receptor%2520antagonist%2520BD1047%2520blocks%2520both%2520mechanical%2520allodynia%2520and%2520increases%2520in%2520spinal%2520NR1%2520expression%2520during%2520the%2520induction%2520phase%2520of%2520rodent%2520neuropathic%2520pain%26jtitle%3DAnesthesiology%26date%3D2008%26volume%3D109%26spage%3D879%26epage%3D889%26doi%3D10.1097%2FALN.0b013e3181895a83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artacho-Cordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Potentiation of morphine-induced mechanical antinociception by sigma(1) receptor inhibition: role of peripheral sigma(1) receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuropharm.2013.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23524304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVSqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=348-358&author=C.+Sanchez-Fernandezauthor=F.+R.+Nietoauthor=R.+Gonzalez-Canoauthor=A.+Artacho-Cordonauthor=L.+Romeroauthor=A.+Montilla-Garciaauthor=D.+Zamanilloauthor=J.+M.+Baeyensauthor=J.+M.+Entrenaauthor=E.+J.+Cobos&title=Potentiation+of+morphine-induced+mechanical+antinociception+by+sigma%281%29+receptor+inhibition%3A+role+of+peripheral+sigma%281%29+receptors&doi=10.1016%2Fj.neuropharm.2013.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of morphine-induced mechanical antinociception by σ1 receptor inhibition: Role of peripheral σ1 receptors</span></div><div class="casAuthors">Sanchez-Fernandez, Cristina; Nieto, Francisco Rafael; Gonzalez-Cano, Rafael; Artacho-Cordon, Antonia; Romero, Lucia; Montilla-Garcia, Angeles; Zamanillo, Daniel; Baeyens, Jose Manuel; Entrena, Jose Manuel; Cobos, Enrique Jose</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">348-358</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We studied the modulation of morphine-induced mech. antinociception and side effects by σ1 receptor inhibition.  Both wild-type (WT) and σ1 receptor knockout (σ1-KO) mice showed similar responses to paw pressure (100-600 g).  The systemic (s.c.) or local (intraplantar) administration of σ1 antagonists (BD-1063, BD-1047, NE-100 and S1RA) was devoid of antinociceptive effects in WT mice.  However, σ1-KO mice exhibited an enhanced mech. antinociception in response to systemic morphine (1-16 mg/kg).  Similarly, systemic treatment of WT mice with σ1 antagonists markedly potentiated morphine-induced antinociception, and its effects were reversed by the selective σ1 agonist PRE-084.  Although the local administration of morphine (50-200 μg) was devoid of antinociceptive effects in WT mice, it induced dose-dependent antinociception in σ1-KO mice.  This effect was limited to the injected paw.  Enhancement of peripheral morphine antinociception was replicated in WT mice locally co-administered with σ1 antagonists and the opioid.  None of the σ1 antagonists tested enhanced morphine-antinociception in σ1-KO mice, confirming a σ1-mediated action.  Morphine-induced side-effects (hyperlocomotion and inhibition of gastrointestinal transit) were unaltered in σ1-KO mice.  These results cannot be explained by a direct interaction of σ1 ligands with μ-opioid receptors or adaptive changes of μ-receptors in σ1-KO mice, given that [3H]DAMGO binding in forebrain, spinal cord, and hind-paw skin membranes was unaltered in mutant mice, and none of the σ1 drugs tested bound to μ-opioid receptors.  These results show that σ1 receptor inhibition potentiates morphine-induced mech. analgesia but not its acute side effects, and that this enhanced analgesia can be induced at peripheral level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc2KFSqih3HbVg90H21EOLACvtfcHk0ljZX5Z7ldxDig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVSqt7s%253D&md5=d21562671453852a7e07c15232726ade</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DGonzalez-Cano%26aufirst%3DR.%26aulast%3DArtacho-Cordon%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DPotentiation%2520of%2520morphine-induced%2520mechanical%2520antinociception%2520by%2520sigma%25281%2529%2520receptor%2520inhibition%253A%2520role%2520of%2520peripheral%2520sigma%25281%2529%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D70%26spage%3D348%26epage%3D358%26doi%3D10.1016%2Fj.neuropharm.2013.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salaman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological modulation of the sigma 1 receptor and the treatment of pain</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>964</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-50174-1_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2F978-3-319-50174-1_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28315267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=964&publication_year=2017&pages=85-107&author=M.+Merlosauthor=J.+Burguenoauthor=E.+Portillo-Salidoauthor=C.+R.+Plata-Salamanauthor=J.+M.+Vela&title=Pharmacological+modulation+of+the+sigma+1+receptor+and+the+treatment+of+pain&doi=10.1007%2F978-3-319-50174-1_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological modulation of the sigma 1 receptor and the treatment of pain</span></div><div class="casAuthors">Merlos, Manuel; Burgueno, Javier; Portillo-Salido, Enrique; Plata-Salaman, Carlos Ramon; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">964</span>
        (<span class="NLM_cas:issue">Sigma Receptors: Their Role in Disease and as Therapeutic Targets</span>),
    <span class="NLM_cas:pages">85-107</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">There is a crit. need for new analgesics acting through new mechanisms of action, which could increase the efficacy with respect to existing therapies and reduce their unwanted effects.  Current preclin. evidence supports the modulatory role of sigma-1 receptors (σ1R) in nociception, mainly based on the pain-attenuated phenotype of σ1R knockout mice and on the antinociceptive effect exerted by σ1R antagonists on pains of different etiologies. σ1R is highly expressed in different pain areas of the CNS and the periphery (particularly dorsal root ganglia), and interacts and modulates the functionality of different receptors and ion channels.  The antagonism of σ1R leads to decreased amplification of pain signaling within the spinal cord (central sensitization), but recent data also support a role at the periphery. σ1R antagonists have consistently demonstrated efficacy in neuropathic pain, but also in other types of pain including inflammatory, orofacial, visceral, and post-operative pain.  Apart from acting alone, when combined with opioids, σ1R antagonists enhance opioid analgesia but not opioid-induced unwanted effects.  Interestingly, unlike opioids, σ1R antagonists do not modify normal sensory mech. and thermal sensitivity thresholds but they exert antihypersensitive effects in sensitizing conditions, enabling the reversal of nociceptive thresholds back to normal values.  Accordingly, σ1R antagonists are not strictly analgesics; they are antiallodynic and antihyperalgesic drugs acting when the system is sensitized following prolonged noxious stimulation or persistent abnormal afferent input (e.g., secondary to nerve injury).  These are distinctive features allowing σ1R antagonists to exert a modulatory effect specifically in pathophysiol. conditions such as chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwcRJqz4BxF7Vg90H21EOLACvtfcHk0ljZX5Z7ldxDig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7O&md5=212a8fac96a772a7888762da8e70fc0d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-50174-1_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-50174-1_8%26sid%3Dliteratum%253Aachs%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBurgueno%26aufirst%3DJ.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DPlata-Salaman%26aufirst%3DC.%2BR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DPharmacological%2520modulation%2520of%2520the%2520sigma%25201%2520receptor%2520and%2520the%2520treatment%2520of%2520pain%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D964%26spage%3D85%26epage%3D107%26doi%3D10.1007%2F978-3-319-50174-1_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span> <span> </span><span class="NLM_article-title">Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fbjp.2008.159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18493253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVGru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1125-1134&author=H.+W.+Kimauthor=D.+H.+Rohauthor=S.+Y.+Yoonauthor=H.+S.+Seoauthor=Y.+B.+Kwonauthor=H.+J.+Hanauthor=K.+W.+Kimauthor=A.+J.+Beitzauthor=J.+H.+Lee&title=Activation+of+the+spinal+sigma-1+receptor+enhances+NMDA-induced+pain+via+PKC-+and+PKA-dependent+phosphorylation+of+the+NR1+subunit+in+mice&doi=10.1038%2Fbjp.2008.159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice</span></div><div class="casAuthors">Kim, H.-W.; Roh, D.-H.; Yoon, S.-Y.; Seo, H.-S.; Kwon, Y.-B.; Han, H.-J.; Kim, K.-W.; Beitz, A. J.; Lee, J.-H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1125-1134</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background and purpose: Previously we demonstrated that the spinal sigma-1 receptor (Sig-1 R) plays an important role in pain transmission, although the exact mechanism is still unclear.  It has been suggested that Sig-1 R agonists increase glutamate-induced calcium influx through N-methyl-D-aspartate (NMDA) receptors.  Despite data suggesting a link between Sig-1 Rs and NMDA receptors, there are no studies addressing whether Sig-1 R activation directly affects NMDA receptor sensitivity.  Exptl. approach: We studied the effect of intrathecal (i.t.) administration of Sig-1 R agonists on protein kinase C (PKC) and protein kinase A (PKA) dependent phosphorylation of the NMDA receptor subunit NR1 (pNR1) as a marker of NMDA receptor sensitization.  In addn., we examd. whether this Sig-1 R mediated phosphorylation of NR1 plays an important role in sensory function using a model of NMDA-induced pain.  Key results: Both Western blot assays and image anal. of pNR1 immunohistochem. staining in the spinal cord indicated that i.t. injection of the Sig-1 R agonists, PRE-084 or carbetapentane dose dependently enhanced pNR1 expression in the murine dorsal horn.  This increased pNR1 expression was significantly reduced by pretreatment with the specific Sig-1 R antagonist, BD-1047.  In another set of expts. Sig-1 R agonists further potentiated NMDA-induced pain behavior and pNR1 immunoreactivity and this was also reversed with BD-1047.  Conclusions and implications: The results of this study suggest that the activation of spinal Sig-1 R enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NMDA receptor NR 1 subunit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt_HsZ1tEMobVg90H21EOLACvtfcHk0lihpaXyQaa20A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVGru7s%253D&md5=03b6027eeecb8ae4b3dfa8695434132f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.159%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DRoh%26aufirst%3DD.%2BH.%26aulast%3DYoon%26aufirst%3DS.%2BY.%26aulast%3DSeo%26aufirst%3DH.%2BS.%26aulast%3DKwon%26aufirst%3DY.%2BB.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DK.%2BW.%26aulast%3DBeitz%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26atitle%3DActivation%2520of%2520the%2520spinal%2520sigma-1%2520receptor%2520enhances%2520NMDA-induced%2520pain%2520via%2520PKC-%2520and%2520PKA-dependent%2520phosphorylation%2520of%2520the%2520NR1%2520subunit%2520in%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1125%26epage%3D1134%26doi%3D10.1038%2Fbjp.2008.159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>964</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-50174-1_9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2F978-3-319-50174-1_9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28315268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=964&publication_year=2017&pages=109-132&author=C.+Sanchez-Fernandezauthor=J.+M.+Entrenaauthor=J.+M.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+receptor+antagonists%3A+a+new+class+of+neuromodulatory+analgesics&doi=10.1007%2F978-3-319-50174-1_9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics</span></div><div class="casAuthors">Sanchez-Fernandez, Cristina; Entrena, Jose Manuel; Baeyens, Jose Manuel; Cobos, Enrique Jose</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">964</span>
        (<span class="NLM_cas:issue">Sigma Receptors: Their Role in Disease and as Therapeutic Targets</span>),
    <span class="NLM_cas:pages">109-132</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The sigma-1 receptor is a unique ligand-operated chaperone present in key areas for pain control, in both the peripheral and central nervous system.  Sigma-1 receptors interact with a variety of protein targets to modify their function.  These targets include several G-protein-coupled receptors such as the μ-opioid receptor, and ion channels such as the N-methyl-D-aspartate receptor (NMDAR).  Sigma-1 antagonists modify the chaperoning activity of sigma-1 receptor by increasing opioid signaling and decreasing NMDAR responses, consequently enhancing opioid antinociception and decreasing the sensory hypersensitivity that characterizes pathol. pain conditions.  However, the participation in pain relief of other protein partners of sigma-1 receptors in addn. to opioid receptors and NMDARs cannot be ruled out.  The enhanced opioid antinociception by sigma-1 antagonism is not accompanied by an increase in opioid side effects, including tolerance, dependence or constipation, so the use of sigma-1 antagonists may increase the therapeutic index of opioids.  Furthermore, sigma-1 antagonists (in the absence of opioids) have been shown to exert antinociceptive effects in preclin. models of neuropathic pain induced by nerve trauma or chem. injury (the antineoplastic paclitaxel), and more recently in inflammatory and ischemic pain.  Although most studies attributed the analgesic properties of sigma-1 antagonists to their central actions, it is now known that peripheral sigma-1 receptors also participate in their effects.  Overwhelming preclin. evidence of the role of sigma-1 receptors in pain has led to the development of the first selective sigma-1 antagonist with an intended indication for pain treatment, which is currently in Phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqngb6OQfqKNbVg90H21EOLACvtfcHk0lihpaXyQaa20A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7L&md5=b8bb957dd762dfdce939ef326e865302</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-50174-1_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-50174-1_9%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520receptor%2520antagonists%253A%2520a%2520new%2520class%2520of%2520neuromodulatory%2520analgesics%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D964%26spage%3D109%26epage%3D132%26doi%3D10.1007%2F978-3-319-50174-1_9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arroyos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera-Arconada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laloya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escriche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Garcia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salaman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">2289</span>– <span class="NLM_lpage">2306</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.01942.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fj.1476-5381.2012.01942.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22404321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1artL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=2289-2306&author=L.+Romeroauthor=D.+Zamanilloauthor=X.+Nadalauthor=R.+Sanchez-Arroyosauthor=I.+Rivera-Arconadaauthor=A.+Dordalauthor=A.+Monteroauthor=A.+Muroauthor=A.+Buraauthor=C.+Segalesauthor=M.+Laloyaauthor=E.+Hernandezauthor=E.+Portillo-Salidoauthor=M.+Escricheauthor=X.+Codonyauthor=G.+Encinaauthor=J.+Burguenoauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=J.+Giraldoauthor=J.+A.+Lopez-Garciaauthor=R.+Maldonadoauthor=C.+R.+Plata-Salamanauthor=J.+M.+Vela&title=Pharmacological+properties+of+S1RA%2C+a+new+sigma-1+receptor+antagonist+that+inhibits+neuropathic+pain+and+activity-induced+spinal+sensitization&doi=10.1111%2Fj.1476-5381.2012.01942.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization</span></div><div class="casAuthors">Romero, L.; Zamanillo, D.; Nadal, X.; Sanchez-Arroyos, R.; Rivera-Arconada, I.; Dordal, A.; Montero, A.; Muro, A.; Bura, A.; Segales, C.; Laloya, M.; Hernandez, E.; Portillo-Salido, E.; Escriche, M.; Codony, X.; Encina, G.; Burgueno, J.; Merlos, M.; Baeyens, J. M.; Giraldo, J.; Lopez-Garcia, J. A.; Maldonado, R.; Plata-Salaman, C. R.; Vela, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2289-2306</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose The sigma-1 (σ1) receptor is a ligand-regulated mol. chaperone that has been involved in pain, but there is limited understanding of the actions assocd. with its pharmacol. modulation.  Indeed, the selectivity and pharmacol. properties of σ1 receptor ligands used as pharmacol. tools are unclear and the demonstration that σ1 receptor antagonists have efficacy in reversing central sensitization-related pain sensitivity is still missing.  Exptl. Approach The pharmacol. properties of a novel σ1 receptor antagonist (S1RA) were first characterized.  S1RA was then used to investigate the effect of pharmacol. antagonism of σ1 receptors on in vivo nociception in sensitizing conditions and on in vitro spinal cord sensitization in mice.  Drug levels and autoradiog., ex vivo binding for σ1 receptor occupancy were measured to substantiate behavioral data.  Key Results Formalin-induced nociception (both phases), capsaicin-induced mech. hypersensitivity and sciatic nerve injury-induced mech. and thermal hypersensitivity were dose-dependently inhibited by systemic administration of S1RA.  Occupancy of σ1 receptors in the CNS was significantly correlated with the antinociceptive effects.  No pharmacodynamic tolerance to the antiallodynic and antihyperalgesic effect developed following repeated administration of S1RA to nerve-injured mice.  As a mechanistic correlate, electrophysiol. recordings demonstrated that pharmacol. antagonism of σ1 receptors attenuated the wind-up responses in spinal cords sensitized by repetitive nociceptive stimulation.  Conclusions and Implications These findings contribute to evidence identifying the σ1 receptor as a modulator of activity-induced spinal sensitization and pain hypersensitivity, and suggest σ1 receptor antagonists as potential novel treatments for neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK7puaGCXwhrVg90H21EOLACvtfcHk0lihpaXyQaa20A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1artL3L&md5=f84eec105e338b08175e476b63f6208f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01942.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01942.x%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DNadal%26aufirst%3DX.%26aulast%3DSanchez-Arroyos%26aufirst%3DR.%26aulast%3DRivera-Arconada%26aufirst%3DI.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DMontero%26aufirst%3DA.%26aulast%3DMuro%26aufirst%3DA.%26aulast%3DBura%26aufirst%3DA.%26aulast%3DSegales%26aufirst%3DC.%26aulast%3DLaloya%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DE.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DEscriche%26aufirst%3DM.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DEncina%26aufirst%3DG.%26aulast%3DBurgueno%26aufirst%3DJ.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DGiraldo%26aufirst%3DJ.%26aulast%3DLopez-Garcia%26aufirst%3DJ.%2BA.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DPlata-Salaman%26aufirst%3DC.%2BR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DPharmacological%2520properties%2520of%2520S1RA%252C%2520a%2520new%2520sigma-1%2520receptor%2520antagonist%2520that%2520inhibits%2520neuropathic%2520pain%2520and%2520activity-induced%2520spinal%2520sensitization%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D2289%26epage%3D2306%26doi%3D10.1111%2Fj.1476-5381.2012.01942.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocasalbas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tourino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bura, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codony, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>711</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2013.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejphar.2013.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23632394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVyksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=711&publication_year=2013&pages=63-72&author=A.+Vidal-Torresauthor=B.+de+la+Puenteauthor=M.+Rocasalbasauthor=C.+Tourinoauthor=S.+A.+Buraauthor=B.+Fernandez-Pastorauthor=L.+Romeroauthor=X.+Codonyauthor=D.+Zamanilloauthor=H.+Buschmannauthor=M.+Merlosauthor=J.+M.+Baeyensauthor=R.+Maldonadoauthor=J.+M.+Vela&title=Sigma-1+receptor+antagonism+as+opioid+adjuvant+strategy%3A+enhancement+of+opioid+antinociception+without+increasing+adverse+effects&doi=10.1016%2Fj.ejphar.2013.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects</span></div><div class="casAuthors">Vidal-Torres, Alba; de la Puente, Beatriz; Rocasalbas, Maria; Tourino, Clara; Andreea Bura, Simona; Fernandez-Pastor, Begona; Romero, Luz; Codony, Xavier; Zamanillo, Daniel; Buschmann, Helmut; Merlos, Manuel; Manuel Baeyens, Jose; Maldonado, Rafael; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">711</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">While opioids are potent analgesics widely used in the management of pain, a no. of well-known adverse effects limit their use.  The sigma-1 receptor is a ligand-regulated mol. chaperone involved in pain processing, including modulation of opioid antinociception.  However, data supporting the potential use of sigma-1 receptor ligands as suitable opioid adjuvants are based on studies that use non selective ligands.  Also, safety issues derived from combination therapy are poorly addressed.  In this study we used the new selective sigma-1 receptor antagonist S1RA (E-52862) to characterize the effect of selective sigma-1 receptor blockade on opioid-induced efficacy- and safety-related outcomes in mice.  S1RA (40 mg/kg) had no effect in the tail-flick test but did enhance the antinociceptive potency of several opioids by a factor between 2 and 3.3.  The potentiating effect of S1RA on morphine antinociception did not occur in sigma-1 receptor knockout mice, which supports the selective involvement of the sigma-1 receptor.  Interestingly, S1RA co-administration restored morphine antinociception in tolerant mice and reverted the reward effects of morphine in the conditioned place preference paradigm.  In addn., enhancement of antinociception was not accompanied by potentiation of other opioid-induced effects, such as the development of morphine analgesic tolerance, phys. dependence, inhibition of gastrointestinal transit, or mydriasis.  The use of sigma-1 receptor antagonists as opioid adjuvants could represent a promising pharmacol. strategy to enhance opioid potency and, most importantly, to increase the safety margin of opioids.  S1RA is currently in phase II clin. trials for the treatment of several pain conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVTGE08MufobVg90H21EOLACvtfcHk0ljudqRr64hubA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVyksLc%253D&md5=c2cd0eb6fe5a9232bff11fe1539f74d4</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DB.%26aulast%3DRocasalbas%26aufirst%3DM.%26aulast%3DTourino%26aufirst%3DC.%26aulast%3DBura%26aufirst%3DS.%2BA.%26aulast%3DFernandez-Pastor%26aufirst%3DB.%26aulast%3DRomero%26aufirst%3DL.%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSigma-1%2520receptor%2520antagonism%2520as%2520opioid%2520adjuvant%2520strategy%253A%2520enhancement%2520of%2520opioid%2520antinociception%2520without%2520increasing%2520adverse%2520effects%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D711%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.ejphar.2013.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Selective sigma-1 receptor antagonists for the treatment of pain</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.4155%2Ffmc.14.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25078137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1179-1199&author=C.+Almansaauthor=J.+M.+Vela&title=Selective+sigma-1+receptor+antagonists+for+the+treatment+of+pain&doi=10.4155%2Ffmc.14.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Selective sigma-1 receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Almansa, Carmen; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1179-1199</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The sigma-1 receptor (σ1R) is located in areas of the CNS key for pain control and belongs to a unique target class with chaperoning functions over different mol. targets involved in transmission and amplification of nociceptive messages.  Preclin. evidence supports a role for σ1R antagonists in the treatment of pain states where hypersensitivity develops as hyperalgesia and allodynia, two common symptoms encountered in neuropathic and other chronic pain conditions.  Addnl., σ1R antagonists increase opioid analgesia without increasing opioid-related unwanted effects, which point to their potential use as opioid adjuvant therapy.  This review summarizes the structure and function of the σ1R as well as the medicinal chem. and pharmacol. studies directed to the identification of σ1R antagonists for the treatment of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ0qGYS21i37Vg90H21EOLACvtfcHk0ljudqRr64hubA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurjK&md5=3ced452012e44f478a377f0fa52995d4</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.54%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DSelective%2520sigma-1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1179%26epage%3D1199%26doi%3D10.4155%2Ffmc.14.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huntington
Study Group, H. I.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1407</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1002/mds.25362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fmds.25362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23450660" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=1407-1415&author=H.+I.+Huntington%0AStudy+Group&title=A+randomized%2C+double-blind%2C+placebo-controlled+trial+of+pridopidine+in+Huntington%E2%80%99s+disease&doi=10.1002%2Fmds.25362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1002%2Fmds.25362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25362%26sid%3Dliteratum%253Aachs%26aulast%3DHuntington%2BStudy%2BGroup%26aufirst%3DH.%2BI.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520pridopidine%2520in%2520Huntington%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2013%26volume%3D28%26spage%3D1407%26epage%3D1415%26doi%3D10.1002%2Fmds.25362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grachev, I. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savola, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowsky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbehn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickenberg, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapetropoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squitieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieburtz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landwehrmeyer, G B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, N. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azulay, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachoud-Levi, A. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biglan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey-Bloom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craufurd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decorte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Michele, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dornhege, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feigin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallehawk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauteul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjermind, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illarioshkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenckes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampstra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konkel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopishinskaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystkowiak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komati, S. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwako, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakoning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latipova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFarlane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevitt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Neill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panegyres, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarrell, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragosta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rialland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romoli, A. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, C. V</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saft, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seppi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shprecher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skitt, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliveri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squitieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sungmee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temirbaeva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torvin-Moller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangsted-Hansen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalyalova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielonka, D.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(18)30391-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS1474-4422%2818%2930391-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30563778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFekur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=165-176&author=R.+Reilmannauthor=A.+McGarryauthor=I.+D+Grachevauthor=J.-M.+Savolaauthor=B.+Borowskyauthor=E.+Eyalauthor=N.+Grossauthor=D.+Langbehnauthor=R.+Schubertauthor=A.+T.+Wickenbergauthor=S.+Papapetropoulosauthor=M.+Haydenauthor=F.+Squitieriauthor=K.+Kieburtzauthor=G+B.+Landwehrmeyerauthor=P.+Agarwalauthor=K.+E+Andersonauthor=N.+A+Azizauthor=J.-P.+Azulayauthor=A.+C+Bachoud-Leviauthor=R.+Barkerauthor=A.+Bebakauthor=M.+Beuthauthor=K.+Biglanauthor=S.+Blinauthor=S.+Bohlenauthor=R.+Bonelliauthor=S.+Caldwellauthor=F.+Calvasauthor=J.+Carlosauthor=S.+Castagliuoloauthor=T.+Chongauthor=P.+Chuaauthor=A.+Colemanauthor=J.+Corey-Bloomauthor=R.+Cousinsauthor=D.+Craufurdauthor=J.+Davisonauthor=E.+Decorteauthor=G.+De+Micheleauthor=L.+Dornhegeauthor=A.+Feiginauthor=S.+Gallehawkauthor=P.+Gauteulauthor=C.+Gonzalesauthor=J.+Griffithauthor=A.+Gustovauthor=M.+Guttmanauthor=B.+Heimauthor=H.+Hellerauthor=L.+Hjermindauthor=S.+Illarioshkinauthor=L.+Ivankoauthor=J.+Jaynesauthor=M.+Jenckesauthor=B.+Kaminskiauthor=A.+Kampstraauthor=A.+Konkelauthor=S.+Kopishinskayaauthor=P.+Krystkowiakauthor=S.+K+Komatiauthor=A.+Kwakoauthor=S.+Lakoningauthor=G.+Latipovaauthor=B.+Leavittauthor=C.+Loyauthor=C.+MacFarlaneauthor=L.+Madsenauthor=K.+Marderauthor=S.+Masonauthor=N.+Mendisauthor=T.+Mendisauthor=A.+Nemethauthor=L.+Nevittauthor=V.+Norrisauthor=C.+O%27Neillauthor=A.+Olivierauthor=M.+Orthauthor=A.+Owensauthor=P.+Panegyresauthor=S.+Perlmanauthor=J.+Prestonauthor=J.+Prillerauthor=A.+Puchauthor=O.+Quarrellauthor=D.+Ragostaauthor=A.+Riallandauthor=H.+Rickardsauthor=A.+M+Romoliauthor=C.+Rossauthor=A.+Rosserauthor=M.+Rudzinskaauthor=C.+V+Russoauthor=C.+Saftauthor=V.+Segroauthor=K.+Seppiauthor=B.+Shannonauthor=D.+Shprecherauthor=C.+Simoninauthor=Z.+Skittauthor=J.+Slawekauthor=P.+Soliveriauthor=S.+Sorbiauthor=F.+Squitieriauthor=V.+Suskiauthor=I.+Stepniakauthor=P.+Sungmeeauthor=S.+Temirbaevaauthor=C.+Testaauthor=A.+Torvin-Mollerauthor=S.+Uhlauthor=C.+Vangsted-Hansenauthor=C.+Vernyauthor=P.+Wallauthor=F.+Walkerauthor=P.+Wassermanauthor=G.+Witkowskiauthor=J.+Wrightauthor=Z.+Zalyalovaauthor=D.+Zielonka&title=Safety+and+efficacy+of+pridopidine+in+patients+with+Huntington%E2%80%99s+disease+%28PRIDE-HD%29%3A+a+phase+2%2C+randomised%2C+placebo-controlled%2C+multicentre%2C+dose-ranging+study&doi=10.1016%2FS1474-4422%2818%2930391-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study</span></div><div class="casAuthors">Reilmann, Ralf; McGarry, Andrew; Grachev, Igor D.; Savola, Juha-Matti; Borowsky, Beth; Eyal, Eli; Gross, Nicholas; Langbehn, Douglas; Schubert, Robin; Wickenberg, Anna Teige; Papapetropoulos, Spyros; Hayden, Michael; Squitieri, Ferdinando; Kieburtz, Karl; Landwehrmeyer, G. Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-176</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Previous trials have shown that pridopidine might reduce motor impairment in patients with Huntington's disease.  The aim of this study was to ascertain whether higher doses of pridopidine than previously tested reduce motor symptoms in a dose-dependent manner while maintaining acceptable safety and tolerability.  PRIDE-HD was a randomised, placebo-controlled, phase 2, dose-ranging study in adults (aged ≥21 years) with Huntington's disease at outpatient clinics in 53 sites across 12 countries (Australia, Austria, Canada, Denmark, France, Germany, Italy, Poland, Russia, the Netherlands, the UK, and the USA).  Eligible patients had clin. onset after age 18 years, 36 or more cytosine-adenine-guanine repeats in the huntingtin gene, motor symptoms (Unified Huntington's Disease Rating Scale total motor score [UHDRS-TMS] ≥25 points), and reduced independence (UHDRS independence score ≤90%).  Patients were randomly assigned (1:1:1:1:1) with centralised interactive-response technol. to receive one of four doses of pridopidine (45, 67.5, 90, or 112.5 mg) or placebo orally twice a day for 52 wk.  Randomisation was stratified within centers by neuroleptic drug use.  The primary efficacy endpoint was change in the UHDRS-TMS from baseline to 26 wk, which was assessed in all randomised patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment (full anal. set).  Participants and investigators were masked to treatment assignment.  This trial is registered with EudraCT (2013-001888-23) and ClinicalTrials.gov (NCT02006472).  Between Feb 13, 2014, and July 5, 2016, 408 patients were enrolled and randomly assigned to receive placebo (n = 82) or pridopidine 45 mg (n = 81), 67.5 mg (n = 82), 90 mg (n = 81), or 112.5 mg (n = 82) twice daily for 26 wk.  The full anal. set included 397 patients (81 in the placebo group, 75 in the 45 mg group, 79 in the 67.5 mg group, 81 in the 90 mg group, and 81 in the 112.5 mg group).  Pridopidine did not significantly change the UHDRS-TMS at 26 wk compared with placebo at any dose.  The most frequent adverse events across all groups were diarrhoea, vomiting, nasopharyngitis, falls, headache, insomnia, and anxiety.  The most common treatment-related adverse events were insomnia, diarrhoea, nausea, and dizziness.  Serious adverse events occurred in the pridopidine groups only and were most frequently falls (n = 5), suicide attempt (n = 4), suicidal ideation (n = 3), head injury (n = 3), and aspiration pneumonia (n = 3).  No new safety or tolerability concerns emerged in this study.  One death in the pridopidine 112.5 mg group due to aspiration pneumonia was considered to be possibly related to the study drug.  Pridopidine did not improve the UHDRS-TMS at week 26 compared with placebo and, thus, the results of secondary or tertiary anal. in previous trials were not replicated.  A potentially strong placebo effect needs to be ruled out in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1SGKkDZwj77Vg90H21EOLACvtfcHk0lgyze8GLkIF7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFekur%252FJ&md5=11fdc45c6b554f7069650126629714f3</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2818%2930391-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252818%252930391-0%26sid%3Dliteratum%253Aachs%26aulast%3DReilmann%26aufirst%3DR.%26aulast%3DMcGarry%26aufirst%3DA.%26aulast%3DGrachev%26aufirst%3DI.%2BD%26aulast%3DSavola%26aufirst%3DJ.-M.%26aulast%3DBorowsky%26aufirst%3DB.%26aulast%3DEyal%26aufirst%3DE.%26aulast%3DGross%26aufirst%3DN.%26aulast%3DLangbehn%26aufirst%3DD.%26aulast%3DSchubert%26aufirst%3DR.%26aulast%3DWickenberg%26aufirst%3DA.%2BT.%26aulast%3DPapapetropoulos%26aufirst%3DS.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DSquitieri%26aufirst%3DF.%26aulast%3DKieburtz%26aufirst%3DK.%26aulast%3DLandwehrmeyer%26aufirst%3DG%2BB.%26aulast%3DAgarwal%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DK.%2BE%26aulast%3DAziz%26aufirst%3DN.%2BA%26aulast%3DAzulay%26aufirst%3DJ.-P.%26aulast%3DBachoud-Levi%26aufirst%3DA.%2BC%26aulast%3DBarker%26aufirst%3DR.%26aulast%3DBebak%26aufirst%3DA.%26aulast%3DBeuth%26aufirst%3DM.%26aulast%3DBiglan%26aufirst%3DK.%26aulast%3DBlin%26aufirst%3DS.%26aulast%3DBohlen%26aufirst%3DS.%26aulast%3DBonelli%26aufirst%3DR.%26aulast%3DCaldwell%26aufirst%3DS.%26aulast%3DCalvas%26aufirst%3DF.%26aulast%3DCarlos%26aufirst%3DJ.%26aulast%3DCastagliuolo%26aufirst%3DS.%26aulast%3DChong%26aufirst%3DT.%26aulast%3DChua%26aufirst%3DP.%26aulast%3DColeman%26aufirst%3DA.%26aulast%3DCorey-Bloom%26aufirst%3DJ.%26aulast%3DCousins%26aufirst%3DR.%26aulast%3DCraufurd%26aufirst%3DD.%26aulast%3DDavison%26aufirst%3DJ.%26aulast%3DDecorte%26aufirst%3DE.%26aulast%3DDe%2BMichele%26aufirst%3DG.%26aulast%3DDornhege%26aufirst%3DL.%26aulast%3DFeigin%26aufirst%3DA.%26aulast%3DGallehawk%26aufirst%3DS.%26aulast%3DGauteul%26aufirst%3DP.%26aulast%3DGonzales%26aufirst%3DC.%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DGustov%26aufirst%3DA.%26aulast%3DGuttman%26aufirst%3DM.%26aulast%3DHeim%26aufirst%3DB.%26aulast%3DHeller%26aufirst%3DH.%26aulast%3DHjermind%26aufirst%3DL.%26aulast%3DIllarioshkin%26aufirst%3DS.%26aulast%3DIvanko%26aufirst%3DL.%26aulast%3DJaynes%26aufirst%3DJ.%26aulast%3DJenckes%26aufirst%3DM.%26aulast%3DKaminski%26aufirst%3DB.%26aulast%3DKampstra%26aufirst%3DA.%26aulast%3DKonkel%26aufirst%3DA.%26aulast%3DKopishinskaya%26aufirst%3DS.%26aulast%3DKrystkowiak%26aufirst%3DP.%26aulast%3DKomati%26aufirst%3DS.%2BK%26aulast%3DKwako%26aufirst%3DA.%26aulast%3DLakoning%26aufirst%3DS.%26aulast%3DLatipova%26aufirst%3DG.%26aulast%3DLeavitt%26aufirst%3DB.%26aulast%3DLoy%26aufirst%3DC.%26aulast%3DMacFarlane%26aufirst%3DC.%26aulast%3DMadsen%26aufirst%3DL.%26aulast%3DMarder%26aufirst%3DK.%26aulast%3DMason%26aufirst%3DS.%26aulast%3DMendis%26aufirst%3DN.%26aulast%3DMendis%26aufirst%3DT.%26aulast%3DNemeth%26aufirst%3DA.%26aulast%3DNevitt%26aufirst%3DL.%26aulast%3DNorris%26aufirst%3DV.%26aulast%3DO%2527Neill%26aufirst%3DC.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DOrth%26aufirst%3DM.%26aulast%3DOwens%26aufirst%3DA.%26aulast%3DPanegyres%26aufirst%3DP.%26aulast%3DPerlman%26aufirst%3DS.%26aulast%3DPreston%26aufirst%3DJ.%26aulast%3DPriller%26aufirst%3DJ.%26aulast%3DPuch%26aufirst%3DA.%26aulast%3DQuarrell%26aufirst%3DO.%26aulast%3DRagosta%26aufirst%3DD.%26aulast%3DRialland%26aufirst%3DA.%26aulast%3DRickards%26aufirst%3DH.%26aulast%3DRomoli%26aufirst%3DA.%2BM%26aulast%3DRoss%26aufirst%3DC.%26aulast%3DRosser%26aufirst%3DA.%26aulast%3DRudzinska%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DC.%2BV%26aulast%3DSaft%26aufirst%3DC.%26aulast%3DSegro%26aufirst%3DV.%26aulast%3DSeppi%26aufirst%3DK.%26aulast%3DShannon%26aufirst%3DB.%26aulast%3DShprecher%26aufirst%3DD.%26aulast%3DSimonin%26aufirst%3DC.%26aulast%3DSkitt%26aufirst%3DZ.%26aulast%3DSlawek%26aufirst%3DJ.%26aulast%3DSoliveri%26aufirst%3DP.%26aulast%3DSorbi%26aufirst%3DS.%26aulast%3DSquitieri%26aufirst%3DF.%26aulast%3DSuski%26aufirst%3DV.%26aulast%3DStepniak%26aufirst%3DI.%26aulast%3DSungmee%26aufirst%3DP.%26aulast%3DTemirbaeva%26aufirst%3DS.%26aulast%3DTesta%26aufirst%3DC.%26aulast%3DTorvin-Moller%26aufirst%3DA.%26aulast%3DUhl%26aufirst%3DS.%26aulast%3DVangsted-Hansen%26aufirst%3DC.%26aulast%3DVerny%26aufirst%3DC.%26aulast%3DWall%26aufirst%3DP.%26aulast%3DWalker%26aufirst%3DF.%26aulast%3DWasserman%26aufirst%3DP.%26aulast%3DWitkowski%26aufirst%3DG.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DZalyalova%26aufirst%3DZ.%26aulast%3DZielonka%26aufirst%3DD.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520pridopidine%2520in%2520patients%2520with%2520Huntington%25E2%2580%2599s%2520disease%2520%2528PRIDE-HD%2529%253A%2520a%2520phase%25202%252C%2520randomised%252C%2520placebo-controlled%252C%2520multicentre%252C%2520dose-ranging%2520study%26jtitle%3DLancet%2520Neurol.%26date%3D2019%26volume%3D18%26spage%3D165%26epage%3D176%26doi%3D10.1016%2FS1474-4422%2818%2930391-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ionescu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maimon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf Avraham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlson, E.</span></span> <span> </span><span class="NLM_article-title">Targeting the sigma-1 receptor via Pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">210</span>, <span class="refDoi"> DOI: 10.1038/s41419-019-1451-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fs41419-019-1451-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30824685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A280%3ADC%252BB3cfpsFSlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=210&author=A.+Ionescuauthor=T.+Gradusauthor=T.+Altmanauthor=R.+Maimonauthor=N.+Saraf+Avrahamauthor=M.+Gevaauthor=M.+Haydenauthor=E.+Perlson&title=Targeting+the+sigma-1+receptor+via+Pridopidine+ameliorates+central+features+of+ALS+pathology+in+a+SOD1%28G93A%29+model&doi=10.1038%2Fs41419-019-1451-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1(G93A) Model</span></div><div class="casAuthors">Ionescu Ariel; Gradus Tal; Altman Topaz; Maimon Roy; Saraf Avraham Noi; Perlson Eran; Ionescu Ariel; Perlson Eran; Geva Michal; Hayden Michael; Geva Michal; Hayden Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease affecting both the upper and lower motor neurons (MNs), with no effective treatment currently available.  Early pathological events in ALS include perturbations in axonal transport (AT), formation of toxic protein aggregates and Neuromuscular Junction (NMJ) disruption, which all lead to axonal degeneration and motor neuron death.  Pridopidine is a small molecule that has been clinically developed for Huntington disease.  Here we tested the efficacy of pridopidine for ALS using in vitro and in vivo models.  Pridopidine beneficially modulates AT deficits and diminishes NMJ disruption, as well as motor neuron death in SOD1(G93A) MNs and in neuromuscular co-cultures.  Furthermore, we demonstrate that pridopidine activates the ERK pathway and mediates its beneficial effects through the sigma-1 receptor (S1R).  Strikingly, in vivo evaluation of pridopidine in SOD1(G93A) mice reveals a profound reduction in mutant SOD1 aggregation in the spinal cord, and attenuation of NMJ disruption, as well as subsequent muscle wasting.  Taken together, we demonstrate for the first time that pridopidine improves several cellular and histological hallmark pathologies of ALS through the S1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtbLKZwETEnn6HPRus0rAafW6udTcc2ebiFxVFHgUwY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfpsFSlsQ%253D%253D&md5=78d838109b873db3b0912223768d9d47</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fs41419-019-1451-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-019-1451-2%26sid%3Dliteratum%253Aachs%26aulast%3DIonescu%26aufirst%3DA.%26aulast%3DGradus%26aufirst%3DT.%26aulast%3DAltman%26aufirst%3DT.%26aulast%3DMaimon%26aufirst%3DR.%26aulast%3DSaraf%2BAvraham%26aufirst%3DN.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DPerlson%26aufirst%3DE.%26atitle%3DTargeting%2520the%2520sigma-1%2520receptor%2520via%2520Pridopidine%2520ameliorates%2520central%2520features%2520of%2520ALS%2520pathology%2520in%2520a%2520SOD1%2528G93A%2529%2520model%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2019%26volume%3D10%26spage%3D210%26doi%3D10.1038%2Fs41419-019-1451-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahmy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmstrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Blockade of Tau hyperphosphorylation and Abeta(1)(−)(4)(2) generation by the aminotetrahydrofuran derivative ANAVEX2–73, a mixed muscarinic and sigma(1) receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1723</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.70</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1038%2Fnpp.2013.70" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23493042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCjs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=1706-1723&author=V.+Lahmyauthor=J.+Meunierauthor=S.+Malmstromauthor=G.+Naertauthor=L.+Givaloisauthor=S.+H.+Kimauthor=V.+Villardauthor=A.+Vamvakidesauthor=T.+Maurice&title=Blockade+of+Tau+hyperphosphorylation+and+Abeta%281%29%28%E2%88%92%29%284%29%282%29+generation+by+the+aminotetrahydrofuran+derivative+ANAVEX2%E2%80%9373%2C+a+mixed+muscarinic+and+sigma%281%29+receptor+agonist%2C+in+a+nontransgenic+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnpp.2013.70"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease</span></div><div class="casAuthors">Lahmy, Valentine; Meunier, Johann; Malmstroem, Susanna; Naert, Gaelle; Givalois, Laurent; Kim, Seung Hyun; Villard, Vanessa; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1706-1723</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The main objective of the present study was to establish whether the mixed σ1/muscarinic ligand ANAVEX2-73, shown to be neuroprotective in Alzheimer's disease (AD) models in vivo and currently in clin. phase I/IIa, could have the ability to reduce the appearance of hyperphosphorylated Tau and amyloid-β1-42 (Aβ1-42) in the Aβ25-35 mouse model of AD.  We therefore first confirmed that Aβ25-35 injection induced hyperphosphorylation of Tau protein, by showing that it rapidly decreased Akt activity and activated glycogen synthase kinase-3β (GSK-3β) in the mouse hippocampus.  Second, we showed that the kinase activation, and resulting Tau alteration, directly contributed to the amyloid toxicity, as co-administration of the selective GSK-3β inhibitor 2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxidiazole blocked both Tau phosphorylation and Aβ25-35-induced memory impairments.  Third, we analyzed the ANAVEX2-73 effect on Tau phosphorylation and activation of the related kinase pathways (Akt and GSK-3β).  And fourth, we also addressed the impact of the drug on Aβ25-35-induced Aβ1-42 seeding and obsd. that the compd. significantly blocked the increase in Aβ1-42 and C99 levels in the hippocampus, suggesting that it may alleviate amyloid load in AD models.  The comparison with PRE-084, a selective and ref. σ1 receptor agonist, and xanomeline, a muscarinic ligand presenting similar profile as ANAVEX2-73 on M1 and M2 subtypes, confirmed that both muscarinic and σ1 targets are involved in the ANAVEX2-73 effects.  The drug, acting synergistically on both targets, but with moderate affinity, presents a promising pharmacol. profile.  Neuropsychopharmacol. (2013) 38, 1706-1723; doi:10.1038/npp.2013.70; published online 3 Apr. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8Ullin5U0GbVg90H21EOLACvtfcHk0lhj8BnruDbFNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCjs7nP&md5=84921702de85f5bc6152b178915adb44</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.70&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.70%26sid%3Dliteratum%253Aachs%26aulast%3DLahmy%26aufirst%3DV.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DMalmstrom%26aufirst%3DS.%26aulast%3DNaert%26aufirst%3DG.%26aulast%3DGivalois%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DBlockade%2520of%2520Tau%2520hyperphosphorylation%2520and%2520Abeta%25281%2529%2528%25E2%2588%2592%2529%25284%2529%25282%2529%2520generation%2520by%2520the%2520aminotetrahydrofuran%2520derivative%2520ANAVEX2%25E2%2580%259373%252C%2520a%2520mixed%2520muscarinic%2520and%2520sigma%25281%2529%2520receptor%2520agonist%252C%2520in%2520a%2520nontransgenic%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuropsychopharmacology%26date%3D2013%26volume%3D38%26spage%3D1706%26epage%3D1723%26doi%3D10.1038%2Fnpp.2013.70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahmy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial protection by the mixed muscarinic/sigma1 ligand ANAVEX2–73, a tetrahydrofuran derivative, in Abeta25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">463</span>, <span class="refDoi"> DOI: 10.3389/fncel.2014.00463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffncel.2014.00463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25653589" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=463&author=V.+Lahmyauthor=R.+Longauthor=D.+Morinauthor=V.+Villardauthor=T.+Maurice&title=Mitochondrial+protection+by+the+mixed+muscarinic%2Fsigma1+ligand+ANAVEX2%E2%80%9373%2C+a+tetrahydrofuran+derivative%2C+in+Abeta25%E2%80%9335+peptide-injected+mice%2C+a+nontransgenic+Alzheimer%E2%80%99s+disease+model&doi=10.3389%2Ffncel.2014.00463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2014.00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2014.00463%26sid%3Dliteratum%253Aachs%26aulast%3DLahmy%26aufirst%3DV.%26aulast%3DLong%26aufirst%3DR.%26aulast%3DMorin%26aufirst%3DD.%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DMitochondrial%2520protection%2520by%2520the%2520mixed%2520muscarinic%252Fsigma1%2520ligand%2520ANAVEX2%25E2%2580%259373%252C%2520a%2520tetrahydrofuran%2520derivative%252C%2520in%2520Abeta25%25E2%2580%259335%2520peptide-injected%2520mice%252C%2520a%2520nontransgenic%2520Alzheimer%25E2%2580%2599s%2520disease%2520model%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2015%26volume%3D8%26spage%3D463%26doi%3D10.3389%2Ffncel.2014.00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, S.</span></span> <span> </span><span class="NLM_article-title">Binding properties of SA4503, a novel and selective sigma 1 receptor agonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00201-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2F0014-2999%2896%2900201-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=8813641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK28Xktl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=1996&pages=271-279&author=K.+Matsunoauthor=M.+Nakazawaauthor=K.+Okamotoauthor=Y.+Kawashimaauthor=S.+Mita&title=Binding+properties+of+SA4503%2C+a+novel+and+selective+sigma+1+receptor+agonist&doi=10.1016%2F0014-2999%2896%2900201-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Binding properties of SA4503, a novel and selective σ1 receptor agonist</span></div><div class="casAuthors">Matsuno, Kiyoshi; Nakazawa, Minako; Okamoto, Kazuyoshi; Kawashima, Yoichi; Mita, Shiro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">271-279</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The binding profiles of SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride), a novel σ receptor ligand, to σ1 and σ2 receptor subtypes in guinea pig and rat brain membranes were evaluated.  SA4503 showed a high affinity for the σ1 receptor subtype labeled by (+)-[3H]pentazocine (IC50 = 17.4±1.9 nM), while it had about 100-fold less affinity for the σ2 receptor subtype labeled by [3H]1,3-di(2-tolyl)guanidine ([3H]DTG) in the presence of 200 nM (+)-pentazocine.  SA4503 showed little affinity for 36 other receptors, ion channels and second messenger systems.  The inhibition curves of SA4503 for (+)-[3H]pentazocine binding were shifted to the right in the presence of guanosine 5'-o-(3-thiotriphosphate)(GTPγS), as similar to those of (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3-PPP) and (+)-pentazocine, σ1 receptor agonists.  SA4503 significantly increased the KD value, but did not affect the Bmax value for specific (+)-[3H]pentazocine binding.  These results indicated that SA4503 is a potent and selective agonist for the σ1 receptor subtype in the brain.  In addn., SA4503 inhibited specific (+)-[3H]pentazocine binding in a competitive manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Wso8XHzUE7Vg90H21EOLACvtfcHk0lg5QuvIxrxx7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xktl2ntbs%253D&md5=587287bfffd018c8b316255cbf14a026</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900201-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900201-4%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DNakazawa%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKawashima%26aufirst%3DY.%26aulast%3DMita%26aufirst%3DS.%26atitle%3DBinding%2520properties%2520of%2520SA4503%252C%2520a%2520novel%2520and%2520selective%2520sigma%25201%2520receptor%2520agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D306%26spage%3D271%26epage%3D279%26doi%3D10.1016%2F0014-2999%2896%2900201-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skuza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoz, Z.</span></span> <span> </span><span class="NLM_article-title">A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1097/00008877-200211000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1097%2F00008877-200211000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=12409992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot12murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=537-543&author=G.+Skuzaauthor=Z.+Rogoz&title=A+potential+antidepressant+activity+of+SA4503%2C+a+selective+sigma+1+receptor+agonist&doi=10.1097%2F00008877-200211000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">A potential antidepressant activity of SA4503, a selective σ1 receptor agonist</span></div><div class="casAuthors">Skuza, G.; Rogoz, Z.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">537-543</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The aim of the present study was to examine SA4503 [1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride], a novel selective σ1 receptor agonist, in respect of its potential antidepressant action.  To this end we used a forced swimming test in rats to study SA4503 alone, as well as its interaction with imipramine, a classic tricyclic antidepressant.  SA4503 decreased the immobility time in the forced swimming test in rats (although only at one of the three doses used); at the same time it did not change the locomotor activity recorded under the same exptl. conditions.  Moreover, SA4503 showed a synergistic effect with imipramine in the forced swimming test (both those compds. given jointly decreased the immobility time, but were ineffective when administered sep.).  It had previously been shown that repeated administration of antidepressants with different pharmacol. profiles enhanced the action of D-amphetamine, quinpirole and other dopamine stimulants.  SA4503 administered repeatedly increased the locomotor hyperactivity induced by D-amphetamine and quinpirole (a dopamine D2/D3 receptor agonist), but not by (±)-7-hydroxy-dipropyloamino-tetralin hydrobromide [(±)-7-OH-DPAT; a dopamine D3 receptor agonist].  The results presented in this paper support the suggestion that SA4503 may have potential antidepressive properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0R2FaXEnYP7Vg90H21EOLACvtfcHk0lg5QuvIxrxx7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot12murs%253D&md5=52790865e6d818b37edaffaf558827d4</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1097%2F00008877-200211000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008877-200211000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DSkuza%26aufirst%3DG.%26aulast%3DRogoz%26aufirst%3DZ.%26atitle%3DA%2520potential%2520antidepressant%2520activity%2520of%2520SA4503%252C%2520a%2520selective%2520sigma%25201%2520receptor%2520agonist%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2002%26volume%3D13%26spage%3D537%26epage%3D543%26doi%3D10.1097%2F00008877-200211000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga, K.</span></span> <span> </span><span class="NLM_article-title">Stimulation of sigma-1 receptor ameliorates depressive-like behaviors in CaMKIV null mice</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1210</span>– <span class="NLM_lpage">1222</span>, <span class="refDoi"> DOI: 10.1007/s12035-014-8923-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs12035-014-8923-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25316382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2015&pages=1210-1222&author=S.+Moriguchiauthor=H.+Sakagamiauthor=Y.+Yabukiauthor=Y.+Sasakiauthor=H.+Izumiauthor=C.+Zhangauthor=F.+Hanauthor=K.+Fukunaga&title=Stimulation+of+sigma-1+receptor+ameliorates+depressive-like+behaviors+in+CaMKIV+null+mice&doi=10.1007%2Fs12035-014-8923-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of Sigma-1 Receptor Ameliorates Depressive-like Behaviors in CaMKIV Null Mice</span></div><div class="casAuthors">Moriguchi, Shigeki; Sakagami, Hiroyuki; Yabuki, Yasushi; Sasaki, Yuzuru; Izumi, Hisanao; Zhang, Chen; Han, Feng; Fukunaga, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1210-1222</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Sigma-1 receptor (Sig-1R) is a mol. chaperone regulating calcium efflux from the neuronal endoplasmic reticulum to the mitochondria.  Calcium/calmodulin-dependent protein kinase IV (CaMKIV) null mice exhibit depressive-like behaviors and impaired neurogenesis as assessed by bromodeoxyuridine (BrdU) incorporation into newborn cells of the hippocampal dentate gyrus (DG).  Here, we demonstrate that chronic stimulation of Sig-1R by treatment with the agonist SA4503 or the SSRI fluvoxamine for 14 days improves depressive-like behaviors in CaMKIV null mice.  By contrast, treatment with paroxetine, which lacks affinity for Sig-1R, did not alter these behaviors.  Reduced nos. of BrdU-pos. cells and decreased brain-derived neurotrophic factor (BDNF) mRNA expression and protein kinase B (Akt; Ser-473) phosphorylation seen in the DG of CaMKIV null mice were significantly rescued by chronic Sig-1R stimulation.  Interestingly, reduced ATP prodn. obsd. in the DG of CaMKIV null mice was improved by chronic Sig-1R stimulation.  Such stimulation also improved hippocampal long-term potentiation (LTP) induction and maintenance, which are impaired in the DG of CaMKIV null mice.  LTP rescue was closely assocd. with both increases in calcium/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation and GluA1 (Ser-831) phosphorylation.  Taken together, Sig-1R stimulation by SA4503 or fluvoxamine treatment increased hippocampal neurogenesis, which is closely assocd. with amelioration of depressive-like behaviors in CaMKIV null mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMv5yHpsoYQLVg90H21EOLACvtfcHk0lg5QuvIxrxx7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjurvM&md5=7b86fcdb769ab1427ae6cbf02b253374</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1007%2Fs12035-014-8923-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-014-8923-2%26sid%3Dliteratum%253Aachs%26aulast%3DMoriguchi%26aufirst%3DS.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DYabuki%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DIzumi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DFukunaga%26aufirst%3DK.%26atitle%3DStimulation%2520of%2520sigma-1%2520receptor%2520ameliorates%2520depressive-like%2520behaviors%2520in%2520CaMKIV%2520null%2520mice%26jtitle%3DMol.%2520Neurobiol.%26date%3D2015%26volume%3D52%26spage%3D1210%26epage%3D1222%26doi%3D10.1007%2Fs12035-014-8923-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urfer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoloudik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamarina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, K. W.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of the sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3304</span>– <span class="NLM_lpage">3310</span>, <span class="refDoi"> DOI: 10.1161/STROKEAHA.114.005835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1161%2FSTROKEAHA.114.005835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25270629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVKrtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=3304-3310&author=R.+Urferauthor=H.+J.+Moebiusauthor=D.+Skoloudikauthor=E.+Santamarinaauthor=W.+Satoauthor=S.+Mitaauthor=K.+W.+Muir&title=Phase+II+trial+of+the+sigma-1+receptor+agonist+cutamesine+%28SA4503%29+for+recovery+enhancement+after+acute+ischemic+stroke&doi=10.1161%2FSTROKEAHA.114.005835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke</span></div><div class="casAuthors">Urfer, Roman; Moebius, Hans J.; Skoloudik, David; Santamarina, Estevo; Sato, Wakao; Mita, Shiro; Muir, Keith W.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3304-3310</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND AND PURPOSE-: The σ-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after exptl. stroke with a treatment initiation window of 48 h and chronic treatment for 28 days.  We conducted a phase 2 clin. trial exploring the safety, tolerability, dose range, and functional effects of cutamesine in patients with ischemic stroke.  METHODS-: Subjects were randomized between 48 and 72 h after stroke to receive cutamesine 1 mg/d, 3 mg/d, or placebo for 28 days.  Effects on safety and function were assessed at baseline, at end of treatment (day 28), and at end of follow-up (day 56).  RESULTS-: In 60 patients, treatment with both cutamesine dosages was safe and well tolerated without significant differences in nos. of treatment emergent or serious adverse events.  No significant effect was obsd. on the primary efficacy measure (change in National Institutes of Health Stroke Scale from baseline to day 56) or modified Rankin Scale and Barthel Index scores.  Post hoc anal. of moderately and severely affected patients (baseline National Institutes of Health Stroke Scale, ≥7 and ≥10) showed greater National Institutes of Health Stroke Scale improvements in the 3 mg/d cutamesine group when compared with placebo (P=0.034 and P=0.038, resp.).  A trend toward a higher proportion being able to complete a 10m timed walk was obsd. for cutamesine-treated subjects.  CONCLUSIONS-: Cutamesine was safe and well tolerated at both dosage levels.  Although no significant effects on functional end points were seen in the population as a whole, greater improvement in National Institutes of Health Stroke Scale scores among patients with greater pretreatment deficits seen in post hoc anal. warrants further investigation.  Addnl. studies should focus on the patient population with moderate-to-severe stroke.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov/show/NCT00639249.  Unique identifier: NCT00639249.  The EudraCT no. is 2007-004840-60 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004840-60/GB).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDEGW1pd0NnLVg90H21EOLACvtfcHk0lg5QuvIxrxx7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVKrtrbP&md5=cdf635de1aff93573aab643921d25acf</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.114.005835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.114.005835%26sid%3Dliteratum%253Aachs%26aulast%3DUrfer%26aufirst%3DR.%26aulast%3DMoebius%26aufirst%3DH.%2BJ.%26aulast%3DSkoloudik%26aufirst%3DD.%26aulast%3DSantamarina%26aufirst%3DE.%26aulast%3DSato%26aufirst%3DW.%26aulast%3DMita%26aufirst%3DS.%26aulast%3DMuir%26aufirst%3DK.%2BW.%26atitle%3DPhase%2520II%2520trial%2520of%2520the%2520sigma-1%2520receptor%2520agonist%2520cutamesine%2520%2528SA4503%2529%2520for%2520recovery%2520enhancement%2520after%2520acute%2520ischemic%2520stroke%26jtitle%3DStroke%26date%3D2014%26volume%3D45%26spage%3D3304%26epage%3D3310%26doi%3D10.1161%2FSTROKEAHA.114.005835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimazawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hozumi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, H.</span></span> <span> </span><span class="NLM_article-title">SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2013.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neulet.2013.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24334165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1Clsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2014&pages=174-178&author=Y.+Onoauthor=H.+Tanakaauthor=M.+Takataauthor=Y.+Nagaharaauthor=Y.+Nodaauthor=K.+Tsurumaauthor=M.+Shimazawaauthor=I.+Hozumiauthor=H.+Hara&title=SA4503%2C+a+sigma-1+receptor+agonist%2C+suppresses+motor+neuron+damage+in+in+vitro+and+in+vivo+amyotrophic+lateral+sclerosis+models&doi=10.1016%2Fj.neulet.2013.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models</span></div><div class="casAuthors">Ono, Yoko; Tanaka, Hirotaka; Takata, Masafumi; Nagahara, Yuki; Noda, Yasuhiro; Tsuruma, Kazuhiro; Shimazawa, Masamitsu; Hozumi, Isao; Hara, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">174-178</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.  Recently, it has been reported that a mutation in the sigma-1 receptor causes juvenile ALS.  Therefore, the function of the sigma-1 receptor may be important in the pathol. of ALS.  In the present study, we investigated the effect of SA4503, a sigma-1 receptor agonist, against in in vitro and in vivo ALS models.  We first investigated whether SA4503, a sigma-1 receptor agonist, prevented superoxide dismutase 1 (SOD1G93A)- and serum free-induced cell death of mice motor neuron cells (NSC34) in in vitro model of an ALS.  At concns. of 1-10 μM, SA4503 reduced SOD1G93A-induced cell death in a concn.-dependent manner, and BD1047, a sigma-1 receptor antagonist, inhibited the protective effect of SA4503.  Next, we investigated whether SA4503 affected the phosphorylation levels of Akt (Ser 473) and extracellular signal-regulated kinase (ERK) 1/2 and the expression of the sigma-1 receptor.  SA4503 promoted the phosphorylation of Akt (Ser 473) and ERK1/2 in a time-dependent manner, but SA4503 did not affect the expression of the sigma-1 receptor.  These results suggest that the protective effect of SA4503 might be involved in promoting the phosphorylation of Akt and ERK1/2.  We then investigated whether SA4503 suppressed the progression of ALS in an SOD1G93A ALS mouse model.  SA4503 did not affect the onset time of ALS.  However, it significantly extended the survival time in the SOD1G93A mice compared with a vehicle-treated group.  These findings indicate that SA4503 is effective in suppressing motor neuron degeneration and symptom progression in ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhpwPNu8EqVbVg90H21EOLACvtfcHk0ljpWafSJsDuKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1Clsw%253D%253D&md5=88135ada3683080b388904b6c63db74b</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2013.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2013.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DTakata%26aufirst%3DM.%26aulast%3DNagahara%26aufirst%3DY.%26aulast%3DNoda%26aufirst%3DY.%26aulast%3DTsuruma%26aufirst%3DK.%26aulast%3DShimazawa%26aufirst%3DM.%26aulast%3DHozumi%26aufirst%3DI.%26aulast%3DHara%26aufirst%3DH.%26atitle%3DSA4503%252C%2520a%2520sigma-1%2520receptor%2520agonist%252C%2520suppresses%2520motor%2520neuron%2520damage%2520in%2520in%2520vitro%2520and%2520in%2520vivo%2520amyotrophic%2520lateral%2520sclerosis%2520models%26jtitle%3DNeurosci.%2520Lett.%26date%3D2014%26volume%3D559%26spage%3D174%26epage%3D178%26doi%3D10.1016%2Fj.neulet.2013.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga, K.</span></span> <span> </span><span class="NLM_article-title">SA4503, a potent sigma-1 receptor ligand, ameliorates synaptic abnormalities and cognitive dysfunction in a mouse model of ATR-X syndrome</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2811</span>, <span class="refDoi"> DOI: 10.3390/ijms19092811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3390%2Fijms19092811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFSgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2811&author=K.+Yamaguchiauthor=N.+Shiodaauthor=Y.+Yabukiauthor=C.+Zhangauthor=F.+Hanauthor=K.+Fukunaga&title=SA4503%2C+a+potent+sigma-1+receptor+ligand%2C+ameliorates+synaptic+abnormalities+and+cognitive+dysfunction+in+a+mouse+model+of+ATR-X+syndrome&doi=10.3390%2Fijms19092811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">SA4503, a potent sigma-1 receptor ligand, ameliorates synaptic abnormalities and cognitive dysfunction in a mouse model of ATR-X syndrome</span></div><div class="casAuthors">Yamaguchi, Kouya; Shioda, Norifumi; Yabuki, Yasushi; Zhang, Chen; Han, Feng; Fukunaga, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2811/1-2811/15</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">α-thalassemia X-linked intellectual disability (ATR-X) syndrome is caused by mutations in ATRX.  An ATR-X model mouse lacking Atrx exon 2 displays phenotypes that resemble symptoms in the human intellectual disability: cognitive defects and abnormal dendritic spine formation.  We herein target activation of sigma-1 receptor (Sig-1R) that can induce potent neuroprotective and neuroregenerative effects by promoting the activity of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF).  We demonstrated that treatment with SA4503, a potent activator of Sig-1R, reverses axonal development and dendritic spine abnormalities in cultured cortical neurons from ATR-X model mice.  Moreover, the SA4503 treatment rescued cognitive deficits exhibited by the ATR-X model mice.  We further found that significant decreases in the BDNF-protein level in the medial prefrontal cortex of ATR-X model mice were recovered with treatment of SA4503.  These results indicate that the rescue of dendritic spine abnormalities through the activation of Sig-1R has a potential for post-diagnostic therapy in ATR-X syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFO975AtzgWbVg90H21EOLACvtfcHk0ljpWafSJsDuKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFSgsrY%253D&md5=4dea390b9f1d534b8b857a46dddf94fd</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.3390%2Fijms19092811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19092811%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShioda%26aufirst%3DN.%26aulast%3DYabuki%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DFukunaga%26aufirst%3DK.%26atitle%3DSA4503%252C%2520a%2520potent%2520sigma-1%2520receptor%2520ligand%252C%2520ameliorates%2520synaptic%2520abnormalities%2520and%2520cognitive%2520dysfunction%2520in%2520a%2520mouse%2520model%2520of%2520ATR-X%2520syndrome%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D2811%26doi%3D10.3390%2Fijms19092811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuberes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrocal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contijoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laggner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of the 1-arylpyrazole class of sigma(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1<i>H</i>-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8211</span>– <span class="NLM_lpage">8224</span>, <span class="refDoi"> DOI: 10.1021/jm3007323</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3007323" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWht7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8211-8224&author=J.+L.+Diazauthor=R.+Cuberesauthor=J.+Berrocalauthor=M.+Contijochauthor=U.+Christmannauthor=A.+Fernandezauthor=A.+Portauthor=J.+Holenzauthor=H.+Buschmannauthor=C.+Laggnerauthor=M.+T.+Serafiniauthor=J.+Burguenoauthor=D.+Zamanilloauthor=M.+Merlosauthor=J.+M.+Velaauthor=C.+Almansa&title=Synthesis+and+biological+evaluation+of+the+1-arylpyrazole+class+of+sigma%281%29+receptor+antagonists%3A+identification+of+4-%7B2-%5B5-methyl-1-%28naphthalen-2-yl%29-1H-pyrazol-3-yloxy%5Dethyl%7Dmorpholine+%28S1RA%2C+E-52862%29&doi=10.1021%2Fjm3007323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of the 1-Arylpyrazole Class of σ1 Receptor Antagonists: Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)</span></div><div class="casAuthors">Diaz, Jose Luis; Cuberes, Rosa; Berrocal, Joana; Contijoch, Montserrat; Christmann, Ute; Fernandez, Ariadna; Port, Adriana; Holenz, Jorg; Buschmann, Helmut; Laggner, Christian; Serafini, Maria Teresa; Burgueno, Javier; Zamanillo, Daniel; Merlos, Manuel; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8211-8224</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 1-arylpyrazoles as potent σ1 receptor (σ1R) antagonists are reported.  The new compds. were evaluated in vitro in human σ1R and guinea pig σ2 receptor (σ2R) binding assays.  The nature of the pyrazole substituents was crucial for activity, and a basic amine was shown to be necessary, in accordance with known receptor pharmacophores.  A wide variety of amines and spacer lengths between the amino and pyrazole groups was tolerated, but only the ethylenoxy spacer and small cyclic amines provided compds. with sufficient selectivity for σ1R vs σ2R.  The most selective compds. were further profiled, and 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862, I), which showed high activity in the mouse capsaicin model of neurogenic pain, emerged as the most interesting candidate.  In addn., compd. I exerted dose-dependent antinociceptive effects in several neuropathic pain models.  This, together with its good physicochem., safety, and ADME properties, led compd. I to be selected as clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQxd7-vnvc7Vg90H21EOLACvtfcHk0lhKwB-dSb4wsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWht7bI&md5=0d6a5c8008d27635117c3901ec1db3c4</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm3007323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3007323%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DCuberes%26aufirst%3DR.%26aulast%3DBerrocal%26aufirst%3DJ.%26aulast%3DContijoch%26aufirst%3DM.%26aulast%3DChristmann%26aufirst%3DU.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DSerafini%26aufirst%3DM.%2BT.%26aulast%3DBurgueno%26aufirst%3DJ.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520the%25201-arylpyrazole%2520class%2520of%2520sigma%25281%2529%2520receptor%2520antagonists%253A%2520identification%2520of%25204-%257B2-%255B5-methyl-1-%2528naphthalen-2-yl%2529-1H-pyrazol-3-yloxy%255Dethyl%257Dmorpholine%2520%2528S1RA%252C%2520E-52862%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8211%26epage%3D8224%26doi%3D10.1021%2Fjm3007323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Pastor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carceller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span> <span> </span><span class="NLM_article-title">Effects of the selective sigma-1 receptor antagonist S1RA on formalin-induced pain behavior and neurotransmitter release in the spinal cord in rats</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1111/jnc.12648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fjnc.12648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24384038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2hsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2014&pages=484-494&author=A.+Vidal-Torresauthor=B.+Fernandez-Pastorauthor=A.+Carcellerauthor=J.+M.+Velaauthor=M.+Merlosauthor=D.+Zamanillo&title=Effects+of+the+selective+sigma-1+receptor+antagonist+S1RA+on+formalin-induced+pain+behavior+and+neurotransmitter+release+in+the+spinal+cord+in+rats&doi=10.1111%2Fjnc.12648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the selective sigma-1 receptor antagonist S1RA on formalin-induced pain behavior and neurotransmitter release in the spinal cord in rats</span></div><div class="casAuthors">Vidal-Torres, Alba; Fernandez-Pastor, Begona; Carceller, Alicia; Vela, Jose Miguel; Merlos, Manuel; Zamanillo, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-494</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We have previously shown that the selective sigma-1 receptor (σ1R) antagonist S1RA (E-52862) inhibits neuropathic pain and activity-induced spinal sensitization in various pre-clin. pain models.  In this study we characterized both the behavioral and the spinal neurochem. effects of S1RA in the rat formalin test.  Systemic administration of S1RA produced a dose-related attenuation of flinching and lifting/licking behaviors in the formalin test.  Neurochem. studies using concentric microdialysis in the ipsilateral dorsal horn of awake, freely moving rats revealed that the systemic S1RA-induced antinociceptive effect occurs concomitantly with an enhancement of noradrenaline levels and an attenuation of formalin-evoked glutamate release in the spinal dorsal horn.  Intrathecal pre-treatment with idazoxan prevented the systemic S1RA antinociceptive effect, suggesting that the S1RA antinociception depends on the activation of spinal α2-adrenoceptors which, in turn, could induce an inhibition of formalin-evoked glutamate release.  When administered locally, intrathecal S1RA inhibited only the flinching behavior, whereas intracerebroventricularly or intraplantarly injected also attenuated the lifting/licking behavior.  These results suggest that S1RA supraspinally activates the descending noradrenergic pain inhibitory system, which may explain part of its antinociceptive properties in the formalin test; however, effects at other central and peripheral sites also account for the overall effect.  Formalin-induced nociceptive effect occurs concomitantly with an enhancement of glutamate (Glu) level in the dorsal horn spinal cord.  The selective σ1 receptor antagonist S1RA results in inhibition of formalin-evoked Glu release, no modification of GABA levels, and enhancement of noradrenaline (NA) levels.  This increased spinal NA activates spinal α2-adrenoceptors producing the attenuation of the formalin-induced pain behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpidtqKXnW5wrVg90H21EOLACvtfcHk0lhKwB-dSb4wsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2hsLw%253D&md5=23e47349eed9a544bbdf70dc9f40626b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12648%26sid%3Dliteratum%253Aachs%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3DFernandez-Pastor%26aufirst%3DB.%26aulast%3DCarceller%26aufirst%3DA.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DZamanillo%26aufirst%3DD.%26atitle%3DEffects%2520of%2520the%2520selective%2520sigma-1%2520receptor%2520antagonist%2520S1RA%2520on%2520formalin-induced%2520pain%2520behavior%2520and%2520neurotransmitter%2520release%2520in%2520the%2520spinal%2520cord%2520in%2520rats%26jtitle%3DJ.%2520Neurochem.%26date%3D2014%26volume%3D129%26spage%3D484%26epage%3D494%26doi%3D10.1111%2Fjnc.12648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bravo-Caparros, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perazzoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeste, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor inhibition reduces neuropathic pain induced by partial sciatic nerve transection in mice by opioid-dependent and -independent mechanisms</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">613</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffphar.2019.00613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31263413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVaqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=613&author=I.+Bravo-Caparrosauthor=G.+Perazzoliauthor=S.+Yesteauthor=D.+Cikesauthor=J.+M.+Baeyensauthor=E.+J.+Cobosauthor=F.+R.+Nieto&title=Sigma-1+receptor+inhibition+reduces+neuropathic+pain+induced+by+partial+sciatic+nerve+transection+in+mice+by+opioid-dependent+and+-independent+mechanisms&doi=10.3389%2Ffphar.2019.00613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor inhibition reduces neuropathic pain induced by partial sciatic nerve transection in mice by opioid-dependent and -independent mechanisms</span></div><div class="casAuthors">Bravo-Caparros, Inmaculada; Perazzoli, Gloria; Yeste, Sandra; Cikes, Domagoj; Baeyens, Jose Manuel; Cobos, Enrique Jose; Nieto, Francisco Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">613</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Sigma-1 (σ1) receptor antagonists are promising tools for neuropathic pain treatment, but it is unknown whether σ1 receptor inhibition ameliorates the neuropathic signs induced by nerve transection, in which the pathophysiol. mechanisms and response to drug treatment differ from other neuropathic pain models.  In addn., σ1 antagonism ameliorates inflammatory pain through modulation of the endogenous opioid system, but it is unknown whether this occurs during neuropathic pain.  We investigated the effect of σ1 inhibition on the painful hypersensitivity assocd. with the spared nerve injury (SNI) model in mice.  Wild-type (WT) mice developed prominent cold (acetone test), mech. (von Frey test), and heat hypersensitivity (Hargreaves test) after SNI. σ1 receptor knockout (σ1-KO) mice did not develop cold allodynia and showed significantly less mech. allodynia, although they developed heat hyperalgesia after SNI.  The systemic acute administration of the selective σ1 receptor antagonist S1RA attenuated all three types of SNI-induced hypersensitivity in WT mice.  These ameliorative effects of S1RA were reversed by the administration of the σ1 agonist PRE-084, and were absent in σ1-KO mice, indicating the selectivity of S1RA-induced effects.  The opioid antagonist naloxone and its peripherally restricted analog naloxone methiodide prevented S1RA-induced effects in mech. and heat hypersensitivity, but not in cold allodynia, indicating that opioid-dependent and -independent mechanisms are involved in the effects of this σ1 antagonist.  The repeated administration of S1RA twice a day during 10 days reduced SNI-induced cold, mech., and heat hypersensitivity without inducing analgesic tolerance during treatment.  These effects were obsd. up to 12 h after the last administration, when S1RA was undetectable in plasma or brain, indicating long-lasting pharmacodynamic effects.  These data suggest that σ1 antagonism may have therapeutic value for the treatment of neuropathic pain induced by the transection of peripheral nerves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEctnyokyyKbVg90H21EOLACvtfcHk0lhKwB-dSb4wsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVaqtLs%253D&md5=2de9eb133abf509e1006d13ebb9d0376</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00613%26sid%3Dliteratum%253Aachs%26aulast%3DBravo-Caparros%26aufirst%3DI.%26aulast%3DPerazzoli%26aufirst%3DG.%26aulast%3DYeste%26aufirst%3DS.%26aulast%3DCikes%26aufirst%3DD.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26atitle%3DSigma-1%2520receptor%2520inhibition%2520reduces%2520neuropathic%2520pain%2520induced%2520by%2520partial%2520sciatic%2520nerve%2520transection%2520in%2520mice%2520by%2520opioid-dependent%2520and%2520-independent%2520mechanisms%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D613%26doi%3D10.3389%2Ffphar.2019.00613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perazzoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1007/s00213-014-3524-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs00213-014-3524-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24639046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=3855-3869&author=M.+A.+Tejadaauthor=A.+Montilla-Garciaauthor=C.+Sanchez-Fernandezauthor=J.+M.+Entrenaauthor=G.+Perazzoliauthor=J.+M.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+receptor+inhibition+reverses+acute+inflammatory+hyperalgesia+in+mice%3A+role+of+peripheral+sigma-1+receptors&doi=10.1007%2Fs00213-014-3524-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors</span></div><div class="casAuthors">Tejada, M. A.; Montilla-Garcia, A.; Sanchez-Fernandez, C.; Entrena, J. M.; Perazzoli, G.; Baeyens, J. M.; Cobos, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Sigma-1 (σ1) receptor inhibition ameliorates neuropathic pain by inhibiting central sensitization.  However, it is unknown whether σ1 receptor inhibition also decreases inflammatory hyperalgesia, or whether peripheral σ1 receptors are involved in this process.  Objective: The purpose of this study was to det. the role of σ1 receptors in carrageenan-induced inflammatory hyperalgesia, particularly at the inflammation site.  Results: The s.c. (s.c.) administration of the selective σ1 antagonists BD-1063 and S1RA to wild-type mice dose-dependently and fully reversed inflammatory mech. (paw pressure) and thermal (radiant heat) hyperalgesia.  These antihyperalgesic effects were abolished by the s.c. administration of the σ1 agonist PRE-084 and also by the intraplantar (i.pl.) administration of this compd. in the inflamed paw, suggesting that blockade of peripheral σ1 receptors in the inflamed site is involved in the antihyperalgesic effects induced by σ1 antagonists.  In fact, the i.pl. administration of σ1 antagonists in the inflamed paw (but not in the contralateral paw) was sufficient to completely reverse inflammatory hyperalgesia. σ1 knockout (σ1-KO) mice did not develop mech. hyperalgesia but developed thermal hypersensitivity; however, the s.c. administration of BD-1063 or S1RA had no effect on thermal hyperalgesia in σ1-KO mice, supporting on-target mechanisms for the effects of both drugs.  The antiedematous effects of σ1 inhibition do not account for the decreased hyperalgesia, since carrageenan-induced edema was unaffected by σ1 knockout or systemic σ1 pharmacol. antagonism.  Conclusions: σ1 receptors play a major role in inflammatory hyperalgesia.  Targeting σ1 receptors in the inflamed tissue may be useful for the treatment of inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTvS0b6PcEhLVg90H21EOLACvtfcHk0ljyQ7__O82lLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlGlsb4%253D&md5=b62ff92aeee8ae0fbc9a4c1c4d272c82</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3524-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3524-3%26sid%3Dliteratum%253Aachs%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DPerazzoli%26aufirst%3DG.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520receptor%2520inhibition%2520reverses%2520acute%2520inflammatory%2520hyperalgesia%2520in%2520mice%253A%2520role%2520of%2520peripheral%2520sigma-1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D3855%26epage%3D3869%26doi%3D10.1007%2Fs00213-014-3524-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Cantero, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">8396</span>– <span class="NLM_lpage">8401</span>, <span class="refDoi"> DOI: 10.1073/pnas.1620068114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1073%2Fpnas.1620068114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28716934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=8396-8401&author=M.+A.+Tejadaauthor=A.+Montilla-Garciaauthor=S.+J.+Croninauthor=D.+Cikesauthor=C.+Sanchez-Fernandezauthor=R.+Gonzalez-Canoauthor=M.+C.+Ruiz-Canteroauthor=J.+M.+Penningerauthor=J.+M.+Velaauthor=J.+M.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+receptors+control+immune-driven+peripheral+opioid+analgesia+during+inflammation+in+mice&doi=10.1073%2Fpnas.1620068114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice</span></div><div class="casAuthors">Tejada, Miguel A.; Montilla-Garcia, Angeles; Cronin, Shane J.; Cikes, Domagoj; Sanchez-Fernandez, Cristina; Gonzalez-Cano, Rafael; Ruiz-Cantero, M. Carmen; Penninger, Josef M.; Vela, Jose M.; Baeyens, Jose M.; Cobos, Enrique J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">8396-8401</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sigma-1 antagonism potentiates the antinociceptive effects of opioid drugs, so sigma-1 receptors constitute a biol. brake to opioid drug-induced analgesia.  The pathophysiol. role of this process is unknown.  We aimed to investigate whether sigma-1 antagonism reduces inflammatory pain through the disinhibition of the endogenous opioidergic system in mice.  The selective sigma-1 antagonists BD-1063 and S1RA abolished mech. and thermal hyperalgesia in mice with carrageenan-induced acute (3 h) inflammation.  Sigma-1-mediated antihyperalgesia was reversed by the opioid antagonists naloxone and naloxone methiodide (a peripherally restricted naloxone analog) and by local administration at the inflamed site of monoclonal antibody 3-E7, which recognizes the pan-opioid sequence Tyr-Gly-Gly-Phe at the N terminus of most endogenous opioid peptides (EOPs).  Neutrophils expressed pro-opiomelanocortin, the precursor of β-endorphin (a known EOP), and constituted the majority of the acute immune infiltrate. β-endorphin levels increased in the inflamed paw, and this increase and the antihyperalgesic effects of sigma-1 antagonism were abolished by reducing the neutrophil load with in vivo administration of an anti-Ly6G antibody.  The opioid-dependent sigma-1 antihyperalgesic effects were preserved 5 d after carrageenan administration, where macrophages/monocytes were found to express pro-opiomelanocortin and to now constitute the majority of the immune infiltrate.  These results suggest that immune cells harboring EOPs are needed for the antihyperalgesic effects of sigma-1 antagonism during inflammation.  In conclusion, sigma-1 receptors curtail immune-driven peripheral opioid analgesia, and sigma-1 antagonism produces local opioid analgesia by enhancing the action of EOPs of immune origin, maximizing the analgesic potential of immune cells that naturally accumulate in painful inflamed areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktSX7oMTPDrVg90H21EOLACvtfcHk0ljyQ7__O82lLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOru73P&md5=ede5abe4e1e51845e9bd46960a39d54a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1620068114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1620068114%26sid%3Dliteratum%253Aachs%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DCronin%26aufirst%3DS.%2BJ.%26aulast%3DCikes%26aufirst%3DD.%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DGonzalez-Cano%26aufirst%3DR.%26aulast%3DRuiz-Cantero%26aufirst%3DM.%2BC.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520receptors%2520control%2520immune-driven%2520peripheral%2520opioid%2520analgesia%2520during%2520inflammation%2520in%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D8396%26epage%3D8401%26doi%3D10.1073%2Fpnas.1620068114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanillo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span> <span> </span><span class="NLM_article-title">Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1121</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2012.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jpain.2012.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23063344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gltr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1107-1121&author=F.+R.+Nietoauthor=C.+M.+Cendanauthor=C.+Sanchez-Fernandezauthor=E.+J.+Cobosauthor=J.+M.+Entrenaauthor=M.+A.+Tejadaauthor=D.+Zamanilloauthor=J.+M.+Velaauthor=J.+M.+Baeyens&title=Role+of+sigma-1+receptors+in+paclitaxel-induced+neuropathic+pain+in+mice&doi=10.1016%2Fj.jpain.2012.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Sigma-1 Receptors in Paclitaxel-Induced Neuropathic Pain in Mice</span></div><div class="casAuthors">Nieto, Francisco Rafael; Cendan, Cruz Miguel; Sanchez-Fernandez, Cristina; Cobos, Enrique Jose; Entrena, Jose Manuel; Tejada, Miguel Angel; Zamanillo, Daniel; Vela, Jose Miguel; Baeyens, Jose Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1107-1121</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sigma-1 (σ1) receptors play a role in different types of pain and in central sensitization mechanisms; however, it is unknown whether they are involved in chemotherapy-induced neuropathic pain.  We compared the ability of paclitaxel to induce cold (acetone test) and mech. (electronic Von Frey test) allodynia in wild-type (WT) and σ1 receptor knockout (σ1-KO) mice.  We also tested the effect on paclitaxel-induced painful neuropathy of BD-1063 (16-64 mg/kg, s.c.) and S1RA (32-128 mg/kg, s.c.), 2 selective σ1 receptor antagonists that bind to the σ1 receptor with high affinity and competitively.  The responses to cold and mech. stimuli were similar in WT and σ1-KO mice not treated with paclitaxel; however, treatment with paclitaxel (2 mg/kg, i.p., once per day during 5 consecutive days) produced cold and mech. allodynia and an increase in spinal cord diphosphorylated extracellular signal-regulated kinase (pERK) in WT but not in σ1-KO mice.  The administration of BD-1063 or S1RA 30 min before each paclitaxel dose prevented the development of cold and mech. allodynia in WT mice.  Moreover, the acute administration of both σ1 receptor antagonists dose dependently reversed both types of paclitaxel-induced allodynia after they had fully developed.  These results suggest that σ1 receptors play a key role in paclitaxel-induced painful neuropathy.  Perspective: Antagonists of the σ1 receptor may have therapeutic value for the treatment and/or prevention of paclitaxel-induced neuropathic pain.  This possibility is esp. interesting in the context of chemotherapy-induced neuropathy, where the onset of nerve damage is predictable and preventive treatment could be administered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHYCYBeIn__bVg90H21EOLACvtfcHk0ljyQ7__O82lLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gltr7I&md5=798467267c69e426eae9df6cde797d6d</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2012.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2012.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DCendan%26aufirst%3DC.%2BM.%26aulast%3DSanchez-Fernandez%26aufirst%3DC.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DZamanillo%26aufirst%3DD.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26atitle%3DRole%2520of%2520sigma-1%2520receptors%2520in%2520paclitaxel-induced%2520neuropathic%2520pain%2520in%2520mice%26jtitle%3DJ.%2520Pain%26date%3D2012%26volume%3D13%26spage%3D1107%26epage%3D1121%26doi%3D10.1016%2Fj.jpain.2012.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abadias, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escriche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sust, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encina, G.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04333.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fj.1365-2125.2012.04333.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=22607269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGmtr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=103-117&author=M.+Abadiasauthor=M.+Escricheauthor=A.+Vaqueauthor=M.+Sustauthor=G.+Encina&title=Safety%2C+tolerability+and+pharmacokinetics+of+single+and+multiple+doses+of+a+novel+sigma-1+receptor+antagonist+in+three+randomized+phase+I+studies&doi=10.1111%2Fj.1365-2125.2012.04333.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies</span></div><div class="casAuthors">Abadias, Montserrat; Escriche, Marisol; Vaque, Anna; Sust, Mariano; Encina, Gregorio</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-117</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • A novel and highly selective sigma-1 receptor antagonist (S1RA) provides a new approach for pain management.  S1RA has shown activity in animal models of neuropathic pain and potentiation of opioid analgesia.  WHAT THIS STUDY ADDS • Phase I studies of single and multiple oral dose administration show that S1RA is safe and well tolerated by healthy subjects.  S1RA is rapidly absorbed and its rate and extent of exposure increases with dose. • The safety, tolerability, pharmacokinetic and pharmacodynamic profiles of S1RA support its further phase II development in different pain indications.  AIM To assess the safety, tolerability, pharmacodynamics and pharmacokinetics in healthy subjects of a novel, highly selective, sigma-1 receptor antagonist (S1RA).  METHODS Three randomized, double-blind, placebo-controlled trials evaluated single oral doses (5-500 mg, study 101; 500-800 mg, study 106) and multiple doses (50-400 mg once daily for 8 days, study 102) of S1RA.  Safety and tolerability were assessed by adverse event reporting, clin. lab., phys. examns., vital signs and electrocardiog., including Holter monitoring.  Pharmacodynamic assessments included computerized cognitive testing.  Plasma samples were analyzed using validated HPLC-MS/MS methods.  RESULTS One hundred and seventy-five subjects were enrolled.  Single and multiple doses were safe and well tolerated, with no serious adverse events.  The most common side effects were headache and dizziness.  The highest single doses were assocd. with some mild to moderate transient CNS effects.  The max. tolerated dose was not reached.  There were no clin. significant changes in the ECG (ECG), 24 h Holter monitoring, or in vital signs and lab. assessments.  Subjective CNS pharmacodynamics evaluations showed no relevant differences vs. placebo.  Cognitive testing showed no effects on visual memory, executive function, attention or somnolence, while revealing some transient slowing of response for simple reaction time and choice reaction time at 2 h following the administration of higher doses.  A fast absorption, rapid distribution and slow elimination were obsd. (tmax 0.75-2.0 h, t1/2 compatible with once a day administration) and steady-state was reached.  No gender differences were obsd.  CONCLUSIONS S1RA exhibited an acceptable safety, tolerability, pharmacodynamic and pharmacokinetic profile in healthy subjects over the dose range studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqhIOMVL8V7Vg90H21EOLACvtfcHk0li0znCBGXnmJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGmtr%252FI&md5=8d45c779e14abd98d209ecf90fe73caa</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04333.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04333.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbadias%26aufirst%3DM.%26aulast%3DEscriche%26aufirst%3DM.%26aulast%3DVaque%26aufirst%3DA.%26aulast%3DSust%26aufirst%3DM.%26aulast%3DEncina%26aufirst%3DG.%26atitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520single%2520and%2520multiple%2520doses%2520of%2520a%2520novel%2520sigma-1%2520receptor%2520antagonist%2520in%2520three%2520randomized%2520phase%2520I%2520studies%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D103%26epage%3D117%26doi%3D10.1111%2Fj.1365-2125.2012.04333.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyriou, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villoria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalofonos, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sust, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salaman, C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: a randomized, double-blind, placebo-controlled phase IIa clinical trial</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1007/s13311-017-0572-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs13311-017-0572-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28924870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=178-189&author=J.+Brunaauthor=S.+Videlaauthor=A.+A.+Argyriouauthor=R.+Velascoauthor=J.+Villoriaauthor=C.+Santosauthor=C.+Nadalauthor=G.+Cavalettiauthor=P.+Albertiauthor=C.+Brianiauthor=H.+P.+Kalofonosauthor=D.+Cortinovisauthor=M.+Sustauthor=A.+Vaqueauthor=T.+Kleinauthor=C.+Plata-Salaman&title=Efficacy+of+a+novel+sigma-1+receptor+antagonist+for+oxaliplatin-induced+neuropathy%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+IIa+clinical+trial&doi=10.1007%2Fs13311-017-0572-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial</span></div><div class="casAuthors">Bruna, Jordi; Videla, Sebastian; Argyriou, Andreas A.; Velasco, Roser; Villoria, Jesus; Santos, Cristina; Nadal, Cristina; Cavaletti, Guido; Alberti, Paola; Briani, Chiara; Kalofonos, Haralabos P.; Cortinovis, Diego; Sust, Mariano; Vaque, Anna; Klein, Thomas; Plata-Salaman, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This trial assessed the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in ameliorating oxaliplatin-induced peripheral neuropathy (oxaipn).  A discontinuous regimen of MR309 (400 mg/day, 5 days per cycle) was tested in patients with colorectal cancer receiving FOLFOX in a phase II, randomized, double-blind, placebo-controlled, multicenter clin. trial.  Outcome measures included changes in 24-wk quant. measures of thermal sensitivity and total neuropathy score.  In total, 124 patients were randomized (1:1) to MR309 or placebo.  Sixty-three (50.8%) patients withdrew prematurely before completing 12 planned oxaliplatin cycles.  Premature withdrawal because of cancer progression was less frequent in the MR309 group (7.4% vs 25.0% with placebo; p = 0.054).  MR309 significantly reduced cold pain threshold temp. [mean treatment effect difference (SE) vs placebo: 5.29 (1.60)°C; p = 0.001] and suprathreshold cold stimulus-evoked pain intensity [mean treatment effect difference: 1.24 (0.57) points; p = 0.032].  Total neuropathy score, health-related quality-of-life measures, and nerve-conduction parameters changed similarly in both arms, whereas the proportion of patients with severe chronic neuropathy (National Cancer Institute Common Terminol. Criteria for Adverse Events ≥ 3) was significantly lower in the MR309 group (3.0% vs 18.2% with placebo; p = 0.046).  The total amt. of oxaliplatin delivered was greater in the active arm (1618.9 mg vs 1453.8 mg with placebo; p = 0.049).  Overall, 19.0% of patients experienced at least 1 treatment-related adverse event (25.8% and 11.9% with MR309 and placebo, resp.).  Intermittent treatment with MR309 was assocd. with reduced acute oxaipn and higher oxaliplatin exposure, and showed a potential neuroprotective role for chronic cumulative oxaipn.  Furthermore, MR309 showed an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkVyo1fPRe7Vg90H21EOLACvtfcHk0li0znCBGXnmJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E&md5=78eac14b1175a004af19c4c9a53af1be</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1007%2Fs13311-017-0572-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-017-0572-5%26sid%3Dliteratum%253Aachs%26aulast%3DBruna%26aufirst%3DJ.%26aulast%3DVidela%26aufirst%3DS.%26aulast%3DArgyriou%26aufirst%3DA.%2BA.%26aulast%3DVelasco%26aufirst%3DR.%26aulast%3DVilloria%26aufirst%3DJ.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DNadal%26aufirst%3DC.%26aulast%3DCavaletti%26aufirst%3DG.%26aulast%3DAlberti%26aufirst%3DP.%26aulast%3DBriani%26aufirst%3DC.%26aulast%3DKalofonos%26aufirst%3DH.%2BP.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DSust%26aufirst%3DM.%26aulast%3DVaque%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DPlata-Salaman%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520a%2520novel%2520sigma-1%2520receptor%2520antagonist%2520for%2520oxaliplatin-induced%2520neuropathy%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520clinical%2520trial%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D178%26epage%3D189%26doi%3D10.1007%2Fs13311-017-0572-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span> <span> </span><span class="NLM_article-title">A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.083543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fjpet.105.083543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=15798005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVeju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2005&pages=252-259&author=K.+Hirataauthor=H.+Yamaguchiauthor=Y.+Takamuraauthor=A.+Takagiauthor=T.+Fukushimaauthor=N.+Iwakamiauthor=A.+Saitohauthor=M.+Nakagawaauthor=T.+Yamada&title=A+novel+neurotrophic+agent%2C+T-817MA+%5B1-%7B3-%5B2-%281-benzothiophen-5-yl%29+ethoxy%5D+propyl%7D-3-azetidinol+maleate%5D%2C+attenuates+amyloid-beta-induced+neurotoxicity+and+promotes+neurite+outgrowth+in+rat+cultured+central+nervous+system+neurons&doi=10.1124%2Fjpet.105.083543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons</span></div><div class="casAuthors">Hirata, Kazunari; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">252-259</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Progressive neuronal loss in Alzheimer's disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-β peptides (Aβ).  T-817MA was screened as a candidate therapeutic agent for the treatment of AD based on its neuroprotective potency against Aβ-induced neurotoxicity and its effect of enhancing axonal regeneration in the sciatic nerve axotomy model.  The neuroprotective effect of T-817MA against Aβ(1-42) or oxidative stress-induced neurotoxicity was assessed using a coculture of rat cortical neurons with glia.  T-817MA (0.1 and 1 μM) was strongly protective against Aβ(1-42)-induced (10 μM for 48 h) or H2O2-induced (100 μM for 24 h) neuronal death.  T-817MA suppressed the decrease of GSH levels induced by H2O2 exposure (30 μM for 4 h) in cortical neuron culture; therefore, T-817MA was likely to alleviate oxidative stress.  Besides the neuroprotective effect, T-817MA (0.1 and 1 μM) promoted neurite outgrowth in hippocampal slice cultures and reaggregation culture of rat cortical neurons.  T-817MA also increased the growth-assocd. protein 43 content in the reaggregation culture of cortical neurons.  These findings suggest that T-817MA exerts neuroprotective effect and promotes neurite outgrowth in rat primary cultured neurons.  Based on these neurotrophic features, T-817MA may have a potential for disease modification and be useful for patients with neurodegenerative diseases, such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYEzJ50bSUcbVg90H21EOLACvtfcHk0liG2lDXSpmkMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVeju7w%253D&md5=bab946365eb087fe5302b3aa91e376d3</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.083543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.083543%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DTakamura%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DIwakami%26aufirst%3DN.%26aulast%3DSaitoh%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DT.%26atitle%3DA%2520novel%2520neurotrophic%2520agent%252C%2520T-817MA%2520%255B1-%257B3-%255B2-%25281-benzothiophen-5-yl%2529%2520ethoxy%255D%2520propyl%257D-3-azetidinol%2520maleate%255D%252C%2520attenuates%2520amyloid-beta-induced%2520neurotoxicity%2520and%2520promotes%2520neurite%2520outgrowth%2520in%2520rat%2520cultured%2520central%2520nervous%2520system%2520neurons%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D314%26spage%3D252%26epage%3D259%26doi%3D10.1124%2Fjpet.105.083543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ago, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nashida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, T.</span></span> <span> </span><span class="NLM_article-title">A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.05.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neuropharm.2008.05.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=18573265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFajtbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=654-660&author=T.+Kawasakiauthor=Y.+Agoauthor=T.+Kitaoauthor=T.+Nashidaauthor=A.+Takagiauthor=K.+Takumaauthor=T.+Matsuda&title=A+neuroprotective+agent%2C+T-817MA+%281-%7B3-%5B2-%281-benzothiophen-5-yl%29ethoxy%5Dpropyl%7D+azetidin-3-ol+maleate%29%2C+prevents+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine-induced+neurotoxicity+in+mice&doi=10.1016%2Fj.neuropharm.2008.05.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice</span></div><div class="casAuthors">Kawasaki, Toshiyuki; Ago, Yukio; Kitao, Tatsuya; Nashida, Tetsuaki; Takagi, Akiko; Takuma, Kazuhiro; Matsuda, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">654-660</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate) is a candidate therapeutic agent for Alzheimer's disease that inhibits oxidative stress and nitric oxide-induced neurotoxicity and acts as a neurotrophic factor.  The present study examines the effect of T-817MA on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in C57BL/6J mice.  MPTP treatment (10 mg/kg, s.c. × 4 at 2-h intervals) impaired rotarod performance, and T-817MA improved this deficit.  MPTP treatment also decreased dopamine levels and tyrosine hydroxylase immunostaining in the substantia nigra (SNc) and striatum.  Pretreatment with T-817MA (10 and 30 mg/kg as T-817, p.o.) attenuated these decreases in dopamine levels and tyrosine hydroxylase immunoreactivity, but did not affect brain levels of 1-methyl-4-phenylpyridinium ion, an active metabolite of MPTP.  The protective effect was almost complete in the SNc, but only partial in the striatum.  MPTP increased levels of the lipid peroxidn. product, thiobarbituric acid reactive substance, only in the midbrain, which could be blocked by T-817MA.  MPTP caused microglial activation both in the SNc and striatum, but T-817MA did not affect the activation of microglia.  These results suggest that T-817MA protects against MPTP-induced neurotoxicity by blocking lipid peroxidn. in the SNc, and imply that this compd. may be useful for treating neurodegenerative disorders related to oxidative stress, such as Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4gZyqmnlb97Vg90H21EOLACvtfcHk0liG2lDXSpmkMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFajtbfN&md5=4d2d266525503b585977551e517019b7</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.05.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.05.032%26sid%3Dliteratum%253Aachs%26aulast%3DKawasaki%26aufirst%3DT.%26aulast%3DAgo%26aufirst%3DY.%26aulast%3DKitao%26aufirst%3DT.%26aulast%3DNashida%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DTakuma%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DT.%26atitle%3DA%2520neuroprotective%2520agent%252C%2520T-817MA%2520%25281-%257B3-%255B2-%25281-benzothiophen-5-yl%2529ethoxy%255Dpropyl%257D%2520azetidin-3-ol%2520maleate%2529%252C%2520prevents%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine-induced%2520neurotoxicity%2520in%2520mice%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D55%26spage%3D654%26epage%3D660%26doi%3D10.1016%2Fj.neuropharm.2008.05.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong Nguyen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishijo, H.</span></span> <span> </span><span class="NLM_article-title">T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-beta peptide</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00141.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fj.1476-5381.2009.00141.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19371351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Ggtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2009&pages=451-463&author=T.+Kimuraauthor=P.+T.+Hong+Nguyenauthor=S.+A.+Hoauthor=A.+H.+Tranauthor=T.+Onoauthor=H.+Nishijo&title=T-817MA%2C+a+neurotrophic+agent%2C+ameliorates+the+deficits+in+adult+neurogenesis+and+spatial+memory+in+rats+infused+i.c.v.+with+amyloid-beta+peptide&doi=10.1111%2Fj.1476-5381.2009.00141.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-β peptide</span></div><div class="casAuthors">Kimura, Tatsuo; Nguyen, Phuong Thi Hong; Ho, Son Anh; Tran, Anh Hai; Ono, Taketoshi; Nishijo, Hisao</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-463</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: Adult neurogenesis occurs throughout life in the subgranular zone and the dentate gyrus of the hippocampus.  Deficient neurogenesis may be responsible for deficient hippocampal functions in neurodegenerative disorders such as Alzheimer's disease (AD).  T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate] is a newly synthesized agent for AD treatment with neuroprotective effects against toxicity from amyloid-β peptide (Aβ) and actions promoting neurite outgrowth in vitro.  Furthermore, systemic administration of T-817MA ameliorated cognitive dysfunctions caused by neurodegeneration in a rat model of AD, induced by intracerebroventricular (i.c.v.) infusion of Aβ.  The present study investigated quant. relationships between spatial memory performance in Aβ-infused rats and hippocampal neurogenesis, and the effects of T-817MA on neuronal proliferation in vivo.  Exptl. approach: Seven weeks after infusion of Aβ (peptide 1-40; 300 pmol/day-1; i.c.v.), rats were tested in a place learning task in which they were required to alternately visit two reward places in an open field to obtain intracranial self-stimulation as rewards.  Key results: Rats given Aβ infusions for 10 wk displayed spatial memory impairments and a decrease in neurogenesis compared with those infused with vehicle.  Treatment of the Aβ-infused rats with T-817MA (8.4 mg/kg-1/day-1, p.o.) significantly increased hippocampal neurogenesis and ameliorated spatial learning impairments.  Furthermore, spatial learning in the task was significantly correlated with neurogenesis.  Conclusions and implications: These results suggest that defective hippocampal neurogenesis is a new target for AD treatment.  The neurotrophic compd. T-817MA increased hippocampal neurogenesis in an AD model and might be useful for treatment of AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotNB9EkGRF4rVg90H21EOLACvtfcHk0ljEHhj8Wv5EZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Ggtr8%253D&md5=0a1d5f87d9212061cc7238fd82ef3213</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00141.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00141.x%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DHong%2BNguyen%26aufirst%3DP.%2BT.%26aulast%3DHo%26aufirst%3DS.%2BA.%26aulast%3DTran%26aufirst%3DA.%2BH.%26aulast%3DOno%26aufirst%3DT.%26aulast%3DNishijo%26aufirst%3DH.%26atitle%3DT-817MA%252C%2520a%2520neurotrophic%2520agent%252C%2520ameliorates%2520the%2520deficits%2520in%2520adult%2520neurogenesis%2520and%2520spatial%2520memory%2520in%2520rats%2520infused%2520i.c.v.%2520with%2520amyloid-beta%2520peptide%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D157%26spage%3D451%26epage%3D463%26doi%3D10.1111%2Fj.1476-5381.2009.00141.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishijo, H.</span></span> <span> </span><span class="NLM_article-title">Effects of the neurotrophic agent T-817MA on oligomeric amyloid-beta-induced deficits in long-term potentiation in the hippocampal CA1 subfield</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2013.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.neurobiolaging.2013.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24112791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyrsbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=532-536&author=Y.+Takamuraauthor=K.+Onoauthor=J.+Matsumotoauthor=M.+Yamadaauthor=H.+Nishijo&title=Effects+of+the+neurotrophic+agent+T-817MA+on+oligomeric+amyloid-beta-induced+deficits+in+long-term+potentiation+in+the+hippocampal+CA1+subfield&doi=10.1016%2Fj.neurobiolaging.2013.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the neurotrophic agent T-817MA on oligomeric amyloid-β-induced deficits in long-term potentiation in the hippocampal CA1 subfield</span></div><div class="casAuthors">Takamura, Yusaku; Ono, Kenjiro; Matsumoto, Jumpei; Yamada, Masahito; Nishijo, Hisao</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">532-536</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Formation of oligomeric amyloid-β (oAβ) is 1 of the most likely causes of Alzheimer's disease (AD).  We hypothesized that in the early phase of AD, cognitive impairments obsd. before marked neuronal loss and brain atrophy might be assocd. with oAβ-induced synaptic dysfunction.  T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol maleate] has both neuroprotective and neurotrophic effects and is used to treat AD.  Although T-817MA has been shown to ameliorate amyloid-induced learning deficits in exptl. AD models, it remains unclear whether this drug would be able to prevent oAβ-induced synaptotoxicity.  In the present study, we investigated the effects of T-817MA on the disturbances in synaptic plasticity induced by oAβ42 and oligomeric photo-cross-linked Aβ42 (oXLAβ42) in a slice prepn. of the CA1 subfield of mouse hippocampus.  Both oAβ42 and oXLAβ42 treatments significantly reduced the induction of long-term potentiation (LTP).  In addn., oAβ42 treatment significantly facilitated long-term depression (LTD).  Treatment with T-817MA ameliorated the LTP redn.; however, T-817MA treatment did not inhibit the facilitation of LTD induction by oAβ42.  These results suggest that T-817MA reverses oAβ-induced LTP redn. as it may occur in the early phase of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDKgeJSLqR17Vg90H21EOLACvtfcHk0ljEHhj8Wv5EZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyrsbjM&md5=6ba73c8065dd3d048a9e5166102d1fcf</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2013.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2013.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DTakamura%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DJ.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DNishijo%26aufirst%3DH.%26atitle%3DEffects%2520of%2520the%2520neurotrophic%2520agent%2520T-817MA%2520on%2520oligomeric%2520amyloid-beta-induced%2520deficits%2520in%2520long-term%2520potentiation%2520in%2520the%2520hippocampal%2520CA1%2520subfield%26jtitle%3DNeurobiol.%2520Aging%26date%3D2014%26volume%3D35%26spage%3D532%26epage%3D536%26doi%3D10.1016%2Fj.neurobiolaging.2013.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terashima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, H.</span></span> <span> </span><span class="NLM_article-title">T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2011.03.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbrc.2011.03.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=21439944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFCjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2011&pages=730-734&author=T.+Fukushimaauthor=A.+Nakamuraauthor=N.+Iwakamiauthor=Y.+Nakadaauthor=H.+Hattoriauthor=S.+Hokiauthor=H.+Yamaguchiauthor=M.+Nakagawaauthor=N.+Terashimaauthor=H.+Narita&title=T-817MA%2C+a+neuroprotective+agent%2C+attenuates+the+motor+and+cognitive+impairments+associated+with+neuronal+degeneration+in+P301L+tau+transgenic+mice&doi=10.1016%2Fj.bbrc.2011.03.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice</span></div><div class="casAuthors">Fukushima, Tetsuo; Nakamura, Asako; Iwakami, Noboru; Nakada, Yasushi; Hattori, Hiroshi; Hoki, Satoru; Yamaguchi, Hidetoshi; Nakagawa, Masaya; Terashima, Nobuo; Narita, Hirokazu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">730-734</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tau pathol. is implicated in mechanisms of neurodegenerative tauopathies, including Alzheimer's disease (AD) and hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).  It was reported that transgenic mice expressing FTDP-17 mutation P301L of human tau (P301L mice) display extensive tau pathol. and exhibit behavioral deficits with aging.  In this study, we investigated the effects of T-817MA, a neuroprotective agent, on the motor and cognitive impairments assocd. with neuronal degeneration in P301L mice.  T-817MA prevented the progression of motor deficit and the loss of spinal cord motor neurons in P301L mice.  Furthermore, T-817MA significantly attenuated the spatial memory impairment and the redn. in synaptic terminal d. in the hippocampal dentate gyrus of P301L mice.  These results indicate that T-817MA improved the motor and cognitive impairments as a result of inhibiting neuronal degeneration derived from tau pathol. in the P301L mice.  Therefore, it is expected that T-817MA has a therapeutic potential for tau-related neurodegenerative diseases such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNXAV7gTEydbVg90H21EOLACvtfcHk0ljEHhj8Wv5EZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFCjsrk%253D&md5=ae64959ce423238551cb56c0d77be371</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2011.03.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2011.03.091%26sid%3Dliteratum%253Aachs%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DIwakami%26aufirst%3DN.%26aulast%3DNakada%26aufirst%3DY.%26aulast%3DHattori%26aufirst%3DH.%26aulast%3DHoki%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DTerashima%26aufirst%3DN.%26aulast%3DNarita%26aufirst%3DH.%26atitle%3DT-817MA%252C%2520a%2520neuroprotective%2520agent%252C%2520attenuates%2520the%2520motor%2520and%2520cognitive%2520impairments%2520associated%2520with%2520neuronal%2520degeneration%2520in%2520P301L%2520tau%2520transgenic%2520mice%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2011%26volume%3D407%26spage%3D730%26epage%3D734%26doi%3D10.1016%2Fj.bbrc.2011.03.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitsuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitsuki-Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochizuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span> <span> </span><span class="NLM_article-title">CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1126/science.aao2300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1126%2Fscience.aao2300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29622647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmvFamsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2018&pages=50-57&author=H.+Abeauthor=S.+Jitsukiauthor=W.+Nakajimaauthor=Y.+Murataauthor=A.+Jitsuki-Takahashiauthor=Y.+Katsunoauthor=H.+Tadaauthor=A.+Sanoauthor=K.+Suyamaauthor=N.+Mochizukiauthor=T.+Komoriauthor=H.+Masuyamaauthor=T.+Okudaauthor=Y.+Goshimaauthor=N.+Higoauthor=T.+Takahashi&title=CRMP2-binding+compound%2C+edonerpic+maleate%2C+accelerates+motor+function+recovery+from+brain+damage&doi=10.1126%2Fscience.aao2300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage</span></div><div class="casAuthors">Abe, Hiroki; Jitsuki, Susumu; Nakajima, Waki; Murata, Yumi; Jitsuki-Takahashi, Aoi; Katsuno, Yuki; Tada, Hirobumi; Sano, Akane; Suyama, Kumiko; Mochizuki, Nobuyuki; Komori, Takashi; Masuyama, Hitoshi; Okuda, Tomohiro; Goshima, Yoshio; Higo, Noriyuki; Takahashi, Takuya</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">6384</span>),
    <span class="NLM_cas:pages">50-57</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Brain damage such as stroke is a devastating neurol. condition that may severely compromise patient quality of life.  No effective medication-mediated intervention to accelerate rehabilitation has been established.  The authors found that a small compd., edonerpic maleate, facilitated experience-driven synaptic glutamate AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic-acid) receptor delivery and resulted in the acceleration of motor function recovery after motor cortex cryoinjury in mice in a training-dependent manner through cortical reorganization.  Edonerpic bound to collapsin-response-mediator-protein 2 (CRMP2) and failed to augment recovery in CRMP2-deficient mice.  Edonerpic maleate enhanced motor function recovery from internal capsule hemorrhage in nonhuman primates.  Thus, edonerpic maleate, a neural plasticity enhancer, could be a clin. potent small compd. with which to accelerate rehabilitation after brain damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBtDXtc6Rd1LVg90H21EOLACvtfcHk0ljKPCFTxB5yCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmvFamsLk%253D&md5=f3a598e5c07cc2c1617c9a0a32f94fa9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.aao2300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aao2300%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DJitsuki%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DW.%26aulast%3DMurata%26aufirst%3DY.%26aulast%3DJitsuki-Takahashi%26aufirst%3DA.%26aulast%3DKatsuno%26aufirst%3DY.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DSano%26aufirst%3DA.%26aulast%3DSuyama%26aufirst%3DK.%26aulast%3DMochizuki%26aufirst%3DN.%26aulast%3DKomori%26aufirst%3DT.%26aulast%3DMasuyama%26aufirst%3DH.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DGoshima%26aufirst%3DY.%26aulast%3DHigo%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DT.%26atitle%3DCRMP2-binding%2520compound%252C%2520edonerpic%2520maleate%252C%2520accelerates%2520motor%2520function%2520recovery%2520from%2520brain%2520damage%26jtitle%3DScience%26date%3D2018%26volume%3D360%26spage%3D50%26epage%3D57%26doi%3D10.1126%2Fscience.aao2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabetani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor is a molecular target for novel neuroprotectant T-817MA</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">P861</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2015.08.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.jalz.2015.08.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=P861&author=T.+Yanoauthor=H.+Tanabeauthor=K.+Kobayashiauthor=H.+Kobayashiauthor=A.+Nabetaniauthor=Y.+Sakaiauthor=T.+Okudaauthor=M.+Nakagawaauthor=T.+Nakamura&title=Sigma-1+receptor+is+a+molecular+target+for+novel+neuroprotectant+T-817MA&doi=10.1016%2Fj.jalz.2015.08.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2015.08.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2015.08.038%26sid%3Dliteratum%253Aachs%26aulast%3DYano%26aufirst%3DT.%26aulast%3DTanabe%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DNabetani%26aufirst%3DA.%26aulast%3DSakai%26aufirst%3DY.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DSigma-1%2520receptor%2520is%2520a%2520molecular%2520target%2520for%2520novel%2520neuroprotectant%2520T-817MA%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2015%26volume%3D11%26spage%3DP861%26doi%3D10.1016%2Fj.jalz.2015.08.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rissman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oltersdorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, H. H.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of Edonerpic maleate for patients with mild to moderate Alzheimer disease: a phase 2 randomized clinical trial</span>. <i>JAMA Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1330</span>– <span class="NLM_lpage">1339</span>, <span class="refDoi"> DOI: 10.1001/jamaneurol.2019.1868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1001%2Fjamaneurol.2019.1868" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2019&pages=1330-1339&author=L.+S.+Schneiderauthor=R.+G.+Thomasauthor=S.+Hendrixauthor=R.+A.+Rissmanauthor=J.+B.+Brewerauthor=D.+P.+Salmonauthor=T.+Oltersdorfauthor=T.+Okudaauthor=H.+H.+Feldman&title=Safety+and+efficacy+of+Edonerpic+maleate+for+patients+with+mild+to+moderate+Alzheimer+disease%3A+a+phase+2+randomized+clinical+trial&doi=10.1001%2Fjamaneurol.2019.1868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1001%2Fjamaneurol.2019.1868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaneurol.2019.1868%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DL.%2BS.%26aulast%3DThomas%26aufirst%3DR.%2BG.%26aulast%3DHendrix%26aufirst%3DS.%26aulast%3DRissman%26aufirst%3DR.%2BA.%26aulast%3DBrewer%26aufirst%3DJ.%2BB.%26aulast%3DSalmon%26aufirst%3DD.%2BP.%26aulast%3DOltersdorf%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DFeldman%26aufirst%3DH.%2BH.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520Edonerpic%2520maleate%2520for%2520patients%2520with%2520mild%2520to%2520moderate%2520Alzheimer%2520disease%253A%2520a%2520phase%25202%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA%2520Neurol.%26date%3D2019%26volume%3D76%26spage%3D1330%26epage%3D1339%26doi%3D10.1001%2Fjamaneurol.2019.1868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaiel, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">el-Ashmawy, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, K. B.</span></span> <span> </span><span class="NLM_article-title">Structural features important for sigma 1 receptor binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1214</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1021/jm00034a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00034a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK2cXksV2lsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1214-1219&author=R.+A.+Glennonauthor=S.+Y.+Ablordeppeyauthor=A.+M.+Ismaielauthor=M.+B.+el-Ashmawyauthor=J.+B.+Fischerauthor=K.+B.+Howie&title=Structural+features+important+for+sigma+1+receptor+binding&doi=10.1021%2Fjm00034a020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Features Important for σ1 Receptor Binding</span></div><div class="casAuthors">Glennon, Richard A.; Ablordeppey, Seth Y.; Ismaiel, Abd M.; El-Ashmawy, Mahmoud B.; Fischer, James B.; Howie, Kathleen Burke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1214-19</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Two problems that have hampered σ receptor research are a lack of high-affinity agents and the recent identification of multiple populations of σ receptors (i.e., σ1 and σ2 sites).  Recently, several high-affinity σ ligands have been identified, and the term superpotent σ ligands has been coined to describe agents with Ki values of <1 nM.  It was previously shown that appropriately N-substituted phenylalkylamines bind at σ receptors with high affinity.  The structure-affinity relationships of these phenylalkylamine derivs. for σ1 binding are examd. and some of the first superpotent σ1 ligands described.  A binding model was developed to account for the structural features of the phenylalkylamines that appear to be important for the interaction of these agents with σ1 sites.  Some of the amines were prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6nnZHspQ0MLVg90H21EOLACvtfcHk0ljKPCFTxB5yCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksV2lsrY%253D&md5=3c9b4ff203d7c304da3779a874837bf5</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm00034a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00034a020%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DIsmaiel%26aufirst%3DA.%2BM.%26aulast%3Del-Ashmawy%26aufirst%3DM.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BB.%26aulast%3DHowie%26aufirst%3DK.%2BB.%26atitle%3DStructural%2520features%2520important%2520for%2520sigma%25201%2520receptor%2520binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1214%26epage%3D1219%26doi%3D10.1021%2Fjm00034a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the “deconstruction-reconstruction-elaboration” approach</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.2174/138955705774329519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F138955705774329519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16250835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWku7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=927-940&author=R.+A.+Glennon&title=Pharmacophore+identification+for+sigma-1+%28sigma1%29+receptor+binding%3A+application+of+the+%E2%80%9Cdeconstruction-reconstruction-elaboration%E2%80%9D+approach&doi=10.2174%2F138955705774329519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore identification for sigma-1 (σ1) receptor binding: Application of the deconstruction - reconstruction - elaboration approach</span></div><div class="casAuthors">Glennon, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">927-940</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  At least two different types of sigma σ (σ1 and σ2) receptors have been identified.  A structural feature common to high-affinity (Ki <10 nM) σ1 ligands is: C-N(R)-X-Ph; both C and Ph are assocd. with regions of bulk tolerance.  Numerous other ligands bind, but typically do so with lower affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot_9JlDBLhrbVg90H21EOLACvtfcHk0lhjLIE7eL0uLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWku7rM&md5=66ae2e51d57fa97cd3954ae90e7e3167</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.2174%2F138955705774329519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774329519%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DPharmacophore%2520identification%2520for%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520binding%253A%2520application%2520of%2520the%2520%25E2%2580%259Cdeconstruction-reconstruction-elaboration%25E2%2580%259D%2520approach%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D927%26epage%3D940%26doi%3D10.2174%2F138955705774329519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posocco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paneni, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3<i>H</i>)-one derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5380</span>– <span class="NLM_lpage">5393</span>, <span class="refDoi"> DOI: 10.1021/jm900366z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900366z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpslaht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5380-5393&author=D.+Zampieriauthor=M.+G.+Mamoloauthor=E.+Lauriniauthor=C.+Florioauthor=C.+Zanetteauthor=M.+Fermegliaauthor=P.+Posoccoauthor=M.+S.+Paneniauthor=S.+Priclauthor=L.+Vio&title=Synthesis%2C+biological+evaluation%2C+and+three-dimensional+in+silico+pharmacophore+model+for+sigma%281%29+receptor+ligands+based+on+a+series+of+substituted+benzo%5Bd%5Doxazol-2%283H%29-one+derivatives&doi=10.1021%2Fjm900366z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Three-Dimensional in Silico Pharmacophore Model for σ1 Receptor Ligands Based on a Series of Substituted Benzo[d]oxazol-2(3H)-one Derivatives</span></div><div class="casAuthors">Zampieri, Daniele; Mamolo, Maria Grazia; Laurini, Erik; Florio, Chiara; Zanette, Caterina; Fermeglia, Maurizio; Posocco, Paola; Paneni, Maria Silvia; Pricl, Sabrina; Vio, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5380-5393</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel benzo[d]oxazol-2(3H)-one derivs. were designed and synthesized, and their affinities against σ receptors were evaluated.  On the basis of 31 compds., a three-dimensional pharmacophore model for the σ1 receptor binding site was developed using the Catalyst 4.9 software package.  The best 3D pharmacophore hypothesis, consisting of one pos. ionizable, one hydrogen bond acceptor, two hydrophobic arom., and one hydrophobic features provided a 3D-QSAR model with a correlation coeff. of 0.89.  The best hypothesis was also validated by three independent methods, i.e., the Fisher randomization test included in the CatScramble functionality of Catalyst, the leave-one-out test, and activity prediction of an addnl. test set.  The achieved results will allow researchers to use this 3D pharmacophore model for the design and synthesis of a second generation of high affinity σ1 ligands, as well as to discover other lead compds. for this class of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ7dYDBRve47Vg90H21EOLACvtfcHk0lhjLIE7eL0uLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpslaht78%253D&md5=678e879dd9b79c55fc61bfec02d3b927</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm900366z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900366z%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFlorio%26aufirst%3DC.%26aulast%3DZanette%26aufirst%3DC.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPosocco%26aufirst%3DP.%26aulast%3DPaneni%26aufirst%3DM.%2BS.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DVio%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520three-dimensional%2520in%2520silico%2520pharmacophore%2520model%2520for%2520sigma%25281%2529%2520receptor%2520ligands%2520based%2520on%2520a%2520series%2520of%2520substituted%2520benzo%255Bd%255Doxazol-2%25283H%2529-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5380%26epage%3D5393%26doi%3D10.1021%2Fjm900366z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Col, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span> <span> </span><span class="NLM_article-title">Another brick in the wall. Validation of the sigma1 receptor 3D model by computer-assisted design, synthesis, and activity of new sigma1 ligands</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3107</span>– <span class="NLM_lpage">3126</span>, <span class="refDoi"> DOI: 10.1021/mp300233y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300233y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVamt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=3107-3126&author=E.+Lauriniauthor=D.+Marsonauthor=V.+Dal+Colauthor=M.+Fermegliaauthor=M.+G.+Mamoloauthor=D.+Zampieriauthor=L.+Vioauthor=S.+Pricl&title=Another+brick+in+the+wall.+Validation+of+the+sigma1+receptor+3D+model+by+computer-assisted+design%2C+synthesis%2C+and+activity+of+new+sigma1+ligands&doi=10.1021%2Fmp300233y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Another Brick in the Wall. Validation of the σ1 Receptor 3D Model by Computer-Assisted Design, Synthesis, and Activity of New σ1 Ligands</span></div><div class="casAuthors">Laurini, Erik; Marson, Domenico; Dal Col, Valentina; Fermeglia, Maurizio; Mamolo, Maria Grazia; Zampieri, Daniele; Vio, Luciano; Pricl, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3107-3126</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Originally considered an enigmatic polypeptide, the σ1 receptor has recently been identified as a unique ligand-regulated protein.  Many studies have shown the potential of σ1 receptor ligands for the treatment of various diseases of the central nervous system (CNS); nevertheless, almost no information about the 3D structure of the receptor and/or the possible modes of interaction of the σ1 protein with its ligands have been unveiled so far.  With the present work we validated our σ1 3D homol. model and assessed its reliability as a platform for σ1 ligand structure-based drug design.  To this purpose, the 3D σ1 model was exploited in the design of 33 new σ1 ligands and in their ranking for receptor affinity by extensive mol. dynamics simulation-based free energy calcns.  Also, the main interactions involved in receptor/ligand binding were analyzed by applying a per residue free energy deconvolution and in silico alanine scanning mutagenesis calcns.  Subsequently, all compds. were synthesized in our lab. and tested for σ1 binding activity in vitro.  The agreement between in silico and in vitro results confirms the reliability of the proposed σ1 3D model in the a priori prediction of the affinity of new σ1 ligands.  Moreover, it also supports and corroborates the currently available biochem. data concerning the σ1 protein residues considered essential for σ1 ligand binding and activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7eSBYAAydoLVg90H21EOLACvtfcHk0lhjLIE7eL0uLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVamt7fL&md5=9f3867b8cbfc2d063a07d1b55fb8354d</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fmp300233y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300233y%26sid%3Dliteratum%253Aachs%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DMarson%26aufirst%3DD.%26aulast%3DDal%2BCol%26aufirst%3DV.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DPricl%26aufirst%3DS.%26atitle%3DAnother%2520brick%2520in%2520the%2520wall.%2520Validation%2520of%2520the%2520sigma1%2520receptor%25203D%2520model%2520by%2520computer-assisted%2520design%252C%2520synthesis%252C%2520and%2520activity%2520of%2520new%2520sigma1%2520ligands%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D3107%26epage%3D3126%26doi%3D10.1021%2Fmp300233y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichiara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittala, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span> <span> </span><span class="NLM_article-title">Hyphenated 3D-QSAR statistical model-scaffold hopping analysis for the identification of potentially potent and selective sigma-2 receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2017.08.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28866257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyrurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=884-891&author=G.+Florestaauthor=A.+Rescifinaauthor=A.+Marrazzoauthor=M.+Dichiaraauthor=V.+Pistaraauthor=V.+Pittalaauthor=O.+Prezzaventoauthor=E.+Amata&title=Hyphenated+3D-QSAR+statistical+model-scaffold+hopping+analysis+for+the+identification+of+potentially+potent+and+selective+sigma-2+receptor+ligands&doi=10.1016%2Fj.ejmech.2017.08.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Hyphenated 3D-QSAR statistical model-scaffold hopping analysis for the identification of potentially potent and selective sigma-2 receptor ligands</span></div><div class="casAuthors">Floresta, Giuseppe; Rescifina, Antonio; Marrazzo, Agostino; Dichiara, Maria; Pistara, Venerando; Pittala, Valeria; Prezzavento, Orazio; Amata, Emanuele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">884-891</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A 3D quant. structure-activity relationship (3D-QSAR) model for predicting the σ2 receptor affinity has been constructed with the aim of providing a useful tool for the identification, design, and optimization of novel σ2 receptor ligands.  The model has been built using a set of 500 selective σ2 receptor ligands recovered from the sigma-2 receptor selective ligand database (S2RSLDB) and developed with the software Forge.  The present model showed high statistical quality as confirmed by its robust predictive potential and satisfactory descriptive capability.  The drawn up 3D map allows for a prompt visual comprehension of the electrostatic, hydrophobic, and shaping features underlying σ2 receptor ligands interaction.  A theoretic approach for the generation of new lead compds. with optimized σ2 receptor affinity has been performed by means of scaffold hopping anal.  Obtained results further confirmed the validity of our model being some of the identified moieties have already been successfully employed in the development of potent σ2 receptor ligands.  For the first time is herein reported a 3D-QSAR model which includes a no. of chem. diverse σ2 receptor ligands and well accounts for the individual ligands affinities.  These features will ensure prospectively advantageous applications to speed up the identification of new potent and selective σ2 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS4b9EH7P7C7Vg90H21EOLACvtfcHk0liayTO7ZWK-tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyrurzO&md5=dcad5568aa0ec2111284f295c216e4e9</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.053%26sid%3Dliteratum%253Aachs%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26aulast%3DMarrazzo%26aufirst%3DA.%26aulast%3DDichiara%26aufirst%3DM.%26aulast%3DPistara%26aufirst%3DV.%26aulast%3DPittala%26aufirst%3DV.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DAmata%26aufirst%3DE.%26atitle%3DHyphenated%25203D-QSAR%2520statistical%2520model-scaffold%2520hopping%2520analysis%2520for%2520the%2520identification%2520of%2520potentially%2520potent%2520and%2520selective%2520sigma-2%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D884%26epage%3D891%26doi%3D10.1016%2Fj.ejmech.2017.08.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kniess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietzsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">(18)F-Labeled 1,4-dioxa-8-azaspiro[4.5]decane derivative: synthesis and biological evaluation of a sigma1 receptor radioligand with low lipophilicity as potent tumor imaging agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5395</span>– <span class="NLM_lpage">5407</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00593</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00593" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKisbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5395-5407&author=F.+Xieauthor=R.+Bergmannauthor=T.+Kniessauthor=W.+Deuther-Conradauthor=C.+Mamatauthor=C.+Neuberauthor=B.+Liuauthor=J.+Steinbachauthor=P.+Brustauthor=J.+Pietzschauthor=H.+Jia&title=%2818%29F-Labeled+1%2C4-dioxa-8-azaspiro%5B4.5%5Ddecane+derivative%3A+synthesis+and+biological+evaluation+of+a+sigma1+receptor+radioligand+with+low+lipophilicity+as+potent+tumor+imaging+agent&doi=10.1021%2Facs.jmedchem.5b00593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">18F-Labeled 1,4-Dioxa-8-azaspiro[4.5]decane Derivative: Synthesis and Biological Evaluation of a σ1 Receptor Radioligand with Low Lipophilicity as Potent Tumor Imaging Agent</span></div><div class="casAuthors">Xie, Fang; Bergmann, Ralf; Kniess, Torsten; Deuther-Conrad, Winnie; Mamat, Constantin; Neuber, Christin; Liu, Boli; Steinbach, Joerg; Brust, Peter; Pietzsch, Jens; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5395-5407</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the syntheses and evaluation of series of novel piperidine compds., e.g., I (R = Me, H, OH, CH2OH, n = 3, 4), with low lipophilicity as σ1 receptor ligands.  8-[4-(2-Fluoroethoxy)benzyl]-1,4-dioxa-8-azaspiro[4.5]decane (II) possessed high affinity (Ki = 5.4 ± 0.4 nM) for σ1 receptors and selectivity for σ2 receptors (30-fold) and the vesicular acetylcholine transporter (1404-fold).  [18F]II was prepd. using a one-pot, two-step labeling procedure in an automated synthesis module, with a radiochem. purity of >95%, and a specific activity of 25-45 GBq/μmol.  Cellular assocn., biodistribution, and autoradiog. with blocking expts. indicated specific binding of [18F]II to σ1 receptors in vitro and in vivo.  Small animal positron emission tomog. (PET) imaging using mouse tumor xenograft models demonstrated a high accumulation in human carcinoma and melanoma.  Treatment with haloperidol significantly reduced the accumulation of the radiotracer in tumors.  These findings suggest that radiotracer with suitable lipophilicity and appropriate affinity for σ1 receptors could be used for tumor imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTTJrIl8aEvLVg90H21EOLACvtfcHk0liayTO7ZWK-tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKisbvE&md5=78e4f3a3b01064869e696fe4615998b3</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00593%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DF.%26aulast%3DBergmann%26aufirst%3DR.%26aulast%3DKniess%26aufirst%3DT.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DMamat%26aufirst%3DC.%26aulast%3DNeuber%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DPietzsch%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DH.%26atitle%3D%252818%2529F-Labeled%25201%252C4-dioxa-8-azaspiro%255B4.5%255Ddecane%2520derivative%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520sigma1%2520receptor%2520radioligand%2520with%2520low%2520lipophilicity%2520as%2520potent%2520tumor%2520imaging%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5395%26epage%3D5407%26doi%3D10.1021%2Facs.jmedchem.5b00593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">1-(4-[(18)F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: a novel suitable radioligand with low lipophilicity for imaging sigma1 receptors in the brain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4161</span>– <span class="NLM_lpage">4172</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4161-4172&author=Y.+Heauthor=F.+Xieauthor=J.+Yeauthor=W.+Deuther-Conradauthor=B.+Cuiauthor=L.+Wangauthor=J.+Luauthor=J.+Steinbachauthor=P.+Brustauthor=Y.+Huangauthor=J.+Luauthor=H.+Jia&title=1-%284-%5B%2818%29F%5DFluorobenzyl%29-4-%5B%28tetrahydrofuran-2-yl%29methyl%5Dpiperazine%3A+a+novel+suitable+radioligand+with+low+lipophilicity+for+imaging+sigma1+receptors+in+the+brain&doi=10.1021%2Facs.jmedchem.6b01723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">1-(4-[18F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: A Novel Suitable Radioligand with Low Lipophilicity for Imaging σ1 Receptors in the Brain</span></div><div class="casAuthors">He, Yingfang; Xie, Fang; Ye, Jiajun; Deuther-Conrad, Winnie; Cui, Bixiao; Wang, Liang; Lu, Jie; Steinbach, Jorg; Brust, Peter; Huang, Yiyun; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4161-4172</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have designed and synthesized novel piperazine compds. with low lipophilicity as σ1 receptor ligands. 1-(4-Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine (10) possessed a low nanomolar σ1 receptor affinity and a high selectivity toward the vesicular acetylcholine transporter (>2000-fold), σ2 receptors (52-fold), and adenosine A2A, adrenergic α2, cannabinoid CB1, dopamine D1, D2L, γ-aminobutyric acid A (GABAA), NMDA, melatonin MT1, MT2, and serotonin 5-HT1 receptors.  The corresponding radiotracer [18F]10 demonstrated high brain uptake and extremely high brain-to-blood ratios in biodistribution studies in mice.  Pretreatment with the selective σ1 receptor agonist SA4503 significantly reduced the level of accumulation of the radiotracer in the brain.  No radiometabolite of [18F]10 was obsd. to enter the brain.  Positron emission tomog. and magnetic resonance imaging confirmed suitable kinetics and a high specific binding of [18F]10 to σ1 receptors in rat brain.  Ex vivo autoradiog. showed a reduced level of binding of [18F]10 in the cortex and hippocampus of the senescence-accelerated prone (SAMP8) compared to that of the senescence-accelerated resistant (SAMR1) mice, indicating the potential dysfunction of σ1 receptors in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNq2WOuF4xHLVg90H21EOLACvtfcHk0liayTO7ZWK-tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCntrs%253D&md5=86a5d03c3129895d3eb6bc61d4730b94</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01723%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DCui%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DH.%26atitle%3D1-%25284-%255B%252818%2529F%255DFluorobenzyl%2529-4-%255B%2528tetrahydrofuran-2-yl%2529methyl%255Dpiperazine%253A%2520a%2520novel%2520suitable%2520radioligand%2520with%2520low%2520lipophilicity%2520for%2520imaging%2520sigma1%2520receptors%2520in%2520the%2520brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4161%26epage%3D4172%26doi%3D10.1021%2Facs.jmedchem.6b01723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115560</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2020.115560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=32616183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFSks77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115560&author=J.+Tianauthor=Y.+Heauthor=W.+Deuther-Conradauthor=H.+Fuauthor=F.+Xieauthor=Y.+Zhangauthor=T.+Wangauthor=X.+Zhangauthor=J.+Zhangauthor=P.+Brustauthor=Y.+Huangauthor=H.+Jia&title=Synthesis+and+evaluation+of+new+1-oxa-8-azaspiro%5B4.5%5Ddecane+derivatives+as+candidate+radioligands+for+sigma-1+receptors&doi=10.1016%2Fj.bmc.2020.115560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors</span></div><div class="casAuthors">Tian, Jiale; He, Yingfang; Deuther-Conrad, Winnie; Fu, Hualong; Xie, Fang; Zhang, Ying; Wang, Tao; Zhang, Xiaojun; Zhang, Jinming; Brust, Peter; Huang, Yiyun; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">115560</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design, synthesis, and evaluation of a series of 1-oxa-8-azaspiro[4.5]decane I (R = F, I, OCH2CH2F) and 1,5-dioxa-9-azaspiro[5.5]undecane derivs. II (R = F, I, OCH2CH2F, OMe) as selective σ1 receptor ligands has been reported.  All seven ligands exhibited nanomolar affinity for σ1 receptors (Ki(σ1) = 0.47 - 12.1 nM) and moderate selectivity over σ2 receptors (Ki(σ2)/ Ki(σ1) = 2 - 44).  Compd. I (R = OCH2CH2F), with the best selectivity among these ligands, was selected for radiolabeling and further evaluation.  Radioligand II (R = OCH2CH2F18) was prepd. via nucleophilic 18F-substitution of the corresponding tosylate precursor, with an overall isolated radiochem. yield of 12-35%, a radiochem. purity of greater than 99%, and molar activity of 94 - 121 GBq/μmol.  Biodistribution studies of II (R = OCH2CH2F18) in mice demonstrated high initial brain uptake at 2 min.  Pretreatment with SA4503 resulted in significantly reduced brain-to-blood ratio (70% - 75% at 30 min).  Ex vivo autoradiog. in ICR mice demonstrated high accumulation of the radiotracer in σ1 receptor-rich brain areas.  These findings suggest that II (R = OCH2CH2F18) could be a lead compd. for further structural modifications to develop potential brain imaging agents for σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowOn8LA7sx17Vg90H21EOLACvtfcHk0lj5UZd52Ku9nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFSks77K&md5=eb642b42faeef2f1b5d6814b2698ba9a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115560%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520new%25201-oxa-8-azaspiro%255B4.5%255Ddecane%2520derivatives%2520as%2520candidate%2520radioligands%2520for%2520sigma-1%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115560%26doi%3D10.1016%2Fj.bmc.2020.115560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien-Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of sigma-1 receptor ligands</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">600</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1071/CH14590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1071%2FCH14590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlCgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2015&pages=600-609&author=M.+Manoharauthor=S.+D.+Banisterauthor=C.+Beinatauthor=J.+O%E2%80%99Brien-Brownauthor=M.+Kassiou&title=Recent+advances+in+the+development+of+sigma-1+receptor+ligands&doi=10.1071%2FCH14590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Development of Sigma-1 Receptor Ligands</span></div><div class="casAuthors">Manohar, Madhura; Banister, Samuel D.; Beinat, Corinne; O'Brien-Brown, James; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Australian Journal of Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">600-609</span>CODEN:
                <span class="NLM_cas:coden">AJCHAS</span>;
        ISSN:<span class="NLM_cas:issn">0004-9425</span>.
    
            (<span class="NLM_cas:orgname">CSIRO Publishing</span>)
        </div><div class="casAbstract">A review.  The existence of two distinct sigma (σ) receptor subtypes was established in the early 1990s.  Sigma-1 and sigma-2 receptors (S1Rs and S2Rs, resp.) were shown to possess distinct mol. size, anatomical distribution, and ligand discrimination.  S2R is overexpressed in numerous human cancers, and has therapeutic potential for the imaging and treatment of certain tumors.  In contrast, S1R is more broadly involved in a wide variety of central nervous system (CNS) diseases including motor disorders, memory deficits, depression, schizophrenia, anxiety, pain, drug addiction, and many more.  Since the human S1R was cloned in 1996, numerous high affinity ligands with excellent selectivity for S1R have been developed.  This review focuses on recent developments in the generation of structurally diverse S1R-selective ligands and novel therapeutic candidates targeting S1Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFO8GN480HerVg90H21EOLACvtfcHk0lj5UZd52Ku9nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlCgtrY%253D&md5=101367291b60831da45faa372bf02f7e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1071%2FCH14590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1071%252FCH14590%26sid%3Dliteratum%253Aachs%26aulast%3DManohar%26aufirst%3DM.%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DBeinat%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien-Brown%26aufirst%3DJ.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520sigma-1%2520receptor%2520ligands%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2015%26volume%3D68%26spage%3D600%26epage%3D609%26doi%3D10.1071%2FCH14590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lever, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allmon, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S. Z.</span></span> <span> </span><span class="NLM_article-title">Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1002/syn.20253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fsyn.20253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16463398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtF2qtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=350-358&author=J.+R.+Leverauthor=J.+L.+Gustafsonauthor=R.+Xuauthor=R.+L.+Allmonauthor=S.+Z.+Lever&title=Sigma1+and+sigma2+receptor+binding+affinity+and+selectivity+of+SA4503+and+fluoroethyl+SA4503&doi=10.1002%2Fsyn.20253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">σ1 and σ2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503</span></div><div class="casAuthors">Lever, John R.; Gustafson, Jennifer L.; Xu, Rong; Allmon, Rachel L.; Lever, Susan Z.</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">350-358</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">SA4503, a potent σ1 receptor agonist, is reported as having 103-fold higher affinity for σ1 (IC50 = 17.4 nM) than σ2 (IC50 = 1784 nM) sites in guinea pig brain membranes.  Modest structural changes appear to have major effects on σ1/σ2 selectivity.  The fluoroethyl analog, FE-SA4503, is described as having high primary affinity for σ2 sites (IC50 = 2.11 nM) and a weaker interaction with σ1 sites (IC50 = 6.48 nM).  SA4503 and FE-SA4503 have been radiolabeled for PET studies, and both bind selectively to σ1 receptors in animal and human brain in vivo.  We prepd. SA4503 and FE-SA4503 as ref. compds. for radioligand development efforts.  In our hands, SA4503 is 14-fold selective for σ1 (Ki = 4.6 nM) over σ2 (Ki = 63.1 nM) sites in guinea pig brain homogenates.  Further, FE-SA4503 exhibits the same 14-fold selectivity for σ1 (Ki = 8.0 nM) over σ2 (Ki = 113.2 nM) receptors.  The main differences from previously reported values stem from σ2 affinity detns.  This protocol, displacement of [3H]DTG binding to σ2 sites using (+)-pentazocine (200 nM) to mask σ1 sites, was validated by the proper rank order of σ2 inhibitory potencies shown by a panel of addnl. ligands: ifenprodil > haloperidol > DTG >> (+)-pentazocine.  Robust Pearson correlation (r = 1.0, P = 0.002; slope = 0.97) was obsd. for our pKi values against those from a prior study by others.  The findings have bearing on structure-activity relationships for this active series, and on conclusions that might be drawn from expts. relying upon defined σ1/σ2 binding selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroCWxEMb91BLVg90H21EOLACvtfcHk0lj5UZd52Ku9nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtF2qtrw%253D&md5=cdde02213b531f7d212f9e00d0e3af74</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20253%26sid%3Dliteratum%253Aachs%26aulast%3DLever%26aufirst%3DJ.%2BR.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DAllmon%26aufirst%3DR.%2BL.%26aulast%3DLever%26aufirst%3DS.%2BZ.%26atitle%3DSigma1%2520and%2520sigma2%2520receptor%2520binding%2520affinity%2520and%2520selectivity%2520of%2520SA4503%2520and%2520fluoroethyl%2520SA4503%26jtitle%3DSynapse%26date%3D2006%26volume%3D59%26spage%3D350%26epage%3D358%26doi%3D10.1002%2Fsyn.20253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yajima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2620</span>– <span class="NLM_lpage">2626</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.11.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2005.11.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=16434200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ymtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=2620-2626&author=K.+Shibaauthor=K.+Ogawaauthor=K.+Ishiwataauthor=K.+Yajimaauthor=H.+Mori&title=Synthesis+and+binding+affinities+of+methylvesamicol+analogs+for+the+acetylcholine+transporter+and+sigma+receptor&doi=10.1016%2Fj.bmc.2005.11.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor</span></div><div class="casAuthors">Shiba, Kazuhiro; Ogawa, Kazuma; Ishiwata, Kiichi; Yajima, Kazuyoshi; Mori, Hirofumi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2620-2626</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We synthesized methylvesamicol analogs 13-16 and investigated the binding characteristics of 2-[4-phenylpiperidino]cyclohexanol (vesamicol) and methylvesamicol analogs 13-16, with a Me group introduced into the 4-phenylpiperidine moiety, to sigma receptors (σ-1, σ-2) and to vesicular acetylcholine transporters (VAChT) in membranes of the rat brain and liver.  In competitive inhibition studies, (-)-o-methylvesamicol [(-)-OMV] (13) (Ki = 6.7 nM), as well as (-)-vesamicol (Ki = 4.4 nM), had a high affinity for VAChT. (+)-p-Methylvesamicol [(+)-PMV] (16) (Ki = 3.0 nM), as well as SA4503 (K i = 4.4 nM), reported as a σ-1 mapping agent for positron emission tomog. (PET), had a high affinity for the σ-1 receptor.  The binding affinity of (+)-PMV (16) for the σ-1 receptor (Ki = 3.0 nM) was about 13 times higher than that for the sigma-2 (σ-2) receptor (Ki = 40.7 nM). (+)-PMV (16) (Ki = 199 nM) had a much lower affinity for VAChT than SA4503 (K i = 50.2 nM) and haloperidol (Ki = 41.4 nM).  These results showed that the binding characteristics of (-)-OMV (13) to VAChT were similar to those of (-)-vesamicol and that (+)-PMV (16) bound to the σ-1 receptor with high affinity.  In conclusion, (-)-OMV (13) and (+)-PMV (16), which had a suitable structure, with a Me group for labeling with 11C, may become not only a new VAChT ligand and a new type of σ receptor ligand, resp., but may also become a new target compd. of VAChT and the σ-1 receptor radioligand for PET, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp22XLhJlJErVg90H21EOLACvtfcHk0lgW5ps-kRhekg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ymtro%253D&md5=13faa91541d6280e4864ba71c130be56</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.11.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.11.044%26sid%3Dliteratum%253Aachs%26aulast%3DShiba%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DYajima%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520binding%2520affinities%2520of%2520methylvesamicol%2520analogs%2520for%2520the%2520acetylcholine%2520transporter%2520and%2520sigma%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D2620%26epage%3D2626%26doi%3D10.1016%2Fj.bmc.2005.11.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">In, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure and quantitative structure-activity relationships of sigma receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl) piperazines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1675</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(97)00093-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2FS0968-0896%2897%2900093-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=9313869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVGrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1997&pages=1675-1683&author=K.+Fujimuraauthor=J.+Matsumotoauthor=M.+Niwaauthor=T.+Kobayashiauthor=Y.+Kawashimaauthor=Y.+Inauthor=T.+Ishida&title=Synthesis%2C+structure+and+quantitative+structure-activity+relationships+of+sigma+receptor+ligands%2C+1-%5B2-%283%2C4-dimethoxyphenyl%29ethyl%5D-4-%283-phenylpropyl%29+piperazines&doi=10.1016%2FS0968-0896%2897%2900093-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure and quantitative structure-activity relationships of σ receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines</span></div><div class="casAuthors">Fujimura, Ken-Ichi; Matsumoto, Junzo; Niwa, Masashi; Kobayashi, Tadayuki; Kawashima, Yoichi; In, Yasuko; Ishida, Toshimasa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1675-1683</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A set of the title compds. (I) (R1 = Cl, H, CF3; R2 = Cl, CF3, H, OH, Br, F, OCH2Ph) was synthesized to find σ receptor binding affinity.  Among the compds., I (R1=R2=Cl) (II) has the most potent σ1-binding activity, while I (R1=R2=H, SA4503) (III) was most selective to σ1 over σ2 receptor.  The crystal structures of III and II were shown, by X-ray crystallog., to be similar except for the one torsional angle of their propylene parts.  Quant. structure-activity relationship study suggested the affinity of the compds. to the σ1 receptor was dependent on the electronic feature, Swain-Lupton's R or Sπ that was derived by MO method, of R1 and R2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJUWcpOIiaGrVg90H21EOLACvtfcHk0lgW5ps-kRhekg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVGrs74%253D&md5=ca4636f167b7252638e16ec6d4fd3551</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2897%2900093-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252897%252900093-X%26sid%3Dliteratum%253Aachs%26aulast%3DFujimura%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DJ.%26aulast%3DNiwa%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DKawashima%26aufirst%3DY.%26aulast%3DIn%26aufirst%3DY.%26aulast%3DIshida%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520structure%2520and%2520quantitative%2520structure-activity%2520relationships%2520of%2520sigma%2520receptor%2520ligands%252C%25201-%255B2-%25283%252C4-dimethoxyphenyl%2529ethyl%255D-4-%25283-phenylpropyl%2529%2520piperazines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1997%26volume%3D5%26spage%3D1675%26epage%3D1683%26doi%3D10.1016%2FS0968-0896%2897%2900093-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">Novel cyclopentadienyl tricarbonyl (99m)tc complexes containing 1-piperonylpiperazine moiety: potential imaging probes for sigma-1 receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7113</span>– <span class="NLM_lpage">7125</span>, <span class="refDoi"> DOI: 10.1021/jm5009488</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5009488" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egs7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7113-7125&author=X.+Wangauthor=D.+Liauthor=W.+Deuther-Conradauthor=J.+Luauthor=Y.+Xieauthor=B.+Jiaauthor=M.+Cuiauthor=J.+Steinbachauthor=P.+Brustauthor=B.+Liuauthor=H.+Jia&title=Novel+cyclopentadienyl+tricarbonyl+%2899m%29tc+complexes+containing+1-piperonylpiperazine+moiety%3A+potential+imaging+probes+for+sigma-1+receptors&doi=10.1021%2Fjm5009488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Cyclopentadienyl Tricarbonyl 99mTc Complexes Containing 1-Piperonylpiperazine Moiety: Potential Imaging Probes for Sigma-1 Receptors</span></div><div class="casAuthors">Wang, Xia; Li, Dan; Deuther-Conrad, Winnie; Lu, Jie; Xie, Ying; Jia, Bing; Cui, Mengchao; Steinbach, Jorg; Brust, Peter; Liu, Boli; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7113-7125</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the design, synthesis, and evaluation of a series of novel cyclopentadienyl tricarbonyl 99mTc complexes as potent σ1 receptor radioligands.  Rhenium compds. 3-(4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl)propylcarbonylcyclopentadienyl tricarbonyl rhenium (10a) and 4-(4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl)butylcarbonylcyclopentadienyl tricarbonyl rhenium (10b) possessed high in vitro affinity for σ1 receptors and moderate to high selectivity for σ2 receptors and the vesicular acetylcholine transporter.  Biodistribution studies in mice demonstrated high initial brain uptake for corresponding 99mTc derivs. [99mTc]23 and [99mTc]24 of 2.94 and 2.13% injected dose (ID)/g, resp., at 2 min postinjection.  Pretreatment of haloperidol significantly reduced the radiotracer accumulation of [99mTc]23 or [99mTc]24 in the brain.  Studies of the cellular uptake of [99mTc]23 in C6 and DU145 tumor cells demonstrated a redn. of accumulation by incubation with haloperidol, 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine (SA4503), or 1,3-di-o-tolyl-guanidine (DTG).  Furthermore, blocking studies in C6 glioma-bearing mice confirmed the specific binding of [99mTc]23 to σ1 receptors in the tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmqY0f1Jf77Vg90H21EOLACvtfcHk0lgW5ps-kRhekg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egs7jJ&md5=47ad2ee73f8711b9f26e27119d1d0a93</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm5009488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5009488%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DB.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DJia%26aufirst%3DH.%26atitle%3DNovel%2520cyclopentadienyl%2520tricarbonyl%2520%252899m%2529tc%2520complexes%2520containing%25201-piperonylpiperazine%2520moiety%253A%2520potential%2520imaging%2520probes%2520for%2520sigma-1%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7113%26epage%3D7125%26doi%3D10.1021%2Fjm5009488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fergason-Cantrell, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S. Z.</span></span> <span> </span><span class="NLM_article-title">Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2014.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25468036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFegsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=222-230&author=R.+Xuauthor=S.+A.+Lordauthor=R.+M.+Petersonauthor=E.+A.+Fergason-Cantrellauthor=J.+R.+Leverauthor=S.+Z.+Lever&title=Ether+modifications+to+1-%5B2-%283%2C4-dimethoxyphenyl%29ethyl%5D-4-%283-phenylpropyl%29piperazine+%28SA4503%29%3A+effects+on+binding+affinity+and+selectivity+for+sigma+receptors+and+monoamine+transporters&doi=10.1016%2Fj.bmc.2014.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): Effects on binding affinity and selectivity for sigma receptors and monoamine transporters</span></div><div class="casAuthors">Xu, Rong; Lord, Sarah A.; Peterson, Ryan M.; Fergason-Cantrell, Emily A.; Lever, John R.; Lever, Susan Z.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">222-230</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two series of novel ether analogs of the sigma (σ) receptor ligand 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503) have been prepd.  In one series, the alkyl portion of the 4-methoxy group was replaced with allyl, Pr, bromoethyl, benzyl, phenethyl, and phenylpropyl moieties.  In the second series, the 3,4-dimethoxy was replaced with cyclic methylenedioxy, ethylenedioxy and propylenedioxy groups.  These ligands, along with 4-O-des-Me SA4503, were evaluated for σ1 and σ2 receptor affinity, and compared to SA4503 and several known ether analogs.  SA4503 and a subset of ether analogs were also evaluated for dopamine transporter (DAT) and serotonin transporter (SERT) affinity.  The highest σ1 receptor affinities, Ki values of 1.75-4.63 nM, were obsd. for 4-O-des-Me SA4503, SA4503 and the methylenedioxy analog.  As steric bulk increased, σ1 receptor affinity decreased, but only to a point.  Allyl, Pr and bromoethyl substitutions gave σ1 receptor Ki values in the 20-30 nM range, while bulkier analogs having phenylalkyl, and Z- and E-iodoallyl, ether substitutions showed higher σ1 affinities, with Ki values in the 13-21 nM range.  Most ligands studied exhibited comparable σ1 and σ2 affinities, resulting in little to no subtype selectivity.  SA4503, the fluoroethyl analog and the methylenedioxy congener showed modest six- to fourteen-fold selectivity for σ1 sites.  DAT and SERT interactions proved much more sensitive than σ receptor interactions to these structural modifications.  For example, the benzyl congener (σ1Ki = 20.8 nM; σ2Ki = 16.4 nM) showed over 100-fold higher DAT affinity (Ki = 121 nM) and 6-fold higher SERT affinity (Ki = 128 nM) than the parent SA4503 (DAT Ki = 12650 nM; SERT Ki = 760 nM).  Thus, ether modifications to the SA4503 scaffold can provide polyfunctional ligands having a broader spectrum of possible pharmacol. actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe5N5hhz8TlLVg90H21EOLACvtfcHk0lhVv-yU63_pPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFegsLrJ&md5=f0ff94c1cb25a64fa002aaa236bcc751</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%26aulast%3DLord%26aufirst%3DS.%2BA.%26aulast%3DPeterson%26aufirst%3DR.%2BM.%26aulast%3DFergason-Cantrell%26aufirst%3DE.%2BA.%26aulast%3DLever%26aufirst%3DJ.%2BR.%26aulast%3DLever%26aufirst%3DS.%2BZ.%26atitle%3DEther%2520modifications%2520to%25201-%255B2-%25283%252C4-dimethoxyphenyl%2529ethyl%255D-4-%25283-phenylpropyl%2529piperazine%2520%2528SA4503%2529%253A%2520effects%2520on%2520binding%2520affinity%2520and%2520selectivity%2520for%2520sigma%2520receptors%2520and%2520monoamine%2520transporters%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D222%26epage%3D230%26doi%3D10.1016%2Fj.bmc.2014.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Col, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis, pharmacological evaluation, and sigma1 receptor interaction analysis of hydroxyethyl substituted piperazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2884</span>– <span class="NLM_lpage">2894</span>, <span class="refDoi"> DOI: 10.1021/jm401707t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401707t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvF2qurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2884-2894&author=F.+Weberauthor=S.+Bruneauthor=K.+Korpisauthor=P.+J.+Bednarskiauthor=E.+Lauriniauthor=V.+Dal+Colauthor=S.+Priclauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis%2C+pharmacological+evaluation%2C+and+sigma1+receptor+interaction+analysis+of+hydroxyethyl+substituted+piperazines&doi=10.1021%2Fjm401707t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Pharmacological Evaluation, and σ1 Receptor Interaction Analysis of Hydroxyethyl Substituted Piperazines</span></div><div class="casAuthors">Weber, Frauke; Brune, Stefanie; Korpis, Katharina; Bednarski, Patrick J.; Laurini, Erik; Dal Col, Valentina; Pricl, Sabrina; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2884-2894</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic arylmethyl piperazineethanols I (R = Ph, 4-PhC6H4, 1-naphthyl, 2-naphthyl, 6-MeO-2-naphthyl, 4-MeOC6H4; R1 = Me, Bu, i-BuCH2, PhCH2CH2, cyclohexylmethyl) or their enantiomers were prepd. from L- or D-aspartic acid as potential selective σ1 receptor ligands; their binding to σ1 and σ2 receptors and the inhibition of human cancer cell lines by selected piperazineethanols was detd.  σ1 Affinities detd. with guinea pig brain and human RPMI 8226 tumor cell lines differed slightly but showed the same binding tendencies.  Of the compds. tested, I (R = 2-naphthyl; R1 = cyclohexylmethyl) bound human σ1 receptors with the highest affinity (Ki = 6.8 nM); it inhibited the growth of three human cancer cell lines at micromolar concns., and the reduced growth in one of the cancer cell lines was caused by apoptosis.  The interaction of I (R = 2-naphthyl; R1 = cyclohexylmethyl) with the σ1 receptor was analyzed in detail using the 3D homol. model of the σ1 receptor; the binding energies and entropies and enthalpies of binding of I to the human σ1 receptor were calcd., and correlated to the exptl. binding affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTSY6dIeenlrVg90H21EOLACvtfcHk0lhVv-yU63_pPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvF2qurw%253D&md5=b2780618ed60d3b36051faf8261fbfb8</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm401707t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401707t%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DDal%2BCol%26aufirst%3DV.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%252C%2520pharmacological%2520evaluation%252C%2520and%2520sigma1%2520receptor%2520interaction%2520analysis%2520of%2520hydroxyethyl%2520substituted%2520piperazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2884%26epage%3D2894%26doi%3D10.1021%2Fjm401707t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span> <span> </span><span class="NLM_article-title">Involvement of apoptosis and autophagy in the death of RPMI 8226 multiple myeloma cells by two enantiomeric sigma receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.11.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2013.11.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24331758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOgsbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=221-233&author=K.+Korpisauthor=F.+Weberauthor=S.+Bruneauthor=B.+Wunschauthor=P.+J.+Bednarski&title=Involvement+of+apoptosis+and+autophagy+in+the+death+of+RPMI+8226+multiple+myeloma+cells+by+two+enantiomeric+sigma+receptor+ligands&doi=10.1016%2Fj.bmc.2013.11.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of apoptosis and autophagy in the death of RPMI 8226 multiple myeloma cells by two enantiomeric sigma receptor ligands</span></div><div class="casAuthors">Korpis, Katharina; Weber, Frauke; Brune, Stefanie; Wuensch, Bernhard; Bednarski, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">221-233</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over-expression of σ receptors by many tumor cell lines makes ligands for these receptors attractive as potential chemotherapeutic drugs.  Enantiomeric piperazines (S)-4 and (R)-4 were prepd. as potential σ-receptor ligands in a chiral pool synthesis starting from (S)- and (R)-aspartate.  Both compds. showed high affinities for the σ1 and σ2 receptors.  In the human multiple myeloma cell line RPMI 8226, a line expressing high levels of σ receptors, both compds. inhibited cell proliferation with IC50 values in the low μM range.  No chiral differentiation between either the σ receptor binding affinity or the cytotoxicity of the two enantiomers was obsd.  Both compds. induced apoptosis, which was evidenced by nuclear condensation, binding of annexin-V to phosphatidylserine in the outer leaf of the cell membrane, cleavage products of poly(ADP-ribose) polymerase-1 (PARP-1) and caspase-8 as well as the expression of bcl2 family members bax, bad and bid.  However, apoptosis appeared to be caspase independent.  Increased levels of the phosphorylated form of the microtubule assocd. protein light chain 3-II (LC3-II), an autophagosome marker, gave evidence that both compds. induced autophagy.  However, further data (e.g., treatment with wortmannin) indicate that autophagy is incomplete and not cytoprotective.  Lipid peroxidn. (LPO) was obsd. in RPMI 8226 cells treated with the two compds., and the lipid antioxidant α-tocopherol attenuated LPO.  Interestingly, α-tocopherol reduced significantly both apoptosis and autophagy induced by the compds.  These results provide evidence that, by initiating LPO and changes in mitochondrial membrane potential, both compds. induce apoptosis and autophagy in RPMI 8226 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcLGqAcjD1xbVg90H21EOLACvtfcHk0lhVv-yU63_pPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOgsbvN&md5=b292b81c7183d928fc153a43ab0829af</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.11.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.11.033%26sid%3Dliteratum%253Aachs%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26atitle%3DInvolvement%2520of%2520apoptosis%2520and%2520autophagy%2520in%2520the%2520death%2520of%2520RPMI%25208226%2520multiple%2520myeloma%2520cells%2520by%2520two%2520enantiomeric%2520sigma%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D221%26epage%3D233%26doi%3D10.1016%2Fj.bmc.2013.11.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battisti, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tait, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cichero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronsisvalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arico, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasili, L.</span></span> <span> </span><span class="NLM_article-title">Scouting new sigma receptor ligands: synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.01.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2016.01.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=26874044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVejtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2016&pages=1-19&author=S.+Franchiniauthor=U.+M.+Battistiauthor=A.+Prandiauthor=A.+Taitauthor=C.+Borsariauthor=E.+Cicheroauthor=P.+Fossaauthor=A.+Ciliaauthor=O.+Prezzaventoauthor=S.+Ronsisvalleauthor=G.+Aricoauthor=C.+Parentiauthor=L.+Brasili&title=Scouting+new+sigma+receptor+ligands%3A+synthesis%2C+pharmacological+evaluation+and+molecular+modeling+of+1%2C3-dioxolane-based+structures+and+derivatives&doi=10.1016%2Fj.ejmech.2016.01.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives</span></div><div class="casAuthors">Franchini, Silvia; Battisti, Umberto Maria; Prandi, Adolfo; Tait, Annalisa; Borsari, Chiara; Cichero, Elena; Fossa, Paola; Cilia, Antonio; Prezzavento, Orazio; Ronsisvalle, Simone; Arico, Giuseppina; Parenti, Carmela; Brasili, Livio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-19</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Herein the authors report the synthesis and biol. activity of new sigma receptor (σR) ligands [i.e., sigma-1 receptors, σ-receptor 1 σ-non-opioid intracellular receptors, sigma-2 receptors, σ-receptor 2 σ-non-opioid intracellular receptors] obtained by combining different substituted five-membered heterocyclic rings with appropriate σR pharmacophoric amines.  Radioligand binding assay, performed on guinea pig brain membranes, identified one 1-(1,4-dioxaspiro[4.5]decan-2-ylmethyl)-4-benzylpiperazine as the most interesting compd. of the series, displaying high affinity and selectivity for σ1R (pKiσ1 = 9.13; σ1/σ2 = 47).  The ability of this compd. to modulate the analgesic effect of the κ agonist (-)-U-50,488H and μ agonist morphine was evaluated in vivo by radiant heat tail-flick test (nociceptive model).  It exhibited anti-opioid effects on both κ and μ receptor-mediated analgesia, suggesting an agonistic behavior at σ1R.  Docking studies were performed on the theor. σ1R homol. model.  The present work represents a new starting point for the design of more potent and selective σ1R ligands.  Suitable starting materials included 4-(chloromethyl)-2,2-diphenyl-1,3-dioxolane, 5-(chloromethyl)-2,2-diphenyl-1,3-oxathiolane, 5-(chloromethyl)-2,2-diphenyl-1,3-dithiolan e derivs. and 4-(benzyl)piperidine and 1-(benzyl)piperazine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzeNBNZCdlLVg90H21EOLACvtfcHk0li3F23RGld0wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVejtrg%253D&md5=a0887c8dcdd728e645d1c58e93ea9dfe</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.01.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.01.059%26sid%3Dliteratum%253Aachs%26aulast%3DFranchini%26aufirst%3DS.%26aulast%3DBattisti%26aufirst%3DU.%2BM.%26aulast%3DPrandi%26aufirst%3DA.%26aulast%3DTait%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DCichero%26aufirst%3DE.%26aulast%3DFossa%26aufirst%3DP.%26aulast%3DCilia%26aufirst%3DA.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DRonsisvalle%26aufirst%3DS.%26aulast%3DArico%26aufirst%3DG.%26aulast%3DParenti%26aufirst%3DC.%26aulast%3DBrasili%26aufirst%3DL.%26atitle%3DScouting%2520new%2520sigma%2520receptor%2520ligands%253A%2520synthesis%252C%2520pharmacological%2520evaluation%2520and%2520molecular%2520modeling%2520of%25201%252C3-dioxolane-based%2520structures%2520and%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D112%26spage%3D1%26epage%3D19%26doi%3D10.1016%2Fj.ejmech.2016.01.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel sigma1 receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4778</span>– <span class="NLM_lpage">4799</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.07.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2017.07.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28764962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Gisb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=4778-4799&author=L.+Fanterauthor=C.+Mullerauthor=D.+Schepmannauthor=F.+Bracherauthor=B.+Wunsch&title=Chiral-pool+synthesis+of+1%2C2%2C4-trisubstituted+1%2C4-diazepanes+as+novel+sigma1+receptor+ligands&doi=10.1016%2Fj.bmc.2017.07.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ1 receptor ligands</span></div><div class="casAuthors">Fanter, Lena; Mueller, Christoph; Schepmann, Dirk; Bracher, Franz; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4778-4799</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from enantiomerically pure amino acids, 1,4-diazepanes with various substituents in 1, 2, and 4-position were synthesized following the late stage diversification strategy.  The key step in the formation of the seven-membered ring was the intramol. EDC coupling of amino acids.  The configuration in 2-position does not influence the σ1 affinity and selectivity over related receptors.  A cyclohexylmethyl or a Bu group are the preferred substituents in 4-position, whereas a Me moiety in 2-position and a (substituted) benzyl moiety in 1-position result in the highest σ1 affinity.  These results fit nicely to the reported σ1 pharmacophore models.  The compds. did not inhibit the structurally related fungal enzyme sterol Δ8,7-isomerase, but showed inhibition of diverse enzymes in late cholesterol biosynthesis at high concns.  In a screening against more than 50 target proteins, (2S)-1-benzyl-4-(4-methoxybenzyl)-2-methyl-1,4-diazepane ((S)-I, Ki(σ1) = 0.86 nM) showed a clean receptor profile.  The dose dependent potentiation of elec. stimulated contractions of guinea pig vas deferens indicates σ1 agonistic activity of (S)-I.  Even at a dose of 100 mg/kg (S)-I did not induce severe toxic or behavioral effects in the Irwin screen.  Clear cognition enhancing effects were obsd. for (S)-I after inducing amnesia by scopolamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooVrEXowkjrbVg90H21EOLACvtfcHk0li3F23RGld0wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Gisb3E&md5=8d998375ecd36b7f93148112912bce74</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.07.027%26sid%3Dliteratum%253Aachs%26aulast%3DFanter%26aufirst%3DL.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DBracher%26aufirst%3DF.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DChiral-pool%2520synthesis%2520of%25201%252C2%252C4-trisubstituted%25201%252C4-diazepanes%2520as%2520novel%2520sigma1%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D4778%26epage%3D4799%26doi%3D10.1016%2Fj.bmc.2017.07.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Solid-phase organic synthesis of chiral, non-racemic 1,2,4-trisubstituted 1,4-diazepanes with high sigma1 receptor affinity</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1700334</span>, <span class="refDoi"> DOI: 10.1002/ardp.201700334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fardp.201700334" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2018&pages=1700334&author=L.+Fanterauthor=D.+Schepmannauthor=B.+Wunsch&title=Solid-phase+organic+synthesis+of+chiral%2C+non-racemic+1%2C2%2C4-trisubstituted+1%2C4-diazepanes+with+high+sigma1+receptor+affinity&doi=10.1002%2Fardp.201700334"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1002%2Fardp.201700334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201700334%26sid%3Dliteratum%253Aachs%26aulast%3DFanter%26aufirst%3DL.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSolid-phase%2520organic%2520synthesis%2520of%2520chiral%252C%2520non-racemic%25201%252C2%252C4-trisubstituted%25201%252C4-diazepanes%2520with%2520high%2520sigma1%2520receptor%2520affinity%26jtitle%3DArch.%2520Pharm.%26date%3D2018%26volume%3D351%26spage%3D1700334%26doi%3D10.1002%2Fardp.201700334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortuna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabretti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menegazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, cytotoxicity evaluation, and computational insights of novel 1,4-diazepane-based sigma ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSnsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=651-656&author=D.+Zampieriauthor=S.+Fortunaauthor=A.+Calabrettiauthor=M.+Romanoauthor=R.+Menegazziauthor=D.+Schepmannauthor=B.+Wunschauthor=M.+G.+Mamolo&title=Synthesis%2C+cytotoxicity+evaluation%2C+and+computational+insights+of+novel+1%2C4-diazepane-based+sigma+ligands&doi=10.1021%2Facsmedchemlett.9b00524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands</span></div><div class="casAuthors">Zampieri, Daniele; Fortuna, Sara; Calabretti, Antonella; Romano, Maurizio; Menegazzi, Renzo; Schepmann, Dirk; Wunsch, Bernhard; Mamolo, Maria Grazia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">651-656</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among several potential applications, sigma receptor ligands can be used as antipsychotics, antiamnesics, and against other neurodegenerative disorders as well as neuroprotective agents.  We present herein a new series of diazepane-contg. derivs. as σR ligands obtained by a conformational expansion approach of our previously synthesized piperidine-based compds.  The best results were reached by benzofuran (e.g., 2c) and quinoline-substituted diazepane derivs., which showed the highest σR affinity.  The cytotoxic activities of synthesized compds. were evaluated against two cancer cell lines, and the results indicated that none of the compds. induced significant toxicity in these cells.  We also evaluated the antioxidant activity by radical scavenging capacity of our best compds. on ABTS and H2O2.  The results obtained reveal that our new derivs. possess an excellent antioxidant profile and could be protective for the cells.  Overall, the benzofurane deriv. 2c due to its strong interaction with the active site of the receptor, as confirmed by mol. dynamic simulations, emerged as the optimum compd. with high σ1R affinity, low cytotoxicity, and a potent antioxidant activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqKPjw5RD9AbVg90H21EOLACvtfcHk0ljTq_YUrCADaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSnsLvK&md5=0c06c9690ccf4d98b0db506b49182e3e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00524%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DFortuna%26aufirst%3DS.%26aulast%3DCalabretti%26aufirst%3DA.%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DMenegazzi%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26atitle%3DSynthesis%252C%2520cytotoxicity%2520evaluation%252C%2520and%2520computational%2520insights%2520of%2520novel%25201%252C4-diazepane-based%2520sigma%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D651%26epage%3D656%26doi%3D10.1021%2Facsmedchemlett.9b00524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golob, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and receptor binding studies of some new arylcarboxamide derivatives as sigma-1 ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1025</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2014.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24486131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1021-1025&author=D.+Zampieriauthor=E.+Lauriniauthor=L.+Vioauthor=S.+Golobauthor=M.+Fermegliaauthor=S.+Priclauthor=M.+G.+Mamolo&title=Synthesis+and+receptor+binding+studies+of+some+new+arylcarboxamide+derivatives+as+sigma-1+ligands&doi=10.1016%2Fj.bmcl.2014.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and receptor binding studies of some new arylcarboxamide derivatives as sigma-1 ligands</span></div><div class="casAuthors">Zampieri, Daniele; Laurini, Erik; Vio, Luciano; Golob, Samuel; Fermeglia, Maurizio; Pricl, Sabrina; Mamolo, Maria Grazia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1021-1025</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors describe here the synthesis and the binding interaction with σ1 and σ2 receptors of a series of new arylcarboxamide derivs. variously substituted on the arom. portions.  Maintaining a partial scaffold of a series of compds. previously synthesized by the authors, the authors evaluate the effect of the substitution on σ binding.  The synthesized compds. were tested to est. their affinity and selectivity toward σ1 and σ2 receptors.  Two out of 16 derivs. showed an interesting σ1 affinity (21.2 and 13.6 nM-compds.) N-((1-benzylpiperidin-4-yl)methyl)-N-ethylfuran-2-carboxamide hydrochloride and N-((1-(4-chlorobenzyl)piperidin-4-yl)methyl)-N-ethylfuran-2-carboxamide hydrochloride and a good selectivity (Ki(σ2)/Ki(σ1) >140 and >40, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrId_zR_Dnz07Vg90H21EOLACvtfcHk0ljTq_YUrCADaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cru7o%253D&md5=710aa2dd4c9e1f27c051c6c1e3f605bd</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DGolob%26aufirst%3DS.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26atitle%3DSynthesis%2520and%2520receptor%2520binding%2520studies%2520of%2520some%2520new%2520arylcarboxamide%2520derivatives%2520as%2520sigma-1%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D1021%26epage%3D1025%26doi%3D10.1016%2Fj.bmcl.2014.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span> <span> </span><span class="NLM_article-title">Improving selectivity preserving affinity: new piperidine-4-carboxamide derivatives as effective sigma-1-ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25528334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=797-808&author=D.+Zampieriauthor=E.+Lauriniauthor=L.+Vioauthor=M.+Fermegliaauthor=S.+Priclauthor=B.+Wunschauthor=D.+Schepmannauthor=M.+G.+Mamolo&title=Improving+selectivity+preserving+affinity%3A+new+piperidine-4-carboxamide+derivatives+as+effective+sigma-1-ligands&doi=10.1016%2Fj.ejmech.2014.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Improving selectivity preserving affinity: New piperidine-4-carboxamide derivatives as effective sigma-1-ligands</span></div><div class="casAuthors">Zampieri, Daniele; Laurini, Erik; Vio, Luciano; Fermeglia, Maurizio; Pricl, Sabrina; Wunsch, Bernhard; Schepmann, Dirk; Mamolo, Maria Grazia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">797-808</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We report the design, synthesis and binding evaluation against σ1 and σ2 receptors of a series of new piperidine-4-carboxamide derivs. variously substituted on the amide nitrogen atom.  Specifically, we assessed the effects exerted on σ receptor affinity by substituting the N-benzylcarboxamide group present on a series of compds. previously synthesized in our lab. with different cyclic or linear moieties.  The synthesized compds. were tested to est. their affinity and selectivity toward σ1 and σ2 receptors.  Very high σ1 affinity (Ki = 3.7 nM) and Kiσ2/Kiσ1 selectivity ratio (351) were found for the tetrahydroquinoline deriv. (I), featuring a 4-chlorobenzyl moiety linked to the piperidine nitrogen atom.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNp9cq6AJhLVg90H21EOLACvtfcHk0ljTq_YUrCADaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFOhtQ%253D%253D&md5=64e12545c5515b59656f239e429b2dad</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26atitle%3DImproving%2520selectivity%2520preserving%2520affinity%253A%2520new%2520piperidine-4-carboxamide%2520derivatives%2520as%2520effective%2520sigma-1-ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D90%26spage%3D797%26epage%3D808%26doi%3D10.1016%2Fj.ejmech.2014.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menegazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span> <span> </span><span class="NLM_article-title">New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3206</span>– <span class="NLM_lpage">3209</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2018.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30143421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGltrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3206-3209&author=D.+Zampieriauthor=M.+Romanoauthor=R.+Menegazziauthor=M.+G.+Mamolo&title=New+piperidine-based+derivatives+as+sigma+receptor+ligands.+Synthesis+and+pharmacological+evaluation&doi=10.1016%2Fj.bmcl.2018.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation</span></div><div class="casAuthors">Zampieri, Daniele; Romano, Maurizio; Menegazzi, Renzo; Mamolo, Maria Grazia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3206-3209</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma receptor (σR) family has been considered mysterious for a long time.  In fact, the σ2R subtype has been cloned only recently, revealing its identity as TMEM97, a NPC1-binding protein involved in cholesterol biosynthesis and implicated in the pathogenesis of cancer and neurol. disorders.  With the aim of developing new chem. entities gifted with σR affinity, herein we report the design and synthesis of new piperidine-based alkylacetamide derivs. with mixed affinity towards both σ1 and σ2R subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxNLFUGT_J7LVg90H21EOLACvtfcHk0li6YtJ5ite-LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGltrnJ&md5=09f6823bcda9917a642140a0727a492f</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DMenegazzi%26aufirst%3DR.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26atitle%3DNew%2520piperidine-based%2520derivatives%2520as%2520sigma%2520receptor%2520ligands.%2520Synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3206%26epage%3D3209%26doi%3D10.1016%2Fj.bmcl.2018.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamagni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.08.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2016.08.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27614411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWisL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=649-665&author=M.+Ruiauthor=D.+Rossiauthor=A.+Marraauthor=M.+Paolilloauthor=S.+Schinelliauthor=D.+Curtiauthor=A.+Teseiauthor=M.+Cortesiauthor=A.+Zamagniauthor=E.+Lauriniauthor=S.+Priclauthor=D.+Schepmannauthor=B.+Wunschauthor=E.+Urbanauthor=V.+Paceauthor=S.+Collina&title=Synthesis+and+biological+evaluation+of+new+aryl-alkyl%28alkenyl%29-4-benzylpiperidines%2C+novel+Sigma+Receptor+%28SR%29+modulators%2C+as+potential+anticancer-agents&doi=10.1016%2Fj.ejmech.2016.08.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents</span></div><div class="casAuthors">Rui, Marta; Rossi, Daniela; Marra, Annamaria; Paolillo, Mayra; Schinelli, Sergio; Curti, Daniela; Tesei, Anna; Cortesi, Michela; Zamagni, Alice; Laurini, Erik; Pricl, Sabrina; Schepmann, Dirk; Wunsch, Bernhard; Urban, Ernst; Pace, Vittorio; Collina, Simona</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">649-665</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis and biol. profile of aryl-alkyl(alkenyl)-4-benzylpiperidine derivs., e.g., I (Ar = 2-naphthyl, phenyl), as novel potential anticancer drugs targeting SR is reported.  Among them, I (Ar = 2-naphthyl) (RC-106) exhibited a preclin. profile of antitumor efficacy on a panel of cell lines representative of different cancer types (i.e. Paca3, MDA-MB 231) expressing both SRs, and emerged as a hit compd. of a new class of SR modulators potentially useful for the treatment of cancer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVGoFaQvZxE7Vg90H21EOLACvtfcHk0li6YtJ5ite-LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWisL3J&md5=4131677175477bfe65931c00e61babf5</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.08.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.08.067%26sid%3Dliteratum%253Aachs%26aulast%3DRui%26aufirst%3DM.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DMarra%26aufirst%3DA.%26aulast%3DPaolillo%26aufirst%3DM.%26aulast%3DSchinelli%26aufirst%3DS.%26aulast%3DCurti%26aufirst%3DD.%26aulast%3DTesei%26aufirst%3DA.%26aulast%3DCortesi%26aufirst%3DM.%26aulast%3DZamagni%26aufirst%3DA.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DUrban%26aufirst%3DE.%26aulast%3DPace%26aufirst%3DV.%26aulast%3DCollina%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520new%2520aryl-alkyl%2528alkenyl%2529-4-benzylpiperidines%252C%2520novel%2520Sigma%2520Receptor%2520%2528SR%2529%2520modulators%252C%2520as%2520potential%2520anticancer-agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D649%26epage%3D665%26doi%3D10.1016%2Fj.ejmech.2016.08.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Rigidity versus flexibility: Is this an issue in sigma1 receptor ligand affinity and activity?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5505</span>– <span class="NLM_lpage">5519</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00585</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00585" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVyitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5505-5519&author=F.+Weberauthor=S.+Bruneauthor=F.+Borgelauthor=C.+Langeauthor=K.+Korpisauthor=P.+J.+Bednarskiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=D.+Schepmannauthor=B.+Wunsch&title=Rigidity+versus+flexibility%3A+Is+this+an+issue+in+sigma1+receptor+ligand+affinity+and+activity%3F&doi=10.1021%2Facs.jmedchem.6b00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?</span></div><div class="casAuthors">Weber, Frauke; Brune, Stefanie; Boergel, Frederik; Lange, Carsten; Korpis, Katharina; Bednarski, Patrick J.; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5505-5519</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stereoisomeric 2,5-diazabicyclo[2.2.2]octanes 14 and 15 were prepd. in a chiral-pool synthesis starting from (S)- or (R)-aspartate.  The key step in the synthesis was a Dieckmann-analogous cyclization of (dioxopiperazinyl)acetates 8, which involved trapping of the intermediate hemiketal anion with Me3SiCl.  The σ1 affinity was tested using membrane prepns. from animal (guinea pig) and human origin.  The binding of bicyclic compds. was analyzed by mol. dynamics simulations based on a 3D homol. model of the σ1 receptor.  The good correlation between Ki values obsd. in the σ1 assays and calcd. free binding energy, coupled with the identification of four crucial ligand/receptor interactions, allowed the formulation of structure-affinity relationships.  In an in vitro antitumor assay with seven human tumor cell lines, the bicyclic compds. inhibited selectively the growth of the cell line A427, which is due to induction of apoptosis.  In this assay, the compds. behave like the known σ1 receptor antagonist haloperidol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMpZXtybW1V7Vg90H21EOLACvtfcHk0li6YtJ5ite-LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVyitr0%253D&md5=d5fc4600fcd605c8b191a921bddf5e56</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00585%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DBorgel%26aufirst%3DF.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DRigidity%2520versus%2520flexibility%253A%2520Is%2520this%2520an%2520issue%2520in%2520sigma1%2520receptor%2520ligand%2520affinity%2520and%2520activity%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5505%26epage%3D5519%26doi%3D10.1021%2Facs.jmedchem.6b00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span> <span> </span><span class="NLM_article-title">Norbenzomorphan scaffold: chemical tool for modulating sigma receptor-subtype selectivity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=455-460&author=J.+J.+Sahnauthor=T.+R.+Hodgesauthor=J.+Z.+Chanauthor=S.+F.+Martin&title=Norbenzomorphan+scaffold%3A+chemical+tool+for+modulating+sigma+receptor-subtype+selectivity&doi=10.1021%2Facsmedchemlett.7b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Norbenzomorphan Scaffold: Chemical Tool for Modulating Sigma Receptor-Subtype Selectivity</span></div><div class="casAuthors">Sahn, James J.; Hodges, Timothy R.; Chan, Jessica Z.; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">455-460</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Some norbenzomorphans exhibit high affinity for sigma 1 and sigma 2 receptors, and varying the position of substituents on the arom. ring of this scaffold has a significant effect on subtype selectivity.  In particular, compds. bearing several different substituents at C7 of the norbenzomorphan ring system exhibit a general preference for the sigma 1 receptor, whereas the corresponding C8-substituted analogs preferentially bind at the sigma 2 receptor.  These findings suggest that the norbenzomorphan scaffold may be a unique chem. template that can be easily tuned to prep. small mols. for use as tool compds. to study the specific biol. effects arising from preferential binding at either sigma receptor subtype.  In the absence of structural characterization data for the sigma 2 receptor, such compds. will be useful toward refining the pharmacophore model of its binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwvE0Es1OLS7Vg90H21EOLACvtfcHk0ljzQrLHCIPH7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKlsLs%253D&md5=2ccfff058d5a97c7f09d42bcf0428ef6</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00066%26sid%3Dliteratum%253Aachs%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DHodges%26aufirst%3DT.%2BR.%26aulast%3DChan%26aufirst%3DJ.%2BZ.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DNorbenzomorphan%2520scaffold%253A%2520chemical%2520tool%2520for%2520modulating%2520sigma%2520receptor-subtype%2520selectivity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D455%26epage%3D460%26doi%3D10.1021%2Facsmedchemlett.7b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linkens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span> <span> </span><span class="NLM_article-title">Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2018.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29656199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslShu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=557-567&author=K.+Linkensauthor=H.+R.+Schmidtauthor=J.+J.+Sahnauthor=A.+C.+Kruseauthor=S.+F.+Martin&title=Investigating+isoindoline%2C+tetrahydroisoquinoline%2C+and+tetrahydrobenzazepine+scaffolds+for+their+sigma+receptor+binding+properties&doi=10.1016%2Fj.ejmech.2018.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties</span></div><div class="casAuthors">Linkens, Kathryn; Schmidt, Hayden R.; Sahn, James J.; Kruse, Andrew C.; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">557-567</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Substituted norbenzomorphans are known to display high affinity and selectivity for the two sigma receptor (σR) subtypes.  In order to study the effects of simplifying the structures of these compds., a scaffold hopping strategy was used to design several novel sets of substituted isoindolines, tetrahydroisoquinolines and tetrahydro-2-benzazepines.  The binding affinities of these new compds. for the sigma 1 (σ1R) and sigma 2 (σ2R) receptors were detd., and some analogs were identified that exhibit high affinity (Ki ≤ 25 nM) and significant selectivity (>10-fold) for σ1R or σ2R.  The preferred binding modes of selected compds. for the σ1R are predicted by modeling studies, and the nature of substituents on the arom. ring and the nitrogen atom of the bicyclic skeleton appears to affect the preferred binding orientation of σ1R-preferring ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmY1yq5EydQLVg90H21EOLACvtfcHk0ljzQrLHCIPH7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslShu7w%253D&md5=f4781ad271db779747c333f55e1c1ada</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DLinkens%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DInvestigating%2520isoindoline%252C%2520tetrahydroisoquinoline%252C%2520and%2520tetrahydrobenzazepine%2520scaffolds%2520for%2520their%2520sigma%2520receptor%2520binding%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D557%26epage%3D567%26doi%3D10.1016%2Fj.ejmech.2018.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasebein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frehland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis, sigma receptor affinity, and pharmacological evaluation of 5-phenylsulfanyl- and 5-benzyl-substituted tetrahydro-2-benzazepines</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fcmdc.201402110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24895069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVegt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1697-1703&author=P.+Hasebeinauthor=B.+Frehlandauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis%2C+sigma+receptor+affinity%2C+and+pharmacological+evaluation+of+5-phenylsulfanyl-+and+5-benzyl-substituted+tetrahydro-2-benzazepines&doi=10.1002%2Fcmdc.201402110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, σ Receptor Affinity, and Pharmacological Evaluation of 5-Phenylsulfanyl- and 5-Benzyl-Substituted Tetrahydro-2-benzazepines</span></div><div class="casAuthors">Hasebein, Peer; Frehland, Bastian; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1697-1703</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">N-Alkyl and N-benzyl benzyl- and phenylthio-substituted benzazepines I [R = H, Me, Bu, BuCH2, i-Bu, Me2C:CHCH2, cyclopropylmethyl, cyclohexylmethyl, Ph(CH2)n, 2-furanylmethyl, 2-thienylmethyl, 4-FC6H4CH2, 4-MeOC6H4CH2; X = S, CH2; n = 1, 2, 4] were prepd. as selective σ-receptor inhibitors; benzazepines with linear or branched alkyl or alkenyl substituents contg. at least an Bu substructure had high affinities for σ1 receptors.  I (X = CH2) were prepd. using a Heck reaction with acrylonitrile, a Stetter reaction with benzaldehyde, reductive cyclization, and reductive amination or alkylation reactions to introduce the azepine substituents as the key steps.  I (R = Bu, 4-FC6H4CH2; X = CH2) showed high selectivity for σ1 receptors over more than 50 other relevant targets, including the σ2 receptor subtype and various binding sites of the N-methyl-D-aspartate receptor; side effects upon i.p. injection of I (R = Bu, 4-FC6H4CH2; X = CH2) were not obsd. in mice at doses < 100 mg/kg.  I (R = Bu, 4-FC6H4CH2; X = CH2) did not show significant analgesic and cognition-enhancing activities, and I (R = 4-FC6H4CH2; X = CH2) did not have any antidepressant-like effects in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzbox_QwlbIbVg90H21EOLACvtfcHk0ljzQrLHCIPH7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVegt7k%253D&md5=83bb1519eca885023b34d39e6ccb25df</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402110%26sid%3Dliteratum%253Aachs%26aulast%3DHasebein%26aufirst%3DP.%26aulast%3DFrehland%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%252C%2520sigma%2520receptor%2520affinity%252C%2520and%2520pharmacological%2520evaluation%2520of%25205-phenylsulfanyl-%2520and%25205-benzyl-substituted%2520tetrahydro-2-benzazepines%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1697%26epage%3D1703%26doi%3D10.1002%2Fcmdc.201402110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasebein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frehland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmkuhl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohlich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of like- and unlike-configured tetrahydro-2-benzazepines with the alpha-substituted benzyl moiety in the 5-position</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5407</span>– <span class="NLM_lpage">5426</span>, <span class="refDoi"> DOI: 10.1039/C4OB00510D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC4OB00510D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24934693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSru7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=5407-5426&author=P.+Hasebeinauthor=B.+Frehlandauthor=K.+Lehmkuhlauthor=R.+Frohlichauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis+and+pharmacological+evaluation+of+like-+and+unlike-configured+tetrahydro-2-benzazepines+with+the+alpha-substituted+benzyl+moiety+in+the+5-position&doi=10.1039%2FC4OB00510D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of like- and unlike-configured tetrahydro-2-benzazepines with the α-substituted benzyl moiety in the 5-position</span></div><div class="casAuthors">Hasebein, Peer; Frehland, Bastian; Lehmkuhl, Kirstin; Froehlich, Roland; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">5407-5426</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A large set of tetrahydro-2-benzazepine derivs. with an α-hydroxy or α-(aryl)alkoxy substituted benzyl moiety in the 5-position was prepd. according to a recently reported [C6C1 + C3N] synthetic strategy.  A Heck reaction of 2-iodobenzaldehyde acetal and a subsequent Stetter reaction led to a ketone intermediate which was reduced diastereoselectively to form a like-configured alc.  A diastereomeric unlike-configured alc. was obtained by a Mitsunobu inversion (Mitsunobu epimerization).  Alkylation and reductive cyclization of the diastereomeric alcs. provided like-configured and unlike-configured 2-benzazepine derivs., which allowed the introduction of various substituents at the N-atom.  Anal. of a relationship between the structure and the σ1-affinity revealed that large substituents such as the Bu, benzyl or 4-phenylbutyl moiety at the benzazepine N-atom resulted in high affinity ligands.  A methoxybenzyl ether is less tolerated by a σ1-receptor [i.e., σ-non-opioid intracellular receptors, σ-receptor 1] than a Me ether or an alc.  Unlike-configured alcs. show slightly higher σ1-affinity than their like-configured diastereomers.  With respect to the σ1-affinity, σ1/σ2 selectivity and lipophilic ligand efficiency, like-configured and unlike-configured alcs. represent the most promising σ1-ligands of this series.  Interactions of the novel 2-benzazepines with various binding sites of the NMDA receptor were not obsd.  The synthesis of the target compds. was achieved using (βR,γR)-rel-γ-hydroxy-β-[2-(dimethoxymethyl)phenyl]benzenebutanenitrile and (βR,γS)-rel-γ-hydroxy-β-[2-(dimethoxymethyl)phenyl]benzenebutanenitrile as key intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDj7RiKA5nS7Vg90H21EOLACvtfcHk0ljzQrLHCIPH7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSru7fL&md5=58bec6e51e01aaf652ca38398aa9537e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1039%2FC4OB00510D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB00510D%26sid%3Dliteratum%253Aachs%26aulast%3DHasebein%26aufirst%3DP.%26aulast%3DFrehland%26aufirst%3DB.%26aulast%3DLehmkuhl%26aufirst%3DK.%26aulast%3DFrohlich%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520like-%2520and%2520unlike-configured%2520tetrahydro-2-benzazepines%2520with%2520the%2520alpha-substituted%2520benzyl%2520moiety%2520in%2520the%25205-position%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26spage%3D5407%26epage%3D5426%26doi%3D10.1039%2FC4OB00510D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship study of a new series of selective sigma(1) receptor ligands for the treatment of pain: 4-aminotriazoles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2441</span>– <span class="NLM_lpage">2451</span>, <span class="refDoi"> DOI: 10.1021/jm501920g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501920g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlWms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2441-2451&author=J.+L.+Diazauthor=U.+Christmannauthor=A.+Fernandezauthor=A.+Torrensauthor=A.+Portauthor=R.+Pascualauthor=I.+Alvarezauthor=J.+Burguenoauthor=X.+Monroyauthor=A.+Monteroauthor=A.+Baladaauthor=J.+M.+Velaauthor=C.+Almansa&title=Synthesis+and+structure-activity+relationship+study+of+a+new+series+of+selective+sigma%281%29+receptor+ligands+for+the+treatment+of+pain%3A+4-aminotriazoles&doi=10.1021%2Fjm501920g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationship Study of a New Series of Selective σ1 Receptor Ligands for the Treatment of Pain: 4-Aminotriazoles</span></div><div class="casAuthors">Diaz, Jose Luis; Christmann, Ute; Fernandez, Ariadna; Torrens, Antoni; Port, Adriana; Pascual, Rosalia; Alvarez, Ines; Burgueno, Javier; Monroy, Xavier; Montero, Ana; Balada, Ariadna; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2441-2451</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 4-aminotriazoles I [R1 = 4-Cl-C6H4, 3,4-Cl2-C6H3, benzyl, cyclohexyl, etc; R2 = H, COMe, SO2Me, etc; R3 = piperidin-1-yl, morpholin-1-yl, 4-cyclohexylpiperizin-1-yl, etc; n = 1, 2] as potent σ1 receptor (σ1R) ligands are reported.  The compds. were prepd. using a 4-5-step process, involving as a key step a click chem. reaction between ynamides and azides.  The most active compds. exhibited nanomolar potency for the σ1R, and the selectivity over the σ2R was improved on decreasing the central amine basicity.  It was concluded that in order to achieve good σ1R potency a min. lipophilicity was required, while limiting to a defined range of cLogP avoided human ether-a-go-go-related gene channel inhibition.  This made the most interesting derivs. to be concd. in a narrow margin of lipophilicity.  Among them, compd. I [R1 = 2,3-Cl2-benzyl, R2 = H, R3 = morpholin-1-yl, n = 1] exhibited the most potent in vivo antinociceptive properties, which are indicative of its antagonist character.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxmyKI9YzVhbVg90H21EOLACvtfcHk0lh_nePwVQpJ2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlWms78%253D&md5=7dc178db143bbce4f8c7f33e62a062b6</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm501920g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501920g%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DChristmann%26aufirst%3DU.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DTorrens%26aufirst%3DA.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DAlvarez%26aufirst%3DI.%26aulast%3DBurgueno%26aufirst%3DJ.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DMontero%26aufirst%3DA.%26aulast%3DBalada%26aufirst%3DA.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520study%2520of%2520a%2520new%2520series%2520of%2520selective%2520sigma%25281%2529%2520receptor%2520ligands%2520for%2520the%2520treatment%2520of%2520pain%253A%25204-aminotriazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2441%26epage%3D2451%26doi%3D10.1021%2Fjm501920g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1010</span>, <span class="refDoi"> DOI: 10.1021/mp300023x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300023x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFWhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=996-1010&author=S.+Wangauthor=Y.+Liauthor=J.+Wangauthor=L.+Chenauthor=L.+Zhangauthor=H.+Yuauthor=T.+Hou&title=ADMET+evaluation+in+drug+discovery.+12.+Development+of+binary+classification+models+for+prediction+of+hERG+potassium+channel+blockage&doi=10.1021%2Fmp300023x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">ADMET Evaluation in Drug Discovery. 12. Development of Binary Classification Models for Prediction of hERG Potassium Channel Blockage</span></div><div class="casAuthors">Wang, Sichao; Li, Youyong; Wang, Junmei; Chen, Lei; Zhang, Liling; Yu, Huidong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">996-1010</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the human ether-a-go-go related gene (hERG) potassium channel may result in QT interval prolongation, which causes severe cardiac side effects and is a major problem in clin. studies of drug candidates.  The development of in silico tools to filter out potential hERG potassium channel blockers in early stages of the drug discovery process is of considerable interest.  Here, a diverse set of 806 compds. with hERG inhibition data was assembled, and the binary hERG classification models using naive Bayesian classification and recursive partitioning (RP) techniques were established and evaluated.  The naive Bayesian classifier based on mol. properties and the ECFP_8 fingerprints yielded 84.8% accuracy for the training set using the leave-one-out (LOO) cross-validation procedure and 85% accuracy for the test set of 120 mols.  For the two addnl. test sets, the model achieved 89.4% accuracy for the WOMBAT-PK test set, and 86.1% accuracy for the PubChem test set.  The naive Bayesian classifiers gave better predictions than the RP classifiers.  Moreover, the Bayesian classifier, employing mol. fingerprints, highlights the important structural fragments favorable or unfavorable for hERG potassium channel blockage, which offers extra valuable information for the design of compds. avoiding undesirable hERG activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJvb2LvQcBbVg90H21EOLACvtfcHk0lh_nePwVQpJ2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFWhsLs%253D&md5=4949da9ed18a0769f471bc200cf475cf</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fmp300023x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300023x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DADMET%2520evaluation%2520in%2520drug%2520discovery.%252012.%2520Development%2520of%2520binary%2520classification%2520models%2520for%2520prediction%2520of%2520hERG%2520potassium%2520channel%2520blockage%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D996%26epage%3D1010%26doi%3D10.1021%2Fmp300023x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span> <span> </span><span class="NLM_article-title">ADMET evaluation in drug discovery. 16. Predicting hERG blockers by combining multiple pharmacophores and machine learning approaches</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2855</span>– <span class="NLM_lpage">2866</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.6b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.6b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2gsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=2855-2866&author=S.+Wangauthor=H.+Sunauthor=H.+Liuauthor=D.+Liauthor=Y.+Liauthor=T.+Hou&title=ADMET+evaluation+in+drug+discovery.+16.+Predicting+hERG+blockers+by+combining+multiple+pharmacophores+and+machine+learning+approaches&doi=10.1021%2Facs.molpharmaceut.6b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches</span></div><div class="casAuthors">Wang, Shuangquan; Sun, Huiyong; Liu, Hui; Li, Dan; Li, Youyong; Hou, Tingjun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2855-2866</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockade of human ether-´a-go-go related gene (hERG) channel by compds. may lead to drug-induced QT prolongation, arrhythmia, and Torsades de Pointes (TdP), and therefore reliable prediction of hERG liability in the early stages of drug design is quite important to reduce the risk of cardiotoxicity-related attritions in the later development stages.  In this study, pharmacophore modeling and machine learning approaches were combined to construct classification models to distinguish hERG active from inactive compds. based on a diverse data set.  First, an optimal ensemble of pharmacophore hypotheses that had good capability to differentiate hERG active from inactive compds. was identified by the recursive partitioning (RP) approach.  Then, the naive Bayesian classification (NBC) and support vector machine (SVM) approaches were employed to construct classification models by integrating multiple important pharmacophore hypotheses.  The integrated classification models showed improved predictive capability over any single pharmacophore hypothesis, suggesting that the broad binding polyspecificity of hERG can only be well characterized by multiple pharmacophores.  The best SVM model achieved the prediction accuracies of 84.7% for the training set and 82.1% for the external test set.  Notably, the accuracies for the hERG blockers and nonblockers in the test set reached 83.6% and 78.2%, resp.  Anal. of significant pharmacophores helps to understand the multimechanisms of action of hERG blockers.  We believe that the combination of pharmacophore modeling and SVM is a powerful strategy to develop reliable theor. models for the prediction of potential hERG liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpus3X-YCxqnbVg90H21EOLACvtfcHk0li1OUgIzyl_CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2gsbbE&md5=4e7e3187e7ce589a48ed78e9d212fdf4</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.6b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.6b00471%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DT.%26atitle%3DADMET%2520evaluation%2520in%2520drug%2520discovery.%252016.%2520Predicting%2520hERG%2520blockers%2520by%2520combining%2520multiple%2520pharmacophores%2520and%2520machine%2520learning%2520approaches%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D2855%26epage%3D2866%26doi%3D10.1021%2Facs.molpharmaceut.6b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuberes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contijoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enrech, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeste, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 1:4-acylamino derivatives</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1039/C7MD00077D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC7MD00077D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30108834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsVWju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1235-1245&author=J.+L.+Diazauthor=J.+Corberaauthor=R.+Cuberesauthor=M.+Contijochauthor=R.+Enrechauthor=S.+Yesteauthor=A.+Monteroauthor=A.+Dordalauthor=X.+Monroyauthor=C.+Almansa&title=Pyrazolo%5B3%2C4-d%5Dpyrimidines+as+sigma-1+receptor+ligands+for+the+treatment+of+pain.+Part+1%3A4-acylamino+derivatives&doi=10.1039%2FC7MD00077D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 1: 4-acylamino derivatives</span></div><div class="casAuthors">Diaz, Jose Luis; Corbera, Jordi; Cuberes, Rosa; Contijoch, Montserrat; Enrech, Raquel; Yeste, Sandra; Montero, Ana; Dordal, Albert; Monroy, Xavier; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-1245</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis of a new series of 4-acylaminopyrazolo[3,4-d]pyrimidines active on the sigma-1 receptor (σ1R) is reported.  Compds. were efficiently prepd. using a two to three step process starting from com. available 1H-pyrazolo[3,4-d]pyrimidin-4-amine.  A SAR study shows that the σ1R requires the presence of relatively highly lipophilic substituents at opposite sides of the central scaffold, while selectivity vs. the σ2R can be improved by shortening the distance of the basic nitrogen to it.  Compd. I was among the most active and selective in vitro derivs. and exhibited potent antinociceptive properties in several pain models in mice, indicating its antagonistic behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzRN1Voysu0rVg90H21EOLACvtfcHk0li1OUgIzyl_CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsVWju7g%253D&md5=32326626a8e324cd3093d2bc9f814919</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1039%2FC7MD00077D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00077D%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DCorbera%26aufirst%3DJ.%26aulast%3DCuberes%26aufirst%3DR.%26aulast%3DContijoch%26aufirst%3DM.%26aulast%3DEnrech%26aufirst%3DR.%26aulast%3DYeste%26aufirst%3DS.%26aulast%3DMontero%26aufirst%3DA.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DPyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520sigma-1%2520receptor%2520ligands%2520for%2520the%2520treatment%2520of%2520pain.%2520Part%25201%253A4-acylamino%2520derivatives%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1235%26epage%3D1245%26doi%3D10.1039%2FC7MD00077D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 2: introduction of cyclic substituents in position 4</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1246</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1039/C7MD00078B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC7MD00078B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30108835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsVWju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1246-1254&author=J.+L.+Diazauthor=J.+Corberaauthor=D.+Martinezauthor=M.+Bordasauthor=C.+Sicreauthor=R.+Pascualauthor=M.+J.+Pretelauthor=A.+P.+Marinauthor=A.+Monteroauthor=A.+Dordalauthor=I.+Alvarezauthor=C.+Almansa&title=Pyrazolo%5B3%2C4-d%5Dpyrimidines+as+sigma-1+receptor+ligands+for+the+treatment+of+pain.+Part+2%3A+introduction+of+cyclic+substituents+in+position+4&doi=10.1039%2FC7MD00078B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 2: Introduction of cyclic substituents in position 4</span></div><div class="casAuthors">Diaz, Jose Luis; Corbera, Jordi; Martinez, Daniel; Bordas, Magda; Sicre, Cristina; Pascual, Rosalia; Pretel, Ma Jose; Marin, Ana Paz; Montero, Ana; Dordal, Albert; Alvarez, Ines; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1246-1254</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The replacement of acylamino group by cyclic substituents in the position 4 of the pyrazolo[3,4-d]pyrimidine scaffold I [R = Ph, pyridin-3-yl, 1-methyl-1H-pyrazol-5-yl, etc.], led to highly active sigma-1 receptor (σ1R) ligands.  Ph or pyrazolyl groups were the best in terms of affinity for the σ1R and the compd. I [R = 1-methyl-1H-pyrazol-5-yl], was the most selective.  Compd. I [R = 1-methyl-1H-pyrazol-5-yl] was also one of the best σ1R ligands ever described in terms of lipophilic ligand efficiency, which translated into a good physicochem. and ADMET profile.  In addn., compd. I [R = 1-methyl-1H-pyrazol-5-yl] was identified as an antagonist of the σ1R in view of its potent antinociceptive profile in several pain models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWZ6GM1HCoxbVg90H21EOLACvtfcHk0li1OUgIzyl_CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsVWju7k%253D&md5=a09c39a7a40cb87acd7ad477fe4a67a9</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1039%2FC7MD00078B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00078B%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DCorbera%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DD.%26aulast%3DBordas%26aufirst%3DM.%26aulast%3DSicre%26aufirst%3DC.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DPretel%26aufirst%3DM.%2BJ.%26aulast%3DMarin%26aufirst%3DA.%2BP.%26aulast%3DMontero%26aufirst%3DA.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DAlvarez%26aufirst%3DI.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DPyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520sigma-1%2520receptor%2520ligands%2520for%2520the%2520treatment%2520of%2520pain.%2520Part%25202%253A%2520introduction%2520of%2520cyclic%2520substituents%2520in%2520position%25204%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1246%26epage%3D1254%26doi%3D10.1039%2FC7MD00078B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1<i>H</i>)-quinolinone scaffold as a potential analgesic</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24735647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=216-230&author=Y.+Lanauthor=Y.+Chenauthor=X.+Xuauthor=Y.+Qiuauthor=S.+Liuauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+a+novel+sigma-1+receptor+antagonist+based+on+3%2C4-dihydro-2%281H%29-quinolinone+scaffold+as+a+potential+analgesic&doi=10.1016%2Fj.ejmech.2014.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic</span></div><div class="casAuthors">Lan, Yu; Chen, Yin; Xu, Xiangqing; Qiu, Yinli; Liu, Shicheng; Liu, Xin; Liu, Bi-Feng; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">216-230</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis and sigma-1 receptor (σ1R) antagonist activity of a new series of 3,4-dihydro-2(1H)-quinolinones, e.g. I [R = PhCH2, 4-MeC6H4CH2, 4-FC6H4CH2, etc.] are reported.  The new compds. were evaluated in vitro in sigma-1 and sigma-2 receptor-binding assays in guinea pig brain membranes.  The structure-activity relationship led us to the promising deriv. I [R = 4-FC6H4CH2].  The compds. with highest affinity and greatest selectivity were further profiled, and compd. I [R = 4-FC6H4CH2] had a high binding const. for sigma-1 receptor (Kiσ1 = 1.22 nM) and high sigma-1/2 selectivity (1066-fold).  Thus, this compd., which proved to be an antagonist of sigma-1 receptor, emerged as the most interesting candidate.  In addn., this compd. exerted dose-dependent antinociceptive effects in the formalin test.  These characteristics suggested that the potent and selective compd. I [R = 4-FC6H4CH2] could be a potent candidate for pain treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo56iTGYzwCw7Vg90H21EOLACvtfcHk0lhtJCbmq0nRtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWns7o%253D&md5=04009cdd675bf12a18a5869979c2cf10</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520sigma-1%2520receptor%2520antagonist%2520based%2520on%25203%252C4-dihydro-2%25281H%2529-quinolinone%2520scaffold%2520as%2520a%2520potential%2520analgesic%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D216%26epage%3D230%26doi%3D10.1016%2Fj.ejmech.2014.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10404</span>– <span class="NLM_lpage">10423</span>, <span class="refDoi"> DOI: 10.1021/jm501207r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501207r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10404-10423&author=Y.+Lanauthor=Y.+Chenauthor=X.+Caoauthor=J.+Zhangauthor=J.+Wangauthor=X.+Xuauthor=Y.+Qiuauthor=T.+Zhangauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+sigma-1+receptor+antagonists+based+on+pyrimidine+scaffold+as+agents+for+treating+neuropathic+pain&doi=10.1021%2Fjm501207r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Novel Sigma-1 Receptor Antagonists Based on Pyrimidine Scaffold As Agents for Treating Neuropathic Pain</span></div><div class="casAuthors">Lan, Yu; Chen, Yin; Cao, Xudong; Zhang, Juecheng; Wang, Jie; Xu, Xiangqing; Qiu, Yinli; Zhang, Tan; Liu, Xin; Liu, Bi-Feng; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10404-10423</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and synthesis of a new series of pyrimidines as potent sigma-1 receptor (σ1R) antagonists, assocd. with pharmacol. antineuropathic pain activity, are the focus of this article.  The new compds. were evaluated in vitro in σ-1 and σ-2 receptor binding assays.  The nature of the pyrimidine scaffold was crucial for activity, and a basic amine was shown to be necessary according to the known pharmacophoric model.  The most promising deriv. was 5-chloro-2-(4-chlorophenyl)-4-methyl-6-(3-(piperidin-1-yl)propoxy)pyrimidine (I), which exhibited a high binding affinity to σ1R receptor (Ki σ1 = 1.06 nM) and good σ-1/2 selectivity (1344-fold).  In in vivo tests, I exerted dose-dependent antinociceptive effects in mice formalin model and rats CCI models of neuropathic pain.  In addn., no motor impairments were found in rotarod tests; acceptable pharmacokinetic properties were also noted.  These data suggest I may constitute a novel class of drugs for the treatment of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-dkiomNDrPLVg90H21EOLACvtfcHk0lhtJCbmq0nRtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsbbE&md5=bd003488b014b40e739cc42c825424ce</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm501207r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501207r%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520sigma-1%2520receptor%2520antagonists%2520based%2520on%2520pyrimidine%2520scaffold%2520as%2520agents%2520for%2520treating%2520neuropathic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10404%26epage%3D10423%26doi%3D10.1021%2Fjm501207r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of sigma-1 (sigma1) receptor ligands based on phenyl-1,2,4-oxadiazole derivatives</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">e1800599</span> <span class="refDoi"> DOI: 10.1002/cbdv.201800599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fcbdv.201800599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30549193" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&author=X.+Caoauthor=Z.+Yaoauthor=F.+Douauthor=Y.+Zhangauthor=Y.+Qiuauthor=S.+Zhaoauthor=X.+Xuauthor=X.+Liuauthor=B.+F.+Liuauthor=Y.+Chenauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+sigma-1+%28sigma1%29+receptor+ligands+based+on+phenyl-1%2C2%2C4-oxadiazole+derivatives&doi=10.1002%2Fcbdv.201800599"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201800599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201800599%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DDou%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520ligands%2520based%2520on%2520phenyl-1%252C2%252C4-oxadiazole%2520derivatives%26jtitle%3DChem.%2520Biodiversity%26date%3D2019%26volume%3D16%26doi%3D10.1002%2Fcbdv.201800599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel sigma1 receptor ligands for treating neuropathic pain: 6-hydroxypyridazinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2942</span>– <span class="NLM_lpage">2961</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2942-2961&author=X.+Caoauthor=Y.+Chenauthor=Y.+Zhangauthor=Y.+Lanauthor=J.+Zhangauthor=X.+Xuauthor=Y.+Qiuauthor=S.+Zhaoauthor=X.+Liuauthor=B.+F.+Liuauthor=G.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+sigma1+receptor+ligands+for+treating+neuropathic+pain%3A+6-hydroxypyridazinones&doi=10.1021%2Facs.jmedchem.5b01416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones</span></div><div class="casAuthors">Cao, Xudong; Chen, Yin; Zhang, Yifang; Lan, Yu; Zhang, Juecheng; Xu, Xiangqing; Qiu, Yinli; Zhao, Song; Liu, Xin; Liu, Bi-Feng; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2942-2961</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By use of the 6-hydroxypyridazinone framework, a new series of potent σ1 receptor ligands assocd. with pharmacol. antineuropathic pain activity was synthesized and is described in this article.  In vitro receptor binding studies revealed high σ1 receptor affinity (Ki σ1 = 1.4 nM) and excellent selectivity over not only σ2 receptor (1366-fold) but also other CNS targets (adrenergic, μ-opioid, sertonerigic receptors, etc.) for 2-(3,4-dichlorophenyl)-6-(3-(piperidin-1-yl)propoxy)pyridazin-3(2H)-one (compd. 54).  Compd. 54 exhibited dose-dependent antiallodynic properties in mouse formalin model and rats chronic constriction injury (CCI) model of neuropathic pain.  In addn., functional activity of compd. 54 was evaluated using phenytoin and indicated that the compd. was a σ1 receptor antagonist.  Moreover, no motor impairments were found in rotarod tests at antiallodynic doses and no sedative side effect was evident in locomotor activity tests.  Last but not least, good safety and favorable pharmacokinetic properties were also noted.  These profiles suggest that compd. 54 may be a member of a novel class of candidate drugs for treatment of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouqLloqg6937Vg90H21EOLACvtfcHk0lj1dpbB9B30OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFGrsL8%253D&md5=fd377bf365861bc550f6d4dd5db20af4</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01416%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520sigma1%2520receptor%2520ligands%2520for%2520treating%2520neuropathic%2520pain%253A%25206-hydroxypyridazinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2942%26epage%3D2961%26doi%3D10.1021%2Facs.jmedchem.5b01416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Songyang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel 6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine and 5,6,7,8-tetrahydroquinazoline derivatives as sigma-1 (sigma1) receptor antagonists for the treatment of pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.02.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2016.02.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=26947609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslGisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2051-2056&author=Y.+Lanauthor=Y.+Songyangauthor=L.+Zhangauthor=Y.+Pengauthor=J.+Song&title=Synthesis+and+biological+evaluation+of+novel+6%2C7-dihydro-5H-cyclopenta%5Bd%5Dpyrimidine+and+5%2C6%2C7%2C8-tetrahydroquinazoline+derivatives+as+sigma-1+%28sigma1%29+receptor+antagonists+for+the+treatment+of+pain&doi=10.1016%2Fj.bmcl.2016.02.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel 6,7-dihydro-5H-cyclopenta[d]pyrimidine and 5,6,7,8-tetrahydroquinazoline derivatives as sigma-1 (σ1) receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Lan, Yu; Songyang, Yiyan; Zhang, Lingli; Peng, Yan; Song, Jinchun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2056</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of new series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine and 5,6,7,8-tetrahydroquinazoline derivs. as selective sigma-1 receptor (σ1R) antagonists are reported.  The receptor affinities of new compds. were evaluated in vitro in σ1 and σ2 receptor binding assays.  The structure-active relationship study leads the authors to the most promising compd., 2-(4-chlorophenyl)-4-(3-(4-methyl-1-piperidinyl)propoxy)-5,6,7,8-tetra-hydroquinazoline.  This compd. has exerted nanomolar affinity for σ1R (Kiσ1 = 15.6 nM) and high σ1/σ2 selectivity (Kiσ2 >2000 nM), and identified to be a σ1R antagonist.  In an animal model, that compd. exhibited dose dependent anti-nociceptive effects in the formalin test.  These results suggest that this compd. could be a potent analgesic for pain treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqStWdqtAESdbVg90H21EOLACvtfcHk0lj1dpbB9B30OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslGisrw%253D&md5=38ada314d89307fc732c1b21a1223920</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.077%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DY.%26aulast%3DSongyang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%25206%252C7-dihydro-5H-cyclopenta%255Bd%255Dpyrimidine%2520and%25205%252C6%252C7%252C8-tetrahydroquinazoline%2520derivatives%2520as%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2051%26epage%3D2056%26doi%3D10.1016%2Fj.bmcl.2016.02.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picconi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catenacci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirante, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peviani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span> <span> </span><span class="NLM_article-title">Identification of RC-33 as a potent and selective sigma1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-scale synthesis, physicochemical characterization and in vitro metabolic stability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2577</span>– <span class="NLM_lpage">2586</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2013.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23498917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlSisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2577-2586&author=D.+Rossiauthor=A.+Marraauthor=P.+Picconiauthor=M.+Serraauthor=L.+Catenacciauthor=M.+Sorrentiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=S.+Brambillaauthor=N.+Almiranteauthor=M.+Pevianiauthor=D.+Curtiauthor=S.+Collina&title=Identification+of+RC-33+as+a+potent+and+selective+sigma1+receptor+agonist+potentiating+NGF-induced+neurite+outgrowth+in+PC12+cells.+Part+2%3A+g-scale+synthesis%2C+physicochemical+characterization+and+in+vitro+metabolic+stability&doi=10.1016%2Fj.bmc.2013.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of RC-33 as a potent and selective σ1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-Scale synthesis, physicochemical characterization and in vitro metabolic stability</span></div><div class="casAuthors">Rossi, Daniela; Marra, Annamaria; Picconi, Pietro; Serra, Massimo; Catenacci, Laura; Sorrenti, Milena; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Brambilla, Stefania; Almirante, Nicoletta; Peviani, Marco; Curti, Daniela; Collina, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2577-2586</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Strong pharmacol. evidences indicate that σ1 receptors are implicated in the pathophysiol. of all major CNS disorders.  In the last years our research group has conducted extensive studies aimed at discovering novel σ1 ligands and we recently selected (R/S)-RC-33 as a novel potent and selective σ1 receptor agonist.  As continuation of our work in this field, here we report our efforts in the development of this new σ1 receptor agonist.  Initially, we investigated the binding of (R) and (S) enantiomers of RC-33 to the σ1 receptor by in silico expts.  The close values of the predicted affinity of (R)-RC-33 and (S)-RC-33 for the protein evidenced the non-stereoselective binding of RC-33 to the σ1 receptor; this, in turn, supported further development and characterization of RC-33 in its racemic form.  Subsequently, we set-up a scaled-up, optimized synthesis of (R/S)-RC-33 along with some compd. characterization data (e.g., soly. in different media and solid state characterization by thermal anal. techniques).  In such conditions, the compd. is subjected to a relevant oxidative metab., with a degrdn. of approx. 65% in rat and 69% in human.  Taken together, our results demonstrated that (R/S)-RC-33 is a highly potent, selective, metabolically stable σ1 agonist, a promising novel neuroprotective drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVi4udNFzvCbVg90H21EOLACvtfcHk0lj1dpbB9B30OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlSisrg%253D&md5=1005960a530e0904e4cde4caa4f016bd</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DMarra%26aufirst%3DA.%26aulast%3DPicconi%26aufirst%3DP.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DCatenacci%26aufirst%3DL.%26aulast%3DSorrenti%26aufirst%3DM.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DBrambilla%26aufirst%3DS.%26aulast%3DAlmirante%26aufirst%3DN.%26aulast%3DPeviani%26aufirst%3DM.%26aulast%3DCurti%26aufirst%3DD.%26aulast%3DCollina%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520RC-33%2520as%2520a%2520potent%2520and%2520selective%2520sigma1%2520receptor%2520agonist%2520potentiating%2520NGF-induced%2520neurite%2520outgrowth%2520in%2520PC12%2520cells.%2520Part%25202%253A%2520g-scale%2520synthesis%252C%2520physicochemical%2520characterization%2520and%2520in%2520vitro%2520metabolic%2520stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2577%26epage%3D2586%26doi%3D10.1016%2Fj.bmc.2013.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuensch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peviani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span> <span> </span><span class="NLM_article-title">A step forward in the sigma enigma: a role for chirality in the sigma1 receptor-ligand interaction?</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1039/C4MD00349G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC4MD00349G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKqsrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=138-146&author=D.+Rossiauthor=A.+Marraauthor=M.+Ruiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=D.+Schepmannauthor=B.+Wuenschauthor=M.+Pevianiauthor=D.+Curtiauthor=S.+Collina&title=A+step+forward+in+the+sigma+enigma%3A+a+role+for+chirality+in+the+sigma1+receptor-ligand+interaction%3F&doi=10.1039%2FC4MD00349G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A step forward in the sigma enigma: a role for chirality in the sigma1 receptor-ligand interaction?</span></div><div class="casAuthors">Rossi, Daniela; Marra, Annamaria; Rui, Marta; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Schepmann, Dirk; Wuensch, Bernhard; Peviani, Marco; Curti, Daniela; Collina, Simona</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">138-146</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In our recent research racemic RC-33 was identified as a potent and highly promising σ1 receptor agonist, showing excellent σ1 receptor affinity and promoting NGF-induced neurite outgrowth in PC12 cells at very low concns.  Surprisingly, both its interaction with the biol. target and its effect on neurite sprouting proved to be non-stereoselective.  Starting from the observation that a hydrogen bond center in the scaffold of a σ1 ligand is an important pharmacophoric element for receptor/ligand interaction, we hypothesized that the absence of such pharmacophoric feature in the structure of RC-33 could be also responsible for the lack of enantioselectivity in its interaction with the target receptor.  To verify our hypothesis, in this paper we evaluated - both in silico and in vitro - the ability of a series of enantiomeric arylalkylaminoalcs. and arylpyrrolidinols 1-5 to interact with the receptor.  All these compds. are structurally related to RC-33 and are characterized by the presence of an -OH group as the addnl. pharmacophore feature.  Interestingly, the results of our study show that the σ1 receptor exhibits enantiopreference toward compds. characterized by (S)-configuration at the stereogenic center bearing the arom. moiety only when the alc. group is also present at that chiral center, thus supporting our original hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOkoAJRbPJnrVg90H21EOLACvtfcHk0licQXi1Fo1mjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKqsrnM&md5=602f5db02f4a3e06feb4a139f2205fe0</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1039%2FC4MD00349G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00349G%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DMarra%26aufirst%3DA.%26aulast%3DRui%26aufirst%3DM.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWuensch%26aufirst%3DB.%26aulast%3DPeviani%26aufirst%3DM.%26aulast%3DCurti%26aufirst%3DD.%26aulast%3DCollina%26aufirst%3DS.%26atitle%3DA%2520step%2520forward%2520in%2520the%2520sigma%2520enigma%253A%2520a%2520role%2520for%2520chirality%2520in%2520the%2520sigma1%2520receptor-ligand%2520interaction%253F%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D138%26epage%3D146%26doi%3D10.1039%2FC4MD00349G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giacomo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteleone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liedl, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span> <span> </span><span class="NLM_article-title">Gaining in pan-affinity towards sigma 1 and sigma 2 receptors. SAR studies on arylalkylamines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2016.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27838169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVarsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=11-19&author=D.+Rossiauthor=M.+Ruiauthor=M.+Di+Giacomoauthor=D.+Schepmannauthor=B.+Wunschauthor=S.+Monteleoneauthor=K.+R.+Liedlauthor=S.+Collina&title=Gaining+in+pan-affinity+towards+sigma+1+and+sigma+2+receptors.+SAR+studies+on+arylalkylamines&doi=10.1016%2Fj.bmc.2016.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Gaining in pan-affinity towards sigma 1 and sigma 2 receptors. SAR studies on arylalkylamines</span></div><div class="casAuthors">Rossi, Daniela; Rui, Marta; Di Giacomo, Marcello; Schepmann, Dirk; Wunsch, Bernhard; Monteleone, Stefania; Liedl, Klaus R.; Collina, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma Receptor (SR) modulators are involved in different signal transduction pathways, representing important pharmacol./therapeutic tools in several pathol. conditions, such as neurodegenerative diseases and cancers.  To this purpose, numerous compds. have been developed in order to target selectively one of the two subtypes (S1R and S2R) as chemotherapeutic agent.  However, expts. have also shown that ligands which are able to bind both SR subtypes can be useful for the diagnosis and/or the treatment of cancers.  Therefore, the discovery of compds. with good affinity towards both S1R and S2R ('pan-modulators') is also of great interest and still represents a challenge up to now.  For this reason, the authors synthesized novel arylalkylamines with the aim to obtain compds. with S1R and S2R affinity in the nM range and, by modeling quant. structure-activity relationships (QSARs), the authors identified the essential structural features to obtain promising pan-compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCZxQQJDaiDbVg90H21EOLACvtfcHk0licQXi1Fo1mjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVarsL7I&md5=5e272850b6f8d9a770f627ba69b6f3c7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DRui%26aufirst%3DM.%26aulast%3DDi%2BGiacomo%26aufirst%3DM.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DMonteleone%26aufirst%3DS.%26aulast%3DLiedl%26aufirst%3DK.%2BR.%26aulast%3DCollina%26aufirst%3DS.%26atitle%3DGaining%2520in%2520pan-affinity%2520towards%2520sigma%25201%2520and%2520sigma%25202%2520receptors.%2520SAR%2520studies%2520on%2520arylalkylamines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D11%26epage%3D19%26doi%3D10.1016%2Fj.bmc.2016.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marottoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span> <span> </span><span class="NLM_article-title">High-affinity sigma-1 (sigma1) receptor ligands based on the sigma1 antagonist PB212</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2562</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.4155%2Ffmc-2019-0042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31633399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvF2hu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=2547-2562&author=M.+Nisoauthor=P.+D.+Mosierauthor=R.+Marottoliauthor=S.+Ferorelliauthor=G.+Cassanoauthor=G.+Gasparreauthor=M.+Leopoldoauthor=F.+Berardiauthor=C.+Abate&title=High-affinity+sigma-1+%28sigma1%29+receptor+ligands+based+on+the+sigma1+antagonist+PB212&doi=10.4155%2Ffmc-2019-0042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity sigma-1 (σ1) receptor ligands based on the σ1 antagonist PB212</span></div><div class="casAuthors">Niso, Mauro; Mosier, Philip D.; Marottoli, Roberta; Ferorelli, Savina; Cassano, Giuseppe; Gasparre, Giuseppe; Leopoldo, Marcello; Berardi, Francesco; Abate, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2547-2562</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The σ1 receptor is a druggable target involved in many physiol. processes and diseases.  To clarify its physiol. and derive therapeutic benefit, nine analogs based on the σ1 antagonist PB212 were synthesized replacing the 4-methylpiperidine with basic moieties of varying size and degree of conformational freedom.  A 3-Phenylpyrrolidine, 4-phenylpiperidine or granatane derivs. displayed the highest affinity (Ki.#x00A0; = 0.12, 0.31 or 1.03 nM).  Calcium flux assays in MCF7s1 cells indicated that the highest σ1 receptor affinity are σ1 antagonists.  Mol. models provided a structural basis for understanding the σ1 affinity and functional activity of the analogs and incorporated Glennon's σ1 pharmacophore model.  Herein, we identify new compds. exploitable as therapeutic drug leads or as tools to study σ1 receptor physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNdKWlbfMVGbVg90H21EOLACvtfcHk0licQXi1Fo1mjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvF2hu77F&md5=7aeacec7b3775acb3dffc268b4cd81be</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0042%26sid%3Dliteratum%253Aachs%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DMosier%26aufirst%3DP.%2BD.%26aulast%3DMarottoli%26aufirst%3DR.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DCassano%26aufirst%3DG.%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26atitle%3DHigh-affinity%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520ligands%2520based%2520on%2520the%2520sigma1%2520antagonist%2520PB212%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D2547%26epage%3D2562%26doi%3D10.4155%2Ffmc-2019-0042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sguazzini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukat, M.</span></span> <span> </span><span class="NLM_article-title">Reevaluation of fenpropimorph as a sigma receptor ligand: structure-affinity relationship studies at human sigma1 receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2912</span>– <span class="NLM_lpage">2919</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2017.04.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28495085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVahu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2912-2919&author=E.+Sguazziniauthor=H.+R.+Schmidtauthor=K.+A.+Iyerauthor=A.+C.+Kruseauthor=M.+Dukat&title=Reevaluation+of+fenpropimorph+as+a+sigma+receptor+ligand%3A+structure-affinity+relationship+studies+at+human+sigma1+receptors&doi=10.1016%2Fj.bmcl.2017.04.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Reevaluation of fenpropimorph as a σ receptor ligand: Structure-affinity relationship studies at human σ1 receptors</span></div><div class="casAuthors">Sguazzini, Elena; Schmidt, Hayden R.; Iyer, Kavita A.; Kruse, Andrew C.; Dukat, Malgorzata</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2912-2919</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fenpropimorph (1) is considered a "super high-affinity" σ1 receptor ligand (Ki = 0.005 nM for guinea pig σ1 receptors).  Here, we examine the binding of 1 and several of its deconstructed analogs at human σ1 (hσ1) receptors.  We monitored their subtype selectivity by detg. the binding affinity at σ2 receptors.  In addn., we validated an existing pharmacophore model at the mol. level by conducting 3D mol. modeling studies, using the crystal structure of hσ1 receptors, and Hydrophatic INTeractions (HINT) anal.  Our structure affinity relationship studies showed that 1 binds with lower affinity at hσ1 receptors (Ki = 17.3 nM) compared to guinea pig; moreover, we found that none of the fenpropimorph Me groups is important for its binding at hσ1 receptors, nor is stereochem.  For example, removal of all Me groups as seen in 4 resulted in an almost 5-fold higher affinity at hσ1 receptors compared to 1 and 350-fold selectivity vs. σ2 receptors.  In addn., although the O atom of the morpholine ring does not contribute to affinity at hσ1 receptors (and might even detract from it), it plays role in subtype (σ1 vs. σ2 receptor) selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMtrUEJ2w9JbVg90H21EOLACvtfcHk0ljCKk9L9TatNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVahu74%253D&md5=0ec7b28d19b5dc29acc1eaefc2dc52f9</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.088%26sid%3Dliteratum%253Aachs%26aulast%3DSguazzini%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DIyer%26aufirst%3DK.%2BA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DDukat%26aufirst%3DM.%26atitle%3DReevaluation%2520of%2520fenpropimorph%2520as%2520a%2520sigma%2520receptor%2520ligand%253A%2520structure-affinity%2520relationship%2520studies%2520at%2520human%2520sigma1%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2912%26epage%3D2919%26doi%3D10.1016%2Fj.bmcl.2017.04.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbabian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of <i>N</i>,<i>N</i>-dialkyl and <i>N</i>-alkyl-<i>N</i>-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4397</span>– <span class="NLM_lpage">4404</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.04.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2010.04.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20493718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2rurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4397-4404&author=A.+R.+Hajipourauthor=D.+Fontanillaauthor=U.+B.+Chuauthor=M.+Arbabianauthor=A.+E.+Ruoho&title=Synthesis+and+characterization+of+N%2CN-dialkyl+and+N-alkyl-N-aralkyl+fenpropimorph-derived+compounds+as+high+affinity+ligands+for+sigma+receptors&doi=10.1016%2Fj.bmc.2010.04.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors</span></div><div class="casAuthors">Hajipour, Abdol R.; Fontanilla, Dominique; Chu, Uyen B.; Arbabian, Marty; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4397-4404</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor is a unique non-opioid, non-PCP binding site that has been implicated in many different pathophysiol. conditions including psychosis, drug addiction, retinal degeneration and cancer.  Based on the structure of fenpropimorph, a high affinity (K i = 0.005 nM) sigma-1 receptor ligand and strong inhibitor of the yeast sterol isomerase (ERG2), we previously deduced a basic sigma-1 receptor pharmacophore or chem. backbone composed of a Ph ring attached to a di-substituted nitrogen atom via an alkyl chain.  Here, we report the design and synthesis of various N,N-dialkyl or N-alkyl-N-aralkyl derivs. based on this pharmacophore as well as their binding affinities to the sigma-1 receptor.  We introduce three high affinity sigma-1 receptor compds., N,N-dibutyl-3-(4-fluorophenyl)propylamine (9)(I), N,N-dibutyl-3-(4-nitrophenyl)propylamine (3)(II), and N-propyl-N'-4-aminophenylethyl-3-(4-nitrophenyl)propylamine (20)(III) with K i values of 17.7 nM, 0.36 nM, and 6 nM, resp.  In addn. to sigma receptor affinity, we show through cytotoxicity assays that growth inhibition of various tumor cell lines occurs with our high affinity N,N-dialkyl or N-alkyl-N-aralkyl derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQLoE6p6LHRrVg90H21EOLACvtfcHk0ljCKk9L9TatNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2rurY%253D&md5=26b58c34a1ba0337bd0f7a4258f7df00</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.04.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.04.078%26sid%3Dliteratum%253Aachs%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DFontanilla%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DU.%2BB.%26aulast%3DArbabian%26aufirst%3DM.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520N%252CN-dialkyl%2520and%2520N-alkyl-N-aralkyl%2520fenpropimorph-derived%2520compounds%2520as%2520high%2520affinity%2520ligands%2520for%2520sigma%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4397%26epage%3D4404%26doi%3D10.1016%2Fj.bmc.2010.04.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarrete-Vazquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austrich-Olivares, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godinez-Chaparro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Soto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Nunez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Gomez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(3,4-dichlorophenoxy)-<i>N</i>-(2-morpholin-4-ylethyl)acetamide: a selective sigma1 receptor ligand with antinociceptive effect</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2016.02.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.biopha.2016.02.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27044839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Wmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=284-293&author=G.+Navarrete-Vazquezauthor=A.+Austrich-Olivaresauthor=B.+Godinez-Chaparroauthor=S.+Hidalgo-Figueroaauthor=S.+Estrada-Sotoauthor=E.+Hernandez-Nunezauthor=H.+Torres-Gomezauthor=D.+Schepmannauthor=B.+Wunsch&title=Discovery+of+2-%283%2C4-dichlorophenoxy%29-N-%282-morpholin-4-ylethyl%29acetamide%3A+a+selective+sigma1+receptor+ligand+with+antinociceptive+effect&doi=10.1016%2Fj.biopha.2016.02.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(3,4-dichlorophenoxy)-N-(2-morpholin-4-ylethyl)acetamide: A selective σ1 receptor ligand with antinociceptive effect</span></div><div class="casAuthors">Navarrete-Vazquez, Gabriel; Austrich-Olivares, Amaya; Godinez-Chaparro, Beatriz; Hidalgo-Figueroa, Sergio; Estrada-Soto, Samuel; Hernandez-Nunez, Emanuel; Torres-Gomez, Hector; Schepmann, Dirk; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">284-293</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Compd. 2-(3,4-dichlorophenoxy)-N-(2-morpholin-4-ylethyl)acetamide (1) was designed, prepd. and the in vitro binding evaluation against σ1 and σ2 receptors was measured.  Compd. 1 showed high σ1 receptor affinity (Ki = 42 nM) and it was 36-times more selective for σ1 than σ2 receptor.  Also, it was performed a mol. docking of compd. 1 into the ligand binding pocket homol. model of σ1 receptor, showing a salt bridge between the ionized morpholine ring and Asp126, as well as important short contacts with residues Tyr120, His154 and Trp164.  Ligand efficiency indexes and predicted toxicity anal. revealed an excellent intrinsic quality of 1.  The antinociceptive effect of compd. 1 was detd. using the formalin test.  The ipsilateral local peripheral (10-300 μg/paw) and intrathecal (100 μg/rat) administration of 1 produced a redn. in formalin-induced nociception.  The in vivo results indicated that 1 may be effective in treating inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6zMh8vU3obVg90H21EOLACvtfcHk0ljCKk9L9TatNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Wmtb8%253D&md5=e3f66f5b70ae674e67db2c368cbaa30f</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2016.02.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2016.02.038%26sid%3Dliteratum%253Aachs%26aulast%3DNavarrete-Vazquez%26aufirst%3DG.%26aulast%3DAustrich-Olivares%26aufirst%3DA.%26aulast%3DGodinez-Chaparro%26aufirst%3DB.%26aulast%3DHidalgo-Figueroa%26aufirst%3DS.%26aulast%3DEstrada-Soto%26aufirst%3DS.%26aulast%3DHernandez-Nunez%26aufirst%3DE.%26aulast%3DTorres-Gomez%26aufirst%3DH.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DDiscovery%2520of%25202-%25283%252C4-dichlorophenoxy%2529-N-%25282-morpholin-4-ylethyl%2529acetamide%253A%2520a%2520selective%2520sigma1%2520receptor%2520ligand%2520with%2520antinociceptive%2520effect%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2016%26volume%3D79%26spage%3D284%26epage%3D293%26doi%3D10.1016%2Fj.biopha.2016.02.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romeo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittala, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modica, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnaturi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiechio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sposito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.04.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2019.04.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=31042618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12isLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=226-235&author=G.+Romeoauthor=O.+Prezzaventoauthor=S.+Intagliataauthor=V.+Pittalaauthor=M.+N.+Modicaauthor=A.+Marrazzoauthor=R.+Turnaturiauthor=C.+Parentiauthor=S.+Chiechioauthor=E.+Arenaauthor=A.+Campisiauthor=G.+Spositoauthor=L.+Salerno&title=Synthesis%2C+in+vitro+and+in+vivo+characterization+of+new+benzoxazole+and+benzothiazole-based+sigma+receptor+ligands&doi=10.1016%2Fj.ejmech.2019.04.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands</span></div><div class="casAuthors">Romeo, Giuseppe; Prezzavento, Orazio; Intagliata, Sebastiano; Pittala, Valeria; Modica, Maria N.; Marrazzo, Agostino; Turnaturi, Rita; Parenti, Carmela; Chiechio, Santina; Arena, Emanuela; Campisi, Agata; Sposito, Giovanni; Salerno, Loredana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">226-235</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new set of 5-chlorobenzoxazole- and 5-chlorobenzothiazole-based derivs. I and II [X = O, S; n = 2, 3, 4] contg. the azepane ring as a basic moiety was designed, synthesized and evaluated through binding assays to measure their affinity and selectivity towards σ1 and σ2 receptors.  Compds. I [X = S; n = 3] and II [X = O; n = 4; X = S, n = 4], with a four units spacer between the bicyclic scaffold and the azepane ring, showed nanomolar affinity towards both receptor subtype and the best Ki values (Ki σ1 = 1.27, 2.30 and 0.78 and Ki σ2 = 7.9, 3.8 and 7.61 nM, resp.).  Evaluation of cytotoxic and apoptotic effects in MCF-7 human cancer cells was useful to assess σ2 receptor activity, while an in-vivo mice model of inflammatory pain allowed to analyze σ1 receptor pharmacol. properties.  In-vitro and in-vivo results suggested that compd. I [X = S, n = 3] was a σ1/σ2 agonist, compd. II [X = S, n = 4] a σ1 antagonist/σ2 agonist, whereas compd. II [X = O, n = 4] might act as σ1 antagonist/σ2 partial agonist.  Due to their pharmacol. profile, a potential therapeutic application in cancer of aforesaid novel σ1/σ2 receptor ligands, esp. compds. II [X = O; n = 4; X = S; n = 4], was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2eACohvx7VLVg90H21EOLACvtfcHk0ljksDR56uTl4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12isLY%253D&md5=6a2ff604f935292ea9d5a0218baefa52</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.056%26sid%3Dliteratum%253Aachs%26aulast%3DRomeo%26aufirst%3DG.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DPittala%26aufirst%3DV.%26aulast%3DModica%26aufirst%3DM.%2BN.%26aulast%3DMarrazzo%26aufirst%3DA.%26aulast%3DTurnaturi%26aufirst%3DR.%26aulast%3DParenti%26aufirst%3DC.%26aulast%3DChiechio%26aufirst%3DS.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DCampisi%26aufirst%3DA.%26aulast%3DSposito%26aufirst%3DG.%26aulast%3DSalerno%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520new%2520benzoxazole%2520and%2520benzothiazole-based%2520sigma%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D226%26epage%3D235%26doi%3D10.1016%2Fj.ejmech.2019.04.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maier, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1021/jm010992z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010992z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFyjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=438-448&author=C.+A.+Maierauthor=B.+Wunsch&title=Novel+spiropiperidines+as+highly+potent+and+subtype+selective+sigma-receptor+ligands.+Part+1&doi=10.1021%2Fjm010992z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Spiropiperidines as Highly Potent and Subtype Selective σ-Receptor Ligands. Part 1</span></div><div class="casAuthors">Maier, Christoph A.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">438-448</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of spiro[[2]benzopyran-1,4'-piperidines] and spiro[[2]benzofuran-1,4'-piperidines] of general structure I [X = (CH2)n] is prepd., and the affinity for σ1- and σ2-receptors is investigated by means of radioligand binding assays.  The synthesis of the spiropiperidines, 1'-benzyl-3-methoxy-3,4-dihydrospiro[[2]benzopyran-1,4'-piperidine] (II) and the 1'-benzyl-3-methoxy-3H-spiro[[2]benzofuran-1,4'-piperidine] (III), proceeds via bromine/lithium exchange of the bromoacetals, e.g., 2-(2-bromophenyl)acetaldehyde di-Me acetal in the case of II, addn. to N-benzylpiperidin-4-one, and subsequent cyclization.  Systematic variations of the substituent R at the nitrogen atom, the group Y in position 3, and the ring size of the oxygen heterocycle are performed.  The σ1- and σ2-receptor affinities are detd. with guinea pig brain and rat liver membrane prepns. using [3H]-labeled (+)-pentazocine and ditolylguanidine, resp.  Test results show that a benzyl residue at the piperidine nitrogen atom and a methoxy group in position 3 are advantageous for high σ1-receptor affinity.  In this series II and III are among the most potent σ1-ligands interacting in the low nanomolar range with σ1-receptors (14a, Ki = 1.29 nM; 23, Ki = 1.14 nM).  Variation of the nitrogen substituent R from benzyl to H, alkyl, Ph, or ω-phenylalkyl and the group Y from methoxy to hydroxy, carbonyl, or alkyloxy led to reduced σ1-receptor affinity.  In addn. to their high σ1-receptor affinity, the spiropiperidines II and III display excellent selectivity toward σ2-receptors (σ1/σ2 = 2708 and 1130) and several other receptor and reuptake systems.  Introduction of a polar hydroxy group in position 3 and elongation of the distance between the piperidine nitrogen atom and the Ph moiety result in ligands with considerable σ2-receptor affinity and therefore diminished σ1/σ2-receptor selectivity.  The hemiacetalic 1'-(3-phenylpropyl)-3,4-dihydrospiro[[2]benzopyran-1,4'-piperidin]-3-ol represents the most active σ2-receptor ligand in this series with a Ki value of 83.1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVYGDmsjdLLVg90H21EOLACvtfcHk0ljksDR56uTl4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFyjsLg%253D&md5=13fb1c59fd2f82c128a18d487a6ee8b8</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fjm010992z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010992z%26sid%3Dliteratum%253Aachs%26aulast%3DMaier%26aufirst%3DC.%2BA.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DNovel%2520spiropiperidines%2520as%2520highly%2520potent%2520and%2520subtype%2520selective%2520sigma-receptor%2520ligands.%2520Part%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D438%26epage%3D448%26doi%3D10.1021%2Fjm010992z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel (18)F-labeled spirocyclic piperidine derivatives as sigma1 receptor ligands for positron emission tomography imaging</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3478</span>– <span class="NLM_lpage">3491</span>, <span class="refDoi"> DOI: 10.1021/jm301734g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301734g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3478-3491&author=Y.+Liauthor=X.+Wangauthor=J.+Zhangauthor=W.+Deuther-Conradauthor=F.+Xieauthor=X.+Zhangauthor=J.+Liuauthor=J.+Qiaoauthor=M.+Cuiauthor=J.+Steinbachauthor=P.+Brustauthor=B.+Liuauthor=H.+Jia&title=Synthesis+and+evaluation+of+novel+%2818%29F-labeled+spirocyclic+piperidine+derivatives+as+sigma1+receptor+ligands+for+positron+emission+tomography+imaging&doi=10.1021%2Fjm301734g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Novel 18F-Labeled Spirocyclic Piperidine Derivatives as σ1 Receptor Ligands for Positron Emission Tomography Imaging</span></div><div class="casAuthors">Li, Yan; Wang, Xia; Zhang, Jinming; Deuther-Conrad, Winnie; Xie, Fang; Zhang, Xiaojun; Liu, Jian; Qiao, Jinping; Cui, Mengchao; Steinbach, Jorg; Brust, Peter; Liu, Boli; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3478-3491</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of spirocyclic piperidine derivs. were designed and synthesized as σ1 receptor ligands.  In vitro competition binding assays showed that 1'-[4-(2-fluoroethoxy)benzyl]-3H-spiro[2-benzofuran-1,4'-piperidine] [I (R = F)] possessed high σ1 receptor affinity (Ki = 0.79 nM) and excellent σ1/σ2 subtype selectivity (350-fold) as well as high σ1/VAChT selectivity (799-fold).  The radiolabeled compd. I (R = 18F) was synthesized by substitution of the tosylate precursor I (R = OTs) with [18F]fluoride, with an isolated radiochem. yield of 35-60%, a radiochem. purity of >99%, and a specific activity of 30-55 GBq/μmol.  Biodistribution studies in imprinting control region mice indicated that I (R = 18F) displayed excellent initial brain uptake and slow washout.  Ex vivo autoradiog. in Sprague-Dawley rats demonstrated high accumulation of the radiotracer in brain areas known to express high levels of σ1 receptors.  Micro positron emission tomog. imaging and blocking studies confirmed the specific binding of I (R = 18F) to σ1 receptors in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosXEMXGF6bF7Vg90H21EOLACvtfcHk0ljksDR56uTl4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt74%253D&md5=ca2ccb146e2722e4ae0d98513b7b53c0</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm301734g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301734g%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DJia%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520%252818%2529F-labeled%2520spirocyclic%2520piperidine%2520derivatives%2520as%2520sigma1%2520receptor%2520ligands%2520for%2520positron%2520emission%2520tomography%2520imaging%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3478%26epage%3D3491%26doi%3D10.1021%2Fjm301734g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and sigma receptor affinity of regioisomeric spirocyclic furopyridines</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.06.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.06.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25016157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1aks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=709-716&author=K.+Miyataauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis+and+sigma+receptor+affinity+of+regioisomeric+spirocyclic+furopyridines&doi=10.1016%2Fj.ejmech.2014.06.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and σ receptor affinity of regioisomeric spirocyclic furopyridines</span></div><div class="casAuthors">Miyata, Kengo; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">709-716</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In order to investigate systematically the effect of the position of the pyridine N-atom on the σ1 receptor affinity four regioisomeric furopyridines, e.g., I, were synthesized and pharmacol. evaluated.  The key steps of the synthesis comprise bromine/lithium exchange at regioisomeric bromopyridinecarbaldehyde acetals, e.g., II, subsequent addn. to 1-benzylpiperidin-4-one and cyclization.  The regioisomeric acetals were obtained either by ortho-metalation of bromopyridines or by oxidn. of bromopicolines.  In radioligand binding studies the regioisomeric furopyridines showed 7- to 12-fold lower σ1 affinity than the benzofuran analog.  The reduced σ1 affinity of the furopyridines is explained with the reduced electron d. of the pyridine ring.  Since the four regioisomeric furopyridines show almost the same σ1 affinity (Ki = 4.9-10 nM), a directed interaction of the pyridine N-atom with the receptor protein can be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbnSxnajUq-bVg90H21EOLACvtfcHk0ljszNHGDaJnYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1aks7vL&md5=c5ef4fc793595e258518d9648fa24c80</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.06.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.06.073%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520sigma%2520receptor%2520affinity%2520of%2520regioisomeric%2520spirocyclic%2520furopyridines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D83%26spage%3D709%26epage%3D716%26doi%3D10.1016%2Fj.ejmech.2014.06.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Pyridine analogues of spirocyclic sigma(1) receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4277</span>– <span class="NLM_lpage">4284</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2014.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24913984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslClsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4277-4284&author=K.+Miyataauthor=G.+M%C3%B6llerauthor=D.+Schepmannauthor=B.+Wunsch&title=Pyridine+analogues+of+spirocyclic+sigma%281%29+receptor+ligands&doi=10.1016%2Fj.bmc.2014.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridine analogues of spirocyclic σ1 receptor ligands</span></div><div class="casAuthors">Miyata, Kengo; Moeller, Guido; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4277-4284</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spirocyclic benzopyrans interact with high affinity and selectivity with σ1 receptors.  Bioisosteric replacement of the benzene ring of the benzopyran substructure with the electron rich thiophene ring led to increased σ1 affinity.  Herein the synthesis and pharmacol. evaluation of electron deficient pyridine bioisosteres are reported.  Homologation of the aldehyde to afford the pyridylacetaldehyde deriv. was performed by a Wittig reaction.  Bromine lithium exchange of the bromopyridine, addn. to 1-benzylpiperidin-4-one and cyclization led to the spirocyclic pyranopyridine.  Hydrogenolytic removal of the N-benzyl moiety provided the secondary amine, which allowed the introduction of various N-substituents.  Cyclization of the hydroxy acetal with HCl led to various modifications of the substituent in 3'-position.  Generally the σ1 affinity of the pyridine derivs. is reduced compared with those of the benzene and thiophene derivs..  However, the relationships between the structure and the σ1 affinity follow the same rules as for the benzene and thiophene derivs.  The most promising σ1 ligand within this class of compds. is the pyranopyridine I with a double bond in the pyran ring revealing a Ki-value of 4.6 nM and a very high selectivity (>217-fold) over the σ2 subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8ha_Wq6zQ7Vg90H21EOLACvtfcHk0ljszNHGDaJnYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslClsLY%253D&md5=4537b04de74f88ae18957cc906ba68bc</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DM%25C3%25B6ller%26aufirst%3DG.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DPyridine%2520analogues%2520of%2520spirocyclic%2520sigma%25281%2529%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4277%26epage%3D4284%26doi%3D10.1016%2Fj.bmc.2014.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knappmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Oxa-Pictet-Spengler reaction as key step in the synthesis of novel sigma receptor ligands with 2-benzopyran structure</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4045</span>– <span class="NLM_lpage">4055</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2016.06.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27396684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFenu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=4045-4055&author=I.+Knappmannauthor=D.+Schepmannauthor=B.+Wunsch&title=Oxa-Pictet-Spengler+reaction+as+key+step+in+the+synthesis+of+novel+sigma+receptor+ligands+with+2-benzopyran+structure&doi=10.1016%2Fj.bmc.2016.06.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Oxa-Pictet-Spengler reaction as key step in the synthesis of novel σ receptor ligands with 2-benzopyran structure</span></div><div class="casAuthors">Knappmann, Inga; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4045-4055</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The oxa-Pictet-Spengler reaction of Me 3-hydroxy-4-phenylbutanoate (8, I) was explored to obtain novel σ receptor ligands.  1-Acyl protected piperidone ketals 10 and 11 (II, R = Ac, Cbz) reacted with phenylethanol 8 to yield spirocyclic compds. III.  Aliph. aldehyde acetals 19 RCH(OR')2 (R' = Me, Et) provided 1,3-disubstituted 2-benzopyrans 20 (IV) with high cis-diastereoselectivity.  The intramol. oxa-Pictet-Spengler reaction of 24 (V) led to the tricyclic compd. 25 (VI).  The spirocyclic compds. 18 (VII) show high σ1 affinity (Ki 20-26 nM) and σ1/σ2 selectivity (>9-fold), when a large substituent (n-octyl, benzyl, phenylpropyl) is attached to the piperidine N-atom.  Opening of the piperidine ring to yield aminoethyl (22, 23; VIII, IX) or aminomethyl derivs. (21, X) resulted in reduced σ1 affinity and σ1/σ2 selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd2o0njHoEFbVg90H21EOLACvtfcHk0ljszNHGDaJnYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFenu7zP&md5=0d1c41129607e3048f679fe3bf7ff082</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DKnappmann%26aufirst%3DI.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DOxa-Pictet-Spengler%2520reaction%2520as%2520key%2520step%2520in%2520the%2520synthesis%2520of%2520novel%2520sigma%2520receptor%2520ligands%2520with%25202-benzopyran%2520structure%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D4045%26epage%3D4055%26doi%3D10.1016%2Fj.bmc.2016.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knappmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmkuhl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Lipase-catalyzed kinetic resolution as key step in the synthesis of enantiomerically pure sigma ligands with 2-benzopyran structure</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3384</span>– <span class="NLM_lpage">3395</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.04.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2017.04.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28501431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsFens74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3384-3395&author=I.+Knappmannauthor=K.+Lehmkuhlauthor=J.+Kohlerauthor=D.+Schepmannauthor=M.+Gieraauthor=F.+Bracherauthor=B.+Wunsch&title=Lipase-catalyzed+kinetic+resolution+as+key+step+in+the+synthesis+of+enantiomerically+pure+sigma+ligands+with+2-benzopyran+structure&doi=10.1016%2Fj.bmc.2017.04.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Lipase-catalyzed kinetic resolution as key step in the synthesis of enantiomerically pure σ ligands with 2-benzopyran structure</span></div><div class="casAuthors">Knappmann, Inga; Lehmkuhl, Kirstin; Koehler, Jens; Schepmann, Dirk; Giera, Martin; Bracher, Franz; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3384-3395</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to obtain enantiomerically pure σ1 receptor ligands with a 2-benzopyran scaffold an Oxa-Pictet-Spengler reaction with the enantiomerically pure 2-phenylethanol derivs. was envisaged.  The kinetic resoln. of racemic alc. using Amano Lipase PS-C II and isopropenyl acetate in tert-Bu Me ether led to the (R)-configured alc. in 42% yield with an enantiomeric excess of 99.6%.  The (S)-configured alc. was obtained by Amano Lipase PS-C II catalyzed hydrolysis of enantiomerically enriched acetate (76.9% ee) and provided in 26% yield and 99.7% ee.  The abs. configuration of (R)-alc. was detd. by exciton coupled CD spectroscopy of the bis(bromobenzoate).  The next important step for the synthesis of 2-benzopyrans and was the Oxa-Pictet-Spengler reaction of the enantiomerically pure alcs. with piperidone ketal and chloropropionaldehyde acetal.  The conformationally restricted spirocyclic 2-benzopyrans revealed higher σ1 affinity than the more flexible aminoethyl derivs..  The (R)- and (R,R)-configured enantiomers represent the eutomers of this class of compds. with eudismic ratios of 4.8 [I (R = Bn)] and 4.5 [I (R = Ph(CH2)3)].  High σ1/σ2 selectivity (>49) was found for the most potent σ1 ligands I [R = Bn, Ph(CH2)3, cyclohexylmethyl] and II (Ki(σ1) 9-15 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqoyTv6coP-bVg90H21EOLACvtfcHk0liX0Flonr765g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsFens74%253D&md5=b10d5e69ea47ab9d2e4107bba778e78e</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.04.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.04.042%26sid%3Dliteratum%253Aachs%26aulast%3DKnappmann%26aufirst%3DI.%26aulast%3DLehmkuhl%26aufirst%3DK.%26aulast%3DKohler%26aufirst%3DJ.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DGiera%26aufirst%3DM.%26aulast%3DBracher%26aufirst%3DF.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DLipase-catalyzed%2520kinetic%2520resolution%2520as%2520key%2520step%2520in%2520the%2520synthesis%2520of%2520enantiomerically%2520pure%2520sigma%2520ligands%2520with%25202-benzopyran%2520structure%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3384%26epage%3D3395%26doi%3D10.1016%2Fj.bmc.2017.04.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kronenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-affinity relationships of spirocyclic benzopyrans with exocyclic amino moiety</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4204</span>– <span class="NLM_lpage">4217</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00449</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00449" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1aisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4204-4217&author=E.+Kronenbergauthor=F.+Weberauthor=S.+Bruneauthor=D.+Schepmannauthor=C.+Almansaauthor=K.+Friedlandauthor=E.+Lauriniauthor=S.+Priclauthor=B.+Wunsch&title=Synthesis+and+structure-affinity+relationships+of+spirocyclic+benzopyrans+with+exocyclic+amino+moiety&doi=10.1021%2Facs.jmedchem.9b00449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Affinity Relationships of Spirocyclic Benzopyrans with Exocyclic Amino Moiety</span></div><div class="casAuthors">Kronenberg, Elisabeth; Weber, Frauke; Brune, Stefanie; Schepmann, Dirk; Almansa, Carmen; Friedland, Kristina; Laurini, Erik; Pricl, Sabrina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4204-4217</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">σ1 And/or σ2 receptors play a crucial role in pathol. conditions such as pain, neurodegenerative disorders, and cancer.  A set of spirocyclic cyclohexanes with diverse O-heterocycles and amino moieties (general structure given in text) was prepd. and pharmacol. evaluated.  In structure-activity relationships studies, the σ1 receptor affinity and σ1:σ2 selectivity were correlated with the stereochem., the kind and substitution pattern of the O-heterocycle, and the substituents at the exocyclic amino moiety. cis-configured 2-benzopyran cis-I bearing a methoxy group and a tertiary cyclohexylmethylamino moiety showed the highest σ1 affinity (Ki = 1.9 nM) of this series of compds.  In a Ca2+ influx assay, cis-I behaved as a σ1 antagonist. cis-I reveals high selectivity over σ2 and opioid receptors.  The interactions of the novel σ1 ligands were analyzed on the mol. level using the recently reported X-ray crystal structure of the σ1 receptor protein.  The protonated amino moiety forms a persistent salt bridge with E172.  The spiro[benzopyran-1,1'-cyclohexane] scaffold and the cyclohexylmethyl moiety occupy two hydrophobic pockets.  Exchange of the N-cyclohexylmethyl moiety by a benzyl group led unexpectedly to potent and selective μ-opioid receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY45Xx2BvrZ7Vg90H21EOLACvtfcHk0liX0Flonr765g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1aisr0%253D&md5=685446a1457bde87e848a7b2e2b46eb4</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00449%26sid%3Dliteratum%253Aachs%26aulast%3DKronenberg%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DFriedland%26aufirst%3DK.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520structure-affinity%2520relationships%2520of%2520spirocyclic%2520benzopyrans%2520with%2520exocyclic%2520amino%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4204%26epage%3D4217%26doi%3D10.1021%2Facs.jmedchem.9b00449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergkemper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniliuc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinoso, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis, receptor affinity, and antiallodynic activity of spirocyclic sigma receptor ligands with exocyclic amino moiety</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9666</span>– <span class="NLM_lpage">9690</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSrsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9666-9690&author=M.+Bergkemperauthor=E.+Kronenbergauthor=S.+Thumauthor=F.+Borgelauthor=C.+Daniliucauthor=D.+Schepmannauthor=F.+R.+Nietoauthor=P.+Brustauthor=R.+F.+Reinosoauthor=I.+Alvarezauthor=B.+Wunsch&title=Synthesis%2C+receptor+affinity%2C+and+antiallodynic+activity+of+spirocyclic+sigma+receptor+ligands+with+exocyclic+amino+moiety&doi=10.1021%2Facs.jmedchem.8b01183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety</span></div><div class="casAuthors">Bergkemper, Melanie; Kronenberg, Elisabeth; Thum, Simone; Boergel, Frederik; Daniliuc, Constantin; Schepmann, Dirk; Nieto, Francisco Rafael; Brust, Peter; Reinoso, Raquel F.; Alvarez, Ines; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9666-9690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spiro(benzopyrancyclohexane)amines such as I and the cis- and trans-cyclohexane diastereomers of II were prepd. and tested as σ1- and σ2-receptor ligands for potential use in the treatment of allodynia.  I was the most promising σ2 receptor ligand of the compds. tested.  The cis- and trans-cyclohexane diastereomers of II possess high σ1 affinity but moderate selectivity over the σ2 subtype and showed antiallodynic activity that is stronger than that of the ref. σ1 antagonist BD-1063.  Since the antiallodynic activity of the trans-cyclohexane diastereomer of II could only be partially reversed by the σ1 agonist PRE-084, a second mechanism likely contributes to its overall antiallodynic effect; the antiallodynic effect of the cis cyclohexane diastereomer of II can be explained solely by σ1 antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvQKzsLReDQrVg90H21EOLACvtfcHk0liX0Flonr765g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSrsbnP&md5=93f7d570bd3d8dfad9fea6c083cbf69d</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01183%26sid%3Dliteratum%253Aachs%26aulast%3DBergkemper%26aufirst%3DM.%26aulast%3DKronenberg%26aufirst%3DE.%26aulast%3DThum%26aufirst%3DS.%26aulast%3DBorgel%26aufirst%3DF.%26aulast%3DDaniliuc%26aufirst%3DC.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DReinoso%26aufirst%3DR.%2BF.%26aulast%3DAlvarez%26aufirst%3DI.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%252C%2520receptor%2520affinity%252C%2520and%2520antiallodynic%2520activity%2520of%2520spirocyclic%2520sigma%2520receptor%2520ligands%2520with%2520exocyclic%2520amino%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9666%26epage%3D9690%26doi%3D10.1021%2Facs.jmedchem.8b01183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherafat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alirezapour, B.</span></span> <span> </span><span class="NLM_article-title">One-pot synthesis and sigma receptor binding studies of novel spirocyclic-2,6-diketopiperazine derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2676</span>– <span class="NLM_lpage">2679</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2016.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27090556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmt1emsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2676-2679&author=M.+Ghandiauthor=F.+Sherafatauthor=M.+Sadeghzadehauthor=B.+Alirezapour&title=One-pot+synthesis+and+sigma+receptor+binding+studies+of+novel+spirocyclic-2%2C6-diketopiperazine+derivatives&doi=10.1016%2Fj.bmcl.2016.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot synthesis and sigma receptor binding studies of novel spirocyclic-2,6-diketopiperazine derivatives</span></div><div class="casAuthors">Ghandi, Mehdi; Sherafat, Fatemeh; Sadeghzadeh, Masoud; Alirezapour, Behrouz</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2676-2679</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spirocyclic-2,6-diketopiperazines I (R = H, MeO; R1 = H, Me, MeO; X = PhCH2N, CH2, t-BuCH; Y = bond, CH2) were prepd. by a one-pot four-component Ugi reaction of N-benzyl-4-piperidinone, cyclopentanone, cyclohexanone, or 4-tert-butylcyclohexanone with benzoic acid 2-R-4-R1C6H3CO2H (R = H, MeO; R1 = H, Me, MeO), cyclohexyl isocyanide, and Et glycinate hydrochloride followed by intramol. amidation in 70-88% yields.  The binding of I to σ1- and σ2-receptors was detd.; the σ1 affinities and subtype selectivities of three spirocyclic piperidine derivs. are generally comparable to those of spirocycloalkane analogs.  The σ1 affinities and subtype selectivities of spirocyclic piperidines were comparable to those of spirocycloalkane analogs; spirocyclopentanes were bound more effectively by σ2-receptors than spirocyclohexanes.  Of the compds. I, the best binding affinity and subtype selectivity was identified for I (R = H; R1 = MeO; X = PhCH2N; Y = CH2) with Ki values for σ1 and σ2 receptors of 5.9 ± 0.5 nM and 563 ± 21 nM, resp. (σ1/σ2 = 95).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWzexVq1WOUrVg90H21EOLACvtfcHk0ljB5Ic5TB6pPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmt1emsLs%253D&md5=1429b80fe70990ad42dc973750d9519e</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DGhandi%26aufirst%3DM.%26aulast%3DSherafat%26aufirst%3DF.%26aulast%3DSadeghzadeh%26aufirst%3DM.%26aulast%3DAlirezapour%26aufirst%3DB.%26atitle%3DOne-pot%2520synthesis%2520and%2520sigma%2520receptor%2520binding%2520studies%2520of%2520novel%2520spirocyclic-2%252C6-diketopiperazine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2676%26epage%3D2679%26doi%3D10.1016%2Fj.bmcl.2016.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uprety, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaoa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redel-Traub, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinberg, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of spiro-2,6-dioxopiperazine and spiro-2,6-dioxopyrazine scaffolds using amino acids in a three-component reaction to generate potential sigma-1 (sigma1) receptor selective ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2018.12.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30597325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlsFSk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=241-251&author=R.+Upretyauthor=A.+Varadiauthor=A.+Allaoaauthor=G.+N.+Redel-Traubauthor=T.+C.+Palmerauthor=E.+N.+Feinbergauthor=A.+C.+Ferrisauthor=V.+S.+Pandeauthor=G.+W.+Pasternakauthor=S.+Majumdar&title=Synthesis+of+spiro-2%2C6-dioxopiperazine+and+spiro-2%2C6-dioxopyrazine+scaffolds+using+amino+acids+in+a+three-component+reaction+to+generate+potential+sigma-1+%28sigma1%29+receptor+selective+ligands&doi=10.1016%2Fj.ejmech.2018.12.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of spiro-2,6-dioxopiperazine and spiro-2,6-dioxopyrazine scaffolds using amino acids in a three-component reaction to generate potential Sigma-1 (σ1) receptor selective ligands</span></div><div class="casAuthors">Uprety, Rajendra; Varadi, Andras; Allaoa, Abdullah; Redel-Traub, Gabriel N.; Palmer, Travis C.; Feinberg, Evan N.; Ferris, Alex C.; Pande, Vijay S.; Pasternak, Gavril W.; Majumdar, Susruta</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">241-251</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design and synthesis of novel heterocycles with spiro-2,6-dioxopiperazine and spiro-2,6-pyrazine scaffolds through a three-component reaction using various amino acids, ketones and isocyanides was presented.  Screening of selected compds. over fifty CNS receptors including G-protein coupled receptors (GPCRs), ion channels, transporters and enzymes through the NIMH psychoactive drug screening program indicated that a novel spiro-2,6-dioxopyrazine scaffold, e.g., I, displayed high binding affinity at sigma-1 (σ1) receptor in the nanomolar range.  In addn., mol. docking of spiro-2,6-dioxopyrazine scaffold, e.g., I at the human σ1 receptor showed that it resides in the same binding site that was occupied by the ligand N-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP) used to obtain a crystal structure of the human sigma-1 (σ1) receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB4kaewGiLqLVg90H21EOLACvtfcHk0ljB5Ic5TB6pPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlsFSk&md5=25959562ec36b0f8a994e7fd38fa24d8</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.048%26sid%3Dliteratum%253Aachs%26aulast%3DUprety%26aufirst%3DR.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DAllaoa%26aufirst%3DA.%26aulast%3DRedel-Traub%26aufirst%3DG.%2BN.%26aulast%3DPalmer%26aufirst%3DT.%2BC.%26aulast%3DFeinberg%26aufirst%3DE.%2BN.%26aulast%3DFerris%26aufirst%3DA.%2BC.%26aulast%3DPande%26aufirst%3DV.%2BS.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DMajumdar%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520spiro-2%252C6-dioxopiperazine%2520and%2520spiro-2%252C6-dioxopyrazine%2520scaffolds%2520using%2520amino%2520acids%2520in%2520a%2520three-component%2520reaction%2520to%2520generate%2520potential%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520selective%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D241%26epage%3D251%26doi%3D10.1016%2Fj.ejmech.2018.12.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lepovitz, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span> <span> </span><span class="NLM_article-title">Diversity-oriented synthesis of bioactive azaspirocycles</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">130637</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2019.130637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.tet.2019.130637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvF2qs7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=130637&author=L.+T.+Lepovitzauthor=S.+F.+Martin&title=Diversity-oriented+synthesis+of+bioactive+azaspirocycles&doi=10.1016%2Fj.tet.2019.130637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-Oriented Synthesis of Bioactive Azaspirocycles</span></div><div class="casAuthors">Lepovitz, Lance T.; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">130637pp.</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A collection of novel azaspirocyclic β-arylethylamines was prepd. in good yield and excellent diastereoselectivity by an expedient strategy that features condensation of a cyclic ketone with an amino allylsilane and a tandem aza-Sakurai cyclization to generate several different spirocyclic N-heterocycles.  Subsequent elaboration of the spirocyclic scaffold was achieved via Pictet-Spengler cyclizations, Suzuki cross-coupling reactions, N-functionalizations, and olefin refunctionalization reactions to create a diverse library of compds., several of which have nanomolar affinity for the sigma 1 receptor and transmembrane protein 97 (TMEM97).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrCl60i0psjbVg90H21EOLACvtfcHk0ljB5Ic5TB6pPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvF2qs7rN&md5=66d43bf39a2294c2744488f71e07e0e0</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2019.130637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2019.130637%26sid%3Dliteratum%253Aachs%26aulast%3DLepovitz%26aufirst%3DL.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DDiversity-oriented%2520synthesis%2520of%2520bioactive%2520azaspirocycles%26jtitle%3DTetrahedron%26date%3D2019%26volume%3D75%26spage%3D130637%26doi%3D10.1016%2Fj.tet.2019.130637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Entrena, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Pozo, E.</span></span> <span> </span><span class="NLM_article-title">Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1007/s00213-009-1513-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1007%2Fs00213-009-1513-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19326101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Kksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2009&pages=21-33&author=J.+M.+Entrenaauthor=E.+J.+Cobosauthor=F.+R.+Nietoauthor=C.+M.+Cendanauthor=J.+M.+Baeyensauthor=E.+Del+Pozo&title=Antagonism+by+haloperidol+and+its+metabolites+of+mechanical+hypersensitivity+induced+by+intraplantar+capsaicin+in+mice%3A+role+of+sigma-1+receptors&doi=10.1007%2Fs00213-009-1513-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors</span></div><div class="casAuthors">Entrena, Jose M.; Cobos, Enrique J.; Nieto, Francisco R.; Cendan, Cruz M.; Baeyens, Jose M.; Del Pozo, Esperanza</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-33</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Rationale: We evaluated the effects of haloperidol and its metabolites on capsaicin-induced mech. hypersensitivity (allodynia) and on nociceptive pain induced by punctate mech. stimuli in mice.  Results: S.c. administration of haloperidol or its metabolites I or II (reduced haloperidol) dose-dependently reversed capsaicin-induced (1 μg, intraplantar) mech. hypersensitivity of the hind paw (stimulated with a nonpainful, 0.5-g force, punctate stimulus).  The order of potency of these drugs to induce antiallodynic effects was the order of their affinity for brain sigma-1 (σ1) receptor ([3H](+)-pentazocine-labeled).  Antiallodynic activity of haloperidol and its metabolites was dose-dependently prevented by the selective σ1 receptor agonist PRE-084, but not by naloxone.  These results suggest the involvement of σ1 receptors, but discard any role of the endogenous opioid system, on the antiallodynic effects.  Dopamine receptor antagonism also appears unlikely to be involved in these effects, since the D2/D3 receptor antagonist (-)-sulpiride, which had no affinity for σ1 receptors, showed no antiallodynic effect.  None of these drugs modified hind-paw withdrawal after a painful (4 g force) punctate mech. stimulus in noncapsaicin-sensitized animals.  As expected, the control drug gabapentin showed antiallodynic but not antinociceptive activity, whereas clonidine exhibited both activities and rofecoxib, used as neg. control, showed neither.  Conclusion: These results show that haloperidol and its metabolites I and II produce antiallodynic but not antinociceptive effects against punctate mech. stimuli and suggest that their antiallodynic effect may be due to blockade of σ1 receptors but not to dopamine receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI0AnJHWbghLVg90H21EOLACvtfcHk0lgtJ6O16gJPmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Kksbg%253D&md5=8b2077efc615a10a83b9dcaa973deeb2</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1007%2Fs00213-009-1513-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-009-1513-8%26sid%3Dliteratum%253Aachs%26aulast%3DEntrena%26aufirst%3DJ.%2BM.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DNieto%26aufirst%3DF.%2BR.%26aulast%3DCendan%26aufirst%3DC.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DDel%2BPozo%26aufirst%3DE.%26atitle%3DAntagonism%2520by%2520haloperidol%2520and%2520its%2520metabolites%2520of%2520mechanical%2520hypersensitivity%2520induced%2520by%2520intraplantar%2520capsaicin%2520in%2520mice%253A%2520role%2520of%2520sigma-1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D205%26spage%3D21%26epage%3D33%26doi%3D10.1007%2Fs00213-009-1513-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinciguerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giurdanella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporarello, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anfuso, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span> <span> </span><span class="NLM_article-title">Antiangiogenic effect of (±)-haloperidol metabolite II valproate ester [(±)-MRJF22] in human microvascular retinal endothelial cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9960</span>– <span class="NLM_lpage">9966</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9960-9966&author=M.+Olivieriauthor=E.+Amataauthor=S.+Vinciguerraauthor=J.+Fioritoauthor=G.+Giurdanellaauthor=F.+Dragoauthor=N.+Caporarelloauthor=O.+Prezzaventoauthor=E.+Arenaauthor=L.+Salernoauthor=A.+Rescifinaauthor=G.+Lupoauthor=C.+D.+Anfusoauthor=A.+Marrazzo&title=Antiangiogenic+effect+of+%28%C2%B1%29-haloperidol+metabolite+II+valproate+ester+%5B%28%C2%B1%29-MRJF22%5D+in+human+microvascular+retinal+endothelial+cells&doi=10.1021%2Facs.jmedchem.6b01039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells</span></div><div class="casAuthors">Olivieri, Melania; Amata, Emanuele; Vinciguerra, Shila; Fiorito, Jole; Giurdanella, Giovanni; Drago, Filippo; Caporarello, Nunzia; Prezzavento, Orazio; Arena, Emanuela; Salerno, Loredana; Rescifina, Antonio; Lupo, Gabriella; Anfuso, Carmelina Daniela; Marrazzo, Agostino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9960-9966</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(±)-MRJF22 [(±)-2], a novel prodrug of haloperidol metabolite II (sigma-1 receptor antagonist/sigma-2 receptor agonist ligand) obtained by conjugation to valproic acid (histone deacetylase inhibitor) via an ester bond, exhibits antiangiogenic activity, being able to reduce human retinal endothelial cell (HREC) viability in a comparable manner to bevacizumab.  Moreover, (±)-2 was able to significantly reduce viable cells count, endothelial cell migration, and tube formation in vascular endothelial growth factor A (VEGF-A) stimulated HREC cultures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJedDLZWd8jbVg90H21EOLACvtfcHk0lgtJ6O16gJPmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77P&md5=f0a092eedd76c583f4dabaa7151774c4</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01039%26sid%3Dliteratum%253Aachs%26aulast%3DOlivieri%26aufirst%3DM.%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DVinciguerra%26aufirst%3DS.%26aulast%3DFiorito%26aufirst%3DJ.%26aulast%3DGiurdanella%26aufirst%3DG.%26aulast%3DDrago%26aufirst%3DF.%26aulast%3DCaporarello%26aufirst%3DN.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DSalerno%26aufirst%3DL.%26aulast%3DRescifina%26aufirst%3DA.%26aulast%3DLupo%26aufirst%3DG.%26aulast%3DAnfuso%26aufirst%3DC.%2BD.%26aulast%3DMarrazzo%26aufirst%3DA.%26atitle%3DAntiangiogenic%2520effect%2520of%2520%2528%25C2%25B1%2529-haloperidol%2520metabolite%2520II%2520valproate%2520ester%2520%255B%2528%25C2%25B1%2529-MRJF22%255D%2520in%2520human%2520microvascular%2520retinal%2520endothelial%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9960%26epage%3D9966%26doi%3D10.1021%2Facs.jmedchem.6b01039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichiara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittala, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span> <span> </span><span class="NLM_article-title">(+)-Methyl (1<i>R</i>,2<i>S</i>)-2-{[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropa necarboxylate [(+)-MR200] derivatives as potent and selective sigma receptor ligands: stereochemistry and pharmacological properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01584</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01584" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCktLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=372-384&author=E.+Amataauthor=A.+Rescifinaauthor=O.+Prezzaventoauthor=E.+Arenaauthor=M.+Dichiaraauthor=V.+Pittalaauthor=A.+Montilla-Garciaauthor=F.+Punzoauthor=P.+Merinoauthor=E.+J.+Cobosauthor=A.+Marrazzo&title=%28%2B%29-Methyl+%281R%2C2S%29-2-%7B%5B4-%284-chlorophenyl%29-4-hydroxypiperidin-1-yl%5Dmethyl%7D-1-phenylcyclopropa+necarboxylate+%5B%28%2B%29-MR200%5D+derivatives+as+potent+and+selective+sigma+receptor+ligands%3A+stereochemistry+and+pharmacological+properties&doi=10.1021%2Facs.jmedchem.7b01584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">(+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties</span></div><div class="casAuthors">Amata, Emanuele; Rescifina, Antonio; Prezzavento, Orazio; Arena, Emanuela; Dichiara, Maria; Pittala, Valeria; Montilla-Garcia, Angeles; Punzo, Francesco; Merino, Pedro; Cobos, Enrique J.; Marrazzo, Agostino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">372-384</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Methoxycarbonyl-1-phenyl-2-cyclopropylmethyl based derivs. [cis-(+)-MR200], [cis-(-)-MR201], and [trans-(±)-MR204], have been identified as new potent sigma (σ) receptor ligands.  In the present paper, novel enantiomerically pure analogs were synthesized and optimized for their σ receptor affinity and selectivity.  Docking studies rationalized the results obtained in the radioligand binding assay.  Abs. stereochem. was unequivocally established by X-ray anal. of a precursor as camphorsulfonyl deriv.  The most promising compd., I, showed remarkable selectivity over a panel of more than 15 receptors as well as good chem. and enzymic stability in human plasma.  An in vivo evaluation evidenced that I, in contrast to its isomers, which behave as σ1 antagonists, exhibited a σ1 agonist profile.  These data clearly demonstrated that compd. I, due to its σ1 agonist activity and favorable receptor selectivity and stability, provided an useful tool for the study of σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHc_luLz8QZLVg90H21EOLACvtfcHk0lgtJ6O16gJPmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCktLzP&md5=48051bdd2674c6bb9f5da0277b26b137</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01584%26sid%3Dliteratum%253Aachs%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DRescifina%26aufirst%3DA.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DDichiara%26aufirst%3DM.%26aulast%3DPittala%26aufirst%3DV.%26aulast%3DMontilla-Garcia%26aufirst%3DA.%26aulast%3DPunzo%26aufirst%3DF.%26aulast%3DMerino%26aufirst%3DP.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26aulast%3DMarrazzo%26aufirst%3DA.%26atitle%3D%2528%252B%2529-Methyl%2520%25281R%252C2S%2529-2-%257B%255B4-%25284-chlorophenyl%2529-4-hydroxypiperidin-1-yl%255Dmethyl%257D-1-phenylcyclopropa%2520necarboxylate%2520%255B%2528%252B%2529-MR200%255D%2520derivatives%2520as%2520potent%2520and%2520selective%2520sigma%2520receptor%2520ligands%253A%2520stereochemistry%2520and%2520pharmacological%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D372%26epage%3D384%26doi%3D10.1021%2Facs.jmedchem.7b01584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokornaczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Microwave-assisted regioselective direct C-H arylation of thiazole derivatives leading to increased σ1 receptor affinity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1039/C5MD00526D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC5MD00526D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCqsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=327-331&author=A.+Kokornaczykauthor=D.+Schepmannauthor=J.+Yamaguchiauthor=K.+Itamiauthor=B.+W%C3%BCnsch&title=Microwave-assisted+regioselective+direct+C-H+arylation+of+thiazole+derivatives+leading+to+increased+%CF%831+receptor+affinity&doi=10.1039%2FC5MD00526D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave-assisted regioselective direct C-H arylation of thiazole derivatives leading to increased σ1 receptor affinity</span></div><div class="casAuthors">Kokornaczyk, Artur; Schepmann, Dirk; Yamaguchi, Junichiro; Itami, Kenichiro; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-331</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">New thiazole analogs I (R = H, 4-H3CC6H4, 5-H3CC6H4) of spirocyclic thiophenes II, which are known to show high σ1 receptor affinities, have been developed as potentially better σ1 receptor ligands.  To introduce an aryl group onto the thiazole core of I (R = 4-H3CC6H4, 5-H3CC6H4) (C4 or C5 positions), Pd-catalyzed regioselective C-H arylation reactions were used.  The Pd-catalyzed C5 arylation of I (R = H) could be considerably improved by using microwave irradn. technique.  The Pd-catalyzed C4 arylation of thiazole I (R = H) with 4-methylphenylboronic acid could be achieved in the presence of Pd(OAc)2, 1,10-phenanthroline, TEMPO, and LiBF4.  Under these conditions, the tertiary amine and the tertiary alc. were well-tolerated.  The regioselective arylation of I (R = H) led to new compds. I (R = 4-H3CC6H4, 5-H3CC6H4), with a 4-tolyl moiety in the C5- and C4-positions, displaying five to nine-fold increased σ1 affinity.  The same σ1 affinity of the regioisomeric thiazoles I (R = 4-H3CC6H4, 5-H3CC6H4) can be explained by fast rotation around the piperidine-thiazole bond.  Compared to spirocyclic thiophenes II, thiazoles I (R = H, 4-H3CC6H4, 5-H3CC6H4) are considerably more polar.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7vYHLlGs97Vg90H21EOLACvtfcHk0lhSQlEuyg4RbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCqsrvK&md5=bab3d4b490ef73b85ff48c5bb816364b</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1039%2FC5MD00526D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00526D%26sid%3Dliteratum%253Aachs%26aulast%3DKokornaczyk%26aufirst%3DA.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DMicrowave-assisted%2520regioselective%2520direct%2520C-H%2520arylation%2520of%2520thiazole%2520derivatives%2520leading%2520to%2520increased%2520%25CF%25831%2520receptor%2520affinity%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D327%26epage%3D331%26doi%3D10.1039%2FC5MD00526D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokornaczyk, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Thiazole-based sigma1 receptor ligands: diversity by late-stage C-H arylation of thiazoles, structure-affinity and selectivity relationships, and molecular interactions</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1002%2Fcmdc.201700166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28544475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVarsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1070-1080&author=A.+K.+Kokornaczykauthor=D.+Schepmannauthor=J.+Yamaguchiauthor=K.+Itamiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=B.+Wunsch&title=Thiazole-based+sigma1+receptor+ligands%3A+diversity+by+late-stage+C-H+arylation+of+thiazoles%2C+structure-affinity+and+selectivity+relationships%2C+and+molecular+interactions&doi=10.1002%2Fcmdc.201700166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazole-Based σ1 Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles, Structure-Affinity and Selectivity Relationships, and Mol. Interactions</span></div><div class="casAuthors">Kokornaczyk, Artur K.; Schepmann, Dirk; Yamaguchi, Junichiro; Itami, Kenichiro; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocyclic thiophene derivs. represent promising σ1 ligands with high σ1 affinity and selectivity over the σ2 subtype.  To increase ligand efficiency, the thiophene ring was replaced bioisosterically by a thiazole ring, and the pyran ring was opened.  Late-stage diversification by regioselective C-H arylation of thiazoles 9 a-c resulted in a set of 53 compds. with high diversity.  This set of compds. was analyzed with respect to σ1 affinity, σ1/σ2 selectivity, lipophilicity (logD7.4), lipophilicity-cor. ligand efficiency (LELP), and mol. target interactions.  The most promising candidates were pyridyl-substituted thiazole derivs. 33 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-3-yl)thiazole) and 34 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-4-yl)thiazole), possessing low-nanomolar σ1 affinity (Ki=1.3 and 1.9 nM), high σ1/σ2 selectivity (>1500-fold), low lipophilicity (logD7.4=1.8) and very good ligand efficiency (LELP=5.5), indicating promising pharmacodynamics and pharmacokinetics.  Mol. simulation studies, including docking and deconvolution of the free binding energy into its major components, led to decreased hydrophobic stabilization of pyridyl derivs. 33 c and 34 c, which was compensated by lower desolvation energy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH1KP3Hivs9rVg90H21EOLACvtfcHk0lhSQlEuyg4RbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVarsL3K&md5=5317bdafd4f74079cf90fc4d86d751fa</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700166%26sid%3Dliteratum%253Aachs%26aulast%3DKokornaczyk%26aufirst%3DA.%2BK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DThiazole-based%2520sigma1%2520receptor%2520ligands%253A%2520diversity%2520by%2520late-stage%2520C-H%2520arylation%2520of%2520thiazoles%252C%2520structure-affinity%2520and%2520selectivity%2520relationships%252C%2520and%2520molecular%2520interactions%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1070%26epage%3D1080%26doi%3D10.1002%2Fcmdc.201700166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikome, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntie-Kang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngemenya, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efange, S. M.</span></span> <span> </span><span class="NLM_article-title">4-Aroylpiperidines and 4-(alpha-hydroxyphenyl)piperidines as selective sigma-1 receptor ligands: synthesis, preliminary pharmacological evaluation and computational studies</span>. <i>Chem. Cent. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">53</span>, <span class="refDoi"> DOI: 10.1186/s13065-016-0200-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1186%2Fs13065-016-0200-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27555879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKkurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=53&author=H.+N.+Ikomeauthor=F.+Ntie-Kangauthor=M.+N.+Ngemenyaauthor=Z.+Tuauthor=R.+H.+Machauthor=S.+M.+Efange&title=4-Aroylpiperidines+and+4-%28alpha-hydroxyphenyl%29piperidines+as+selective+sigma-1+receptor+ligands%3A+synthesis%2C+preliminary+pharmacological+evaluation+and+computational+studies&doi=10.1186%2Fs13065-016-0200-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">4-aroylpiperidines and 4-(α-hydroxyphenyl)piperidines as selective sigma-1 receptor ligands: synthesis, preliminary pharmacological evaluation and computational studies</span></div><div class="casAuthors">Ikome, Hermia N.; Ntie-Kang, Fidele; Ngemenya, Moses N.; Tu, Zhude; Mach, Robert H.; Efange, Simon M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Central Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53/1-53/15</span>CODEN:
                <span class="NLM_cas:coden">CCJHA2</span>;
        ISSN:<span class="NLM_cas:issn">1752-153X</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Sigma (σ) receptors are membrane-bound proteins characterized by an unusual promiscuous ability to bind a wide variety of drugs and their high affinity for typical neuroleptic drugs, such as haloperidol, and their potential as alternative targets for antipsychotic agents.  Sigma receptors display diverse biol. activities and represent potential fruitful targets for therapeutic development in combating many human diseases.  Therefore, they present an interesting avenue for further exploration.  It was our goal to evaluate the potential of ring opened spipethiane (1) analogs as functional ligands (agonists) for σ receptors by chem. modification.  Chem. modification of the core structure of the lead compd., (1), by replacement of the sulfur atom with a carbonyl group, hydroxyl group and 3-bromobenzylamine with the simultaneous presence of 4-fluorobenzoyl replacing the spirofusion afforded novel potent sigma-1 receptor ligands 7a-f, 8a-f and 9d-e.  The sigma-1 receptor affinities of 7e, 8a and 8f were slightly lower than that of 1 and their selectivities for this receptor two to threefold greater than that of 1.  It was found that these compds. have higher selectivities for sigma-1 receptors compared to 1.  Quantitatitive structure-activity relationship studies revealed that sigma-1 binding is driven by hydrophobic interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTVi2CN-ZgibVg90H21EOLACvtfcHk0lhSQlEuyg4RbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKkurrP&md5=f47df06b9948f9ef8b37ef57eb5228d2</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1186%2Fs13065-016-0200-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13065-016-0200-1%26sid%3Dliteratum%253Aachs%26aulast%3DIkome%26aufirst%3DH.%2BN.%26aulast%3DNtie-Kang%26aufirst%3DF.%26aulast%3DNgemenya%26aufirst%3DM.%2BN.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DEfange%26aufirst%3DS.%2BM.%26atitle%3D4-Aroylpiperidines%2520and%25204-%2528alpha-hydroxyphenyl%2529piperidines%2520as%2520selective%2520sigma-1%2520receptor%2520ligands%253A%2520synthesis%252C%2520preliminary%2520pharmacological%2520evaluation%2520and%2520computational%2520studies%26jtitle%3DChem.%2520Cent.%2520J.%26date%3D2016%26volume%3D10%26spage%3D53%26doi%3D10.1186%2Fs13065-016-0200-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Bello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piergentili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimarelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flammini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amantini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quaglia, W.</span></span> <span> </span><span class="NLM_article-title">Novel potent <i>N</i>-methyl-d-aspartate (NMDA) receptor antagonists or sigma1 receptor ligands based on properly substituted 1,4-dioxane ring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8601</span>– <span class="NLM_lpage">8615</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01214</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01214" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Slsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8601-8615&author=A.+Bonifaziauthor=F.+Del+Belloauthor=V.+Mammoliauthor=A.+Piergentiliauthor=R.+Petrelliauthor=C.+Cimarelliauthor=M.+Pelleiauthor=D.+Schepmannauthor=B.+Wunschauthor=E.+Barocelliauthor=S.+Bertoniauthor=L.+Flamminiauthor=C.+Amantiniauthor=M.+Nabissiauthor=G.+Santoniauthor=G.+Vistoliauthor=W.+Quaglia&title=Novel+potent+N-methyl-d-aspartate+%28NMDA%29+receptor+antagonists+or+sigma1+receptor+ligands+based+on+properly+substituted+1%2C4-dioxane+ring&doi=10.1021%2Facs.jmedchem.5b01214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Potent N-Methyl-D-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring</span></div><div class="casAuthors">Bonifazi, Alessandro; Del Bello, Fabio; Mammoli, Valerio; Piergentili, Alessandro; Petrelli, Riccardo; Cimarelli, Cristina; Pellei, Maura; Schepmann, Dirk; Wunsch, Bernhard; Barocelli, Elisabetta; Bertoni, Simona; Flammini, Lisa; Amantini, Consuelo; Nabissi, Massimo; Santoni, Giorgio; Vistoli, Giulio; Quaglia, Wilma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8601-8615</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two series of 1,4-dioxanes (4-11 and 12-19) were rationally designed and prepd. to interact either with the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA) receptor or with σ1 receptors, resp.  The biol. profiles of the novel compds. were assessed using radioligand binding assays, and the compds. with the highest affinities were investigated for their functional activity.  The results were in line with the available pharmacophore models and highlighted that the 1,4-dioxane scaffold is compatible with potent antagonist activity at NMDA receptor or high affinity for σ1 receptors.  The primary amines I [R = C6H11, trans] and I [R = Ph] bearing a cyclohexyl and a Ph ring or two Ph rings in position 6, resp., were the most potent noncompetitive antagonists at the NMDA receptor with IC50 values similar to those of the dissociative anesthetic (S)-(+)-ketamine.  The 5,5-di-Ph substitution assocd. with a benzylaminomethyl moiety in position 2, as in II, favored the interaction with σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom9Lw-lUtPSLVg90H21EOLACvtfcHk0ljQ9HtTQPNvfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Slsb%252FN&md5=0c053c67bc8f4f3449c1af2a3470df2e</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01214%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DDel%2BBello%26aufirst%3DF.%26aulast%3DMammoli%26aufirst%3DV.%26aulast%3DPiergentili%26aufirst%3DA.%26aulast%3DPetrelli%26aufirst%3DR.%26aulast%3DCimarelli%26aufirst%3DC.%26aulast%3DPellei%26aufirst%3DM.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DBertoni%26aufirst%3DS.%26aulast%3DFlammini%26aufirst%3DL.%26aulast%3DAmantini%26aufirst%3DC.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DQuaglia%26aufirst%3DW.%26atitle%3DNovel%2520potent%2520N-methyl-d-aspartate%2520%2528NMDA%2529%2520receptor%2520antagonists%2520or%2520sigma1%2520receptor%2520ligands%2520based%2520on%2520properly%2520substituted%25201%252C4-dioxane%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8601%26epage%3D8615%26doi%3D10.1021%2Facs.jmedchem.5b01214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asare-Nkansah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of conformationally restricted 1,3-dioxanes to analyze the bioactive conformation of 1,3-dioxane-based sigma1 and PCP receptor antagonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2472</span>– <span class="NLM_lpage">2481</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2017.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28320613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksFCjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2472-2481&author=S.+Asare-Nkansahauthor=D.+Schepmannauthor=B.+Wunsch&title=Synthesis+of+conformationally+restricted+1%2C3-dioxanes+to+analyze+the+bioactive+conformation+of+1%2C3-dioxane-based+sigma1+and+PCP+receptor+antagonists&doi=10.1016%2Fj.bmc.2017.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of conformationally restricted 1,3-dioxanes to analyze the bioactive conformation of 1,3-dioxane-based σ1 and PCP receptor antagonists</span></div><div class="casAuthors">Asare-Nkansah, Samuel; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2472-2481</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The receptor binding profile of 2-phenyl-4-(aminoethyl)-1,3-dioxanes was dependent on the addnl. substituent in 2-position, the substituents at the amino moiety and the stereochem.  The conformationally restricted 1,3-dioxanes bearing an axially oriented Ph moiety in 2-position were prepd. and pharmacol. evaluated.  Two subsequent intramol. transacetalization reactions represented the key steps in the synthesis of the tricyclic system.  The resulting alc. I [R = OH] was transformed into amines II [X = NH2, benzylamine, dibenzylamine and dimethylamine] and III [X = NH2, benzylamine, dibenzylamine and dimethylamine] with axially (a-series) or equatorially oriented aminoethyl moiety (b-series).  The primary amines II [X = NH2] and III [X = NH2] did not interact with the PCP binding site of the NMDA receptor, which is explained by the addnl. methylene moiety between the acetalic center and the Ph moiety, the missing substituent at the acetalic position and/or a non-optimal three-dimensional arrangement of the pharmacophoric elements.  The benzylamine III [X = benzylamine] with an equatorially oriented aminoethyl moiety showed high σ1 affinity (Ki = 5.9 nM).  Compared with the conformationally flexible 1,3-dioxane, the σ1 affinity of III [X = benzylamine] is 3-fold and the σ1/σ2 selectivity was 5-fold increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkYGJ8bTyTubVg90H21EOLACvtfcHk0ljQ9HtTQPNvfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksFCjtbs%253D&md5=6e6b3e1d2b8fedd11339c308116d8c3e</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DAsare-Nkansah%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520conformationally%2520restricted%25201%252C3-dioxanes%2520to%2520analyze%2520the%2520bioactive%2520conformation%2520of%25201%252C3-dioxane-based%2520sigma1%2520and%2520PCP%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D2472%26epage%3D2481%26doi%3D10.1016%2Fj.bmc.2017.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strydom, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greyling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">V. Dyk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malan, S. F.</span></span> <span> </span><span class="NLM_article-title">Hexacyclododecylamines with sigma-1 receptor affinity and calcium channel modulating ability</span>. <i>Open Med. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.2174/1874104501913010029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2174%2F1874104501913010029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWqsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=29-39&author=J.+Joubertauthor=N.+Strydomauthor=W.+J.+Geldenhuysauthor=Y.+Greylingauthor=S.+V.+Dykauthor=S.+F.+Malan&title=Hexacyclododecylamines+with+sigma-1+receptor+affinity+and+calcium+channel+modulating+ability&doi=10.2174%2F1874104501913010029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Hexacyclododecylamines with sigma-1 receptor affinity and calcium channel modulating ability</span></div><div class="casAuthors">Joubert, Jacques; Strydom, Natasha; Geldenhuys, Werner J.; Greyling, Yolande; Dyk, Sandra V.; Malan, Sarel F.</div><div class="citationInfo"><span class="NLM_cas:title">Open Medicinal Chemistry Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">OMCJB6</span>;
        ISSN:<span class="NLM_cas:issn">1874-1045</span>.
    
            (<span class="NLM_cas:orgname">Bentham Open</span>)
        </div><div class="casAbstract">Introduction: Recent research points to the Sigma Receptor (σR) as a possible neuromodulatory system with multifunctional action and σ1Rs have been suggested as a drug target for a no. of CNS conditions.  Hexacyclododecylamines have shown σ1R activity and provide an advantageous scaffold for drug design that can improve the blood-brain barrier permeability of privileged structures.  Methods and Materials: A series of oxa and aza hexaxcyclododecylamines were synthesized and evaluated for sigma 1 receptor activity and voltage gated calcium channel blocking ability to det. the effect of inclusion of amine contg. heterocycles.  Results & Discussion: The compds. had promising σ1R activities (Ki = 0.067- 11.86 μM) with the aza hexacyclododecylamines 12, 24 and 27 showing some of the highest affinities (Ki = 0.067 μM, 0.215 μM and 0.496 μM resp.).  This confirms, as obsd. in previous studies, that the aza compds. are more favorable for σ1R binding than their oxa counterparts.  The addn. of the amine heterocycle showed affinities similar to that of related structures with only two lipophilic binding regions.  This indicates that the inclusion of an amine heterocycle into these structures is a viable option in the design of new σ1R ligands.  Conclusion: The σ1R activity and potential effect on other receptor classes and calcium channels could prove beneficial in pharmacol. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWB0dLMmX7UrVg90H21EOLACvtfcHk0ljQ9HtTQPNvfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWqsr3O&md5=40736af7853100e4e1d6a9e7d58df777</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.2174%2F1874104501913010029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874104501913010029%26sid%3Dliteratum%253Aachs%26aulast%3DJoubert%26aufirst%3DJ.%26aulast%3DStrydom%26aufirst%3DN.%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DGreyling%26aufirst%3DY.%26aulast%3DV.%2BDyk%26aufirst%3DS.%26aulast%3DMalan%26aufirst%3DS.%2BF.%26atitle%3DHexacyclododecylamines%2520with%2520sigma-1%2520receptor%2520affinity%2520and%2520calcium%2520channel%2520modulating%2520ability%26jtitle%3DOpen%2520Med.%2520Chem.%2520J.%26date%3D2019%26volume%3D13%26spage%3D29%26epage%3D39%26doi%3D10.2174%2F1874104501913010029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aube, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span> <span> </span><span class="NLM_article-title">Decahydrobenzoquinolin-5-one sigma receptor ligands: divergent development of both sigma 1 and sigma 2 receptor selective examples</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5689</span>– <span class="NLM_lpage">5694</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmcl.2016.10.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27839919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5689-5694&author=M.+C.+McLeodauthor=J.+Aubeauthor=K.+J.+Frankowski&title=Decahydrobenzoquinolin-5-one+sigma+receptor+ligands%3A+divergent+development+of+both+sigma+1+and+sigma+2+receptor+selective+examples&doi=10.1016%2Fj.bmcl.2016.10.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples</span></div><div class="casAuthors">McLeod, Michael C.; Aube, Jeffrey; Frankowski, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5689-5694</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Analogs of the decahydrobenzoquinolin-5-one class of sigma (σ) receptor ligands were used to probe the structure-activity relationship trends for this recently discovered series of σ ligands.  In all, 29 representatives were tested for σ and opioid receptor affinity, leading to the identification of compds. possessing improved σ1 selectivity and, for the first time in this series, examples possessing preferential σ2 affinity.  Several structural features assocd. with these selectivity trends have been identified.  Two analogs of improved selectivity were evaluated in a binding panel of 43 CNS-relevant targets to confirm their sigma receptor preference.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3DbJ3TPJurVg90H21EOLACvtfcHk0li1xPq9SoGWvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3L&md5=c71a5ddb62936d09ef826ce9c8628f28</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.065%26sid%3Dliteratum%253Aachs%26aulast%3DMcLeod%26aufirst%3DM.%2BC.%26aulast%3DAube%26aufirst%3DJ.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26atitle%3DDecahydrobenzoquinolin-5-one%2520sigma%2520receptor%2520ligands%253A%2520divergent%2520development%2520of%2520both%2520sigma%25201%2520and%2520sigma%25202%2520receptor%2520selective%2520examples%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5689%26epage%3D5694%26doi%3D10.1016%2Fj.bmcl.2016.10.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topczewski, J. J.</span></span> <span> </span><span class="NLM_article-title">3-Amino-chromanes and tetrahydroquinolines as selective 5-HT2B, 5-HT7, or sigma 1 receptor ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1436</span>– <span class="NLM_lpage">1442</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00225</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00225" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVent77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1436-1442&author=M.+R.+Porterauthor=H.+Xiaoauthor=J.+Wangauthor=S.+B.+Smithauthor=J.+J.+Topczewski&title=3-Amino-chromanes+and+tetrahydroquinolines+as+selective+5-HT2B%2C+5-HT7%2C+or+sigma+1+receptor+ligands&doi=10.1021%2Facsmedchemlett.9b00225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands</span></div><div class="casAuthors">Porter, Matthew R.; Xiao, Haiyan; Wang, Jing; Smith, Sylvia B.; Topczewski, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1436-1442</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phenethylamine backbone is a privileged substructure found in a wide variety of G protein-coupled receptor (GPCR) ligands.  This includes both endogenous neurotransmitters and active pharmaceutical agents.  More than 20 structurally unique heterocyclic phenethylamine derivs. were broadly evaluated for GPCR affinity.  Selective ligands for the 5-HT2B, 5-HT7, and σ1 receptors were identified, each with low nanomolar binding affinities.  The σ1 receptor affinity was supported in a cellular assay that provided evidence for increased cell survival under oxidative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0d2zLDIyGCrVg90H21EOLACvtfcHk0li1xPq9SoGWvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVent77M&md5=9c51129feafc5b64c80813f98a6107c1</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00225%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DM.%2BR.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%2BB.%26aulast%3DTopczewski%26aufirst%3DJ.%2BJ.%26atitle%3D3-Amino-chromanes%2520and%2520tetrahydroquinolines%2520as%2520selective%25205-HT2B%252C%25205-HT7%252C%2520or%2520sigma%25201%2520receptor%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1436%26epage%3D1442%26doi%3D10.1021%2Facsmedchemlett.9b00225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">From alpha4beta2 nicotinic ligands to the discovery of sigma1 receptor ligands: pharmacophore analysis and rational design</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1058</span>, <span class="refDoi"> DOI: 10.1021/ml3002715</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3002715" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1054-1058&author=L.+F.+Yuauthor=H.+K.+Zhangauthor=H.+Gunosewoyoauthor=A.+P.+Kozikowski&title=From+alpha4beta2+nicotinic+ligands+to+the+discovery+of+sigma1+receptor+ligands%3A+pharmacophore+analysis+and+rational+design&doi=10.1021%2Fml3002715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design</span></div><div class="casAuthors">Yu, Li-Fang; Zhang, Han-Kun; Gunosewoyo, Hendra; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1054-1058</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Comparative analyses of the pharmacophoric elements required for σ1 and nicotinic ligands led to the identification of a potent and selective σ1 ligand (15, I).  Compd. 15 displayed high selectivity for the σ1 receptor (Ki, σ1 = 4.1 nM; Ki, σ2 = 1312 nM) with moderate binding affinity for the DAT (Ki = 373 nM) and NET (Ki = 203 nM) in the PDSP broad screening panel of common CNS neurotransmitter transporters and receptors.  The key finding in this present work is that a subtle structural modification could be used as a tool to switch a ligand's selectivity between nAChRs and sigma receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp00SphSwYKLrVg90H21EOLACvtfcHk0li1xPq9SoGWvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtr3K&md5=908dc6a13498beb6e751249b33d35e71</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Fml3002715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3002715%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DH.%2BK.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DFrom%2520alpha4beta2%2520nicotinic%2520ligands%2520to%2520the%2520discovery%2520of%2520sigma1%2520receptor%2520ligands%253A%2520pharmacophore%2520analysis%2520and%2520rational%2520design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D1054%26epage%3D1058%26doi%3D10.1021%2Fml3002715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span> <span> </span><span class="NLM_article-title">Development of novel alkoxyisoxazoles as sigma-1 receptor antagonists with antinociceptive efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6329</span>– <span class="NLM_lpage">6343</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00571</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00571" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFyntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6329-6343&author=H.+Sunauthor=M.+Shiauthor=W.+Zhangauthor=Y.+M.+Zhengauthor=Y.+Z.+Xuauthor=J.+J.+Shiauthor=T.+Liuauthor=H.+Gunosewoyoauthor=T.+Pangauthor=Z.+B.+Gaoauthor=F.+Yangauthor=J.+Tangauthor=L.+F.+Yu&title=Development+of+novel+alkoxyisoxazoles+as+sigma-1+receptor+antagonists+with+antinociceptive+efficacy&doi=10.1021%2Facs.jmedchem.6b00571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Development of novel alkoxyisoxazoles as sigma-1 receptor antagonists with antinociceptive efficacy</span></div><div class="casAuthors">Sun, Hao; Shi, Min; Zhang, Wei; Zheng, Yue-Ming; Xu, Ya-Zhou; Shi, Jun-Jie; Liu, Ting; Gunosewoyo, Hendra; Pang, Tao; Gao, Zhao-Bing; Yang, Fan; Tang, Jie; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6329-6343</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of sigma (σ) receptor ligands based on an alkoxyisoxazole scaffold has been designed and synthesized.  Preliminary receptor binding assays identified highly potent (Ki < 1 nM) and selective σ1 ligands devoid of binding interactions with the monoamine transporters DAT, NET, and SERT.  In particular, compd. I was shown to possess significant antinociceptive activity in the mouse formalin-induced inflammation pain model when administered i.p. at 40 and 80 mg/kg.  Initial pharmacokinetics evaluation indicated an excellent brain exposure following oral dosing in mice, suggesting that further investigation into the use of alkoxyisoxazoles as σ1 ligands for antinociception is warranted.  This study supports the notion that selective σ1 antagonism could be a useful strategy in the development of novel antipain therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHMyTThgBAs7Vg90H21EOLACvtfcHk0ljkJtfcAPLysQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFyntb4%253D&md5=ec9ef2824ddeaef099b4326025130d09</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00571%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DY.%2BM.%26aulast%3DXu%26aufirst%3DY.%2BZ.%26aulast%3DShi%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DZ.%2BB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DL.%2BF.%26atitle%3DDevelopment%2520of%2520novel%2520alkoxyisoxazoles%2520as%2520sigma-1%2520receptor%2520antagonists%2520with%2520antinociceptive%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6329%26epage%3D6343%26doi%3D10.1021%2Facs.jmedchem.6b00571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.-F.</span></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i>-cyclobutylaminoethoxyisoxazole derivatives as novel sigma-1 receptor ligands with neurite outgrowth efficacy in cells</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">7080</span>– <span class="NLM_lpage">7088</span>, <span class="refDoi"> DOI: 10.1039/C8RA00072G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1039%2FC8RA00072G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=7080-7088&author=H.+Sunauthor=Y.-J.+Wangauthor=W.-W.+Shiauthor=F.+Yangauthor=J.+Tangauthor=T.+Pangauthor=L.-F.+Yu&title=Discovery+of+N-cyclobutylaminoethoxyisoxazole+derivatives+as+novel+sigma-1+receptor+ligands+with+neurite+outgrowth+efficacy+in+cells&doi=10.1039%2FC8RA00072G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-cyclobutylaminoethoxyisoxazole derivatives as novel sigma-1 receptor ligands with neurite outgrowth efficacy in cells</span></div><div class="casAuthors">Sun, Hao; Wang, Yun-Jie; Shi, Wen-Wen; Yang, Fan; Tang, Jie; Pang, Tao; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7080-7088</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Herein we reported a series of 14 novel derivs. based on the N-cyclobutylaminoethoxyisoxazole scaffold.  In vitro binding studies of these compds. demonstrated their low nanomolar to subnanomolar potencies as σ1 receptor ligands, with moderate to excellent selectivity over the σ2 receptor as represented by compds. 17-30.  The majority of the derivs. scored high (>4.7) in the CNS MPO appraisal system, indicating their high likelihood in penetrating the blood-brain barrier.  A no. of these compds. exhibited significant neurite outgrowth efficacy in N1E-115 neuronal cells and displayed excellent selectivity for σ1 receptors over the selected endogenous neurotransmitter transporters, such as DAT, NET and SERT.  Among the mini-series, compd. 28 (Ki σ1 = 0.2 nM, Ki σ2 = 198 nM, CNS MPO score = 5.4) emerged as a promising selective σ1 receptor ligand that warrants its further evaluation as a potential therapeutic for neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiYUOZSg4iE7Vg90H21EOLACvtfcHk0ljkJtfcAPLysQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSlsrw%253D&md5=acccca6c662001d63d4e6d6872608a76</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1039%2FC8RA00072G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8RA00072G%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DShi%26aufirst%3DW.-W.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DL.-F.%26atitle%3DDiscovery%2520of%2520N-cyclobutylaminoethoxyisoxazole%2520derivatives%2520as%2520novel%2520sigma-1%2520receptor%2520ligands%2520with%2520neurite%2520outgrowth%2520efficacy%2520in%2520cells%26jtitle%3DRSC%2520Adv.%26date%3D2018%26volume%3D8%26spage%3D7080%26epage%3D7088%26doi%3D10.1039%2FC8RA00072G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toussaint, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousset, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemard, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 ligands: Tic-hydantoin as a key pharmacophore</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2009.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2009.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=19875205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2ju7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=256-263&author=M.+Toussaintauthor=D.+Moussetauthor=C.+Foulonauthor=U.+Jacquemardauthor=C.+Vaccherauthor=P.+Melnyk&title=Sigma-1+ligands%3A+Tic-hydantoin+as+a+key+pharmacophore&doi=10.1016%2Fj.ejmech.2009.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 ligands: Tic-hydantoin as a key pharmacophore</span></div><div class="casAuthors">Toussaint, Marion; Mousset, Deborah; Foulon, Catherine; Jacquemard, Ulrich; Vaccher, Claude; Melnyk, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">256-263</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sigma-1 receptors are involved in numerous pathol. dysfunctions and the synthesis of selective ligands is of interest.  The authors identified a fused tetrahydroisoquinoline-hydantoin (Tic-hydantoin) structure with high affinity and selectivity for these receptors.  They report here their efforts towards the pharmacomodulation of this substructure, the synthesis of 9 analogs, e.g., I (R = H, Cl, I), with stereochem. inversion, opening of isoquinoline ring, removal of isoquinoline nitrogen, replacement of isoquinoline by pyridine, of Tic-hydantoin moiety by quinazolinedione heterocycle.  All these analogs provided a loss in the affinity for the sigma-1 receptor.  The present work underlines the real importance of the Tic-hydantoin moiety for the obtainment of high affinity ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZHp1sO6otxLVg90H21EOLACvtfcHk0ljkJtfcAPLysQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2ju7vL&md5=c38f1c0fa851af2eac0e20d55c021c09</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DToussaint%26aufirst%3DM.%26aulast%3DMousset%26aufirst%3DD.%26aulast%3DFoulon%26aufirst%3DC.%26aulast%3DJacquemard%26aufirst%3DU.%26aulast%3DVaccher%26aufirst%3DC.%26aulast%3DMelnyk%26aufirst%3DP.%26atitle%3DSigma-1%2520ligands%253A%2520Tic-hydantoin%2520as%2520a%2520key%2520pharmacophore%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D256%26epage%3D263%26doi%3D10.1016%2Fj.ejmech.2009.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnier-Marechal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larchanche, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Broc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, P.</span></span> <span> </span><span class="NLM_article-title">Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.10.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25462240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOqtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=198-206&author=M.+Donnier-Marechalauthor=P.+E.+Larchancheauthor=D.+Le+Brocauthor=C.+Furmanauthor=P.+Caratoauthor=P.+Melnyk&title=Carboline-+and+phenothiazine-derivated+heterocycles+as+potent+SIGMA-1+protein+ligands&doi=10.1016%2Fj.ejmech.2014.10.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Carboline and phenothiazine derivatives as potent SIGMA-1 protein ligands</span></div><div class="casAuthors">Donnier-Marechal, Marion; Larchanche, Paul-Emmanuel; Le Broc, Delphine; Furman, Christophe; Carato, Pascal; Melnyk, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">198-206</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sigma 1 receptors are assocd. with neurodegenerative and psychiatric disorders.  These receptors, via their chaperoning functions that counteract endoplasmic reticulum stress and block neurodegeneration, may serve as a target for a new generation of antidepressants or neuroprotective agents.  The involvement of these receptors has also been obsd. in neuropathic pain and cancer.  Only a few ligands, such as Igmesine and Anavex 2-73, have been involved in clin. trials.  Thus the development of sigma 1 ligands is of interest to a new generation of drugs.  Previous work in the lab. underlined the potency of benzannulated bicyclic compds. as interesting ligands.  Herein the work was extended to a series of novel tricyclic compds.  Carboline and phenothiazine derivs. were designed and synthesized.  In vitro competition binding assays for sigma 1 and 2 receptors showed that most of them have high affinity for sigma 1 receptor (Ki = 2.5-18 nM), and selectivity toward sigma 2 receptor, without cytotoxic effects on SY5Y cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm1NcJb9IIs7Vg90H21EOLACvtfcHk0ljTvA0Aw1LYsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOqtb7F&md5=e53f5f17f8baa47cbc36531b7d3bb34f</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.053%26sid%3Dliteratum%253Aachs%26aulast%3DDonnier-Marechal%26aufirst%3DM.%26aulast%3DLarchanche%26aufirst%3DP.%2BE.%26aulast%3DLe%2BBroc%26aufirst%3DD.%26aulast%3DFurman%26aufirst%3DC.%26aulast%3DCarato%26aufirst%3DP.%26aulast%3DMelnyk%26aufirst%3DP.%26atitle%3DCarboline-%2520and%2520phenothiazine-derivated%2520heterocycles%2520as%2520potent%2520SIGMA-1%2520protein%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D198%26epage%3D206%26doi%3D10.1016%2Fj.ejmech.2014.10.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnier-Marechal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Broc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of benzannulated derivatives as potent and selective sigma-1 protein ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25602932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVertrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=575-582&author=M.+Donnier-Marechalauthor=P.+Caratoauthor=D.+Le+Brocauthor=C.+Furmanauthor=P.+Melnyk&title=Synthesis+and+pharmacological+evaluation+of+benzannulated+derivatives+as+potent+and+selective+sigma-1+protein+ligands&doi=10.1016%2Fj.ejmech.2014.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of benzannulated derivatives as potent and selective sigma-1 protein ligands</span></div><div class="casAuthors">Donnier-Marechal, Marion; Carato, Pascal; Le Broc, Delphine; Furman, Christophe; Melnyk, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">575-582</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The σ1 proteins are considered to be a new class of target structures for several central nervous system disorders, including depression, anxiety, psychosis, and Parkinson's and Alzheimer's diseases.  Recently, the involvement of these receptors in neuropathic pain and cancer also was obsd.  So far, only a few ligands are in clin. trials.  In a continuation of the authors' previous studies on the development of σ1 ligands, a new series of benzannulated heterocycles was designed and synthesized.  In vitro competition binding assays showed that many of them possessed high σ1 receptor affinity (Ki = 0.6-10.3 nM), and good σ2/σ1 subtype selectivity, without cytotoxic effects on SY5Y cells (human neuroblastoma cell line).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqysWvGfSMtqrVg90H21EOLACvtfcHk0ljTvA0Aw1LYsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVertrc%253D&md5=cf877e45fcf78478d55919ae3d1bced5</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DDonnier-Marechal%26aufirst%3DM.%26aulast%3DCarato%26aufirst%3DP.%26aulast%3DLe%2BBroc%26aufirst%3DD.%26aulast%3DFurman%26aufirst%3DC.%26aulast%3DMelnyk%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520benzannulated%2520derivatives%2520as%2520potent%2520and%2520selective%2520sigma-1%2520protein%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D575%26epage%3D582%26doi%3D10.1016%2Fj.ejmech.2014.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnier-Marechal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larchanche, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulahjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxombre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermersch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">964</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2017.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28756263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GkurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=964-978&author=M.+Donnier-Marechalauthor=P.+Caratoauthor=P.+E.+Larchancheauthor=S.+Ravezauthor=R.+Boulahjarauthor=A.+Barczykauthor=B.+Oxombreauthor=P.+Vermerschauthor=P.+Melnyk&title=Synthesis+and+pharmacological+evaluation+of+benzamide+derivatives+as+potent+and+selective+sigma-1+protein+ligands&doi=10.1016%2Fj.ejmech.2017.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligands</span></div><div class="casAuthors">Donnier-Marechal, Marion; Carato, Pascal; Larchanche, Paul-Emmanuel; Ravez, Severine; Boulahjar, Rajaa; Barczyk, Amelie; Oxombre, Benedicte; Vermersch, Patrick; Melnyk, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">964-978</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel N-(aminoalkyl)benzamide derivs. such as I [m = 2, 3; R1 = Me; R2 = Bn, (CH2)2C6H4; R1R2 = (CH2)4, (CH2)2O(CH2)2, (CH2)2NMe(CH2)2, etc.; R3 = H, 4-n-Bu, 4-Cl, etc.] and N-benzyl-N-methyl-propan-1-amine derivs. II [X = CH2NH, SO2NH, NHC(O)] was designed, synthesized and pharmacol. evaluated.  In vitro competition binding assays against sigma proteins (sigma-1 S1R and sigma-2 S2R) revealed that most of them conferred S2R/S1R selectivity toward without cytotoxic effects on SY5Y cells, esp. with compds. I [m = 2, 3; R1 = Me; R2 = Bn].  Some selected compds. were also evaluated for their agonist and antagonist activities on a panel of 40 receptors and results showed the importance of the nature and the position with halogeno atom on the benzamide scaffold, the length chain and also the contribution of the hydrophobic part on the amine group.  Among them, compds. I [m = 2, 3; R1 = Me; R2 = Bn; R3 = 4-Cl, 4-CN, 4-NO2] showed excellent affinity for S1R (Ki = 1.2-3.6 nM), selectivity for S2R (Ki up to 1400 nM) and high selectivity index (IC50(SY5Y)/Ki(S1R) ratio from 28/000 to 83/000).  Furthermore, these compds. I and II presented an excellent safety profile over 40 other receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2VybgDKUtbVg90H21EOLACvtfcHk0ljTvA0Aw1LYsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GkurnE&md5=6dd003ecd4f63615b8fbf3a68e2445c9</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DDonnier-Marechal%26aufirst%3DM.%26aulast%3DCarato%26aufirst%3DP.%26aulast%3DLarchanche%26aufirst%3DP.%2BE.%26aulast%3DRavez%26aufirst%3DS.%26aulast%3DBoulahjar%26aufirst%3DR.%26aulast%3DBarczyk%26aufirst%3DA.%26aulast%3DOxombre%26aufirst%3DB.%26aulast%3DVermersch%26aufirst%3DP.%26aulast%3DMelnyk%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520benzamide%2520derivatives%2520as%2520potent%2520and%2520selective%2520sigma-1%2520protein%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D964%26epage%3D978%26doi%3D10.1016%2Fj.ejmech.2017.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span> <span> </span><span class="NLM_article-title">Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2016.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27366902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSgu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=712-726&author=D.+Zampieriauthor=L.+Vioauthor=M.+Fermegliaauthor=S.+Priclauthor=B.+Wunschauthor=D.+Schepmannauthor=M.+Romanoauthor=M.+G.+Mamoloauthor=E.+Laurini&title=Computer-assisted+design%2C+synthesis%2C+binding+and+cytotoxicity+assessments+of+new+1-%284-%28aryl%28methyl%29amino%29butyl%29-heterocyclic+sigma+1+ligands&doi=10.1016%2Fj.ejmech.2016.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands</span></div><div class="casAuthors">Zampieri, Daniele; Vio, Luciano; Fermeglia, Maurizio; Pricl, Sabrina; Wunsch, Bernhard; Schepmann, Dirk; Romano, Maurizio; Mamolo, Maria Grazia; Laurini, Erik</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">712-726</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work a blend of computational and synthetic techniques were applied with the aim to design, synthesize, and characterize new σ1 receptor (σ1R) ligands.  Starting from the structure of previously reported, high-affinity benzoxazolone-based σ1 ligands, the three-dimensional homol. model of the σ1R was exploited for retrieving the mol. determinants to fulfill the optimal pharmacophore requirements.  Accordingly, the benzoxazolone moiety was replaced by other heterocyclic scaffolds, the relevant conformational space in the σ1R binding cavity was explored, and the effect on σ1R binding affinity was ultimately assessed.  Next, the compds. designed in silico were synthesized, and their affinity and selectivity toward σ1 and σ2 receptors were tested.  Finally, a representative series of best σ1R binders were assayed for cytotoxic activity on the SH-SY5Y human neuroblastoma cell line.  Specifically, the new 4-phenyloxazolidin-2-one derivs. (i.e., (R)- and (S)-3-(4-((4-chlorobenzyl)-(methyl)-amino)-butyl)-4-phenyl-oxazolidin-2-one) emerged as potential leads for further development as σ1R agents, as they were found endowed with the highest σ1R affinity (Kiσ1 values in the range 0.95-9.3 nM), and showed minimal cytotoxic levels exhibited in the selected, cell-based test, in line with a σ1R agonist behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGpvF0Y7uR7Vg90H21EOLACvtfcHk0lg3D4PS2dZLOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSgu77K&md5=1fae4fb45c6c9807766ed6b3573b5e3d</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DLaurini%26aufirst%3DE.%26atitle%3DComputer-assisted%2520design%252C%2520synthesis%252C%2520binding%2520and%2520cytotoxicity%2520assessments%2520of%2520new%25201-%25284-%2528aryl%2528methyl%2529amino%2529butyl%2529-heterocyclic%2520sigma%25201%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D712%26epage%3D726%26doi%3D10.1016%2Fj.ejmech.2016.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based sigma1 receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2014.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24996139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1aks7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=526-533&author=E.+Lauriniauthor=D.+Harelauthor=D.+Marsonauthor=D.+Schepmannauthor=T.+J.+Schmidtauthor=S.+Priclauthor=B.+Wunsch&title=Identification%2C+pharmacological+evaluation+and+binding+mode+analysis+of+novel+chromene+and+chromane+based+sigma1+receptor+ligands&doi=10.1016%2Fj.ejmech.2014.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands</span></div><div class="casAuthors">Laurini, Erik; Harel, Dipak; Marson, Domenico; Schepmann, Dirk; Schmidt, Thomas J.; Pricl, Sabrina; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">526-533</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A set of aminoethyl substituted chromenes 3 and chromanes 4, originally developed as antiprotozoal drugs was evaluated as novel types of σ1 receptor ligands.  Anal. of SAR showed that chromenes 3 have a higher σ1 affinity than chromanes 4.  A distance of four bond lengths between the basic amino moiety and the Ph ring (3c), an alicyclic N-substituent such as the cyclohexylmethyl moiety (3l), and methylation of the secondary amine to afford a tertiary amine (3n) result in very high σ1 affinity and selectivity over the σ2 subtype.  Compds. 3a-n and 4a-e were docked into the putative binding site of the σ1 receptor model and the relevant binding mode was analyzed and scored.  Specifically, for the best σ1 ligand 3n, a salt bridge between Asp126 and the protonated amino group, an H-bond between the receptor backbone NH group (Ala122-Glu123) and the methoxy moiety of 3n, a lipophilic protein cavity encasing the chromene ring, and a T-shaped π-π stacking between the indole ring of Trp121 and the Ph ring of 3n represent the most important ligand/protein stabilizing interactions.  The binding pose of 3n was compared with the binding poses of the non-methylated chromene 3c, the satd. chromane 4c, and the N-cyclohexylmethyl deriv. 3l.  The contribution of the single amino acids to the overall free binding enthalpy was analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWhkbKyV7MDrVg90H21EOLACvtfcHk0lg3D4PS2dZLOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1aks7vM&md5=9038e0e68b27b0618d7a6bf77a8e2035</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DHarel%26aufirst%3DD.%26aulast%3DMarson%26aufirst%3DD.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DSchmidt%26aufirst%3DT.%2BJ.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DIdentification%252C%2520pharmacological%2520evaluation%2520and%2520binding%2520mode%2520analysis%2520of%2520novel%2520chromene%2520and%2520chromane%2520based%2520sigma1%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D83%26spage%3D526%26epage%3D533%26doi%3D10.1016%2Fj.ejmech.2014.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyamu, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiltz, G. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel class of potent and selective tetrahydroindazole-based sigma-1 receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1824</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.03.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2019.03.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30904383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1egsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1824-1835&author=I.+D.+Iyamuauthor=W.+Lvauthor=N.+Malikauthor=R.+K.+Mishraauthor=G.+E.+Schiltz&title=Discovery+of+a+novel+class+of+potent+and+selective+tetrahydroindazole-based+sigma-1+receptor+ligands&doi=10.1016%2Fj.bmc.2019.03.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel class of potent and selective tetrahydroindazole-based sigma-1 receptor ligands</span></div><div class="casAuthors">Iyamu, Iredia D.; Lv, Wei; Malik, Neha; Mishra, Rama K.; Schiltz, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1824-1835</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 and sigma-2 receptors have been shown to play important roles in CNS diseases, cancer, and other disorders.  These findings suggest that targeting these proteins with small-mol. modulators may be of important therapeutic value.  Here we report the development of a new class of tetrahydroindazoles that are highly potent and selective ligands for sigma-1.  Mol. modeling was used to rationalize the obsd. structure-activity relationships and identify key interactions responsible for increased potency of the optimized compds.  Assays for soly. and microsomal stability showed this series possesses favorable characteristics and is amenable to further therapeutic development.  The compds. described herein will be useful in the development of new chem. probes for sigma-1 and to aid in future work therapeutically targeting this protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr89UFpukY567Vg90H21EOLACvtfcHk0lg3D4PS2dZLOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1egsbg%253D&md5=6de5b22c574c4dc707ff3b7a16799bcf</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.03.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.03.030%26sid%3Dliteratum%253Aachs%26aulast%3DIyamu%26aufirst%3DI.%2BD.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DMalik%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DSchiltz%26aufirst%3DG.%2BE.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520potent%2520and%2520selective%2520tetrahydroindazole-based%2520sigma-1%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1824%26epage%3D1835%26doi%3D10.1016%2Fj.bmc.2019.03.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+modulation+of+class+A+GPCRs%3A+targets%2C+agents%2C+and+emerging+concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0liXJTYP6VUnKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520modulation%2520of%2520class%2520A%2520GPCRs%253A%2520targets%252C%2520agents%252C%2520and%2520emerging%2520concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vavers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvejniece, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambrova, M.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of sigma-1 receptor: a review</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">223</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.3389%2Ffphar.2019.00223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=30941035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGns7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=223&author=E.+Vaversauthor=L.+Zvejnieceauthor=T.+Mauriceauthor=M.+Dambrova&title=Allosteric+modulators+of+sigma-1+receptor%3A+a+review&doi=10.3389%2Ffphar.2019.00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulators of sigma-1 receptor: a review</span></div><div class="casAuthors">Vavers, Edijs; Zvejniece, Liga; Maurice, Tangui; Dambrova, Maija</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">223</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Allosteric modulators of sigma-1 receptor (Sig1R) are described as compds. that can increase the activity of some Sig1R ligands that compete with (+)-pentazocine, one of the classic prototypical ligands that binds to the orthosteric Sig1R binding site.  Sig1R is an endoplasmic reticulum membrane protein that, in addn. to its promiscuous high-affinity ligand binding, has been shown to have chaperone activity.  Different exptl. approaches have been used to describe and validate the activity of allosteric modulators of Sig1R.  Sig1R-modulatory activity was first found for phenytoin, an anticonvulsant drug that primarily acts by blocking the voltage-gated sodium channels.  Accumulating evidence suggests that allosteric Sig1R modulators affect processes involved in the pathophysiol. of depression, memory and cognition disorders as well as convulsions.  This review will focus on the description of selective and non-selective allosteric modulators of Sig1R, including mol. structure properties and pharmacol. activity both in vitro and in vivo, with the aim of providing the latest overview from compd. discovery approaches to eventual clin. applications.  In this review, the possible mechanisms of action will be discussed, and future challenges in the development of novel compds. will be addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdr0ABFjLtSLVg90H21EOLACvtfcHk0liXJTYP6VUnKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGns7nL&md5=1b87ec1c67abe315b40134b80b4aa90f</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00223%26sid%3Dliteratum%253Aachs%26aulast%3DVavers%26aufirst%3DE.%26aulast%3DZvejniece%26aufirst%3DL.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDambrova%26aufirst%3DM.%26atitle%3DAllosteric%2520modulators%2520of%2520sigma-1%2520receptor%253A%2520a%2520review%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D223%26doi%3D10.3389%2Ffphar.2019.00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craviso, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span> <span> </span><span class="NLM_article-title">High-affinity dextromethorphan binding sites in guinea pig brain. II. Competition experiments</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">640</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=6865909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL3sXktFKntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=629-640&author=G.+L.+Cravisoauthor=J.+M.+Musacchio&title=High-affinity+dextromethorphan+binding+sites+in+guinea+pig+brain.+II.+Competition+experiments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity dextromethorphan binding sites in guinea pig brain.  II.  Competition experiments</span></div><div class="casAuthors">Craviso, Gale L.; Musacchio, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-40</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Binding of dextromethorphan (DM)(I)  [125-71-3] to guinea pig brain is stereoselective, since levomethorphan  [125-70-2] is 20 times weaker than DM in competing for DM sites.  In general, opiate agonists and antagonists as well as their corresponding dextrorotatory isomers are weak competitors for tritiated dextromethorphan ([3H]DM) binding sites and display IC50 values in the micromolar range.  In contrast, several nonnarcotic, centrally acting antitussives are inhibitory in the nanomolar range (IC50 values for caramiphen  [77-22-5], carbetapentane  [77-23-6], dimethoxanate  [477-93-0], and pipazethate  [2167-85-3] are 25, 9, 41, and 190 nM, resp.).  Other antitussives, such as levopropoxyphene  [2338-37-6], chlophedianol  [791-35-5], and fominoben  [18053-31-1], have poor affinity for DM sites whereas the antitussive noscapine  [128-62-1] enhances DM binding by increasing the affinity of DM for its central binding sites.  Addnl. competition studies indicate that there is no correlation of DM binding with any of the known or putative neurotransmitters in the central nervous system.  DM binding is also not related to tricyclic antidepressant binding sites or biogenic amine uptake sites.  However, certain phenothiazine neuroleptics and typical and atypical antidepressants inhibit binding with IC50 values in the nanomolar range.  Moreover, the anticonvulsant drug diphenylhydantoin  [57-41-0] enhances DM binding in a manner similar to that of noscapine.  Preliminary expts. utilizing acid exts. of brain have not demonstrated the presence of an endogenous ligand for DM sites.  The binding characteristics of DM sites studied in rat and mouse brain indicate that the relative potencies of several antitussives to inhibit specific DM binding vary according to species.  High-affinity, saturable, and stereoselective [3H]DM binding sites are present in liver homogenates, but several differences were n found for these peripheral binding sites and those described for brain.  Although the nature of central DM binding sites is not known, the potent interaction of several classes of centrally acting antitussives with DM sites suggests that they may be related to the mechanism of action of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXo7IRZP6ldLVg90H21EOLACvtfcHk0liXJTYP6VUnKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXktFKntrc%253D&md5=613b43e28c91ab1f427c5aa7ce2facd1</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCraviso%26aufirst%3DG.%2BL.%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26atitle%3DHigh-affinity%2520dextromethorphan%2520binding%2520sites%2520in%2520guinea%2520pig%2520brain.%2520II.%2520Competition%2520experiments%26jtitle%3DMol.%2520Pharmacol.%26date%3D1983%26volume%3D23%26spage%3D629%26epage%3D640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paturzo, J. J.</span></span> <span> </span><span class="NLM_article-title">Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[<sup>3</sup>H]3-(−3-hydroxyphenyl)-<i>N</i>-(1-propyl)piperidine</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=2536463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL1MXhsVOlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1989&pages=1-5&author=J.+M.+Musacchioauthor=M.+Kleinauthor=J.+J.+Paturzo&title=Effects+of+dextromethorphan+site+ligands+and+allosteric+modifiers+on+the+binding+of+%28%2B%29-%5B3H%5D3-%28%E2%88%923-hydroxyphenyl%29-N-%281-propyl%29piperidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine</span></div><div class="casAuthors">Musacchio, Jose M.; Klein, Martine; Paturzo, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Equil. binding anal. demonstrated that (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine [(+)-[3H]3-PPP] binds in guinea pig brain homogenates to high and low affinity sites with Kd values of 25 nM and 0.9 μM, resp.  Competition studies with dextromethorphan (DM) site ligands and other drugs against (+)-[3H]3-PPP demonstrated that their Ki values and rank order of potency are identical to those found previously against [3H] DM.  Most significant, ropizine produced a concn-dependent increase in the binding of (+)-[3H]3-PPP, with an inhibitory component at high concns., as described previously for [3H]DM.  Similarly, phenytoin increased the binding of (+)-[3H]3-PPP in the same fashion as that of [3H]DM.  Computer-assisted anal. of equil. binding of (+)-[3H]3-PPP in the presence of 10 μM ropizine demonstrated that the binding increase produced is due to a 3-fold increase in the affinity for (+)-[3H]3-PPP.  These results, and previous finding that σ ligands inhibit [3H] DM binding with a rank order of potency similar to that for sites labeled with (+)-[3H]3-PPP or (+)-[3H]SKF10,047 strongly suggest that σ ligands bind to the high affinity DM site.  These findings, and the inability of DM and other antitussives to produce psychotomimetic side effects, suggest that the high affinity DM sites can mediate only the nonpsychotomimetic effects of σ ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsH901CqfnKLVg90H21EOLACvtfcHk0ljyoKHav2Lt_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhsVOlsLo%253D&md5=ba18c7810eb4da7a5a37701f7aecfa58</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DPaturzo%26aufirst%3DJ.%2BJ.%26atitle%3DEffects%2520of%2520dextromethorphan%2520site%2520ligands%2520and%2520allosteric%2520modifiers%2520on%2520the%2520binding%2520of%2520%2528%252B%2529-%255B3H%255D3-%2528%25E2%2588%25923-hydroxyphenyl%2529-N-%25281-propyl%2529piperidine%26jtitle%3DMol.%2520Pharmacol.%26date%3D1989%26volume%3D35%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">SKF83959 is a potent allosteric modulator of sigma-1 receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1124/mol.112.083840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1124%2Fmol.112.083840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23295385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVCrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=577-586&author=L.+Guoauthor=J.+Zhaoauthor=G.+Jinauthor=B.+Zhaoauthor=G.+Wangauthor=A.+Zhangauthor=X.+Zhen&title=SKF83959+is+a+potent+allosteric+modulator+of+sigma-1+receptor&doi=10.1124%2Fmol.112.083840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">SKF83959 is a potent allosteric modulator of sigma-1 receptor</span></div><div class="casAuthors">Guo, Lin; Zhao, Jianghao; Jin, Guozhang; Zhao, Bin; Wang, Guanghui; Zhang, Ao; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-586</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">SKF83959 (3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine), an atypical dopamine receptor-1 (D1 receptor) agonist, has shown many D1 receptor-independent effects, such as neuroprotection, blockade of Na+ channel, and promotion of spontaneous glutamate release, which resemble the effects of the sigma-1 receptor activation.  In the present work, we explored the potential modulation of SKF83959 on the sigma-1 receptor.  The results indicated that SKF83959 dramatically promoted the binding of 3H(+)-pentazocine (a selective sigma-1 receptor agonist) to the sigma-1 receptor in brain and liver tissues but produced no effect on 3H-progesterone binding (a sigma-1 receptor antagonist).  The satn. assay and the dissocn. kinetics assay confirmed the allosteric effect.  We further demonstrated that the SKF83959 analogs, such as SCH22390 [(R)-(1)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride] and SKF38393 [(+/-)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrobromide], also showed the similar allosteric effect on the sigma-1 receptor in the liver tissue but not in the brain tissue.  Moreover, all three tested chems. elicited no significant effect on 3H-1,3-di(2-tolyl)-guanidine (3H-DTG) binding to the sigma-2 receptor.  The present data uncovered a new role of SKF83959 and its analogs on the sigma-1 receptor, which, in turn, may reveal the underlying mechanism for the D1 receptor-independent effect of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLPGE6uCA_2bVg90H21EOLACvtfcHk0ljyoKHav2Lt_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVCrur8%253D&md5=75fee11a994695b5065c7946c6a23226</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.083840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.083840%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DSKF83959%2520is%2520a%2520potent%2520allosteric%2520modulator%2520of%2520sigma-1%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D577%26epage%3D586%26doi%3D10.1124%2Fmol.112.083840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santiago, L. J.</span></span> <span> </span><span class="NLM_article-title">High affinity dextromethorphan binding sites in guinea pig brain: further characterization and allosteric interactions</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">431</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=3183944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADyaL1MXhvVCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1988&pages=424-431&author=J.+M.+Musacchioauthor=M.+Kleinauthor=L.+J.+Santiago&title=High+affinity+dextromethorphan+binding+sites+in+guinea+pig+brain%3A+further+characterization+and+allosteric+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">High affinity dextromethorphan binding sites in guinea pig brain:  further characterization and allosteric interactions</span></div><div class="casAuthors">Musacchio, Jose M.; Klein, Martine; Santiago, Lucia J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">424-31</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Dextromethorphan (DN), a non-narcotic antitussive with anticonvulsant activity, binds to high (Kd, 57 nM)- and low-affinity sites (Kd, 24 μM) in the guinea pig brain.  This work, done at physiol. pH, expands previous results obtained at pH 8.3.  Phenytoin (PHT) produces an allosteric increase in the binding of [3H]DM, which is more marked than that reported previously: PHT (100 μM,) at pH 7.4, increased the binding affinity of [3H] DM to brain homogenates 4-fold, without changing the concn. of DM sites.  Ropizine (SC-13504) an anticonvulsant benzhydryl piperazine, also produced a marked concn.-dependent increase in the binding of [3H]DM, which is mediated by a decrease in the dissocn. rate of [3H]DM.  The effects of ropizine are fully apparent at 10 μM, 10-fold lower than those of PHT.  The effects of PHT and ropizine show that the affinity of the DM sites can be increased by other ligands, suggesting that these sites are located on macromols. that can exist in at least 2 conformational states.  [3H]DM also binds to peripheral tissues, but the brain displays the highest affinity.  Besides, the central and peripheral sites are different as detd. by competition studies with caramiphen and carbetapentane, which are DM site ligands with antitussive and anticonvulsant activity.  The results reported are consistent with the hypothesis that the high-affinity DM binding sites mediate antitussive and anticonvulsant activity when occupied by the appropriate ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkMuLF6ry25LVg90H21EOLACvtfcHk0ljyoKHav2Lt_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhvVCmuw%253D%253D&md5=8e90e55e69aa92b4fca3614ed3a284fd</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DSantiago%26aufirst%3DL.%2BJ.%26atitle%3DHigh%2520affinity%2520dextromethorphan%2520binding%2520sites%2520in%2520guinea%2520pig%2520brain%253A%2520further%2520characterization%2520and%2520allosteric%2520interactions%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1988%26volume%3D247%26spage%3D424%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malykh, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadaie, M. R.</span></span> <span> </span><span class="NLM_article-title">Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.2165/11319230-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.2165%2F11319230-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=20166767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFOnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=287-312&author=A.+G.+Malykhauthor=M.+R.+Sadaie&title=Piracetam+and+piracetam-like+drugs%3A+from+basic+science+to+novel+clinical+applications+to+CNS+disorders&doi=10.2165%2F11319230-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders</span></div><div class="casAuthors">Malykh, Andrei G.; Sadaie, M. Reza</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-312</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  There is an increasing interest in nootropic drugs for the treatment of CNS disorders.  Since the last meta-anal. of the clin. efficacy of piracetam, more information has accumulated.  The primary objective of this systematic survey is to evaluate the clin. outcomes as well as the scientific literature relating to the pharmacol., pharmacokinetics/pharmacodynamics, mechanism of action, dosing, toxicol. and adverse effects of marketed and investigational drugs.  The major focus of the literature search was on articles demonstrating evidence-based clin. investigations during the past 10 years for the following therapeutic categories of CNS disorders: (i) cognition/memory; (ii) epilepsy and seizure; (iii) neurodegenerative diseases; (iv) stroke/ischemia; and (v) stress and anxiety.  In this article, piracetam-like compds. are divided into three subgroups based on their chem. structures, known efficacy and intended clin. uses.  Subgroup 1 drugs include piracetam, oxiracetam, aniracetam, pramiracetam and phenylpiracetam, which have been used in humans and some of which are available as dietary supplements.  Of these, oxiracetam and aniracetam are no longer in clin. use.  Pramiracetam reportedly improved cognitive deficits assocd. with traumatic brain injuries.  Although piracetam exhibited no long-term benefits for the treatment of mild cognitive impairments, recent studies demonstrated its neuroprotective effect when used during coronary bypass surgery.  It was also effective in the treatment of cognitive disorders of cerebrovascular and traumatic origins; however, its overall effect on lowering depression and anxiety was higher than improving memory.  As add-on therapy, it appears to benefit individuals with myoclonus epilepsy and tardive dyskinesia.  Phenylpiracetam is more potent than piracetam and is used for a wider range of indications.  In combination with a vasodilator drug, piracetam appeared to have an additive beneficial effect on various cognitive disabilities.  Subgroup 2 drugs include levetiracetam, seletracetam and brivaracetam, which demonstrate antiepileptic activity, although their cognitive effects are unclear.  Subgroup 3 includes piracetam derivs. with unknown clin. efficacies, and of these nefiracetam failed to improve cognition in post-stroke patients and rolipram is currently in clin. trials as an antidepressant.  The remaining compds. of this subgroup are at various preclin. stages of research.  The modes of action of piracetam and most of its derivs. remain an enigma.  Differential effects on subtypes of glutamate receptors, but not the GABAergic actions, have been implicated.  Piracetam seems to activate calcium influx into neuronal cells; however, this function is questionable in the light of findings that a persistent calcium inflow may have deleterious impact on neuronal cells.  Although subgroup 2 compds. act via binding to another neuronal receptor (synaptic vesicle 2A), some of the subgroup 3 compds., such as nefiracetam, are similar to those of subgroup 1.  Based on calcns. of the efficacy rates, our assessments indicate notable improvements in clin. outcomes with some of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoATfClrTw8t7Vg90H21EOLACvtfcHk0ljyoKHav2Lt_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFOnu7g%253D&md5=67c0bc575dc0ac3b48c399593f5656ac</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.2165%2F11319230-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11319230-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DMalykh%26aufirst%3DA.%2BG.%26aulast%3DSadaie%26aufirst%3DM.%2BR.%26atitle%3DPiracetam%2520and%2520piracetam-like%2520drugs%253A%2520from%2520basic%2520science%2520to%2520novel%2520clinical%2520applications%2520to%2520CNS%2520disorders%26jtitle%3DDrugs%26date%3D2010%26volume%3D70%26spage%3D287%26epage%3D312%26doi%3D10.2165%2F11319230-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veinberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvejniece, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilskersts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vavers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liepinsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyakov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishnev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznecovs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vikainis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponomaryov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambrova, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2764</span>– <span class="NLM_lpage">2771</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bmc.2013.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=23582449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVWgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2764-2771&author=G.+Veinbergauthor=M.+Voronaauthor=L.+Zvejnieceauthor=R.+Vilskerstsauthor=E.+Vaversauthor=E.+Liepinshauthor=H.+Kazokaauthor=S.+Belyakovauthor=A.+Mishnevauthor=J.+Kuznecovsauthor=S.+Vikainisauthor=N.+Orlovaauthor=A.+Lebedevauthor=Y.+Ponomaryovauthor=M.+Dambrova&title=Synthesis+and+biological+evaluation+of+2-%285-methyl-4-phenyl-2-oxopyrrolidin-1-yl%29-acetamide+stereoisomers+as+novel+positive+allosteric+modulators+of+sigma-1+receptor&doi=10.1016%2Fj.bmc.2013.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor</span></div><div class="casAuthors">Veinberg, Grigory; Vorona, Maxim; Zvejniece, Liga; Vilskersts, Reinis; Vavers, Edijs; Liepinsh, Edvards; Kazoka, Helena; Belyakov, Sergey; Mishnev, Anatoly; Kuznecovs, Jevgenijs; Vikainis, Sergejs; Orlova, Natalja; Lebedev, Anton; Ponomaryov, Yuri; Dambrova, Maija</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2764-2771</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel pos. allosteric modulators of sigma-1 receptor represented by 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide enantiomers I were synthesized using an asym. Michael addn. of 2-nitroprop-1-enylbenzene to di-Et malonate.  Following the chromatog. sepn. of the Me erythro- and threo-4-nitro-3R- and 3S-phenylpentanoate diastereoisomers, target compds. were obtained by their reductive cyclization into 5-methyl-4-phenylpyrrolidin-2-one enantiomers and the attachment of the acetamide group to the heterocyclic nitrogen.  Expts. with elec. stimulated rat vas deference contractions induced by the PRE-084, an agonist of sigma-1 receptor, showed that (4R,5S)- and (4R,5R)-2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamides with an R-configuration at the C-4 chiral center in the 2-pyrrolidone ring were more effective pos. allosteric modulators of sigma-1 receptor than were their optical antipodes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj9i0QUZ1gs7Vg90H21EOLACvtfcHk0lgR0fnzVvMyJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVWgs70%253D&md5=05a11b153e7a0e928df4e4b6962c4133</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DVeinberg%26aufirst%3DG.%26aulast%3DVorona%26aufirst%3DM.%26aulast%3DZvejniece%26aufirst%3DL.%26aulast%3DVilskersts%26aufirst%3DR.%26aulast%3DVavers%26aufirst%3DE.%26aulast%3DLiepinsh%26aufirst%3DE.%26aulast%3DKazoka%26aufirst%3DH.%26aulast%3DBelyakov%26aufirst%3DS.%26aulast%3DMishnev%26aufirst%3DA.%26aulast%3DKuznecovs%26aufirst%3DJ.%26aulast%3DVikainis%26aufirst%3DS.%26aulast%3DOrlova%26aufirst%3DN.%26aulast%3DLebedev%26aufirst%3DA.%26aulast%3DPonomaryov%26aufirst%3DY.%26aulast%3DDambrova%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-%25285-methyl-4-phenyl-2-oxopyrrolidin-1-yl%2529-acetamide%2520stereoisomers%2520as%2520novel%2520positive%2520allosteric%2520modulators%2520of%2520sigma-1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2764%26epage%3D2771%26doi%3D10.1016%2Fj.bmc.2013.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zvejniece, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vavers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svalbe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilskersts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domracheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veinberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misane, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stonans, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalvinsh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambrova, M.</span></span> <span> </span><span class="NLM_article-title">The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1111/bph.12506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fbph.12506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=24490863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFWqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=761-771&author=L.+Zvejnieceauthor=E.+Vaversauthor=B.+Svalbeauthor=R.+Vilskerstsauthor=I.+Domrachevaauthor=M.+Voronaauthor=G.+Veinbergauthor=I.+Misaneauthor=I.+Stonansauthor=I.+Kalvinshauthor=M.+Dambrova&title=The+cognition-enhancing+activity+of+E1R%2C+a+novel+positive+allosteric+modulator+of+sigma-1+receptors&doi=10.1111%2Fbph.12506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors</span></div><div class="casAuthors">Zvejniece, L.; Vavers, E.; Svalbe, B.; Vilskersts, R.; Domracheva, I.; Vorona, M.; Veinberg, G.; Misane, I.; Stonans, I.; Kalvinsh, I.; Dambrova, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">761-771</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Here, we describe the in vitro and in vivo effects of (4R,5S)-2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide (E1R), a novel pos. allosteric modulator of sigma-1 receptors.  Exptl. Approach : E1R was tested for sigma receptor binding activity in a [3H](+)-pentazocine assay, in bradykinin (BK)-induced intracellular Ca2+ concn. ([Ca2+]i) assays and in an elec. stimulated rat vas deferens model.  E1R's effects on cognitive function were tested using passive avoidance (PA) and Y-maze tests in mice.  A selective sigma-1 receptor antagonist (NE-100), was used to study the involvement of the sigma-1 receptor in the effects of E1R.  The open-field test was used to detect the effects of E1R on locomotion.  Key Results : Pretreatment with E1R enhanced the selective sigma-1 receptor agonist PRE-084's stimulating effect during a model study employing elec. stimulated rat vasa deferentia and an assay measuring the BK-induced [Ca2+]i increase.  Pretreatment with E1R facilitated PA retention in a dose-related manner.  Furthermore, E1R alleviated the scopolamine-induced cognitive impairment during the PA and Y-maze tests in mice.  The in vivo and in vitro effects of E1R were blocked by treatment with the selective sigma-1 receptor antagonist NE-100.  E1R did not affect locomotor activity.  Conclusion and Implications : E1R is a novel 4,5-disubstituted deriv. of piracetam that enhances cognition and demonstrates efficacy against scopolamine-induced cholinergic dysfunction in mice.  These effects are attributed to its pos. modulatory action on the sigma-1 receptor and this activity may be relevant when developing new drugs for treating cognitive symptoms related to neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC_B_s0roD07Vg90H21EOLACvtfcHk0lgR0fnzVvMyJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFWqtA%253D%253D&md5=16177e5a4ebd9dfad1950ce26aaee874</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1111%2Fbph.12506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12506%26sid%3Dliteratum%253Aachs%26aulast%3DZvejniece%26aufirst%3DL.%26aulast%3DVavers%26aufirst%3DE.%26aulast%3DSvalbe%26aufirst%3DB.%26aulast%3DVilskersts%26aufirst%3DR.%26aulast%3DDomracheva%26aufirst%3DI.%26aulast%3DVorona%26aufirst%3DM.%26aulast%3DVeinberg%26aufirst%3DG.%26aulast%3DMisane%26aufirst%3DI.%26aulast%3DStonans%26aufirst%3DI.%26aulast%3DKalvinsh%26aufirst%3DI.%26aulast%3DDambrova%26aufirst%3DM.%26atitle%3DThe%2520cognition-enhancing%2520activity%2520of%2520E1R%252C%2520a%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520sigma-1%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D761%26epage%3D771%26doi%3D10.1111%2Fbph.12506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vavers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svalbe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauberte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stonans, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misane, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambrova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvejniece, L.</span></span> <span> </span><span class="NLM_article-title">The activity of selective sigma-1 receptor ligands in seizure models in vivo</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2017.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.bbr.2017.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=28389336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2017&pages=13-18&author=E.+Vaversauthor=B.+Svalbeauthor=L.+Lauberteauthor=I.+Stonansauthor=I.+Misaneauthor=M.+Dambrovaauthor=L.+Zvejniece&title=The+activity+of+selective+sigma-1+receptor+ligands+in+seizure+models+in+vivo&doi=10.1016%2Fj.bbr.2017.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">The activity of selective sigma-1 receptor ligands in seizure models in vivo</span></div><div class="casAuthors">Vavers, Edijs; Svalbe, Baiba; Lauberte, Lasma; Stonans, Ilmars; Misane, Ilga; Dambrova, Maija; Zvejniece, Liga</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-18</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma-1 receptor (Sig1R) is a ligand-regulated protein which, since its discovery, has been widely studied as a novel target to treat neurol. disorders, including seizures.  However, the roles and mechanisms of Sig1R in the regulation of seizures are not fully understood.  The aim of the present study was to test and compare effects of often used selective Sig1R ligands in models of exptl. induced seizures.  The anti-seizure activities and interactions of selective Sig1R agonist PRE-084, selective Sig1R antagonist NE-100 and novel pos. allosteric Sig1R modulator E1R were evaluated in pentylenetetrazol (PTZ) and (+)-bicuculline (BIC)-induced seizure models in mice.  Sig1R antagonist NE-100 at a dose of 25 mg/kg demonstrated pro-convulsive activity on PTZ-induced seizures.  Agonist PRE-084 did not change the thresholds of chemoconvulsant-induced seizures.  Pos. allosteric modulator E1R at a dose of 50 mg/kg showed anti-convulsive effects on PTZ- and BIC-induced clonic and tonic seizures.  The anti-seizure activity of E1R was blocked by NE-100.  Surprisingly, NE-100 at a dose of 50 mg/kg induced convulsions, but E1R significantly alleviated the convulsive behavior induced by NE-100.  In conclusion, the selective Sig1R antagonist NE-100 induced seizures that could be partially attenuated by pos. allosteric Sig1R modulator.  Our results confirm that Sig1R could be a novel mol. target for new anti-convulsive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeOFzQ4WCPN7Vg90H21EOLACvtfcHk0lgR0fnzVvMyJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFCisr0%253D&md5=30018fac502e22da158ad722b8cf689c</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2017.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2017.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DVavers%26aufirst%3DE.%26aulast%3DSvalbe%26aufirst%3DB.%26aulast%3DLauberte%26aufirst%3DL.%26aulast%3DStonans%26aufirst%3DI.%26aulast%3DMisane%26aufirst%3DI.%26aulast%3DDambrova%26aufirst%3DM.%26aulast%3DZvejniece%26aufirst%3DL.%26atitle%3DThe%2520activity%2520of%2520selective%2520sigma-1%2520receptor%2520ligands%2520in%2520seizure%2520models%2520in%2520vivo%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2017%26volume%3D328%26spage%3D13%26epage%3D18%26doi%3D10.1016%2Fj.bbr.2017.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span> <span> </span><span class="NLM_article-title">SKF83959 has protective effects in the scopolamine model of dementia</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1248/bpb.b17-00877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1248%2Fbpb.b17-00877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=29491219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWhsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=427-434&author=G.+Shengauthor=J.+Zhangauthor=S.+Gaoauthor=Y.+Guauthor=B.+Jiangauthor=Q.+Gao&title=SKF83959+has+protective+effects+in+the+scopolamine+model+of+dementia&doi=10.1248%2Fbpb.b17-00877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">SKF83959 has protective effects in the scopolamine model of dementia</span></div><div class="casAuthors">Sheng, Gaofeng; Zhang, Jinlin; Gao, Shengfeng; Gu, Yuanyuan; Jiang, Bo; Gao, Qiufang</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-434</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Patients with Alzheimer's disease (AD) always have cognitive impairments.  In this study we investigated whether 6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine (SKF83959) has improvements on cognitive dysfunction.  The scopolamine model of dementia was used to investigate the anti-amnesic activities of SKF83959, and then, Western blotting and pharmacol. inhibitor were used to assay the anti-amnesic mechanisms of SKF83959.  It was found that SKF83959 administration significantly improved the scopolamine-induced memory impairments in the passive avoidance task, Y-maze test, and Morris water maze task.  Moreover, SKF83959 treatment significantly antagonized the down-regulating effects of scopolamine on brain-derived neurotrophic factor (BDNF) signaling cascade in the hippocampus, but not cortex.  Importantly, the usage of K252a, a selective inhibitor of tyrosine kinase B (TrkB), significantly attenuated the protective effects of SKF83959 in the scopolamine model.  Collectively, this study shows that SKF83959 has beneficial effects in the scopolamine model of dementia by modulation of hippocampal BDNF signaling, implying a novel and potential therapeutic agent for treating dementia in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM1lahHSV9UbVg90H21EOLACvtfcHk0lj2c04tFFnsew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWhsbvI&md5=d3588ebff447cff7be6effd068e353eb</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b17-00877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b17-00877%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DSKF83959%2520has%2520protective%2520effects%2520in%2520the%2520scopolamine%2520model%2520of%2520dementia%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2018%26volume%3D41%26spage%3D427%26epage%3D434%26doi%3D10.1248%2Fbpb.b17-00877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of sigma-1 receptors elicits anti-seizure activities</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">4052</span>– <span class="NLM_lpage">4065</span>, <span class="refDoi"> DOI: 10.1111/bph.13195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1111%2Fbph.13195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=25989224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=4052-4065&author=L.+Guoauthor=Y.+Chenauthor=R.+Zhaoauthor=G.+Wangauthor=E.+Friedmanauthor=A.+Zhangauthor=X.+Zhen&title=Allosteric+modulation+of+sigma-1+receptors+elicits+anti-seizure+activities&doi=10.1111%2Fbph.13195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of sigma-1 receptors elicits anti-seizure activities</span></div><div class="casAuthors">Guo, Lin; Chen, Yanke; Zhao, Rui; Wang, Guanghui; Friedman, Eitan; Zhang, Ao; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4052-4065</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Application of orthosteric sigma-1 receptor agonists as anti-seizure drugs has been hindered by questionable efficacy and potential adverse effects.  Here, we have investigated the anti-seizure effects of the novel and potent allosteric modulator of sigma-1 receptors, SKF83959 and its deriv. SOMCL-668 (3-methyl-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol).  Exptl. Approach : The anti-seizure effects of SKF83959 were investigated in three mouse models, maximal electroshock seizures, pentylenetetrazole-induced convulsions and kainic acid-induced 'status epilepticus'.  Also, in rats, the cortical epileptiform activity induced by topical application of picrotoxin was recorded in electrocorticograms.  In rat hippocampal brain slices, effects of the drugs on the high potassium-evoked epileptiform local field potentials were studied.  Anti-seizure activities of SOMCL-668, a newly developed sigma-1 receptor selective allosteric modulator, were also investigated.  Key Results : SKF83959 (20, 40 mg·kg-1) exhibited anti -seizure activity in the three mouse models and reduced the cortical epileptiform activity without alteration of spontaneous motor activity and motor coordination.  These effects were blocked by the sigma-1 receptor antagonist BD1047, but not the dopamine D1 receptor antagonist SCH23390.  SKF83959 alone did not directly inhibit the epileptiform firing of CA3 neurons induced by high potassium in hippocampal slices, but did potentiate inhibition by the orthosteric sigma-1 receptor agonist SKF10047.  Lastly, a selective sigma-1 receptor allosteric modulator SOMCL-668, which does not bind to dopamine receptors, exerted similar anti-seizure activities.  Conclusions and Implications : SKF83959 and SOMCL-668 displayed anti-seizure activities, indicating that allosteric modulation of sigma-1 receptors may provide a novel approach for discovering new anti-seizure drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdZQgIVi8TZbVg90H21EOLACvtfcHk0lj2c04tFFnsew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurnJ&md5=e15ae86b8e6af8a7cb3ca3846b77d3e8</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1111%2Fbph.13195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13195%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DAllosteric%2520modulation%2520of%2520sigma-1%2520receptors%2520elicits%2520anti-seizure%2520activities%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D4052%26epage%3D4065%26doi%3D10.1111%2Fbph.13195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virgili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as dual mu-opioid receptor agonists and sigma1 receptor antagonists for the treatment of pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01256</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2nur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2434-2454&author=M.+Garciaauthor=M.+Virgiliauthor=M.+Alonsoauthor=C.+Alegretauthor=B.+Fernandezauthor=A.+Portauthor=R.+Pascualauthor=X.+Monroyauthor=A.+Vidal-Torresauthor=M.+T.+Serafiniauthor=J.+M.+Velaauthor=C.+Almansa&title=4-Aryl-1-oxa-4%2C9-diazaspiro%5B5.5%5Dundecane+derivatives+as+dual+mu-opioid+receptor+agonists+and+sigma1+receptor+antagonists+for+the+treatment+of+pain&doi=10.1021%2Facs.jmedchem.9b01256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as dual μ-opioid receptor agonists and σ1 receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Garcia, Monica; Virgili, Marina; Alonso, Monica; Alegret, Carles; Fernandez, Begona; Port, Adriana; Pascual, Rosalia; Monroy, Xavier; Vidal-Torres, Alba; Serafini, Maria-Teresa; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2434-2454</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivs. as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are reported.  The different positions of the central scaffold, designed using a merging strategy of both targets pharmacophores, were explored using a versatile synthetic approach.  Phenethyl derivs. in position 9, substituted pyridyl moieties in position 4 and small alkyl groups in position 2 provided the best profiles.  One of the best compds., I, showed a balanced dual profile (i.e. MOR agonism and sigma antagonism) and potent analgesic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice.  Contrary to oxycodone, as expected from the addn. of σ1R antagonism, I showed local, peripheral activity in this test, which was reversed by the σ1R agonist PRE-084.  At equianalgesic doses, I showed less constipation than oxycodone, providing evidence that dual MOR agonism and σ1R antagonism may be a useful strategy for obtaining potent and safer analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_96WgxDmIbVg90H21EOLACvtfcHk0ljZDNxKuuYbXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2nur3M&md5=6ff458638f9069ade1ccca8adabebb9a</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01256%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DM.%26aulast%3DVirgili%26aufirst%3DM.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DAlegret%26aufirst%3DC.%26aulast%3DFernandez%26aufirst%3DB.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3DSerafini%26aufirst%3DM.%2BT.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3D4-Aryl-1-oxa-4%252C9-diazaspiro%255B5.5%255Dundecane%2520derivatives%2520as%2520dual%2520mu-opioid%2520receptor%2520agonists%2520and%2520sigma1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2434%26epage%3D2454%26doi%3D10.1021%2Facs.jmedchem.9b01256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">112144</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.1016%2Fj.ejmech.2020.112144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=32087465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1KqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2020&pages=112144&author=J.+Xiongauthor=J.+Jinauthor=L.+Gaoauthor=C.+Haoauthor=X.+Liuauthor=B.+F.+Liuauthor=Y.+Chenauthor=G.+Zhang&title=Piperidine+propionamide+as+a+scaffold+for+potent+sigma-1+receptor+antagonists+and+mu+opioid+receptor+agonists+for+treating+neuropathic+pain&doi=10.1016%2Fj.ejmech.2020.112144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain</span></div><div class="casAuthors">Xiong, Jiaying; Jin, Jian; Gao, Lanchang; Hao, Chao; Liu, Xin; Liu, Bi-Feng; Chen, Yin; Zhang, Guisen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112144pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of piperidine propionamide derivs. as potent sigma-1 (σ1) receptor antagonists and mu (μ) opioid receptor agonists, and measured their affinity for σ1 and μ receptors in-vitro through binding assays was designed and synthesized .  The basic scaffold of the new compds. contained a 4-substituted piperidine ring and N-aryl propionamide.  Compd. N-(2-(4-(4-fluorobenzyl)piperidin-1-yl)ethyl)-N-(4-methoxyphenyl)propionamide, showed the highest affinity for σ1 receptor (Ki σ1 = 1.86 nM) and μ receptor (Ki μ = 2.1 nM).  It exhibited potent analgesic activity in the formalin test (ED50 = 15.1 ± 1.67 mg/kg) and has equiv. analgesic effects to S1RA (σ1 antagonist) in a CCI model.  Therefore, Compd. N-(2-(4-(4-fluorobenzyl)piperidin-1-yl)ethyl)-N-(4-methoxyphenyl)propionamide, which has mixed σ1/μ receptor profiles, was a potential candidate for treating neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorVklStH7JO7Vg90H21EOLACvtfcHk0ljZDNxKuuYbXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1KqsLs%253D&md5=d7563536f3b04ef267b2fa1c0a67af4b</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112144%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%2BF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DPiperidine%2520propionamide%2520as%2520a%2520scaffold%2520for%2520potent%2520sigma-1%2520receptor%2520antagonists%2520and%2520mu%2520opioid%2520receptor%2520agonists%2520for%2520treating%2520neuropathic%2520pain%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D191%26spage%3D112144%26doi%3D10.1016%2Fj.ejmech.2020.112144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Garcia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Franco, M. I.</span></span> <span> </span><span class="NLM_article-title">New neurogenic lipoic-based hybrids as innovative Alzheimer’s drugs with sigma-1 agonism and beta-secretase inhibition</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1191</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.4155/fmc-2016-0036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=10.4155%2Ffmc-2016-0036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=27402296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gitb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1191-1207&author=M.+Estradaauthor=C.+Perezauthor=E.+Sorianoauthor=E.+Lauriniauthor=M.+Romanoauthor=S.+Priclauthor=J.+A.+Morales-Garciaauthor=A.+Perez-Castilloauthor=M.+I.+Rodriguez-Franco&title=New+neurogenic+lipoic-based+hybrids+as+innovative+Alzheimer%E2%80%99s+drugs+with+sigma-1+agonism+and+beta-secretase+inhibition&doi=10.4155%2Ffmc-2016-0036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition</span></div><div class="casAuthors">Estrada, Martin; Perez, Concepcion; Soriano, Elena; Laurini, Erik; Romano, Maurizio; Pricl, Sabrina; Morales-Garcia, Jose A.; Perez-Castillo, Ana; Rodriguez-Franco, Maria Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1191-1207</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Neurogenic agents emerge as innovative drugs for the treatment of Alzheimer's disease (AD), whose pathol. complexity suggests strengthening research in the multi-target directed ligands strategy.  Results: By combining the lipoic acid structure with N-benzylpiperidine or N,N-dibenzyl(N-methyl)amine fragments, new multi-target directed ligands were obtained that act at three relevant targets in AD: σ-1 receptor (σ1R), β-secretase-1 (BACE1) and acetylcholinesterase (AChE).  Moreover, they show potent neurogenic properties, good antioxidant capacity and favorable CNS permeability.  Mol. modeling studies on AChE, σ1R and BACE1 highlight relevant drug-protein interactions that may contribute to the development of new disease-modifying drugs.  Conclusion: New lipoic-based σ1 agonists endowed with neurogenic, antioxidant, cholinergic and amyloid β-peptide-reducing properties have been discovered for the potential treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_JgBqiAyiQ7Vg90H21EOLACvtfcHk0ljZDNxKuuYbXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gitb3P&md5=e72c02533e11501f236a9448956d0d12</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0036%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DMorales-Garcia%26aufirst%3DJ.%2BA.%26aulast%3DPerez-Castillo%26aufirst%3DA.%26aulast%3DRodriguez-Franco%26aufirst%3DM.%2BI.%26atitle%3DNew%2520neurogenic%2520lipoic-based%2520hybrids%2520as%2520innovative%2520Alzheimer%25E2%2580%2599s%2520drugs%2520with%2520sigma-1%2520agonism%2520and%2520beta-secretase%2520inhibition%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D1191%26epage%3D1207%26doi%3D10.4155%2Ffmc-2016-0036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1','PDB','5HK1'); return false;">PDB: 5HK1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK1','PDB','6DK1'); return false;">PDB: 6DK1</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01192&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01192%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01192" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992b184f90234a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
